

SQ Sequence 16 BP; 4 A; 5 C; 2 G; 4 T; 0 U; 1 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 768 TGATGACATACGTGGC 783  
||||||| |  
Db 16 TGATGACANATGTGGC 1

RESULT 189  
ADF92303  
ID ADF92303 standard; DNA; 16 BP.  
XX  
AC ADF92303;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
DE Human cytokeratin 19-related loop F PCR primer - SEQ ID 391.  
XX  
KW human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;  
KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;  
KW PCR; loop F.  
XX  
OS Homo sapiens.  
XX  
XX WO2003097878-A1.  
PN  
XX  
PD 27-NOV-2003.  
XX  
PF 20-MAY-2003; 2003WO-JP006256.  
XX  
PR 21-MAY-2002; 2002JP-00145689.  
PR 17-JUN-2002; 2002JP-00175271.  
PR 09-JUL-2002; 2002JP-00199759.  
XX  
PA (SYSM-) SYSMEX CORP.  
XX  
PI Tada S, Akai Y, Imura Y, Abe S, Minekawa H;  
XX  
XX WPI; 2004-012543/01.  
DR  
XX  
PT LAMP nucleic acid amplification primers for detection of cytokeratin  
PT expression as indicator in diagnosis of tumour metastasis.  
XX  
PS Claim 19; SEQ ID NO 391; 266pp; Japanese.  
XX  
CC The invention relates to novel nucleic acid amplification primers for the  
CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP  
CC (loop mediated isothermal amplification) method. The primers of the  
CC invention may be useful for the detecting cytokeratin 18-20 expression as  
CC an indicator for the diagnosis of tumour metastasis, particularly  
CC prostate cancer and lymphoma. The amplification using the primers is  
CC highly efficient and allows very sensitive detection of tumour  
CC metastasis. The current sequence is that of the human CK19-related PCR  
CC primer of the invention.  
XX  
SQ Sequence 16 BP; 0 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 42 GGCCACTGCTTCTGG 56  
||||| |  
Db 1 GGCCCTGCTTCTGG 15

RESULT 190  
ADR06487  
ID ADR06487 standard; DNA; 16 BP.  
XX

AC ADR06487;  
XX  
DT 21-OCT-2004 (first entry)  
XX  
DE Murine sequence tag.  
XX  
KW Identification; gene expression; cell differentiation;  
KW stem cell differentiation; murine; ss.  
XX  
OS Mus musculus.  
XX  
PN WO2004065553-A2.  
XX  
PD 05-AUG-2004.  
XX  
PF 16-JAN-2004; 2004WO-US001482.  
XX  
PR 16-JAN-2003; 2003US-0440510P.  
XX  
PA (HEAL-) HEALTH RES INC.  
XX  
PI Pruitt SC, Maslov A;  
XX  
DR WPI; 2004-571677/55.  
XX  
PT Identifying genes expressed during differentiation of a cell, useful,  
PT e.g. in research into mechanisms leading to differentiation of stem  
PT cells, comprises integrating a cell lineage targeting vector into the  
PT genome of a host cell,.  
XX  
PS Example 6; SEQ ID NO 38; 45pp; English.  
XX  
CC The present invention relates to a method (M1) for identifying genes  
CC expressed during cell differentiation. The method is useful in research  
CC into the mechanisms that lead to differentiation of stem cells. Knowledge  
CC of these mechanisms is important in understanding embryonic development  
CC and homeostasis within somatic tissues, and is also relevance to the  
CC therapeutic use of stem cells. The method comprises: integrating into a  
CC site in a host cell genome, a cell lineage targeting vector comprising a  
CC pair of recombinease recognition sites flanking one or more  
CC polyadenylation sites, a first selectable marker placed downstream or  
CC between the two recombinease recognition sites, a reporter gene placed  
CC downstream of the recombinease recognition sites, and a cell lineage  
CC specific gene promoter placed upstream of the recombinease recognition  
CC sites or a cell specific lineage gene placed downstream of the  
CC recombinease recognition sites; amplifying cells generated from the host  
CC cell; integrating into the genome of a plurality of the amplified cells,  
CC a gene-trap vector comprising a splice acceptor, a type IIS restriction  
CC endonuclease cleavage site, one or more polyadenylation sites, a second  
CC selectable marker and a splice donor; allowing the cells to differentiate  
CC ; isolating cells in which the reporter gene is expressed indicating  
CC expression of the cell lineage specific gene; and identifying trapped  
CC genes in the isolated cells. The present sequence was used to illustrate  
CC the invention.  
XX  
SQ Sequence 16 BP; 5 A; 1 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1216 AGGTATGATGAAAGG 1230  
||||| |  
Db 1 AGGTATGATGACAGG 15

Search completed: May 13, 2005, 11:26:56  
Job time : 4 secs





Best Local Similarity 93.3%; Pred. NO. 1e+02; Mismatches 1; Indels 0; Gaps 0; Matches 14; Conservative 0;

QY 1040 AAGTTTTTCTTTTA 1054  
15 AAGTTTTTCTTATTA 1

Db

RESULT 185  
AAH84366/c  
ID AAH84366 standard; cDNA; 15 BP.  
XX  
AC AAH84366;  
XX  
DT 21-SEP-2001 (first entry)  
XX  
DE Human cell death protective cDNA clone CNI-00723 ORF51, SEQ:460.  
XX  
KW Cell death protective; apoptosis; necrosis; human; drug screening;  
KW cell death-associated disorder; central nervous system disorder;  
KW psychiatric disorder; neurological disorder; ischaemia-related disorder;  
KW stroke; cerebral infarction; ischaemic encephalopathy;  
KW neurodegenerative disorder; Alzheimer's disease; Huntington's disease;  
KW Parkinson's disease; infection; meningitis; malaria; trypanosomiasis;  
KW vascular disease; ophthalmological disorder; diabetic retinopathy;  
KW macular degeneration; hypertension; myocardial infarction;  
KW atherosclerosis; respiratory disorder; asthma; transgenic animal;  
KW chronic obstructive pulmonary disease; neoplastic condition; cancer;  
KW benign tumour; anaemia; gastrointestinal disorder; gastritis;  
KW ulcerative colitis; liver disease; biliary cirrhosis; kidney disorder;  
KW glomerulonephritis; cystitis; endometriosis; endocrine disorder;  
KW Grave's disease; Hashimoto's thyroiditis; skin condition; dermatitis;  
KW urticaria; immune disorder; acquired immunodeficiency syndrome; AIDS;  
KW open reading frame; ORF; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200145638-A2.  
XX  
PD 28-JUN-2001.  
XX  
PF 11-DEC-2000; 2000WO-US033547.  
XX  
PR 14-DEC-1999; 99US-00461697.  
XX  
PA (COGE-) COGENT NEUROSCIENCE INC.  
XX  
PI Lo DC, Barney S, Thomas MB, Portbury SD, Puranam K, Katz LC;  
XX  
DR WPI; 2001-390297/41.  
DR P-PSDB; AAG98828.  
XX  
PT Novel protective sequence polynucleotides and polypeptides, used to  
PT identify modulators of their expression and activity, which are used in  
PT to treat central nervous system conditions, diseases and disorders.  
XX  
PS Claim 2; Fig 12AY; 325pp; English.  
XX  
CC Sequences AAH84132-AAH84370 represent human nucleic acid sequences which  
CC protect against cell death (i.e., apoptosis or necrosis). Sequences  
CC AAH84132, AAH84145, AAH84170, AAH84201, AAH84210, AAH84226, AAH84265,  
CC AAH84281, AAH84315 and AAH84367 represent 10 full-length cDNA clones,  
CC while the remaining nucleic acid sequences within the range given above  
CC represent the open reading frames (ORFs) of these cDNA clones. Sequences  
CC AAG98610-AAG98829 represent the polypeptides encoded by the cell death  
CC protective ORFs. The cell death protective cDNA clones are able to  
CC prevent, delay or reverse progression through the apoptotic or necrotic  
CC pathways when injected into a cell predisposed to or undergoing cell  
CC death. The cell death protective nucleic acids and polypeptides can be  
CC used in the diagnosis and treatment of disorders associated with cell  
CC death, and to screen for compounds which modulate their activity or  
CC expression. Such modulators, preferably a small organic molecule, an  
CC antibody, a ribozyme, or an antisense molecule, can also be used to treat

cell death-related diseases. Such diseases include those associated with the central nervous system including psychiatric or neurological disorders, especially ischaemia-related conditions such as strokes, and also includes neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, or Parkinson's disease. The modulators may also be used to treat infections such as meningitis, malaria, or trypanosomiasis; vascular diseases such as ischaemic encephalopathy or cerebral infarction; eye conditions such as diabetic retinopathy or macular degeneration; hypertension; myocardial infarction; atherosclerosis; respiratory conditions such as asthma or chronic obstructive pulmonary disease; neoplastic conditions such as cancers or benign tumours; blood cell conditions such as anaemia; gastrointestinal conditions such as gastritis or ulcerative colitis; liver conditions such as biliary cirrhosis; kidney disorders such as glomerulonephritis; cystitis; endometriosis; endocrine disorders such as Grave's disease or Hashimoto's thyroiditis; skin conditions such as dermatitis or urticaria; or immune system disorders such as acquired immunodeficiency syndrome (AIDS). The nucleic acids may additionally be used to generate animal models of cell death-associated disorders. The present sequence represents a cell death protective ORF

Sequence 15 BP; 7 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1561 TTATATAAAATACAT 1575  
15 TTATATAAAATACAT 1

Db

RESULT 186  
AAD54049/c  
ID AAD54049 standard; DNA; 15 BP.  
XX  
AC AAD54049;  
XX  
DT 17-JUN-2003 (first entry)  
XX  
DE Human TEM7alpha exon6/intron6 junction DNA.  
XX  
KW Human; tumour endothelial marker 7 alpha; TEM7alpha; osteopetrosis;  
KW osteoporosis; cancer; inflammatory disease; inflammatory bowel disease;  
KW rheumatoid arthritis; arrhythmia; congestive heart failure; hypertension;  
KW myocardial infarction; acute respiratory distress syndrome; bronchospasm;  
KW asthma; angiogenesis; polycystic kidney disease; acute renal failure;  
KW angina; gene therapy; osteopathic; cytostatic; nephrotropic; cardiant;  
ds.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT exon 1. .9  
FT /\*tag= a  
FT /number= 6  
FT /partial  
FT intron 10. .15  
FT /\*tag= b  
FT /number= 6  
FT /partial  
XX  
PN WO200297110-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 28-MAY-2002; 2002WO-US016639.  
XX  
PR 25-MAY-2001; 2001US-0293852P.  
XX  
PA (AMGE-) AMGEN INC.  
XX  
PI Juan T, Bass MB, Oliner JD;  
XX

PT New nucleic acid encoding a tumor suppressor or marker, used for  
PT diagnosis, monitoring progress or treatment, and gene therapy of breast  
PT cancer.  
XX Example 5; Page 50; 120pp; English.  
PS  
XX This sequence represents a PCR primer used in a differential display  
CC experiment to amplify a human antizua1-1 (AZ-1) DNA fragment sequence  
CC (see AA290111). The AZ-1 gene is located on chromosome 10q26, and encodes  
CC a protein that acts as a tumour suppressor or marker of malignancy  
CC progression or reversion. The AZ-1 protein is a tumour suppressor, it  
CC interacts with E-cadherin and beta-catenin. Detecting low levels of AZ-1  
CC nucleotide or amino acid sequences are used to diagnose a breast cell  
CC malignancy, also for monitoring disease progression, particularly  
CC assessment of therapeutic efficacy. The nucleotide sequence is used in in  
CC vivo or ex vivo gene therapy, and AZ-1 polypeptides are used for treating  
CC or preventing breast cancer. AZ-1 polypeptides are also used to raise  
CC specific antibodies, for diagnostic detection of AZ-1. Fragments of the  
CC AZ-1 nucleotide sequence are useful as probes or primers for detecting  
CC expression of the AZ-1 gene  
XX  
SQ Sequence 15 BP; 3 A; 0 C; 1 G; 11 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1040 AAGTTTCTTTT 1054  
DB 1 AAGTTTCTTTT 15  
RESULT 183  
AAF53972  
ID AAF53972 standard; DNA; 15 BP.  
XX  
AC AAF53972;  
XX  
DT 30-MAR-2001 (first entry)  
XX  
DE IGF-I oligonucleotide #4932.  
XX  
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;  
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;  
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;  
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
KW hyperneovascular condition; hyperplasia; kidney disease;  
KW neovascular condition of the retina; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200078341-A1.  
XX  
PD 28-DEC-2000.  
XX  
PF 21-JUN-2000; 2000WO-AU000693.  
XX  
PR 21-JUN-1999; 99US-0140345P.  
XX  
PA (MURD-) MURDOCH CHILDRENS RES INST.  
XX  
PI Wright CJ, Werther GA, Edmondson SR;  
XX  
DR WPI; 2001-041421/05.  
XX  
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
PT inhibits or reduces growth factor mediated cell proliferation and/or  
PT inflammation.  
XX  
PS Example 8; Page 93; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of  
CC skin disorders. The method comprises contacting the skin with an  
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
CC inhibiting or reducing growth factor mediated cell proliferation,  
CC inflammation and/or other disorders. The present sequence is an  
CC oligonucleotide which can be used to design the antisense  
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-  
CC F45161). The method is useful for ameliorating the effects of psoriasis,  
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,  
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
CC hyperneovascular condition such as a neovascular condition of the retina,  
CC brain or skin, growth factor-mediated malignancies, other sclerotic  
CC disease, kidney disease, hyperproliferation of the inside of blood  
CC vessels or any other hyperplasia  
XX  
SQ Sequence 15 BP; 5 A; 3 C; 6 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 241 GGGCAACTGGACACA 255  
DB 1 GGGGAACTGGACACA 15  
RESULT 184  
AAF77611/c  
ID AAF77611 standard; DNA; 15 BP.  
XX  
AC AAF77611;  
XX  
DT 29-MAY-2001 (first entry)  
XX  
DE Modified transcription initiation site Paramyxovirus related oligo #31.  
XX  
KW Transcription initiation sequence; viral vector; vaccine; therapy; ds.  
XX  
OS Unidentified.  
XX  
PN WO200118223-A1.  
XX  
PD 15-MAR-2001.  
XX  
PF 06-SEP-2000; 2000WO-JP006051.  
XX  
PR 06-SEP-1999; 99JP-00252231.  
XX  
PA (DNAV-) Dनावेक रेस इं.  
XX  
PI Nagai Y, Kato A, Hasegawa M;  
XX  
DR WPI; 2001-244576/25.  
XX  
PT Paramyxovirus vectors with modified transcription initiation sequences  
PT for increased expression of foreign genes in production of drugs and  
PT vaccines.  
XX  
PS Example 1; Fig 2; 65pp; Japanese.  
XX  
CC The present invention describes a paramyxovirus vector DNA in which the  
CC transcription initiation sequence has been modified to modify the  
CC expression of a gene located downstream of the transcription initiation  
CC sequence. This is useful in the production of mutant paramyxovirus  
CC vectors with elevated gene expression and a more rapid proliferation than  
CC the wild-type vector, which can then be used for more efficient  
CC production of drug substances and vaccines  
XX  
SQ Sequence 15 BP; 9 A; 1 C; 1 G; 4 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 15;

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX Disclosure; SEQ ID NO 8637; Opp; English.  
PS The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 200 AAATCCAAGAAATGCAG 216  
Db | | | | | | | | | | | | | | | |  
1 AGATCCAAGAACTGCAG 17  
RESULT 181  
ACN69859  
ID ACN69859 standard; DNA; 17 BP.  
XX ACN69859;  
AC  
XX 02-DEC-2004 (first entry)  
DT Human GDMLP-1 probe SEQ ID NO:6761.  
DE  
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX Homo sapiens.  
OS  
XX US2004137589-A1.  
PN  
XX 15-JUL-2004.  
PD  
XX 26-NOV-2003; 2003US-00723361.  
PF  
XX 26-MAY-2000; 2000US-0207456P.  
PR  
XX 21-SEP-2000; 2000US-0234687P.  
PR  
XX 27-SEP-2000; 2000US-0236359P.  
PR  
XX 04-OCT-2000; 2000GB-00024263.  
PR  
XX 30-JAN-2001; 2001WO-US000661.  
PR  
XX 30-JAN-2001; 2001WO-US000662.  
PR  
XX 30-JAN-2001; 2001WO-US000663.  
PR  
XX 30-JAN-2001; 2001WO-US000664.  
PR  
XX 30-JAN-2001; 2001WO-US000665.  
PR  
XX 30-JAN-2001; 2001WO-US000666.  
PR  
XX 30-JAN-2001; 2001WO-US000667.  
PR  
XX 30-JAN-2001; 2001WO-US000668.  
PR  
XX 30-JAN-2001; 2001WO-US000669.  
PR  
XX 30-JAN-2001; 2001WO-US000670.  
PR  
XX 05-FEB-2001; 2001US-0266860P.  
PR  
XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX Disclosure; SEQ ID NO 6761; Opp; English.  
PS The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 506 GTGGAGCTCATGGAGAC 522  
Db | | | | | | | | | | | | | | | |  
1 GAGGAGCTCTGGAGAC 17  
RESULT 182  
AAZ90118  
ID AAZ90118 standard; DNA; 15 BP.  
XX AAZ90118;  
AC  
XX 19-MAY-2000 (first entry)  
DT PCR primer H-T11A used to amplify AZ-1.  
DE  
XX Antizuai-1; AZ-1; human; breast cancer; ss; PCR primer;  
KW tumour suppressor; malignancy progression marker; malignancy reversion.  
KW Homo sapiens.  
OS  
XX WO200000503-A1.  
PN  
XX 06-JAN-2000.  
PD  
XX 25-JUN-1999; 99WO-US014482.  
PF  
XX 26-JUN-1998; 98US-0090747P.  
PR  
XX (CHEN/) CHEN H.  
PA (BISS/) BISSELL M.  
XX  
PI Chen H, Bissell M;  
XX WPI; 2000-170903/15.  
DR  
XX

CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 874 TTTGATGCTGTCACTAC 890  
Db 17 TTTGATGCTGTCAGCAC 1  
  
RESULT 179  
ACN73532/c  
ID ACN73532 standard; DNA; 17 BP.  
XX  
AC ACN73532;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:10434.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
DR  
XX  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.  
XX Disclosure; SEQ ID NO 10434; Opp; English.  
PS  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 868 TTGAGTTTGTGCTGT 884  
Db 17 TCGACTTTGTGCTGT 1  
  
RESULT 180  
ACN71735  
ID ACN71735 standard; DNA; 17 BP.  
XX  
AC ACN71735;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:8637.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.



XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human NOGO  
CC receptor inozyme substrate sequence.

XX  
SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 34 CTCCTGCAGGCCACTGC 50  
| | | | | | | | | | | | | | | | | |  
Db 17 CTCCTGCAGGCCCGCAGC 1

RESULT 177  
ADF90161  
ID ADF90161 standard; DNA; 17 BP.  
XX  
AC ADF90161;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
DE Blocking probe used in Listeria detection.  
XX  
KW probe; Listeria; ss.  
XX  
OS Synthetic.  
XX  
PN WO2003100076-A2.  
XX  
PD 04-DEC-2003.  
XX  
PF 13-MAY-2003; 2003WO-US014951.  
XX  
PR 17-MAY-2002; 2002US-0381132P.  
XX  
PA (APPL-) APPLERA CORP.  
PA (WISC ) WISCONSIN ALUMNI RES FOUND.  
XX  
PI Hyldeg-Nielsen JJ, Rigby S, Brehm-Stecher B, Johnson EA;  
XX WPI; 2004-035157/03.  
XX  
PT New PNA probe comprising a probing nucleobase sequence, useful for  
PT detecting, identifying or quantitating Listeria in a sample.  
XX  
PS Claim 40; SEQ ID NO 35; 47pp; English.  
XX  
CC The present sequence is that of a blocking probe which can be used with  
CC peptide nucleic acid (PNA) probes of the invention ADF90127-ADF90152 for  
CC detecting, identifying and quantifying Listeria genus organisms or  
CC Listeria monocytes in a sample by in situ hybridisation. PNA probes,  
CC probe sets, methods and kits of the invention provide sensitive and  
CC reliable detection, and can be used for determination of Listeria spp. or  
CC Listeria monocytes in food, beverages, water, pharmaceutical samples  
CC products, personal care products, dairy products, environmental samples  
CC and clinical samples.

SQ Sequence 17 BP; 6 A; 1 C; 3 G; 7 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 120 CTTAGAAAAATTTTATG 136  
| | | | | | | | | | | | | | | | | |  
Db 1 CTGAGAAATAATTTTATG 17

RESULT 178  
ACN73526/c  
ID ACN73526 standard; DNA; 17 BP.  
XX  
AC ACN73526;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:10428.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10428; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human NOGO  
CC receptor inozyme substrate sequence.  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 33 GCTCCTGCAGGCCACTG 49  
Db 17 GCTCCTGCAGGCCGCAG 1  
RESULT 175  
ADL49415  
ID ADL49415 standard; RNA; 17 BP.  
XX  
AC ADL49415;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human PKR substrate sequence #529.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
OS Unidentified.  
XX  
FN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX  
PF 03-APR-2002; 2002WO-US010512.  
XX  
PR 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX WPI; 2003-058513/05.  
XX  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 59; SEQ ID NO 2948; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human PKR  
CC substrate sequence.  
XX  
SQ Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.1e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
QY 907 TTTTCTTCAAGACAG 923  
Db 1 UUUUUUUUAAAGACAG 17  
RESULT 176  
ADL46696/c  
ID ADL46696 standard; RNA; 17 BP.  
XX  
AC ADL46696;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human NOGO receptor inozyme substrate sequence #129.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis;  
KW NOGO receptor inozyme; substrate; ds.  
XX  
OS Unidentified.  
XX  
FN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX  
PF 03-APR-2002; 2002WO-US010512.  
XX  
PR 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX WPI; 2003-058513/05.  
XX  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 9; SEQ ID NO 229; 317pp; English.

PI Tuijnder M, Telerman A, Amson R;  
XX WPI; 2003-250498/25.  
XX New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.  
XX Claim 1; Page 613; 798pp; French.  
XX This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX  
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1346 GATCTAACCAATTGAA 1362  
Db 1 GATCTCAGCAATTGAA 17  
  
RESULT 173  
ADL50557/c  
ID ADL50557 standard; RNA; 17 BP.  
XX  
AC ADL50557;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human PKR substrate sequence #1671.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
OS Unidentified.  
XX  
PN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX  
PF 03-APR-2002; 2002WO-US010512.  
XX  
PR 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX WPI; 2003-058513/05.  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 59; SEQ ID NO 4090; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human PKR  
CC substrate sequence.  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 2 G; 0 T; 3 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 14 TGAAGTTTCTTCTAATA 30  
Db 17 TGAGGTTTCTTCTGATA 1  
  
RESULT 174  
ADL46697/c  
ID ADL46697 standard; RNA; 17 BP.  
XX  
AC ADL46697;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human NOGO receptor inozyme substrate sequence #130.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis;  
KW NOGO receptor inozyme; substrate; ds.  
XX  
OS Unidentified.  
XX  
PN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX  
PF 03-APR-2002; 2002WO-US010512.  
XX  
PR 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX WPI; 2003-058513/05.  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 9; SEQ ID NO 230; 317pp; English.

RESULT 170  
ADI50768/c  
ID ADI50768 standard; DNA; 17 BP.  
XX  
AC ADI50768;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human tumour suppression/reversion-related DNA sequence SeqID3271.  
XX  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW cytosstatic; virucide; neuroprotective; nootropic; neuroleptic; probe;  
KW primer; PCR; gene chip; antisense; viral disease; tumour;  
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025177-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313354/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; SEQ ID NO 3271; 30pp; French.  
XX  
CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytosstatic, virucide, neuroprotective,  
CC nootropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, indentifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
XX  
SQ Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 562 GCCTTTGGACCTGGATC 578  
Db 17 GCCTTTGNACTTGATC 1  
  
RESULT 171  
ACC52701  
ID ACC52701 standard; DNA; 17 BP.  
XX  
AC ACC52701;  
XX  
DT 27-JUN-2003 (first entry)  
XX

DE Human tumour suppressor sequence #1468.  
XX  
KW ss; tumour suppressor; antitumour; cytosstatic; tumour suppression;  
KW tumour regression; apoptosis; virus resistance; diagnosis;  
KW cellular degeneration.  
XX  
OS Homo sapiens.  
XX  
PN FR2826373-A1.  
XX  
PD 27-DEC-2002.  
XX  
PF 20-JUN-2001; 2001FR-00008139.  
XX  
PR 20-JUN-2001; 2001FR-00008139.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB SA.  
XX  
PI Tuijnder M, Telerman A, Amson R;  
XX  
DR WPI; 2003-250498/25.  
XX  
PT New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.  
XX  
PS Claim 1; Page 379; 798pp; French.  
XX  
CC This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX  
SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 720 GTTCCCCCACCCTACAAAT 736  
Db 1 GATCCCCCACCCTCCAAAT 17  
  
RESULT 172  
ACC53715  
ID ACC53715 standard; DNA; 17 BP.  
XX  
AC ACC53715;  
XX  
DT 27-JUN-2003 (first entry)  
XX  
DE Human tumour suppressor sequence #2482.  
XX  
KW ss; tumour suppressor; antitumour; cytosstatic; tumour suppression;  
KW tumour regression; apoptosis; virus resistance; diagnosis;  
KW cellular degeneration.  
XX  
OS Homo sapiens.  
XX  
PN FR2826373-A1.  
XX  
PD 27-DEC-2002.  
XX  
PF 20-JUN-2001; 2001FR-00008139.  
XX  
PR 20-JUN-2001; 2001FR-00008139.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB SA.  
XX



CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
xx  
SQ Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 903 GATCTTTTCTTCAAAG 919  
|||||  
Db 1 GATCCTTTTCTTGAAAG 17

RESULT 168	
ADI52571	
ID	ADI52571 standard; DNA; 17 BP.
XX	
XX	
AC	ADI52571;
XX	
DT	15-APR-2004 (first entry)
XX	
DE	Human tumour suppression/reversion-related DNA sequence SeqID5074.
XX	
KW	tumour suppression; tumour reversion; apoptosis; virus resistance;
KW	cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
KW	primer; PCR; gene chip; antisense; viral disease; tumour;
KW	cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity	88.2%;	Pred. NO. 1.1e+02;
Matches	15;	Conservative
	0;	Mismatches
	2;	Indels
	0;	Gaps
QY	720	GTTCCTCCACCTACAAAT
		736
Db	1	GATCCCCCACCTCCAAAT
		17

RESULT 169  
ADI52496  
ID ADI52496 standard: DNA: 17 BP.

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels

Qy 1346 GATCTAACCAATTGAA 1362  
|||||  
Db 1. GATCTCAGCAATTGAA 17

CC The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
SQ Sequence 17 BP; 6 A; 5 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1346 GATCTAACCAATTGGAA 1362  
||||| ||||| ||||| |||||  
Db 1 GATCCAACCACTTTGAA 17

RESULT 166  
ADI51278  
ID ADI51278 standard; DNA; 17 BP.  
XX  
AC ADI51278;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human tumour suppression/reversion-related DNA sequence SeqID3781.  
XX  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;  
KW primer; PCR; gene chip; antisense; viral disease; tumour;  
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025177-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313354/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; SEQ ID NO 3781; 30pp; French.  
XX  
CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC probes and primers for detecting, identifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC development of compounds with a cytostatic, virucide, neuroprotective,

CC nontropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, indentifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration. The  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpat\_sequences  
XX  
SQ Sequence 17 BP; 3 A; 2 C; 2 G; 10 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 903 GATCTTTTCTTCAAAG 919  
||||| ||||| ||||| |||||  
Db 1 GATCTTTTCTTTCATAG 17  
  
RESULT 167  
ADI49691  
ID ADI49691 standard; DNA; 17 BP.  
XX  
AC ADI49691;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human tumour suppression/reversion-related DNA sequence SeqID2194.  
XX  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;  
KW primer; PCR; gene chip; antisense; viral disease; tumour;  
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025177-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313354/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; SEQ ID NO 2194; 30pp; French.  
XX  
CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC nontropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, indentifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The

XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX  
PS Disclosure; Page 33; 771pp; French.  
XX  
CC The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1346 GATCTAACCAATTGAA 1362  
Db 1 GATCTCAGCAATTGAA 17  
RESULT 164  
ADB41975  
ID ADB41975 standard; DNA; 17 BP.  
XX  
AC ADB41975;  
XX  
DT 18-DEC-2003 (revised)  
DT 04-DEC-2003 (first entry)  
XX  
DE Tumour suppression/reversion associated nucleotide #2298.  
XX  
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX  
OS Homo sapiens.  
XX  
PN WO2003040369-A2.  
XX  
PD 15-MAY-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004219.  
XX  
PR 17-SEP-2001; 2001FR-00011981.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-441574/41.  
XX  
PT New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related

PT polypeptide and antibodies.  
XX  
PS Disclosure; Page 300; 771pp; French.  
XX  
CC The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 720 GTTCCCCACCTACAAAT 736  
Db 1 GATCCCCACCTCCAAAT 17  
RESULT 165  
ADB44591  
ID ADB44591 standard; DNA; 17 BP.  
XX  
AC ADB44591;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Tumour suppression/reversion associated nucleotide #4914.  
XX  
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX  
OS Homo sapiens.  
XX  
PN WO2003040369-A2.  
XX  
PD 15-MAY-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004219.  
XX  
PR 17-SEP-2001; 2001FR-00011981.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-441574/41.  
XX  
PT New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX  
PS Disclosure; Page 606; 771pp; French.  
XX



XX Mus musculus.  
OS  
XX WO2003025176-A2.  
PN  
XX 27-MAR-2003.  
PD  
XX  
PF 17-SEP-2002; 2002WO-IB004210.  
XX  
PR 17-SEP-2001; 2001FR-00011979.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX WPI; 2003-333167/31.  
DR  
XX  
XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; Page 693; 738pp; French.  
XX  
XX The present invention relates to murine oligonucleotides (ACC62754-  
CC ACC68806), which are associated with tumour suppression, tumour  
CC reversion, apoptosis and virus resistance. The oligonucleotides are  
CC useful as (1) as probes and primers for detecting, identifying,  
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
CC recombinant polypeptides. The oligonucleotides are useful for preparation  
CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia  
XX  
SQ Sequence 17 BP; 7 A; 2 C; 5 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 535 GATGCAAAAGGTGGAAT 551  
DB 1 GATCACAAGGTGGAAT 17  
  
RESULT 162  
ADB43853/c  
ID ADB43853 standard; DNA; 17 BP.  
XX  
AC ADB43853;  
XX  
DT 18-DEC-2003 (revised)  
DT 04-DEC-2003 (first entry)  
DE Tumour suppression/reversion associated nucleotide #4176.  
XX  
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX  
OS Homo sapiens.  
XX  
PN WO2003040369-A2.  
XX  
PD 15-MAY-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004219.  
XX  
PR 17-SEP-2001; 2001FR-00011981.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX

PI Telerman A, Amson R, Tuijnder M;  
XX WPI; 2003-441574/41.  
DR  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX  
PS Disclosure; Page 520; 771pp; French.  
XX  
XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
SQ Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 562 GCTTTTGGACCTGGATC 578  
DB 17 GCTTTTGAACCTTGATC 1  
  
RESULT 163  
ADB39685  
ID ADB39685 standard; DNA; 17 BP.  
XX  
AC ADB39685;  
XX  
DT 18-DEC-2003 (revised)  
DT 04-DEC-2003 (first entry)  
XX  
DE Tumour suppression/reversion associated nucleotide #8.  
XX  
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX  
OS Homo sapiens.  
XX  
PN WO2003040369-A2.  
XX  
PD 15-MAY-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004219.  
XX  
PR 17-SEP-2001; 2001FR-00011981.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX WPI; 2003-441574/41.  
DR





CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy, or in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MDZ3, MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic acids and proteins are also useful for diagnosing or monitoring a disease caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic acids can also be used as probes to detect and characterize gross alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are useful in constructing microarrays for measuring gene expression. The proteins are useful as therapeutic agents for gene therapy or as vaccines. The present sequence was used to illustrate the invention.

XX  
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 261 CCTGGAGATGATGCACG 277  
Db 1 CCTGGAGATGAGACACG 17

RESULT 157  
ADB04816  
ID ADB04816 standard; DNA; 17 BP.  
XX  
AC ADB04816;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ12 scanning oligonucleotide SEQ ID 5802.  
XX  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1281758-A2.  
XX  
PD 05-FEB-2003.  
XX  
PF 30-JUL-2002; 2002EP-00016874.  
XX  
PR 02-AUG-2001; 2001US-00922181.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
PT New zinc finger-containing proteins and nucleic acids, useful in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MDZ3, MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
PS Example 8; SEQ ID NO 5802; 103pp; English.  
XX  
CC The present invention relates to novel human zinc finger-containing proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2, MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy, or in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MDZ3, MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic acids and proteins are also useful for diagnosing or monitoring a disease caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic acids can also be used as probes to detect and characterize gross alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are useful in constructing microarrays for measuring gene expression. The proteins are useful as therapeutic agents for gene therapy or as vaccines. The present sequence was used to illustrate the invention.

CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are useful in constructing microarrays for measuring gene expression. The proteins are useful as therapeutic agents for gene therapy or as vaccines. The present sequence was used to illustrate the invention.

XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 GACAATTCAGAACACG 851  
Db 1 GACAATTCAGAACACG 17

RESULT 158  
ADA99700  
ID ADA99700 standard; DNA; 17 BP.  
XX  
AC ADA99700;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ3 scanning oligonucleotide SEQ ID 689.  
XX  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1281758-A2.  
XX  
PD 05-FEB-2003.  
XX  
PF 30-JUL-2002; 2002EP-00016874.  
XX  
PR 02-AUG-2001; 2001US-00922181.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
PT New zinc finger-containing proteins and nucleic acids, useful in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MDZ3, MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
PS Example 8; SEQ ID NO 689; 103pp; English.  
XX  
CC The present invention relates to novel human zinc finger-containing proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2, MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy, or in manufacturing a medicament for treating or preventing a disorder associated with decreased or increased expression or activity of MDZ3, MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic acids and proteins are also useful for diagnosing or monitoring a disease caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic acids can also be used as probes to detect and characterize gross alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are useful in constructing microarrays for measuring gene expression. The proteins are useful as therapeutic agents for gene therapy or as vaccines. The present sequence was used to illustrate the invention.

XX  
SQ Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; Page 296; 720pp; French.  
XX  
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
CC given in the specification, a sequence containing at least 15 consecutive  
CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
CC hybridizes to them under highly stringent conditions, or the complement  
CC of any of them, or the corresponding RNA. The novel isolated nucleic  
CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 720 GTTCCCCACCTACAAAT 736  
| | | | | | | | | | | | | | | | | |  
Db 1 GATCCCCACCTCCAAAT 17

RESULT 155  
ADA99699  
ID ADA99699 standard; DNA; 17 BP.  
XX  
AC ADA99699;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ3 scanning oligonucleotide SEQ ID 688.  
XX  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1281758-A2.  
XX  
PD 05-FEB-2003.  
XX  
PF 30-JUL-2002; 2002EP-00016874.  
XX  
PR 02-AUG-2001; 2001US-00922181.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
PT New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder

PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
PS Example 8; SEQ ID NO 688; 103pp; English.  
XX  
CC The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 ACCCTGGAGATGATGCA 275  
| | | | | | | | | | | | | | | | | |  
Db 1 ACCCTGGAGATGAGACA 17

RESULT 156  
ADA99701  
ID ADA99701 standard; DNA; 17 BP.  
XX  
AC ADA99701;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ3 scanning oligonucleotide SEQ ID 690.  
XX  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1281758-A2.  
XX  
PD 05-FEB-2003.  
XX  
PF 30-JUL-2002; 2002EP-00016874.  
XX  
PR 02-AUG-2001; 2001US-00922181.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
PT New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
PS Example 8; SEQ ID NO 690; 103pp; English.  
XX  
CC The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,

XX WO2003031621-A2.  
PN 17-APR-2003.  
XX 11-OCT-2002; 2002WO-US032599.  
XX 12-OCT-2001; 2001US-0329000P.  
PR (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
XX Zhang J;  
XX WPI; 2003-381720/36.  
DR New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,  
XX investigating and/or treating disorders associated with aberrant  
PT expression or activity of GPCR-A-1, such as tumors and cancers.  
XX  
XX Example 2; SEQ ID NO 1322; 156pp; English.  
PS The invention describes an isolated nucleic acid encoding a G protein  
XX coupled receptor (GPCR), mutations of which cause cancer, comprising a  
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a  
CC 409 residue amino acid sequence, all given in the specification, with or  
CC without conservative amino acid substitutions, or complements of the  
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in  
CC length. The methods and compositions of the present invention are useful  
CC for diagnosing, investigating and/or treating disorders associated with  
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.  
CC This sequence represents an oligonucleotide used to analyse the gene  
CC encoding human G-protein coupled receptor GPCR-A-1  
XX  
SQ Sequence 17 BP; 5 A; 3 C; 2 G; 7 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1461 CAGCTTAATAAGTATTT 1477  
Db 1 CTGCTCAATAAGTATTT 17  
  
RESULT 153  
ABT34768  
ID ABT34768 standard; DNA; 17 BP.  
XX  
AC ABT34768;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
XX Tumour suppression related human fukutin oligo SEQ ID No 405.  
DE  
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
XX Homo sapiens.  
OS  
XX WO2003025175-A2.  
XX  
PN 27-MAR-2003.  
XX  
PD 17-SEP-2002; 2002WO-IB004208.  
XX  
PF 17-SEP-2001; 2001FR-00011978.  
XX  
PR (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PA Telerman A, Amson R, Tuijnder M;  
XX  
PI WPI; 2003-313353/30.  
XX

DR WPI; 2003-313353/30.  
XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; Page 81; 720pp; French.  
XX  
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
CC given in the specification, a sequence containing at least 15 consecutive  
CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
CC alignment, at least 80 % identity to the 17 mer sequence, or a sequence that  
CC hybridizes to them under highly stringent conditions, or the complement  
CC of any of them, or the corresponding RNA. The novel isolated nucleic  
CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
XX related human fukutin oligonucleotide of the invention  
SQ Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 903 GATCTTTTCTTCAAAAG 919  
Db 1 GATCCTTTTCTTGAAAG 17  
  
RESULT 154  
ABT36617  
ID ABT36617 standard; DNA; 17 BP.  
XX  
AC ABT36617;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
XX Tumour suppression related human fukutin oligo SEQ ID No 2254.  
DE  
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
XX Homo sapiens.  
OS  
XX WO2003025175-A2.  
XX  
PN 27-MAR-2003.  
XX  
PD 17-SEP-2002; 2002WO-IB004208.  
XX  
PF 17-SEP-2001; 2001FR-00011978.  
XX  
PR (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PA Telerman A, Amson R, Tuijnder M;  
XX  
PI WPI; 2003-313353/30.  
DR  
XX



```
RESULT 150
ACN09806
ID ACN09806 standard; RNA; 17 BP.
XX
AC ACN09806;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Inozyme substrate SEQ ID NO 9809.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
DR
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 9809; 495pp; English.
PS
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 7 A; 2 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 305 ATCATTTCAGGGAAATG 321
|:|:|:|:|:|:|:|:|
Db 1 AUCAAUUCAGUGAAUG 17
RESULT 151
ACN05603/c
ID ACN05603 standard; RNA; 17 BP.
XX
AC ACN05603;
XX
DT 22-APR-2004 (first entry)
XX
```

```
XX WNV Amberzyme substrate SEQ ID NO 5606.
DE
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
DR
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 5606; 495pp; English.
PS
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 1 C; 7 G; 0 T; 7 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1341 CCAAGGATCTAACCAAT 1357
|:|:|:|:|:|:|:|:|
Db 17 CCAAGCATCCAACCAAT 1
RESULT 152
ACD00825
ID ACD00825 standard; DNA; 17 BP.
XX
AC ACD00825;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1298.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
```

CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX Sequence 17 BP; 5 A; 4 C; 3 G; 0 T; 5 U; 0 Other; 0;  
SQ

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.1e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 761 TCTCTGCTGATGACATA 777  
Db 1 UCUAUGCUGAGACACA 17  
:|:|:|:|:|:|

RESULT 148  
ACN03239/c  
ID ACN03239 standard; RNA; 17 BP.  
XX  
AC ACN03239;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV Inozyme substrate SEQ ID NO 3242.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 3242; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 5 A; 3 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 305 ATCATTTTCAGGAAATG 321  
Db 17 ATCAATTCAGTGAATG 1  
|||||

RESULT 149  
ACN01009/c  
ID ACN01009 standard; RNA; 17 BP.  
XX  
AC ACN01009;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV Hammerhead Ribozyme substrate SEQ ID NO 999.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 999; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
: Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 911 TCTTCAAAGACAGGTTTC 927  
Db 17 TCTTCACAGACGGGTTTC 1  
|||||

PS Claim 23; SEQ ID NO 9326; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

XX SQ Sequence 17 BP; 7 A; 7 C; 1 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 76.5%; Pred. No. 1.1e+02;  
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1341 CCAAGGATCTAACCRAAT 1357  
Db 1 CCAAGCAUCCAACCAU 17

RESULT 146  
ACN14538  
ID ACN14538 standard; RNA; 17 BP.

XX AC ACN14538;

XX 22-APR-2004 (first entry)

XX WNV minus strand Amberzyme substrate SEQ ID NO 14541.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.  
(BLAT/) BLATT L.  
(MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 14541; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

XX SQ Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.1e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 911 TCITCAAGACAGGTTTC 927  
Db 1 UCUUCACAGACGGGUUC 17

RESULT 147  
ACN07069  
ID ACN07069 standard; RNA; 17 BP.

XX AC ACN07069;

XX 22-APR-2004 (first entry)

XX WNV Amberzyme substrate SEQ ID NO 7072.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.  
(BLAT/) BLATT L.  
(MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 7072; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

PA (THOM/) THOMPSON J.  
XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;  
PI Grupe A;  
XX WPI; 2002-217145/27.  
DR Enzymatic polynucleotide that down regulates expression of chloride  
XX channel calcium activated gene, useful for treating Chronic obstructive  
PT pulmonary disease (COPD), chronic bronchitis and asthma.  
PT Claim 4; Page 75; 152pp; English.  
XX The invention relates to enzymatic nucleic acid molecules that down  
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes  
CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
CC useful as pharmaceutical agents for treating conditions such as chronic  
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
CC that are related to or will respond to the levels of CLCA1 in a cell or  
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
CC hence, are useful for treatment of a patient having a condition  
CC associated with the level of CLCA1, where the invention further comprises  
CC the use of one or more therapies under conditions suitable for the  
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The  
CC nucleic acids of the invention are also used as diagnostic tools to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of CLCA1 RNA in a cell. This sequence represents an  
CC enzymatic nucleic acid molecule of the invention  
XX  
SQ Sequence 17 BP; 10 A; 4 C; 2 G; 0 T; 1 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 484 GACATTTTGGTGGTTT 500  
Db 17 GCCATTTTGGTGGTTT 1  
  
RESULT 144  
ACN07730/C  
ID ACN07730 standard; RNA; 17 BP.  
AC ACN07730;  
XX 22-APR-2004 (first entry)  
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7733.  
DE  
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX WO200268637-A2.  
PN 06-SEP-2002.  
XX 19-OCT-2001; 2001WO-US048350.  
PF 20-OCT-2000; 2000US-0242411P.  
PR (RIBO-) RIBOZYME PHARM INC.  
XX (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX Blatt L, Mcswiggen JA;  
PI WPI; 2002-217145/27.

XX WPI; 2002-706994/76.  
DR New nucleic acid molecule that modulates replication of West Nile Virus  
XX (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
PT Claim 23; SEQ ID NO 7733; 495pp; English.  
XX The invention relates to nucleic acid molecules that modulate replication  
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 761 TCTCTGCTGATGACATA 777  
Db 17 TCTATGCTGATGACACA 1  
  
RESULT 145  
ACN09323  
ID ACN09323 standard; RNA; 17 BP.  
XX ACN09323;  
AC 22-APR-2004 (first entry)  
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9326.  
DE  
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX WO200268637-A2.  
PN 06-SEP-2002.  
XX 19-OCT-2001; 2001WO-US048350.  
PF 20-OCT-2000; 2000US-0242411P.  
PR (RIBO-) RIBOZYME PHARM INC.  
XX (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX Blatt L, Mcswiggen JA;  
PI WPI; 2002-706994/76.  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
XX (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
PT



XX Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX Example 2; Page 218; 718pp; English.  
PS  
XX The present invention relates to human testis expressed Patched like  
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX  
SQ Sequence 17 BP; 9 A; 0 C; 5 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1143 GAAAGAAATTGATGCAG 1159  
Db 1 GAAAGAAATTGAGGTAG 17  
  
RESULT 142  
ABK19347/c  
ID ABK19347 standard; RNA; 17 BP.  
XX  
AC ABK19347;  
XX  
DT 09-APR-2002 (first entry)  
XX  
DE Human ERG Amberzyme target sequence Seq ID No 1994.  
XX  
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;  
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
KW angiofibroma of tuberos sclerosis; port-wine stain; wound healing;  
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;  
KW amberzyme.  
XX  
OS Homo sapiens.  
XX  
PN WO200188124-A2.  
XX  
PD 22-NOV-2001.  
XX  
PF 16-MAY-2001; 2001WO-US015866.  
XX  
PR 16-MAY-2000; 2000US-00572021.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (GLAX ) GLAXO GROUP LTD.  
PA  
XX  
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;  
XX

DR WPI; 2002-082995/11.  
XX  
PT Novel polynucleotide which down regulates expression of Ets-related gene,  
PT useful for treating cancer, diabetic retinopathy, macular degeneration,  
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
XX  
PS Claim 4; Page 126; 149pp; English.  
XX  
CC The invention relates to a nucleic acid molecule (I) which down regulates  
CC expression of an Ets-related gene (ERG). (I) is useful for treating  
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,  
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
CC vulgaris, angiofibroma of tuberos sclerosis, port-wine stains, Sturge  
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu  
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
CC treating a patient having a condition associated with the level of ERG,  
CC by contacting cells of the patient with (I) under conditions suitable for  
CC the treatment. The method comprises the use of one or more therapies  
CC under conditions suitable for the treatment. Leukaemia or tumour  
CC angiogenesis is treated by administering (I) to the patient in  
CC conjunction with one or more of other therapies such as radiation or  
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and  
CC diseases related to the expression of ERG, and as diagnostic tool to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of ERG RNA in a cell. (I) is useful for specifically  
CC targeting genes that share homology with ERG gene or ERG fusion genes.  
CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
CC related PCR primers of the invention  
XX  
SQ Sequence 17 BP; 7 A; 1 C; 4 G; 0 T; 5 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1620 ACTCTACTATTAAGTTT 1636  
Db 17 ACTCTACTCTAAAGTTT 1  
  
RESULT 143  
ABK56577/c  
ID ABK56577 standard; RNA; 17 BP.  
XX  
AC ABK56577;  
XX  
DT 02-JUL-2002 (first entry)  
XX  
DE Human CLCA1 gene enzymatic nucleic acid #948.  
XX  
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;  
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;  
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;  
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;  
KW acetylcysteine.  
XX  
OS Homo sapiens.  
XX  
PN WO200211674-A2.  
XX  
PD 14-FEB-2002.  
XX  
PF 09-AUG-2001; 2001WO-US024970.  
XX  
PR 09-AUG-2000; 2000US-0224383P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (SYNT ) SYNTEX USA LLC.

PI Zhang J;  
XX WPI; 2002-479509/51.  
DR  
XX  
XX  
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX  
XX  
PS Example 2; Page 266; 418pp; English.  
XX  
CC The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
SQ Sequence 17 BP; 3 A; 4 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 568 GGACCTGGATCTGGCAT 584  
Db 1 GCACCTGGATTGGCAT 17  
RESULT 140  
ABV79930  
ID ABV79930 standard; DNA; 17 BP.  
XX  
AC ABV79930;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 1176.  
XX  
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1229046-A2.  
XX  
PD 07-AUG-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001167.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 23-MAY-2001; 2001US-00864761.  
PR 09-OCT-2001; 2001US-0327898P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhan J;  
XX  
DR WPI; 2002-676582/73.  
XX  
PT Novel isolated human testis expressed Patched like protein (HTPL), useful

PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX  
PS Example 2; Page 218; 718pp; English.  
XX  
CC The present invention relates to human testis expressed Patched like  
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX  
SQ Sequence 17 BP; 9 A; 0 C; 4 G; 4 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1142 TGAATAAATGTGATGCA 1158  
Db 1 TGAATAAATGTGAGGTA 17  
RESULT 141  
ABV79931  
ID ABV79931 standard; DNA; 17 BP.  
XX  
AC ABV79931;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 1177.  
XX  
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1229046-A2.  
XX  
PD 07-AUG-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001167.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 23-MAY-2001; 2001US-00864761.  
PR 09-OCT-2001; 2001US-0327898P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhan J;  
XX  
DR WPI; 2002-676582/73.

CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 874 TTTGATGCTGTCACTAC 890  
Db 17 TTTGATGCTGTGACGAC 1  
  
RESULT 138  
ABN10442/c  
ID ABN10442 standard; DNA; 17 BP.  
XX  
AC ABN10442;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10434.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000US-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
DR  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 10434; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 868 TTGAGTTTTTGATGCTGT 884  
Db 17 TCGACTTTTGATGCTGT 1  
  
RESULT 139  
ABQ64120  
ID ABQ64120 standard; DNA; 17 BP.  
XX  
AC ABQ64120;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 833.  
XX  
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX



RESULT 136  
ABN06769  
ID ABN06769 standard; DNA; 17 BP.  
XX AC ABN06769;  
XX DT 29-MAY-2002 (first entry)  
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6761.  
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN WO200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX PA (AEOM-) AEOMICA INC.  
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX PS Disclosure; SEQ ID NO 6761; 214pp; English.  
XX CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX

SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 506 GTGGAGCTCATGGAGAC 522  
DB 1 GAGGAGCTCTGGAGAC 17  
RESULT 137  
ABN10436/c  
ID ABN10436 standard; DNA; 17 BP.  
XX AC ABN10436;  
XX DT 29-MAY-2002 (first entry)  
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10428.  
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN WO200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX PA (AEOM-) AEOMICA INC.  
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX PS Disclosure; SEQ ID NO 10428; 214pp; English.  
XX CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as



PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
XX  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
PS Claim 88; Page 73; 200pp; English.  
XX  
CC The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a hammerhead ribozyme of the invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 2 G; 0 T; 6 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 908 TTTTCTTCAAGACAGG 924  
Db | ||||| ||||| |||||  
17 TGTCTTCAAGAAAGG 1  
  
RESULT 135  
ABN08645  
ID ABN08645 standard; DNA; 17 BP.  
XX  
AC ABN08645;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8637.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
PF  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
DR  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 8637; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 200 AAATCCAAGAAATGCAG 216  
Db | ||||| ||||| |||||  
1 AGATCCAAGAACTGCAG 17

CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a DNzyme molecule of the invention  
XX  
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.1e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
  
QY 477 CATGGCTGACATTTTGG 493  
Db 1 CAGGGCUGACAUGUGG 17  
  
RESULT 133  
ABK00330  
ID ABK00330 standard; RNA; 17 BP.  
XX  
AC ABK00330;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human NOGO Hammerhead Ribozyme #330.  
XX  
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX  
DR WPI; 2001-607195/69.  
XX  
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
PS Claim 88; Page 71; 200pp; English.  
XX  
CC The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The

CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a hammerhead ribozyme of the invention  
XX  
SQ Sequence 17 BP; 8 A; 2 C; 2 G; 0 T; 5 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.1e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1145 AAAAAATTGATGCAGCT 1161  
Db 1 AAAAAUUAUUAUGCAGCU 17  
  
RESULT 134  
ABK00480/c  
ID ABK00480 standard; RNA; 17 BP.  
XX  
AC ABK00480;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human NOGO Hammerhead Ribozyme #480.  
XX  
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.

```
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 6 A; 2 C; 1 G; 8 T; 0 U; 0 Other;
      Query Match      0.8%; Score 13.8; DB 1; Length 17;
      Best Local Similarity 88.2%; Pred. No. 1.1e+02;
      Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      898 AATAAGATCTTTTCTT 914
      || ||||| |||||
Db      1 AACAGATATTTTCTT 17

RESULT 131
AAF03080
ID      AAF03080 standard; DNA; 17 BP.
XX
AC      AAF03080;
XX
DT      16-FEB-2001 (first entry)
XX
DE      Hammerhead ribozyme substrate #1375.
XX
KW      Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW      interferon alpha; ss.
XX
OS      Homo sapiens.
XX
PN      WO200061729-A2.
XX
PD      19-OCT-2000.
XX
PF      11-APR-2000; 2000WO-US009721.
XX
PR      12-APR-1999; 99US-0129390P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
WPI; 2000-647423/62.
XX
PT      Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT      useful for producing e.g. granulocyte colony stimulating factor protein,
PT      interferon alpha and erythropoietin.
XX
PS      Claim 37; Page 87; 164pp; English.
XX
CC      The present invention relates to enzymatic and antisense nucleic acid
CC      molecules that act as inhibitors of the expression of repressor genes
CC      encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC      factor gene, IRF-2 and/or the CAAT Displacement protein (CDP).
CC      Inhibition of the repressors removes prevents inhibition (and
CC      consequently increases expression of) genes involved in the production of
CC      erythropoietin, granulocyte colony stimulating factor protein and
CC      interferon alpha
XX
SQ      Sequence 17 BP; 5 A; 3 C; 1 G; 8 T; 0 U; 0 Other;
      Query Match      0.8%; Score 13.8; DB 1; Length 17;
      Best Local Similarity 88.2%; Pred. No. 1.1e+02;
      Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      901 AAGATCTTTTCTTCAA 917
      ||||| |||||
Db      1 AAGATATTTTCTTCCA 17

RESULT 132
ABK03648
ID      ABK03648 standard; RNA; 17 BP.
XX
```

```
AC      ABK03648;
XX
DT      12-MAR-2002 (first entry)
XX
DE      Human CD20 DNazyme #102.
XX
KW      Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW      cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW      muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW      DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW      B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW      human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW      MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW      inflammatory arthropathy; central nervous system injury;
KW      cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW      chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW      Parkinson's disease; ataxia; Huntington's disease;
KW      Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS      Homo sapiens.
OS      Synthetic.
XX
PN      WO200159103-A2.
XX
PD      16-AUG-2001.
XX
PF      09-FEB-2001; 2001WO-US004273.
XX
PR      11-FEB-2000; 2000US-0181797P.
PR      28-FEB-2000; 2000US-0185516P.
PR      06-MAR-2000; 2000US-0187128P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
PA      (BLAT/) BLATT L.
PA      (MCSW/) MCSWIGGEN J.
PA      (CHOW/) CHOWRIRA B M.
XX
PI      Blatt L, Mcswiggen J, Chowrira BM;
XX
WPI; 2001-607195/69.
XX
DR
XX
PT      Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT      constructs, which down regulate expression of a CD20 gene or neurite
PT      growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT      central nervous system injury.
XX
PS      Claim 30; Page 161; 200pp; English.
XX
CC      The invention relates to a nucleic acid molecule which down regulates
CC      expression of a CD20 gene and a nucleic acid molecule which down
CC      regulates expression of a neurite growth inhibitor gene (NOGO). The
CC      nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC      DNazyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC      possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC      an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC      with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC      of CD20 in the presence of a divalent cation that is preferably Mg2+.
CC      Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC      the cell and treat a patient having a condition associated with the level
CC      of CD20. The treatment may further comprise the use of one or more
CC      therapies. In particular, the CD20 targetting nucleic acid may be used to
CC      treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC      Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC      leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC      lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC      immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC      targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC      presence of a divalent cation that is preferably Mg2+. Furthermore, the
CC      nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC      cell and treat a patient having a condition associated with the level of
CC      NOGO. The treatment may further comprise the use of one or more
CC      therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC      treat central nervous system (CNS) injury and cerebrovascular accident
```



PS Claim 77; Page 71; 148pp; English.

XX The present invention describes nucleic acids (A) that interact stably

CC with a target sequence and contain at least one phosphoro(di)thioate

CC link, having endonuclease activity. (A), and more generally any catalytic

CC nucleic acid (A') that modulates expression of the oestrogen receptor

CC gene, are used to treat cancer (particularly of breast or endometrium),

CC in vivo or by transforming cells ex vivo and implanting treated cells, or

CC for other conditions associated with levels of oestrogen receptor.

CC Because of the high selectivity for targeted RNA, (A) can also be used to

CC correlate inhibition of gene expression with alterations in phenotype,

CC particularly for identification of therapeutic targets, and as research

CC reagents (for RNA, in the same way that restriction endonucleases are

CC used with DNA). The combination of modifications in (A) improves

CC resistance to nucleases, binding affinity and/or activity. AAA23503 to

CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and

CC AAA24748 to AAA25992 represent their corresponding target sequences.

CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme

CC sequences, and AAA26107 to AAA26218 represent their corresponding target

CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and

CC antisense oligonucleotides used in the exemplification of the present

CC invention

XX

SQ Sequence 17 BP; 2 A; 1 C; 2 G; 12 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1523 GTATCATATAAAATAAAA 1539

Db 17 GTAACACAAAAATAAAA 1

RESULT 129

AA25187/c

ID AA25187 standard; DNA; 17 BP.

XX

AC AA25187;

XX

DT 19-JUL-2000 (first entry)

XX

DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1685.

XX

KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;

KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;

KW gene expression modification; cancer; phosphorothioate; endonuclease;

KW anticancer; breast cancer; endometrium cancer; ss.

XX

OS Homo sapiens.

XX

PN WO9954459-A2.

XX

PD 28-OCT-1999.

XX

PF 19-APR-1999; 99WO-US008547.

XX

PR 20-APR-1998; 98US-0082404P.

PR 23-JUN-1998; 98US-00103636.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;

PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;

PI Matulic-Adamic J;

XX

DR WPI; 2000-013248/01.

XX

PT New nucleic acids that interact, and optionally cleave, target sequences,

PT used to treat cancer.

XX

PS Claim 77; Page 71; 148pp; English.

XX

CC The present invention describes nucleic acids (A) that interact stably

CC with a target sequence and contain at least one phosphoro(di)thioate

CC link, having endonuclease activity. (A), and more generally any catalytic

CC nucleic acid (A') that modulates expression of the oestrogen receptor

CC gene, are used to treat cancer (particularly of breast or endometrium),

CC in vivo or by transforming cells ex vivo and implanting treated cells, or

CC for other conditions associated with levels of oestrogen receptor.

CC Because of the high selectivity for targeted RNA, (A) can also be used to

CC correlate inhibition of gene expression with alterations in phenotype,

CC particularly for identification of therapeutic targets, and as research

CC reagents (for RNA, in the same way that restriction endonucleases are

CC used with DNA). The combination of modifications in (A) improves

CC resistance to nucleases, binding affinity and/or activity. AAA23503 to

CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and

CC AAA24748 to AAA25992 represent their corresponding target sequences.

CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme

CC sequences, and AAA26107 to AAA26218 represent their corresponding target

CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and

CC antisense oligonucleotides used in the exemplification of the present

CC invention

XX

SQ Sequence 17 BP; 3 A; 1 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1522 TGATCATATAAAATAAAA 1538

Db 17 TGTACACAAAAATAAAA 1

RESULT 130

AAF03078

ID AAF03078 standard; DNA; 17 BP.

XX

AC AAF03078;

XX

DT 16-FEB-2001 (first entry)

XX

DE Hammerhead ribozyme substrate #1373.

XX

KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;

KW interferon alpha; ss.

XX

OS Homo sapiens.

XX

PN WO200061729-A2.

XX

PD 19-OCT-2000.

XX

PF 11-APR-2000; 2000WO-US009721.

XX

PR 12-APR-1999; 99US-0129390P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Blatt L, Zwick M, Pavco P, Mcswiggen J;

XX

DR WPI; 2000-647423/62.

XX

PT Enzymatic and antisense nucleic acid inhibition of repressor genes,

PT useful for producing e.g. granulocyte colony stimulating factor protein,

PT interferon alpha and erythropoietin.

XX

PS Claim 37; Page 87; 164pp; English.

XX

CC The present invention relates to enzymatic and antisense nucleic acid

CC molecules that act as inhibitors of the expression of repressor genes

CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription

CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).

CC Inhibition of the repressors removes prevents inhibition (and

CC consequently increases expression of) genes involved in the production of



CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberos scleriosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 5 A; 2 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 AAGTTTACAATGAAGTT 20  
|||||||  
Db 17 AAGTTTACAAGAAGTT 1

RESULT 127  
AAA23041  
ID AAA23041 standard; RNA; 17 BP.  
XX  
AC AAA23041;  
XX  
DT 19-JUN-2000 (first entry)  
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6267.  
XX  
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytosstatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9950403-A2.  
XX  
PD 07-OCT-1999.  
XX  
PF 24-MAR-1999; 99WO-US0006507.  
XX  
PR 27-MAR-1998; 98US-0079678P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
XX  
DR WPI; 1999-591315/50.  
XX  
PT Novel ribozymes for modulating the synthesis, expression and/or stability  
PT of an mRNA encoding an angiogenic factors.  
XX  
PS Claim 54; Page 258; 305pp; English.  
XX  
CC The present invention describes enzymatic nucleic acid molecules with RNA

CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberos scleriosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 4 A; 1 C; 1 G; 0 T; 11 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 29.4%; Pred. No. 1.1e+02;  
Matches 5; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

QY 1037 ATCAAGTTTTTCTTTT 1053  
|:|||||: : : :  
Db 1 AUCAAGUUUUUAUUUU 17

RESULT 128  
AAA25186/c  
ID AAA25186 standard; DNA; 17 BP.  
XX  
AC AAA25186;  
XX  
DT 19-JUL-2000 (first entry)  
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1684.  
XX  
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9954459-A2.  
XX  
PD 28-OCT-1999.  
XX  
PF 19-APR-1999; 99WO-US008547.  
XX  
PR 20-APR-1998; 98US-0082404P.  
PR 23-JUN-1998; 98US-00103636.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
PI Matulic-Adamic J;  
XX  
DR WPI; 2000-013248/01.  
XX  
PT New nucleic acids that interact, and optionally cleave, target sequences,  
PT used to treat cancer.  
XX

CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberos scleriosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 0 T; 6 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.1e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
  
QY 643 AACTTGTTCTCCTCACTGC 659  
Db 1 AACUCGUUCCUCAUUGC 17  
  
RESULT 125  
AAAA23042  
ID AAA23042 standard; RNA; 17 BP.  
XX  
AC AAA23042;  
XX  
DT 19-JUN-2000 (first entry)  
XX  
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6268.  
XX  
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytotstatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX  
OS Homo sapiens.  
XX  
XN WO9950403-A2.  
XX  
PD 07-OCT-1999.  
XX  
PF 24-MAR-1999; 99WO-US006507.  
XX  
PR 27-MAR-1998; 98US-0079678P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
XX  
DR WPI; 1999-591315/50.  
XX  
PT Novel ribozymes for modulating the synthesis, expression and/or stability  
PT of an mRNA encoding an angiogenic factors.  
XX  
PS Claim 54; Page 258; 305pp; English.  
XX  
CC The present invention describes enzymatic nucleic acid molecules with RNA  
CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA18385 and AAA19087 to  
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC and AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberos scleriosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 4 A; 1 C; 1 G; 0 T; 11 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 29.4%; Pred. No. 1.1e+02;  
Matches 5; Conservative 10; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1038 TCAAGTTTTCCTTTT 1054  
Db 1 UCAAGUUUUUUUUUA 17  
  
RESULT 126  
AAA18827/c  
ID AAA18827 standard; RNA; 17 BP.  
XX  
AC AAA18827;  
XX  
DT 19-JUN-2000 (first entry)  
XX  
DE Human TIE-2 substrate sequence SEQ ID NO:2053.  
XX  
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytotstatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX  
OS Homo sapiens.  
XX  
XN WO9950403-A2.  
XX  
PD 07-OCT-1999.  
XX  
PF 24-MAR-1999; 99WO-US006507.  
XX  
PR 27-MAR-1998; 98US-0079678P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
XX  
DR WPI; 1999-591315/50.  
XX  
PT Novel ribozymes for modulating the synthesis, expression and/or stability  
PT of an mRNA encoding an angiogenic factors.  
XX  
PS Claim 56; Page 119; 305pp; English.  
XX  
CC The present invention describes enzymatic nucleic acid molecules with RNA  
CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their





KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
OS Mus sp.  
XX  
XX  
PN WO9715662-A2.  
XX  
PD 01-MAY-1997.  
XX  
XX  
PF 25-OCT-1996; 96WO-US017480.  
XX  
XX 26-OCT-1995; 95US-0005974P.  
PR 11-JAN-1996; 96US-00584040.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX  
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
XX WPI; 1997-259017/23.  
XX  
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
XX  
XX Claim 4; Page 158; 218pp; English.  
XX  
XX The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 9 A; 3 C; 4 G; 0 T; 1 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1679 TGCTCTGTAAGTTGCTT 1695  
Db 17 TGCTCTCTTAGTTGCTT 1  
  
RESULT 121  
AAX68927  
ID AAX68927 standard; RNA; 17 BP.  
XX  
AC AAX68927;  
XX  
DT 28-JUL-1999 (first entry)  
XX  
DE Human flt1 VEGF receptor hammerhead ribozyme substrate #222.  
XX  
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO9715662-A2.  
PN  
XX  
PD 01-MAY-1997.  
XX

PF 25-OCT-1996; 96WO-US017480.  
XX  
XX 26-OCT-1995; 95US-0005974P.  
PR 11-JAN-1996; 96US-00584040.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX  
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
XX WPI; 1997-259017/23.  
XX  
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
XX  
XX Claim 4; Page 53; 218pp; English.  
XX  
XX The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 6 A; 3 C; 1 G; 0 T; 7 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 1.1e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1066 TACTGGTTAATTAGCAA 1082  
Db 1 UACUCGUUAAUUAUCAA 17  
  
RESULT 122  
AAV97951  
ID AAV97951 standard; RNA; 17 BP.  
XX  
AC AAV97951;  
XX  
DT 17-MAR-1999 (first entry)  
XX  
DE Human EGF-R target sequence nucleotide position 5188.  
XX  
KW Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;  
KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;  
KW cancer; genetic drift; detection; mutation; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO9833893-A2.  
PN  
XX  
PD 06-AUG-1998.  
XX  
XX 14-JAN-1998; 98WO-US000730.  
PF  
XX  
XX 31-JAN-1997; 97US-0036476P.  
PR 04-DEC-1997; 97US-00985162.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (UYAS-) UNIV ASTON.  
XX  
XX Akhtar S, Fell P, Mcswiggen JA;  
XX WPI; 1998-437449/37.  
XX  
XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal  
PT





CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.1e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
QY 918 AGACAGGTTCTTCTGGC 934  
Db 1 AGACAGGUAUUCUGGC 17  
RESULT 116  
AAX63966  
ID AAX63966 standard; RNA; 17 BP.  
XX  
AC AAX63966;  
XX  
DT 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hammerhead target SEQ ID NO:598.  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
XX  
PN WO9618736-A2.  
XX  
PD 20-JUN-1996.  
XX  
PF 22-NOV-1995; 95WO-US015516.  
XX  
PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
PS Example 1; Page 155; 307pp; English.  
XX  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance

CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 7 A; 2 C; 4 G; 0 T; 4 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 1.1e+02;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;  
QY 1144 AAAAAAATTGATGCAGC 1160  
Db 1 AGAAAAAUUGAUGCUGC 17  
RESULT 117  
AAX71351  
ID AAX71351 standard; RNA; 17 BP.  
XX  
AC AAX71351;  
XX  
DT 28-JUL-1999 (first entry)  
XX  
DE Human KDR VEGF receptor hammerhead ribozyme substrate #363.  
XX  
KW Vascular endothelial growth factor receptor; VEGF receptor; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9715662-A2.  
XX  
PD 01-MAY-1997.  
XX  
PF 25-OCT-1996; 96WO-US017480.  
XX  
PR 26-OCT-1995; 95US-0005974P.  
PR 11-JAN-1996; 96US-00584040.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX  
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
XX  
DR WPI; 1997-259017/23.  
XX  
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
XX  
PS Claim 4; Page 108; 218pp; English.  
XX  
CC The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX

RESULT 1114  
AAX63909  
ID AAX63909 standard; RNA; 17 BP.  
XX AC AAX63909;  
XX DT 20-JUL-1999 (first entry)  
XX DE Rabbit stromelysin hammerhead target SEQ ID NO:541.  
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX OS Oryctolagus cuniculus.  
XX PN WO9618736-A2.  
XX PD 20-JUN-1996.  
XX PF 22-NOV-1995; 95WO-US015516.  
XX PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX PA (RIBO-) RIBOZYME PHARM INC.  
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX DR WPI; 1996-300653/30.  
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX PS Example 1; Page 154; 307pp; English.  
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX SQ Sequence 17 BP; 5 A; 2 C; 4 G; 0 T; 6 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 1.1e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 908 TTTTCTTCAAAAGACAGG 924  
: : : : :  
Db 1 UGUUCUUUAAAGACAGG 17  
RESULT 115  
AAX63910  
ID AAX63910 standard; RNA; 17 BP.  
XX AC AAX63910;  
XX DT 20-JUL-1999 (first entry)  
XX DE Rabbit stromelysin hammerhead target SEQ ID NO:542.  
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX OS Oryctolagus cuniculus.  
XX PN WO9618736-A2.  
XX PD 20-JUN-1996.  
XX PF 22-NOV-1995; 95WO-US015516.  
XX PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX PA (RIBO-) RIBOZYME PHARM INC.  
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX DR WPI; 1996-300653/30.  
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX PS Example 1; Page 154; 307pp; English.  
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention

OS Homo sapiens.  
XX US2004137589-A1.  
PN  
XX 15-JUL-2004.  
PD  
XX 26-NOV-2003; 2003US-00723361.  
PF  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX  
DR Novel myosin-like protein-1, useful for treating or preventing disorder  
XX associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10430; Opp; English.  
XX  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGMLP-1, or as an inhibitor of hGMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA' 886  
Db 16 TTTTGATGCTGTCA 3  
RESULT 113  
AAX63973  
ID AAX63973 standard; RNA; 17 BP.  
XX  
AC AAX63973;  
XX

DT 20-JUL-1999 (first entry)  
XX Rabbit stromelysin hammerhead target SEQ ID NO:605.  
DE  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
PN WO9618736-A2.  
XX  
PD 20-JUN-1996.  
XX  
PF 22-NOV-1995; 95WO-US015516.  
XX  
PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
PS Example 1; Page 155; 307pp; English.  
XX  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 3 G; 0 T; 7 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.1e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1186 ACCTACTTCTTTGTAGA 1202  
Db 1 ACAUACUUCUUGUGGA 17



XX Homo sapiens.  
OS  
XX  
PN WO2003025177-A2.  
XX  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
XX WPI; 2003-313354/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; SEQ ID NO 1211; 30pp; French.  
XX  
CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC nootropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, indentifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
XX  
SQ Sequence 17 BP; 4 A; 4 C; 1 G; 8 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 893 TGGGAATAAGATC 906  
|||||  
Db 14 TGGGAATAAGATC 1  
  
RESULT 111  
ACN73527/c  
ID ACN73527 standard; DNA; 17 BP.  
XX  
AC ACN73527;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:10429.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX

PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUIY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10429; 0pp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 873 TTTTGATGCTGTCA 886  
|||||  
Db 17 TTTTGATGCTGTCA 4  
  
RESULT 112  
ACN73528/c  
ID ACN73528 standard; DNA; 17 BP.  
XX  
AC ACN73528;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:10430.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX

RESULT 108  
ADB00378/c  
ID ADB00378 standard; DNA; 17 BP.  
XX  
AC ADB00378;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ3 scanning oligonucleotide SEQ ID 1364.  
XX  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1281758-A2.  
XX  
PD 05-FEB-2003.  
XX  
PF 30-JUL-2002; 2002EP-00016874.  
XX  
PR 02-AUG-2001; 2001US-00922181.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
CC New zinc finger-containing proteins and nucleic acids, useful in  
CC manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
PS Example 8; SEQ ID NO 1364; 103pp; English.  
XX  
CC The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 6 A; 6 C; 3 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 929 TCTGGCTGAAGGTT 942  
Db 14 TCTGGCTGAAGTT 1  
RESULT 109  
ADB00374/c  
ID ADB00374 standard; DNA; 17 BP.  
XX  
AC ADB00374;  
XX

DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ3 scanning oligonucleotide SEQ ID 1360.  
XX  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1281758-A2.  
XX  
PD 05-FEB-2003.  
XX  
PF 30-JUL-2002; 2002EP-00016874.  
XX  
PR 02-AUG-2001; 2001US-00922181.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
CC New zinc finger-containing proteins and nucleic acids, useful in  
CC manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
PS Example 8; SEQ ID NO 1360; 103pp; English.  
XX  
CC The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 930 CTGGCTGAAGGTTT 943  
Db 17 CTGGCTGAAGGTTT 4  
RESULT 110  
ADI48708/c  
ID ADI48708 standard; DNA; 17 BP.  
XX  
AC ADI48708;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human tumour suppression/reversion-related DNA sequence SeqID1211.  
XX  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW cytosstatic; virucide; neuroprotective; nootropic; neuroleptic; probe;  
KW primer; PCR; gene chip; antisense; viral disease; tumour;  
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10430.

DE Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.

KW

XX Homo sapiens.

OS

XX WO200192524-A2.

PN

XX 06-DEC-2001.

XX

XX 25-MAY-2001; 2001WO-US016981.

PF

XX 26-MAY-2000; 2000US-0207456P.

PR

PR 21-SEP-2000; 2000US-0234687P.

PR

PR 27-SEP-2000; 2000US-0236359P.

PR

PR 04-OCT-2000; 2000GB-00024263.

PR

PR 30-JAN-2001; 2001WO-US000661.

PR

PR 30-JAN-2001; 2001WO-US000662.

PR

PR 30-JAN-2001; 2001WO-US000663.

PR

PR 30-JAN-2001; 2001WO-US000664.

PR

PR 30-JAN-2001; 2001WO-US000665.

PR

PR 30-JAN-2001; 2001WO-US000666.

PR

PR 30-JAN-2001; 2001WO-US000667.

PR

PR 30-JAN-2001; 2001WO-US000668.

PR

PR 30-JAN-2001; 2001WO-US000669.

PR

PR 30-JAN-2001; 2001WO-US000670.

PR

PR 05-FEB-2001; 2001US-0266860P.

XX

PA (AEOM-) AEOMICA INC.

XX

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

PI

XX WPI; 2002-179446/23.

DR

XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,

PT

PT or as specific biomolecule capture probes for surface-enhanced laser

PT

PT desorption ionization, comprises human myosin-like protein hGDMLP-1.

XX

PS Disclosure; SEQ ID NO 10430; 214pp; English.

XX

CC The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequence

XX

SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886

Db 16 TTTTGATGCTGTCA 3

RESULT 107

ABT36548/c

ID ABT36548 standard; DNA; 17 BP.

XX

AC ABT36548;

XX

DT 12-JUN-2003 (first entry)

XX

DE Tumour suppression related human fukutin oligo SEQ ID No 2185.

XX

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizopphrenia; protein chip; gene therapy; tumour suppression;

KW human fukutin; ds.

XX

OS Homo sapiens.

XX

PN WO2003025175-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004208.

XX

PR 17-SEP-2001; 2001FR-00011978.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijnder M;

XX

DR WPI; 2003-313353/30.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; Page 288; 720pp; French.

XX

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15 consecutive

CC nucleotides from the 17 mer sequence, a sequence with, after optimal

CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that

CC hybridizes to them under highly stringent conditions, or the complement

CC of any of them, or the corresponding RNA. The novel isolated nucleic

CC acids of the invention are useful as probes and primers for detecting,

CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

CC component of a gene chip, in vitro as (anti)sense reagents, and for

CC production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizopphrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention

XX

SQ Sequence 17 BP; 11 A; 1 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1580 TTTTTCATTTTGA 1593

Db 16 TTTTTCATTTTGA 3



XX Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX Claim 88; Page 114; 200pp; English.  
XX The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving a NYN motif) pr  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
CC an amberyyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a VGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a DNzyme molecule of the invention  
XX Sequence 17 BP; 10 A; 0 C; 5 G; 0 T; 2 U; 0 Other;  
SQ Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 969 TTTAATTCTCTCCT 982  
Db |||||||||  
14 TTTAATTCTCTCCT 1  
RESULT 105  
ABN10437/C  
ID ABN10437 standard; DNA; 17 BP.  
XX ABN10437;  
XX 29-MAY-2002 (first entry)  
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10429.  
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
OS WO200192524-A2.  
XX  
PN  
XX

PD 06-DEC-2001.  
XX 25-MAY-2001; 2001WO-US016981.  
PF 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX (AEOM-) AEOMICA INC.  
PA Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
PI WPI; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
or as specific biomolecule capture probes for surface-enhanced laser  
desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX Disclosure; SEQ ID NO 10429; 214pp; English.  
PS The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 873 TTTTGATGCTGTCA 886  
Db |||||||||  
17 TTTTGATGCTGTCA 4  
RESULT 106  
ABN10438/C  
ID ABN10438 standard; DNA; 17 BP.  
XX AC ABN10438;  
XX 29-MAY-2002 (first entry)  
DT



DE H. pylori strain J99 genome fragment SEQ ID NO:58.  
XX ds; stroke; phosphodiesterase 4D; PDE4D.  
XX Helicobacter pylori.  
OS  
XX  
PN US2004091865-A1.  
XX  
PD 13-MAY-2004.  
XX  
PF 25-SEP-2002; 2002US-00255120.  
XX  
PR 19-MAR-2001; 2001US-00811352.  
PR 04-FEB-2002; 2002US-00067514.  
XX  
PA (DECO-) DECODE GENETICS EHF.  
XX  
PI Gretarsdottir S, Jonsdottir S, Reynisdottir ST, Thorleifsson G;  
XX WPI; 2004-374932/35.  
XX  
PT Diagnosing susceptibility to a stroke in an individual comprising  
PT screening for an at-risk haplotype in the phosphodiesterase 4D gene.  
XX  
PS Disclosure; SEQ ID NO 58; 574pp; English.  
XX  
CC The invention relates to a method of diagnosing susceptibility to a  
CC stroke in an individual comprising screening for an at-risk haplotype in  
CC the phosphodiesterase 4D (PDE4D) gene that is more frequently present in  
CC an individual susceptible to stroke (affected) compared to a healthy  
CC individual (control), where the at-risk haplotype increases risk of  
CC stroke significantly. The composition, methods and kit are useful for  
CC diagnosing, predicting of clinical course and treating stroke using  
CC polymorphisms in the PDE4D gene. These may also be used in identifying  
CC agents that enhance or inhibit PDE4D polypeptide expression or activity.  
CC The present sequence represents a fragment of H. pylori strain J99 genome  
CC which is not referred to at all in the main body of the specification.  
XX  
SQ Sequence 15 BP; 11 A; 2 C; 1 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 198 AAAAATCCAAGAA 211  
Db |||||  
1 AAAAATCCAAGAA 14  
  
RESULT 103  
ADO49479  
ID ADO49479 standard; DNA; 16 BP.  
XX  
AC ADO49479;  
XX  
DT 29-JUL-2004 (first entry)  
XX  
DE H. pylori strain J99 genome fragment SEQ ID NO:102.  
XX  
KW ds; stroke; phosphodiesterase 4D; PDE4D.  
XX Helicobacter pylori.  
OS  
XX  
PN US2004091865-A1.  
XX  
PD 13-MAY-2004.  
XX  
PF 25-SEP-2002; 2002US-00255120.  
XX  
PR 19-MAR-2001; 2001US-00811352.  
PR 04-FEB-2002; 2002US-00067514.  
XX  
PA (DECO-) DECODE GENETICS EHF.

XX  
PI Gretarsdottir S, Jonsdottir S, Reynisdottir ST, Thorleifsson G;  
XX WPI; 2004-374932/35.  
XX  
PT Diagnosing susceptibility to a stroke in an individual comprising  
PT screening for an at-risk haplotype in the phosphodiesterase 4D gene.  
XX  
PS Disclosure; SEQ ID NO 102; 574pp; English.  
XX  
CC The invention relates to a method of diagnosing susceptibility to a  
CC stroke in an individual comprising screening for an at-risk haplotype in  
CC the phosphodiesterase 4D (PDE4D) gene that is more frequently present in  
CC an individual susceptible to stroke (affected) compared to a healthy  
CC individual (control), where the at-risk haplotype increases risk of  
CC stroke significantly. The composition, methods and kit are useful for  
CC diagnosing, predicting of clinical course and treating stroke using  
CC polymorphisms in the PDE4D gene. These may also be used in identifying  
CC agents that enhance or inhibit PDE4D polypeptide expression or activity.  
CC The present sequence represents a fragment of H. pylori strain J99 genome  
CC which is not referred to at all in the main body of the specification.  
XX  
SQ Sequence 16 BP; 11 A; 2 C; 1 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 99;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 197 AAAAATCCAAGAA 210  
Db |||||  
3 AAAAATCCAAGAA 16  
  
RESULT 104  
ABK02203/c  
ID ABK02203 standard; RNA; 17 BP.  
XX  
AC ABK02203;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human NOGO DNazyme #115.  
XX  
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.

CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.2; DB 1; Length 19;  
Best Local Similarity 84.2%; Pred. No. 1.2e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 204 CCAAGAAATGCAGCACTTC 222  
Db 1 CCAAGAAGTGCTGCATTC 19  
  
RESULT 100  
ABZ02308/c  
ID ABZ02308 standard; DNA; 50 BP.  
XX  
AC ABZ02308;  
XX  
DT 09-JAN-2003 (first entry)  
XX  
DE Human leukocyte gene expression profiling probe SEQ ID NO 2299.  
XX  
KW T7; leukocyte; gene expression profiling; allograft rejection;  
KW atherosclerosis; congestive heart failure; systemic lupus erythematosus;  
KW rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;  
KW ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200257414-A2.  
XX  
PD 25-JUL-2002.  
XX  
PF 22-OCT-2001; 2001WO-US047856.  
XX  
PR 20-OCT-2000; 2000US-0241994P.  
PR 08-JUN-2001; 2001US-0296764P.  
XX  
PA (BIOC-) BIOCARDIA INC.  
XX  
PI Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;  
PI Ly N, Woodward R, Quertemous T, Johnson F;  
XX  
DR WPI; 2002-636525/68.  
XX  
PT New system for leukocyte expression profiling, diagnosing a disease, or  
PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis  
PT or congestive heart failure, comprises diagnostic oligonucleotides.  
XX  
PS Claim 1; Page 399; Opp; English.  
XX  
CC The invention relates to a system for detecting gene expression, which  
CC comprises one or two isolated DNA molecules that detect expression of a  
CC gene, where the gene corresponds to any of 8143 oligonucleotides  
CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful  
CC for leukocyte expression profiling. It is particularly useful for  
CC diagnosing a disease, monitoring (rate of) progression of a disease,  
CC predicting therapeutic outcome, determining prognosis for a patient,  
CC predicting disease complications in an individual or monitoring response  
CC to treatment in an individual. The diseases include cardiac allograft  
CC rejection, kidney allograft rejection, liver allograft rejection,  
CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,  
CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection  
XX  
SQ Sequence 50 BP; 14 A; 11 C; 8 G; 17 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.2; DB 1; Length 50;  
Best Local Similarity 58.1%; Pred. No. 1.4e+02;  
Matches 25; Conservative 0; Mismatches 18; Indels 0; Gaps 0;  
  
QY 1314 TTCTAAAAACAATACTACTATTCTTCCAGGATCTTAACCAA 1356  
Db 50 TGCCAGAAGTAAGTATAATTCTCAGTCCCAAGGATGTAGGAA 8  
  
RESULT 101  
AAZ90906  
ID AAZ90906 standard; DNA; 15 BP.  
XX  
AC AAZ90906;  
XX  
DT 24-MAY-2000 (first entry)  
XX  
DE Human NR8 gene probe #134.  
XX  
KW Haemopoietin receptor family; NR8; antibody; diagnosis;  
KW blood formation disorder; fusion protein; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9967290-A1.  
XX  
PD 29-DEC-1999.  
XX  
PF 23-JUN-1999; 99WO-JP003351.  
XX  
PR 24-JUN-1998; 98JP-00214720.  
PR 19-OCT-1998; 98JP-00297409.  
XX  
PA (CHUS ) CHUGAI RES INST MOLECULAR MEDICINE INC.  
XX  
PI Nomura H, Maeda M;  
XX  
DR WPI; 2000-116933/10.  
XX  
PT Hemopoietin receptor protein family NR8 used for diagnosis of blood  
PT formation disorders.  
XX  
PS Example 1; Page 44; 176pp; Japanese.  
XX  
CC The invention relates to the isolation of sequences encoding human  
CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences  
CC were initially searched for comparison on a nucleic acid database with  
CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid  
CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-  
CC Z90925 represent specific examples of probe sequences used in the search.  
CC Antibodies to the NR8 family proteins are used for the diagnosis of blood  
CC formation disorders. Compounds identified as binding to the proteins are  
CC used for the treatment of such disorders  
XX  
SQ Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 507 TGGAGCTCATGGAG 520  
Db 1 TGGAGCTCATGGAG 14  
  
RESULT 102  
ADO49435  
ID ADO49435 standard; DNA; 15 BP.  
XX  
AC ADO49435;  
XX  
DT 29-JUL-2004 (first entry)  
XX

PR 29-MAY-2001; 2001US-0294170P.  
XX (SEQU-) SEQUELLA INC.  
PA (YOUN/) YOUNG D B.  
PA (STEW/) STEWART G R.  
PA (OGAO/) O'GAORA P C E.  
XX Young DB, Stewart GR, O'gaora PCE;  
XX WPI; 2002-698637/75.  
DR Immunogenic composition of mycobacterial mutants with modified protein  
XX production capabilities, useful for vaccinating and treating infections  
PT in particular mycobacterial diseases such as tuberculosis and Crohn's  
PT disease.  
XX Example 2; Page 22; 59pp; English.  
XX The invention relates to an immunogenic composition of mycobacterial  
CC mutants with modified protein production capabilities. The invention also  
CC relates to methods for the treatment and prevention of infectious  
CC diseases. The methods and compositions of the invention are useful for  
CC vaccinating and treating infections in particular mycobacterial diseases  
CC such as tuberculosis and Crohn's disease. The invention is also used in  
CC gene therapy. The present sequence is a PCR primer used for amplifying  
CC Mycobacterium tuberculosis deltapr mutant gene. This sequence is used  
CC to illustrate the method of the invention  
XX  
SQ Sequence 18 BP; 5 A; 4 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 623 CTACACATTTCAGGAGG 638  
DB 16 CTACATATTTCAGGAGG 1  
RESULT 98  
ABX03799  
ID ABX03799 standard; cDNA; 18 BP.  
XX  
AC ABX03799;  
XX  
DT 09-JAN-2003 (first entry)  
XX  
DE DNA encoding secreted protein signal peptide sequence #8.  
XX  
KW Differential display method; leucine-rich motif; transmembrane protein;  
KW secreted protein; secreted protein signal peptide; ss.  
XX  
OS Unidentified.  
XX  
PN WO200259259-A2.  
XX  
PD 01-AUG-2002.  
XX  
PF 23-JAN-2002; 2002WO-IL000071.  
XX  
PR 23-JAN-2001; 2001US-0263158P.  
XX  
PA (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.  
XX  
PI Wreschner DH;  
XX  
XX WPI; 2002-599769/64.  
DR P-PSDB; ABG98328.  
XX  
PT Differential display method for identifying secreted or transmembrane  
PT protein, comprises contacting a DNA with a first primer that hybridizes  
PT to a sequence coding for a leucine-rich motif and with a second  
PT oligonucleotide primer.

XX Disclosure; Fig 2; 37pp; English.  
XX  
CC The invention relates to a differential display comprising contacting  
CC cDNA with a first primer that hybridises to an oligonucleic sequence  
CC coding for a leucine-rich motif, and with a second oligonucleotide primer  
CC to form a cDNA-hybrid molecule. The method comprises obtaining mRNA from  
CC at least 2 samples, synthesising cDNA from the RNA of each sample,  
CC contacting the cDNA with a first primer that hybridises to an  
CC oligonucleic sequence coding for a leucine-rich motif, and with a second  
CC oligonucleotide primer to form cDNA-hybrid molecules, amplifying the cDNA  
CC hybrid molecules, detecting amplified products and comparing the  
CC amplified products from each sample to identify distinctive amplified  
CC products coding for at least one secreted or transmembrane protein. The  
CC method is useful for discovering novel secreted and/or transmembrane  
CC proteins which are important for cell processes and play an important  
CC role in determining its phenotype, and which act as mediators for the  
CC transfer of signals from external environment into the cell itself, thus  
CC modulating gene expression. Sequences ABX03792-ABX03869 represent DNA  
CC encoding secreted protein signal peptide sequences  
XX  
SQ Sequence 18 BP; 1 A; 8 C; 5 G; 4 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 30 ACTGCTCCTGCAGGCC 45  
DB 3 ACTGCTCCTGCTGGCC 18  
RESULT 99  
ADI53698  
ID ADI53698 standard; DNA; 19 BP.  
XX  
AC ADI53698;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 11.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX WPI; 2004-123288/12.  
DR  
XX New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 11; 55pp; English.  
XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-

XX 24-SEP-1997; 97WO-US016828.  
PF  
XX  
PR 02-OCT-1996; 96US-00720625.  
XX  
PA (UYNC-) UNIV NORTH CAROLINA.  
PI  
XX Naik UP, Parise LV;  
XX WPI; 1998-240018/21.  
DR  
XX  
XX New isolated calcium-integrin binding protein - is expressed in platelets  
PT and activates the fibrinogen receptor, used to develop products for  
PT treating e.g. vascular disorders.  
XX  
XX  
PS Example 4; Page 34; 44pp; English.  
XX  
XX This is the nucleotide sequence of the PCR primer used in the  
CC amplification of the human calcium-integrin binding (CIB) protein, that  
CC binds to the integrin alpha IIB cytoplasmic domain. The CIB protein is  
CC expressed in platelets and interacts with the alpha IIB subunit of  
CC integrin alpha IIB- beta 3, to activate the fibrinogen receptor.  
CC Inhibitory compounds can be used to inhibit the activation of the  
CC fibrinogen receptor where it is desired to reduce blood coagulation for  
CC therapeutic, diagnostic or pharmaceutical reasons. The products can be  
CC used for treating vascular disorders, and for isolating or purifying  
CC integrins or fibrinogen. They can also be used for detection and  
CC diagnosis  
XX  
SQ Sequence 18 BP; 3 A; 5 C; 5 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 781 GGCATTTCAGTCCCTGT 796  
Db 1 GGCATTTCAGTCGCTGT 16  
  
RESULT 96  
AAV33107  
ID AAV33107 standard; DNA; 18 BP.  
XX  
AC AAV33107;  
XX  
DT 18-NOV-1998 (first entry)  
XX  
DE Stromelysin primer 1.  
XX  
KW Multiplex competitive PCR reaction; MC-PCR; reverse-transcriptase PCR;  
KW RT-PCR; tagging reaction; competitive amplification reaction; primer;  
KW housekeeping gene; Stromelysin; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO9835058-A2.  
XX  
PD 13-AUG-1998.  
XX  
XX 27-JAN-1998; 98WO-US001471.  
PF  
XX 07-FEB-1997; 97US-0037841P.  
PR  
PR 18-DEC-1997; 97US-00993731.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Thompson JD;  
XX  
XX WPI; 1998-447252/38.  
DR  
XX  
PT Determining relative amounts of different nucleic acids by multiplex

PT competitive polymerase chain reaction - involves tagging target and  
PT control sequences then amplification with generic primer pair  
PT corresponding to tagging sequences, used e.g. to determine response to  
XX drugs.  
PS Example 1; Page 23; 45pp; English.  
XX  
XX The present invention provides a method for determining the relative  
CC amounts of two or more different nucleic acid molecules by using the  
CC multiplex competitive PCR reaction (MC-PCR). A MC-PCR reaction involves a  
CC reverse-transcriptase (RT-PCR) reaction followed by a tagging reaction  
CC and a competitive amplification reaction. The RT-PCR reaction uses a  
CC primer #2 to convert target mRNA into cDNA. Primer #1 in combination with  
CC primer #2 is then used to convert the region of the resulting cDNA to be  
CC amplified during the MC-PCR reaction into a double-stranded molecule.  
CC Primers #3 and #4, nested relative to primers #1 and #2 respectively, are  
CC used as tagging primers in the tagging reaction. A forward tagging primer  
CC has a defined sequence at its 5' end (+TAG sequence) while a reverse  
CC tagging primer has a different defined sequence at its 3' end (-TAG  
CC sequence). The purpose of the tagging reaction is to introduce the two  
CC defined sequences at the correct ends of the sequence to be amplified.  
CC The competitive amplification reaction involves using a single pair of  
CC generic primers, whose sequences are complementary to the +TAG and -TAG  
CC sequences, to amplify the different products generated from the cDNAs  
CC during the tagging step. This amplification reaction is competitive due  
CC to the use of a single primer pair to amplify the different target RNAs.  
CC Probe #5, complementary to the region of target RNA being amplified, is  
CC used to specifically detect the amplified product. The MC-PCR reaction  
CC can amplify one or more target mRNAs in a sample using the primer set #1-  
CC #5 for each target mRNA. In the example given, primers #1, #2, #3, #4 and  
CC probe #5 are the Stromelysin primers 1, 2 (AAV33108), 3a (AAV33109) or 3b  
CC (AAV33110), 4 (AAV33111) and probe 5 (AAV33112) respectively. These  
CC primers/probes were used to illustrate the method of the invention. The  
CC method claims to allow detection of low-abundance mRNA in small samples  
CC (e.g. 10 ng is sufficient) with high precision, and uses housekeeping  
CC genes as controls for RNA input and integrity. Also, a large number of  
CC samples may be processed simultaneously, making the process suitable for  
CC high throughput screening, and does not require continuous monitoring  
XX  
SQ Sequence 18 BP; 4 A; 3 C; 5 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1012 GCTGCTTATGAAATTG 1027  
Db 2 GCTGCTCATGAAATTG 17  
  
RESULT 97  
AAD42840/c  
ID AAD42840 standard; DNA; 18 BP.  
XX  
AC AAD42840;  
XX  
DT 27-DEC-2002 (first entry)  
XX  
DE M. tuberculosis deltaxspr mutant gene amplifying primer, PEX1.  
XX  
KW Immunogenic; infection; vaccine; mycobacterial disease; tuberculosis;  
KW Crohn's disease; gene therapy; antiinflammatory; antibacterial; PCR;  
KW primer; ss.  
XX  
OS Mycobacterium tuberculosis.  
XX  
PN WO200267982-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 20-FEB-2002; 2002WO-US005038.  
XX  
PR 20-FEB-2001; 2001US-0269801P.



XX 15-JUL-2004.  
PD 26-NOV-2003; 2003US-00723361.  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX Disclosure; SEQ ID NO 10433; Opp; English.  
PS The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 870 GAGTTTGTGCTGTC 885  
Db 16 GACTTTGTGCTGTC 1  
RESULT 94  
AAT86051/C  
ID AAT86051 standard; cDNA; 18 BP.  
XX AAT86051;  
AC AAT86051;  
XX 20-NOV-1997 (first entry)  
DT  
XX Primer 1 amplifies cDNA's expressed from V-alpha-1 intron promoter.

XX Antisense; T-cell receptor; signalling protein; intron; murine;  
KW V-alpha-1 gene; cytoplasmic tail; Ig-beta; P8.6; primer; amplify;  
KW polymerase chain reaction; PCR; ss.  
XX Synthetic.  
OS WO9704010-A1.  
XX 06-FEB-1997.  
PD 19-JUL-1996; 96WO-US011884.  
XX 20-JUL-1995; 95US-0001270P.  
PR (SYNT ) SYNTX USA INC.  
XX Webb DR, Maeda T;  
PI WPI; 1997-132579/12.  
XX New T-cell receptor V-alpha gene signalling protein - encoded by the  
PT antisense strand of the V-alpha-1 gene, includes proline-rich region and  
PT Tyr-X-X-Ile/Leu signal motif.  
XX Example 4; Page 18; 47pp; English.  
PS The sequences givne in AAT86051-52 are primers which were used to amplify  
XX sequences which have been expressed from a sequence in the murine V-alpha  
CC -1 intron 1. The intronic sequence drives expression of a sequence on the  
CC antisense strand of the T-cell receptor gene which encodes a signalling  
CC protein which comprises a proline rich region, a YxxI/L motif and a  
CC TANYSNI motif. Expression of the signalling protein sequence is  
CC specifically activated by a regulatory element which is found in the  
CC intron of the murine V-alpha-1 gene. The encoded protein has a molecular  
CC weight of 8.6 kD and has a high degree of homology (e.g. 70%) to the  
CC cytoplasmic tail of Ig-beta. The murine signalling protein P8.6 and its  
CC homologues, e.g. from human lymphoid cells, can be used to further  
CC elucidate the role of the T cell receptor V-alpha-1 gene locus in the  
CC functioning of T cells  
XX  
SQ Sequence 18 BP; 3 A; 3 C; 3 G; 9 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 206 AAGAAATGCAGCACTT 221  
Db 18 AAGAAATACAGCACTT 3  
RESULT 95  
AAV07215  
ID AAV07215 standard; DNA; 18 BP.  
XX AAV07215;  
AC AAV07215;  
XX 21-AUG-1998 (first entry)  
DT Calcium-integrin binding protein PCR primer 3.  
XX Human,calcium-integrin binding protein; CIB; integrin alpha IIb;  
KW cytoplasmic domain; platelet; alpha IIb-beta-3; fibrinogen receptor;  
KW Inhibition; blood coagulation; vascular disorder; RT-PCR; primer;  
KW amplification; ss.  
XX Synthetic.  
OS Homo sapiens.  
XX WO9814471-A1.  
PN 09-APR-1998.  
PD

PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUYV/) GU Y.  
PA (JIYY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
DR  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 8638; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 202 ATCCAAGAAATGCAGC 217  
Db 2 ATCCAAGAACTGCAGC 17  
RESULT 92  
ACN71737  
ID ACN71737 standard; DNA; 17 BP.  
XX  
AC ACN71737;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPLP-1 probe SEQ ID NO:8639.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.

04-OCT-2000; 2000GB-00024263.  
30-JAN-2001; 2001WO-US000661.  
30-JAN-2001; 2001WO-US000662.  
30-JAN-2001; 2001WO-US000663.  
30-JAN-2001; 2001WO-US000664.  
30-JAN-2001; 2001WO-US000665.  
30-JAN-2001; 2001WO-US000666.  
30-JAN-2001; 2001WO-US000667.  
30-JAN-2001; 2001WO-US000668.  
30-JAN-2001; 2001WO-US000669.  
30-JAN-2001; 2001WO-US000670.  
05-FEB-2001; 2001US-0266860P.  
25-MAY-2001; 2001US-00866108.  
XX  
PA (GUYV/) GU Y.  
PA (JIYY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
DR  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 8639; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 6 A; 5 C; 3 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 202 ATCCAAGAAATGCAGC 217  
Db 1 ATCCAAGAACTGCAGC 16  
RESULT 93  
ACN73531/c  
ID ACN73531 standard; DNA; 17 BP.  
XX  
AC ACN73531;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPLP-1 probe SEQ ID NO:10433.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.

PA (MACE/) MACEJACK D.  
XX  
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
XX  
DR WPI; 2004-031273/03.  
XX  
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived  
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
PT especially in combination with type I interferon therapy.  
XX  
PS Claim 1; SEQ ID NO 2114; 198pp; English.  
XX  
CC The invention relates to an enzymatic nucleic acid molecule which  
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
CC the binding arms of the enzymatic nucleic acid molecule comprises  
CC sequences complementary to any of the defined substrate sequences given  
CC in the specification. The nucleic acid molecule may be administered for  
CC the treatment of HCV infections, especially in combination with type I  
CC interferons. The present sequence represents a HCV DNazyme substrate  
CC sequence.  
XX  
SQ Sequence 17 BP; 4 A; 7 C; 2 G; 0 T; 4 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 99;  
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
  
QY . 1372 CTACTCCAACGTATCA 1387  
| : ||||| : ||  
Db 1 CUCCUCCAACGUAUCA 16  
  
RESULT 90  
ACN73529/c  
ID ACN73529 standard; DNA; 17 BP.  
XX  
AC ACN73529;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:10431.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.

PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX  
DR WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10431; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 871 AGTTTGTGCTGTCA 886  
| ||||| |||||  
Db 17 ACTTTGTGCTGTCA 2  
  
RESULT 91  
ACN71736  
ID ACN71736 standard; DNA; 17 BP.  
XX  
AC ACN71736;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:8638.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.

PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2946; 317pp; English.	PS	Claim 59; SEQ ID NO 2945; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human PKR	CC	target RNA in a cell. The present RNA sequence represents a human PKR
CC	substrate sequence.	CC	substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 4 A; 1 C; 1 G; 0 T; 11 U; 0 Other;	SQ	Sequence 17 BP; 4 A; 0 C; 1 G; 0 T; 12 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;		Query Match 0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity 31.2%; Pred. No. 99;		Best Local Similarity 31.2%; Pred. No. 99;	
Matches 5; Conservative 10; Mismatches 1; Indels 0; Gaps 0;		Matches 5; Conservative 10; Mismatches 1; Indels 0; Gaps 0;	
QY	1043 TTTTCTTTTAAAGA 1058	QY	1043 TTTTCTTTTAAAGA 1058
	:::: ::::		:::: ::::
Db	1 UUUUUUUUUUAAAGA 16	Db	2 UUUUUUUUUUAAAGA 17
RESULT 88		RESULT 89	
ADL49412		ADL49412	
ID	ADL49412 standard; RNA; 17 BP.	ID	ADL49412 standard; RNA; 17 BP.
XX		XX	
AC	ADL49412;	AC	ADL49412;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	03-JUN-2004 (first entry)
XX		XX	
DE	Human PKR substrate sequence #526.	DE	HCV DNazyme substrate sequence #2114.
XX		XX	
KW	antisense oligonucleotide; neurite growth inhibitor; NOGO;	KW	ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	HCV infection; type I interferon; DNazyme.
KW	protein kinase PKR; cerebrovascular accident;	XX	Hepatitis C virus.
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	OS	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	PN	US2003125270-A1.
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	XX	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	PD	03-JUL-2003.
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	XX	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;	PF	18-DEC-2000; 2000US-00740332.
KW	substrate; ds.	XX	
XX		XX	
OS	Unidentified.	PR	18-DEC-2000; 2000US-00740332.
XX		XX	
PN	WO200281628-A2.	PA	(BLAT/) BLATT L.
XX		PA	(MCSW/) MCSWIGGEN J.
XX		PA	(ROBE/) ROBERTS E.
PD	17-OCT-2002.	PA	(PAVC/) PAVCO P A.
XX			



Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1113 CATACATTCTTTTGGT 1128  
Db 17 CATACATTCTTTTGAT 2

RESULT 85  
ACC51404  
ID ACC51404 standard; DNA; 17 BP.  
XX  
AC ACC51404;  
XX  
DT 27-JUN-2003 (first entry)  
XX  
DE Human tumour suppressor sequence #171.  
XX  
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;  
KW tumour regression; apoptosis; virus resistance; diagnosis;  
XX cellular degeneration.  
OS Homo sapiens.  
XX  
PN FR2826373-A1.  
XX  
PD 27-DEC-2002.  
XX  
PF 20-JUN-2001; 2001FR-00008139.  
XX  
PR 20-JUN-2001; 2001FR-00008139.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB SA.  
XX  
PI Tuijnder M, Telerman A, Amson R;  
XX  
DR WPI; 2003-250498/25.  
XX  
PT New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.  
XX  
OS Homo sapiens.  
XX  
PN FR2826373-A1.  
XX  
PD 27-DEC-2002.  
XX  
PF 20-JUN-2001; 2001FR-00008139.  
XX  
PR 20-JUN-2001; 2001FR-00008139.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB SA.  
XX  
PI Tuijnder M, Telerman A, Amson R;  
XX  
DR WPI; 2003-250498/25.  
XX  
PT New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.  
XX  
PS Claim 1; Page 79; 798pp; French.  
XX  
CC This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX  
SQ Sequence 17 BP; 7 A; 2 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1655 AGCAAGATAATTCTAT 1670  
Db 2 ATCAAGATAATTCTAT 17

RESULT 86  
ACC51914  
ID ACC51914 standard; DNA; 17 BP.  
XX  
AC ACC51914;  
XX  
DT 27-JUN-2003 (first entry)  
XX  
DE Human tumour suppressor sequence #681.

XX  
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;  
KW tumour regression; apoptosis; virus resistance; diagnosis;  
KW cellular degeneration.  
XX  
OS Homo sapiens.  
XX  
PN FR2826373-A1.  
XX  
PD 27-DEC-2002.  
XX  
PF 20-JUN-2001; 2001FR-00008139.  
XX  
PR 20-JUN-2001; 2001FR-00008139.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB SA.  
XX  
PI Tuijnder M, Telerman A, Amson R;  
XX  
DR WPI; 2003-250498/25.  
XX  
PT New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.  
XX  
PS Claim 1; Page 197; 798pp; French.  
XX  
CC This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX  
SQ Sequence 17 BP; 10 A; 2 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1559 GATTATATAAATAACA 1574  
Db 1 GATCATATAAATAACA 16

RESULT 87  
ADL49413  
ID ADL49413 standard; RNA; 17 BP.  
XX  
AC ADL49413;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human PKR substrate sequence #527.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
OS Unidentified.  
XX  
PN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX

XX Disclosure; Page 165; 771pp; French.

XX The invention relates to the isolation of 6327 nucleotide sequences,

CC fragments of at least 15 consecutive nucleotides of these nucleotides, a

CC sequence having at least 80% identity, after optimal alignment, with the

CC nucleotides, a sequence that hybridizes under stringent conditions with

CC the nucleotides, or the complement, or corresponding RNA, of the

CC nucleotides. The nucleotides are used as probes or primers for detecting,

CC identifying, quantifying and/or amplifying nucleic acids, as in vitro

CC sense and antisense sequences, of nucleotides involved in tumour

CC suppression or reversion, apoptosis and or viral resistance, to produce

CC recombinant polypeptides, and to prepare transgenic animals, as

CC experimental models. The nucleotides (also vectors containing them and

CC cells containing the vectors), the encoded polypeptides and antibodies

CC (Ab) against the polypeptide are useful for prevention and/or treatment

CC of viral infections or diseases characterized by development of tumours

CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).

CC Analysis of the expression of the nucleotides can be used for diagnosis

CC and/or prognosis of these diseases. The nucleotides and polypeptides can

CC also be used to screen for their specific interactive molecules,

CC potentially useful for treating diseases associated with abnormal

CC expression of the nucleotides.

XX SQ. Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 99;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 ATCTTTGGACTGAGAA 1717

Db 2 ATCTTTGGACTGAGAA 17

RESULT 83

ADI52546

ID ADI52546 standard; DNA; 17 BP.

XX AC ADI52546;

XX 15-APR-2004 (first entry)

XX Human tumour suppression/reversion-related DNA sequence SeqID5049.

DE tumour suppression; tumour reversion; apoptosis; virus resistance;

XX cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

OS WO2003025177-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004523.

PF 17-SEP-2001; 2001FR-00011980.

XX (MOLE-) MOLECULAR ENGINES LAB.

PA Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX Disclosure; SEQ ID NO 5049; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC nootropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, indentifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration,

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct\_sequences

XX SQ. Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 99;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1103 ATCCCAAGAGCATACA 1118

Db 2 ATCCAAAGAGCATACA 17

RESULT 84

ACC51264/c

ID ACC51264 standard; DNA; 17 BP.

XX AC ACC51264;

XX 27-JUN-2003 (first entry)

XX Human tumour suppressor sequence #31.

DE ss; tumour suppressor; antitumour; cytostatic; tumour suppression;

XX tumour regression; apoptosis; virus resistance; diagnosis;

KW cellular degeneration.

KW Homo sapiens.

XX FR2826373-A1.

XX 27-DEC-2002.

XX 20-JUN-2001; 2001FR-00008139.

XX 20-JUN-2001; 2001FR-00008139.

XX (MOLE-) MOLECULAR ENGINES LAB SA.

XX Tuijnder M, Telerman A, Amson R;

XX WPI; 2003-250498/25.

XX New nucleic acid sequences associated with tumor suppression, regression,

PT apoptosis or virus resistance are useful to diagnose and treat viral

PT disease, development of tumor cells and cell degeneration.

XX Claim 1; Page 47; 798pp; French.

XX This sequence represents an isolated nucleic acid sequence associated

CC with tumour suppression or regression, apoptosis or virus resistance. The

CC invention relates to these sequences or sequences having at least 80%

CC identity to them, and polypeptides encoded by the sequences or

CC polypeptides having 80% identity to the polypeptide sequences. The

CC invention is used to diagnose or treat viral disease or disease

CC characterized by development of tumour cells or cellular degeneration

XX SQ. Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;

CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
CC useful as pharmaceutical agents for treating conditions such as chronic  
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
CC that are related to or will respond to the levels of CLCA1 in a cell or  
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
CC hence, are useful for treatment of a patient having a condition  
CC associated with the level of CLCA1, where the invention further comprises  
CC the use of one or more therapies under conditions suitable for the  
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The  
CC nucleic acids of the invention are also used as diagnostic tools to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of CLCA1 RNA in a cell. This sequence represents an  
CC enzymatic nucleic acid molecule of the invention  
XX  
SQ Sequence 17 BP; 6 A; 2 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 56.2%; Pred. No. 99;  
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1712 TGAGAAATTATCTTA 1727  
          :|||||:::|::|  
Db 1 UGAGAAAUUCUACUUA 16

RESULT 81  
ACD60984  
ID ACD60984 standard; RNA; 17 BP.

XX  
AC ACD60984;  
XX  
DT 24-SEP-2003 (first entry)  
XX  
DE HCV DNazyme substrate sequence #2114.  
XX  
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; zinzyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.

XX  
OS Hepatitis C virus.  
XX  
PN WO200281494-A1.

XX  
PD 17-OCT-2002.

XX  
PF 26-MAR-2002; 2002WO-US009187.

XX  
PR 26-MAR-2001; 2001US-00817879.  
PR 08-JUN-2001; 2001US-00877478.  
PR 08-JUN-2001; 2001US-0296876P.  
PR 24-OCT-2001; 2001US-0335059P.  
PR 05-DEC-2001; 2001US-0337055P.

XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.

XX  
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;

DR WPI; 2003-229207/22.  
XX  
PT Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
XX  
PS Claim 1; Page 271; 387pp; English.

XX  
CC The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV, and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNazyme or minus strand DNazyme sequences disclosed in the present  
CC invention

XX  
SQ Sequence 17 BP; 4 A; 7 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 99;  
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1372 CTACTCCACGTATCA 1387  
          |:|:|||||:|:  
Db 1 CUCCUCCAACGUACA 16

RESULT 82  
ADB40821  
ID ADB40821 standard; DNA; 17 BP.

XX  
AC ADB40821;

XX  
DT 18-DEC-2003 (revised)  
DT 04-DEC-2003 (first entry)

XX  
DE Tumour suppression/reversion associated nucleotide #1144.

XX  
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.

XX  
OS Homo sapiens.

XX  
PN WO2003040369-A2.

XX  
PD 15-MAY-2003.

XX  
PF 17-SEP-2002; 2002WO-IB004219.

XX  
PR 17-SEP-2001; 2001FR-00011981.

XX  
PA (MOLE-) MOLECULAR ENGINES LAB.

XX  
PI Telerman A, Amson R, Tuijnder M;

XX  
DR WPI; 2003-441574/41.

XX  
PT New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.





RESULT 77  
ABN08646  
ID ABN08646 standard; DNA; 17 BP.  
XX  
AC ABN08646;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8638.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
XX  
PD 06-DEC-2001.  
XX  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 8638; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence

XX  
SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 202 ATCCAAGAAATGCAGC 217  
Db 2 ATCCAAGAACTGCAGC 17  
RESULT 78  
ABN08647  
ID ABN08647 standard; DNA; 17 BP.  
XX  
AC ABN08647;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8639.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 8639; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 10433; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 870 GAGTTTGTGCTGTC 885  
DB |||||||||||  
16 GACTTTGTGCTGTC 1  
  
RESULT 76  
ABN10439/c  
ID ABN10439 standard; DNA; 17 BP.  
XX  
AC ABN10439;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10431.  
XX

KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
PA  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 10431; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 871 AGTTTGTGCTGTC 886  
DB |||||||||||  
17 ACTTTGTGCTGTC 2

CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a hammerhead ribozyme of the invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTCAAAGACAGGT 925  
|||||  
Db 16 TTCTTCAAAGAAAGGT 1

RESULT 74  
ABK01343/c  
ID ABK01343 standard; RNA; 17 BP.

XX AC ABK01343;

DT 12-MAR-2002 (first entry)

XX DE Human NOGO Inozyme #613.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX OS Homo sapiens.  
OS Synthetic.

XX PN WO200159103-A2.

PD 16-AUG-2001.

XX PF 09-FEB-2001; 2001WO-US004273.

XX PR 11-FEB-2000; 2000US-0181797P.

PR 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

PA (CHOW/) CHOWRIRA B M.

XX Blatt L, Mcswiggen J, Chowrira BM;

DR WPI; 2001-607195/69.

XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.

XX PS Claim 88; Page 87; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNazyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is an inozyme of the invention

XX SQ Sequence 17 BP; 5 A; 3 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTCAAAGACAGGT 925  
|||||  
Db 17 TTCTTCAAAGAAAGGT 2

RESULT 75

ABN10441/c

ID ABN10441 standard; DNA; 17 BP.

XX AC ABN10441;

XX 29-MAY-2002 (first entry)

DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10433.

DE Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

XX WO200192524-A2.

XX PD 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.



KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
XX 09-FEB-2001; 2001WO-US004273.  
PF  
XX 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
DR  
XX  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
XX Claim 88; Page 89; 200pp; English.  
PS  
XX  
XX The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is an inozyme of the invention  
XX  
SQ Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 68.8%; Pred. No. 99;  
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
QY 847 CCAGCTCTCTGTGACC 862  
||| |||.:|.:|||  
Db 2 CCUGCUCUCUGUGACC 17  
RESULT 73  
ABK00479/c  
ID ABK00479 standard; RNA; 17 BP.  
XX  
AC ABK00479;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human NOGO Hammerhead Ribozyme #479.  
XX  
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
XX 09-FEB-2001; 2001WO-US004273.  
PF  
XX 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
DR  
XX  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
XX Claim 88; Page 73; 200pp; English.  
PS  
XX  
XX The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is an inozyme of the invention  
XX  
SQ Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;



CC The present invention describes enzymatic nucleic acid molecules with RNA  
CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 1 G; 0 T; 9 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 172 AAATATAGTGGAACACT 187  
|||||  
Db 17 AAATATAGTAGAACACT 2

RESULT 71  
ABK00554  
ID ABK00554 standard; RNA; 17 BP.  
XX  
AC ABK00554;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human NOGO Hammerhead Ribozyme #554.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX

PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
XX  
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
PS Claim 88; Page 74; 200pp; English.  
XX  
CC The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNazyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a hammerhead ribozyme of the invention  
XX  
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 99;  
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
QY 847 CCAGCTCTCTGTGACC 862  
|||  
Db 1 CCUGCUCUCUGUGACC 16

RESULT 72  
ABK01422  
ID ABK01422 standard; RNA; 17 BP.  
XX  
AC ABK01422;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human NOGO Inozyme #692.  
XX

Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;

sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 5 A; 1 C; 4 G; 0 T; 7 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1265 TTACCAAGAACTTCCA 1280  
Db 16 TTACAAAGAACTTCCA 1  
  
RESULT 69  
AAAA18824/c  
ID AAA18824 standard; RNA; 17 BP.  
XX  
AC AAA18824;  
XX  
XX 19-JUN-2000 (first entry)  
DT  
XX Human TIE-2 substrate sequence SEQ ID NO:2050.  
DE  
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytotstatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW age related macular degeneration; inflammation; diabetic retinopathy; arthritis;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX  
OS Homo sapiens.  
XX WO9950403-A2.  
XX 07-OCT-1999.  
XX  
XX 24-MAR-1999; 99WO-US006507.  
XX  
XX 27-MAR-1998; 98US-0079678P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
PI  
XX WPI; 1999-591315/50.  
DR  
XX Novel ribozymes for modulating the synthesis, expression and/or stability  
XX of an mRNA encoding an angiogenic factors.  
XX  
XX Claim 56; Page 119; 305pp; English.  
XX  
XX The present invention describes enzymatic nucleic acid molecules with RNA  
CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 4 A; 2 C; 4 G; 0 T; 7 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1265 TTACCAAGAACTTCCA 1280  
Db 17 TTACAAAGAACTTCCA 2  
  
RESULT 70  
AAA23011/c  
ID AAA23011 standard; RNA; 17 BP.  
XX  
AC AAA23011;  
XX  
XX 19-JUN-2000 (first entry)  
DT  
XX Integrin subunit beta 3 substrate sequence SEQ ID NO:6237.  
DE  
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytotstatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX  
OS Homo sapiens.  
XX WO9950403-A2.  
XX  
XX 07-OCT-1999.  
XX  
XX 24-MAR-1999; 99WO-US006507.  
XX  
XX 27-MAR-1998; 98US-0079678P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
PI  
XX WPI; 1999-591315/50.  
DR  
XX Novel ribozymes for modulating the synthesis, expression and/or stability  
XX of an mRNA encoding an angiogenic factors.  
XX  
XX Claim 54; Page 256; 305pp; English.

XX (SYSM-) SYSMEX CORP.  
XX Tada S., Akai Y, Imura Y, Abe S, Minekawa H;  
XX WPI; 2004-012543/01.  
XX LAMP nucleic acid amplification primers for detection of cytokeratin  
PT expression as indicator in diagnosis of tumour metastasis.  
XX Claim 19; SEQ ID NO 390; 266pp; Japanese.  
XX The invention relates to novel nucleic acid amplification primers for the  
CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP  
CC (loop mediated isothermal amplification) method. The primers of the  
CC invention may be useful for the detecting cytokeratin 18-20 expression as  
CC an indicator for the diagnosis of tumour metastasis, particularly  
CC prostate cancer and lymphoma. The amplification using the primers is  
CC highly efficient and allows very sensitive detection of tumour  
CC metastasis. The current sequence is that of the human CK19-related PCR  
CC primer of the invention.  
XX  
SQ Sequence 16 BP; 1 A; 6 C; 5 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 90;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 41 AGGCCACTGCTTCTGG 56  
Db 1 AGGCCCTGCTTCTGG 16  
  
RESULT 67  
AAX71309/c  
ID AAX71309 standard; RNA; 17 BP.  
XX AAX71309;  
AC AAX71309;  
XX 28-JUL-1999 (first entry)  
XX Human KDR VEGF receptor hammerhead ribozyme substrate #321.  
DE  
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
OS Homo sapiens.  
XX WO9715662-A2.  
PN 01-MAY-1997.  
PD 25-OCT-1996; 96WO-US017480.  
XX 26-OCT-1995; 95US-0005974P.  
PR 11-JAN-1996; 96US-00584040.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
XX WPI; 1997-259017/23.  
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
XX Claim 4; Page 106; 218pp; English.

CC The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 99;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 518 GAGACTTCCATGCTTT 533  
Db 17 GAGACTTCGATGCTTT 2  
  
RESULT 68  
AAA18825/c  
ID AAA18825 standard; RNA; 17 BP.  
XX AAA18825;  
AC AAA18825;  
XX 19-JUN-2000 (first entry)  
XX Human TIE-2 substrate sequence SEQ ID NO:2051.  
DE  
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX Homo sapiens.  
OS WO9950403-A2.  
PN 07-OCT-1999.  
XX 24-MAR-1999; 99WO-US006507.  
PF 27-MAR-1998; 98US-0079678P.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
XX WPI; 1999-591315/50.  
XX Novel ribozymes for modulating the synthesis, expression and/or stability  
PT of an mRNA encoding an angiogenic factors.  
XX Claim 56; Page 119; 305pp; English.  
XX The present invention describes enzymatic nucleic acid molecules with RNA  
CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme



Fri May 13 12:26:37 2005

KW male pattern alopecia; acne vulgaris; seborrhea; female hirsutism;  
KW prostatic hypertrophy; ds.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT misc\_feature 17..18  
FT /\*tag= a  
FT /note= "2 deoxynucleotide overhang"  
XX  
XX WO2004063331-A2.  
XX  
XX 29-JUL-2004.  
XX  
XX 05-JAN-2004; 2004WO-US000128.  
XX PF  
XX PR 03-JAN-2003; 2003US-0437842P.  
XX  
XX (GENC-) GENCIA CORP.  
XX PA  
XX PI Kahn S;  
XX  
XX WPI; 2004-561892/54.  
DR  
XX Inhibitory nucleic acid that inhibits expression of an androgen signal  
PT transduction pathway protein useful for treating hair loss, comprises a  
PT double stranded RNA having a partial sequence encoding a pathway protein  
PT in one strand.  
XX  
XX Claim 11; Page 59; 92pp; English.  
XX  
XX The present invention relates to novel small interfering RNAs (siRNAs),  
CC comprising a double stranded RNA, where one strand comprises a partial  
CC nucleic acid sequence of an androgen signal transduction pathway protein,  
CC and where the double-stranded RNA inhibits translation of mRNA encoding  
CC the nucleic acid sequence of the androgen signal transduction pathway  
CC protein thereby blocking the androgen signal transduction pathway. The  
CC androgen signal transduction pathway protein is chosen from isozymes I  
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen  
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-  
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-  
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-  
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-  
CC hydroxysteroidoxidoreductase (ADQ93722), and steroid sulfatase  
CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss  
CC in a mammal which involves contacting several mammal's hair cells with  
CC the siRNA, where the siRNA interferes with the translation of mRNA of the  
CC androgen signal transduction protein. The siRNAs are useful for treating  
CC hyperandrogenic conditions of androgenic alopecia, including male pattern  
CC alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic  
CC hypertrophy. The present sequence is the sense strand for one such siRNA  
CC of the invention.  
XX  
SQ Sequence 18 BP; 4 A; 5 C; 4 G; 2 T; 3 U; 0 Other;  
  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 98;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 418 AAAGCTTTCCAGTATGG 435  
Db |||||  
18 AAAGCTTTCCAGGCTGG 1  
  
RESULT 65  
ABL91853  
ID ABL91853 standard; DNA; 15 BP.  
XX  
AC ABL91853;  
XX  
DT 11-JUL-2002 (first entry)  
XX  
DE Human LIPG gene allele specific oligonucleotide primer 32.

XX  
KW Human; ss; allele specific oligonucleotide; primer;  
KW single nucleotide polymorphism; SNP; lipase endothelial isogene; LIPG;  
KW drug screening; atherosclerosis; cardiovascular disorder;  
KW LIPG haplotyping; LIPG genotyping.  
XX  
OS Homo sapiens.  
XX WO200216397-A2.  
PN  
XX 28-FEB-2002.  
PD  
XX 17-AUG-2001; 2001WO-US026639.  
PF  
XX 25-AUG-2000; 2000US-0227825P.  
XX  
XX (GENA-) GENAISSANCE PHARM INC.  
PA  
XX Duda A, Kazemi A, Kliem SE, Messer C;  
PI  
XX WPI; 2002-292055/33.  
DR  
XX Novel genetic variants of Lipase, Endothelial isogenes, useful for  
PT improving efficiency and reliability in drug development for treating  
PT diseases associated with LIPG activity, e.g. atherosclerosis.  
PT  
XX Claim 16; Page 14; 134pp; English.  
XX  
XX The invention comprises the DNA and amino acid sequence of the human  
CC lipase, endothelial (LIPG) isogene. Specifically, the invention relates  
CC to the discovery of 20 novel polymorphic sites within the LIPG gene. The  
CC LIPG coding sequence and protein are useful for screening drugs that can  
CC be used to treat atherosclerosis and other cardiovascular disorders. The  
CC LIPG coding sequence can also be used to haplotype and genotype the LIPG  
CC gene of an individual. The DNA sequences ABL91822 - ABL91861 represent  
CC LIPG gene allele specific oligonucleotide primers  
XX  
SQ Sequence 15 BP; 3 A; 6 C; 1 G; 4 T; 0 U; 1 Other;  
  
Query Match 0.8%; Score 14.6; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 76;  
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
QY 719 TGTTCCTCCACCTACA 733  
Db |||||  
1 TGTTCCTCCACCTAYA 15  
  
RESULT 66  
ADF92302  
ID ADF92302 standard; DNA; 16 BP.  
XX  
AC ADF92302;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
DE Human cytokeatin 19-related loop F PCR primer - SEQ ID 390.  
XX  
KW human; cytokeatin; CK; LAMP; loop mediated isothermal amplification;  
KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;  
KW PCR; loop F.  
XX  
OS Homo sapiens.  
XX  
XX WO2003097878-A1.  
PN  
XX 27-NOV-2003.  
PD  
XX  
XX 20-MAY-2003; 2003WO-JP006256.  
XX  
XX 21-MAY-2002; 2002JP-00145689.  
PR 17-JUN-2002; 2002JP-00175271.  
PR 09-JUL-2002; 2002JP-00199759.  
PR



DT 26-JAN-2000 (first entry)  
XX Human CD40 phosphorothioate antisense oligonucleotide SEQ ID NO:57.  
DE  
XX  
KW Identification; genetic target; gene modulation; human; probe;  
KW antisense oligonucleotide; phosphorothioate; PCR primer;  
KW nucleotide sequence-based technology; antisense drug discovery;  
KW target validation; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO9953101-A1.  
XX  
XX 21-OCT-1999.  
XX  
XX 13-APR-1999; 99WO-US008268.  
XX  
PR 13-APR-1998; 98US-0081483P.  
PR 28-APR-1998; 98US-00067638.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Cowser LM, Baker BF, Mcneil J, Freier SM, Sasnor HM, Brooks DG;  
PI Ohasi C, Wyatt JR, Borchers AH, Vickers TA;  
PI  
XX WPI; 1999-620446/53.  
DR  
XX Identifying compounds which modulate expression of nucleic acids, used to  
PT provide compounds having defined physical, chemical or bioactive  
PT properties, e.g. antisense activity.  
XX  
XX Example 8; Page 78; 264pp; English.  
PS  
XX A method has been developed of defining a set of compounds that modulate  
CC the expression of a target nucleic acid (tNA) sequence via binding of the  
CC compounds with the tNA sequence. The method comprises generating a  
CC library of virtual compounds in silico according to defined criteria, and  
CC evaluating in silico the binding of the virtual compounds with the tNA  
CC according to defined criteria. Also described are: (1) a method of  
CC defining a set of oligonucleotides (ONs) that modulate the expression of  
CC a tNA sequence via binding of the ONs with the tNA sequence comprising  
CC generating a library of virtual compounds in silico according to defined  
CC criteria, and evaluating in silico the binding of the virtual ONs with  
CC the tNA according to defined criteria; and (2) a method of defining a set  
CC of compounds that modulate the expression of a tNA sequence via binding  
CC of the compounds with the tNA. The methods can be used for the generation  
CC and identification of synthetic compounds having defined physical,  
CC chemical or bioactive properties. Information gathered from assays of  
CC such compounds is used to identify nucleic acid sequences that are  
CC tractable to a variety of nucleotide sequence-based technologies, e.g.  
CC antisense drug discovery and target validation. AAZ40852 to AAZ41220, and  
CC AAY52701 to AAY52706, represent sequences used in the exemplification of  
CC the present invention  
XX  
SQ Sequence 18 BP; 3 A; 5 C; 4 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 98;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 945 TGAGAGACCAAGACCAG 962  
Db |||||||||||||  
18 TGTGAGACCAAGACCTG 1  
  
RESULT 63  
AAZ47741/c  
ID AAZ47741 standard; DNA; 18 BP.  
XX  
AC AAZ47741;  
XX  
DT 02-MAR-2000 (first entry)

XX Human CD40 antisense oligonucleotide SEQ ID NO:57.  
DE  
XX  
KW Human; CD40; antisense oligonucleotide; phosphorothioate; modulation;  
KW expression; immune disease; inflammatory disease; immunomodulatory;  
KW anti-inflammatory; anti-arthritic; anti-asthmatic; antiproliferative;  
KW anticancer; immuno-suppressive; anti-psoriatic; allograft rejection;  
KW hyperproliferative disease; autoimmune disease; rheumatoid arthritis;  
KW inflammatory bowel disease; asthma; psoriasis; cancer; tumour; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO9957320-A1.  
XX  
XX 11-NOV-1999.  
XX  
XX 22-APR-1999; 99WO-US008765.  
XX  
PR 01-MAY-1998; 98US-00071433.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Bennett CF, Cowser LM;  
PI  
XX WPI; 2000-062158/05.  
DR  
XX  
XX Antisense molecules directed against nucleic acid encoding human CD40,  
PT for treating e.g. immune, inflammatory or hyperproliferative diseases.  
PT  
XX  
XX Claim 3; Page 44; 102pp; English.  
XX  
XX AAZ47685 to AAZ47768 represent phosphorothioate antisense  
CC oligonucleotides targeted to human CD40, which can be used to inhibit the  
CC expression of human CD40. CD40 is involved in lymphocyte activation,  
CC tumour growth and/or angiogenesis. Inhibition of CD40 is used to treat or  
CC prevent immune-associated diseases (specifically guest vs. host disease,  
CC allograft rejection or autoimmune diseases); inflammation (specifically  
CC asthma, rheumatoid arthritis, allograft rejection, inflammatory bowel  
CC disease or psoriasis) or hyperproliferation (specifically cancer and  
CC tumours). the antisense oligonucleotides are also useful as diagnostic  
CC and research reagents. AAZ47769 represents the human CD40 nucleotide  
CC sequence. AAZ47770 to AAZ47772 represent human CD40 forward and reverse  
CC PCR primers, and a human CD40 PCR probe, respectively. AAZ47773 to  
CC AAZ47775 represent other PCR primers and a probe used in the  
CC exemplification of the present invention  
XX  
SQ Sequence 18 BP; 3 A; 5 C; 4 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 98;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 945 TGAGAGACCAAGACCAG 962  
Db |||||||||||||  
18 TGTGAGACCAAGACCTG 1  
  
RESULT 64  
ADQ93226/c  
ID ADQ93226 standard; RNA; 18 BP.  
XX  
AC ADQ93226;  
XX  
XX 21-OCT-2004 (first entry)  
DT  
DE 3-alpha-hydroxysteroiddehydrogenase siRNA sense strand, SEQ ID 802.  
XX  
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;  
KW small interfering RNA; siRNA;  
KW androgen signal transduction pathway protein;  
KW androgen signal transduction; 3-alpha-hydroxysteroiddehydrogenase;  
KW hair loss; hyperandrogenic condition; androgenic alopecia;

```
Query Match      0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      929 TCTGGCTGAAGGTTT 943
      |||||
Db      15 TCTGGCTGAAGGTTT 1

RESULT 60
ADB00376/c
ID ADB00376 standard; DNA; 17 BP.
XX
AC ADB00376;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MDZ3 scanning oligonucleotide SEQ ID 1362.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
WPI; 2003-423107/40.
XX
New zinc finger-containing proteins and nucleic acids, useful in
manufacturing a medicament for treating or preventing a disorder
associated with decreased or increased expression or activity of MDZ3,
MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS Example 8; SEQ ID NO 1362; 103pp; English.
XX
The present invention relates to novel human zinc finger-containing
proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
or in manufacturing a medicament for treating or preventing a disorder
associated with decreased or increased expression or activity of MDZ3,
MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
acids and proteins are also useful for diagnosing or monitoring a disease
caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
acids can also be used as probes to detect and characterize gross
alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
useful in constructing microarrays for measuring gene expression. The
proteins are useful as therapeutic agents for gene therapy or as
vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;

Query Match      0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      929 TCTGGCTGAAGGTTT 943
      |||||
Db      16 TCTGGCTGAAGGTTT 2
```

```
RESULT 61
AAV57794
ID AAV57794 standard; DNA; 18 BP.
XX
AC AAV57794;
XX
DT 18-NOV-1998 (first entry)
XX
DE Human chromosome 18 PCR mapping primer clone 47r.
XX
KW Manic-depressive illness; susceptibility; genotype; diagnosis;
KW chromosomal marker; polymorphic marker; chromosome 18; human;
KW myo-inositol monophosphatase protein; IMP-18p; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9818963-A1.
XX
PD 07-MAY-1998.
XX
PF 28-OCT-1997; 97WO-US019381.
XX
PR 28-OCT-1996; 96US-0029278P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Detera-Wadleigh SD, Gershon ES, Badner JA, Goldin LR;
PI Berrettini WH, Yoshikawa T, Sanders AR, Esterling LE;
XX
WPI; 1998-272247/24.
XX
New isolated IMP.18p myo-inositol monophosphatase - used to develop
products for determining susceptibility to manic depressive illness and
as targets for preventive and therapeutic treatments.
XX
PS Example 5; Page 71; 118pp; English.
XX
A method has been developed for determining a genotype associated with
increased susceptibility to manic-depressive (MD) illness. The method
comprises determining the genotype of an affected individual with at
least one polymorphic marker localised within the chromosomal region
defined by and including markers D18S843 and D18S869 and determining the
genotype associated with increased susceptibility to MD disorder. The
method can be used for determining susceptibility to MD illness including
bipolar disorder, genetic counselling of individuals from families
affected with MD illness, and aid in the differential diagnosis of MD
illness from other psychiatric pathologies. Products from the present
invention can also be used to obtain modulators of IMP.18p myo-inositol
monophosphatase protein activity and as targets for preventive and
therapeutic treatments. The present sequence represents a PCR primer used
in the mapping of human chromosome 18 for determining the genotype of MD
illness susceptibility, used in an example from the present invention
XX
SQ Sequence 18 BP; 2 A; 4 C; 4 G; 8 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      46 ACTGCTTCTGGAGCTCTT 63
      |||||
Db      1 AGTGCTTCTGTAGTCTT 18

RESULT 62
AAZ40908/c
ID AAZ40908 standard; DNA; 18 BP.
XX
AC AAZ40908;
XX
```

CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 3 A; 5 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 85;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 GATCTCCATCATTTTC 312  
Db 1 GATCTCCATCATTTTC 15  
|||||

RESULT 58  
ADB00375/c  
ID ADB00375 standard; DNA; 17 BP.  
XX  
AC ADB00375;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ3 scanning oligonucleotide SEQ ID 1361.  
XX  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1281758-A2.  
XX  
PD 05-FEB-2003.  
XX  
PF 30-JUL-2002; 2002EP-00016874.  
XX  
PR 02-AUG-2001; 2001US-00922181.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
PT New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
PS Example 8; SEQ ID NO 1361; 103pp; English.  
XX

CC The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease

CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 85;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943  
Db 17 TCTGGCTGAAGGTTT 3  
|||||

RESULT 59  
ADB00377/c  
ID ADB00377 standard; DNA; 17 BP.  
XX  
AC ADB00377;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ3 scanning oligonucleotide SEQ ID 1363.  
XX  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1281758-A2.  
XX  
PD 05-FEB-2003.  
XX  
PF 30-JUL-2002; 2002EP-00016874.  
XX  
PR 02-AUG-2001; 2001US-00922181.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
PT New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
PS Example 8; SEQ ID NO 1363; 103pp; English.  
XX

CC The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;



Fri May 13 12:26:37 2005

CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is an amberzyme molecule of the invention  
XX  
SQ Sequence 17 BP; 11 A; 0 C; 3 G; 0 T; 3 U; 0 Other;  
Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 85;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 969 TTTAATTTCTTCCTT 983  
|||||  
Db 17 TTTAATTTCTTCCTT 3  
RESULT 57  
ABT35046  
ID ABT35046 standard; DNA; 17 BP.  
XX  
AC ABT35046;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
DE Tumour suppression related human fukutin oligo SEQ ID No 683.  
XX  
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025175-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004208.  
XX  
PR 17-SEP-2001; 2001FR-00011978.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313353/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; Page 113; 720pp; French.  
XX  
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
CC given in the specification, a sequence containing at least 15 consecutive  
CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
CC hybridizes to them under highly stringent conditions, or the complement  
CC of any of them, or the corresponding RNA. The novel isolated nucleic  
CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

QY 507 TGGAGCTCATGGAGACT 523  
|||||  
Db 18 TGGAGGTCATGGAGACT 2  
RESULT 56  
ABK02552/c  
ID ABK02552 standard; RNA; 17 BP.  
XX  
AC ABK02552;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human NOGO Amberzyme #224.  
XX  
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX  
DR WPI; 2001-607195/69.  
XX  
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
PS Claim 88; Page 135; 200pp; English.  
XX  
CC The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic



PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
DR WPI; 2004-677362/66.  
XX  
PT Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 952; 378pp; English.  
XX  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that  
CC can be used to control ApoB gene expression.  
XX  
SQ Sequence 19 BP; 4 A; 8 C; 3 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 93;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 507 TGGAGCTCATGGAGACT 523  
Db 18 TGGAGGTCATGGAGACT 2  
  
RESULT 55  
ADR79085/c  
ID ADR79085 standard; DNA; 19 BP.  
XX  
AC ADR79085;  
XX  
XX 16-DEC-2004 (first entry)  
XX  
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 3570.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;

KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX (ALNY-) ALNYLAM PHARM.  
PA  
XX Manoharan M, Bumcrot D;  
PI  
XX WPI; 2004-677362/66.  
DR  
XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 3570; 378pp; English.  
XX  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that  
CC can be used to control ApoB gene expression.  
XX  
SQ Sequence 19 BP; 4 A; 8 C; 3 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 93;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

CC	stabilising (I), involves selecting a sequence with activity and	CC	Sequence 19 BP; 11 A; 2 C; 2 G; 4 T; 0 U; 0 Other;
CC	introducing one or more asymmetrical modification in the sequence, where	CC	Query Match 0.9%; Score 15.4; DB 1; Length 19;
CC	the modification decreases nuclease sensitivity while not decreasing its	CC	Best Local Similarity 94.1%; Pred. No. 93;
CC	activity; a kit comprising (I) and instruction for its use; and a device	CC	Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
CC	that can be dispense or administer a composition comprising (I). (I) is	CC	
CC	useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)	CC	
CC	is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.	CC	
CC	The subject is suffering from a disorder characterised by elevated or	CC	
CC	otherwise unwanted expression of apoB-100, elevated or otherwise unwanted	CC	
CC	levels of cholesterol, and/or dysregulation of lipid metabolism. The	CC	
CC	disorder is chosen from the HDL/LDL cholesterol imbalance,	CC	
CC	dyslipidaemias, hypercholesterolaemia, statin-resistant	CC	
CC	hypercholesterolaemia, coronary artery disease (CAD), coronary heart	CC	
CC	disease (CHD) and atherosclerosis. (I) is administered to a subject to	CC	
CC	inhibit hepatic glucose production or for treating glucose-metabolism-	CC	
CC	related disorder e.g. diabetes or type-2 diabetes. (I) is useful for	CC	
CC	treating the diseases as mentioned above, cancer (e.g. breast, colon or	CC	
CC	lung cancer), neurological disease (e.g., Huntington disease or	CC	
CC	spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence	CC	
CC	represents a human glucose-6-phosphatase antisense oligonucleotide that	CC	
CC	can be used to control glucose-6-phosphatase gene expression.	CC	
XX		XX	
SQ		SQ	
Query Match 0.9%; Score 15.4; DB 1; Length 19;			
Best Local Similarity 94.1%; Pred. No. 93;			
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
QY	1044 TTTTCTTTTAAAGATG 1060	QY	
Db	19 TTTTCTTTTCAAGATG 3	Db	
RESULT 54			
ADR76467/c			
ID	ADR76467 standard; DNA; 19 BP.	ID	
XX		XX	
AC	ADR76467;	AC	
XX		XX	
DT	16-DEC-2004 (first entry)	DT	
XX		XX	
DE	Human apolipoprotein B (ApoB) oligonucleotide seqid 952.	DE	
XX		XX	
KW	antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;	KW	
KW	cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;	KW	
KW	RNA interference; iRNA; antisense technology; lipid metabolism;	KW	
KW	cholesterol imbalance; dyslipidaemia hypercholesterolaemia;	KW	
KW	coronary artery disease; CAD; coronary heart disease; CHD;	KW	
KW	atherosclerosis; hepatic glucose production;	KW	
KW	glucose-metabolism-related disorder; diabetes; cancer; breast cancer;	KW	
KW	colon cancer; lung cancer; neurological disease; Huntington disease;	KW	
KW	spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.	KW	
XX		XX	
OS	Homo sapiens.	OS	
XX		XX	
PN	WO2004080406-A2.	PN	
XX		XX	
PD	23-SEP-2004.	PD	
XX		XX	
PF	08-MAR-2004; 2004WO-US007070.	PF	
XX		XX	
PR	07-MAR-2003; 2003US-0452682P.	PR	
PR	12-MAR-2003; 2003US-0454265P.	PR	
PR	13-MAR-2003; 2003US-0454962P.	PR	
PR	13-MAR-2003; 2003US-0455050P.	PR	
PR	14-APR-2003; 2003US-0462894P.	PR	
PR	17-APR-2003; 2003US-0463772P.	PR	
PR	25-APR-2003; 2003US-0465665P.	PR	
PR	25-APR-2003; 2003US-0465802P.	PR	
PR	09-MAY-2003; 2003US-0493986P.	PR	
PR	08-AUG-2003; 2003US-0494597P.	PR	
PR	26-SEP-2003; 2003US-0506341P.	PR	
PR	09-OCT-2003; 2003US-0510246P.	PR	
PR	10-OCT-2003; 2003US-0510318P.	PR	
PR	07-NOV-2003; 2003US-0518453P.	PR	
XX		XX	
PA	(ALNY-) ALNYLAM PHARM.	PA	
XX		XX	
PI	Manoharan M, Bumcrot D;	PI	
XX		XX	
DR	WPI; 2004-677362/66.	DR	
XX		XX	
PT	Interference RNA agent useful for treating dyslipidemias, coronary artery	PT	
PT	disease, diabetes, cancer or neurological disease, comprises sense	PT	
PT	sequence and antisense sequence which has specific modifications.	PT	
XX		XX	
PS	Example 5; SEQ ID NO 5379; 378pp; English.	PS	
XX		XX	
CC	The invention describes a RNA interference (iRNA) agent (I) comprising a	CC	
CC	sense sequence and an antisense sequence, where the sense sequences have	CC	
CC	one or more asymmetrical 2'-O alkyl modifications, the antisense	CC	
CC	sequences have one or more asymmetrical phosphorothioate modifications	CC	
CC	and the antisense sequence targets a human gene sequence. Also described	CC	
CC	are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100	CC	
CC	levels or glucose-6-phosphatase levels in a subject; producing (I);	CC	

KW Cytostatic; vasotropic; protozoacide; immunosuppressive; dermatological;  
KW neuroprotective; anti-HIV; ophthalmological; antiulcer; antirheumatic;  
KW antiarthritic; antiinflammatory; gene therapy; telomerase; human; terc;  
KW RNA interference; short interfering nucleic acid; siNA;  
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;  
KW short hairpin RNA; shRNA; expression modulation; gene therapy;  
KW drug screening; diagnosis; therapeutic target identification;  
KW pharmacogenomics; gene function analysis; gene mapping; TERC; TERT; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO2003070742-A1.  
XX  
XX 28-AUG-2003.  
XX  
XX 11-FEB-2003; 2003WO-US004088.  
PR 20-FEB-2002; 2002US-0358580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 17-JUL-2002; 2002US-0396600P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Mcswiggen J, Beigelman L;  
PI  
XX  
XX WPI; 2003-689777/65.  
XX  
XX New short interfering nucleic acid downregulates expression of the  
PT telomerase gene useful e.g. for treatment and diagnosis of cancer.  
XX  
XX Example 3; SEQ ID NO 254; 145pp; English.  
PS  
XX  
CC The invention relates to short interfering nucleic acids (siNA) which  
CC downregulate expression of the one or more telomerase genes by RNA  
CC interference. The siNAs may or may not comprise ribonucleotides and may  
CC be double or single stranded. They further comprise sense and antisense  
CC regions, or alternatively are assembled from a sense oligonucleotide and  
CC an antisense oligonucleotide. Specifically, the siNAs include short  
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short  
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,  
CC can contain deoxyribonucleotides, and can be chemically synthesised,  
CC expressed from a vector or enzymatically synthesised. The invention also  
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates  
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are  
CC used to modulate expression of the telomerase genes in cells, tissue  
CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and  
CC transplants for the treatment of a variety of conditions. They may be  
CC used for treating cancer, restenosis, infectious diseases (specifically  
CC protozoal), transplant rejection, or autoimmune or age-related diseases,  
CC e.g. multiple sclerosis, lupus erythematosus, AIDS, macular degeneration,  
CC skin ulcers and rheumatoid arthritis. The siNAs are also useful for drug  
CC screening, diagnosis, therapeutic target identification and validation,  
CC genetic engineering, pharmacogenomics, studying gene function, and gene  
CC mapping (e.g., of single nucleotide polymorphisms). The present sequence  
CC represents the upper strand of a human TERT-targeted double-stranded  
CC siNA, which is identical to the c-fos transcript target sequence.  
XX  
SQ Sequence 19 BP; 6 A; 1 C; 3 G; 0 T; 9 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 41.2%; Pred. No. 93;  
Matches 7; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY 1580 TTTTTC AATTTTG AAAA 1596  
: : : : : | : : : : : | : : : : : | : : : : : | : : : : : |  
Db 2 UUUUUCAGUUUUUGAAAA 18

RESULT 52  
ADF93791/c  
ID ADF93791 standard; RNA; 19 BP.  
XX  
AC ADF93791;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
DE Human TERT siNA lower strand, SEQ ID 518.  
XX  
KW Cytostatic; vasotropic; protozoacide; immunosuppressive; dermatological;  
KW neuroprotective; anti-HIV; ophthalmological; antiulcer; antirheumatic;  
KW antiarthritic; antiinflammatory; gene therapy; telomerase; human; terc;  
KW RNA interference; short interfering nucleic acid; siNA;  
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;  
KW short hairpin RNA; shRNA; expression modulation; gene therapy;  
KW drug screening; diagnosis; therapeutic target identification;  
KW pharmacogenomics; gene function analysis; gene mapping; TERC; TERT; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO2003070742-A1.  
XX  
XX 28-AUG-2003.  
XX  
XX 11-FEB-2003; 2003WO-US004088.  
XX  
XX 20-FEB-2002; 2002US-0358580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 17-JUL-2002; 2002US-0396600P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Mcswiggen J, Beigelman L;  
PI  
XX  
XX WPI; 2003-689777/65.  
XX  
XX New short interfering nucleic acid downregulates expression of the  
PT telomerase gene useful e.g. for treatment and diagnosis of cancer.  
XX  
XX Example 3; SEQ ID NO 518; 145pp; English.  
PS  
XX  
CC The invention relates to short interfering nucleic acids (siNA) which  
CC downregulate expression of the one or more telomerase genes by RNA  
CC interference. The siNAs may or may not comprise ribonucleotides and may  
CC be double or single stranded. They further comprise sense and antisense  
CC regions, or alternatively are assembled from a sense oligonucleotide and  
CC an antisense oligonucleotide. Specifically, the siNAs include short  
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short  
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,  
CC can contain deoxyribonucleotides, and can be chemically synthesised,  
CC expressed from a vector or enzymatically synthesised. The invention also  
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates  
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are  
CC used to modulate expression of the telomerase genes in cells, tissue  
CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and  
CC transplants for the treatment of a variety of conditions. They may be  
CC used for treating cancer, restenosis, infectious diseases (specifically  
CC protozoal), transplant rejection, or autoimmune or age-related diseases,  
CC e.g. multiple sclerosis, lupus erythematosus, AIDS, macular degeneration,  
CC skin ulcers and rheumatoid arthritis. The siNAs are also useful for drug  
CC screening, diagnosis, therapeutic target identification and validation,  
CC genetic engineering, pharmacogenomics, studying gene function, and gene  
CC mapping (e.g., of single nucleotide polymorphisms). The present sequence  
CC represents the lower strand of a human TERT-targeted double-stranded  
CC siNA.  
XX  
SQ Sequence 19 BP; 9 A; 3 C; 1 G; 0 T; 6 U; 0 Other;



PR 30-JAN-2001; 2001WO-US0000664.  
PR 30-JAN-2001; 2001WO-US0000665.  
PR 30-JAN-2001; 2001WO-US0000666.  
PR 30-JAN-2001; 2001WO-US0000667.  
PR 30-JAN-2001; 2001WO-US0000668.  
PR 30-JAN-2001; 2001WO-US0000669.  
PR 30-JAN-2001; 2001WO-US0000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 10432; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 870 GAGTTTGTGCTGTCA 886  
Db |||||||||||||  
17 GACTTTTGATGCTGTCA 1  
  
RESULT 50  
ACN73530/c  
ID ACN73530 standard; DNA; 17 BP.  
XX  
AC ACN73530;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPLP-1 probe SEQ ID NO:10432.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX

PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US0000661.  
PR 30-JAN-2001; 2001WO-US0000662.  
PR 30-JAN-2001; 2001WO-US0000663.  
PR 30-JAN-2001; 2001WO-US0000664.  
PR 30-JAN-2001; 2001WO-US0000665.  
PR 30-JAN-2001; 2001WO-US0000666.  
PR 30-JAN-2001; 2001WO-US0000667.  
PR 30-JAN-2001; 2001WO-US0000668.  
PR 30-JAN-2001; 2001WO-US0000669.  
PR 30-JAN-2001; 2001WO-US0000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX  
DR WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10432; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 870 GAGTTTGTGCTGTCA 886  
Db |||||||||||||  
17 GACTTTTGATGCTGTCA 1  
  
RESULT 51  
ADF93537  
ID ADF93537 standard; RNA; 19 BP.  
XX  
AC ADF93537;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
DE Human TERT transcript target sequence/siNA upper strand, SEQ ID 254.  
XX

CC related to excessive formation of vascular tissue or blood vessels in a  
CC patient. These include neovascular glaucoma, any form of retinopathy; all  
CC proliferative retinopathies, including proliferative diabetic  
CC retinopathy, retinopathy of prematurity, macular degeneration,  
CC maculopathy, micro- or macro-vascular eye complications caused by  
CC diabetes, nephropathy, diabetic nephropathy, rubeosis iridis,  
CC haemangiomas, angiofibromas, psoriasis, predisposition to vision loss and  
CC blindness, which are consequences of retinopathy, a metabolic disease, a  
CC cardiovascular disease, or a cancerous disease, e.g. tumours and  
CC neoplasms, including malignant tumours and neoplasms, blastomas,  
CC carcinomas or sarcomas, highly vascular tumours and neoplasms, epidermoid  
CC tumours, squamous tumours, head and neck tumours, colorectal tumours,  
CC prostate tumours, breast tumours, lung tumours, including small cell and  
CC non-small cell lung tumours, pancreatic tumours, thyroid tumours, ovarian  
CC tumours, and liver tumours, vascularised skin cancers, including squamous  
CC cell carcinoma, basal cell carcinoma, and skin cancers that can be  
CC treated by suppressing the growth of neovasculature, Kaposi's sarcoma,  
CC CNS neoplasms including neuroblastomas, capillary haemangioblastomas,  
CC meningiomas and cerebral metastases, melanoma, gastrointestinal and renal  
CC carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, glioblastoma  
CC multiforme, or leiomyosarcoma (all claimed). The antisense  
CC oligonucleotides may have locked nucleic acid and peptide-nucleic acid  
CC modifications, or have modified sugar units or internucleotide linkages.  
CC They are also useful for investigating the development of a disease or  
CC disorder related to excessive formation of vascular tissue or blood  
CC vessels in an experimental animal.  
XX  
SQ Sequence 20 BP; 2 A; 3 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 87;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CATTTTGGTGGTTTTT 501  
|||||  
Db 5 CATTTTGGTGGTTTTT 20

RESULT 48  
ADI28398  
ID ADI28398 standard; DNA; 20 BP.  
XX  
AC ADI28398;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human neuropeptide Y2 receptor antisense oligonucleotide.

XX  
KW Human; neuropeptide Y2; antisense; antiangiogenic; ophthalmological;  
KW nephrotropic; antipsoriatic; cardiovascular-gen.; cytostatic; anti-HIV;  
KW receptor; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004002535-A1.  
XX  
PD 08-JAN-2004.  
XX  
PF 17-JUN-2003; 2003WO-FI000487.  
XX  
PR 27-JUN-2002; 2002US-00180967.  
XX  
PA (HORM-) HORMOS MEDICAL CORP.  
XX  
PI Koulu M, Tuohimaa J, Pesonen U, Kallio J, Karvonen M;  
XX  
DR WPI; 2004-082891/08.  
XX  
PT Use of an agent affecting the neuropeptide Y Y2 receptor, i.e. antisense  
PT oligonucleotide, for treating or preventing a disease or disorder related  
PT to excessive formation of vascular tissue or blood vessels, e.g.  
PT retinopathy or cancer.  
XX

PS  
XX  
CC Claim 11; SEQ ID NO 25; 73pp; English.  
CC The present sequence is that of an antisense oligonucleotide targeted to  
CC human neuropeptide Y2 receptor mRNA ADI28374. It is an example of  
CC neuropeptide Y2 receptor-targeted antisense oligonucleotides of the  
CC invention useful in the treatment or prevention of a disease or disorder  
CC related to excessive formation of vascular tissue or blood vessels in a  
CC patient. These include neovascular glaucoma, any form of retinopathy, all  
CC proliferative retinopathies, including proliferative diabetic  
CC retinopathy, retinopathy of prematurity, macular degeneration,  
CC maculopathy, micro- or macro-vascular eye complications caused by  
CC diabetes, nephropathy, diabetic nephropathy, rubeosis iridis,  
CC haemangiomas, angiofibromas, psoriasis, predisposition to vision loss and  
CC blindness, which are consequences of retinopathy, a metabolic disease, a  
CC cardiovascular disease, or a cancerous disease, e.g. tumours and  
CC neoplasms, including malignant tumours and neoplasms, blastomas,  
CC carcinomas or sarcomas, highly vascular tumours and neoplasms, epidermoid  
CC tumours, squamous tumours, head and neck tumours, colorectal tumours,  
CC prostate tumours, breast tumours, lung tumours, including small cell and  
CC non-small cell lung tumours, pancreatic tumours, thyroid tumours, ovarian  
CC tumours, and liver tumours, vascularised skin cancers, including squamous  
CC cell carcinoma, basal cell carcinoma, and skin cancers that can be  
CC treated by suppressing the growth of neovasculature, Kaposi's sarcoma,  
CC CNS neoplasms including neuroblastomas, capillary haemangioblastomas,  
CC meningiomas and cerebral metastases, melanoma, gastrointestinal and renal  
CC carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, glioblastoma  
CC multiforme, or leiomyosarcoma (all claimed). The antisense  
CC oligonucleotides may have locked nucleic acid and peptide-nucleic acid  
CC modifications, or have modified sugar units or internucleotide linkages.  
CC They are also useful for investigating the development of a disease or  
CC disorder related to excessive formation of vascular tissue or blood  
CC vessels in an experimental animal.  
XX  
SQ Sequence 20 BP; 1 A; 2 C; 6 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 87;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CATTTTGGTGGTTTTT 501  
|||||  
Db 2 CATTTTGGTGGTTTTT 17

RESULT 49  
ABN10440/c  
ID ABN10440 standard; DNA; 17 BP.  
XX  
AC ABN10440;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10432.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.

XX The invention relates to a compound targeted to a nucleic acid molecule  
CC encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound  
CC is an antisense oligonucleotide that specifically hybridises with the  
CC nucleic acid and inhibits expression of the polypeptide. The antisense  
CC oligonucleotide comprises at least one modified internucleoside linkage  
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,  
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified  
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are  
CC useful for modulating the expression of the MMP11 polypeptide and in  
CC preparation of a composition for treating hyperproliferative disorders,  
CC e.g. cancer. This sequence represents an antisense oligonucleotide  
CC targeted to DNA encoding the human MMP11 polypeptide of the invention.  
XX  
SQ Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 902 AGATCTTTTCTTCAAAG 919  
DB 19 AGCTCTTTTCTTCAAAG 2  
  
RESULT 46  
AAX63796  
ID AAX63796 standard; RNA; 17 BP.  
XX  
AC AAX63796;  
XX  
DT 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hammerhead target SEQ ID NO:428.  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
PN WO9618736-A2.  
XX  
PD 20-JUN-1996.  
XX  
PF 22-NOV-1995; 95WO-US015516.  
XX  
PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX

PS  
XX Example 1; Page 153; 307pp; English.  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 12 A; 2 C; 1 G; 0 T; 2 U; 0 Other;  
  
Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 66;  
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
  
QY 197 AAAAAATCCAAGAAAT 212  
DB 2 AAAAAAUCCAAGAAAU 17  
  
RESULT 47  
ADI28399  
ID ADI28399 standard; DNA; 20 BP.  
XX  
AC ADI28399;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human neuropeptide Y2 receptor antisense oligonucleotide.  
XX  
KW Human; neuropeptide Y2; antisense; antiangiogenic; ophthalmological;  
KW nephrotropic; antipsoriatic; cardiovascular-gen.; cytostatic; anti-HIV;  
KW receptor; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004002535-A1.  
XX  
PD 08-JAN-2004.  
XX  
PF 17-JUN-2003; 2003WO-FI000487.  
XX  
PR 27-JUN-2002; 2002US-00180967.  
XX  
PA (HORM-) HORMOS MEDICAL CORP.  
XX  
PI Koulu M, Tuohimaa J, Pesonen U, Kallio J, Karvonen M;  
XX  
DR WPI; 2004-082891/08.  
XX  
PT Use of an agent affecting the neuropeptide Y Y2 receptor, i.e. antisense  
PT oligonucleotide, for treating or preventing a disease or disorder related  
PT to excessive formation of vascular tissue or blood vessels, e.g.  
PT retinopathy or cancer.  
XX  
PS Claim 11; SEQ ID NO 26; 73pp; English.  
XX  
CC The present sequence is that of an antisense oligonucleotide targeted to  
CC human neuropeptide Y2 receptor mRNA ADI28374. It is an example of  
CC neuropeptide Y2 receptor-targeted antisense oligonucleotides of the  
CC invention useful in the treatment or prevention of a disease or disorder



KW infantile epilepsy; ataxia; ss.  
XX  
OS Synthetic.  
XX  
PN WO2004016754-A2.  
XX  
PD 26-FEB-2004.  
XX  
PF 14-AUG-2003; 2003WO-US025465.  
XX  
XX  
PR 14-AUG-2002; 2002US-0403416P.  
XX  
PA (PHAA ) PHARMACIA CORP.  
XX  
PI Roberds SL;  
XX  
DR WPI; 2004-203785/19.  
XX  
PT New antisense compound targeted to a nucleic acid molecule encoding  
PT Navl.3, useful for treating a disease or condition associated  
PT with Navl.3, e.g. pain, seizure disorder such as childhood seizure  
PT disorder, or ataxia.  
XX  
PS Claim 4; SEQ ID NO 3692; 417pp; English.  
XX  
CC The present invention relates to an antisense compound targeted to a  
CC nucleic acid molecule encoding Navl.3, where the antisense compound  
CC specifically hybridizes with and inhibits the expression of Navl.3. The  
CC compound and composition are useful for treating a disease or condition  
CC associated with Navl.3, e.g. pain including but not limited to  
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,  
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,  
CC pain from burns, migraine headache, cluster headache, mild-to-moderate  
CC headache; seizure disorder such as childhood seizure disorder, including  
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present  
CC sequence represents a chimeric phosphorothioate oligonucleotide with  
CC 2'MOE wings and a decoy gap. Used during the antisense inhibition of  
CC human Navl.3 expression, the oligonucleotides are designed to target  
CC different regions of the human Navl.3 RNA.  
XX  
SQ Sequence 20 BP; 9 A; 0 C; 0 G; 11 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1745 ATTAAGTATATATATATTT 1762  
Db 1 ATTAATTATATATATATTT 18  
|||||  
  
RESULT 44  
ADP27276  
ID ADP27276 standard; DNA; 20 BP.  
XX  
AC ADP27276;  
XX  
DT 26-AUG-2004 (first entry)  
XX  
DE Human MMP11 DNA antisense oligonucleotide target region #30.  
XX  
KW Human; matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;  
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;  
KW 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.  
XX  
OS Homo sapiens.  
OS  
XX US2004110152-A1.  
PN  
XX  
PD 10-JUN-2004.  
XX  
PF 10-DEC-2002; 2002US-00316755.  
XX

PR 10-DEC-2002; 2002US-00316755.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Baker BF, Cowsert LM;  
XX  
DR WPI; 2004-440341/41.  
XX  
PT New oligonucleotide compound that inhibits expression of matrix  
PT metalloproteinase 11, useful for preparing a composition for treating  
PT hyperproliferative disorder, e.g., cancer.  
XX  
PS Example 16; SEQ ID NO 202; 76pp; English.  
XX  
CC The invention relates to a compound targeted to a nucleic acid molecule  
CC encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound  
CC is an antisense oligonucleotide that specifically hybridises with the  
CC nucleic acid and inhibits expression of the polypeptide. The antisense  
CC oligonucleotide comprises at least one modified internucleoside linkage  
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,  
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified  
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are  
CC useful for modulating the expression of the MMP11 polypeptide and in  
CC preparation of a composition for treating hyperproliferative disorders,  
CC e.g. cancer. This sequence represents a human MMP11 DNA antisense  
CC oligonucleotide target region of the invention.  
XX  
SQ Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 902 AGATCTTTTCTTCAAAG 919  
Db 2 AGCTCTTTTCTTCAAAG 19  
|||||  
  
RESULT 45  
ADP27131/c  
ID ADP27131 standard; DNA; 20 BP.  
XX  
AC ADP27131;  
XX  
DT 26-AUG-2004 (first entry)  
XX  
DE Human matrix metalloproteinase 11 DNA antisense oligonucleotide #40.  
XX  
KW Human; matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;  
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;  
KW 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.  
XX  
OS Homo sapiens.  
XX  
PN US2004110152-A1.  
XX  
PD 10-JUN-2004.  
XX  
PF 10-DEC-2002; 2002US-00316755.  
XX  
PR 10-DEC-2002; 2002US-00316755.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Baker BF, Cowsert LM;  
XX  
DR WPI; 2004-440341/41.  
XX  
PT New oligonucleotide compound that inhibits expression of matrix  
PT metalloproteinase 11, useful for preparing a composition for treating  
PT hyperproliferative disorder, e.g., cancer.  
XX  
PS Example 15; SEQ ID NO 57; 76pp; English.

Best Local Similarity 94.4%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1414 TTGGTTGTTAGAAATGG 1431  
| | | | | | | | | | | | | | | | | |  
Db 19 TCTGGTTGTTAGAAATGG 2

RESULT 41  
ADK76164  
ID ADK76164 standard; DNA; 20 BP.  
XX  
AC ADK76164;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #3498.  
XX  
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;  
KW diabetic neuropathy; arthritic pain; migraine headache;  
KW infantile epilepsy; ataxia; ss.  
XX  
OS Synthetic.  
XX  
PN WO2004016754-A2.  
XX  
DT 26-FEB-2004.  
XX  
DE New antisense compound targeted to a nucleic acid molecule encoding  
Nav1.3, useful for treating a disease or condition associated  
with Nav1.3, e.g. pain, seizure disorder such as childhood seizure  
disorder, or ataxia.  
XX  
PA (PHAA ) PHARMACIA CORP.  
XX  
PI Roberds SL;  
XX  
DR WPI; 2004-203785/19.  
XX  
PT New antisense compound targeted to a nucleic acid molecule encoding  
Nav1.3, useful for treating a disease or condition associated  
with Nav1.3, e.g. pain, seizure disorder such as childhood seizure  
disorder, or ataxia.  
XX  
PS Claim 4; SEQ ID NO 3498; 417pp; English.  
XX  
CC The present invention relates to an antisense compound targeted to a  
nucleic acid molecule encoding Nav1.3, where the antisense compound  
specifically hybridizes with and inhibits the expression of Nav1.3. The  
compound and composition are useful for treating a disease or condition  
associated with Nav1.3, e.g. pain including but not limited to  
neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,  
diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,  
pain from burns, migraine headache, cluster headache, mild-to-moderate  
headache; seizure disorder such as childhood seizure disorder, including  
but not limited to neonatal or infantile epilepsy; or ataxia. The present  
sequence represents a chimeric phosphorothioate oligonucleotide with  
2'MOE wings and a deoxy gap. Used during the antisense inhibition of  
human Nav1.3 expression, the oligonucleotides are designed to target  
different regions of the human Nav1.3 RNA.

Sequence 20 BP; 8 A; 0 C; 0 G; 12 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1745 ATTAAGTATATATATTTT 1762  
| | | | | | | | | | | | | | | | | |  
Db 2 ATTAATTATATATATTTT 19

RESULT 42  
ADK76981

ID ADK76981 standard; DNA; 20 BP.  
XX  
AC ADK76981;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4315.  
XX  
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;  
KW diabetic neuropathy; arthritic pain; migraine headache;  
KW infantile epilepsy; ataxia; ss.  
XX  
OS Synthetic.  
XX  
PN WO2004016754-A2.  
XX  
DT 26-FEB-2004.  
XX  
DE New antisense compound targeted to a nucleic acid molecule encoding  
Nav1.3, useful for treating a disease or condition associated  
with Nav1.3, e.g. pain, seizure disorder such as childhood seizure  
disorder, or ataxia.  
XX  
PA (PHAA ) PHARMACIA CORP.  
XX  
PI Roberds SL;  
XX  
DR WPI; 2004-203785/19.  
XX  
PT New antisense compound targeted to a nucleic acid molecule encoding  
Nav1.3, useful for treating a disease or condition associated  
with Nav1.3, e.g. pain, seizure disorder such as childhood seizure  
disorder, or ataxia.  
XX  
PS Claim 4; SEQ ID NO 4315; 417pp; English.  
XX  
CC The present invention relates to an antisense compound targeted to a  
nucleic acid molecule encoding Nav1.3, where the antisense compound  
specifically hybridizes with and inhibits the expression of Nav1.3. The  
compound and composition are useful for treating a disease or condition  
associated with Nav1.3, e.g. pain including but not limited to  
neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,  
diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,  
pain from burns, migraine headache, cluster headache, mild-to-moderate  
headache; seizure disorder such as childhood seizure disorder, including  
but not limited to neonatal or infantile epilepsy; or ataxia. The present  
sequence represents a chimeric phosphorothioate oligonucleotide with  
2'MOE wings and a deoxy gap. Used during the antisense inhibition of  
human Nav1.3 expression, the oligonucleotides are designed to target  
different regions of the human Nav1.3 RNA.

Sequence 20 BP; 7 A; 0 C; 0 G; 13 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1745 ATTAAGTATATATATTTT 1762  
| | | | | | | | | | | | | | | | | |  
Db 3 ATTAATTATATATATTTT 20

RESULT 43  
ADK76358  
ID ADK76358 standard; DNA; 20 BP.  
XX  
AC ADK76358;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #3692.  
XX  
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;  
KW diabetic neuropathy; arthritic pain; migraine headache;

KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
DR WPI; 2004-677362/66.  
XX  
PT Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
PS  
XX Example 5; SEQ ID NO 5375; 378pp; English.  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a human glucose-6-phosphatase antisense oligonucleotide that

CC can be used to control glucose-6-phosphatase gene expression.  
XX  
SQ Sequence 19 BP; 11 A; 2 C; 2 G; 4 T; 0 U; 0 Other;  
Query Match 0.9%; Score 16.4; DB 1; Length 19;  
Best Local Similarity 94.4%; Pred. No. 72;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1043 TTTTCTTTTAAAGATG 1060  
||||||| |||||  
Db 19 TTTTCTTTCAAGATG 2  
RESULT 40  
AAQ39422/c  
ID AAQ39422 standard; DNA; 20 BP.  
XX  
AC AAQ39422;  
XX  
DT 25-MAR-2003 (revised)  
DT 20-MAY-1993 (first entry)  
XX  
DE PCR Primer #2 for mapping EST's to specific chromosome.  
XX expressed sequence tag; human genome project; chromosome;  
KW human gene sequencing; PCR mapping; somatic cell hybrids;  
KW sublocalisation; gene tagging; tissue typing.  
XX Synthetic.  
XX WO9300353-A1.  
XX  
PD 07-JAN-1993.  
XX  
PF 19-JUN-1992; 92WO-US005222.  
XX  
PR 20-JUN-1991; 91US-00716831.  
PR 12-FEB-1992; 92US-00837195.  
XX  
PA (USSH ) US DEPT HEALTH & HUMAN SERVICE.  
XX Venter JC, Adams MD;  
XX WPI; 1993-036325/04.  
XX  
PT Particular expressed sequence tags from human CDNA - corresponds to  
PT transcription prods. of genes, useful for tagging genes, mapping  
PT chromosomes and tissue typing.  
XX  
PS Example 3; Page 42; 199pp; English.  
XX  
CC This PCR primer was used together with AAQ39421 for the PCR mapping of  
CC somatic cell hybrids. This is a method of assigning an EST (expressed  
CC sequence tag) to a particular chromosome. ESTs are markers for human  
CC genes actually transcribed in vivo. Unlike the random genomic DNA  
CC sequence tagged sites (STSs), ESTs point directly to expressed genes. The  
CC use of ESTs could facilitate the tagging of most expressed human genes  
CC within a few years at a fraction of the cost of complete genomic  
CC sequencing. Using these primers and disclosed methods sublocalisation can  
CC be achieved with panels of fragments from specific chromosomes or pools  
CC of large genomic clones in an analogous manner. This PCR primer sequence  
CC was designed from EST00058 by the computer program INTRON (National  
CC Institutes of Mental Health, Bethesda, MD) to minimise the chance of  
CC amplifying through an intron using the assumptions that: 1) introns are  
CC genomic sequences that interrupt the coding and non-coding sequences of  
CC genes. 2) there are consensus sequences for splice junctions. 3) 90% of  
CC the human genes studied have 3' UTR of mRNA not interrupted by introns in  
CC the genomic DNA. This PCR primer localised EST00058 to chromosome 1.  
CC (Updated on 25-MAR-2003 to correct PN field.)  
XX  
SQ Sequence 20 BP; 7 A; 6 C; 3 G; 4 T; 0 U; 0 Other;  
Query Match 0.9%; Score 16.4; DB 1; Length 20;





XX PS Claim 12; Page 70; 77pp; English.

XX CC The synthetic oligomer is capable of forming a triplex at physiological

CC\_ pH with a purine rich target sequence by coupling into the major groove

CC of the duplex. The specific target sequence of this oligomer is the human

CC tumour necrosis factor beginning at nucleotide 1137 contg. a purine rich

CC sequence concd. on one strand of the duplex. The oligomer, and others

CC like it are useful in diagnosis and therapy of diseases characterised by

CC specific DNA duplex targets, e.g. HPV; HER; HIV, hepatitis B, herpes,

CC malignant tumours and inflammation. The triple helices form under mild

CC conditions thus assays may be carried out without subjecting the test

CC specimen to harsh conditions. See also AAQ25452-25501 and AAQ30226-448.

CC (Updated on 25-MAR-2003 to correct PN field.)

XX SQ Sequence 21 BP; 11 A; 0 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 77;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1742 AAAATTAAAGTATATATATTT 1761

Db 1 AAAATTATATATATATATTT 20

RESULT 36

AAQ30387

ID AAQ30387 standard; DNA; 21 BP.

XX AC AAQ30387;

XX 25-MAR-2003 (revised)

DT 07-DEC-1992 (first entry)

XX Oligomer TNF218 for forming triplex with HUMTNFAA target duplex.

DE Tumour necrosis factor; herpes simplex; AIDS; modified; HIV; RSV; HPV;

XX malignancy; hepatitis; inflammation; ss.

KW Synthetic.

XX OS

XX FH Key Location/Qualifiers

FT modified\_base 1 /\*tag= a

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT modified\_base 2 /\*tag= b

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT modified\_base 3 /\*tag= c

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT modified\_base 4 /\*tag= d

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT modified\_base 7 /\*tag= e

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT modified\_base 9 /\*tag= f

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT modified\_base 11 /\*tag= g

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT modified\_base 13 /\*tag= h

FT FT /mod\_base= OTHER

FT FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT 15

FT modified\_base /\*tag= i

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT 17

FT modified\_base /\*tag= j

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"

FT 21

FT modified\_base /\*tag= k

FT /\*mod\_base= OTHER

FT /\*note= "OTHER= N4 N4 ethanocytosine"

XX XX

PN WO9209705-A1.

XX.

PD 11-JUN-1992.

XX 25-NOV-1991; 91WO-US008811.

PF XX

PR 23-NOV-1990; 90US-00617907.

PR 18-JAN-1991; 91US-00643382.

PR 08-APR-1991; 91US-00683420.

PR 17-APR-1991; 91US-00686544.

PR 17-APR-1991; 91US-00686546.

PR 17-APR-1991; 91US-00686547.

PR 27-SEP-1991; 91US-00766733.

XX XX

PA (GILE-) GILEAD SCI INC.

XX XX

PI Froehler B, Krawczyk S, Matteucci MD, Milligan J;

XX WPI; 1992-217083/26.

DR

XX New oligomers contg. modified bases - which form a triplex with G-C

PT doublet in a DNA duplex, for treating and diagnosing HIV, hepatitis,

PT herpes malignancy and inflammation.

XX Claim 12; Page 70; 77pp; English.

XX

CC The synthetic oligomer is capable of forming a triplex at physiological

CC pH with a purine rich target sequence by coupling into the major groove

CC of the duplex. The specific target sequence of this oligomer is the human

CC tumour necrosis factor beginning at nucleotide 1137 contg. a purine rich

CC sequence concd. on one strand of the duplex. The oligomer, and others

CC like it are useful in diagnosis and therapy of diseases characterised by

CC specific DNA duplex targets, e.g. HPV; HER; HIV, hepatitis B, herpes,

CC malignant tumours and inflammation. The triple helices form under mild

CC conditions thus assays may be carried out without subjecting the test

CC specimen to harsh conditions. See also AAQ25452-25501 and AAQ30226-448.

CC (Updated on 25-MAR-2003 to correct PN field.)

XX XX

SQ Sequence 21 BP; 10 A; 1 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 77;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1742 AAAATTAAAGTATATATATTT 1761

Db 1 AAAATTATATATATATATTT 20

RESULT 37

AAQ64428

ID AAQ64428 standard; RNA; 18 BP.

XX AC AAQ64428;

XX 20-JUL-1999 (first entry)

DT

XX Human stromelysin hairpin target sequence SEQ ID NO:1060.

DE

FT modified\_base 9 /tag= f /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT 11  
FT /tag= g /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT 13  
FT /tag= h /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT 15  
FT /tag= i /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT 17  
FT /tag= j /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT 21  
FT /tag= k /mod\_base= OTHER  
FT /note= "N4N4-ethanocytosine"  
FT  
XX  
PN WO9118997-A.  
XX  
PD 12-DEC-1991.  
XX  
PF 25-MAY-1990; 90US-00529346.  
XX  
PR 25-MAY-1990; 90US-00529346.  
PR 14-JAN-1991; 91US-00640654.  
XX  
PA (GILE-) GILEAD SCIE INC.  
XX  
PI Matteucci MD, Krawczyk S;  
XX  
DR WPI; 1992-007480/01.  
XX  
PT New sequence-specific non-photo-activated crosslinking agents - bind to  
PT the major groove of duplex DNA and are esp. useful for treating latent  
PT infections e.g. HIV.  
XX  
PS Example 4; Page 25; 42pp; English.  
XX  
CC The sequence is designed to target the Human tumour necrosis factor  
CC beginning at nucleotide 1137 and to covalently cross-link to it via the  
CC N4N4-ethanocytosine group. See also AAQ20031-Q20038  
XX  
SQ Sequence 21 BP; 10 A; 1 C; 0 G; 10 T; 0 U; 0 Other;  
Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 77;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1742 AAAATTAACTATATATATTT 1761  
Db 1 AAAATTATATATATATATTT 20  
RESULT 35  
AAQ30386  
ID AAQ30386 standard; DNA; 21 BP.  
XX  
AC AAQ30386;  
XX  
DT 25-MAR-2003 (revised)  
DT 07-DEC-1992 (first entry)  
XX  
DE Oligomer TNF217 for forming triplex with HUMTNFAA target duplex.  
XX Tumour necrosis factor; herpes simplex; AIDS; modified; HIV; RSV; HPV;

KW malignancy; hepatitis; inflammation; ss.  
XX Synthetic.  
OS  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1 /tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 2  
FT /tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 3  
FT /tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 4  
FT /tag= d  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 7  
FT /tag= e  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 9  
FT /tag= f  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 11  
FT /tag= g  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 13  
FT /tag= h  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 15  
FT /tag= i  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 17  
FT /tag= j  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT 21  
FT /tag= k  
FT /mod\_base= OTHER  
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"  
FT  
XX WO9209705-A1.  
PN  
XX 11-JUN-1992.  
PD  
XX 25-NOV-1991; 91WO-US008811.  
PF  
XX 23-NOV-1990; 90US-00617907.  
PR 18-JAN-1991; 91US-00643382.  
PR 08-APR-1991; 91US-00683420.  
PR 17-APR-1991; 91US-00686544.  
PR 17-APR-1991; 91US-00686546.  
PR 17-APR-1991; 91US-00686547.  
PR 27-SEP-1991; 91US-00766733.  
XX  
PA (GILE-) GILEAD SCI INC.  
XX  
PI Froehler B, Krawczyk S, Matteucci MD, Milligan J;  
XX WPI; 1992-217083/26.  
DR  
XX New oligomers contg. modified bases - which form a triplex with G-C  
PT doublet in a DNA duplex, for treating and diagnosing HIV, hepatitis,  
PT herpes malignancy and inflammation.



PT nucleic acids associated with lung airway or lung dysfunction, and  
PT bronchodilating agent.  
XX  
PS Claim 15; SEQ ID NO 4151; 763pp; English.  
XX  
CC This invention describes a novel composition (a) a first active agent,  
CC comprising oligonucleotides, effective for alleviating  
CC bronchoconstriction, respiratory tract inflammation, allergies and  
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,  
CC surfactant depletion or hyposecretion, when administered to a mammal. The  
CC oligonucleotides are derived from a gene encoding or regulating  
CC expression of a target polypeptide associated with lung airway or lung  
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.  
CC The invention also describes a kit, that comprises: (a) a delivery  
CC device, in separate containers, (b) the oligonucleotides, (c)  
CC instructions for adding a carrier and for use of the kit. The composition  
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,  
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a  
CC beta-adrenergic agonist. The composition is useful for preventing or  
CC treating a respiratory, lung or malignant disease. The administered  
CC composition comprises oligo and is administered to reduce the production  
CC or availability, or to increase the degradation of the target mRNA or to  
CC reduce the amount of target polypeptide present in the lungs. The  
CC pulmonary obstruction, and/or bronchoconstriction and/or lung  
CC inflammation, allergies and/or surfactant hypoproduction are associated  
CC with a disease or condition such as pulmonary vasoconstriction,  
CC inflammation, allergies, asthma, impeded respiration, respiratory  
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary  
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary  
CC transplantation rejection, pulmonary infections, bronchitis or cancer.  
CC The reduced adenosine content of the anti-sense oligos corresponding to  
CC thymidines present in the target RNA serves to prevent the breakdown of  
CC the oligonucleotides into products that free adenosine into the system  
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to  
CC prevent any unwanted effects due to it  
XX  
SQ Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 71;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1559 GATTATATAAAATACATAAT 1578  
||||||| |  
Db 20 GATTATATACAGTACATAAT 1

RESULT 33  
ADK81657/c  
ID ADK81657 standard; DNA; 20 BP.  
XX  
AC ADK81657;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8991.  
XX  
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;  
KW diabetic neuropathy; arthritic pain; migraine headache;  
KW infantile epilepsy; ataxia; ss.  
XX  
OS Synthetic.  
XX  
PN WO2004016754-A2.  
XX  
PD 26-FEB-2004.  
XX  
PF 14-AUG-2003; 2003WO-US025465.  
XX  
PR 14-AUG-2002; 2002US-0403416P.  
XX  
PA (PHAA ) PHARMACIA CORP.

PI Roberds SL;  
XX  
DR WPI; 2004-203785/19.  
XX  
PT New antisense compound targeted to a nucleic acid molecule encoding  
PT Nav1.3, useful for treating a disease or condition associated  
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure  
PT disorder, or ataxia.  
XX  
PS Claim 4; SEQ ID NO 8991; 417pp; English.  
XX  
CC The present invention relates to an antisense compound targeted to a  
CC nucleic acid molecule encoding Nav1.3, where the antisense compound  
CC specifically hybridizes with and inhibits the expression of Nav1.3. The  
CC compound and composition are useful for treating a disease or condition  
CC associated with Nav1.3, e.g. pain including but not limited to  
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,  
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,  
CC pain from burns, migraine headache, cluster headache, mild-to-moderate  
CC headache; seizure disorder such as childhood seizure disorder, including  
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present  
CC sequence represents a chimeric phosphorothioate oligonucleotide with  
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of  
CC human Nav1.3 expression, the oligonucleotides are designed to target  
CC different regions of the human Nav1.3 RNA.  
XX  
SQ Sequence 20 BP; 8 A; 1 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 71;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1569 AATACATATATTTTCAAT 1588  
||||| |  
Db 20 AATCCATAGATTTCAT 1

RESULT 34  
AAQ20036  
ID AAQ20036 standard; DNA; 21 BP.  
XX

AC AAQ20036;

DT 01-APR-1992 (first entry)

XX Cross-linking oligomer 218 for targetting human TNF.

KW deoxyribonucleic acid; major groove; ethanoamino group;  
KW aziridinylcytosine; cross-linking group; tumour necrosis factor; ss.

OS Synthetic.

Key	Location/Qualifiers
modified_base 1	/tag= a
	/mod_base= OTHER
	/note= "N-methyl-8-oxo-2'-deoxyadenine"
modified_base 2	/tag= b
	/mod_base= OTHER
	/note= "N-methyl-8-oxo-2'-deoxyadenine"
modified_base 3	/tag= c
	/mod_base= OTHER
	/note= "N-methyl-8-oxo-2'-deoxyadenine"
modified_base 4	/tag= d
	/mod_base= OTHER
	/note= "N-methyl-8-oxo-2'-deoxyadenine"
modified_base 7	/tag= e
	/mod_base= OTHER
	/note= "N-methyl-8-oxo-2'-deoxyadenine"

PT metalloproteinases, growth factors and cell-cycle dependent kinases.

XX

PS Example 1; Page 261; 408pp; English.

XX

CC The present invention describes a method for treating a proliferative

CC skin or eye disease and scarring. The method involves administering a

CC ribozyme (I) which cleaves RNA encoding a cytokine involved in

CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle

CC dependent kinase, growth factor or a reductase, or administering a

CC nucleic acid molecule (II) comprising a promoter operably linked to a

CC nucleic acid segment encoding (I). (I) can have antipsoriatic,

CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,

CC ophthalmological, vulnery, keratolytic and virucide activities, and

CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used

CC in gene therapy. (I) and (II) are useful for treating proliferative skin

CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,

CC squamous or basal cell carcinoma and viral or seborrheic wart. They can

CC also be used for treating proliferative eye diseases such as diabetic

CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of

CC prematurity and retinal detachment, and for treating and preventing

CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn

CC scar. AAH57577 to AAH62099 represent sequences used in the

CC exemplification of the present invention

XX

SQ Sequence 19 BP; 7 A; 2 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 17.4; DB 1; Length 19;

Best Local Similarity 94.7%; Pred. No. 56;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 901 AAGATCTTTTCTTCAAG 919

Db ||||||| |||||||

19 AAGATCTTTTACTTCAAG 1

RESULT 31

ABZ88909/c

ID ABZ88909 standard; DNA; 20 BP.

XX

AC ABZ88909;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

XX Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

PT ubiquinone.

XX Disclosure; SEQ ID NO 4151; 872pp; English.

PS

XX

CC The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequences

XX

SQ Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 71;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1559 GATTATATAAAATACATAAT 1578

Db ||||||| |||||||

20 GATTATATACAGTACATAAT 1

RESULT 32

ABD25139/c

ID ABD25139 standard; DNA; 20 BP.

XX

AC ABD25139;

XX

DT 29-JUL-2004 (first entry)

XX

DE AI041482-derived oligonucleotide SEQ ID 4151.

XX

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX

OS Homo sapiens.

XX

PN WO200285309-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013143.

XX

PR 24-APR-2001; 2001US-0286036P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-093058/08.

XX

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to

DE Human MMP-12 antisense oligonucleotide, SEQ ID 11.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
XX 17-JUL-2003; 2003WO-SE001223.  
PF  
XX 18-JUL-2002; 2002SE-00002253.  
PR  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
XX  
PA (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
XX WPI; 2004-123288/12.  
DR  
XX New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
XX Claim 7; SEQ ID NO 11; 55pp; English.  
PS  
XX The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 208 GAAATGCAGCACTTCTTGG 226  
Db 19 GAAATGCAGCACTTCTTGG 1  
  
RESULT 29  
AAA85022/c  
ID AAA85022 standard; DNA; 19 BP.  
XX  
AC AAA85022;  
XX  
DT 04-DEC-2000 (first entry)  
XX  
DE Cyclin G1 ribozyme binding site #47.  
XX  
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
XX  
XX Mammalia.  
OS  
XX WO200032765-A2.  
PN  
XX 08-JUN-2000.  
PD  
XX 06-DEC-1999; 99WO-US028772.  
PF  
XX 04-DEC-1998; 98US-0110954P.  
PR

XX (IMMU-) IMMUSOL INC.  
XX  
XX Tritz R, Welch PJ, Barber JR, Robbins JM;  
XX WPI; 2000-412314/35.  
DR  
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.  
XX  
XX Disclosure; Page 86; 109pp; English.  
XX  
XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
CC Representative examples of ribozyme recognition sites are given in  
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for  
CC inhibiting restenosis by introduction of the ribozyme into cells. The  
CC ribozyme is resistant to endonuclease activity and hence is efficient in  
CC restenosis treatment  
XX  
SQ Sequence 19 BP; 7 A; 2 C; 3 G; 7 T; 0 U; 0 Other;  
  
Query Match 1.0%; Score 17.4; DB 1; Length 19;  
Best Local Similarity 94.7%; Pred. No. 56;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 901 AAGATCTTTTCTTCAAAG 919  
Db 19 AAGATCTTTTACTTCAAAG 1  
  
RESULT 30  
AAH60184/c  
ID AAH60184 standard; DNA; 19 BP.  
XX  
AC AAH60184;  
XX  
DT 10-SEP-2001 (first entry)  
XX  
DE Cyclin G1 ribozyme binding site SEQ ID NO:2608.  
XX  
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;  
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
KW antisking; ophthalmological; keratolytic; gene therapy; viral wart;  
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
KW sickle cell retinopathy; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200130362-A2.  
XX  
PD 03-MAY-2001.  
XX  
XX 26-OCT-2000; 2000WO-US029500.  
PF  
XX 26-OCT-1999; 99US-0161532P.  
PR  
XX (IMMU-) IMMUSOL INC.  
XX  
PI Robbins JM, Tritz R;  
XX  
XX WPI; 2001-300427/31.  
DR  
XX Treating proliferative skin or eye diseases and scarring, using ribozymes  
PT that cleave RNA encoding cytokines involved in inflammation, matrix



CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 5 A; 1 C; 4 G; 9 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 355 ACCTACAGAAATCAATAATT 373  
Db 19 ACCTACAGAAATCAATAATT 1

RESULT 26  
ADI53696/c  
ID ADI53696 standard; DNA; 19 BP.

XX  
AC ADI53696;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 9.

XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.

OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.

XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.

XX (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
DR WPI; 2004-123288/12.

XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.

XX Claim 7; SEQ ID NO 9; 55pp; English.

XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.

XX Sequence 19 BP; 3 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 814 AACCAACGCTTGCCAAATC 832  
Db 19 AACCAACGCTTGCCAAATC 1

RESULT 27  
ADI53697/c  
ID ADI53697 standard; DNA; 19 BP.  
XX  
AC ADI53697;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 10.

XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.

XX Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.

XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.

XX (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
DR WPI; 2004-123288/12.

XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.

XX Claim 7; SEQ ID NO 10; 55pp; English.

XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.

XX Sequence 19 BP; 4 A; 2 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1097 CAAATTATCCCAAGAGCAT 1115  
Db 19 CAAATTATCCCAAGAGCAT 1

RESULT 28  
ADI53698/c  
ID ADI53698 standard; DNA; 19 BP.

XX  
AC ADI53698;

XX  
DT 22-APR-2004 (first entry)

OS Synthetic.  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
DR WPI; 2004-123288/12.  
XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 13; 55pp; English.  
XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 913 TTCAAAGACAGGTTCTTCT 931  
Db 19 TTCAAAGACAGGTTCTTCT 1  
  
RESULT 24  
ADI53690/c  
ID ADI53690 standard; DNA; 19 BP.  
XX  
AC ADI53690;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 3.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX

PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
DR WPI; 2004-123288/12.  
XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 3; 55pp; English.  
XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 7 A; 3 C; 7 G; 2 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 751 ACATTTCGCCTCTCTGCTG 769  
Db 19 ACATTTCGCCTCTCTGCTG 1  
  
RESULT 25  
ADI53692/c  
ID ADI53692 standard; DNA; 19 BP.  
XX  
AC ADI53692;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 5.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
DR WPI; 2004-123288/12.  
XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 5; 55pp; English.  
XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and

Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 946 GAGAGACCAAGACCAAGTG 964  
Db 19 GAGAGACCAAGACCAAGTG 1  
|||||

RESULT 21  
ADI53701/c  
ID ADI53701 standard; DNA; 19 BP.  
XX  
AC ADI53701;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 14.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 14.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
XX (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
XX WPI; 2004-123288/12.  
XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 14; 55pp; English.  
XX  
XX The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1231 AGACAGATGATGGACCTG 1249  
Db 19 AGACAGATGATGGACCTG 1  
|||||

RESULT 22  
ADI53693/c  
ID ADI53693 standard; DNA; 19 BP.

XX  
AC ADI53693;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 6.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
DE 17-JUL-2003; 2003WO-SE001223.  
XX  
PF 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
XX WPI; 2004-123288/12.  
XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 6; 55pp; English.  
XX  
XX The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 5 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 512 CTCATGGAGACTTCCATGC 530  
Db 19 CTCATGGAGACTTCCATGC 1  
|||||

RESULT 23  
ADI53700/c  
ID ADI53700 standard; DNA; 19 BP.  
XX  
AC ADI53700;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 13.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.



PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX WPI; 2004-123288/12.  
XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 7; 55pp; English.  
XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 6 A; 4 C; 5 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 855 CTGTGACCCCAATTGAGT 873  
Db 19 CTGTGACCCCAATTGAGT 1  
  
RESULT 19  
ADI53695/c  
ID ADI53695 standard; DNA; 19 BP.  
XX  
AC ADI53695;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 8.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 8.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX WPI; 2004-123288/12.  
DR  
XX New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.

XX Claim 7; SEQ ID NO 8; 55pp; English.  
PS  
XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 8 A; 3 C; 4 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1182 TAGGACCTACTTCTTTGTA 1200  
Db 19 TAGGACCTACTTCTTTGTA 1  
  
RESULT 20  
ADI53699/c  
ID ADI53699 standard; DNA; 19 BP.  
XX  
AC ADI53699;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 12.  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.  
XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX WPI; 2004-123288/12.  
DR  
XX New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 12; 55pp; English.  
XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 1 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;  
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
KW sickle cell retinopathy; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
XX WO200130362-A2.  
XX  
XX 03-MAY-2001.  
XX  
XX 26-OCT-2000; 2000WO-US029500.  
XX  
XX 26-OCT-1999; 99US-0161532P.  
XX  
XX (IMMU-) IMMUSOL INC.  
XX  
XX Robbins JM, Tritz R;  
PI  
XX  
XX WPI; 2001-300427/31.  
DR  
XX  
XX Treating proliferative skin or eye diseases and scarring, using ribozymes  
PT that cleave RNA encoding cytokines involved in inflammation, matrix  
PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
XX  
XX Example 1; Page 23; 408pp; English.  
PS  
XX  
XX The present invention describes a method for treating a proliferative  
CC skin or eye disease and scarring. The method involves administering a  
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
CC dependent kinase, growth factor or a reductase, or administering a  
CC nucleic acid molecule (II) comprising a promoter operably linked to a  
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,  
CC ophthalmological, vulnary, keratolytic and virucide activities, and  
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
CC also be used for treating proliferative eye diseases such as diabetic  
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
CC prematurity and retinal detachment, and for treating and preventing  
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
CC scar. AAH57577 to AAH62099 represent sequences used in the  
CC exemplification of the present invention  
XX  
SQ Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19.4; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 39;  
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 781 GGCATTGAGTCCCTGTATGGA 801  
Db 1 GGCATTGAGTCCCTGTATGGA 21  
  
RESULT 17  
ADI53691/c  
ID ADI53691 standard; DNA; 19 BP.  
XX  
XX ADI53691;  
XX  
XX 22-APR-2004 (first entry)  
DT  
XX  
XX Human MMP-12 antisense oligonucleotide, SEQ ID 4.  
DE  
XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;

KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
XX WO2004009098-A1.  
XX  
XX 29-JAN-2004.  
XX  
XX 17-JUL-2003; 2003WO-SE001223.  
XX  
XX 18-JUL-2002; 2002SE-00002253.  
XX  
XX 04-SEP-2002; 2002US-0407680P.  
XX  
XX (INDE-) INDEX PHARM AB.  
XX  
XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
PI  
XX  
XX WPI; 2004-123288/12.  
DR  
XX  
XX New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
XX Claim 7; SEQ ID NO 4; 55pp; English.  
PS  
XX  
XX The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 4 A; 3 C; 4 G; 8 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 137 GCCTTGAGATAAACAACACT 155  
Db 19 GCCTTGAGATAAACAACACT 1  
  
RESULT 18  
ADI53694/c  
ID ADI53694 standard; DNA; 19 BP.  
XX  
XX ADI53694;  
XX  
XX 22-APR-2004 (first entry)  
DT  
XX  
XX Human MMP-12 antisense oligonucleotide, SEQ ID 7.  
DE  
XX  
XX Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
XX WO2004009098-A1.  
XX  
XX 29-JAN-2004.  
XX  
XX 17-JUL-2003; 2003WO-SE001223.  
XX

CC invention is useful for determining whether a woman has, or is likely to  
CC develop stress urinary incontinence. The human elastase of the invention  
CC is also useful for treating a woman for stress urinary incontinence and a  
CC disease of undesired elastin degradation (e.g. pelvic organ prolapse,  
CC emphysema, abdominal aortic aneurysm, atherosclerosis, pancreatitis and  
CC inflammatory disease). The present DNA sequence represents a PCR primer  
CC that was used in an example of the invention.

XX  
SQ Sequence 21 BP; 5 A; 5 C; 3 G; 8 T; 0 U; 0 Other;  
  
Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 26;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1015 GCTTATGAAATTGAAGCCAGA 1035  
|||||  
Db 21 GCTTATGAAATTGAAGCCAGA 1

RESULT 14  
ACC57867/c  
ID ACC57867 standard; DNA; 20 BP.  
XX  
AC ACC57867;  
XX  
DT 11-AUG-2003 (first entry)  
XX Matrix metalloproteinase 12 antisense PCR primer.  
DE  
XX Matrix metalloproteinase 12; MMP-12; human; transcription;  
KW cis-acting element; transcription factor; PCR; primer; ss.  
XX  
OS Homo sapiens.  
XX WO2003033679-A2.  
XX  
PD 24-APR-2003.  
XX  
PF 17-OCT-2002; 2002WO-US0333579.  
XX  
PR 17-OCT-2001; 2001US-0329961P.  
XX  
PA (ADRE-) ADVANCED RES & TECHNOLOGY INST.  
XX  
PI Yokota H, Sun HB;  
XX  
XX WPI; 2003-393526/37.  
XX  
PT Predicting an expression level of a target gene or gene family comprises  
PT experimentally determining the number and type of cis-acting elements  
PT provided in 5' untranslated regulatory regions of the target gene.

XX  
PS Example 4; Page 36; 78pp; English.  
XX  
CC The present sequence is an antisense primer for the PCR amplification of  
CC human matrix metalloproteinase 12 (MMP-12) cDNA. A 369 bp product is  
CC obtained using this antisense primer with the sense primer given in  
CC ACC57866. Rt-PCR was performed in an example from the invention to  
CC determine expression profiles of MMP genes in human synovial cells in  
CC response to mechanical shear. A model-based analysis was used to identify  
CC the role of transcription factor binding motifs in gene regulation. The  
CC results provide an example of the method of the invention for determining  
CC expression levels of target genes based on sequence elements present in  
CC untranslated regulatory regions

XX Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 31;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 CGTGAGGATGTTGACTACGC 410  
|||||

Db 20 CGTGAGGATGTTGACTACGC 1  
  
RESULT 15  
ACC57866  
ID ACC57866 standard; DNA; 20 BP.  
XX  
AC ACC57866;  
XX  
DT 11-AUG-2003 (first entry)  
XX Matrix metalloproteinase 12 sense PCR primer.  
DE  
XX Matrix metalloproteinase 12; MMP-12; human; transcription;  
KW cis-acting element; transcription factor; PCR; primer; ss.  
XX  
OS Homo sapiens.  
XX WO2003033679-A2.  
XX  
PD 24-APR-2003.  
XX  
PF 17-OCT-2002; 2002WO-US0333579.  
XX  
PR 17-OCT-2001; 2001US-0329961P.  
XX  
PA (ADRE-) ADVANCED RES & TECHNOLOGY INST.  
XX  
PI Yokota H, Sun HB;  
XX  
DR WPI; 2003-393526/37.  
XX  
PT Predicting an expression level of a target gene or gene family comprises  
PT experimentally determining the number and type of cis-acting elements  
PT provided in 5' untranslated regulatory regions of the target gene.

XX  
PS Example 4; Page 36; 78pp; English.  
XX  
CC The present sequence is a sense primer for the PCR amplification of human  
CC matrix metalloproteinase 12 (MMP-12) cDNA. A 369 bp product is obtained  
CC using this sense primer with the antisense primer given in ACC57867. Rt-  
CC PCR was performed in an example from the invention to determine  
CC expression profiles of MMP genes in human synovial cells in response to  
CC mechanical shear. A model-based analysis was used to identify the role of  
CC transcription factor binding motifs in gene regulation. The results  
CC provide an example of the method of the invention for determining  
CC expression levels of target genes based on sequence elements present in  
CC untranslated regulatory regions

XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 31;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 CCACTGCTTCTGGAGCTCTT 63  
|||||  
Db 1 CCACTGCTTCTGGAGCTCTT 20

RESULT 16  
AAH62035  
ID AAH62035 standard; DNA; 21 BP.  
XX  
AC AAH62035;  
XX  
DT 10-SEP-2001 (first entry)

XX MMP3 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4459.  
DE  
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
KW recognition site; target; ribozyme binding site; eye disease; vulneryary;  
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;



XX PD 12-DEC-2002.

XX PF 05-JUN-2002; 2002WO-NZ000106.

XX PR 05-JUN-2001; 2001NZ-00512169.

XX PR 17-JUL-2001; 2001NZ-00513016.

XX PR 18-SEP-2001; 2001NZ-00514275.

XX PA (AUCK-) AUCKLAND UNISERVICES LTD.

XX PI Young RP;

XX DR WPI; 2003-140633/13.

XX PT Diagnosing predisposition to and/or severity of chronic obstructive

XX PT pulmonary disease in smokers/non-smokers, by analyzing polymorphisms in

XX PT regulatory and/or promoter regions of genes encoding matrix

XX PT metalloproteinase.

XX PS Example 1; Col 18; 79pp; English.

XX CC The present invention relates to a method of determining a subject's

XX CC predisposition to or at risk of developing chronic obstructive pulmonary

XX CC disease (COPD), impaired lung function, morbidity/mortality risk of the

XX CC disease associated with impaired lung function in smokers/non-smokers.

XX CC The method involves analysing genetic polymorphisms in regulatory and/or

XX CC promoter regions of genes encoding matrix metalloproteinase (MMP). The

XX CC present DNA sequence is a PCR primer used to determine MMP12 (human

XX CC macrophage elastase) promoter polymorphism. This sequence is used in the

XX CC exemplification of the invention

XX SQ Sequence 21 BP; 3 A; 3 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 26;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 65 CCCTGAACAGCTCTACAAGCC 85

Db 21 CCCTGAACAGCTCTACAAGCC 1

RESULT 12

ADP44842

ID ADP44842 standard; DNA; 21 BP.

XX AC ADP44842;

XX AC

XX DT 12-AUG-2004 (first entry)

XX DE Human matrix metalloproteinase-12 (MMP-12) PCR primer #3.

XX KW human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;

XX KW phenylmethyl-sulfonyl fluoride; stress urinary incontinence;

XX KW undesired elastin degradation disease; pelvic organ prolapse; emphysema;

XX KW abdominal aortic aneurysm; atherosclerosis; pancreatitis;

XX KW inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;

XX KW MMP-12.

XX OS Homo sapiens.

XX OS

XX PN WO2004041115-A2.

XX PD 21-MAY-2004.

XX PF 12-JUN-2003; 2003WO-US018696.

XX PF 14-JUN-2002; 2002US-0389094P.

XX PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.

XX PI Kushner L, Mathrubutham M, Rao SK;

XX DR WPI; 2004-400506/37.

XX PT Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not

XX PT by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary

XX PT incontinence in woman.

XX PS Example 6; SEQ ID NO 9; 54pp; English.

XX CC The invention comprises a human elastase that has an optimum pH of about

XX CC 8.5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and

XX CC EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the

XX CC invention is useful for determining whether a woman has, or is likely to

XX CC develop stress urinary incontinence. The human elastase of the invention

XX CC is also useful for treating a woman for stress urinary incontinence and a

XX CC disease of undesired elastin degradation (e.g. pelvic organ prolapse,

XX CC emphysema, abdominal aortic aneurysm, atherosclerosis, pancreatitis and

XX CC inflammatory disease). The present DNA sequence represents a PCR primer

XX CC that was used in an example of the invention.

XX SQ Sequence 21 BP; 4 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 26;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 663 TCACGAGATTGGCCATTCCCTT 683

Db 1 TCACGAGATTGGCCATTCCCTT 21

RESULT 13

ADP44843/C

ID ADP44843 standard; DNA; 21 BP.

XX AC ADP44843;

XX AC

XX DT 12-AUG-2004 (first entry)

XX DE Human matrix metalloproteinase-12 (MMP-12) PCR primer #4.

XX KW human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;

XX KW phenylmethyl-sulfonyl fluoride; stress urinary incontinence;

XX KW undesired elastin degradation disease; pelvic organ prolapse; emphysema;

XX KW abdominal aortic aneurysm; atherosclerosis; pancreatitis;

XX KW inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;

XX KW MMP-12.

XX OS Homo sapiens.

XX OS

XX PN WO2004041115-A2.

XX PD 21-MAY-2004.

XX PF 12-JUN-2003; 2003WO-US018696.

XX PF 14-JUN-2002; 2002US-0389094P.

XX PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.

XX PI Kushner L, Mathrubutham M, Rao SK;

XX OS

XX PN WO2004-400506/37.

XX PT Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not

XX PT by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary

XX PT incontinence in woman.

XX PS Example 6; SEQ ID NO 10; 54pp; English.

XX CC The invention comprises a human elastase that has an optimum pH of about

XX CC 8.5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and

XX CC EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the

```
Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1014 TGCTTATGAAATTGAAGCCAGAAA 1037
Db      24 TGCTTATGAAATTGAAGCCAGAAA 1

RESULT 9
ADI53707
ID      ADI53707 standard; DNA; 24 BP.
XX
AC      ADI53707;
XX
DT      22-APR-2004 (first entry)
XX
DE      MMP-12 forward primer, SEQ ID 20.
XX
KW      Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW      Respiratory; matrix metalloproteinase 12; MMP-12;
KW      inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW      rheumatoid arthritis; psoriasis; emphysema; asthma; PCR; primer; ss.
XX
OS      Homo sapiens.
XX
PN      WO2004009098-A1.
XX
DT      22-APR-2004 (first entry)
XX
DE      MMP-12 forward primer, SEQ ID 20.
XX
KW      Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW      Respiratory; matrix metalloproteinase 12; MMP-12;
KW      inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW      rheumatoid arthritis; psoriasis; emphysema; asthma; PCR; primer; ss.
XX
OS      Homo sapiens.
XX
PN      WO2004009098-A1.
XX
PD      29-JAN-2004.
XX
PF      17-JUL-2003; 2003WO-SEQ001223.
XX
PR      18-JUL-2002; 2002SE-00002253.
PR      04-SEP-2002; 2002US-0407680P.
XX
PA      (INDE-) INDEX PHARM AB.
XX
PI      Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX
DR      WPI; 2004-123288/12.
XX
PT      New compound having a sequence targeted to a nucleic acid encoding
PT      metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT      treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT      asthma or psoriasis.
XX
PS      Example 1; SEQ ID NO 20; 55pp; English.
XX
CC      The present invention relates to antisense oligonucleotides (ADI53690-
CC      ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
CC      ADI53689), which specifically hybridise with the nucleic acid encoding
CC      MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC      oligonucleotides are useful for preparing a composition for treating or
CC      preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC      bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC      arthritis, psoriasis, emphysema or asthma. The present sequence is a PCR
CC      primer, which was used in an example from the invention.
XX
SQ      Sequence 24 BP; 6 A; 10 C; 2 G; 6 T; 0 U; 0 Other;

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1366 GACTTCCTACTCCAACGTATCACC 1389
Db      1 GACTTCCTACTCCAACGTATCACC 24

RESULT 10
ADI53708/c
ID      ADI53708 standard; DNA; 24 BP.
XX
```

```
AC      ADI53708;
XX
DT      22-APR-2004 (first entry)
XX
DE      MMP-12 reverse primer, SEQ ID 21.
XX
KW      Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW      Respiratory; matrix metalloproteinase 12; MMP-12;
KW      inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW      rheumatoid arthritis; psoriasis; emphysema; asthma; PCR; primer; ss.
XX
OS      Homo sapiens.
XX
PN      WO2004009098-A1.
XX
PD      29-JAN-2004.
XX
PF      17-JUL-2003; 2003WO-SEQ001223.
XX
PR      18-JUL-2002; 2002SE-00002253.
PR      04-SEP-2002; 2002US-0407680P.
XX
PA      (INDE-) INDEX PHARM AB.
XX
PI      Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX
DR      WPI; 2004-123288/12.
XX
PT      New compound having a sequence targeted to a nucleic acid encoding
PT      metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT      treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT      asthma or psoriasis.
XX
PS      Example 1; SEQ ID NO 21; 55pp; English.
XX
CC      The present invention relates to antisense oligonucleotides (ADI53690-
CC      ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
CC      ADI53689), which specifically hybridise with the nucleic acid encoding
CC      MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC      oligonucleotides are useful for preparing a composition for treating or
CC      preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC      bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC      arthritis, psoriasis, emphysema or asthma. The present sequence is a PCR
CC      primer, which was used in an example from the invention.
XX
SQ      Sequence 24 BP; 7 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1692 GCTTCCTAACATCCTTGGACTGAG 1715
Db      24 GCTTCCTAACATCCTTGGACTGAG 1

RESULT 11
AAD51522/c
ID      AAD51522 standard; DNA; 21 BP.
XX
AC      AAD51522;
XX
DT      16-APR-2003 (first entry)
XX
DE      Hmep2 PCR primer used for MMP12 promoter polymorphism genotyping.
XX
KW      Chronic obstructive pulmonary disease; COPD; impaired lung function;
KW      morbidity; genetic polymorphism; matrix metalloproteinase; MMP12; PCR;
KW      primer; ss.
XX
OS      Homo sapiens.
XX
PN      WO200299134-A1.
```

XX The present invention describes a method for predicting, diagnosing or  
CC prognosing chronic lung disease by detecting a chronic obstructive  
CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to  
CC ACC46777, which encode the COPD related proteins in ABP96779 to  
CC ABP96806). The method is useful for predicting, diagnosing or prognosing  
CC chronic lung disease in a biological sample. The COPD genes and proteins  
CC encoded by them from the present invention (I) can be used for treating  
CC or preventing chronic lung disease in a mammal. (I) can be used in an  
CC animal model for determining the efficacy, toxicity, or side effects of  
CC treatment with (I), and determining the mechanism of action of (I).  
CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used  
CC in an example from the present invention  
XX  
SQ Sequence 25 BP; 4 A; 9 C; 5 G; 7 T; 0 U; 0 Other;  
Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 980 CCTTATGGCCCAACCTTGCCATCTGG 1004  
Db 1 CCTTATGGCCCAACCTTGCCATCTGG 25  
RESULT 7  
ABZ84127  
ID ABZ84127 standard; DNA; 25 BP.  
XX  
AC ABZ84127;  
XX  
DT 14-MAY-2003 (first entry)  
XX  
DE Toxicologically relevant human PCR primer #1286.  
XX  
KW Toxicologically relevant gene; toxicological response; PCR primer; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2003016500-A2.  
XX  
PD 27-FEB-2003.  
XX  
PF 16-AUG-2002; 2002WO-US026514.  
XX  
PR 16-AUG-2001; 2001US-0313080P.  
XX  
PA (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.  
XX  
PI Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schmeiser K;  
PI Alen P;  
XX  
DR WPI; 2003-268322/26.  
XX  
PT Determining a toxicological response to an agent, useful for screening of  
PT drugs, comprises comparing the expression profile of one or more human  
PT toxic response genes to a reference gene expression profile indicative of  
PT toxicity.  
XX  
PS Claim 1; Page 332; 455pp; English.  
XX  
CC The present invention describes a method (M1) for determining a  
CC toxicological response to an agent, which comprises comparing the  
CC expression profile of one or more human toxic response genes to a  
CC reference gene expression profile indicative of toxicity, and so  
CC determining the presence of a toxic response to the agent. Also  
CC described: (1) an array comprising one or more polynucleotides selected  
CC from the genes corresponding to the partial sequences given in ABZ82842  
CC to ABZ84764, or their fragments of at least 20 nucleotides, or homologues  
CC ; and (2) determining if a gene putatively identified to be a toxic  
CC response gene plays a role on toxic response pathways by determining the  
CC expression profile of the gene after exposure of cells or a human subject

CC to a known toxic pharmaceutical or industrial agent, comprising: (a)  
CC exposing cells to an agent or isolating cells from a human subject who  
CC was exposed to an agent; (b) obtaining the test gene expression profile  
CC for a putatively identified toxic response gene after exposure to a known  
CC toxic pharmaceutical or industrial agent; and (c) comparing the test  
CC profile to the expression profile of a gene with a similar function or  
CC comparing the test profile to the expression profile of that gene after  
CC exposure to other known toxic compounds. The methods are useful for  
CC predicting and determining toxicological responses on a cellular, organ  
CC or system level. The arrays comprising the human genes are useful for  
CC toxicological screening of drugs, pharmaceutical compounds and chemicals  
XX  
SQ Sequence 25 BP; 4 A; 8 C; 3 G; 10 T; 0 U; 0 Other;  
Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 973 ATTTCTTCCTTATGGCCCAACCTTGC 997  
Db 1 ATTTCTTCCTTATGGCCCAACCTTGC 25  
RESULT 8  
ACC46843/c  
ID ACC46843 standard; DNA; 24 BP.  
XX  
AC ACC46843;  
XX  
DT 05-JUN-2003 (first entry)  
XX  
DE Human COPD related gene reverse PCR primer SEQ ID NO:122.  
XX  
KW Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;  
KW PCR primer; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200297127-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 28-MAY-2002; 2002WO-EP005835.  
XX  
PR 31-MAY-2001; 2001GB-00013266.  
XX  
PA (FARB ) BAYER AG.  
XX  
PI Oellers N, Gehrman M, Kallabis H, Hall R, Schulze T, Kroegel C;  
XX  
DR WPI; 2003-140492/13.  
XX  
PT Predicting, diagnosing or prognosing chronic lung disease, by detecting a  
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.  
XX  
PS Example 1; Page 212; 214pp; English.  
XX  
CC The present invention describes a method for predicting, diagnosing or  
CC prognosing chronic lung disease by detecting a chronic obstructive  
CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to  
CC ACC46777, which encode the COPD related proteins in ABP96779 to  
CC ABP96806). The method is useful for predicting, diagnosing or prognosing  
CC chronic lung disease in a biological sample. The COPD genes and proteins  
CC encoded by them from the present invention (I) can be used for treating  
CC or preventing chronic lung disease in a mammal. (I) can be used in an  
CC animal model for determining the efficacy, toxicity, or side effects of  
CC treatment with (I), and determining the mechanism of action of (I).  
CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used  
CC in an example from the present invention  
XX  
SQ Sequence 24 BP; 6 A; 5 C; 3 G; 10 T; 0 U; 0 Other;

PD 05-DEC-2002.  
XX  
PF 28-MAY-2002; 2002WO-EP005835.  
XX  
PR 31-MAY-2001; 2001GB-00013266.  
XX  
PA (FARB ) BAYER AG.  
XX  
PI Oellers N, Gehrman M, Kallabis H, Hall R, Schulze T, Kroegel C;  
XX  
DR WPI; 2003-140492/13.  
XX  
XX Predicting, diagnosing or prognosing chronic lung disease, by detecting a  
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.  
PT  
XX  
PS Example 1; Page 212; 214pp; English.  
XX  
CC The present invention describes a method for predicting, diagnosing or  
CC prognosing chronic lung disease by detecting a chronic obstructive  
CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to  
CC ACC46777, which encode the COPD related proteins in ABP96779 to  
CC ABP96806). The method is useful for predicting, diagnosing or prognosing  
CC chronic lung disease in a biological sample. The COPD genes and proteins  
CC encoded by them from the present invention (I) can be used for treating  
CC or preventing chronic lung disease in a mammal. (I) can be used in an  
CC animal model for determining the efficacy, toxicity, or side effects of  
CC treatment with (I), and determining the mechanism of action of (I).  
CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used  
CC in an example from the present invention  
XX  
SQ Sequence 26 BP; 10 A; 5 C; 6 G; 5 T; 0 U; 0 Other;  
Query Match 1.5%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 9.7;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 944 CTGAGAGACCAAGACCAGCTGTTAAT 969  
|||||  
Db 1 CTGAGAGACCAAGACCAGCTGTTAAT 26  
RESULT 5  
ABZ84121/c  
ID ABZ84121 standard; DNA; 26 BP.  
XX  
AC ABZ84121;  
XX  
DT 14-MAY-2003 (first entry)  
XX  
DE Toxicologically relevant human PCR primer #1280.  
XX  
KW Toxicologically relevant gene; toxicological response; PCR primer; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2003016500-A2.  
XX  
PD 27-FEB-2003.  
XX  
PF 16-AUG-2002; 2002WO-US026514.  
XX  
PR 16-AUG-2001; 2001US-0313080P.  
XX  
PA (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.  
XX  
PI Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schmeiser K;  
PI Alen P;  
XX  
DR WPI; 2003-268322/26.  
XX  
XX Determining a toxicological response to an agent, useful for screening of  
PT drugs, comprises comparing the expression profile of one or more human

PT toxic response genes to a reference gene expression profile indicative of  
PT toxicity.  
PS Claim 1; Page 332; 455pp; English.  
XX  
CC The present invention describes a method (M1) for determining a  
CC toxicological response to an agent, which comprises comparing the  
CC expression profile of one or more human toxic response genes to a  
CC reference gene expression profile indicative of toxicity, and so  
CC determining the presence of a toxic response to the agent. Also  
CC described: (1) an array comprising one or more polynucleotides selected  
CC from the genes corresponding to the partial sequences given in ABZ82842  
CC to ABZ84764, or their fragments of at least 20 nucleotides, or homologues  
CC ; and (2) determining if a gene putatively identified to be a toxic  
CC response gene plays a role on toxic response pathways by determining the  
CC expression profile of the gene after exposure of cells or a human subject  
CC to a known toxic pharmaceutical or industrial agent, comprising: (a)  
CC exposing cells to an agent or isolating cells from a human subject who  
CC was exposed to an agent; (b) obtaining the test gene expression profile  
CC for a putatively identified toxic response gene after exposure to a known  
CC toxic pharmaceutical or industrial agent; and (c) comparing the test  
CC profile to the expression profile of a gene with a similar function or  
CC comparing the test profile to the expression profile of that gene after  
CC exposure to other known toxic compounds. The methods are useful for  
CC predicting and determining toxicological responses on a cellular, organ  
CC or system level. The arrays comprising the human genes are useful for  
CC toxicological screening of drugs, pharmaceutical compounds and chemicals  
XX  
SQ Sequence 26 BP; 11 A; 10 C; 1 G; 4 T; 0 U; 0 Other;  
Query Match 1.5%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 9.7;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1409 GCTGGTTTGGTTGTTAGAAATGGTGT 1434  
|||||  
Db 26 GCTGGTTTGGTTGTTAGAAATGGTGT 1  
RESULT 6  
ACC46841  
ID ACC46841 standard; DNA; 25 BP.  
XX  
AC ACC46841;  
XX  
DT 05-JUN-2003 (first entry)  
XX  
DE Human COPD related gene probe SEQ ID NO:120.  
XX  
KW Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;  
KW probe; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200297127-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 28-MAY-2002; 2002WO-EP005835.  
XX  
PR 31-MAY-2001; 2001GB-00013266.  
XX  
PA (FARB ) BAYER AG.  
XX  
PI Oellers N, Gehrman M, Kallabis H, Hall R, Schulze T, Kroegel C;  
XX  
DR WPI; 2003-140492/13.  
XX  
PT Predicting, diagnosing or prognosing chronic lung disease, by detecting a  
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.  
XX  
PS Example 1; Page 212; 214pp; English.



Fri May 13 12:26:37 2005

QY 1687 AAGTTGCTTCCTAACATCCTTGGACTGGAGAAATATATACTTACTTCTGGCA 1736  
|||||  
Db 1 AAGTTGCTTCCTAACATCCTTGGACTGGAGAAATATATACTTACTTCTGGCA 50  
RESULT 2  
ADP44841/c  
ID ADP44841 standard; DNA; 30 BP.  
XX  
AC ADP44841;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human matrix metalloproteinase-12 (MMP-12) PCR primer #2.  
XX  
KW human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;  
KW phenylmethyl-sulfonyl fluoride; stress urinary incontinence;  
KW undesired elastin degradation disease; pelvic organ prolapse; emphysema;  
KW abdominal aortic aneurysm; atherosclerosis; pancreatitis;  
KW inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;  
KW MMP-12.  
XX  
OS Homo sapiens.  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human matrix metalloproteinase-12 (MMP-12) PCR primer #2.  
XX  
KW human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;  
KW phenylmethyl-sulfonyl fluoride; stress urinary incontinence;  
KW undesired elastin degradation disease; pelvic organ prolapse; emphysema;  
KW abdominal aortic aneurysm; atherosclerosis; pancreatitis;  
KW inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;  
KW MMP-12.  
XX  
OS Homo sapiens.  
XX  
PN WO2004041115-A2.  
XX  
PD 21-MAY-2004.  
XX  
PF 12-JUN-2003; 2003WO-US018696.  
XX  
PR 14-JUN-2002; 2002US-0389094P.  
XX  
PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.  
XX  
PI Kushner L, Mathrubutham M, Rao SK;  
XX  
DR WPI; 2004-400506/37.  
XX  
KW Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not  
PT by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary  
PT incontinence in woman.  
XX  
PS Example 6; SEQ ID NO 8; 54pp; English.  
XX  
CC The invention comprises a human elastase that has an optimum pH of about  
CC 8.5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and  
CC EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the  
CC invention is useful for determining whether a woman has, or is likely to  
CC develop stress urinary incontinence. The human elastase of the invention  
CC is also useful for treating a woman for stress urinary incontinence and a  
CC disease of undesired elastin degradation (e.g. pelvic organ prolapse,  
CC emphysema, abdominal aortic aneurysm, atherosclerosis, pancreatitis and  
CC inflammatory disease). The present DNA sequence represents a PCR primer  
CC that was used in an example of the invention.  
XX  
SQ Sequence 30 BP; 9 A; 6 C; 9 G; 6 T; 0 U; 0 Other;  
XX  
Query Match 1.7%; Score 30; DB 1; Length 30;  
Best Local Similarity 100.0%; Pred. No. 4.2;  
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 549 AATCCTAGCCCATGCTTTTGGACCTGGATC 578  
|||||  
Db 30 AATCCTAGCCCATGCTTTTGGACCTGGATC 1  
RESULT 3  
ADP44840  
ID ADP44840 standard; DNA; 30 BP.  
XX  
AC ADP44840;  
XX

DT 12-AUG-2004 (first entry)  
XX  
DE Human matrix metalloproteinase-12 (MMP-12) PCR primer #1.  
XX  
KW human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;  
KW phenylmethyl-sulfonyl fluoride; stress urinary incontinence;  
KW undesired elastin degradation disease; pelvic organ prolapse; emphysema;  
KW abdominal aortic aneurysm; atherosclerosis; pancreatitis;  
KW inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;  
KW MMP-12.  
XX  
OS Homo sapiens.  
XX  
PN WO2004041115-A2.  
XX  
PD 21-MAY-2004.  
XX  
PF 12-JUN-2003; 2003WO-US018696.  
XX  
PR 14-JUN-2002; 2002US-0389094P.  
XX  
PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.  
XX  
PI Kushner L, Mathrubutham M, Rao SK;  
XX  
DR WPI; 2004-400506/37.  
XX  
PT Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not  
PT by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary  
PT incontinence in woman.  
XX  
PS Example 6; SEQ ID NO 7; 54pp; English.  
XX  
CC The invention comprises a human elastase that has an optimum pH of about  
CC 8.5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and  
CC EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the  
CC invention is useful for determining whether a woman has, or is likely to  
CC develop stress urinary incontinence. The human elastase of the invention  
CC is also useful for treating a woman for stress urinary incontinence and a  
CC disease of undesired elastin degradation (e.g. pelvic organ prolapse,  
CC emphysema, abdominal aortic aneurysm, atherosclerosis, pancreatitis and  
CC inflammatory disease). The present DNA sequence represents a PCR primer  
CC that was used in an example of the invention.  
XX  
SQ Sequence 30 BP; 9 A; 10 C; 5 G; 6 T; 0 U; 0 Other;  
XX  
Query Match 1.7%; Score 30; DB 1; Length 30;  
Best Local Similarity 100.0%; Pred. No. 4.2;  
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 62 TTCCCTGAACAGCTCTACAGCCTGGAAA 91  
|||||  
Db 1 TTCCCTGAACAGCTCTACAGCCTGGAAA 30  
RESULT 4  
ACC46842  
ID ACC46842 standard; DNA; 26 BP.  
XX  
AC ACC46842;  
XX  
DT 05-JUN-2003 (first entry)  
XX  
DE Human COPD related gene forward PCR primer SEQ ID NO:121.  
XX  
KW Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;  
KW PCR primer; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200297127-A2.  
XX

C 107	14	0.8	17	1	ABT36548	Tumour suppression
C 108	14	0.8	17	1	ADB00378	Human MDZ3 scannin
C 109	14	0.8	17	1	ADB00374	Human MDZ3 scannin
C 110	14	0.8	17	1	ADI48708	Human tumour suppress
C 111	14	0.8	17	1	ACN73527	Human GDMLP-1 prob
C 112	14	0.8	17	1	ACN73528	Human GDMLP-1 prob
C 113	13.8	0.8	17	1	AAAX63973	Rabbit stromelysin
C 114	13.8	0.8	17	1	AAAX63909	Rabbit stromelysin
C 115	13.8	0.8	17	1	AAAX63910	Rabbit stromelysin
C 116	13.8	0.8	17	1	AAAX63966	Rabbit stromelysin
C 117	13.8	0.8	17	1	AAAX71351	Human KDR VEGF rec
C 118	13.8	0.8	17	1	AAAX72925	Mouse flk-1 VEGF r
C 119	13.8	0.8	17	1	AAAX75153	Mouse flt-1 VEGF r
C 120	13.8	0.8	17	1	AAAX74584	Mouse flt-1 VEGF r
C 121	13.8	0.8	17	1	AAAX68927	Human flt1 VEGF re
C 122	13.8	0.8	17	1	AAV97951	Human EGF-R target
C 123	13.8	0.8	17	1	AAV98035	Human EGF-R target
C 124	13.8	0.8	17	1	AAA23189	Integrin subunit b
C 125	13.8	0.8	17	1	AAA23042	Integrin subunit b
C 126	13.8	0.8	17	1	AAA18827	Human Tie-2 substr
C 127	13.8	0.8	17	1	AAA23041	Integrin subunit b
C 128	13.8	0.8	17	1	AAA25186	Oestrogen receptor
C 129	13.8	0.8	17	1	AAA25187	Oestrogen receptor
C 130	13.8	0.8	17	1	AAF03078	Hammerhead ribozym
C 131	13.8	0.8	17	1	AAF03080	Hammerhead ribozym
C 132	13.8	0.8	17	1	ABK03648	Human CD20 DNazyme
C 133	13.8	0.8	17	1	ABK00330	Human NOGO Hammerh
C 134	13.8	0.8	17	1	ABK00480	Human NOGO Hammerh
C 135	13.8	0.8	17	1	ABN08645	Human GDMLP-1 17-m
C 136	13.8	0.8	17	1	ABN06769	Human GDMLP-1 17-m
C 137	13.8	0.8	17	1	ABN10436	Human GDMLP-1 17-m
C 138	13.8	0.8	17	1	ABN10442	Human GDMLP-1 17-m
C 139	13.8	0.8	17	1	ABQ64120	Human KTOM1a porti
C 140	13.8	0.8	17	1	ABV79930	Human HTPL scannin
C 141	13.8	0.8	17	1	ABV79931	Human HTPL scannin
C 142	13.8	0.8	17	1	ABK19347	Human ERG Amberzym
C 143	13.8	0.8	17	1	ABK56577	Human ClCAL gene e
C 144	13.8	0.8	17	1	ACN07730	WNV minus strand H
C 145	13.8	0.8	17	1	ACN09323	WNV minus strand H
C 146	13.8	0.8	17	1	ACN14538	WNV minus strand A
C 147	13.8	0.8	17	1	ACN07069	WNV Amberzyme subs
C 148	13.8	0.8	17	1	ACN03239	WNV Inozyme substr
C 149	13.8	0.8	17	1	ACN01009	WNV Hammerhead Rib
C 150	13.8	0.8	17	1	ACN09806	WNV minus strand I
C 151	13.8	0.8	17	1	ACN05603	WNV Amberzyme subs
C 152	13.8	0.8	17	1	ACD00825	G-protein coupled
C 153	13.8	0.8	17	1	ABT34768	Tumour suppression
C 154	13.8	0.8	17	1	ABT36617	Tumour suppression
C 155	13.8	0.8	17	1	ADA99699	Human MDZ3 scannin
C 156	13.8	0.8	17	1	ADA99701	Human MDZ3 scannin
C 157	13.8	0.8	17	1	ADB04816	Human MDZ12 scanni
C 158	13.8	0.8	17	1	ADA99700	Human MDZ3 scannin
C 159	13.8	0.8	17	1	ABZ60192	Human K-Ras DNazym
C 160	13.8	0.8	17	1	ABZ64887	Human HER2 DNazyme
C 161	13.8	0.8	17	1	ACC68419	Murine oligonucleo
C 162	13.8	0.8	17	1	ADB43853	Tumour suppression
C 163	13.8	0.8	17	1	ADB39685	Tumour suppression
C 164	13.8	0.8	17	1	ADB41975	Tumour suppression
C 165	13.8	0.8	17	1	ADB44591	Tumour suppression
C 166	13.8	0.8	17	1	ADI51278	Human tumour suppress
C 167	13.8	0.8	17	1	ADI49691	Human tumour suppress
C 168	13.8	0.8	17	1	ADI52571	Human tumour suppress
C 169	13.8	0.8	17	1	ADI52496	Human tumour suppress
C 170	13.8	0.8	17	1	ADI50768	Human tumour suppress
C 171	13.8	0.8	17	1	ACC52701	Human tumour suppress
C 172	13.8	0.8	17	1	ACC53715	Human tumour suppress
C 173	13.8	0.8	17	1	ADL50557	Human PKR substrat
C 174	13.8	0.8	17	1	ADL46697	Human NOGO recepto
C 175	13.8	0.8	17	1	ADL49415	Human PKR substrat
C 176	13.8	0.8	17	1	ADL46696	Human NOGO recepto
C 177	13.8	0.8	17	1	ADF90161	Blocking probe use
C 178	13.8	0.8	17	1	ACN73526	Human GDMLP-1 prob
C 179	13.8	0.8	17	1	ACN73532	Human GDMLP-1 prob

180	13.8	0.8	17	1	ACN71735	Human GDMLP-1 prob
181	13.8	0.8	17	1	ACN69859	Human GDMLP-1 prob
182	13.4	0.8	15	1	AAZ90118	PCR primer H-T11A
183	13.4	0.8	15	1	AAF53972	IGF-I oligonucleot
C 184	13.4	0.8	15	1	AAF77611	Modified transcrip
C 185	13.4	0.8	15	1	AAH84366	Human cell death p
C 186	13.4	0.8	15	1	AAD54049	Human TEM7alpha ex
C 187	13.4	0.8	15	1	ADF92297	Human cytokeratin
C 188	13.4	0.8	16	1	AAH91807	Human inflammatory
C 189	13.4	0.8	16	1	ADF92303	Human cytokeratin
190	13.4	0.8	16	1	ADR06487	Murine sequence ta

ALIGNMENTS

RESULT 1

ABZ02308	ID	ABZ02308	standard; DNA; 50 BP.
XX	AC	ABZ02308;	
XX	DT	09-JAN-2003	(first entry)
XX	DE	Human leukocyte gene expression profiling probe SEQ ID NO 2299.	
XX	KW	T7; leukocyte; gene expression profiling; allograft rejection;	
XX	KW	atherosclerosis; congestive heart failure; systemic lupus erythematosus;	
XX	KW	rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;	
XX	OS	Homo sapiens.	
XX	PN	WO200257414-A2.	
XX	PD	25-JUL-2002.	
XX	PF	22-OCT-2001; 2001WO-US047856.	
XX	PR	20-OCT-2000; 2000US-0241994P.	
XX	PR	08-JUN-2001; 2001US-0296764P.	
XX	PA	(BIOC-) BIOCARDIA INC.	
XX	PI	Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;	
XX	PI	Ly N, Woodward R, Quertermous T, Johnson F;	
XX	DR	WPI; 2002-636525/68.	
XX	PT	New system for leukocyte expression profiling, diagnosing a disease, or	
XX	PT	monitoring (the rate of) progression of a disease, e.g. atherosclerosis	
XX	XX	or congestive heart failure, comprises diagnostic oligonucleotides.	
XX	PS	Claim 1; Page 399; Opp; English.	
XX	CC	The invention relates to a system for detecting gene expression, which	
XX	CC	comprises one or two isolated DNA molecules that detect expression of a	
XX	CC	gene, where the gene corresponds to any of 8143 oligonucleotides	
XX	CC	(ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful	
XX	CC	for leukocyte expression profiling. It is particularly useful for	
XX	CC	diagnosing a disease, monitoring (rate of) progression of a disease,	
XX	CC	predicting therapeutic outcome, determining prognosis for a patient,	
XX	CC	predicting disease complications in an individual or monitoring response	
XX	CC	to treatment in an individual. The diseases include cardiac allograft	
XX	CC	rejection, kidney allograft rejection, liver allograft rejection,	
XX	CC	atherosclerosis, congestive heart failure, systemic lupus erythematosus,	
XX	CC	rheumatoid arthritis, osteoarthritis or cytomegalovirus infection	
XX	SQ	Sequence 50 BP; 14 A; 11 C; 8 G; 17 T; 0 U; 0 Other;	

Query Match

Best Local Similarity 2.8%; Score 50; DB 1; Length 50;

Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:26:51 ; Search time 3 Seconds  
(without alignments)  
4.037 Million cell updates/sec

Title: US-10-619-906-1  
Perfect score: 1778  
Sequence: 1 tagaagtttacaatgaagtt.....ttttgggtcaataaaattg 1778

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 188 seqs, 3406 residues

Total number of hits satisfying chosen parameters: 376

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 190 summaries

Database : rng1.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	50	2.8	50	1	Human leukocyte ge
2	30	1.7	30	1	Human matrix metal
3	30	1.7	30	1	Human matrix metal
4	26	1.5	26	1	Human COPD related
5	26	1.5	26	1	Toxicologically re
6	25	1.4	25	1	Human COPD related
7	25	1.4	25	1	Toxicologically re
8	24	1.3	24	1	Human COPD related
9	24	1.3	24	1	MMP-12 forward pri
10	24	1.3	24	1	MMP-12 reverse pri
11	21	1.2	21	1	Hmep2 PCR primer u
12	21	1.2	21	1	Human matrix metal
13	21	1.2	21	1	Matrix metalloprot
14	20	1.1	20	1	Matrix metalloprot
15	20	1.1	20	1	MMP3 hairpin/hamme
16	19.4	1.1	21	1	Human MMP-12 antis
17	19	1.1	19	1	Human MMP-12 antis
18	19	1.1	19	1	Human MMP-12 antis
19	19	1.1	19	1	Human MMP-12 antis
20	19	1.1	19	1	Human MMP-12 antis
21	19	1.1	19	1	Human MMP-12 antis
22	19	1.1	19	1	Human MMP-12 antis
23	19	1.1	19	1	Human MMP-12 antis
24	19	1.1	19	1	Human MMP-12 antis
25	19	1.1	19	1	Human MMP-12 antis
26	19	1.1	19	1	Human MMP-12 antis
27	19	1.1	19	1	Human MMP-12 antis
28	19	1.1	19	1	Human MMP-12 antis
29	17.4	1.0	19	1	Cyclin G1 ribozyme
30	17.4	1.0	19	1	Cyclin G1 ribozyme
31	16.8	0.9	20	1	Human oligonucleot
32	16.8	0.9	20	1	At041482-derived o
33	16.8	0.9	20	1	Chimeric phosphoro

34	16.8	0.9	21	1	AAQ200036	Cross-linking olig
35	16.8	0.9	21	1	AAQ30386	Oligomer TNF217 fo
36	16.8	0.9	21	1	AAQ30387	Oligomer TNF218 fo
37	16.4	0.9	18	1	AAQ64428	Human stromelysin
38	16.4	0.9	19	1	AAZ71398	Human biallelic ma
39	16.4	0.9	19	1	ADR80876	Human glucose-6-ph
40	16.4	0.9	20	1	AAQ39422	PCR Primer #2 for
41	16.4	0.9	20	1	ADK76164	Chimeric phosphoro
42	16.4	0.9	20	1	ADK76981	Chimeric phosphoro
43	16.4	0.9	20	1	ADK76358	Chimeric phosphoro
44	16.4	0.9	20	1	ADP27276	Human MMP11 DNA an
45	16.4	0.9	20	1	ADP27131	Human matrix metal
46	16	0.9	17	1	AAQ63796	Rabbit stromelysin
47	16	0.9	20	1	ADI28399	Human neuropeptide
48	16	0.9	20	1	ADI28398	Human neuropeptide
49	15.4	0.9	17	1	ABN10440	Human GDMLP-1 17-m
50	15.4	0.9	17	1	ACN73530	Human GDMLP-1 prob
51	15.4	0.9	19	1	ADF93537	Human TERT transcr
52	15.4	0.9	19	1	ADF93791	Human TERT siNA lo
53	15.4	0.9	19	1	ADR80880	Human glucose-6-ph
54	15.4	0.9	19	1	ADR76467	Human apolipoprote
55	15.4	0.9	19	1	ADR79085	Human apolipoprote
56	15	0.8	17	1	ABK02552	Human NOGO Amberzy
57	15	0.8	17	1	ABT35046	Tumour suppression
58	15	0.8	17	1	ADB00375	Human MDZ3 scannin
59	15	0.8	17	1	ADB00377	Human MDZ3 scannin
60	15	0.8	17	1	ADB00376	Human MDZ3 scannin
61	14.8	0.8	18	1	AAV57794	Human chromosome 1
62	14.8	0.8	18	1	AAZ40908	Human CD40 phospho
63	14.8	0.8	18	1	AAZ47741	Human CD40 antisen
64	14.8	0.8	18	1	ADQ93226	3-alpha-hydroxyste
65	14.6	0.8	15	1	ABL91853	Human LIPG gene al
66	14.4	0.8	16	1	ADF92302	Human cytokekeratin
67	14.4	0.8	17	1	AAAX711309	Human KDR VEGF rec
68	14.4	0.8	17	1	AAA18825	Human TIE-2 substr
69	14.4	0.8	17	1	AAA18824	Human TIE-2 substr
70	14.4	0.8	17	1	AAA23011	Integrin subunit b
71	14.4	0.8	17	1	ABK00554	Human NOGO Hammerh
72	14.4	0.8	17	1	ABK01422	Human NOGO Inozyme
73	14.4	0.8	17	1	ABK00479	Human NOGO Hammerh
74	14.4	0.8	17	1	ABK01343	Human NOGO Inozyme
75	14.4	0.8	17	1	ABN10441	Human GDMLP-1 17-m
76	14.4	0.8	17	1	ABN10439	Human GDMLP-1 17-m
77	14.4	0.8	17	1	ABN08646	Human GDMLP-1 17-m
78	14.4	0.8	17	1	ABN08647	Human GDMLP-1 17-m
79	14.4	0.8	17	1	ABK17764	Human ERG hammerhe
80	14.4	0.8	17	1	ABK55789	Human CLCA1 gene e
81	14.4	0.8	17	1	ACD60984	HCV DNazyme substr
82	14.4	0.8	17	1	ADB40821	Tumour suppression
83	14.4	0.8	17	1	ADI52546	Human tumour suppr
84	14.4	0.8	17	1	ACC51264	Human tumour suppr
85	14.4	0.8	17	1	ACC51404	Human tumour suppr
86	14.4	0.8	17	1	ACN51914	Human PKR substrat
87	14.4	0.8	17	1	ADL49413	Human PKR substrat
88	14.4	0.8	17	1	ADL49412	Human PKR substrat
89	14.4	0.8	17	1	ADI84868	HCV DNazyme substr
90	14.4	0.8	17	1	ACN73529	Human GDMLP-1 prob
91	14.4	0.8	17	1	ACN71736	Human GDMLP-1 prob
92	14.4	0.8	17	1	ACN71737	Human GDMLP-1 prob
93	14.4	0.8	17	1	ACN73531	Human GDMLP-1 prob
94	14.4	0.8	18	1	AAT86051	Primer 1 amplifies
95	14.4	0.8	18	1	AAV07215	Calcium-integrin b
96	14.4	0.8	18	1	AAV33107	Stromelysin primer
97	14.4	0.8	18	1	AAD42840	M. tuberculosis de
98	14.4	0.8	18	1	ABX03799	DNA encoding secre
99	14.2	0.8	19	1	ABX03799	Human MMP-12 antis
100	14.2	0.8	50	1	ABZ02308	Human leukocyte ge
101	14	0.8	15	1	AAZ90906	Human NR8 gene pro
102	14	0.8	15	1	ADO49435	H. pylori strain J
103	14	0.8	16	1	ADO49479	H. pylori strain J
104	14	0.8	17	1	ABK02203	Human NOGO DNazyme
105	14	0.8	17	1	ABN10437	Human GDMLP-1 17-m
106	14	0.8	17	1	ABN10438	Human GDMLP-1 17-m

**THIS PAGE BLANK (USPTO)**



Fri May 13 12:26:36 2005

```
FEATURES             FT             /organism='Unknown'.
source              Location/Qualifiers
                    1..16
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 89;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058
    ||| | |||||
Db 16 TTGTTTTTAAAGA 1
```

Search completed: May 13, 2005, 11:25:04  
Job time : 3 secs

DEFINITION Sequence 116 from patent US 6656731.  
ACCESSION AR435857  
VERSION AR435857.1 GI:40198941  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.  
TITLE Nucleic acid catalysts with endonuclease activity  
JOURNAL Patent: US 6656731-A 116 02-DEC-2003;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned RNA"  
  
Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1568 AAATACATAATATTTT 1583  
Db 16 AAAATATAATATTTT 1  
  
RESULT 152  
AX268349  
LOCUS AX268349 16 bp DNA linear PAT 29-OCT-2001  
DEFINITION Sequence 2 from Patent WO0175162.  
ACCESSION AX268349  
VERSION AX268349.1 GI:16541567  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
  
REFERENCE 1  
AUTHORS Wang,E.  
TITLE Microarrays to screen regulatory genes  
JOURNAL Patent: WO 0175162-A 2 11-OCT-2001;  
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US)  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="primer"  
  
Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 230 TGAAAGTGACCGGGCA 245  
Db 1 TAAAGTGACCCAGGCA 16  
  
RESULT 153  
AX405167  
LOCUS AX405167 16 bp DNA linear PAT 14-JUN-2002  
DEFINITION Sequence 4 from Patent WO0224930.  
ACCESSION AX405167  
VERSION AX405167.1 GI:21438336  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
  
REFERENCE 1  
AUTHORS Antoniou,M. and Crombie,R.  
TITLE Polynucleotide  
JOURNAL Patent: WO 0224930-A 4 28-MAR-2002;  
Cobra Therapeutics Limited (GB)  
FEATURES  
source  
1. .16  
Location/Qualifiers

/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Primer"  
  
Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 73 AGCTCTACAAGCCTGG 88  
Db 1 AGCTCCACAGGCCTGG 16  
  
RESULT 154  
AX796642/c  
LOCUS AX796642 16 bp DNA linear PAT 04-OCT-2003  
DEFINITION Sequence 16 from Patent EP1323835.  
ACCESSION AX796642  
VERSION AX796642.1 GI:37517297  
KEYWORDS Gallus gallus (chicken)  
SOURCE Gallus gallus  
ORGANISM Gallus gallus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;  
Phasianinae; Gallus.  
  
REFERENCE 1  
AUTHORS Yano,H., Nishida,M. and Suzuki,O.  
TITLE Method for determining biospecies contained in test specimen and kit used for the same  
JOURNAL Patent: EP 1323835-A 16 02-JUL-2003;  
Nisshinbo Industries, Inc. (JP)  
FEATURES  
source  
1. .16  
Location/Qualifiers  
/organism="Gallus gallus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9031"  
/note="capture"  
  
Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1748 AAGTATATATATTTTG 1763  
Db 16 AAGTATATATTTATTG 1  
  
RESULT 155  
BD065824/c  
LOCUS BD065824 16 bp DNA linear PAT 27-AUG-2002  
DEFINITION An antisense oligonucleotide preparation method.  
ACCESSION BD065824  
VERSION BD065824.1 GI:22611427  
KEYWORDS JP 2001511000-A/459.  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.  
  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Schlingensiepen,K.H. and Brysch,W.  
TITLE An antisense oligonucleotide preparation method  
JOURNAL Patent: JP 2001511000-A 459 07-AUG-2001;  
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH  
COMMENT  
OS Unknown  
PN JP 2001511000-A/459  
PD 07-AUG-2001  
PF 30-JAN-1998 JP 1998532533  
PR 31-JAN-1997 EP 97101531.8  
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH  
PC C12N15/11,C07H21/04,A61K31/70  
CC An antisense oligonucleotide preparation method FH Key  
Location/Qualifiers  
FT source  
1. .16

ORGANISM unidentified  
unclassified.

REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kieich,K., Matulic-Adamic,J., Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 5545 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1572 ACATAAATATTTT 1584  
Db 14 ACATAAATATTTT 2

RESULT 147  
AR002582/c  
LOCUS AR002582 16 bp DNA linear PAT 04-DEC-1998  
DEFINITION Sequence 23 from patent US 5741706.  
ACCESSION AR002582  
VERSION AR002582.1 GI:3964136  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Leavitt,M.C., Tritz,R., Duarte,E., Barber,J. and Yu,M.  
TITLE Anti-HIV ribozymes  
JOURNAL Patent: US 5741706-A 23 21-APR-1998;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 TCTTCTAATACTG 33  
Db 16 TCTTCTAATACTG 4

RESULT 148  
A88311/c  
LOCUS A88311 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 459 from Patent WO9833904.  
ACCESSION A88311  
VERSION A88311.1 GI:6736881  
KEYWORDS unidentified  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL Patent: WO 9833904-A 459 06-AUG-1998;  
FEATURES BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
source Location/Qualifiers  
1..16  
/organism="unidentified"

/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058  
Db 16 TTGTGTTTTTAAAGA 1

RESULT 149  
A90278/c  
LOCUS A90278 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 459 from Patent EP0856579.  
ACCESSION A90278  
VERSION A90278.1 GI:6738792  
KEYWORDS unidentified  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.  
TITLE An antisense oligonucleotide preparation method  
JOURNAL Patent: EP 0856579-A 459 05-AUG-1998;  
FEATURES BIOGNOSTIK GES (DE)  
source Location/Qualifiers  
1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058  
Db 16 TTGTGTTTTTAAAGA 1

RESULT 150  
AR002566/c  
LOCUS AR002566 16 bp DNA linear PAT 04-DEC-1998  
DEFINITION Sequence 7 from patent US 5741706.  
ACCESSION AR002566  
VERSION AR002566.1 GI:3964120  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Leavitt,M.C., Tritz,R., Duarte,E., Barber,J. and Yu,M.  
TITLE Anti-HIV ribozymes  
JOURNAL Patent: US 5741706-A 7 21-APR-1998;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 89;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 794 TGTATGGAGACCCCAA 809  
Db 16 TGTATGCAGACCCCAA 1

RESULT 151  
AR435857/c  
LOCUS AR435857 16 bp RNA linear PAT 18-DEC-2003

LOCUS AR156872 15 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 29 from patent US 6242427.  
ACCESSION AR156872  
VERSION AR156872.1 GI:15125576  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Schreiber,A.D. and Park,J.-G.  
TITLE Methods of inhibiting phagocytosis  
JOURNAL Patent: US 6242427-A 29 05-JUN-2001;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
Db 14 GGCATGGCTGACA 2

RESULT 142  
I77892/c  
LOCUS I77892 15 bp DNA linear PAT 03-APR-1998  
DEFINITION Sequence 599 from patent US 5693532.  
ACCESSION I77892  
VERSION I77892.1 GI:3014046  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.  
TITLE Respiratory syncytial virus ribozymes  
JOURNAL Patent: US 5693532-A 599 02-DEC-1997;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1572 ACATAATATTTTT 1584  
Db 14 ACATAATATTTTT 2

RESULT 143  
AR180094/c  
LOCUS AR180094 15 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 162 from patent US 6333152.  
ACCESSION AR180094  
VERSION AR180094.1 GI:20222127  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.  
TITLE Gene expression profiles in normal and cancer cells  
JOURNAL Patent: US 6333152-A 162 25-DEC-2001;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TTTTGTAGTTCA 1457  
Db 15 TTTTGTAGTTCA 3

RESULT 144  
AR412066/c  
LOCUS AR412066 15 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 25 from patent US 6638764.  
ACCESSION AR412066  
VERSION AR412066.1 GI:40164615  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Schreiber,A.D. and Park,J.-G.  
TITLE Methods of inhibiting phagocytosis  
JOURNAL Patent: US 6638764-A 25 28-OCT-2003;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
Db 14 GGCATGGCTGACA 2

RESULT 145  
AR412070/c  
LOCUS AR412070 15 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 29 from patent US 6638764.  
ACCESSION AR412070  
VERSION AR412070.1 GI:40164619  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Schreiber,A.D. and Park,J.-G.  
TITLE Methods of inhibiting phagocytosis  
JOURNAL Patent: US 6638764-A 29 28-OCT-2003;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
Db 14 GGCATGGCTGACA 2

RESULT 146  
AX638406/c  
LOCUS AX638406 15 bp RNA linear PAT 21-FEB-2003  
DEFINITION Sequence 5545 from Patent EPI260586.  
ACCESSION AX638406  
VERSION AX638406.1 GI:28474020  
KEYWORDS  
SOURCE unidentified



Db 2 GATGACAAATAGTGG 16 linear RNA PAT 17-AUG-2003

RESULT 136  
AR328342  
LOCUS AR328342  
DEFINITION Sequence 5744 from patent US 6566127.  
ACCESSION AR328342  
VERSION AR328342.1 GI:33714150  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
UNCLASSIFIED.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 5744 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 75;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1596 ACTCTAATTGTCCAT 1610  
|||||  
Db 2 ACTCTAATTGTCAAT 16

RESULT 137  
AR436137  
LOCUS AR436137  
DEFINITION Sequence 396 from patent US 6656731.  
ACCESSION AR436137  
VERSION AR436137.1 GI:40199221  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
UNCLASSIFIED.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.  
TITLE Nucleic acid catalysts with endonuclease activity  
JOURNAL Patent: US 6656731-A 396 02-DEC-2003;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 75;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1643 AGTTACCTTCAAAGC 1657  
|||||  
Db 2 AGTTACCTTGAAGC 16

RESULT 138  
AR028986/c  
LOCUS AR028986  
DEFINITION Sequence 25 from patent US 5858981.  
ACCESSION AR028986  
VERSION AR028986.1 GI:5940959  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
UNCLASSIFIED.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Schreiber,A.D. and Park,J.-G.  
TITLE Method of inhibiting phagocytosis

JOURNAL Patent: US 5858981-A 25 12-JAN-1999;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
|||||  
Db 14 GGCATGGCTGACA 2

RESULT 139  
AR028990/c  
LOCUS AR028990  
DEFINITION Sequence 29 from patent US 5858981.  
ACCESSION AR028990  
VERSION AR028990.1 GI:5940963  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
UNCLASSIFIED.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Schreiber,A.D. and Park,J.-G.  
TITLE Method of inhibiting phagocytosis  
JOURNAL Patent: US 5858981-A 29 12-JAN-1999;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
|||||  
Db 14 GGCATGGCTGACA 2

RESULT 140  
AR156868/c  
LOCUS AR156868  
DEFINITION Sequence 25 from patent US 6242427.  
ACCESSION AR156868  
VERSION AR156868.1 GI:15125572  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
UNCLASSIFIED.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Schreiber,A.D. and Park,J.-G.  
TITLE Methods of inhibiting phagocytosis  
JOURNAL Patent: US 6242427-A 25 05-JUN-2001;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
|||||  
Db 14 GGCATGGCTGACA 2

RESULT 141  
AR156872/c

BD067891  
LOCUS BD067891 17 bp RNA linear PAT 27-AUG-2002  
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related  
to levels of epidermal growth factor receptors.  
ACCESSION BD067891  
VERSION BD067891.1 GI:22613494  
KEYWORDS JP 2001511003-A/731.  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.  
TITLE Enzymatic nucleic acid treatment of diseases or conditions related  
to levels of epidermal growth factor receptors  
JOURNAL Patent: JP 2001511003-A 731 07-AUG-2001;  
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV  
COMMENT OS Unidentified  
PN JP 2001511003-A/731  
PD 07-AUG-2001  
PF 14-JAN-1998 JP 1998532913  
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI  
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC  
C12N9/00,C07K14/71  
CC Strandedness: Single;  
CC Topology: Linear;  
CC Enzymatic nucleic acid treatment of diseases or conditions CC  
related to  
CC levels of epidermal growth factor receptors  
FH Key Location/Qualifiers  
FT source 1..17  
FT /organism='Unidentified'.  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unidentified"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:32644"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1687 AAGTTGCTTCCTAACAT 1703  
||||| ||||||| ||  
Db 1 AAGTTCCTTCCTAAAAAT 17

RESULT 133  
BD067975/c  
LOCUS BD067975 17 bp RNA linear PAT 27-AUG-2002  
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related  
to levels of epidermal growth factor receptors.  
ACCESSION BD067975  
VERSION BD067975.1 GI:22613578  
KEYWORDS JP 2001511003-A/815.  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.  
TITLE Enzymatic nucleic acid treatment of diseases or conditions related  
to levels of epidermal growth factor receptors  
JOURNAL Patent: JP 2001511003-A 815 07-AUG-2001;  
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV  
COMMENT OS Unidentified  
PN JP 2001511003-A/815  
PD 07-AUG-2001  
PF 14-JAN-1998 JP 1998532913  
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI  
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC  
C12N9/00,C07K14/71  
CC Strandedness: Single;  
CC Topology: Linear;  
CC Enzymatic nucleic acid treatment of diseases or conditions CC

related to  
CC levels of epidermal growth factor receptors  
FH Key Location/Qualifiers  
FT source 1..17  
FT /organism='Unidentified'.  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unidentified"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:32644"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 160 GTGACAAAAATGAAATA 176  
||||| ||||||| |||||  
Db 17 GAGACAAAAATCAAATA 1

RESULT 134  
AR560062  
LOCUS AR560062 15 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 28 from patent US 6753154.  
ACCESSION AR560062  
VERSION AR560062.1 GI:53970361  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Chen,H.-M. and Bissell,M.  
TITLE Human AZU-1 gene, variants thereof and expressed gene products  
JOURNAL Patent: US 6753154-A 28 22-JUN-2004;  
FEATURES  
source Location/Qualifiers  
1..15  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 69;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1040 AAGTTTTCTTTT 1054  
||||| ||||||| |||||  
Db 1 AAGTTTTTTT 15

RESULT 135  
I71540  
LOCUS I71540 16 bp DNA linear PAT 03-APR-1998  
DEFINITION Sequence 8 from patent US 5681943.  
ACCESSION I71540  
VERSION I71540.1 GI:3007675  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Letsinger,R.Lewis. and Gryaznov,S.M.  
TITLE Method for covalently linking adjacent oligonucleotides  
JOURNAL Patent: US 5681943-A 8 28-OCT-1997;  
FEATURES  
source Location/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 75;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1057 GATGACAAATCTGG 1071  
||||| ||||||| |||

/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1461 CAGCTTAATAAGTATT 1477  
Db 1 CTGCTCAATAAGTATT 17

RESULT 128  
AX756687  
LOCUS AX756687 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 8 from Patent WO03040369.  
ACCESSION AX756687  
VERSION AX756687.1 GI:32251241  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 8 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1346 GATCTAACCAATTGAA 1362  
Db 1 GATCTCAGCAATTGAA 17

RESULT 129  
AX758977  
LOCUS AX758977 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 2298 from Patent WO03040369.  
ACCESSION AX758977  
VERSION AX758977.1 GI:32253593  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 2298 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 2; Gaps 0;

QY 720 GTTCCCCACCTACAAAT 736  
Db 1 GATCCCCACCTCCAAAT 17

RESULT 130  
AX760855/c  
LOCUS AX760855 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 4176 from Patent WO03040369.  
ACCESSION AX760855  
VERSION AX760855.1 GI:32255471  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 4176 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 562 GCTTTTGGACCTGGATC 578  
Db 17 GCTTTTGAACCTTGATC 1

RESULT 131  
AX761593  
LOCUS AX761593 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 4914 from Patent WO03040369.  
ACCESSION AX761593  
VERSION AX761593.1 GI:32256209  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 4914 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1346 GATCTAACCAATTGAA 1362  
Db 1 GATCCAACCACTTGAA 17

RESULT 132

ACCESSION AX737681  
VERSION AX737681.1 GI:30516969  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 3271 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 562 GCTTTTGGACCTGGATC 578  
||||| |||||  
Db 17 GCTTTTGAACCTTGATC 1  
RESULT 124  
AX738191  
LOCUS AX738191 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 3781 from Patent WO03025177.  
ACCESSION AX738191  
VERSION AX738191.1 GI:30517479  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 3781 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 903 GATCTTTTCTTCAAAG 919  
||||| |||||  
Db 1 GATCTTTTCTTTCATAG 17  
RESULT 125  
AX739409  
LOCUS AX739409 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 4999 from Patent WO03025177.  
ACCESSION AX739409  
VERSION AX739409.1 GI:30518706  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 5074 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1346 GATCTAACCAATTGAA 1362  
||||| |||||  
Db 1 GATCTCAGCAATTGAA 17  
RESULT 126  
AX739484  
LOCUS AX739484 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 5074 from Patent WO03025177.  
ACCESSION AX739484  
VERSION AX739484.1 GI:30518781  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 5074 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1346 GATCTAACCAATTGAA 1362  
||||| |||||  
Db 1 GATCTCAGCAATTGAA 17  
RESULT 127  
AX745357  
LOCUS AX745357 17 bp DNA linear PAT 14-MAY-2003  
DEFINITION Sequence 1322 from Patent WO03031621.  
ACCESSION AX745357  
VERSION AX745357.1 GI:30724024  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE A human G protein coupled receptor  
JOURNAL Patent: WO 03031621-A 1322 17-APR-2003;  
Amersham Biosciences (SV) Corp. (US)  
FEATURES  
source  
1. .17  
Location/Qualifiers

REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 4999 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1346 GATCTAACCAATTGAA 1362  
||||| |||||  
Db 1 GATCTCAGCAATTGAA 17  
RESULT 126  
AX739484  
LOCUS AX739484 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 5074 from Patent WO03025177.  
ACCESSION AX739484  
VERSION AX739484.1 GI:30518781  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 5074 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 720 GTTCCCCACCTACAAAT 736  
||||| |||||  
Db 1 GATCCCCACCTCCAAAT 17  
RESULT 127  
AX745357  
LOCUS AX745357 17 bp DNA linear PAT 14-MAY-2003  
DEFINITION Sequence 1322 from Patent WO03031621.  
ACCESSION AX745357  
VERSION AX745357.1 GI:30724024  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE A human G protein coupled receptor  
JOURNAL Patent: WO 03031621-A 1322 17-APR-2003;  
Amersham Biosciences (SV) Corp. (US)  
FEATURES  
source  
1. .17  
Location/Qualifiers



Db	1	GATCCTTTTCTTGAAAG	17																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
----	---	-------------------	----	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

VERSION AX674037.1 GI:29332385  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
 JOURNAL Patent: WO 03004526-A 2482 16-JAN-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 74;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1346 GATCTAACCAATTGAA 1362  
 ||||| |||||  
 Db 1 GATCTCAGCAATTGAA 17  
 RESULT 115  
 AX687956  
 LOCUS AX687956 17 bp DNA linear PAT 31-MAR-2003  
 DEFINITION Sequence 688 from Patent EP1281758.  
 ACCESSION AX687956  
 VERSION AX687956.1 GI:29410654  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
 JOURNAL Patent: EP 1281758-A 688 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 74;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 259 ACCCTGGAGATGATGCA 275  
 ||||| |||||  
 Db 1 ACCCTGGAGATGAGACA 17  
 RESULT 116  
 AX687957  
 LOCUS AX687957 17 bp DNA linear PAT 01-APR-2003  
 DEFINITION Sequence 689 from Patent EP1281758.  
 ACCESSION AX687957  
 VERSION AX687957.1 GI:29410655  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.

TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
 JOURNAL Patent: EP 1281758-A 689 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 74;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 260 CCCTGGAGATGATGCAC 276  
 ||||| |||||  
 Db 1 CCCTGGAGATGAGACAC 17  
 RESULT 117  
 AX687958  
 LOCUS AX687958 17 bp DNA linear PAT 31-MAR-2003  
 DEFINITION Sequence 690 from Patent EP1281758.  
 ACCESSION AX687958  
 VERSION AX687958.1 GI:29410656  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
 JOURNAL Patent: EP 1281758-A 690 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 74;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 261 CCTGGAGATGATGCACG 277  
 ||||| |||||  
 Db 1 CCTGGAGATGAGACACG 17  
 RESULT 118  
 AX693070  
 LOCUS AX693070 17 bp DNA linear PAT 31-MAR-2003  
 DEFINITION Sequence 5802 from Patent EP1281758.  
 ACCESSION AX693070  
 VERSION AX693070.1 GI:29416034  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
 JOURNAL Patent: EP 1281758-A 5802 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 568 GGACCTGGATCTGGCAT 584  
| | | | | | | | | | | | | | | |  
Db 1 GCACCTGGATTGGCAT 17

RESULT 110  
AX499869  
LOCUS AX499869 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1176 from Patent EP1229046.  
ACCESSION AX499869  
VERSION AX499869.1 GI:23382162  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1176 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1142 TGAAGAAAATTGATGCA 1158  
| | | | | | | | | | | | | | | |  
Db 1 TGAAGAAAATTGAGGTA 17

RESULT 111  
AX499870  
LOCUS AX499870 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1177 from Patent EP1229046.  
ACCESSION AX499870  
VERSION AX499870.1 GI:23382163  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1177 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 GAAAAAAATTGATGAG 1159  
| | | | | | | | | | | | | | | |  
Db 1 GAAAAAAATTGAGGTAG 17

RESULT 112  
AX579110/c  
LOCUS AX579110 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 948 from Patent WO0211674.  
ACCESSION AX579110  
VERSION AX579110.1 GI:27648312  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.  
and Grupe, A.  
TITLE Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
JOURNAL Patent: WO 0211674-A 948 14-FEB-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 484 GACATTTTGGTGGTTT 500  
| | | | | | | | | | | | | | | |  
Db 17 GCCATTTTGGTGGTTT 1

RESULT 113  
AX673023  
LOCUS AX673023 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 1468 from Patent WO03004526.  
ACCESSION AX673023  
VERSION AX673023.1 GI:29331371  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 1468 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 720 GTTCCCCACCTACAAAT 736  
| | | | | | | | | | | | | | | |  
Db 1 GATCCCCACCTCCAAAT 17

RESULT 114  
AX674037  
LOCUS AX674037 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 2482 from Patent WO03004526.  
ACCESSION AX674037

ACCESSION AX214888  
VERSION AX214888.1 GI:15524931  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.  
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source 1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1145 AAAAATTGATGCAGCT 1161  
Db 1 AAATATTAAATGCAGCT 17  
RESULT 106  
AX215038/c  
LOCUS AX215038 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 480 from Patent WO0159103.  
ACCESSION AX215038  
VERSION AX215038.1 GI:15525081  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.  
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source 1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 908 TTTTCTTCAAAGACAGG 924  
Db 17 TGTTCCTCAAAGAAAGG 1  
RESULT 107  
AX218206  
LOCUS AX218206 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 3648 from Patent WO0159103.  
ACCESSION AX218206  
VERSION AX218206.1 GI:15528267  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.

AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source 1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 477 CATGGCTGACATTTTGG 493  
Db 1 CAGGGCTGACATTGTGG 17  
RESULT 108  
AX423658/c  
LOCUS AX423658 17 bp RNA linear PAT 18-JUN-2002  
DEFINITION Sequence 1994 from Patent WO0188124.  
ACCESSION AX423658  
VERSION AX423658.1 GI:21527040  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and Randi,A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 1994 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)  
FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1620 ACTCTACTATTAAAGTTT 1636  
Db 17 ACTCTACTCTAAAGTTT 1  
RESULT 109  
AX475675  
LOCUS AX475675 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 896 from Patent WO0224750.  
ACCESSION AX475675  
VERSION AX475675.1 GI:22214960  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 896 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1. .17  
/organism="Homo sapiens"



SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.  
TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors  
JOURNAL Patent: US 6623962-A 815 23-SEP-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match. 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 160 GTGACAAAATGAAATA 176  
Db | ||||| ||||| |||||  
17 GAGACAAAATCAATA 1  
RESULT 101  
AR463084 AR463084 17 bp DNA PAT 20-FEB-2004  
LOCUS  
DEFINITION Sequence 6761 from patent US 6686188.  
ACCESSION AR463084  
VERSION AR463084.1 GI:42698141  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 6761 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 506 GTGGAGCTCATGGAGAC 522  
Db | ||||| ||||| |||||  
1 GAGGAGCTCCTGGAGAC 17  
RESULT 102  
AR464960 AR464960 17 bp DNA PAT 20-FEB-2004  
LOCUS  
DEFINITION Sequence 8637 from patent US 6686188.  
ACCESSION AR464960  
VERSION AR464960.1 GI:42700017  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8637 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 200 AAATCCAAGAAATGCAG 216  
Db | ||||| ||||| |||||  
1 AGATCCAAGAACTGCAG 17  
RESULT 103  
AR466751/c AR466751 17 bp DNA PAT 20-FEB-2004  
LOCUS  
DEFINITION Sequence 10428 from patent US 6686188.  
ACCESSION AR466751  
VERSION AR466751.1 GI:42701808  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10428 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 874 TTTGATGCTGTCACTAC 890  
Db | ||||| ||||| |||||  
17 TTTGATGCTGTCAGCAC 1  
RESULT 104  
AR466757/c AR466757 17 bp DNA PAT 20-FEB-2004  
LOCUS  
DEFINITION Sequence 10434 from patent US 6686188.  
ACCESSION AR466757  
VERSION AR466757.1 GI:42701814  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10434 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 868 TTGAGTTTGTGCTGT 884  
Db | ||||| ||||| |||||  
17 TCGACTTTGTGCTGT 1  
RESULT 105  
AX214888 AX214888 17 bp RNA PAT 07-SEP-2001  
LOCUS  
DEFINITION Sequence 330 from Patent WO0159103.

KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 3143 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1679 TGCTCTGTAAGTTGCTT 1695  
Db 17 TGCTCTCTTAGTTGCTT 1  
RESULT 96  
AR326284/c  
LOCUS AR326284 3686 from patent US 6566127. linear PAT 17-AUG-2003  
DEFINITION Sequence  
ACCESSION AR326284  
VERSION AR326284.1 GI:33712092  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 3686 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 527 ATGCTTTTGGATGGCAAA 543  
Db 17 ATGCTTTGGATGGTAAA 1  
RESULT 97  
AR328170/c  
LOCUS AR328170 5572 from patent US 6566127. linear PAT 17-AUG-2003  
DEFINITION Sequence  
ACCESSION AR328170  
VERSION AR328170.1 GI:33713978  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 5572 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1221 TGATGAAGGAGACAGA 1237  
Db 17 TTATGAAGGAGACAGA 1  
RESULT 98  
AR362733/c  
LOCUS AR362733 67 from patent US 5182195. linear PAT 03-SEP-2003  
DEFINITION Sequence  
ACCESSION AR362733  
VERSION AR362733.1 GI:34423113  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Nakahama,K., Kaisho,Y. and Yoshimura,K.  
TITLE Method for increasing gene expression using protease deficient yeasts  
JOURNAL Patent: US 5182195-A 67 26-JAN-1993;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 933 GCTGAAGGTTTCTGAGA 949  
Db 17 GATGAAGGTTTGTGAGA 1  
RESULT 99  
AR402391  
LOCUS AR402391 731 from patent US 6623962. linear PAT 18-DEC-2003  
DEFINITION Sequence  
ACCESSION AR402391  
VERSION AR402391.1 GI:40149841  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.  
TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors  
JOURNAL Patent: US 6623962-A 731 23-SEP-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1687 AAGTTGCTTCCTAACAT 1703  
Db 1 AAGTTCCITCCTAAAAT 17  
RESULT 100  
AR402475/c  
LOCUS AR402475 815 from patent US 6623962. linear PAT 18-DEC-2003  
DEFINITION Sequence  
ACCESSION AR402475  
VERSION AR402475.1 GI:40149925  
KEYWORDS

VERSION AR190187.1 GI:20236152
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5675 12-FEB-2002;
FEATURES
source
1. .17
/organism="unknown"
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 GACAGGTTCTTCTGGCT 935
Db 1 GCCATGTTCTTCTGGCT 17

RESULT 91
AR191846/c
LOCUS AR191846 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7334 from patent US 6346398.
ACCESSION AR191846
VERSION AR191846.1 GI:20237811
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7334 12-FEB-2002;
FEATURES
source
1. .17
/organism="unknown"
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAAGTTGCTT 1695
Db 17 TGCTCTCTTAGTTGCTT 1

RESULT 92
AR192415/c
LOCUS AR192415 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7903 from patent US 6346398.
ACCESSION AR192415
VERSION AR192415.1 GI:20238380
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7903 12-FEB-2002;
FEATURES
source
1. .17
/organism="unknown"
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 527 ATGCTTTTGATGGCAAA 543
Db 17 ATGCTTTGGATGGTAAA 1

RESULT 93
AR322820
LOCUS AR322820 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 222 from patent US 6566127.
ACCESSION AR322820
VERSION AR322820.1 GI:33708628
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 222 20-MAY-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1066 TACTGGTTAATTAGCAA 1082
Db 1 TACTCGTTAATTATCAA 17

RESULT 94
AR324466
LOCUS AR324466 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1868 from patent US 6566127.
ACCESSION AR324466
VERSION AR324466.1 GI:33710274
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1868 20-MAY-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 GACAGGTTCTTCTGGCT 935
Db 1 GCCATGTTCTTCTGGCT 17

RESULT 95
AR325741/c
LOCUS AR325741 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3143 from patent US 6566127.
ACCESSION AR325741
VERSION AR325741.1 GI:33711549

ACCESSION I94379  
VERSION I94379.1 GI:3938849  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 542 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 918 AGACAGGTTCTTCTGGC 934  
Db 1 AGACAGGTATTCTGGC 17  
RESULT 86  
I94435  
LOCUS I94435 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 598 from patent US 5731295.  
ACCESSION I94435  
VERSION I94435.1 GI:3938905  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 598 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1144 AAAAAAATTGATGCACG 1160  
Db 1 AGAAAAATTGATGCTGC 17  
RESULT 87  
I94442  
LOCUS I94442 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 605 from patent US 5731295.  
ACCESSION I94442  
VERSION I94442.1 GI:3938912  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 605 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1186 ACCTACTTCTTTGTAGA 1202  
Db 1 ACATACTTCTTTGTGGA 17  
RESULT 88  
AR186189  
LOCUS AR186189 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 1677 from patent US 6346398.  
ACCESSION AR186189  
VERSION AR186189.1 GI:20232154  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 1677 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1066 TACTCGTTAATTAGCAA 1082  
Db 1 TACTCGTTAATTATCAA 17  
RESULT 89  
AR188613  
LOCUS AR188613 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 4101 from patent US 6346398.  
ACCESSION AR188613  
VERSION AR188613.1 GI:20234578  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 4101 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 919 GACAGGTTCTTCTGGCT 935  
Db 1 GCCATGTTCTTCTGGCT 17  
RESULT 90  
AR190187  
LOCUS AR190187 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 5675 from patent US 6346398.  
ACCESSION AR190187



RESULT 80  
I37592  
LOCUS I37592 linear PAT 13-MAY-1997  
DEFINITION Sequence 605 from patent US 5612215.  
ACCESSION I37592  
VERSION I37592.1 GI:2085552  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 605 18-MAR-1997;  
FEATURES Location/Qualifiers  
source  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1186 ACCTACTTCTTTGTAGA 1202  
|| |||||  
Db 1 ACATACTTCTTTGTGGA 17  
RESULT 81  
I54288/c  
LOCUS I54288 linear PAT 07-OCT-1997  
DEFINITION Sequence 2029 from patent US 5646042.  
ACCESSION I54288  
VERSION I54288.1 GI:2475491  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 2029 08-JUL-1997;  
FEATURES Location/Qualifiers  
source  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1571 TACATAATATTTTCAA 1587  
|| |||||  
Db 17 TACATAATACTTTCAA 1  
RESULT 82  
I54290/c  
LOCUS I54290 linear PAT 07-OCT-1997  
DEFINITION Sequence 2031 from patent US 5646042.  
ACCESSION I54290  
VERSION I54290.1 GI:2475493  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 2031 08-JUL-1997;  
FEATURES Location/Qualifiers  
source  
1..17

/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1570 ATACATAATATTTTCA 1586  
|| |||||  
Db 17 ATACATAATACTTTCA 1  
RESULT 83  
I54678  
LOCUS I54678 17 bp DNA PAT 07-OCT-1997  
DEFINITION Sequence 2419 from patent US 5646042.  
ACCESSION I54678  
VERSION I54678.1 GI:2475881  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 2419 08-JUL-1997;  
FEATURES Location/Qualifiers  
source  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 416 GGAAAGCTTCTCCAAGTA 432  
|| |||||  
Db 1 GGAAAGCTCTCCAAGAA 17  
RESULT 84  
I94378  
LOCUS I94378 17 bp DNA PAT 01-DEC-1998  
DEFINITION Sequence 541 from patent US 5731295.  
ACCESSION I94378  
VERSION I94378.1 GI:3938848  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 541 24-MAR-1998;  
FEATURES Location/Qualifiers  
source  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 908 TTTTCTTCAAAGACAGG 924  
|| |||||  
Db 1 TGTTCCTTTAAAGACAGG 17  
RESULT 85  
I94379  
LOCUS I94379 17 bp DNA PAT 01-DEC-1998  
DEFINITION Sequence 542 from patent US 5731295.

VERSION CQ625688.1 GI:41675906  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10428 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 874 TTGTGATGCTGTCACTAC 890  
Db 17 TTTGATGCTGTTCAGCAC 1  
RESULT 76  
LOCUS CQ625694/c 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10434 from Patent WO0192524.  
ACCESSION CQ625694  
VERSION CQ625694.1 GI:41675912  
KEYWORDS  
SOURCE Homo-sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10434 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 868 TTGAGTTTGTGATGCTGT 884  
Db 17 TCGACTTTTGTGATGCTGT 1  
RESULT 77  
I37528  
LOCUS I37528 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 541 from patent US 5612215.  
ACCESSION I37528  
VERSION I37528.1 GI:2085488  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes

JOURNAL Patent: US 5612215-A 541 18-MAR-1997;  
FEATURES  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 908 TTTTCTTCAAAGACAGG 924  
Db 1 TGTTCCTTTAAAGACAGG 17  
RESULT 78  
I37529  
LOCUS I37529 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 542 from patent US 5612215.  
ACCESSION I37529  
VERSION I37529.1 GI:2085489  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 542 18-MAR-1997;  
FEATURES  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 918 AGACAGGTTCTTCTGGC 934  
Db 1 AGACAGGTATTCTGGC 17  
RESULT 79  
I37585  
LOCUS I37585 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 598 from patent US 5612215.  
ACCESSION I37585  
VERSION I37585.1 GI:2085545  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 598 18-MAR-1997;  
FEATURES  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1144 AAAAAAATTGATGCAGC 1160  
Db 1 AGAAAAAATTGATGCTGC 17

PR 12-APR-1999 US 60/129390  
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC  
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC  
C12R1:91),  
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,  
PC A61K37/02,  
PC (C12N5/00, C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1.17  
FT /organism='Eukaryote'.  
FEATURES  
source  
1.17  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 898 AATAAGATCTTTTCTT 914  
Db |||||||  
1 AACAGATATTTTCTT 17  
RESULT 72  
BD255278 17 bp DNA linear PAT 17-JUL-2003  
LOCUS Regulation of repressor genes using nucleic acid molecules.  
DEFINITION BD255278  
ACCESSION BD255278  
VERSION BD255278.1 GI:33065048  
KEYWORDS JP 2002541795-A/3071.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.  
TITLE Regulation of repressor genes using nucleic acid molecules  
JOURNAL Patent: JP 2002541795-A 3071 10-DEC-2002;  
RIBOZYME PHARMACEUTICALS INC  
COMMENT OS Eukaryote  
PN JP 2002541795-A/3071  
PD 10-DEC-2002  
PF 11-APR-2000 JP 2000611654  
PR 12-APR-1999 US 60/129390  
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC  
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC  
C12R1:91),  
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,  
PC A61K37/02,  
PC (C12N5/00, C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1.17  
FT /organism='Eukaryote'.  
FEATURES  
source  
1.17  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 901 AAGATCTTTTCTTCAA 917

|||||  
1 AAGATATTTTCTTCCA 17  
Db  
RESULT 73  
CQ622021 17 bp DNA linear PAT 02-FEB-2004  
LOCUS Sequence 6761 from Patent WO0192524.  
DEFINITION CQ622021  
ACCESSION CQ622021  
VERSION CQ622021.1 GI:41672239  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 6761 06-DEC-2001;  
FEATURES  
source  
1.17  
Location/Qualifiers  
/organism='Homo sapiens'  
/mol\_type='unassigned DNA'  
/db\_xref='taxon:9606'  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 506 GTGGAGCTCATGGAGAC 522  
Db |||||||  
1 GAGGAGCTCCTGGAGAC 17  
RESULT 74  
CQ623897 17 bp DNA linear PAT 02-FEB-2004  
LOCUS Sequence 8637 from Patent WO0192524.  
DEFINITION CQ623897  
ACCESSION CQ623897  
VERSION CQ623897.1 GI:41674115  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8637 06-DEC-2001;  
FEATURES  
source  
1.17  
Location/Qualifiers  
/organism='Homo sapiens'  
/mol\_type='unassigned DNA'  
/db\_xref='taxon:9606'  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 200 AAATCCAAGAAATGCAG 216  
Db |||||||  
1 AGATCCAAGAACTGCAG 17  
RESULT 75  
CQ625688/c  
LOCUS Sequence 10428 from Patent WO0192524.  
DEFINITION CQ625688  
ACCESSION CQ625688

C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00  
CC Method and reagent for treating diseases or conditions CC concerning molecule  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1. .17  
FT /organism='Homo sapiens (human)'.  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1037 ATCAAGTTTTTCTTTT 1053  
|||||  
Db 1 ATCAAGTTTTTTATTT 17  
RESULT 69  
BD203242  
LOCUS 17 bp RNA linear PAT 17-JUL-2003  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD203242  
VERSION BD203242.1 GI:33013012  
KEYWORDS JP 2002509721-A/6268.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 6268 02-APR-2002;  
COMMENT RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/6268  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00  
CC Method and reagent for treating diseases or conditions CC concerning molecule  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1. .17  
FT /organism='Homo sapiens (human)'.  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1038 TCAAGTTTTTCTTTT 1054  
|||||

Db 1 TCAAGTTTTTTATTTA 17  
RESULT 70  
BD203389 17 bp RNA linear PAT 17-JUL-2003  
LOCUS 17 bp RNA linear PAT 17-JUL-2003  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD203389  
VERSION BD203389.1 GI:33013159  
KEYWORDS JP 2002509721-A/6415.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 6415 02-APR-2002;  
COMMENT RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/6415  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00  
CC Method and reagent for treating diseases or conditions CC concerning molecule  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1. .17  
FT /organism='Homo sapiens (human)'.  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 643 AACTTGTTCTCCTGC 659  
|||||  
Db 1 AACTCGTTCTCATTCG 17  
RESULT 71  
BD255276 17 bp DNA linear PAT 17-JUL-2003  
LOCUS 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Regulation of repressor genes using nucleic acid molecules.  
ACCESSION BD255276  
VERSION BD255276.1 GI:33065046  
KEYWORDS JP 2002541795-A/3069.  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.  
TITLE Regulation of repressor genes using nucleic acid molecules  
JOURNAL Patent: JP 2002541795-A 3069 10-DEC-2002;  
COMMENT RIBOZYME PHARMACEUTICALS INC  
OS Eukaryote  
PN JP 2002541795-A/3069  
PD 10-DEC-2002  
PF 11-APR-2000 JP 2000611654



source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1571 TACATAATATTTTCAA 1587  
Db 17 TACATAATAACTTTCAA 1  
  
RESULT 65  
AR047238/c 17 bp DNA PAT 29-SEP-1999  
LOCUS  
DEFINITION Sequence 2031 from patent US 5817796.  
ACCESSION AR047238  
VERSION AR047238.1 GI:5968703  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues  
JOURNAL Patent: US 5817796-A 2031 06-OCT-1998;  
FEATURES  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1570 ATACATAATATTTTCA 1586  
Db 17 ATACATAATACTTTCA 1  
  
RESULT 66  
AR047626 17 bp DNA PAT 29-SEP-1999  
LOCUS  
DEFINITION Sequence 2419 from patent US 5817796.  
ACCESSION AR047626  
VERSION AR047626.1 GI:5969091  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues  
JOURNAL Patent: US 5817796-A 2419 06-OCT-1998;  
FEATURES  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 416 GGAAAGCTTTCCAGTA 432  
Db 1 GGAAAGCTCTCCAGAA 17  
  
RESULT 67  
BD199027/c 17 bp RNA linear PAT 17-JUL-2003  
LOCUS  
DEFINITION Method and reagent for treating diseases or conditions concerning

molecule participating in vasculogenic response.  
BD199027  
BD199027.1 GI:33008797  
JP 2002509721-A/2053.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 17)  
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
Method and reagent for treating diseases or conditions concerning  
molecule participating in vasculogenic response  
Patent: JP 2002509721-A 2053 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/2053  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC  
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC  
A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC  
C12N5/00  
CC Method and reagent for treating diseases or conditions CC  
concerning molecule  
CC participating in vasculogenic response  
FH key Location/Qualifiers  
FT source 1. .17  
/organism='Homo sapiens (human)'.  
FT Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:9606"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 4 AAGTTTACAATGAAGTT 20  
Db 17 AAGTTTACAAGAACTT 1  
  
RESULT 68  
BD203241 17 bp RNA linear PAT 17-JUL-2003  
LOCUS  
DEFINITION Method and reagent for treating diseases or conditions concerning  
molecule participating in vasculogenic response.  
BD203241  
BD203241.1 GI:33013011  
JP 2002509721-A/6267.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 17)  
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
Method and reagent for treating diseases or conditions concerning  
molecule participating in vasculogenic response  
Patent: JP 2002509721-A 6267 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/6267  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC

Db 17 CTGGCTGAAGGTTT 4

RESULT 60  
AX688632/c  
LOCUS AX688632 1364 from Patent EP1281758. 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1364 from Patent EP1281758.  
ACCESSION AX688632  
VERSION AX688632.1 GI:29411334  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1364 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTT 942 17 bp DNA linear PAT 08-MAY-2003  
LOCUS AX730551  
DEFINITION Sequence 2185 from Patent WO03025175.  
ACCESSION AX730551  
VERSION AX730551.1 GI:30509894  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025175-A 2185 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTT 942 17 bp DNA linear PAT 08-MAY-2003  
LOCUS AX730551/c  
DEFINITION Sequence 2185 from Patent WO03025175.  
ACCESSION AX730551  
VERSION AX730551.1 GI:30509894  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025175-A 2185 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1580 TTTTTCAAATTTGA 1593 17 bp DNA linear PAT 08-MAY-2003  
LOCUS AX735621  
DEFINITION Sequence 1211 from Patent WO03025177.  
ACCESSION AX735621

VERSION AX735621.1 GI:30514898  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 1211 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 893 TGGGAATAAGATC 906 17 bp DNA linear PAT 03-DEC-1993  
Db 14 TGGGAATAAGATC 1

RESULT 63  
A11108/c  
LOCUS A11108  
DEFINITION Oligonucleotide L1.  
ACCESSION A11108  
VERSION A11108.1 GI:490958  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Ikehara,M. and Kida,M.  
TITLE Synthetic gene for human lysozyme  
JOURNAL Patent: EP 0181634-A 52 21-MAY-1986;  
Takeda Chemical Industries, Ltd  
FEATURES  
source 1..17  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 74;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 933 GCTGAAGGTTTCTGAGA 949 17 bp DNA linear PAT 29-SEP-1999  
Db 17 GATGAAGGTTTGTGAGA 1

RESULT 64  
AR047236/c  
LOCUS AR047236 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 2029 from patent US 5817796.  
ACCESSION AR047236  
VERSION AR047236.1 GI:5968701  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues  
JOURNAL Patent: US 5817796-A 2029 06-OCT-1998;  
FEATURES Location/Qualifiers

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and  
Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10430 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 873 TTTTGATGCTGTCA 886  
|||||  
Db 16 TTTTGATGCTGTCA 3  
RESULT 56  
AR466752/c  
LOCUS AR466752 17 bp DNA  
DEFINITION Sequence 10429 from patent US 6686188.  
ACCESSION AR466752  
VERSION AR466752.1 GI:42701809  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and  
Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed  
predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10429 03-FEB-2004;  
Location/Qualifiers  
FEATURES  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 873 TTTTGATGCTGTCA 886  
|||||  
Db 17 TTTTGATGCTGTCA 4  
RESULT 57  
AR466753/c  
LOCUS AR466753 17 bp DNA  
DEFINITION Sequence 10430 from patent US 6686188.  
ACCESSION AR466753  
VERSION AR466753.1 GI:42701810  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and  
Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed  
predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10430 03-FEB-2004;  
Location/Qualifiers  
FEATURES  
source 1..17  
/organism="unknown"

/mol\_type="genomic DNA"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 873 TTTTGATGCTGTCA 886  
|||||  
Db 16 TTTTGATGCTGTCA 3  
RESULT 58  
AX216761/c  
LOCUS AX216761 17 bp RNA  
DEFINITION Sequence 2203 from Patent WO0159103.  
ACCESSION AX216761  
VERSION AX216761.1 GI:15526822  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and  
nogo gene expression  
JOURNAL Patent: WO 0159103-A 2203 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source 1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 969 TTTAATTTCTTCCT 982  
|||||  
Db 14 TTTAATTTCTTCCT 1  
RESULT 59  
AX688628/c  
LOCUS AX688628 17 bp DNA  
DEFINITION Sequence 1360 from Patent EPI281758.  
ACCESSION AX688628  
VERSION AX688628.1 GI:29411330  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and  
mdz12  
JOURNAL Patent: EP 1281758-A 1360 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 70;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 930 CTGGCTGAAGGTTT 943  
|||||

```

source      1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1103 ATCCCAAGAGCATACA 1118
      ||||| ||||| ||||| |||||
Db      2 ATCCAAAGAGCATACA 17

RESULT 51
AX757823
LOCUS      AX757823
DEFINITION Sequence 1144 from Patent WO03040369.
ACCESSION AX757823
VERSION    AX757823.1 GI:32252439
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL     Patent: WO 03040369-A 1144 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
source      1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1702 ATCCTTGAGCTGAGAA 1717
      ||||| ||||| ||||| |||||
Db      2 ATCTTTGGAGCTGAGAA 17

RESULT 52
AR157063
LOCUS      AR157063
DEFINITION Sequence 8 from patent US 6242587.
ACCESSION  AR157063
VERSION    AR157063.1 GI:15125767
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Naik,U.P. and Parise,L.V.
TITLE       DNA molecules encoding a calcium-integrin binding protein
JOURNAL     Patent: US 6242587-A 8 05-JUN-2001;
FEATURES    Location/Qualifiers
source      1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      781 GGCATTGAGTCCCTGT 796
      ||||| ||||| ||||| |||||
Db      1 GGCATTCAGTCGCTGT 16
```

```

RESULT 53
AX839863/c
LOCUS      AX839863
DEFINITION Sequence 14 from Patent WO0267982.
ACCESSION  AX839863
VERSION    AX839863.1 GI:39978396
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct
other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Young,D.B., Stewart,G.R. and O'Gaora,P.C.
TITLE       Mycobacterial vaccines
JOURNAL     Patent: WO 0267982-A 14 06-SEP-2002;
Imperial College Innovations Limited (GB)
FEATURES    Location/Qualifiers
source      1. .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic primer"

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      623 CTACACATTCAGGAGG 638
      ||||| ||||| ||||| |||||
Db      16 CTACATATTCAGGAGG 1

RESULT 54
CQ625689/c
LOCUS      CQ625689
DEFINITION Sequence 10429 from Patent WO0192524.
ACCESSION  CQ625689
VERSION    CQ625689.1 GI:41675907
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 10429 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
source      1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      873 TTTTGATGCTGTCA 886
      ||||| ||||| ||||| |||||
Db      17 TTTTGATGCTGTCA 4

RESULT 55
CQ625690/c
LOCUS      CQ625690
DEFINITION Sequence 10430 from Patent WO0192524.
ACCESSION  CQ625690
VERSION    CQ625690.1 GI:41675908
KEYWORDS   .
SOURCE     Homo sapiens (human)
```



KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.  
and Grupe, A.  
TITLE Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
JOURNAL Patent: WO 0211674-A 160 14-FEB-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1712 TGAGAAATTACTTA 1727  
|||||  
Db 1 TGAGAAATTCTACTTA 16  
RESULT 47  
AX671586/c  
LOCUS AX671586 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 31 from Patent WO03004526.  
ACCESSION AX671586  
VERSION AX671586.1 GI:29329934  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 31 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1113 CATACATTCCTTTGGT 1128  
|||||  
Db 17 CATACATTCCTTTGAT 2  
RESULT 48  
AX671726  
LOCUS AX671726 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 171 from Patent WO03004526.  
ACCESSION AX671726  
VERSION AX671726.1 GI:29330074  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1

AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 171 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1655 AGCAAGATAATTCTAT 1670  
|||||  
Db 2 ATCAAGATAATTCTAT 17  
RESULT 49  
AX672236  
LOCUS AX672236 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 681 from Patent WO03004526.  
ACCESSION AX672236  
VERSION AX672236.1 GI:29330584  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 681 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1559 GATTATATAAATACA 1574  
|||||  
Db 1 GATCATATAAATACA 16  
RESULT 50  
AX739459  
LOCUS AX739459 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 5049 from Patent WO03025177.  
ACCESSION AX739459  
VERSION AX739459.1 GI:30518756  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 5049 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTCAAAGACAGGT 925  
Db 16 TTCTTCAAAGAAAGGT 1

RESULT 42  
AX215112  
LOCUS AX215112 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 554 from Patent WO0159103.  
ACCESSION AX215112  
VERSION AX215112.1 GI:15525155  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 554 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 847 CCAGCTCTCTGTGACC 862  
Db 1 CCTGCTCTCTGTGACC 16

RESULT 43  
AX215901/c  
LOCUS AX215901 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1343 from Patent WO0159103.  
ACCESSION AX215901  
VERSION AX215901.1 GI:15525944  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 1343 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTCAAAGACAGGT 925  
Db 17 TTCTTCAAAGAAAGGT 2

RESULT 44  
AX215980  
LOCUS AX215980 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1422 from Patent WO0159103.  
ACCESSION AX215980  
VERSION AX215980.1 GI:15526023  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 1422 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 847 CCAGCTCTCTGTGACC 862  
Db 2 CCTGCTCTCTGTGACC 17

RESULT 45  
AX422075/c  
LOCUS AX422075 17 bp RNA linear PAT 18-JUN-2002  
DEFINITION Sequence 411 from Patent WO0188124.  
ACCESSION AX422075  
VERSION AX422075.1 GI:21525457  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and Randi,A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 411 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1555 TAATGATTATATAAAA 1570  
Db 16 TAATTATTATATAAAA 1

RESULT 46  
AX578322  
LOCUS AX578322 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 160 from Patent WO0211674.  
ACCESSION AX578322  
VERSION AX578322.1 GI:27647524

RESULT 37  
AR464961 LOCUS linear PAT 20-FEB-2004  
DEFINITION Sequence 8638 from patent US 6686188.  
ACCESSION AR464961 17 bp DNA  
VERSION AR464961.1 GI:42700018  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE Uncl. 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8638 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 202 ATCCAAGAAATGCAGC 217  
Db 2 ATCCAAGAACTGCAGC 17  
|||  
RESULT 38  
AR464962 LOCUS linear PAT 20-FEB-2004  
DEFINITION Sequence 8639 from patent US 6686188.  
ACCESSION AR464962 17 bp DNA  
VERSION AR464962.1 GI:42700019  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Uncl. 1 (bases 1 to 17)  
REFERENCE Uncl. Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
AUTHORS Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8639 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 202 ATCCAAGAAATGCAGC 217  
Db 2 ATCCAAGAACTGCAGC 17  
|||  
RESULT 39  
AR466754/c LOCUS linear PAT 20-FEB-2004  
DEFINITION Sequence 10431 from patent US 6686188.  
ACCESSION AR466754 17 bp DNA  
VERSION AR466754.1 GI:42701811  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Uncl. 1 (bases 1 to 17)  
REFERENCE Uncl.

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10431 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 871 AGTTTGTGATGCTGTCA 886  
Db 17 ACTTTGTGATGCTGTCA 2  
|||||  
RESULT 40  
AR466756/c LOCUS linear PAT 20-FEB-2004  
DEFINITION Sequence 10433 from patent US 6686188.  
ACCESSION AR466756 17 bp DNA  
VERSION AR466756.1 GI:42701813  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Uncl. 1 (bases 1 to 17)  
REFERENCE Uncl. Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
AUTHORS Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10433 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 870 GAGTTTGTGATGCTGTC 885  
Db 16 GACTTTTGTGATGCTGTC 1  
|||||  
RESULT 41  
AX215037/c LOCUS linear PAT 07-SEP-2001  
DEFINITION Sequence 479 from Patent WO0159103.  
ACCESSION AX215037 17 bp RNA  
VERSION AX215037.1 GI:15525080  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE other sequences; artificial sequences.  
AUTHORS 1 Blatt, L., Mcswiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 479 16-AUG-2001;  
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
source McSwiggen, James (US); Chowrira, Bharat M. (US)  
1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8639 06-DEC-2001;  
FEATURES source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 202 ATCCAAGAAATGCAGC 217  
Db 1 ATCCAAGAACTGCAGC 16  
RESULT 33  
CQ625691/c  
LOCUS CQ625691 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10431 from Patent.WO0192524.  
ACCESSION CQ625691  
VERSION CQ625691.1 GI:41675909  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10431 06-DEC-2001;  
FEATURES source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 871 AGTTTGTGATGCTGTCA 886  
Db 17 ACTTTGTGATGCTGTCA 2  
RESULT 34  
CQ625693/c  
LOCUS CQ625693 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10433 from Patent WO0192524.  
ACCESSION CQ625693  
VERSION CQ625693.1 GI:41675911  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 10433 06-DEC-2001;  
FEATURES source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 870 GAGTTTGTGATGCTGTC 885  
Db 16 GACTTTGTGATGCTGTC 1  
RESULT 35  
AR188571/c  
LOCUS AR188571 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 4059 from patent US 6346398.  
ACCESSION AR188571  
VERSION AR188571.1 GI:20234536  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 4059 12-FEB-2002;  
FEATURES source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 518 GAGACTTCCATGCTTT 533  
Db 17 GAGACTTCGATGCTTT 2  
RESULT 36  
AR324424/c  
LOCUS AR324424 17 bp RNA linear PAT 17-AUG-2003  
DEFINITION Sequence 1826 from patent US 6566127.  
ACCESSION AR324424  
VERSION AR324424.1 GI:33710232  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 1826 20-MAY-2003;  
FEATURES source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 518 GAGACTTCCATGCTTT 533  
Db 17 GAGACTTCGATGCTTT 2



QY 1265 TTACCAAGAACTTCCA 1280  
Db 17 TTACAAAGAACTTCCA 2

RESULT 29  
BD199025/c  
LOCUS  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD199025  
VERSION BD199025.1 GI:33008795  
KEYWORDS JP 2002509721-A/2051.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 2051 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC  
COMMENT OS Homo sapiens (human)  
PN JP 2002509721-A/2051  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00  
CC Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1..17  
FT /organism='Homo sapiens (human)'.  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 172 AAATATAGTGAAACT 187  
Db 17 AAATATAGTAGAAACT 2

RESULT 31  
CQ623898  
LOCUS  
DEFINITION Sequence 8638 from Patent WO0192524.  
ACCESSION CQ623898  
VERSION CQ623898.1 GI:41674116  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8638 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAACTGCAGC 217  
Db 2 ATCCAAGAACTGCAGC 17

RESULT 32  
CQ623899  
LOCUS  
DEFINITION Sequence 8639 from Patent WO0192524.  
ACCESSION CQ623899  
VERSION CQ623899.1 GI:41674117

JOURNAL Patent: JP 2002509721-A 6237 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC  
COMMENT OS Homo sapiens (human)  
PN JP 2002509721-A/6237  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00  
CC Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1..17  
FT /organism='Homo sapiens (human)'.  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 172 AAATATAGTGAAACT 187  
Db 17 AAATATAGTAGAAACT 2

RESULT 31  
CQ623898  
LOCUS  
DEFINITION Sequence 8638 from Patent WO0192524.  
ACCESSION CQ623898  
VERSION CQ623898.1 GI:41674116  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8638 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 62;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAACTGCAGC 217  
Db 2 ATCCAAGAACTGCAGC 17

RESULT 32  
CQ623899  
LOCUS  
DEFINITION Sequence 8639 from Patent WO0192524.  
ACCESSION CQ623899  
VERSION CQ623899.1 GI:41674117



RESULT 22  
AX729049 LOCUS AX729049 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 683 from Patent WO03025175.  
ACCESSION AX729049  
VERSION AX729049.1 GI:30508392  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
TITLE  
Teleman, A., Anson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 683 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 298 GATCTCCATCATTTTC 312  
|||||  
Db 1 GATCTCCATCATTTTC 15  
RESULT 23  
AR138047/c LOCUS AR138047 18 bp DNA linear PAT 16-JUN-2001  
DEFINITION Sequence 57 from patent US 6197584.  
ACCESSION AR138047  
VERSION AR138047.1 GI:14479556  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Bennett, C. Frank. and Cowsert, L. M.  
TITLE Antisense modulation of CD40 expression  
JOURNAL Patent: US 6197584-A 57 06-MAR-2001;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 60;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 945 TGAGAGACCAAGACCCAG 962  
|||  
Db 18 TGTGAGACCAAGACCTG 1  
RESULT 24  
BD226598/c LOCUS BD226598 18 bp DNA linear PAT 17-JUL-2003  
DEFINITION Antisense modulation of CD40 expression.  
ACCESSION BD226598  
VERSION BD226598.1 GI:33036368  
KEYWORDS JP 2002513593-A/57.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Bennett, C. F. and Cowsert, L. M.

TITLE Antisense modulation of CD40 expression  
JOURNAL Patent: JP 2002513593-A 57 14-MAY-2002;  
COMMENT ISIS PHARMACEUTICALS INC  
OS Unidentified  
PN JP 2002513593-A/57  
PD 14-MAY-2002  
PF 22-APR-1999 JP 2000547271  
PR 01-MAY-1998 US 09/071433  
PI C1 FRANK BENNETT, LEX M COWSERT  
PC C12N15/09, A61K9/10, A61K45/00, A61K48/00, A61P1/00, A61P11/06, PC  
A61P17/06,  
PC A61P29/00, A61P35/00, A61P37/02, A61P37/06, A61P43/00, C12P19/34,  
C12Q1/68,  
PC C12N15/00  
CC Strandedness: Single;  
CC Topology: Linear;  
CC Antisense modulation of CD40 expression  
FH Key Location/Qualifiers  
FT source 1. .18  
FT /organism='Unidentified'.  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 60;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 945 TGAGAGACCAAGACCCAG 962  
|||  
Db 18 TGTGAGACCAAGACCTG 1  
RESULT 25  
BD250503/c LOCUS BD250503 18 bp DNA linear PAT 17-JUL-2003  
DEFINITION Identification of genetic targets for modulation by  
oligonucleotides and generation of oligonucleotides for gene  
modulation.  
ACCESSION BD250503  
VERSION BD250503.1 GI:33060273  
KEYWORDS JP 2002511276-A/57.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Cowsert, L. M., Baker, B. F., Mcneil, J., Freier, S. M., Sasmor, H. M.,  
Brooks, D. G., Ohasi, C., Wyatt, J. R., Borchers, A. H. and Vikkars, T. A.  
TITLE Identification of genetic targets for modulation by  
oligonucleotides and generation of oligonucleotides for gene  
modulation  
JOURNAL Patent: JP 2002511276-A 57 16-APR-2002;  
COMMENT ISIS PHARMACEUTICALS INC  
OS Artificial Sequence  
PN JP 2002511276-A/57  
PD 16-APR-2002  
PF 13-APR-1999 JP 2000543647  
PR 13-APR-1998 US 60/081483, 28-APR-1998 US 09/067638 PI  
LEX M COWSERT, BRENDA F BAKER, JOHN MCNEIL, SUSAN M FREIER, HENRI PI  
M SASMOR,  
PI DOUGLAS G BROOKS, CARA OHASI, JACQUELINE R WYATT, ALEXANDER H PI  
BORCHERS,  
PI TIMOTHY A VIKKARS  
PC C12N15/09, C07B61/00, C07B61/00, C12Q1/68, G06F17/30, G06F17/50, PC  
C12N15/00  
CC Antisense Oligonucleotide  
FH Key Location/Qualifiers  
FT source 1. .18  
FT /organism='Artificial Sequence'.  
FEATURES Location/Qualifiers  
source 1. .18

FEATURES  
source  
Wa Pharm AB (SE)  
Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="PCR primer"

Query Match  
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 17;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 200 AAATCCAAGAAATGCAG 216  
Db 17 AGATCCAAGAAATGCAG 1

RESULT 18  
AX217110/c  
LOCUS AX217110 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 2552 from Patent WO0159103.  
ACCESSION AX217110  
VERSION AX217110.1 GI:15527171  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.

REFERENCE 1  
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 2552 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match  
Best Local Similarity 0.8%; Score 15; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 969 TTTAATTTCTTCCTT 983  
Db 17 TTTAATTTCTTCCTT 3

RESULT 19  
AX688629/c  
LOCUS AX688629 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1361 from Patent EPI281758.  
ACCESSION AX688629  
VERSION AX688629.1 GI:29411331  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1361 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match  
Best Local Similarity 0.8%; Score 15; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943  
Db 17 TCTGGCTGAAGGTTT 3

RESULT 20  
AX688630/c  
LOCUS AX688630 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1362 from Patent EPI281758.  
ACCESSION AX688630  
VERSION AX688630.1 GI:29411332  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1362 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match  
Best Local Similarity 0.8%; Score 15; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943  
Db 16 TCTGGCTGAAGGTTT 2

RESULT 21  
AX688631/c  
LOCUS AX688631 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1363 from Patent EPI281758.  
ACCESSION AX688631  
VERSION AX688631.1 GI:29411333  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1363 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match  
Best Local Similarity 0.8%; Score 15; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943  
Db 15 TCTGGCTGAAGGTTT 1





/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Cyclin G1 ribozyme binding site"

Query Match 1.0%; Score 17.4; DB 1; Length 19;  
Best Local Similarity 94.7%; Pred. No. 31;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 901 AAGATCTTTTCTTCAAG 919  
|||||  
Db 19 AAGATCTTTTACTTCAAG 1

RESULT 8  
I38057  
LOCUS I38057 18 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 1070 from patent US 5612215.  
ACCESSION I38057  
VERSION I38057.1 GI:2086047  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 1070 18-MAR-1997;  
FEATURES Location/Qualifiers  
source 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 94.4%; Pred. No. 38;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 782 GCATTCAGTCCCTGTATG 799  
|||||  
Db 1 GCATTCAGTCCCTCTATG 18

RESULT 9  
I94907  
LOCUS I94907 18 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 1070 from patent US 5731295.  
ACCESSION I94907  
VERSION I94907.1 GI:3939377  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 1070 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 94.4%; Pred. No. 38;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 782 GCATTCAGTCCCTGTATG 799  
|||||  
Db 1 GCATTCAGTCCCTCTATG 18

RESULT 10  
AR294019/c

LOCUS AR294019 19 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 5754 from patent US 6537751.  
ACCESSION AR294019  
VERSION AR294019.1 GI:31681303  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.  
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome  
JOURNAL Patent: US 6537751-A 5754 25-MAR-2003;  
FEATURES Location/Qualifiers  
source 1..19  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 16.4; DB 1; Length 19;  
Best Local Similarity 94.4%; Pred. No. 41;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1190 ACTTCTTTGTAGATAACC 1207  
|||||  
Db 18 ACTTCTTTGCAGATAACC 1

RESULT 11  
I37415  
LOCUS I37415 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 428 from patent US 5612215.  
ACCESSION I37415  
VERSION I37415.1 GI:2085375  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 428 18-MAR-1997;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 197 AAAAAATCCAAGAAAT 212  
|||||  
Db 2 AAAAAATCCAAGAAAT 17

RESULT 12  
I94265  
LOCUS I94265 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 428 from patent US 5731295.  
ACCESSION I94265  
VERSION I94265.1 GI:3938735  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 428 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17

PC	C12N15/00
CC	Description of Artificial Sequence:Antisense Primer FH Key Location/Qualifiers
FT	source 1..20 /organism='Artificial Sequence'.
FT	Location/Qualifiers 1..20 /organism="unidentified" /mol_type="genomic DNA" /db_xref="taxon:32644"
FEATURES	
source	
Query Match	1.1%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 15;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1243 GACCTGGTTATCCCAAACT 1262
Dd	 20 GACCTGGTTATCCCAAACT 1
RESULT 6	
AX133241	
LOCUS	AX133241               21 bp    DNA                    linear         PAT 15-MAY-2001
DEFINITION	Sequence 4459 from Patent WO0130362.
ACCESSION	AX133241
VERSION	AX133241.1 GI:14139551
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Robbins,J.M. and Tritz,R.
TITLE	Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL	Patent: WO 0130362-A 4459 03-MAY-2001; IMMUSOL, INC. (US)
FEATURES	
source	
Query Match	1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity	95.2%; Pred. No. 20;
Matches	20; Conservative 0; Mismatches 1; Indels 0; Gaps 0
Qy	781 GGCATTGAGTCCCCTGTATGGA 801
Dd	 1 GGCATTGAGTCCCCTGTATGGA 21
RESULT 7	
AX131390/c	
LOCUS	AX131390               19 bp    DNA                    linear         PAT 15-MAY-2000
DEFINITION	Sequence 2608 from Patent WO0130362.
ACCESSION	AX131390
VERSION	AX131390.1 GI:14137695
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Robbins,J.M. and Tritz,R.
TITLE	Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL	Patent: WO 0130362-A 2608 03-MAY-2001; IMMUSOL, INC. (US)
FEATURES	
source	
Query Match	1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity	95.2%; Pred. No. 20;
Matches	20; Conservative 0; Mismatches 1; Indels 0; Gaps 0
Qy	781 GGCATTGAGTCCCCTGTATGGA 801
Dd	 1 GGCATTGAGTCCCCTGTATGGA 21

107 13.8 0.8 17 1 AX218206 ACCESSION:AX218206  
c 108 13.8 0.8 17 1 AX423658 ACCESSION:AX423658  
109 13.8 0.8 17 1 AX475675 ACCESSION:AX475675  
110 13.8 0.8 17 1 AX499869 ACCESSION:AX499869  
111 13.8 0.8 17 1 AX499870 ACCESSION:AX499870  
c 112 13.8 0.8 17 1 AX579110 ACCESSION:AX579110  
113 13.8 0.8 17 1 AX673023 ACCESSION:AX673023  
114 13.8 0.8 17 1 AX674037 ACCESSION:AX674037  
115 13.8 0.8 17 1 AX687956 ACCESSION:AX687956  
116 13.8 0.8 17 1 AX687957 ACCESSION:AX687957  
117 13.8 0.8 17 1 AX687958 ACCESSION:AX687958  
118 13.8 0.8 17 1 AX693070 ACCESSION:AX693070  
119 13.8 0.8 17 1 AX727979 ACCESSION:AX727979  
120 13.8 0.8 17 1 AX728771 ACCESSION:AX728771  
121 13.8 0.8 17 1 AX730620 ACCESSION:AX730620  
122 13.8 0.8 17 1 AX736604 ACCESSION:AX736604  
c 123 13.8 0.8 17 1 AX737681 ACCESSION:AX737681  
124 13.8 0.8 17 1 AX738191 ACCESSION:AX738191  
125 13.8 0.8 17 1 AX739409 ACCESSION:AX739409  
126 13.8 0.8 17 1 AX739484 ACCESSION:AX739484  
127 13.8 0.8 17 1 AX745357 ACCESSION:AX745357  
128 13.8 0.8 17 1 AX756687 ACCESSION:AX756687  
129 13.8 0.8 17 1 AX758977 ACCESSION:AX758977  
c 130 13.8 0.8 17 1 AX760855 ACCESSION:AX760855  
131 13.8 0.8 17 1 AX761593 ACCESSION:AX761593  
132 13.8 0.8 17 1 BD067891 ACCESSION:BD067891  
c 133 13.8 0.8 17 1 BD067975 ACCESSION:BD067975  
134 13.4 0.8 15 1 AR560062 ACCESSION:AR560062  
135 13.4 0.8 16 1 I71540 ACCESSION:I71540  
136 13.4 0.8 16 1 AR328342 ACCESSION:AR328342  
137 13.4 0.8 16 1 AR436137 ACCESSION:AR436137  
c 138 13 0.7 15 1 AR028986 ACCESSION:AR028986  
c 139 13 0.7 15 1 AR028990 ACCESSION:AR028990  
c 140 13 0.7 15 1 AR156868 ACCESSION:AR156868  
c 141 13 0.7 15 1 AR156872 ACCESSION:AR156872  
c 142 13 0.7 15 1 I77892 ACCESSION:I77892  
c 143 13 0.7 15 1 AR180094 ACCESSION:AR180094  
c 144 13 0.7 15 1 AR412066 ACCESSION:AR412066  
c 145 13 0.7 15 1 AR412070 ACCESSION:AR412070  
c 146 13 0.7 15 1 AX638406 ACCESSION:AX638406  
c 147 13 0.7 16 1 AR002582 ACCESSION:AR002582  
c 148 12.8 0.7 16 1 A88311 ACCESSION:A88311  
c 149 12.8 0.7 16 1 A90278 ACCESSION:A90278  
c 150 12.8 0.7 16 1 AR002566 ACCESSION:AR002566  
c 151 12.8 0.7 16 1 AR435857 ACCESSION:AR435857  
152 12.8 0.7 16 1 AX268349 ACCESSION:AX268349  
153 12.8 0.7 16 1 AX405167 ACCESSION:AX405167  
c 154 12.8 0.7 16 1 AX796642 ACCESSION:AX796642  
c 155 12.8 0.7 16 1 BD065824 ACCESSION:BD065824

ALIGNMENTS

RESULT 1  
AX663746  
LOCUS AX663746 26 bp DNA linear PAT 22-MAR-2003  
DEFINITION Sequence 121 from Patent WO02097127.  
ACCESSION AX663746  
VERSION AX663746.1 GI:29163926  
KEYWORDS .  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.  
AUTHORS Oellers,N., Gehrman,M., Kallabis,H., Hall,R., Schulze,T. and  
 Kroegel,C.  
TITLE Genes and proteins for prevention, prediction, diagnosis, prognosis  
 and treatment of chronic lung disease  
JOURNAL Patent: WO 02097127-A 121 05-DEC-2002;  
 Bayer Aktiengesellschaft (DE)  
FEATURES  
 source  
 1. .26

/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="L23808 forward primer"  
Query Match 1.5%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 3.6;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 944 CTGAGAGACCAAGACCAGTGTAAAT 969  
 |||||  
Db 1 CTGAGAGACCAAGACCAGTGTAAAT 26  
RESULT 2  
AX663745  
LOCUS AX663745 25 bp DNA linear PAT 22-MAR-2003  
DEFINITION Sequence 120 from Patent WO02097127.  
ACCESSION AX663745  
VERSION AX663745.1 GI:29163925  
KEYWORDS .  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.  
AUTHORS Oellers,N., Gehrman,M., Kallabis,H., Hall,R., Schulze,T. and  
 Kroegel,C.  
TITLE Genes and proteins for prevention, prediction, diagnosis, prognosis  
 and treatment of chronic lung disease  
JOURNAL Patent: WO 02097127-A 120 05-DEC-2002;  
 Bayer Aktiengesellschaft (DE)  
FEATURES  
 source  
 1. .25  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="L23808 probe"  
Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 4.7;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 980 CCTATGGCCAACTTGCCATCTGG 1004  
 |||||  
Db 1 CCTATGGCCAACTTGCCATCTGG 25  
RESULT 3  
AX663747/c  
LOCUS AX663747 24 bp DNA linear PAT 22-MAR-2003  
DEFINITION Sequence 122 from Patent WO02097127..  
ACCESSION AX663747  
VERSION AX663747.1 GI:29163927  
KEYWORDS .  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.  
AUTHORS Oellers,N., Gehrman,M., Kallabis,H., Hall,R., Schulze,T. and  
 Kroegel,C.  
TITLE Genes and proteins for prevention, prediction, diagnosis, prognosis  
 and treatment of chronic lung disease  
JOURNAL Patent: WO 02097127-A 122 05-DEC-2002;  
 Bayer Aktiengesellschaft (DE)  
FEATURES  
 source  
 1. .24  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="L23808 reverse primer"  
Query Match 1.3%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 6;



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:25:01 ; Search time 3 Seconds  
(without alignments)  
3.141 Million cell updates/sec

Title: US-10-619-906-1  
Perfect score: 1778  
Sequence: 1 tagaagtttacaatgaagt.....ttttggtcacaataaaattg 1778

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 155 seqs, 2650 residues

Total number of hits satisfying chosen parameters: 310

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 155 summaries

Database : rgel.seq.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	26	1.5	26	1	AX663746
2	25	1.4	25	1	AX663745
3	24	1.3	24	1	AX663747
4	20	1.1	20	1	BD167388
5	20	1.1	20	1	BD167389
6	19.4	1.1	21	1	AX133241
7	17.4	1.0	19	1	AX131390
8	16.4	0.9	18	1	I38057
9	16.4	0.9	18	1	I94907
10	16.4	0.9	19	1	AR294019
11	16	0.9	17	1	I37415
12	16	0.9	17	1	I94265
13	15.4	0.9	17	1	A73892
14	15.4	0.9	17	1	CQ625692
15	15.4	0.9	17	1	AR228318
16	15.4	0.9	17	1	AR466755
17	15.4	0.9	17	1	AX316540
18	15	0.8	17	1	AX217110
19	15	0.8	17	1	AX688629
20	15	0.8	17	1	AX688630
21	15	0.8	17	1	AX688631
22	15	0.8	17	1	AX729049
23	14.8	0.8	18	1	AR138047
24	14.8	0.8	18	1	BD226598
25	14.8	0.8	18	1	BD250503
26	14.8	0.8	18	1	AR233564
27	14.8	0.8	18	1	ATH520245
28	14.4	0.8	17	1	BD199024
29	14.4	0.8	17	1	BD199025
30	14.4	0.8	17	1	BD203211
31	14.4	0.8	17	1	CQ623898
32	14.4	0.8	17	1	CQ623899
33	14.4	0.8	17	1	CQ625691

17	1	CQ625693	14.4	0.8	17	1	AR188571	14.4	0.8	17	1	AR188571
17	1	AR324424	14.4	0.8	17	1	AR324424	14.4	0.8	17	1	AR324424
17	1	AR464961	14.4	0.8	17	1	AR464961	14.4	0.8	17	1	AR464961
17	1	AR464962	14.4	0.8	17	1	AR464962	14.4	0.8	17	1	AR464962
17	1	AR466754	14.4	0.8	17	1	AR466754	14.4	0.8	17	1	AR466754
17	1	AR466756	14.4	0.8	17	1	AR466756	14.4	0.8	17	1	AR466756
17	1	AX215037	14.4	0.8	17	1	AX215037	14.4	0.8	17	1	AX215037
17	1	AX215112	14.4	0.8	17	1	AX215112	14.4	0.8	17	1	AX215112
17	1	AX215901	14.4	0.8	17	1	AX215901	14.4	0.8	17	1	AX215901
17	1	AX215980	14.4	0.8	17	1	AX215980	14.4	0.8	17	1	AX215980
17	1	AX422075	14.4	0.8	17	1	AX422075	14.4	0.8	17	1	AX422075
17	1	AX578322	14.4	0.8	17	1	AX578322	14.4	0.8	17	1	AX578322
17	1	AX671586	14.4	0.8	17	1	AX671586	14.4	0.8	17	1	AX671586
17	1	AX671726	14.4	0.8	17	1	AX671726	14.4	0.8	17	1	AX671726
17	1	AX672236	14.4	0.8	17	1	AX672236	14.4	0.8	17	1	AX672236
17	1	AX739459	14.4	0.8	17	1	AX739459	14.4	0.8	17	1	AX739459
17	1	AX757823	14.4	0.8	17	1	AX757823	14.4	0.8	17	1	AX757823
18	1	AR157063	14.4	0.8	18	1	AR157063	14.4	0.8	18	1	AR157063
18	1	AX839863	14.4	0.8	18	1	AX839863	14.4	0.8	18	1	AX839863
17	1	CQ625689	14	0.8	17	1	CQ625689	14	0.8	17	1	CQ625689
17	1	CQ625690	14	0.8	17	1	CQ625690	14	0.8	17	1	CQ625690
17	1	AR466752	14	0.8	17	1	AR466752	14	0.8	17	1	AR466752
17	1	AR466753	14	0.8	17	1	AR466753	14	0.8	17	1	AR466753
17	1	AX216761	14	0.8	17	1	AX216761	14	0.8	17	1	AX216761
17	1	AX688628	14	0.8	17	1	AX688628	14	0.8	17	1	AX688628
17	1	AX688632	14	0.8	17	1	AX688632	14	0.8	17	1	AX688632
17	1	AX730551	14	0.8	17	1	AX730551	14	0.8	17	1	AX730551
17	1	AX735621	14	0.8	17	1	AX735621	14	0.8	17	1	AX735621
17	1	A11108	13.8	0.8	17	1	A11108	13.8	0.8	17	1	A11108
17	1	AR047236	13.8	0.8	17	1	AR047236	13.8	0.8	17	1	AR047236
17	1	AR047238	13.8	0.8	17	1	AR047238	13.8	0.8	17	1	AR047238
17	1	AR047626	13.8	0.8	17	1	AR047626	13.8	0.8	17	1	AR047626
17	1	BD199027	13.8	0.8	17	1	BD199027	13.8	0.8	17	1	BD199027
17	1	BD203241	13.8	0.8	17	1	BD203241	13.8	0.8	17	1	BD203241
17	1	BD203242	13.8	0.8	17	1	BD203242	13.8	0.8	17	1	BD203242
17	1	BD203389	13.8	0.8	17	1	BD203389	13.8	0.8	17	1	BD203389
17	1	BD255276	13.8	0.8	17	1	BD255276	13.8	0.8	17	1	BD255276
17	1	BD255278	13.8	0.8	17	1	BD255278	13.8	0.8	17	1	BD255278
17	1	CQ622021	13.8	0.8	17	1	CQ622021	13.8	0.8	17	1	CQ622021
17	1	CQ623897	13.8	0.8	17	1	CQ623897	13.8	0.8	17	1	CQ623897
17	1	CQ625688	13.8	0.8	17	1	CQ625688	13.8	0.8	17	1	CQ625688
17	1	CQ625694	13.8	0.8	17	1	CQ625694	13.8	0.8	17	1	CQ625694
17	1	I37528	13.8	0.8	17	1	I37528	13.8	0.8	17	1	I37528
17	1	I37529	13.8	0.8	17	1	I37529	13.8	0.8	17	1	I37529
17	1	I37585	13.8	0.8	17	1	I37585	13.8	0.8	17	1	I37585
17	1	I37592	13.8	0.8	17	1	I37592	13.8	0.8	17	1	I37592
17	1	I54288	13.8	0.8	17	1	I54288	13.8	0.8	17	1	I54288
17	1	I54290	13.8	0.8	17	1	I54290	13.8	0.8	17	1	I54290
17	1	I54678	13.8	0.8	17	1	I54678	13.8	0.8	17	1	I54678
17	1	I94378	13.8	0.8	17	1	I94378	13.8	0.8	17	1	I94378
17	1	I94379	13.8	0.8	17	1	I94379	13.8	0.8	17	1	I94379
17	1	I94435	13.8	0.8	17	1	I94435	13.8	0.8	17	1	I94435
17	1	I94442	13.8	0.8	17	1	I94442	13.8	0.8	17	1	I94442
17	1	AR186189	13.8	0.8	17	1	AR186189	13.8	0.8	17	1	AR186189
17	1	AR188613	13.8	0.8	17	1	AR188613	13.8	0.8	17	1	AR188613
17	1	AR190187	13.8	0.8	17	1	AR190187	13.8	0.8	17	1	AR190187
17	1	AR191846	13.8	0.8	17	1	AR191846	13.8	0.8	17	1	AR191846
17	1	AR192415	13.8	0.8	17	1	AR192415	13.8	0.8	17	1	AR192415
17	1	AR322820	13.8	0.8	17	1	AR322820	13.8	0.8	17	1	AR322820
17	1	AR324466	13.8	0.8	17	1	AR324466	13.8	0.8	17	1	AR324466
17	1	AR325741	13.8	0.8	17	1	AR325741	13.8	0.8	17	1	AR325741
17	1	AR326284	13.8	0.8	17	1	AR326284	13.8	0.8	17	1	AR326284
17	1	AR326284	13.8	0.8	17	1	AR326284	13.8	0.8	17	1	AR326284
17	1	AR328170	13.8	0.8	17	1	AR328170	13.8	0.8	17	1	AR328170
17	1	AR362733	13.8	0.8	17	1	AR362733	13.8	0.8	17	1	AR362733
17	1	AR402391	13.8	0.8	17	1	AR402391	13.8	0.8	17	1	AR402391
17	1	AR402475	13.8	0.8	17	1	AR402475	13.8	0.8	17	1	AR402475
17	1	AR463084	13.8	0.8	17	1	AR463084	13.8	0.8	17	1	AR463084
17	1	AR464960	13.8	0.8	17	1	AR464960	13.8	0.8	17	1	AR464960
17	1	AR466751	13.8	0.8	17	1	AR466751	13.8	0.8	17	1	AR466751
17	1	AR466757	13.8	0.8	17	1	AR466757	13.8	0.8	17	1	AR466757
17	1	AX214888	13.8	0.8	17	1	AX214888	13.8	0.8	17	1	AX214888
17	1	AX215038	13.8	0.8	17	1	AX215038	13.8	0.8	17	1	AX215038

R. Site2: NotI 5' Seq Primer M13F Normalised library constructed from pooled ovaries. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS, [www.ark-genomics.org](http://www.ark-genomics.org).

FEATURES

source

Location/Qualifiers  
1. .14  
/organism="Sus scrofa"  
/mol\_type="mRNA"  
/db\_xref="taxon:9823"  
/clone="C0003273\_I16"  
/tissue\_type="ovary"  
/clone\_lib="CSEQRAN19"  
/note="Vector: pBluescript11(KS+); Site 1: EcoRI; Site 2:  
NotI; Single pass sequencing; Normalised library  
constructed from pooled ovaries"

Query Match 0.6%; Score 11.4; DB 1; Length 14;  
Best Local Similarity 92.3%; Pred. No. 9.6;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 623 CTACACATTCAGG 635  
|||  
Db 13 CTGCACATTCAGG 1

Search completed: May 13, 2005, 11:34:01  
Job time : 1 secs

/clone\_lib="Aspergillus terreus random genomic DNA clone library"  
/note="Vector: pZerOTM-2; Site 1: Sau3A; Site 2: BamHI; Sau3A genomic fragments ligated into BamHI digested pZerOTM-2 "  
pZerOTM-2 "

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 2.1;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 692 GCCATTCTAGTGATCCAA 709  
| | | | | | | | | | | | | | | |  
Db 1 GCCGTTCTAGTGATCCGA 18

RESULT 6  
AW246518/c  
LOCUS  
DEFINITION 2821785.3prime NIH\_MGC\_7 Homo sapiens cDNA clone IMAGE:2821785 3',  
mRNA sequence.  
ACCESSION AW246518  
VERSION AW246518.1 GI:6589511  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 17)  
NIH-MGC http://mgc.nci.nih.gov/.  
National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Other ESTs: 2821785.5prime  
Contact: Robert Strausberg, Ph.D.  
Email: cgapbs-r@mail.nih.gov  
Tissue Procurement: DCTD/DTP cDNA Library Preparation: Ling  
Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E.  
Consortium (LLNL) DNA Sequencing by: Berkeley MGC sequencing  
project  
Clone distribution: MGC clone distribution information can  
be found through the I.M.A.G.E. Consortium/LLNL at:  
www-bio.llnl.gov/bbrp/image/image.html Base Calling / Quality  
Scores: PHRED from University of Washington Genome Center.  
Vector  
Trimming: cross match from University of Washington Genome Center  
PHRAP suite. Poly-T Identification: patMatch.pl from Berkeley  
Drosophila Genome Project. University of Washington Genome Center:  
http://www.genome.washington.edu Low Quality Sequence: 15  
contiguous PHRED high quality bases following vector sequence. Very  
Low Quality Sequence: Trace file contained 17 contiguous distinct  
peaks following vector sequence. Polyadenylation: Based upon the  
presence of a XhoI site followed by a run of 14 or more T residues  
at the beginning of the sequence, this cDNA insert was  
polyadenylated.  
Plate: LLCM7 row: L column: 10  
High quality sequence stop: 15.  
Location/Qualifiers

FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:2821785"  
/tissue\_type="small cell carcinoma"  
/cell\_line="MGC3"  
/lab\_host="DH10B (phage-resistant)"  
/clone\_lib="NIH\_MGC\_7"  
/note="Organ: lung; Vector: pOTB7; Site 1: XhoI; Site 2:  
EcoRI; cDNA made by oligo-dT priming. Directionally  
cloned into EcoRI/XhoI sites using the following 5'  
adaptor: GGCACGAG(G). Size-selected >500bp for average  
insert size 1.8kb. Library constructed by Ling Hong in  
the laboratory of Gerald M. Rubin (University of  
California, Berkeley) using ZAP-cDNA synthesis kit  
(Stratagene) and Superscript II RT (Life Technologies)."

Query Match 0.8%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 3;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1137 CTTTGTGAAAAAAA 1150  
| | | | | | | | | | | | | | | |  
Db 17 CTTTGTGAAAAAAA 4

RESULT 7  
AL037434/c  
LOCUS  
DEFINITION AL037434 16 bp mRNA linear EST 06-JUL-2004  
DKFZp564O1471.s1 564 (synonym: hfbr2) Homo sapiens cDNA clone  
DKFZp564O1471. mRNA sequence.  
ACCESSION AL037434  
VERSION AL037434.1 GI:49681994  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 16)  
REFERENCE Bloecker,H., Boecher,M., Brandt,P., Mewes,H.W., Gassenhuber,J. and  
AUTHORS Wiemann,S.  
TITLE EST (Bloecker, et al.)  
JOURNAL Unpublished (1999)  
COMMENT Contact: MIPS  
MIPS  
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.  
Location/Qualifiers

FEATURES  
source  
1..16  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="DKFZp564O1471"  
/tissue\_type="brain"  
/dev\_stage="fetal"  
/lab\_host="Xl-2blue"  
/clone\_lib="564 (synonym: hfbr2)"  
/note="Vector: pAMP1; Site\_1: NotI; Site\_2: SalI"

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 5.2;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1524 TATCATATAAATAAAAA 1539  
| | | | | | | | | | | | | | | |  
Db 16 TGTATATAAATAAAAA 1

RESULT 8  
AJ649806/c  
LOCUS  
DEFINITION AJ649806 CSEQPAN19 Sus scrofa cDNA clone C0003273\_I16, mRNA  
sequence.  
ACCESSION AJ649806  
VERSION AJ649806.1 GI:49326651  
KEYWORDS EST.  
SOURCE Sus scrofa (pig)  
ORGANISM Sus scrofa  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.  
1 (bases 1 to 14)  
REFERENCE Anderson,S.I., Finlayson,H.A. and Archibald,A.L.  
AUTHORS Development of cDNA and EST resources for studying reproduction and  
TITLE embryo development in pigs and cattle  
JOURNAL Unpublished (2004)  
COMMENT Contact: Anderson SI  
Genomics and Bioinformatics  
Roslin Institute  
Roslin, Midlothian, EH25 9PS, UNITED KINGDOM  
Single pass sequencing. Bases called and trimmed with phred  
v0.020425.c. Vector identified by cross\_match with the -minscore 20  
and -minmatch 12 options. Vector:pBlueScriptII(KS) R. Sitel: EcoRI

```

REFERENCE
AUTHORS
1 (bases 1 to 18)
Askenazi,M., Driggers,E.M., Holtzman,D.A., Norman,T.C., Iverson,S.,
Zimmer,D.P., Boers,M-E., Blomquist,P.R., Martinez,E.J.,
Monreal,A.W., Feibelman,T.P., Mayorga,M.E., Maxon,M.E., Sykes,K.,
Tobin,J., Cordero,E., Salama,S.R., Trueheart,J., Royer,J.C. and
Madden,K.T.
TITLE
Integrating transcriptional and metabolite profiles to direct the
engineering of lovastatin-producing strains
JOURNAL
COMMENT
Unpublished (2002)
Contact: Zimmer DP
Microbia, Inc.
One Kendall Square Building 1400 W, Cambridge, MA 02139, USA
Tel: 617-621-8322
Fax: 617-
Email: dzimmer@microbia.com
Class: plasmid ends.
FEATURES
source
1. .18
/organism="Aspergillus terreus"
/mol_type="genomic DNA"
/strain="ATCC 20542 (A. terreus Thom, anamorph)"
/db_xref="taxon:33178"
/lab_host="Escherichia coli"
/clone_lib="Aspergillus terreus random genomic DNA clone
library"
/note="Vector: pZerOTM-2; Site 1: Sau3A; Site 2: BamHI;
Sau3A genomic fragments ligated into BamHI digested
pZerOTM-2"
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 692 GCCATTCTAGTGATCCAA 709
Db 1 GCCGTTCCTAGTGATCCGA 18
RESULT 3
BZ424774
LOCUS
DEFINITION
10019211-4775 Aspergillus terreus random genomic DNA clone library
Aspergillus terreus genomic, genomic survey sequence.
ACCESSION
BZ424774
VERSION
BZ424774.1 GI:26666229
KEYWORDS
GSS.
SOURCE
Aspergillus terreus
ORGANISM
Aspergillus terreus
Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
REFERENCE
1 (bases 1 to 18)
Askenazi,M., Driggers,E.M., Holtzman,D.A., Norman,T.C., Iverson,S.,
Zimmer,D.P., Boers,M-E., Blomquist,P.R., Martinez,E.J.,
Monreal,A.W., Feibelman,T.P., Mayorga,M.E., Maxon,M.E., Sykes,K.,
Tobin,J., Cordero,E., Salama,S.R., Trueheart,J., Royer,J.C. and
Madden,K.T.
TITLE
Integrating transcriptional and metabolite profiles to direct the
engineering of lovastatin-producing strains
JOURNAL
COMMENT
Unpublished (2002)
Contact: Zimmer DP
Microbia, Inc.
One Kendall Square Building 1400 W, Cambridge, MA 02139, USA
Tel: 617-621-8322
Fax: 617-
Email: dzimmer@microbia.com
Class: plasmid ends.
FEATURES
source
1. .18
/organism="Aspergillus terreus"
/mol_type="genomic DNA"
/strain="ATCC 20542 (A. terreus Thom, anamorph)"
/db_xref="taxon:33178"
/lab_host="Escherichia coli"
/clone_lib="Aspergillus terreus random genomic DNA clone
library"
/note="Vector: pZerOTM-2; Site 1: Sau3A; Site 2: BamHI;
Sau3A genomic fragments ligated into BamHI digested
pZerOTM-2"
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 692 GCCATTCTAGTGATCCAA 709
Db 1 GCCGTTCCTAGTGATCCGA 18
RESULT 4
BZ425093
LOCUS
DEFINITION
100024697-5033 Aspergillus terreus random genomic DNA clone library
Aspergillus terreus genomic, genomic survey sequence.
ACCESSION
BZ425093
VERSION
BZ425093.1 GI:26666548
KEYWORDS
GSS.
SOURCE
Aspergillus terreus
ORGANISM
Aspergillus terreus
Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
REFERENCE
1 (bases 1 to 18)
Askenazi,M., Driggers,E.M., Holtzman,D.A., Norman,T.C., Iverson,S.,
Zimmer,D.P., Boers,M-E., Blomquist,P.R., Martinez,E.J.,
Monreal,A.W., Feibelman,T.P., Mayorga,M.E., Maxon,M.E., Sykes,K.,
Tobin,J., Cordero,E., Salama,S.R., Trueheart,J., Royer,J.C. and
Madden,K.T.
TITLE
Integrating transcriptional and metabolite profiles to direct the
engineering of lovastatin-producing strains
JOURNAL
COMMENT
Unpublished (2002)
Contact: Zimmer DP
Microbia, Inc.
One Kendall Square Building 1400 W, Cambridge, MA 02139, USA
Tel: 617-621-8322
Fax: 617-
Email: dzimmer@microbia.com
Class: plasmid ends.
FEATURES
source
1. .18
/organism="Aspergillus terreus"
/mol_type="genomic DNA"
/strain="ATCC 20542 (A. terreus Thom, anamorph)"
/db_xref="taxon:33178"
/lab_host="Escherichia coli"
/clone_lib="Aspergillus terreus random genomic DNA clone
library"
/note="Vector: pZerOTM-2; Site 1: Sau3A; Site 2: BamHI;
Sau3A genomic fragments ligated into BamHI digested
pZerOTM-2"
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 692 GCCATTCTAGTGATCCAA 709
Db 1 GCCGTTCCTAGTGATCCGA 18
RESULT 5
BZ425186
LOCUS
DEFINITION
100026457-2989 Aspergillus terreus random genomic DNA clone library
Aspergillus terreus genomic, genomic survey sequence.
ACCESSION
BZ425186
VERSION
BZ425186.1 GI:26666641
KEYWORDS
GSS.
SOURCE
Aspergillus terreus
ORGANISM
Aspergillus terreus
Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
REFERENCE
1 (bases 1 to 18)
Askenazi,M., Driggers,E.M., Holtzman,D.A., Norman,T.C., Iverson,S.,
Zimmer,D.P., Boers,M-E., Blomquist,P.R., Martinez,E.J.,
Monreal,A.W., Feibelman,T.P., Mayorga,M.E., Maxon,M.E., Sykes,K.,
Tobin,J., Cordero,E., Salama,S.R., Trueheart,J., Royer,J.C. and
Madden,K.T.
TITLE
Integrating transcriptional and metabolite profiles to direct the
engineering of lovastatin-producing strains
JOURNAL
COMMENT
Unpublished (2002)
Contact: Zimmer DP
Microbia, Inc.
One Kendall Square Building 1400 W, Cambridge, MA 02139, USA
Tel: 617-621-8322
Fax: 617-
Email: dzimmer@microbia.com
Class: plasmid ends.
FEATURES
source
1. .18
/organism="Aspergillus terreus"
/mol_type="genomic DNA"
/strain="ATCC 20542 (A. terreus Thom, anamorph)"
/db_xref="taxon:33178"
/lab_host="Escherichia coli"
/clone_lib="Aspergillus terreus random genomic DNA clone
library"
/note="Vector: pZerOTM-2; Site 1: Sau3A; Site 2: BamHI;
Sau3A genomic fragments ligated into BamHI digested
pZerOTM-2"
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.1;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 692 GCCATTCTAGTGATCCAA 709
Db 1 GCCGTTCCTAGTGATCCGA 18
```



Fri May 13 12:26:38 2005

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:34:00 ; Search time 0.001 Seconds  
(without alignments)  
497.840 Million cell updates/sec

Title: US-10-619-906-1  
Perfect score: 1778  
Sequence: 1 tagaagtttacaatgaagt.....ttttggctcaataaaattg 1778

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 8 seqs, 140 residues

Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 8 summaries

Database : rstl.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	17.8	1.0	21	1	AG187907 ACCESSION:AG187907
2	14.8	0.8	18	1	BZ424714 ACCESSION:BZ424714
3	14.8	0.8	18	1	BZ424774 ACCESSION:BZ424774
4	14.8	0.8	18	1	BZ425093 ACCESSION:BZ425093
5	14.8	0.8	18	1	BZ425186 ACCESSION:BZ425186
6	14	0.8	17	1	AW246518 ACCESSION:AW246518
C 7	12.8	0.7	16	1	AL037434 ACCESSION:AL037434
C 8	11.4	0.6	14	1	AJ649806 ACCESSION:AJ649806

ALIGNMENTS

RESULT 1  
AG187907/c  
LOCUS  
DEFINITION Pan troglodytes DNA, clone: RP43-061C06.T7, genomic survey  
sequence.  
ACCESSION AG187907  
VERSION AG187907.1 GI:45220076  
KEYWORDS GSS.  
SOURCE Pan troglodytes (chimpanzee)  
ORGANISM Pan troglodytes  
REFERENCE 1  
AUTHORS Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,  
Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.  
TITLE BAC end sequences of Library RP-43  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 21)  
AUTHORS Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,  
Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.

TITLE Direct Submission  
JOURNAL Submitted (07-JAN-2002) Hong-Seog Park, Korea Research Institute of  
Bioscience and Biotechnology (KRIBB), Genome Research Center (GRC);  
52, Oun-dong, Yusong-gu, Daejeon 305-333, Korea  
(E-mail:redstone@mail.krribb.re.kr, URL:http://phs.grc.krribb.re.kr/,  
Tel:82-42-866-7181, Fax:82-42-860-4409)  
COMMENT Clones are derived from the chimpanzee BAC library RP-43 This BAC  
end was generated during the R&D process and may have higher chance  
of clone tracking errors.

PRIMERS

Sequencing: T7

LIBRARY

Vector : pBACe3.6

R.Site 1 : ECORI

R.Site 2 : ECORI.

Location/Qualifiers

source

1. .21  
/organism="Pan troglodytes"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9598"  
/clone="RP43-061C06.T7"  
/sex="male"  
/cell\_type="lymphocytes"  
/clone\_lib="RP-43 Chimpanzee Male BAC Library"

Query Match 1.0%; Score 17.8; DB 1; Length 21;  
Best Local Similarity 90.5%; Pred. No. 0.48;  
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 194 AGGAAAAATCCAGAAATGC 214  
|||||

Db 21 AGGAAAAATATAGAAATGC 1  
|||||

RESULT 2

BZ424714

LOCUS

DEFINITION

100018520-2995 Aspergillus terreus random genomic DNA clone library

Aspergillus terreus genomic, genomic survey sequence.

BZ424714

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Contact: Zimmer DP

Microbia, Inc.

One Kendall Square Building 1400 W, Cambridge, MA 02139, USA

Tel: 617-621-8322

Fax: 617-

Email: dzimmer@microbia.com

Class: plasmid ends.

Location/Qualifiers

1. .18

/organism="Aspergillus terreus"

/mol\_type="genomic DNA"

/strain="ATCC 20542 (A. terreus Thom, anamorph)"

/db\_xref="taxon:33178"

/lab\_host="Escherichia coli"

/clone\_lib="Aspergillus terreus random genomic DNA clone library"

/note="Vector: pZEROTM-2; Site 1: Sau3A; Site 2: BamHI;

Sau3A genomic fragments ligated into BamHI digested



```

; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10774
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-751-736-10774

```

```

Query Match      0.8%; Score 13.6; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

Qy 209 AAATGCAGCACTTCTTGGGT 228  
||| ||| ||| ||| ||| ||| ||| |||  
pb 21 AAGTGTGCATTTCTTGGAT 2

RESULT 629

```

US-10-736-11161/c
; Sequence 11161, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11161
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11161

```

```

Query Match      0.8%; Score 13.6; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

**Qy** 635 GAGGCACAAACTTGTTCCTC 654  
|||||  
**pB** 20 GAGGAACAAGTTTGTCCTC 1

**RESULT 630**

```

US-10-751-736-10772/c
; Sequence 10772, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2

```

```

; SEQ ID NO 10772
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-10772

```

```

Query Match      0.8%; Score 13.6; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 5.7e+02;
Matches 16: Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

QY 209 AAATGCAGCACTTCTTGGGT 228  
||| ||| ||| ||| ||| ||| ||| |||  
pb 20 AAGTGCTGCATTTCTTGGAT 1

**RESULT 631**

US-10-736-10775/c  
; Sequence 10775, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10775  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-10775

Query Match	0.8%	Score 13.6;	DB 1;	Length 21;
Best Local Similarity	80.0%	Pred. No. 5.7e+02;		
Matches 16:	Conservative	0;	Mismatches 4;	Indels 0; Gaps 0

QY 207 AGAAATGCAGCACTTCTTGG 226  
| | | | | | | | | |  
db 21 AAAAGTGTGCATTTCTTGG 2  
| | | | | | | | | |

RESULT 632

US-09-922-261-460/c  
; Sequence 460, Application US/09922261  
; Patent No. US20020111471A1  
; GENERAL INFORMATION:  
; APPLICANT: COGENT NEUROSCIENCE, Inc.  
; APPLICANT: Lo, Donald C.  
; APPLICANT: Barney, Shawn  
; APPLICANT: Thomas, Mary Beth  
; APPLICANT: Portbury, Stuart D.  
; APPLICANT: Puranam, Kasturi  
; APPLICANT: Katz, Lawrence C.  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING  
; TITLE OF INVENTION: AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING  
; TITLE OF INVENTION: CELL DEATH  
; FILE REFERENCE: 10001-005-999  
; CURRENT APPLICATION NUMBER: US/09/922,261  
; CURRENT FILING DATE: 2001-08-03  
; PRIOR APPLICATION NUMBER: US/09/461,697  
; PRIOR FILING DATE: 1999-12-14  
; NUMBER OF SEQ ID NOS: 466  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 460  
; LENGTH: 15  
; TYPE: DNA

; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1625
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1625

Query'Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 898 AATAAGATCTTTTCTT 914
Db 17 AAAAAGAGCTTTTCTT 1

RESULT 626
US-10-724-270-304/c
; Sequence 304, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0.
; SEQ ID NO 304
; LENGTH: 17
; TYPE: RNA

; ORGANISM: Homo sapiens
US-10-724-270-304
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1567 AAAATACATAATATTTT 1583
Db 17 AAAAATATAATATTTT 1

RESULT 627
US-10-724-270-4999
; Sequence 4999, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4999
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-4999

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.6e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 607 GAGGACGAATCTGGAC 623
Db 1 GGGGACGAAUUCUGCAC 17

RESULT 628
US-10-751-736-10774/c
; Sequence 10774, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TYPE OF INVENTION: CANCERS



; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8637
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8637

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 200 AAATCCAAGAAATGCAG 216
Db 1 AGATCCAAGAACTGCAG 17

RESULT 623
US-10-723-361-10428/c
; Sequence 10428, Application US/107233361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10428
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10428

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 874 TTTCATGCTGTCTACTAC 890
Db 17 TTTCATGCTGTCTAGCAC 1

RESULT 624
US-10-723-361-10434/c
; Sequence 10434, Application US/107233361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10434
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10434

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 868 TTGAGTTTTCATGCTGT 884
Db 17 TCGACTTTTCATGCTGT 1

RESULT 625
US-10-712-633-1625/c
; Sequence 1625, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO

```

; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 81
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-712-672-81

```

```

Query Match      0.8%;      Score 13.8;  DB 1;   Length 17;
Best Local Similarity 64.7%;  Pred. No. 3.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

Qy 43 GCCACTGCTTCTGGAGC 59  
||| | : : |||  
Db 1 GCCCUGUUUCUGGAGC 17

RESULT 620  
US-10-712-672-82  
; Sequence 82, Application US/10712672  
; Publication No. US20040102413A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Chowrira, Bharat  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; TITLE OF INVENTION: Method and Reagent for  
; FILE REFERENCE: MBHB00-882-C (400/019)  
; CURRENT APPLICATION NUMBER: US/10/712,672  
; CURRENT FILING DATE: 2003-11-13  
; PRIOR APPLICATION NUMBER: US/09/653,225  
; PRIOR FILING DATE: 2000-08-31  
; PRIOR APPLICATION NUMBER: 60/197,769  
; PRIOR FILING DATE: 2000-04-14  
; PRIOR APPLICATION NUMBER: 60/150,713  
; PRIOR FILING DATE: 1999-08-31  
; NUMBER OF SEQ ID NOS: 5586  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 82  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-712-672-82

```

Query Match      0.8%;   Score 13.8;   DB 1;   Length 17;
Best Local Similarity 58.8%;   Pred. No. 3.6e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```

Qy 44 CCACTGCTTCTGGAGCT 60  
|||:::||||:  
Db 1 CCCUGUUUCUGGAGCU 17

RESULT 621  
US-10-723-361-6761  
; Sequence 6761, Application US/10723361  
; Publication No. US20040137589A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.

```

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-6761

```

```

Query Match      0.8%;   Score 13.8;   DB 1;   Length 17;
Best Local Similarity 88.2%;   Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 506 GTGGAGCTCATGGAGAC 522  
| | | | | | | | | |  
Db 1 GAGGAGCTCCTGGAGAC 17

RESULT 622  
US-10-723-361-8637  
; Sequence 8637, Application US/10723361  
; Publication No. US20040137589A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE  
; FILE REFERENCE: PB0105  
; CURRENT APPLICATION NUMBER: US/10/723  
; CURRENT FILING DATE: 2003-11-26  
; PRIOR APPLICATION NUMBER: US 09/866,1  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,4  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,3  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00  
; PRIOR FILING DATE: 2001-01-30

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 3.6e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 919 GACAGGTTCTTCTGGCT 935  
| | | | | : : : : :  
Db 1 GCCAUGUUCUUCUGGCU 17

RESULT 615  
US-10-287-949A-3143/c  
; Sequence 3143, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3143  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-287-949A-3143

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAAGTTGCTT 1695  
| | | | | : : : : :  
Db 17 TGCTCTCTTAGTTGCTT 1

RESULT 616  
US-10-287-949A-3686/c  
; Sequence 3686, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3686  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-287-949A-3686

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 527 ATGCTTTTGATGGCAA 543  
| | | | | : : : : :  
Db 17 ATGCTTTGGATGGTAA 1

RESULT 617  
US-10-287-949A-5572/c  
; Sequence 5572, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5572  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-5572

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1221 TGATGAAAGGAGACAGA 1237  
| | | | | : : : : :  
Db 17 TTATGGAAGGAGACAGA 1

RESULT 618  
US-10-287-949A-8308/c  
; Sequence 8308, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 8308  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-8308

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 898 AATAAGATCTTTTCTT 914  
| | | | | : : : : :  
Db 17 AAAAAGAGCTTTTCTT 1

RESULT 619  
US-10-712-672-81  
; Sequence 81, Application US/10712672  
; Publication No. US20040102413A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Chowrira, Bharat  
; APPLICANT: McSwiggen, Jim

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3686
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3686

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY . 527 ATGCTTTTGATGGCAA 543
Db 17 ATGCTTTGGATGGTAAA 1

RESULT 611
US-10-138-674-5572/c
; Sequence 5572, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5572
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5572

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1221 TGATGAAAGGAGACAGA 1237
Db 17 TTATGGAAGGAGACAGA 1

RESULT 612
US-10-138-674-8308/c
; Sequence 8308, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8308
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8308

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 898 AATAAGATCTTTTCTT 914
Db 17 AAAAAGAGCTTTTCTT 1

RESULT 613
US-10-287-949A-222
; Sequence 222, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 222
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-222

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.6e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1066 TACTGGTTAATTAGCAA 1082
Db 1 UACUCGUAAUUAUCAA 17

RESULT 614
US-10-287-949A-1868
; Sequence 1868, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1868



```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-230

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 33 GTCCTGCAGGCCACTG 49
Db 17 GCTCCTGCAGGCCGCAG 1

RESULT 606
US-10-322-685-6/c
; Sequence 6, Application US/10322685
; Publication No. US20040019921A1
; GENERAL INFORMATION:
; APPLICANT: Fingerle-Rowson, Gunter R.
; TITLE OF INVENTION: No. US20040019921A1-Human Mammal with Disrupted or Modified MIF
; TITLE OF INVENTION: and Uses Thereof
; FILE REFERENCE: 9511-095-27
; CURRENT APPLICATION NUMBER: US/10/322,685
; CURRENT FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US 60/340,956
; PRIOR FILING DATE: 2001-12-19
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PIG-mutant (proline)
US-10-322-685-6

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 465 GATTAACACAGGCATGG 481
Db 17 GATGAACATAGGCATGG 1

RESULT 607
US-10-138-674-222
; Sequence 222, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 222
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-222

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.6e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAGTTGCTT 1695
Db 17 TGCTCTCTTAGTTGCTT 1

RESULT 610
US-10-138-674-3686/c
; Sequence 3686, Application US/10138674
; Publication No. US20040077565A1
```

```

QY 1066 TACTGGTTAATTAGCAA 1082
Db 1 UACUCGUUAAUUAUCAA 17

RESULT 608
US-10-138-674-1868
; Sequence 1868, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1868

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.6e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 919 GACAGGTTCTTCTGGCT 935
Db 1 GCCAUGUUCUUCUGGCU 17

RESULT 609
US-10-138-674-3143/c
; Sequence 3143, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3143
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3143

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAGTTGCTT 1695
Db 17 TGCTCTCTTAGTTGCTT 1

RESULT 610
US-10-138-674-3686/c
; Sequence 3686, Application US/10138674
; Publication No. US20040077565A1
```

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 529
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-529

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 3.6e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 907 TTTTCTTCAAAGACAG 923
Db 1 UUUUUUUUAAAGACAG 17

RESULT 602

US-10-156-306-3602/c
; Sequence 3602, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3602

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 14 TGAAGTTTCTTCTAATA 30
Db 17 TGAGGTTTCTTCTGATA 1

RESULT 603

US-10-238-700-304/c
; Sequence 304, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 304
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-304

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 AAAATACATAATATTTT 1583
Db 17 AAAAAATATATATATTTT 1

RESULT 604

US-10-430-882-229/c
; Sequence 229, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
; FILE REFERENCE: MBHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 229
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-229

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 34 CTCCTGCAGGCCACTGC 50
Db 17 CTCCTGCAGGCCGCAGC 1

RESULT 605

US-10-430-882-230/c
; Sequence 230, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
; FILE REFERENCE: MBHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 230

```

; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 230
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-230

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 33 GCTCCTGCAGGCCACTG 49
Db 17 GCTCCTGCAGGCCGCAG 1

RESULT 598
US-10-060-756A-1176
; Sequence 1176, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1176
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1176

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1142 TGAAGAAAATTGATGCA 1158
Db 1 TGAAGAAAATTGAGGTA 17

RESULT 599
US-10-060-756A-1177
; Sequence 1177, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1176
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1176

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1142 TGAAGAAAATTGATGCA 1158
Db 1 TGAAGAAAATTGAGGTA 17

RESULT 599
US-10-060-756A-1177
; Sequence 1177, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1176
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1177

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1143 GAAAAAAATTGATGCAG 1159
Db 1 GAAAAAAATTGAGGTAG 17

RESULT 600
US-10-163-552-344
; Sequence 344, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 344
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-344

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.6e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 607 GAGGACGAATTCTGGAC 623
Db 1 GGGGACGAUUCUGCAC 17

RESULT 601
US-10-156-306-529
; Sequence 529, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.6e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      1687 AAGTTGCTTCCTAACAT 1703
DB      1 AAGUCCUCCUAAAAAU 17

RESULT 593
US-09-848-754A-815/c
; Sequence 815, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-815

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      160 GTGACAAAAAATGAAATA 176
DB      17 GAGACAAAAAATCAAATA 1

RESULT 594
US-09-848-754A-2380/c
; Sequence 2380, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2380
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2380

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      532 TTGTATGGCAAAGGTGG 548
DB      17 TTGGATGGCACAGGTGG 1

RESULT 595
US-09-780-164-947
; Sequence 947, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
```

```

; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 947
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-947

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      477 CATGGCTGACATTTTGG 493
DB      1 CAGGGCUGACAUUGUGG 17

RESULT 596
US-09-827-395A-229/c
; Sequence 229, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 229
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-229

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      34 CTCCTGCAGGCCACTGC 50
DB      17 CTCCTGCAGGCCGCAGC 1

RESULT 597
US-09-827-395A-230/c
; Sequence 230, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
```



```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10434
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10434

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      868 TTGAGTTTGTGCTGT 884
      ||| ||||| |||||
Db      17 TCGACTTTGTGCTGT 1

RESULT 589
US-09-780-533A-330
; Sequence 330, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 330
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-330

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1145 AAAAAATTGATGCAGCT 1161
      ||||| : : : |||||
Db      1 AAAAAUAUAUAGCAGCU 17

RESULT 590
US-09-780-533A-480/c
; Sequence 480, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
```

```
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 480
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-480

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      908 TTTTCTTCAAAGACAGG 924
      ||| ||||| ||||| |||
Db      17 TGTTCCTCAAAGAAAGG 1

RESULT 591
US-09-927-046-948/c
; Sequence 948, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 948
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-948

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      484 GACATTTTGGTGGTTT 500
      ||| ||||| ||||| |||
Db      17 GCCATTTTGGTGGTTT 1

RESULT 592
US-09-848-754A-731
; Sequence 731, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 731
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-731
```

; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 8637  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-8637

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 200 AAATCCAAGAAATGCAG 216  
| ||||| |||||  
Db 1 AGATCCAAGAACTGCAG 17

RESULT 587  
US-09-866-108-10428/c  
; Sequence 10428, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 10428  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-10428

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 TTTGATGCTGTCACACTAC 890  
| ||||| ||||| ||  
Db 17 TTTGATGCTGTCAGCAC 1

RESULT 588  
US-09-866-108-10434/c  
; Sequence 10434, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10429

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      873 TTTTGATGCTGTCA 886
Db      17 TTTTGATGCTGTCA 4

RESULT 584
US-10-723-361-10430/c
; Sequence 10430, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10430
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10430

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      873 TTTTGATGCTGTCA 886
Db      16 TTTTGATGCTGTCA 3

RESULT 585
US-09-866-108-6761
; Sequence 6761, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

```

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6761

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      506 GTGGAGCTCATGGAGAC 522
Db      1 GAGGAGCTCCTGGAGAC 17

RESULT 586
US-09-866-108-8637
; Sequence 8637, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886  
Db 17 TTTTGATGCTGTCA 4

RESULT 581  
US-09-866-108-10430/c  
; Sequence 10430, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 10430  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-10430

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886  
Db 16 TTTTGATGCTGTCA 3

RESULT 582  
US-09-780-533A-2203/c  
; Sequence 2203, Application US/09780533A  
; Publication No. US20030060611A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Chowrira, Bharat  
; APPLICANT: Haerberli, Pete  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
; FILE REFERENCE: MBHB00,878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780,533A  
; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2203  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-2203

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 969 TTTAATTTCTTCCT 982  
Db 14 TTTAATTTCTTCCT 1

RESULT 583  
US-10-723-361-10429/c  
; Sequence 10429, Application US/10723361  
; Publication No. US20040137589A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI  
; FILE REFERENCE: PB0105  
; CURRENT APPLICATION NUMBER: US/10/723,361  
; CURRENT FILING DATE: 2003-11-26  
; PRIOR APPLICATION NUMBER: US 09/866,108  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 10429



```
; Sequence 2299, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
; TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131,827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2299
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-2299

Query Match      0.8%; Score 14.2; DB 1; Length 50;
Best Local Similarity 58.1%; Pred. No. 5.1e+02;
Matches 25; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 1314 TTCTAAAAACAATACTACTATTCTTCCAGGATCTAACCA 1356
Db 50 TGCCAGAGTAAGTATATAATTCTCAGTCCAAGGATGTTAGGAA 8

RESULT 578
US-10-255-120-58
; Sequence 58, Application US/10255120
; Publication No. US20040091865A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Helicobacter pylori, strain J99 complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/255,120
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 903
; SOFTWARE: Proprietary
; SEQ ID NO 58
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Helicobacter pylori, strain J99 complete genome.
; FEATURE:
; LOCATION: (104076)...(104091)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 92
US-10-255-120-58

Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 AAAAAATCCAAGAAA 211
Db 1 AAAAAATCCAAGAAA 14

RESULT 579
US-10-255-120-102
; Sequence 102, Application US/10255120
; Publication No. US20040091865A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Helicobacter pylori, strain J99 complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/255,120
; CURRENT FILING DATE: 2002-11-19
```

```
; NUMBER OF SEQ ID NOS: 903
; SOFTWARE: Proprietary
; SEQ ID NO 102
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Helicobacter pylori, strain J99 complete genome.
; FEATURE:
; LOCATION: (170536)...(170551)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 157
US-10-255-120-102

Query Match      0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 197 AAAAAATCCAAGAA 210
Db 3 AAAAAATCCAAGAA 16

RESULT 580
US-09-866-108-10429/c
; Sequence 10429, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10429
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10429
```

Best Local Similarity 93.8%; Pred. No. 3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 870 GAGTTTGTGCTGTC 885  
Db 16 GACTTTGTGCTGTC 1  
RESULT 573  
US-10-079-136-14/c  
; Sequence 14, Application US/10079136  
; Publication No. US20020172685A1  
; GENERAL INFORMATION:  
; APPLICANT: Stewart, Graham  
; APPLICANT: O'Gaora, Peadar  
; APPLICANT: Young, Douglas  
; TITLE OF INVENTION: Methods and Compositions for Therapeutic Intervention in Infectio  
; TITLE OF INVENTION: Disease  
; FILE REFERENCE: 19626-0211 (45454-270653)  
; CURRENT APPLICATION NUMBER: US/10/079,136  
; CURRENT FILING DATE: 2002-06-04  
; PRIOR APPLICATION NUMBER: US 60/269,801  
; PRIOR FILING DATE: 2001-02-20  
; PRIOR APPLICATION NUMBER: US 60/294,170  
; PRIOR FILING DATE: 2001-05-29  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 14  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic primer  
US-10-079-136-14  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 3.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 623 CTACACATTCAGGAGG 638  
Db 16 CTACATATTCAGGAGG 1  
RESULT 574  
US-10-807-963-14/c  
; Sequence 14, Application US/10807963  
; Publication No. US20040219159A1  
; GENERAL INFORMATION:  
; APPLICANT: Stewart, Graham  
; APPLICANT: O'Gaora, Peadar  
; APPLICANT: Young, Douglas  
; TITLE OF INVENTION: Methods and Compositions for Therapeutic Intervention in Infectio  
; TITLE OF INVENTION: Disease  
; FILE REFERENCE: 19626-0211 (45454-270653)  
; CURRENT APPLICATION NUMBER: US/10/807,963  
; CURRENT FILING DATE: 2004-03-24  
; PRIOR APPLICATION NUMBER: US 60/269,801  
; PRIOR FILING DATE: 2001-02-20  
; PRIOR APPLICATION NUMBER: US 60/294,170  
; PRIOR FILING DATE: 2001-05-29  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 14  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic primer  
US-10-807-963-14  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 3.4e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 623 CTACACATTCAGGAGG 638  
Db 16 CTACATATTCAGGAGG 1  
RESULT 575  
US-10-619-906-11  
; Sequence 11, Application US/10619906  
; Publication No. US20040087533A1  
; GENERAL INFORMATION:  
; APPLICANT: Index Pharmaceuticals  
; TITLE OF INVENTION: New Compound  
; FILE REFERENCE: 50299  
; CURRENT APPLICATION NUMBER: US/10/619,906  
; CURRENT FILING DATE: 2003-07-16  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 11  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: (1)..(19)  
; OTHER INFORMATION: SEQ ID NO. 11, antisense oligonucleotide  
US-10-619-906-11  
Query Match 0.8%; Score 14.2; DB 1; Length 19;  
Best Local Similarity 84.2%; Pred. No. 4e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 204 CCAAGAAATGCAGCACTTC 222  
Db 1 CCAAGAAGTGTGTCATTTC 19  
RESULT 576  
US-10-751-736-10931/c  
; Sequence 10931, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10931  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-10931  
Query Match 0.8%; Score 14.2; DB 1; Length 21;  
Best Local Similarity 84.2%; Pred. No. 4.9e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 205 CAAGAAATGCAGCACTTCT 223  
Db 19 CAAGAAGTGTGTCATTTC 1  
RESULT 577  
US-10-131-827-2299/c



; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 382
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-382

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 3e+02;
Matches 7; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1581 TTTTCAATTTTGAAAA 1596
; : : : : : : : : : : : : : : : : : :
Db 1 UUUUCAGUUUUGAAAA 16

RESULT 568
US-10-669-841-4707
; Sequence 4707, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS A VIRUS
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4707
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc\_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate

US-10-669-841-4707
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1372 CTACTCCAACGTATCA 1387
; : : : : : : : : : : : : : : : : : :
Db 1 CUCCUCCAACGUAUCA 16

RESULT 569
US-10-723-361-8638
; Sequence 8638, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8638
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8638

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAAATGCAGC 217
; : : : : : : : : : : : : : : : : : :
Db 2 ATCCAAGAACTGCAGC 17

RESULT 570
US-10-723-361-8639
; Sequence 8639, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.



```

Query Match      0.8%;   Score 14.4;  DB 1;  Length 17;
Best Local Similarity 68.8%;   Pred. No. 3e+02;
Matches 11;  Conservative 4;  Mismatches 1;  Indels 0;  Gaps 0;

QY 1372 CTACTCCAACGTATCA 1387
   |:|:|:|:|:|:|:|:|
Db 1 CUCCUCCAACGUAUCA 16

RESULT 563
US-10-156-306-526
; Sequence 526, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 526
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-526

Query Match      0.8%;   Score 14.4;  DB 1;  Length 17;
Best Local Similarity 31.2%;   Pred. No. 3e+02;
Matches 5;  Conservative 10;  Mismatches 1;  Indels 0;  Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058
   :::: ::::|:|:|
Db 2 UUUUUUUUUUAAAGA 17

RESULT 564
US-10-156-306-527
; Sequence 527, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 527
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-527

Query Match      0.8%;   Score 14.4;  DB 1;  Length 17;
Best Local Similarity 31.2%;   Pred. No. 3e+02;
Matches 5;  Conservative 10;  Mismatches 1;  Indels 0;  Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058
   :::: ::::|:|:|
Db 1 UUUUUUUUUUAAAGA 16

RESULT 565
US-10-138-674-1826/c
; Sequence 1826, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```

; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1826

Query Match      0.8%;   Score 14.4;  DB 1;  Length 17;
Best Local Similarity 93.8%;   Pred. No. 3e+02;
Matches 15;  Conservative 0;  Mismatches 1;  Indels 0;  Gaps 0;

QY 518 GAGACTTCCATGCTTT 533
   |||||:|:|:|:|:|
Db 17 GAGACTTCGATGCTTT 2

RESULT 566
US-10-287-949A-1826/c
; Sequence 1826, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1826

Query Match      0.8%;   Score 14.4;  DB 1;  Length 17;
Best Local Similarity 93.8%;   Pred. No. 3e+02;
Matches 15;  Conservative 0;  Mismatches 1;  Indels 0;  Gaps 0;

QY 518 GAGACTTCCATGCTTT 533
   |||||:|:|:|:|:|
Db 17 GAGACTTCGATGCTTT 2

RESULT 567
US-10-712-672-382
; Sequence 382, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
```

```
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1343
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1343

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      910 TTCTTCAAAGACAGGT 925
Db      17 TTCTTCAAAGAAAGGT 2

RESULT 559
US-09-780-533A-1422
; Sequence 1422, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1422
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1422

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      847 CCAGCTCTCTGTGACC 862
Db      2 CCUGCUCUCUGUGACC 17

RESULT 560
US-09-927-046-160
; Sequence 160, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
```

```
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 160
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-160

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      1712 TGAGAAATTATACTTA 1727
Db      1 UGAGAAAUUCUACUUA 16

RESULT 561
US-09-740-332-2114
; Sequence 2114, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2114
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2114

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1372 CTACTCCAACGTATCA 1387
Db      1 CUCCUCCACCGUAUCA 16

RESULT 562
US-09-817-879-2114
; Sequence 2114, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2114
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2114
```

```

; Sequence 479, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-533A-479

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      910 TTCTTCAAAGACAGGT 925
Db      16 TTCTTCAAAGAAAGGT 1

RESULT 557
US-09-780-533A-554
; Sequence 554, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 554
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-533A-554

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      847 CCAGCTCTCTGTGACC 862
Db      1 CCUGCUCUCUGUGACC 16

RESULT 558
US-09-780-533A-1343/c
; Sequence 1343, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
```

```

; Sequence 479, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-533A-479

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      871 AGTTTGTGCTGTCA 886
Db      17 ACTTTGTGCTGTCA 2

RESULT 555
US-09-866-108-10433/c
; Sequence 10433, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10433
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-10433

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      870 GAGTTTGTGCTGTC 885
Db      16 GACTTTGTGCTGTC 1

RESULT 556
US-09-780-533A-479/c
```

; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 8638  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-8638

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAAATGCAGC 217  
|||||||  
Db 2 ATCCAAGAACTGCAGC 17

RESULT 553  
US-09-866-108-8639  
; Sequence 8639, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 8639  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-8639

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAAATGCAGC 217  
|||||||  
Db 1 ATCCAAGAACTGCAGC 16

RESULT 554  
US-09-866-108-10431/c  
; Sequence 10431, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 10431  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-10431  
Query Match 0.8%; Score 14.4; DB 1; Length 17;



```

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16: Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

; APPLICANT: Freier, Susan M.
; APPLICANT: Sasmor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; TITLE OF INVENTION: MODULATION BY OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 57
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-57

```

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 3e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 945 TGAGAGACCAAGACCAG 962  
Db 18 TGTGAGACCAAGACCTG 1

```

RESULT 547
US-10-698-689-57/c
; Sequence 57, Application US/10698689
; Publication No. US20040186071A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cowser, Lex M.
; APPLICANT: Malik, Leila
; APPLICANT: Siwkowski, Andrew
; APPLICANT: Eldrup, Anne B.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 EXPRESSION
; FILE REFERENCE: ISIS-5315
; CURRENT APPLICATION NUMBER: US/10/698,689
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: PCT/US03/31166
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 10/261,382
; PRIOR FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US 09/067,638
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: US 60/081,483
; PRIOR FILING DATE: 1998-04-13
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-698-689-57

```

```

Query Match          0.8%;   Score 14.8;   DB 1;   Length 18;
Best Local Similarity 88.9%;   Pred. NO. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Qy 945 TGAGAGACCAAGACCAG 962  
|||  
Db 18 TGTGAGACCAAGACCTG 1

```

RESULT 548
US-10-698-689-221
; Sequence 221, Application US/10698689
; Publication No. US20040186071A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cowser, Lex M.
; APPLICANT: Malik, Leila
; APPLICANT: Siwkowski, Andrew
; APPLICANT: Eldrup, Anne B.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 EXPRESSION
; FILE REFERENCE: ISIS-5315
; CURRENT APPLICATION NUMBER: US/10/698,689
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: PCT/US03/31166
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 10/261,382
; PRIOR FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US 09/067,638
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: US 60/081,483
; PRIOR FILING DATE: 1998-04-13
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 221
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-698-689-221

```

```

Query Match      0.8%;   Score 14.8;   DB 1;   Length 18;
Best Local Similarity 88.9%;   Pred. No. 3e+02;
Matches 16;   Conservative 0;   Mismatches 2;   Indels 0;   Gaps 0;

```

Qy 945 TGAGAGACCAAGACCAG 962  
|||  
Db 1 TGTGAGACCAAGACCTG 18

RESULT 549  
US-10-830-475-57/c  
; Sequence 57, Application US/10830475  
; Publication No. US20040197814A1  
; GENERAL INFORMATION:  
; APPLICANT: Lex M. Cowser  
; Brenda F. Baker  
; John McNeil  
; Susan M. Freier  
; Henri M. Sasnor  
; Douglas G. Brooks  
; Cara Ohashi  
; Jacqueline R. Wyatt  
; Alexander Borchers  
; Timothy A. Vickers  
; TITLE OF INVENTION: Identification of Genetic  
; Targets for Modulation By Oligonucleotides and  
; Generation of Oligonucleotides for Gene  
; Modulation  
; NUMBER OF SEQUENCES: 112  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: WOODCOCK WASHBURN KURTZ  
; MACKIEWICZ & NORRIS LLP  
; STREET: 1 LIBERTY PLACE 46TH FLOOR  
; CITY: PHILADELPHIA  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19103  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB  
; COMPUTER: IBM  
; OPERATING SYSTEM: PC-Windows NT

```

; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2034
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-2034

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      105 ATTTGCTGAGAGATACCTT 122
Db      18 ATTTGCTGGGAGATGCTT 1

RESULT 544
US-10-116-325-57/c
; Sequence 57, Application US/10116325
; Publication No. US20030113739A1
; GENERAL INFORMATION:
; APPLICANT: Cowser, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John
; APPLICANT: Freier, Susan M.
; APPLICANT: Sasmor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: Identification Of Genetic Targets For Modulation By Oligonucleotides
; TITLE OF INVENTION: Generation Of Oligonucleotides For Gene Modulation
; FILE REFERENCE: ISIS5026
; CURRENT APPLICATION NUMBER: US/10/116,325
; CURRENT FILING DATE: 2002-04-04
; PRIOR APPLICATION NUMBER: 09/067,638
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/081,483
; PRIOR FILING DATE: 1998-04-13
; NUMBER OF SEQ ID NOS: 112
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 57
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. US20030113739A1 Sequence
US-10-116-325-57

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      945 TGAGAGACCAAGACCAG 962
Db      18 TGTGAGACCAAGACCCTG 1

RESULT 545
US-10-251-598-193
; Sequence 193, Application US/10251598
; Publication No. US20030170668A1
; GENERAL INFORMATION:
; APPLICANT: Cowser, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John

```

```

; APPLICANT: Detera-Wadleigh, Sevilla D.
; Gerston, Elliot S.
; Badner, Judith A.
; Goldin, Lynn R.
; Berrettini, Wade H.
; Yoshikawa, Takeo
; Sanders, Alan R.
; Esterling, Lisa E.
; TITLE OF INVENTION: Chromosomal Markers and Diagnostic Tests for Manic-Depressive Illness
; NUMBER OF SEQUENCES: 197
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/251,598
; FILING DATE: 19-Sep-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/091,952
; FILING DATE: 19-Apr-1999
; APPLICATION NUMBER: US 60/029,278
; FILING DATE: 28-OCT-1996
; APPLICATION NUMBER: PCT/US97/19381
; FILING DATE: 28-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, Timothy L.
; REGISTRATION NUMBER: 35,367
; REFERENCE/DOCKET NUMBER: 015280-297100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 193:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: -
; LOCATION: 1...18
; OTHER INFORMATION: Clone 47 reverse primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 193:
US-10-251-598-193

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      46 ACTGCTTCTGGAGCTCTT 63
Db      1 AGTGCTTCTGTAGCTCTT 18

RESULT 546
US-10-388-263-57/c
; Sequence 57, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
; APPLICANT: Cowser, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John

```

```

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10432
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10432

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      870 GAGTTTGTGCTGTCA 886
Db      17 GACTTTGTGCTGTCA 1

RESULT 541
US-09-780-533A-2552/c
; Sequence 2552, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2552
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2552

Query Match      0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      969 TTTAATTTCTTCCTT 983
Db      17 TTTAATTTCTTCCTT 3
```

```

RESULT 542
US-09-067-638B-57/c
; Sequence 57, Application US/09067638B
; Patent No. US20020028923A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Brenda F. Baker
; APPLICANT: John McNeil
; APPLICANT: Susan M. Freier
; APPLICANT: Henri M. Sasmor
; APPLICANT: Douglas G. Brooks
; APPLICANT: Cara Ohashi
; APPLICANT: Jacqueline R. Wyatt
; APPLICANT: Alexander Borchers
; APPLICANT: Timothy A. Vickers
; TITLE OF INVENTION: Identification of Genetic
; TITLE OF INVENTION: Targets for Modulation By Oligonucleotides and
; TITLE OF INVENTION: Generation of Oligonucleotides for Gene
; TITLE OF INVENTION: Modulation
; NUMBER OF SEQUENCES: 112
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: WOODCOCK WASHBURN KURTZ
; ADDRESSEE: MACKIEWICZ & NORRIS LLP
; STREET: 1 LIBERTY PLACE 46TH FLOOR
; CITY: PHILADELPHIA
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; COMPUTER: IBM
; OPERATING SYSTEM: PC-Windows NT
; SOFTWARE: WORD PERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/067,638B
; FILING DATE: 28-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/081,483
; FILING DATE: 13-APR-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-2960
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-067-638B-57

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      945 TGAGAGACCAAGACCAG 962
Db      18 TGTGAGACCAAGACCTG 1

RESULT 543
US-09-969-373-2034/c
; Sequence 2034, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
```



```

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0
QY 314 GGGAAATGCCAGGGGGGCC 332
    ||||| ||||| |||||
Db 19 GGGAAATGCCAGGGGGGCC 1

RESULT 538
US-09-866-108-10432/c
; Sequence 10432, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10432
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10432

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0
QY 870 GAGTTTGTGCTGTCA 886
    || ||||| |||||
Db 17 GACTTTGTGCTGTCA 1

RESULT 539
US-10-052-545-19/c
; Sequence 19, Application US/10052545

```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-462-039-25

Query Match      0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      486 CATTTTGGTGGTTTTT 501
Db      2 CATTTTGGTGGTTTTT 17

RESULT 535
US-10-462-039-26
; Sequence 26, Application US/10462039
; Publication No. US20040254131A1
; GENERAL INFORMATION:
; APPLICANT: Hormos Medical Corporation
; APPLICANT: Koulou, Markku
; APPLICANT: Tsuchimaa, Jukka
; APPLICANT: Pesonen, Ullamari
; APPLICANT: Kallio, Jaana
; APPLICANT: Karvonen, Matti
; TITLE OF INVENTION: Method for Prevention or Treatment of Diseases or Disorders Relat
; TITLE OF INVENTION: Excessive Formation of Vascular Tissue or Blood Vessels
; FILE REFERENCE: 2630-123
; CURRENT APPLICATION NUMBER: US/10/462,039
; CURRENT FILING DATE: 2003-06-16
; PRIOR APPLICATION NUMBER: US 60/
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-462-039-26

Query Match      0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      486 CATTTTGGTGGTTTTT 501
Db      5 CATTTTGGTGGTTTTT 20

RESULT 536
US-10-830-569-140
; Sequence 140, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/153 (MBHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/153 (MBHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 140
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-830-569-140

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.5e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      314 GGGAATGCCAGGGGCC 332
Db      1 GGGAAGUGCCAGGAGGCC 19

RESULT 537
US-10-830-569-447/c
; Sequence 447, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/153 (MBHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 447
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-830-569-447

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
```

```
RESULT 530
US-10-316-755-57/c
; Sequence 57, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381
; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-755-57

Query Match          0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 902 AGATCTTTTCTTCAAAG 919
Db 19 AGCTCTTTTCTTCAAAG 2

RESULT 531
US-10-316-755-202
; Sequence 202, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381
; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 202
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-755-202

Query Match          0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 902 AGATCTTTTCTTCAAAG 919
Db 2 AGCTCTTTTCTTCAAAG 19

RESULT 532
US-10-751-736-10777/c
; Sequence 10777, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; SEQ ID NO 25
```

```
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10777
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10777

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 204 CCAAGAAATGCAGCACTTCTT 224
Db 21 CCAAGAGTGTGTCATTCTT 1

RESULT 533
US-10-751-736-10930/c
; Sequence 10930, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10930
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10930

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 205 CAAGAAATGCAGCACTTCTTG 225
Db 21 CAAGAGTGTGTCATTCTTG 1

RESULT 534
US-10-462-039-25
; Sequence 25, Application US/10462039
; Publication No. US20040254131A1
; GENERAL INFORMATION:
; APPLICANT: Hormos Medical Corporation
; APPLICANT: Koulu, Markku
; APPLICANT: Tuohimaa, Jukka
; APPLICANT: Pesonen, Ullamari
; APPLICANT: Kallio, Jaana
; APPLICANT: Karvonen, Matti
; TITLE OF INVENTION: Method for Prevention or Treatment of Diseases or Disorders Related
; TITLE OF INVENTION: Excessive Formation of Vascular Tissue or Blood Vessels
; FILE REFERENCE: 2630-123
; CURRENT APPLICATION NUMBER: US/10/462,039
; CURRENT FILING DATE: 2003-06-16
; PRIOR APPLICATION NUMBER: US 60/
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 25
```

```
Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1208 AGTATTGGAGGTATGATGAA 1227
Db      2 AATACTGGAGGTATGATGAA 21

RESULT 526
US-10-751-736-8707
; Sequence 8707, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8707
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8707

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1208 AGTATTGGAGGTATGATGAA 1227
Db      1 AATACTGGAGGTATGATGAA 20

RESULT 527
US-10-751-736-10057
; Sequence 10057, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10057
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10057

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1402 AGCAATAGCTGGTTTGGTTG 1421
Db      2 AGCAATAGCTGGTTTAATTG 21
```

```
RESULT 528
US-10-751-736-10162
; Sequence 10162, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10162
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10162

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1395 ACTGAAAGCAATAGCTGGT 1414
Db      2 ATTGAAGAGCAATAGCTGGT 21

RESULT 529
US-10-349-143-5754/c
; Sequence 5754, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5754
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-6628 for SEQ 1820,
US-10-349-143-5754

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1190 ACTTCTTTGTAGATAACC 1207
Db      18 ACTTCTTTGCAGATAACC 1
```



; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10012
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10012

Query Match 1.0%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1185 GACCTACTTCTTTGTAGA 1202
Db 1 GACCTACTTCTTTGTAGA 18

RESULT 522
US-10-751-736-10058
; Sequence 10058, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10058
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10058

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 1.8e+02;
Matches 10; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY 1403 GCAATAGCTGGTTGGTTGTT 1423
Db 1 GCAAUAGCUGGUUUAUUGUU 21

RESULT 523
US-10-751-736-10054
; Sequence 10054, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10054
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10054

Query Match 1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1398 GAAAAGCAATAGCTGGTTT 1416
Db 1 GAAGAGCAATAGCTGGTTT 19

RESULT 524
US-10-751-736-8698
; Sequence 8698, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8698
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8698

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1186 ACCTACTTCTTTGTAGATAA 1205
Db 2 ACCTACTTCTTTGTGTCTAA 21

RESULT 525
US-10-751-736-8704
; Sequence 8704, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8704
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8704

```
Db      1 UAGGACCUACUUCUUGUA 19
      :|||||:|:|:|:|:|:|
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9562
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9562

Query Match      1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1183 AGGACCTACTTCTTTGTAGA 1202
      | ||||| ||||| ||||| |||||
Db      1 AAGACCTACTTCTTTGTAGA 20

RESULT 518
US-10-751-736-10009
; Sequence 10009, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10009
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10009

Query Match      1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1183 AGGACCTACTTCTTTGTAGA 1202
      | ||||| ||||| ||||| |||||
Db      2 AAGACCTACTTCTTTGTAGA 21

RESULT 519
US-10-751-736-10163
; Sequence 10163, Application US/10751736

Db      1 UAGGACCUACUUCUUGUA 19
      :|||||:|:|:|:|:|:|
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9562
; LENGTH: 21
; TYPE: DNA
; ORGANISM: RNAi
US-10-751-736-10163

Query Match      1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      1397 TGAAAAGCAATAGCTGGTTT 1416
      :||| |||||:|:|:|:|:|:|
Db      2 UGAAGAGCAAUAGCUGGUUU 21

RESULT 520
US-10-751-736-9563
; Sequence 9563, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9563
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-9563

Query Match      1.0%; Score 18; DB 1; Length 21;
Best Local Similarity 61.1%; Pred. No. 1.7e+02;
Matches 11; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      1185 GACCTACTTCTTTGTAGA 1202
      ||||:|:|:|:|:|:|
Db      1 GACCUACUUCUUGUAGA 18

RESULT 521
US-10-751-736-10012
; Sequence 10012, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11453
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11453

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 606 TGAGGACGAATTCTGGACT 624
Db 1 UGAGGACGAUUCUGGACU 19

RESULT 513
US-10-751-736-11456
; Sequence 11456, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11456
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11456

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 609 GGACGAATCTGGACTACA 627
Db 1 GGACGAUUCUGGACUACA 19

RESULT 514
US-10-751-736-11468
; Sequence 11468, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11468
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl

US-10-751-736-11468

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 813 GAACCAACGCTGCCAAAT 831
Db 1 GAACCAACGCUUGCCAAAU 19

RESULT 515
US-10-751-736-11480
; Sequence 11480, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11480
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11480

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 375 CACACCTGACATGAACCGT 393
Db 1 CACACCTUGACAUGAACCGU 19

RESULT 516
US-10-751-736-11483
; Sequence 11483, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11483
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11483

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1182 TAGGACCTACTTCTTTGTA 1200

US-10-751-736-11438  
; Sequence 11438, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11438  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNai  
US-10-751-736-11438  
  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 73.7%; Pred. No. 1.2e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;  
  
QY 389 ACCGTGAGGATGTTGACTA 407  
Db 1 ACCGUGAGGAUGUUGACUA 19  
  
RESULT 509  
US-10-751-736-11441  
; Sequence 11441, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11441  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNai  
US-10-751-736-11441  
  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 73.7%; Pred. No. 1.2e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;  
  
QY 396 GGATGTTGACTACGCAATC 414  
Db 1 GGAUGUUGACUACGCAUAC 19  
  
RESULT 510  
US-10-751-736-11444  
; Sequence 11444, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11444  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNai  
US-10-751-736-11444  
  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 73.7%; Pred. No. 1.2e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;  
  
QY 399 TGTGTACTACGCAATCCGG 417  
Db 1 UGUUGACUACGCAAUCCGG 19  
  
RESULT 511  
US-10-751-736-11450  
; Sequence 11450, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11450  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNai  
US-10-751-736-11450  
  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 73.7%; Pred. No. 1.2e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;  
  
QY 594 TGCACATTTCGATGAGGAC 612  
Db 1 UGCACAUUUCGAUGAGGAC 19  
  
RESULT 512  
US-10-751-736-11453  
; Sequence 11453, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000



```

; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11402

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      377 CACCTGACATGAACCGTGA 395
Db      1 CACCUGACAUGAACCGUGA 19

RESULT 504
US-10-751-736-11408
; Sequence 11408, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11408
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11408

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      429 AGTATGGAGTAATGTTACC 447
Db      1 AGUAUGGAGUAUGUUAACC 19

RESULT 505
US-10-751-736-11411
; Sequence 11411, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11411
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11411

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      384 CATGAACCGTGAGGATGTT 402
Db      1 CAUGAACCGUGAGGAUGUU 19

RESULT 508
```

```

QY      461 GCAAGATTAAACACAGGCAT 479
Db      1 GCAAGAUUAACACAGGCAU 19

RESULT 506
US-10-751-736-11426
; Sequence 11426, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11426
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11426

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      656 CTGCTGTTCCAGCATGG 674
Db      1 CUGCUGUUCACGAGAUUGG 19

RESULT 507
US-10-751-736-11435
; Sequence 11435, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11435
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11435

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      384 CATGAACCGTGAGGATGTT 402
Db      1 CAUGAACCGUGAGGAUGUU 19

RESULT 508
```

```

; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11381
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11381

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      390 CCGTGAGGATGTTGACTAC 408
Db      1 CCGUGAGGAUGUUGACUAC 19

RESULT 500
US-10-751-736-11387
; Sequence 11387, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11387
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11387

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      457 TTCAGCAAGATTACACAG 475
Db      1 UUCAGCAAGAUUAACACAG 19

RESULT 501
US-10-751-736-11393
; Sequence 11393, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```

; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11393
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11393

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      810 AGAGAACCAACGCTTGCCA 828
Db      1 AGAGAACCAACGCUUGCCA 19

RESULT 502
US-10-751-736-11399
; Sequence 11399, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11399
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11399

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      816 CCAACGCTTGCCAAATCCT 834
Db      1 CCAACGCUUGCCAAAUCCU 19

RESULT 503
US-10-751-736-11402
; Sequence 11402, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11402
; LENGTH: 21
```



```

; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11306
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11306

Query Match
Best Local Similarity 84.2%; Score 19; DB 1; Length 21;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY . 1087 AGACCAGAGCCAAATTATC 1105
Db 1 AGACCAGAGCCAAAUUAUC 19

RESULT 491
US-10-751-736-11309
; Sequence 11309, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11309
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11309

Query Match
Best Local Similarity 57.9%; Score 19; DB 1; Length 21;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1182 TAGGACCTACTTCTTTGTA 1200
Db 1 UAGGACCUACUUCUUGUA 19

RESULT 492
US-10-751-736-11324
; Sequence 11324, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
```

```

; SEQ ID NO 11324
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11324

Query Match
Best Local Similarity 73.7%; Score 19; DB 1; Length 21;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1212 TTGGAGGTATGATGAAAGG 1230
Db 1 UUGGAGGUUGAUGAAAGG 19

RESULT 493
US-10-751-736-11330
; Sequence 11330, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11330
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11330

Query Match
Best Local Similarity 84.2%; Score 19; DB 1; Length 21;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1268 CCAAGAACTTCCAAGGAAT 1286
Db 1 CCAAGAACTUCCAAGGAU 19

RESULT 494
US-10-751-736-11336
; Sequence 11336, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11336
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11336

Query Match
Best Local Similarity 84.2%; Score 19; DB 1; Length 21;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```



RESULT 488  
US-10-751-736-11300  
; Sequence 11300, Application US/10751736  
; Publication No. US20040265230A1

```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11267
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11267

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 179 GTGAAACTTAATGAAGGA 197
Db 1 GUGGAACCUUAUGAAGGA 19

RESULT 482
US-10-751-736-11270
; Sequence 11270, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11270
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11270

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 371 ATTACACACCTGACATGAA 389
Db 1 AUUACACACCUGACAUGAA 19

RESULT 483
US-10-751-736-11273
; Sequence 11273, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11273
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11273

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11267
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11267

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 179 GTGAAACTTAATGAAGGA 197
Db 1 GUGGAACCUUAUGAAGGA 19

RESULT 482
US-10-751-736-11270
; Sequence 11270, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11270
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11270

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 371 ATTACACACCTGACATGAA 389
Db 1 AUUACACACCUGACAUGAA 19

RESULT 483
US-10-751-736-11273
; Sequence 11273, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11273
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11273
```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 375 CACACCTGACATGAACCGT 393
Db 1 CACACCUGACAUGAACCGU 19

RESULT 484
US-10-751-736-11276
; Sequence 11276, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11276
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11276

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 408 CGCAATCCGGAAGCTTTC 426
Db 1 CGCAAUCCGGAAGCUUUC 19

RESULT 485
US-10-751-736-11291
; Sequence 11291, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11291
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11291

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 732 CAAATATGTCGACATCAAC 750
Db 1 CAAATATGTCGACATCAAC 750
```

```
; Sequence 11237, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11237
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11237

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1362 ATATGACTTCCTACTCCAA 1380
      |:|:|:|:|:|:|:|:|:|:|:|
Db      1 AUAUGACUUCUCCUACUCCAA 19

RESULT 478
US-10-751-736-11240
; Sequence 11240, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11240
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11240

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1368 CTTCTACTCCAACTATC 1386
      |:|:|:|:|:|:|:|:|:|:|:|
Db      1 CUUCCUACUCCUACGUUAUC 19

RESULT 479
US-10-751-736-11258
; Sequence 11258, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
```

```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11258
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11258

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.2e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      106 TTTGCTGAGAGATACCTTAG 124
      ::|:|:|:|:|:|:|:|:|:|:|
Db      1 UUGGUGAGAGAUACUUG 19

RESULT 480
US-10-751-736-11264
; Sequence 11264, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11264
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11264

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      148 AACAAACTTCCAGTGACAA 166
      |||:|:|:|:|:|:|:|:|:|:|
Db      1 AACAAACUCCAGUGACAA 19

RESULT 481
US-10-751-736-11267
; Sequence 11267, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

; ORGANISM: RNai
US-10-751-736-11222

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1217 GGTATGATGAAAGGAGACA 1235
||:||||:||||:||||:
Db 1 GGUAUGAUGAAAGGAGACA 19

RESULT 473
US-10-751-736-11225
; Sequence 11225, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11225
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11225

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1224 TGAAGGAGACAGATGATG 1242
:||||:||||:||||:
Db 1 UGAAAGGAGACAGAUG 19

RESULT 474
US-10-751-736-11228
; Sequence 11228, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11228
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11228

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1227 AAGGAGACAGATGATGGAC 1245
||||:||||:||||:||||:
Db 1 AAGGAGACAGAUGGAC 19

RESULT 475
US-10-751-736-11231
; Sequence 11231, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11231
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11231

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1265 TTACCAAGAACTTCCAAGG 1283
:||||:||||:||||:
Db 1 UUACCAAGAAACUCCAAGG 19

RESULT 476
US-10-751-736-11234
; Sequence 11234, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11234
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11234

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1302 TGCAGTCTTCTATTCTAAA 1320
:||||:||||:||||:
Db 1 UGCAGUCUCUUAUUCUAAA 19

RESULT 477
US-10-751-736-11237



```

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11216
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11216

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1187 CCTACTTCTTTGTAGATAA 1205
      ||::||::||::||::||
Db      1 CCUACUUCUUGUAGAUAA 19

RESULT 471
US-10-751-736-11219
; Sequence 11219, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11219
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11219

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1203 TAACCACTATTGGAGGTAT 1221
      :|||||::|||::|
Db      1 UAACCAUAUUGGAGGUAA 19

RESULT 472
US-10-751-736-11222
; Sequence 11222, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11222
; LENGTH: 21
; TYPE: RNA

```

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 623 CTACACATTGAGGCGAC 641  
|:|||||:|||||  
Db 1 CUACACAUCAGGAGGCAC 19

RESULT 464  
US-10-751-736-11171  
; Sequence 11171, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11171  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11171

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.2e+02;  
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 705 TCCAAAGGCTGTATGTTTC 723  
:|||||:|:|:|:  
Db 1 UCCAAAGGCGUAAUGUUC 19

RESULT 465  
US-10-751-736-11183  
; Sequence 11183, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11183  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11183

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 84.2%; Pred. No. 1.2e+02;  
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 813 GAACCAACGCTTGCCAAAT 831  
|||||:|:|:|:  
Db 1 GAACCAACGCUUGCCAAAU 19

RESULT 466  
US-10-751-736-11195  
; Sequence 11195, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11195  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11195

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 78.9%; Pred. No. 1.2e+02;  
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 938 AGGTTTCTGAGAGACCAAA 956  
|||:::|:|||||  
Db 1 AGGUUUCUGAGAGACCAAA 19

RESULT 467  
US-10-751-736-11198  
; Sequence 11198, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11198  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11198

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 84.2%; Pred. No. 1.2e+02;  
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 948 GAGACCAAGACCAAGTGT 966  
|||||:|:|:|:  
Db 1 GAGACCAAGACCAAGUGU 19

RESULT 468  
US-10-751-736-11207  
; Sequence 11207, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert

Fri May 13 12:26:37 2005

```

; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11144
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11144

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      594 TGCACATTTCGATGAGGAC 612
Db      1 UGCACAUUUCGAGGAC 19

RESULT 460
US-10-751-736-11147
; Sequence 11147, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11147
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11147

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      606 TGAGGACGAATTCGGACT 624
Db      1 UGAGGACGAUUCUGGACU 19

RESULT 461
US-10-751-736-11150
; Sequence 11150, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11150
```

```

; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11150

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      609 GGACGAATTCGGACTACA 627
Db      1 GGACGAUUCUGGACUACA 19

RESULT 462
US-10-751-736-11156
; Sequence 11156, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11156
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11156

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      615 ATTCTGGACTACACATTCA 633
Db      1 AUUCUGGACUACACAUUCA 19

RESULT 463
US-10-751-736-11159
; Sequence 11159, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11159
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11159

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
```

```
RESULT 455
US-10-751-736-11129
; Sequence 11129, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11129
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11129

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 455 AATTCAGCAAGATTAAACAC 473
Db 1 AAUUCAGCAAGAUUAACAC 19

RESULT 456
US-10-751-736-11132
; Sequence 11132, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11132

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 467 TTAACACAGGCATGGCTGA 485
Db 1 UUAACACAGGCAUGGCTGA 19

RESULT 457
US-10-751-736-11138
; Sequence 11138, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11138
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11138

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 537 TGGCAAAGTGGGAATCCTA 555
Db 1 UGGCAAAGGUGGAUCCUA 19

RESULT 458
US-10-751-736-11141
; Sequence 11141, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11141
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11141

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 571 CCTGGATCTGGCATTGGAG 589
Db 1 CCUGGAUCUGGCAUUGGAG 19

RESULT 459
US-10-751-736-11144
; Sequence 11144, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
```



```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11108
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11108

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      364 ATCAATAATTACACACCTG 382
Db      1 AUCAAUAUACACACACUG 19

RESULT 451
US-10-751-736-11111
; Sequence 11111, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11111
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11111

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      384 CATGAACCGTGAGGATGTT 402
Db      1 CAUGAACCGUGAGGAUGUU 19

RESULT 452
US-10-751-736-11114
; Sequence 11114, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11114
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11114

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11108
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11108

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      389 ACCGTGAGGATGTTGACTA 407
Db      1 ACCGUGAGGAUGUGACUA 19

RESULT 453
US-10-751-736-11117
; Sequence 11117, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11117
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11117

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      396 GGATGTTGACTACGCAATC 414
Db      1 GGAUGUGACUACGCAUUC 19

RESULT 454
US-10-751-736-11120
; Sequence 11120, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11120
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11120

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      399 TGTGACTACGCAATCCGG 417
Db      1 UGUUGACUACGCAAUCCGG 19
```

```

; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11090
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11090

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      146 TAAACAAACTTCCAGTGAC 164
Db      :|||||:|||||:|||||:
        1 UAAACAACUCCAGUGAC 19

RESULT 447
US-10-751-736-11099
; Sequence 11099, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11099
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11099

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      272 TGCACGCACCTCGATGCG 290
Db      :|||||:|||||:|||||:
        1 UGCACGCACCUCCGAUGGG 19

RESULT 448
US-10-751-736-11102
; Sequence 11102, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```

; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11102
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11102

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      341 GGAAACATTATATCACCTA 359
Db      |||||:|||||:|||||:
        1 GGAAACAUAUAUACCUA 19

RESULT 449
US-10-751-736-11105
; Sequence 11105, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11105
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11105

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      344 AACATTATATCACCTACAG 362
Db      |||||:|||||:|||||:
        1 AACAUUAUAUACCUACAG 19

RESULT 450
US-10-751-736-11108
; Sequence 11108, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

Fri May 13 12:26:37 2005

chong906-1.rnpb

```
US-10-751-736-11054
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1271 AGAACTTCCAAGGAATCGG 1289
      |||||:|||||:|||||:
Db      1 AGAACUCCAGGAUCCG 19

RESULT 442
US-10-751-736-11060
; Sequence 11060, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11060
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11060

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 52.6%; Pred. No. 1.2e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      1406 ATAGCTGGTTGGTTGTTA 1424
      |||||:|||||:|||||:
Db      1 AUAGCUGGUUUGGUUGUA 19

RESULT 443
US-10-751-736-11081
; Sequence 11081, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11081
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11081

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 52.6%; Pred. No. 1.2e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      17 AGTTCTTCTAATACTGCT 35
```

```
|||:|:|:|:|:|:|:|:|:
Db      1 AGUUUCUUAUAUCUGCU 19

RESULT 444
US-10-751-736-11084
; Sequence 11084, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11084
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11084

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      71 ACAGCTCTACAAGCCTGGA 89
      |||||:|||||:|||||:
Db      1 ACAGCUCUACAAGCCUGGA 19

RESULT 445
US-10-751-736-11087
; Sequence 11087, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11087
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11087

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      144 GATAAACAAACTTCCAGTG 162
      |||||:|||||:|||||:
Db      1 GAUAAACAAACUUCACUG 19

RESULT 446
US-10-751-736-11090
; Sequence 11090, Application US/10751736
```

```
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11030
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11030

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      917 AAGACAGGTTCTTCTGGCT 935
Db      1 AAGACAGGUUCUUCUGGCU 19

RESULT 438
US-10-751-736-11036
; Sequence 11036, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11036
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11036

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      991 ACCTGGCCATCTGGCATTG 1009
Db      1 ACCUUGCCAUCUGGCAUUG 19

RESULT 439
US-10-751-736-11048
; Sequence 11048, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
```

```
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11048
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11048

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1209 GTATTGGAGGTATGATGAA 1227
Db      1 GUAUUGGAGGUAUGAUGAA 19

RESULT 440
US-10-751-736-11051
; Sequence 11051, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11051
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11051

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1259 AACTGATTACCAAGAACTT 1277
Db      1 AACUGAUUACCAAGAACUU 19

RESULT 441
US-10-751-736-11054
; Sequence 11054, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11054
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
```



US-10-751-736-11021  
; Sequence 11021, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11021  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11021  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 78.9%; Pred. No. 1.2e+02;  
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 829 AATCTGACAATTCAGAAC 847  
Db 1 AAUCCUGACAAUUCAGAAC 19  
RESULT 436  
US-10-751-736-11027  
; Sequence 11027, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11027  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11027  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 78.9%; Pred. No. 1.2e+02;  
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 844 GAACCAGCTCTCTGTGACC 862  
Db 1 GAACCAGCTCUCUGUGACC 19  
RESULT 437  
US-10-751-736-11030  
; Sequence 11030, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene

728 CCTACAAATATGTCGACAT 746  
Db 1 CCUACAAAU AUGUGCAU 19  
RESULT 433  
US-10-751-736-11015  
; Sequence 11015, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11015  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11015  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 57.9%; Pred. No. 1.2e+02;  
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;  
QY 754 TTTCGCCTCTCTGCTGATG 772  
Db 1 UUUCGCCUCUCUGCUGAUG 19  
RESULT 434  
US-10-751-736-11018  
; Sequence 11018, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11018  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11018  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 78.9%; Pred. No. 1.2e+02;  
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 819 ACGCTTGCCAAATCCTGAC 837  
Db 1 ACGCUUGCCAAAUCCUGAC 19  
RESULT 435

```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10958
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10958

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      429 AGTATGGAGTAATGTTACC 447
      ||:||||:||||:|:|:|
Db      1 AGUAUGGAGUAAUGUUAACC 19

RESULT 429
US-10-751-736-10961
; Sequence 10961, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10961
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10961

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      461 GCAAGATTAACACAGGCAT 479
      |||||:|||||:|:|:|
Db      1 GCAAGAUAUACACAGGCAU 19

RESULT 430
US-10-751-736-10988
; Sequence 10988, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10988
; LENGTH: 21
```

```
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10988

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      656 CTGCTGTTACGAGATTGG 674
      |:|:|:|:|:|:|:|:|
Db      1 CUGCUGUUCACGAGAUUGG 19

RESULT 431
US-10-751-736-10991
; Sequence 10991, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10991
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10991

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      666 CGAGATTGCCATTCTTA 684
      |||||:|||||:|:|:|
Db      1 CGAGAUAUGGCAUUCUUA 19

RESULT 432
US-10-751-736-11000
; Sequence 11000, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11000
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11000

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

RESULT 424  
US-10-751-736-10934  
; Sequence 10934, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10934  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-10934

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 78.9%; Pred. No. 1.2e+02;  
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 276 CGCACCTCGATGTGGAGTC 294  
Db 1 CGCACCUUGAGUGGAGUC 19

RESULT 425  
US-10-751-736-10937  
; Sequence 10937, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10937  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-10937

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.2e+02;  
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 348 TTATATCACCTACAGATC 366  
Db 1 UUAUAUACCUACAGAU 19

RESULT 426  
US-10-751-736-10943  
; Sequence 10943, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10943  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-10943

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 73.7%; Pred. No. 1.2e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 368 ATAATTACACACCTGACAT 386  
Db 1 AUAUAUACACACCCUGACAU 19

RESULT 427  
US-10-751-736-10946  
; Sequence 10946, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10946  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-10946

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 84.2%; Pred. No. 1.2e+02;  
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 377 CACCTGACATGACCGTGA 395  
Db 1 CACCUGACAUACCGUGA 19

RESULT 428  
US-10-751-736-10958  
; Sequence 10958, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10751,736

```

; SEQ ID NO 10886
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10886

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1261 CTGATTACCAAGAACTTCC 1279
Db      1 CUGAUUACCAAGAACUCC 19

RESULT 420
US-10-751-736-10901
; Sequence 10901, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10901
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10901

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 52.6%; Pred. No. 1.2e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      1407 TAGCTGGTTTGGTTGTTAG 1425
Db      1 UAGCUGGUUUGGUUUGUAG 19

RESULT 421
US-10-751-736-10919
; Sequence 10919, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10919
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10919

Query Match      1.1%; Score 19; DB 1; Length 21;
```

```

Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1689 GTTGCTTCCTAACATCCTT 1707
Db      1 GUUGCUCUCCUAACAUCUU 19

RESULT 422
US-10-751-736-10928
; Sequence 10928, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10928
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10928

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.2e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      47 CTGCTTCTGAGCTCTTCC 65
Db      1 CUGCUUCUGGAGCUCUCC 19

RESULT 423
US-10-751-736-10931
; Sequence 10931, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10931
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10931

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      207 AGAAATGCAGCACTTCTTG 225
Db      1 AGAAAUAGCAGCACUUCUUG 19
```





Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.2e+02;  
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTCAGAACCAAGCTCTCTGT 858  
Db 1 UUCAGAACCAAGCUCUCUGU 19

RESULT 411  
US-10-751-736-10847  
; Sequence 10847, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version.3.2  
; SEQ ID NO 10847  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-10847

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.2e+02;  
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 918 AGACAGGTTCTTCTGCGTG 936  
Db 1 AGACAGGUUCUUCUGGCUG 19

RESULT 412  
US-10-751-736-10850  
; Sequence 10850, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10850  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-10850

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.2e+02;  
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 919 GACAGGTTCTTCTGGCTGA 937  
|||||:|:|:|:|

Db 1 GACAGGUUCUUCUGGCUGA 19

RESULT 413  
US-10-751-736-10853  
; Sequence 10853, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10853  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-10853

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 78.9%; Pred. No. 1.2e+02;  
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 939 GGTTCGTGAGACCAAG 957  
||:|:|:|:|:|:|:|:|:|  
Db 1 GGUUCUGAGACCAAG 19

RESULT 414  
US-10-751-736-10859  
; Sequence 10859, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10859  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-10859

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.2e+02;  
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 992 CCTTGCCATCTGGCATTGA 1010  
||:|:|:|:|:|:|:|:|:|  
Db 1 CCUUGCCAUCUGGCAUUGA 19

RESULT 415  
US-10-751-736-10862  
; Sequence 10862, Application US/10751736  
; Publication No. US20040265230A1

```

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10826
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10826

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      810 AGAGAACCAACGCTTGCCA 828
Db      1 AGAGAACCAACGCUUGCCA 19

RESULT 407
US-10-751-736-10832
; Sequence 10832, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10832
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10832

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      816 CCAACGCTTGCCAAATCCT 834
Db      1 CCAACGCUUGCCAAAUCCU 19

RESULT 408
US-10-751-736-10838
; Sequence 10838, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; 
```

```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10838
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10838

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      830 ATCTGACAATTCAGAACCC 848
Db      1 AUCCUGACAAUUCAGAACCC 19

RESULT 409
US-10-751-736-10841
; Sequence 10841, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10841
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10841

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      831 TCCTGACAATTCAGAACCCA 849
Db      1 UCCUGACAAUUCAGAACCCA 19

RESULT 410
US-10-751-736-10844
; Sequence 10844, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10844
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10844
; 
```

QY 457 TTCAGCAAGATTAAACACAG 475  
:|||||:|||||  
Db 1 UUCAGCAAGAUUAACACAG 19

RESULT 402

US-10-751-736-10802  
; Sequence 10802, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10802  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-10802

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 78.9%; Pred. No. 1.2e+02;  
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 465 GATTAACACAGGCTGGCT 483  
||:|||||:|||||  
Db 1 GAUUAACACAGGCAUGGCU 19

RESULT 403

US-10-751-736-10808  
; Sequence 10808, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10808  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-10808

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.2e+02;  
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 616 TTCTGGACTACACATTTCAG 634  
:|||||:|||||  
Db 1 UUCUGGACUACACAUCAG 19

RESULT 404

US-10-751-736-10814

; Sequence 10814, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10814  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-10814

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 52.6%; Pred. No. 1.2e+02;  
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 645 CTTGTTCTCACTGCTGTT 663  
|::||:||||:|::|  
Db 1 CUUGUCCUCACUGCUGUU 19

RESULT 405

US-10-751-736-10823  
; Sequence 10823, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10823  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-10823

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 63.2%; Pred. No. 1.2e+02;  
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 750 CACATTTGCCTCTCTGCT 768  
||||::|::|::|::|  
Db 1 CACAUUCCGCCUCUCGU 19

RESULT 406

US-10-751-736-10826  
; Sequence 10826, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei



Fri May 13 12:26:37 2005

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10781
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10781

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 369 TAATTACACACCTGACATG 387
Db 1 UAAUACACACCUGACAUG 19

RESULT 398
US-10-751-736-10784
; Sequence 10784, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10784
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10784

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 372 TTACACACCTGACATGAAC 390
Db 1 UUACACACCUGACAUGAAC 19

RESULT 399
US-10-751-736-10787
; Sequence 10787, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10787
; LENGTH: 21
; TYPE: RNA

; ORGANISM: RNai
US-10-751-736-10787
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 390 CCGTGAGGATGTTGACTAC 408
Db 1 CCGUGAGGAUGUGACUAC 19

RESULT 400
US-10-751-736-10793
; Sequence 10793, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10793
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10793

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 420 AGCTTCCCAAGTATGGAGT 438
Db 1 AGCUUCCCAAGUAGGAGU 19

RESULT 401
US-10-751-736-10799
; Sequence 10799, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10799
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10799

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```

RESULT 393
US-10-751-736-10010
; Sequence 10010, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10010
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10010

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 1185 GACCTACTTCTTTGTAGAT 1203
Db 2 GACCUACUUCUUGUAGAU 20

RESULT 394
US-10-751-736-10760
; Sequence 10760, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10760
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10760

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 72 CAGCTCTACAAGCCTGGAA 90
Db 1 CAGCUUACAAGCCUGGAA 19

RESULT 395
US-10-751-736-10763
; Sequence 10763, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert

```

```

; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10763
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10763

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 96 TAATGTGCTATTGGTGAG 114
Db 1 UAAUGUGCUAUUGGUGAG 19

RESULT 396
US-10-751-736-10769
; Sequence 10769, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10769
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10769

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 149 ACAAACTTCCAGTGACAAA 167
Db 1 ACAAACTTCCAGTGACAAA 167

RESULT 397
US-10-751-736-10781
; Sequence 10781, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06

```

```

; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 11, antisense oligonucleotide
US-10-619-906-11

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      208 GAAATGCAGCACTTCTTGG 226
Db      19  GAAATGCAGCACTTCTTGG 1

RESULT 389
US-10-619-906-12/c
; Sequence 12, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 12, antisense oligonucleotide
US-10-619-906-12

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      946 GAGAGACCAAGACCAGTG 964
Db      19  GAGAGACCAAGACCAGTG 1

RESULT 390
US-10-619-906-13/c
; Sequence 13, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 13, antisense oligonucleotide
US-10-619-906-13

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
```

```

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      913 TTCAAAGACAGTTCTTCT 931
Db      19  TTCAAAGACAGTTCTTCT 1

RESULT 391
US-10-619-906-14/c
; Sequence 14, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 14, antisense oligonucleotide
US-10-619-906-14

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1231 AGACAGATGATGGACCCCTG 1249
Db      19  AGACAGATGATGGACCCCTG 1

RESULT 392
US-10-872-063-160
; Sequence 160, Application US/10872063
; Publication No. US20050079518A1
; GENERAL INFORMATION:
; APPLICANT: BAKER, Joffre
; APPLICANT: BRYANT, John L.
; APPLICANT: PAIK, Soonmyung
; APPLICANT: SHAK, Steven
; TITLE OF INVENTION: Prediction of Likelihood of Cancer
; TITLE OF INVENTION: Recurrence
; FILE REFERENCE: 39740-0012 US
; CURRENT APPLICATION NUMBER: US/10/872,063
; CURRENT FILING DATE: 2004-06-17
; PRIOR APPLICATION NUMBER: US 60/482,339
; PRIOR FILING DATE: 2003-06-24
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 160
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer-probe
US-10-872-063-160

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      816 CCAACGCTTGCCAAATCCT 834
Db      1  CCAACGCTTGCCAAATCCT 19
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      512 CTCATGGAGACTTCCATGC 530
Db      19 CTCATGGAGACTTCCATGC 1
|||||

RESULT 384
US-10-619-906-7/c
; Sequence 7, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 7, antisense oligonucleotide
US-10-619-906-7

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      855 CTGTGACCCCAATTGAGT 873
Db      19 CTGTGACCCCAATTGAGT 1
|||||

RESULT 385
US-10-619-906-8/c
; Sequence 8, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 8, antisense oligonucleotide
US-10-619-906-8

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1182 TAGGACCTACTTCTTTGTA 1200
Db      19 TAGGACCTACTTCTTTGTA 1
|||||

RESULT 386
US-10-619-906-9/c
```

```
; Sequence 9, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 9, antisense oligonucleotide
US-10-619-906-9

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      814 AACCAACGCTGCCAAATC 832
Db      19 AACCAACGCTGCCAAATC 1
|||||

RESULT 387
US-10-619-906-10/c
; Sequence 10, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 10, antisense oligonucleotide
US-10-619-906-10

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1097 CAAATTATCCCAAGAGCAT 1115
Db      19 CAAATTATCCCAAGAGCAT 1
|||||

RESULT 388
US-10-619-906-11/c
; Sequence 11, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
```



```
; Sequence 11465, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11465
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11465

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      774 CATACGTGGCATTTCAGTCCCT 794
Db      1 CAUACGGUGCAUUCAGUCCUU 21

RESULT 380
US-10-619-906-3/c
; Sequence 3, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO.3, antisense oligonucleotide
US-10-619-906-3

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      751 ACATTTGCGCTCTCTGCTG 769
Db      19 ACATTTGCGCTCTCTGCTG 1

RESULT 381
US-10-619-906-4/c
; Sequence 4, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
```

```
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO.4, antisense oligonucleotide
US-10-619-906-4

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      137 GCCTTGAGATAAACAAACT 155
Db      19 GCCTTGAGATAAACAAACT 1

RESULT 382
US-10-619-906-5/c
; Sequence 5, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 5, antisense oligonucleotide
US-10-619-906-5

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      355 ACCTACAGAATCAATAATT 373
Db      19 ACCTACAGAATCAATAATT 1

RESULT 383
US-10-619-906-6/c
; Sequence 6, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 6, antisense oligonucleotide
US-10-619-906-6
```



```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11345
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11345

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 52.4%; Pred. No. 1.1e+02;
Matches 11; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY      1409 GCTGGTTTGGTTGTAGAAAT 1429
Db      1 GTUGGUUUGGUUGUAGAAUU 21

RESULT 371
US-10-751-736-11354
; Sequence 11354, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11354
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11354

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY      1493 TGTCTCAGTGTTACTACT 1513
Db      1 UGUCCUCAGUGUACCACUAUU 21

RESULT 372
US-10-751-736-11357
; Sequence 11357, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11357
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11357

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY      1506 CCACTACTTAGAGATATGTAT 1526
Db      1 CCACUACUUGAGAUUGUUU 21

RESULT 373
US-10-751-736-11360
; Sequence 11360, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11360
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11360

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 1.1e+02;
Matches 10; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY      1602 ATTGTCCATTCTTGCTTGACT 1622
Db      1 AUUGUCCAUUCUUGCUUGAUU 21

RESULT 374
US-10-751-736-11366
; Sequence 11366, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11366
; LENGTH: 21
; TYPE: RNA
```

```

RESULT 368
US-10-751-736-11327
; Sequence 11327, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11327
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11327

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.1e+02;
Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy    1221 TGATGAAAGGAGACAGATGAT 1241
       :||:|||||:|||||:|:
Db    1   UGAUGAAAGGAGACAGAUGUU 21

RESULT 369
US-10-751-736-11342
; Sequence 11342, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11342
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11342

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy    1365 TGACTTCCTACTCCAACGTAT 1385
       :||:||||:|||||:|:
Db    1   UGACUUCUCCAUCCCAACGUUU 21

RESULT 370
US-10-751-736-11345
; Sequence 11345, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert

```



```

; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11252
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11252

```

Query Match 1.1%; Score 19.4; DB 1; Length 21;  
Best Local Similarity 71.4%; Pred. No. 1.1e+02;  
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

**QY** 31 CTGCTCCTGCAGGCCACTGCT 51  
| : | : | : | : | : | : | :  
**pB** 1 CUGCUCCUGCAGGCCACUGUU 21

## RESULT 362

```

US-10-736-11255
; Sequence 11255, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION:  CANCERS
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11255

```

```

; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNa1
US-10-751-736-11255

```

```

Query Match          1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.1e+02;
Matches 12: Conservative 8; Mismatches 1; Indels 0; Gaps 0;

```

Qy 98 ATGTGCTATTGGTGAGAGAT 118  
| : | : | : | : | : | : | :  
pb 1 AUGUGCUAUUUGGUGAGAGUU 21

**RESULT 363**

US-10-751-736-11261  
; Sequence 11261, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11261

```

; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11261

```

Query Match 1.1%; Score 19.4; DB 1; Length 21;  
Best Local Similarity 71.4%; Pred. No. 1.1e+02;  
Matches 15: Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 135 TGGCTTGAGATAAAACAAACT 155  
:  
pb 1 UGGCCUUGAGAUAACAACAAAU 21

**RESULT 364**

```

US-10-751-736-11282
; Sequence 11282, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND M
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-00200
; CURRENT APPLICATION NUMBER: US/10/751,
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provision
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11282
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11282

```

```

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

```

QY 626 CACATT CAGGAGGCACAAACT 646  
|||||:|||||:|||||:  
nb 1 CACATT CAGGAGGCACAAAUU 21

## RESULT 365

```

US-10-751-736-11285
; Sequence 11285, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;   APPLICANT: Wyeth
;   APPLICANT: Martinez, Robert
;   APPLICANT: Brown, Eugene
;   APPLICANT: Liu, Wei
;   TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;   TITLE OF INVENTION: CANCERS
;   FILE REFERENCE: AM100927 (031896-002000)
;   CURRENT APPLICATION NUMBER: US/10/751,736
;   CURRENT FILING DATE: 2003-01-06
;   PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;   PRIOR FILING DATE: 2003-01-06
;   NUMBER OF SEQ ID NOS: 54873
;   SOFTWARE: PatentIn version 3.2
;   SEQ ID NO 11285
;     LENGTH: 21
;     TYPE: RNA
;     ORGANISM: RNAi
US-10-751-736-11285

```

Query Match 1.1%; Score 19.4; DB 1; Length 21;  
Best Local Similarity 57.1%; Pred. No. 1.1e+02;

```

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11246
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11246

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 52.4%; Pred. No. 1.1e+02;
Matches 11; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY      1717 AATTATACTTACTTCTGGCAT 1737
      ||:::||:::||:::||:::||::||
Db      1 AAUAUACUACUUCUGGCUU 21

RESULT 360
US-10-751-736-11249
; Sequence 11249, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11249
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11249

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      28 ATACTGCTCTGCGAGGCCACT 48
      ||:::||:::||:::||:::||::||
Db      1 AUACUGCUCCUGCAGGCCAUU 21

RESULT 361
US-10-751-736-11252
; Sequence 11252, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
```

```

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11192
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11192

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY      921 CAGGTTCTTCTGGCTGAAGGT 941
      ||||::||::||::||::||::||
Db      1 CAGGUUCUUCUGGCGUGAAGUU 21

RESULT 358
US-10-751-736-11210
; Sequence 11210, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11210
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11210

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.1e+02;
Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1023 AATTGAAGCCAGAAATCAACT 1043
      ||:::||:::||:::||:::||::||
Db      1 AAUUGAAGCCAGAAAUCAUU 21

RESULT 359
US-10-751-736-11246
; Sequence 11246, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```

```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11069
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11069

```

Query Match 1.1%; Score 19.4; DB 1; Length 21;  
Best Local Similarity 57.1%; Pred. No. 1.le+02;  
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

**QY** 1509 CTACTTAGAGATATGTATCAT 1529  
| : | : | : | : | : | : | : | :  
**pb** 1 CUACUUGAGAGAAUGUAUCUU 21

```

RESULT 353
US-10-751-736-11135
; Sequence 11135, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11135
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Rnai
US-10-751-736-11135

```

Query Match	1.1%;	Score 19.4;	DB 1;	Length 21;
Best Local Similarity	66.7%;	Pred. No. 1.1e+02;		
Matches 14:	Conservative	6;	Mismatches 1;	Indels 0;
				Gaps 0;

Qy 511 GCTCATGGAGACTTCCATGCT 531  
||:||:||:||:||:||:||:  
nb' 1 GCUCAGUGGAGACUCCAUUU 21

RESULT 354  
US-10-751-736-11162  
; Sequence 11162, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11162  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-11162

Query Match	1.1%;	Score 19.4;	DB 1;	Length 21;
Best Local Similarity	66.7%;	Pred. No. 1.1e+02;		
Matches 14;	Conservative	6;	Mismatches 1;	Indels 0;
				Gaps 0;

QY 637 GGCAAAACTTGTTCCTCACT 657  
|||||:::|::|:  
nb 1 GGCAAAACUUGUCCUCAU 21

RESULT 355  
 US-10-751-736-11165  
 ; Sequence 11165, Application US/10751736  
 ; Publication No. US20040265230A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Martinez, Robert  
 ; APPLICANT: Brown, Eugene  
 ; APPLICANT: Liu, Wei  
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
 ; TITLE OF INVENTION: CANCERS  
 ; FILE REFERENCE: AM100927 (031896-002000)  
 ; CURRENT APPLICATION NUMBER: US/10/751,736  
 ; CURRENT FILING DATE: 2003-01-06  
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
 ; PRIOR FILING DATE: 2003-01-06  
 ; NUMBER OF SEQ ID NOS: 54873  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 11165  
 ; LENGTH: 21  
 ; TYPE: RNA  
 ; ORGANISM: Rnai  
 US-10-751-736-11165

Query Match	1.1%;	Score 19.4;	DB 1;	Length 21;
Best Local Similarity	57.1%;	Pred. No. 1.1e+02;		
Matches 12: Conservative	8;	Mismatches 1;	Indels 0;	Gaps 0;

Qy 669 GATTGGCCATTCTTAGGTCT 689  
|||:|||||:|:|:|:|:|:|:  
nb 1 GAUTGGCCAUCCUAGGUUU 21

RESULT 356  
 US-10-751-736-11180  
 ; Sequence 11180, Application US/10751736  
 ; Publication No. US20040265230A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Martinez, Robert  
 ; APPLICANT: Brown, Eugene  
 ; APPLICANT: Liu, Wei  
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
 ; TITLE OF INVENTION: CANCERS  
 ; FILE REFERENCE: AM100927 (031896-002000)  
 ; CURRENT APPLICATION NUMBER: US/10/751,736  
 ; CURRENT FILING DATE: 2003-01-06  
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
 ; PRIOR FILING DATE: 2003-01-06  
 ; NUMBER OF SEQ ID NOS: 54873  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 11180  
 ; LENGTH: 21  
 ; TYPE: RNA  
 ; ORGANISM: Rnai  
 US-10-751-736-11180

```

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14: Conservative 6; Mismatches 1; Indels 0; Gaps 0;

```

Qy 774 CATACTGGCATTCAGTCCCT 794  
||:|||||:|||||:|:  
Db 1 CAUACGUGGCAUUCAGUCCUU 21









Fri May 13 12:26:37 2005

```
US-10-751-736-10829
; Sequence 10829, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10829
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10829

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      811 GAGAACCAACGCTTGCCAAAT 831
      |||||
Db      1 GAGAACCAACGCUUGCCAAU 21

RESULT 338
US-10-751-736-10835
; Sequence 10835, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10835
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10835

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      820 CGCTTGCCAAATCCTGACAAT 840
      |||||
Db      1 CGCUUGCCAAAUCCUGACAU 21

RESULT 339
US-10-751-736-10856
; Sequence 10856, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
```

```
QY      208 GAAATGCAGCACITTCITGGT 228
      |||||
Db      1 GAAAUGCAGCACUUCUUGGUU 21

RESULT 335
US-10-751-736-10790
; Sequence 10790, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10790
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10790

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      413 TCCGGAAGCTTTCCAAGTAT 433
      :|||
Db      1 UCCGGAAGCUUCCAAGUU 21

RESULT 336
US-10-751-736-10796
; Sequence 10796, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10796
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10796

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY      421 GCTTCCAAGTATGGAGTAAT 441
      ||::|
Db      1 GCUUCCAAGUAGGAGUAU 21

RESULT 337
```

```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11471
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11471

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      815 ACCAAGCTTGCCAAATCCT 834
Db      1 ACCAAGCUUGCCAAAUCCU 20

RESULT 331
US-10-751-736-11477
; Sequence 11477, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11477
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11477

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      952 CCAAAGACCAGTGTAAATT 971
Db      1 CCAAAGACCAGUGUAAUUU 20

RESULT 332
US-10-751-736-10754
; Sequence 10754, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10754
; LENGTH: 21
```

```
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10754

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 1.1e+02;
Matches 10; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY      18 GTTCTTCTAATAGTCTCCT 38
Db      1 GUUUCUUCUAAUACUGCUCUU 21

RESULT 333
US-10-751-736-10775
; Sequence 10775, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10775
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10775

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      203 TCCAAGAAATGCAGCACTTCT 223
Db      1 UCCAAGAAAUAGCAGCACUUUU 21

RESULT 334
US-10-751-736-10778
; Sequence 10778, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10778
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10778

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
```



```
RESULT 326
US-10-751-736-11420
; Sequence 11420, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11420
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11420

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 600 TTTCGATGAGGACGAATTCT 619
Db 1 UUUCGAGGAGCGAAUUCU 20

RESULT 327
US-10-751-736-11432
; Sequence 11432, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11432
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11432

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 746 TCAACACATTTTCGCTCTCT 765
Db 1 UCAACACAUUUCGCCUCUCU 20

RESULT 328
US-10-751-736-11459
; Sequence 11459, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11459
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11459

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 671 TTGGCCATTCCTTAGTCTT 690
Db 1 UUGGCCAUUCCUAGGUCUU 20

RESULT 329
US-10-751-736-11462
; Sequence 11462, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11462
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11462

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 744 CATCAACACATTTTCGCTCT 763
Db 1 CAUCAACACAUUUCGCCUCU 20

RESULT 330
US-10-751-736-11471
; Sequence 11471, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```

; SEQ ID NO 11369
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11369

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1688 AGTTGCTTCCTAATCCTT 1707
Db      1 AGUUGCUUCCUAACAUCUU 20

RESULT 322
US-10-751-736-11375
; Sequence 11375, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11375
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11375

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1722 TACTTACTTCTGGCATAACT 1741
Db      1 UACUUAUUCUGGCAUAACU 20

RESULT 323
US-10-751-736-11390
; Sequence 11390, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11390
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11390

Query Match      1.1%; Score 20; DB 1; Length 21;
```

```

Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      644 ACTTGTTCCCTCACTGCTGTT 663
Db      1 ACUUGUCCUCACUGCUGUU 20

RESULT 324
US-10-751-736-11414
; Sequence 11414, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11414
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11414

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      464 AGATTAAACACAGGCATGGCT 483
Db      1 AGAUUAACACAGGCAUGGCU 20

RESULT 325
US-10-751-736-11417
; Sequence 11417, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11417
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11417

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      598 CATTTCGATGAGGACGAATT 617
Db      1 CAUUCGAUGAGGACGAUU 20
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11315
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11315

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1191 CTTCTTTGTAGATAACCACT 1210
      |||:::|||||:
Db      1 CUUCUUUGUAGUAACCAAGU 20

RESULT 318
US-10-751-736-11321
; Sequence 11321, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11321
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11321

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1205 ACCAGTATGGAGGTATGAT 1224
      |||:::|||||:
Db      1 ACCAGUAUUGGAGGUAUGAU 20

RESULT 319
US-10-751-736-11333
; Sequence 11333, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11333
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11333

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1329 CTACTATTCTTCCAAGGAT 1348
      |||:::|||||:
Db      1 CUACUAUUUCUCCCAAGGAU 20

RESULT 320
US-10-751-736-11348
; Sequence 11348, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11348
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11348

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 89;
Matches 10; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY      1479 TTGCATATTGCTATGTCCT 1498
      ::|||:::|||||:
Db      1 UUGCAUAUUUGUAUGUCCU 20

RESULT 321
US-10-751-736-11369
; Sequence 11369, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
```

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 70.0%; Pred. No. 89;  
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 771 TGACATACGTGGCATTTCAGT 790  
Db :||||:||||:||||:||||:  
1 UGACAUACGUGGCAUUCAGU 20

RESULT 313  
US-10-751-736-11186  
; Sequence 11186, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11186  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI  
US-10-751-736-11186

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 80.0%; Pred. No. 89;  
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 815 ACCAACGCTTGCCAAATCCT 834  
Db :||||:||||:||||:||||:  
1 ACCAACGCUUGCCAAAUCCU 20

RESULT 314  
US-10-751-736-11189  
; Sequence 11189, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11189  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI  
US-10-751-736-11189

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 75.0%; Pred. No. 89;  
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 837 CAATTGACGACGCTCTCT 856  
:||||:||||:||||:||||:

Db 1 CAAUUCAGAACGACUCUCU 20

RESULT 315  
US-10-751-736-11204  
; Sequence 11204, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11204  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI  
US-10-751-736-11204

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 70.0%; Pred. No. 89;  
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 952 CCAAAGACCAGTGTAAATT 971  
Db :||||:||||:||||:||||:  
1 CCAAAGACCAGUGUUAUUU 20

RESULT 316  
US-10-751-736-11312  
; Sequence 11312, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11312  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI  
US-10-751-736-11312

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 60.0%; Pred. No. 89;  
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1184 GGACCTACTTCTTTGTAGAT 1203  
Db :||||:||||:||||:||||:  
1 GGACCUACUCUUGUAGAU 20

RESULT 317  
US-10-751-736-11315  
; Sequence 11315, Application US/10751736  
; Publication No. US20040265230A1



```

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11126
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11126

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      419 AAGCTTTCCAAGTATGGAGT 438
Db      1 AAGCUUCCAGUAUGGAGU 20
      |||:::|||||:|:|||||:
RESULT 309
US-10-751-736-11153
; Sequence 11153, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11153
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11153

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      612 CGAATTCGGACTACACATT 631
Db      1 CGAAUUCUGGACUACACAU 20
      |||:::|||||:|:|||||:
RESULT 310
US-10-751-736-11168
; Sequence 11168, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11168
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11168

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      671 TTGGCCATTCCTTAGGTCTT 690
Db      1 UUGGCCAUUCCUAGGUCUU 20
      ::|||||:|:|||||:|:|:
RESULT 311
US-10-751-736-11174
; Sequence 11174, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11174
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11174

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      744 CATCAACACATTCGCCTCT 763
Db      1 CAUCAACACAUUUGCCUCU 20
      ||:|||||:|:|||||:|:
RESULT 312
US-10-751-736-11177
; Sequence 11177, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11177
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-11177
```

QY 1501 GTGTACCACTACTTAGAT 1520  
Db 1 GUGUACCACUACUUAGAGAU 20

RESULT 304  
US-10-751-736-11075  
; Sequence 11075, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11075  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNai  
US-10-751-736-11075

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 55.0%; Pred. No. 89;  
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAAGTTGCTTCCT 1698  
Db 1 UGCUCUGAAGUUGCUCCU 20

RESULT 305  
US-10-751-736-11078  
; Sequence 11078, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11078  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNai  
US-10-751-736-11078

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 65.0%; Pred. No. 89;  
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1703 TCCTTGACTGAGAAATTAT 1722  
Db 1 UCCUUGGACUGAGAAAUUAU 20

RESULT 306  
US-10-751-736-11093

; Sequence 11093, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11093  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNai  
US-10-751-736-11093

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 80.0%; Pred. No. 89;  
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 267 GATGATGCACGCACCTCGAT 286  
Db 1 GAUGAUGCACGCACCUUGAU 20

RESULT 307  
US-10-751-736-11096  
; Sequence 11096, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11096  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNai  
US-10-751-736-11096

Query Match 1.1%; Score 20; DB 1; Length 21;  
Best Local Similarity 75.0%; Pred. No. 89;  
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 269 TGATGCACGCACCTCGATGT 288  
Db 1 UGAUGCACGCACCUUGAU 20

RESULT 308  
US-10-751-736-11126  
; Sequence 11126, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei



```
RESULT 295
US-10-751-736-10982
; Sequence 10982, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10982
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10982

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 641 CAAACTTGTTCTCTCACTGCT 660
Db 1 CAAACUUGUCCUCACUGCU 20

RESULT 296
US-10-751-736-10994
; Sequence 10994, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10994
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10994

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 678 TTCCTTAGGTCTTGCCATT 697
Db 1 UUCCUAGGUCUUGGCCAUU 20

RESULT 297
US-10-751-736-11006
; Sequence 11006, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11006
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11006

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCAACACATTTGCGCTCTCT 765
Db 1 UCAACACAUUCCGCCUCUCU 20

RESULT 298
US-10-751-736-11009
; Sequence 11009, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11009
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11009

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 749 ACACATTTGCGCTCTCTGCT 768
Db 1 ACACAUUUCGCCUCUCUGCU 20

RESULT 299
US-10-751-736-11012
; Sequence 11012, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```



```

; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10964

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      464 AGATTACACAGGCGATGGCT 483
Db      1 AGAUUACACAGGCGAUGGCU 20

RESULT 291
US-10-751-736-10967
; Sequence 10967, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10967
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10967

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      598 CATTTCGATGAGGACGAATT 617
Db      1 CAUUUGAUGAGGACGAUU 20

RESULT 292
US-10-751-736-10970
; Sequence 10970, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10970
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10970

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
```

```

Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      600 TTTTCGATGAGGACGAATTCT 619
Db      1 UUUCGAUGAGGACGAUUCU 20

RESULT 293
US-10-751-736-10973
; Sequence 10973, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10973
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10973

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      628 CATTACGAGGACACAACTT 647
Db      1 CAUUCAGGAGGCACAAACUU 20

RESULT 294
US-10-751-736-10979
; Sequence 10979, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10979
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10979

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      634 GGAGGCACAACTTCTCCT 653
Db      1 GGAGGCACAAACUUGUCCU 20
```

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10916
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10916

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1676 GCATGCTCTGTAAAGTTGCTT 1695
Db      1 GCAUGCUCUGAAGUGCUU 20

RESULT 287
US-10-751-736-10922
; Sequence 10922, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10922
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10922

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1701 CATCCTTGACTGAGAAATT 1720
Db      1 CAUCCUUGGACUGAGAAUU 20

RESULT 288
US-10-751-736-10940
; Sequence 10940, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
```

```
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10940
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10940

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      362 GAATCAATAATTACACACCT 381
Db      1 GAAUCAUAUAUACACACCU 20

RESULT 289
US-10-751-736-10955
; Sequence 10955, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10955
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10955

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      412 ATCCGGAAGCTTTCCAAGT 431
Db      1 AUCCGGAAGCUUCCAAAGU 20

RESULT 290
US-10-751-736-10964
; Sequence 10964, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10964
```

```
Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      644 ACTTGTTCTCACTGCTGTT 663
Db      1 ACUUGUCCUCACUGCUGUU 20

RESULT 282
US-10-751-736-10871
; Sequence 10871, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10871
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10871

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1083 TTTAAGACCAGAGCCAAATT 1102
Db      1 UUUAGACCAGAGCCAAAUU 20

RESULT 283
US-10-751-736-10889
; Sequence 10889, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10889
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10889

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 89;
Matches 10; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY      1298 TTGATGCAGTCTTCTATTCT 1317
Db      1 UUGAUGCAGUCUUAUUCU 20
```

```
RESULT 284
US-10-751-736-10907
; Sequence 10907, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10907
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10907

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 89;
Matches 10; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY      1603 TTGTCCATTCTTGCTTGACT 1622
Db      1 UUGUCCAUCUUGCUUGACU 20

RESULT 285
US-10-751-736-10913
; Sequence 10913, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10913
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10913

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      1665 TTCTATTTGAAGCATGCTCT 1684
Db      1 UUCUAUUUGAAGCAUGCUCU 20

RESULT 286
US-10-751-736-10916
; Sequence 10916, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```





```
US-10-719-900-879471
Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1241 TGGACCCCTGTTTATCCCAAACTGAT 1265
          ||||| ||||| ||||| ||||| |||||
Db       1 TGGACCTGCTTACCCCAAGCTGAT 25

RESULT 273
US-10-719-900-908158
; Sequence 908158, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 908158
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-908158

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1197 TGATATAACCACTATTGGAGGTAT 1221
          ||| ||||| ||||| ||||| |||||
Db       1 TGTGATAAACAAGTACTGGAGGTAT 25

RESULT 274
US-10-719-900-967442/c
; Sequence 967442, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 967442
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-967442

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      161 TGACAAAATGAATATAGTGGAAA 185
          ||||| ||||| ||||| |||||
Db       25 TGACAAGAATGAATCTATTGGAAA 1

RESULT 275
US-10-809-189-125366
; Sequence 125366, Application US/10809189
; Publication No. US20050048531A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125366
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125366

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1276 TTCCAAGGAATCGGGCCTAAATTTG 1300
          ||||| ||||| ||||| ||||| |||||
Db       1 TTCCAGGAATCAAGCCTAAATTTG 25

RESULT 276
US-10-274-095-35
; Sequence 35, Application US/10274095
; Publication No. US20030120433A1
; GENERAL INFORMATION:
; APPLICANT: Yokota, Hiroki
; APPLICANT: Sun, Hui Bin
; TITLE OF INVENTION: Methods for Predicting Transcription
; FILE REFERENCE: ARTI.0137US
; CURRENT APPLICATION NUMBER: US/10/274,095
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/329,961
; PRIOR FILING DATE: 2001-10-17
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-274-095-35

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      44 CCACTGCTTCTGGAGCTCTT 63
          ||||| ||||| ||||| |||||
Db       1 CCACTGCTTCTGGAGCTCTT 20

RESULT 277
US-10-274-095-36/c
; Sequence 36, Application US/10274095
; Publication No. US20030120433A1
; GENERAL INFORMATION:
; APPLICANT: Yokota, Hiroki
; APPLICANT: Sun, Hui Bin
; TITLE OF INVENTION: Methods for Predicting Transcription
; FILE REFERENCE: ARTI.0137US
```

```
US-10-751-736-11479
; Sequence 11479, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11479
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11479

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      373 TACACACCTGACATGAACCGT 393
      |||||||
Db      1 TACACACCTGACATGAACCGT 21

RESULT 269
US-10-751-736-11482
; Sequence 11482, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11482
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11482

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1180 TATAGGACCTACTTCTTGTA 1200
      |||||||
Db      1 TATAGGACCTACTTCTTGTA 21

RESULT 270
US-10-719-900-174230
; Sequence 174230, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
```

```
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 174230
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-174230

Query Match      1.2%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1290 GCCTAAATTCAGTCAGTCTTCTA 1313
      |||||||
Db      2 GCCTAAATTCGTGCAGTCCTCTA 25

RESULT 271
US-10-809-189-127779
; Sequence 127779, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 127779
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-127779

Query Match      1.1%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      781 GGCATTTCAGTCCCTGTATGGAG 802
      |||||||
Db      3 GGCATTCAATCCCTGTATGGAG 24

RESULT 272
US-10-719-900-879471
; Sequence 879471, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 879471
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
```

```

; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11467

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      811 GAGAACCAACGCTTGCCAAAT 831
Db      1 GAGAACCAACGCTTGCCAAAT 21

RESULT 264
US-10-751-736-11470
; Sequence 11470, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11470
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11470

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      813 GAACCAACGCTTGCCAAATCC 833
Db      1 GAACCAACGCTTGCCAAATCC 21

RESULT 265
US-10-751-736-11473
; Sequence 11473, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11473
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11473

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      948 GAGACCAAGACCAGTGTAA 968
Db      1 GAGACCAAGACCAGTGTAA 21

RESULT 266
US-10-751-736-11474
; Sequence 11474, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11474
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11474

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 65;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      950 GACCAAGACCAGTGTAAAT 970
Db      1 GACCAAGACCAGUGUAAU 21

RESULT 267
US-10-751-736-11476
; Sequence 11476, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11476
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11476

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      950 GACCAAGACCAGTGTAAAT 970
Db      1 GACCAAGACCAGTGTAAAT 21

RESULT 268
US-10-751-736-11476
; Sequence 11476, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11476
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11476

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      950 GACCAAGACCAGTGTAAAT 970
Db      1 GACCAAGACCAGTGTAAAT 21

RESULT 268
US-10-751-736-11476
; Sequence 11476, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11476
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11476

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11455
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11455

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      607 GAGGACGAATTCCTGGACTACA 627
Db      1 GAGGACGAATTCCTGGACTACA 21

RESULT 260
US-10-751-736-11458
; Sequence 11458, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11458
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11458

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669 GATTGGCCATTCCTTAGGTCT 689
Db      1 GATTGGCCATTCCTTAGGTCT 21

RESULT 261
US-10-751-736-11461
; Sequence 11461, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11461
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11461

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      742 GACATCAACACATTCGCCTC 762
Db      1 GACATCAACACATTCGCCTC 21

RESULT 262
US-10-751-736-11464
; Sequence 11464, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11464
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11464

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      772 GACATACGTGGCATTGAGTCC 792
Db      1 GACATACGTGGCATTGAGTCC 21

RESULT 263
US-10-751-736-11467
; Sequence 11467, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11467
; LENGTH: 21
```





; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11431
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11431

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 744 CATCAACACATTTCGCCTCTC 764
|||||
Db 1 CATCAACACATTTCGCCTCTC 21

RESULT 251

US-10-751-736-11434
; Sequence 11434, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11434
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11434

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 382 GACATGAACCGTGAGGATGTT 402
|||||
Db 1 GACATGAACCGTGAGGATGTT 21

RESULT 252

US-10-751-736-11437
; Sequence 11437, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 11437
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11437

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 GAACCGTGAGGATGTTGACTA 407
|||||
Db 1 GAACCGTGAGGATGTTGACTA 21

RESULT 253

US-10-751-736-11440
; Sequence 11440, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11440
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11440

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 394 GAGGATGTTGACTACGCAATC 414
|||||
Db 1 GAGGATGTTGACTACGCAATC 21

RESULT 254

US-10-751-736-11443
; Sequence 11443, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11443
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11443

Query Match 1.2%; Score 21; DB 1; Length 21;

```
Db      1  CATTTCGATGAGGACGAATTC 21

RESULT 246
US-10-751-736-11422
; Sequence 11422, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11422
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11422

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      641  CAAACTTGTTCCTCACTGCTG 661
Db      1  CAAACTTGTTCCTCACTGCTG 21

RESULT 247
US-10-751-736-11423
; Sequence 11423, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11423
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11423

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 65;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      643  AACTTGTTCCTCACTGCTGTT 663
Db      1  AACUUGUCCUCACUGCUGUU 21

RESULT 248
US-10-751-736-11425
; Sequence 11425, Application US/10751736
; Publication No. US20040265230A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11425
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11425

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      654  CACTGCTGTTCAAGAGATTGG 674
Db      1  CACTGCTGTTCAAGAGATTGG 21

RESULT 249
US-10-751-736-11428
; Sequence 11428, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11428
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11428

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      694  CATTCTAGTGTATCCAAAGGCT 714
Db      1  CATTCTAGTGTATCCAAAGGCT 21

RESULT 250
US-10-751-736-11431
; Sequence 11431, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
```

```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11407
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11407

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      427 CAAGTATGGAGTAATGTACC 447
Db      1 CAAGTATGGAGTAATGTACC 21

RESULT 242
US-10-751-736-11410
; Sequence 11410, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11410
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11410

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      459 CAGCAAGATTAACACAGGCAT 479
Db      1 CAGCAAGATTAACACAGGCAT 21

RESULT 243
US-10-751-736-11413
; Sequence 11413, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11413
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11413
```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      462 CAAGATTAACACAGGCATGGC 482
Db      1 CAAGATTAACACAGGCATGGC 21

RESULT 244
US-10-751-736-11416
; Sequence 11416, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11416
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11416

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      596 CACATTTTCGATGAGGACGAAT 616
Db      1 CACATTTTCGATGAGGACGAAT 21

RESULT 245
US-10-751-736-11419
; Sequence 11419, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11419
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11419

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      598 CATTTCGATGAGGACGAATTC 618
Db      1 CATTTCGATGAGGACGAATTC 618
```



03

0:

; APPLICANT: Liu, Wei  
 ;  
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
 ;  
 ; TITLE OF INVENTION: CANCERS  
 ;  
 ; FILE REFERENCE: AML00927 (031896-002000)  
 ;  
 ; CURRENT APPLICATION NUMBER: US/10/751,736  
 ;  
 ; CURRENT FILING DATE: 2003-01-06  
 ;  
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
 ;  
 ; PRIOR FILING DATE: 2003-01-06  
 ;

```

; ORGANISM: homo sapiens
US-10-751-736-11380

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      388 AACCGTGAGGATGTTGACTAC 408
Db      1 AACCGTGAGGATGTTGACTAC 21

RESULT 233
US-10-751-736-11383
; Sequence 11383, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11383
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11383

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      419 AAGCTTTCCAAGTATGGAGTA 439
Db      1 AAGCTTTCCAAGTATGGAGTA 21

RESULT 234
US-10-751-736-11386
; Sequence 11386, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11386
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11386

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-751-736-11386
```

```

QY      455 AATTCAGCAAGATTAAACACAG 475
Db      1 AATTCAGCAAGATTAAACACAG 21

RESULT 235
US-10-751-736-11389
; Sequence 11389, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11389
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11389

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      642 AAAC TTGTTCTCTCACTGCTGT 662
Db      1 AAAC TTGTTCTCTCACTGCTGT 21

RESULT 236
US-10-751-736-11392
; Sequence 11392, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11392
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11392

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      808 AAAGAGAACCAACGCTTGCCA 828
Db      1 AAAGAGAACCAACGCTTGCCA 21

RESULT 237
US-10-751-736-11395
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11371
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11371

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1698 TAACATCCTTGGACTGAGAAA 1718
Db      1 TAACATCCTTGGACTGAGAAA 21

RESULT 229
US-10-751-736-11372
; Sequence 11372, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11372
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11372

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 65;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1700 ACATCCTTGGACTGAGAAATT 1720
Db      1 ACAUCCUUGGACUGAGAAAUU 21

RESULT 230
US-10-751-736-11374
; Sequence 11374, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11374
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11374

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1720 TATACCTACTTCTGGCATAAC 1740
Db      1 TATACCTACTTCTGGCATAAC 21

RESULT 231
US-10-751-736-11377
; Sequence 11377, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11377
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11377

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1722 TACTTACTTCTGGCATAACTA 1742
Db      1 TACTTACTTCTGGCATAACTA 21

RESULT 232
US-10-751-736-11380
; Sequence 11380, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11380
; LENGTH: 21
; TYPE: DNA
```





; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11344
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11344

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1407 TAGCTGGTTTGGTTGTAGAA 1427
|||||
Db 1 TAGCTGGTTTGGTTGTAGAA 21

RESULT 220
US-10-751-736-11347
; Sequence 11347, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11347
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11347

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1477 TATTGCATATTTGCTATGTC 1497
|||||
Db 1 TATTGCATATTTGCTATGTC 21

RESULT 221
US-10-751-736-11350
; Sequence 11350, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11350

; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11350
Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1484 TATTGCTATGCTCAGTGT 1504
|||||
Db 1 TATTGCTATGCTCAGTGT 21

RESULT 222
US-10-751-736-11353
; Sequence 11353, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11353
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11353

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1491 TATGTCCTCAGTGTAACCTA 1511
|||||
Db 1 TATGTCCTCAGTGTAACCTA 21

RESULT 223
US-10-751-736-11356
; Sequence 11356, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11356
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11356

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;

```
RESULT 215
US-10-751-736-11332
; Sequence 11332, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11332
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11332

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1327 TACTACTATTTCTTCCAAGGA 1347
Db      1 TACTACTATTTCTTCCAAGGA 21

RESULT 216
US-10-751-736-11335
; Sequence 11335, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11335
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11335

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1330 TACTATTTCTTCCAAGGATCT 1350
Db      1 TACTATTTCTTCCAAGGATCT 21

RESULT 217
US-10-751-736-11338
; Sequence 11338, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11338
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11338

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1333 TATTTCTTCCAAGGATCTAAC 1353
Db      1 TATTTCTTCCAAGGATCTAAC 21

RESULT 218
US-10-751-736-11341
; Sequence 11341, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11341
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11341

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1363 TATGACTTCCTTACTCCAACGT 1383
Db      1 TATGACTTCCTTACTCCAACGT 21

RESULT 219
US-10-751-736-11344
; Sequence 11344, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
```

Qy 1266 TACCAAGAACTTCCAAGGAAT 1286

```

; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11305
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11305

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1085 TAAGACCAGAGCCAAATTATC 1105
Db      1 TAAGACCAGAGCCAAATTATC 21

RESULT 207
US-10-751-736-11308
; Sequence 11308, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11308
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11308

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1180 TATAGGACCTACTTCTTTGTA 1200
Db      1 TATAGGACCTACTTCTTTGTA 21

RESULT 208
US-10-751-736-11311
; Sequence 11311, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```

; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11311
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11311

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1182 TAGGACCTACTTCTTTGTAGA 1202
Db      1 TAGGACCTACTTCTTTGTAGA 21

RESULT 209
US-10-751-736-11314
; Sequence 11314, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11314
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11314

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1189 TACTTCTTTGTAGATAACCAG 1209
Db      1 TACTTCTTTGTAGATAACCAG 21

RESULT 210
US-10-751-736-11317
; Sequence 11317, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```



US-10-751-736-11290

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 TACAAATATGTCGACATCAAC 750  
|||||

Db 1 TACAAATATGTCGACATCAAC 21

RESULT 202

US-10-751-736-11293

; Sequence 11293, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11293  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens

US-10-751-736-11293

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 736 TATGTCGACATCAACACATTT 756  
|||||

Db 1 TATGTCGACATCAACACATTT 21

RESULT 203

US-10-751-736-11296

; Sequence 11296, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11296  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens

US-10-751-736-11296

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 971 TAATTTCTTCTTATGGCAA 991

Db 1 TAATTTCTTCTTATGGCAA 21  
|||||

RESULT 204

US-10-751-736-11299

; Sequence 11299, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11299  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens

US-10-751-736-11299

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 983 TATGGCCAACTTGCCATCTG 1003  
|||||

Db 1 TATGGCCAACTTGCCATCTG 21

RESULT 205

US-10-751-736-11302

; Sequence 11302, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11302  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens

US-10-751-736-11302

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1077 TAGCAATTTAAGACCAGAGCC 1097  
|||||

Db 1 TAGCAATTTAAGACCAGAGCC 21

RESULT 206

US-10-751-736-11305

; Sequence 11305, Application US/10751736

; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11279  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-11279

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 76.2%; Pred. No. 65;  
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 470 ACACAGGCATGGCTGACATTT 490  
|||||:|:|:|:|:|:  
Db 1 ACACAGGCAUGGCUGACAUUU 21

RESULT 198

US-10-751-736-11281  
; Sequence 11281, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11281  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11281

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 699 TAGTGATCCAAAGGCTGTAAT 719  
|||||:|:|:|:|:|:  
Db 1 TAGTGATCCAAAGGCTGTAAT 21

RESULT 201

US-10-751-736-11290  
; Sequence 11290, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11290  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens

; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11284  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11284

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 683 TAGGTCTTGGCCATTCTAGTG 703  
|||||:|:|:|:|:|:  
Db 1 TAGGTCTTGGCCATTCTAGTG 21

RESULT 200

US-10-751-736-11287  
; Sequence 11287, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11287  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11287

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 699 TAGTGATCCAAAGGCTGTAAT 719  
|||||:|:~|:~|:~|:~|:  
Db 1 TAGTGATCCAAAGGCTGTAAT 21

RESULT 201

US-10-751-736-11290  
; Sequence 11290, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11290  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens

; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11279  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-11279

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 76.2%; Pred. No. 65;  
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 470 ACACAGGCATGGCTGACATTT 490  
|||||:|:~|:~|:~|:~|:  
Db 1 ACACAGGCAUGGCUGACAUUU 21

RESULT 198

US-10-751-736-11281  
; Sequence 11281, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11281  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11281

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 624 TACACATTCAGGAGGCACAAA 644  
|||||:|:~|:~|:~|:~|:  
Db 1 TACACATTCAGGAGGCACAAA 21

RESULT 199

US-10-751-736-11284  
; Sequence 11284, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

QY 177 TAGTGGAAACTTAATGAAGGA 197  
Db 1 TAGTGGAAACTTAATGAAGGA 21

RESULT 193

US-10-751-736-11269  
; Sequence 11269, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11269  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11269

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 369 TAATTACACACCTGACATGAA 389  
Db 1 TAATTACACACCTGACATGAA 21

RESULT 194

US-10-751-736-11272  
; Sequence 11272, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11272  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11272

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 373 TACACACCTGACATGAACCGT 393  
Db 1 TACACACCTGACATGAACCGT 21

RESULT 195

US-10-751-736-11275  
; Sequence 11275, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11275  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11275

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 406 TAGCAATCCGGAAGCTTTC 426  
Db 1 TAGCAATCCGGAAGCTTTC 21

RESULT 196

US-10-751-736-11278  
; Sequence 11278, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11278  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11278

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 468 TAACACAGGCATGGCTGACAT 488  
Db 1 TAACACAGGCATGGCTGACAT 21

RESULT 197

US-10-751-736-11279  
; Sequence 11279, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene

; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11254  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11254

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 96 TAATGTGCTATTGGTGAG 116  
| | | | | | | | | | | | | | | | | | | | |  
Db 1 TAATGTGCTATTGGTGAG 21

RESULT 189  
US-10-751-736-11257  
; Sequence 11257, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11257  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11257

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 104 TATTGGTGAGATACTTAG 124  
| | | | | | | | | | | | | | | | | | | | |  
Db 1 TATTGGTGAGATACTTAG 21

RESULT 190  
US-10-751-736-11260  
; Sequence 11260, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11260  
; LENGTH: 21

; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11260

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 133 TATGGCCTTGAGATAACAA 153  
| | | | | | | | | | | | | | | | | | | | |  
Db 1 TATGGCCTTGAGATAACAA 21

RESULT 191  
US-10-751-736-11263  
; Sequence 11263, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11263  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11263

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 146 TAAACAAACTTCCAGTGACAA 166  
| | | | | | | | | | | | | | | | | | | | |  
Db 1 TAAACAAACTTCCAGTGACAA 21

RESULT 192  
US-10-751-736-11266  
; Sequence 11266, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11266  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11266

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;





```
; SEQ ID NO 11230
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11230

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1263 GATTACCAAGAACTTCCAAGG 1283
Db 1 GATTACCAAGAACTTCCAAGG 21

RESULT 180
US-10-751-736-11233
; Sequence 11233, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11233
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11233

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GATGCAGTCTTCTATTCTAAA 1320
Db 1 GATGCAGTCTTCTATTCTAAA 21

RESULT 181
US-10-751-736-11236
; Sequence 11236, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11236
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11236

Query Match      1.2%; Score 21; DB 1; Length 21;
```

```
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1360 GAATATGACTTCCTACTCCAA 1380
Db 1 GAATATGACTTCCTACTCCAA 21

RESULT 182
US-10-751-736-11239
; Sequence 11239, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11239
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11239

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1366 GACTTCCTACTCCAAAGTATC 1386
Db 1 GACTTCCTACTCCAAAGTATC 21

RESULT 183
US-10-751-736-11242
; Sequence 11242, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11242
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11242

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1673 GAAGCATGCTCTGTAAAGTTGC 1693
Db 1 GAAGCATGCTCTGTAAAGTTGC 21
```

```

; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11218
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11218

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1201 GATAACCAAGTATTGGAGGTAT 1221
Db      1 GATAACCAAGTATTGGAGGTAT 21

RESULT 176
US-10-751-736-11221
; Sequence 11221, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11221
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11221

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1215 GAGGTATGATGAAAGGAGACA 1235
Db      1 GAGGTATGATGAAAGGAGACA 21

RESULT 177
US-10-751-736-11224
; Sequence 11224, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
```

```

; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11224
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11224

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1222 GATGAAAGGAGACAGATGATG 1242
Db      1 GATGAAAGGAGACAGATGATG 21

RESULT 178
US-10-751-736-11227
; Sequence 11227, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11227
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11227

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1225 GAAAGGAGACAGATGGAC 1245
Db      1 GAAAGGAGACAGATGGAC 21

RESULT 179
US-10-751-736-11230
; Sequence 11230, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
```

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 950 GACCAAGACCAGTGTAAAT 970  
Db 1 GACCAAGACCAGTGTAAAT 21

RESULT 171  
US-10-751-736-11206  
; Sequence 11206, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11206  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11206

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 GAAGCTGCTTATGAAATTGAA 1029  
Db 1 GAAGCTGCTTATGAAATTGAA 21

RESULT 172  
US-10-751-736-11209  
; Sequence 11209, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11209  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11209

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1021 GAAATTGAAGCCAGAAATCAA 1041  
Db 1 GAAATTGAAGCCAGAAATCAA 21

Db 1 GAAATTGAAGCCAGAAATCAA 21

RESULT 173  
US-10-751-736-11212  
; Sequence 11212, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11212  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11212

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1060 GACAAATACTGTTAATTAGC 1080  
Db 1 GACAAATACTGTTAATTAGC 21

RESULT 174  
US-10-751-736-11215  
; Sequence 11215, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11215  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11215

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1185 GACCTACTTCTTGTAGATAA 1205  
Db 1 GACCTACTTCTTGTAGATAA 21

RESULT 175  
US-10-751-736-11218  
; Sequence 11218, Application US/10751736  
; Publication No. US20040265230A1



```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11194
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11194

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      936 GAAGGTTTCTGAGAGACCAAA 956
      |||||
Db      1 GAAGGTTTCTGAGAGACCAAA 21

RESULT 167
US-10-751-736-11197
; Sequence 11197, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11197
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11197

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      946 GAGAGACCAAGACCAGTGTT 966
      |||||
Db      1 GAGAGACCAAGACCAGTGTT 21

RESULT 168
US-10-751-736-11200
; Sequence 11200, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11200
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11200

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      948 GAGACCAAGACCAGTGTTAA 968
      |||||
Db      1 GAGACCAAGACCAGTGTTAA 21

RESULT 169
US-10-751-736-11201
; Sequence 11201, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11201
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11201

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 65;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      950 GACCAAGACCAGTGTTAATT 970
      |||||
Db      1 GACCAAGACCAGUGUUAUU 21

RESULT 170
US-10-751-736-11203
; Sequence 11203, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11203
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11203
```

QY 772 GACATACGTGGCATTCAATCC 792  
Db 1 GACATACGTGGCATTCAATCC 21

RESULT 162

US-10-751-736-11182  
; Sequence 11182, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11182  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11182

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 811 GAGAACCAACGCTTGCCAAAT 831  
Db 1 GAGAACCAACGCTTGCCAAAT 21

RESULT 163

US-10-751-736-11185  
; Sequence 11185, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11185  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11185

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 813 GAACCAACGCTTGCCAAATCC 833  
Db 1 GAACCAACGCTTGCCAAATCC 21

RESULT 164

US-10-751-736-11188

; Sequence 11188, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11188  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11188

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 835 GACAATTCAAGAACGCTCTC 855  
Db 1 GACAATTCAAGAACGCTCTC 21

RESULT 165

US-10-751-736-11191  
; Sequence 11191, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11191  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11191

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 919 GACAGGTTCTTCTGGCTGAAG 939  
Db 1 GACAGGTTCTTCTGGCTGAAG 21

RESULT 166

US-10-751-736-11194  
; Sequence 11194, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei

;  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11167  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11167

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 GATTGGCCATTCTTAGGTCT 689  
Db 1 GATTGGCCATTCTTAGGTCT 21

RESULT 158  
US-10-751-736-11170  
; Sequence 11170, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11170  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11170

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 703 GATCCAAAGCGTGTAATGTC 723  
Db 1 GATCCAAAGCGTGTAATGTC 21

RESULT 159  
US-10-751-736-11173  
; Sequence 11173, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11173  
; LENGTH: 21  
; TYPE: DNA

;  
; ORGANISM: homo sapiens  
US-10-751-736-11173  
  
Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 742 GACATCAACACATTTCGCCTC 762  
Db 1 GACATCAACACATTTCGCCTC 21  
  
RESULT 160  
US-10-751-736-11176  
; Sequence 11176, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11176  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11176

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 769 GATGACATACGTGGCATTTCAG 789  
Db 1 GATGACATACGTGGCATTTCAG 21

RESULT 161  
US-10-751-736-11179  
; Sequence 11179, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11179  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11179

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
RESULT 153
US-10-751-736-11155
; Sequence 11155, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11155
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11155

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      613 GAATTCTGGACTACACATTCA 633
Db      1 GAATTCTGGACTACACATTCA 21

RESULT 154
US-10-751-736-11158
; Sequence 11158, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11158
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11158

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      621 GACTACACATTTCAGGAGGCAC 641
Db      1 GACTACACATTTCAGGAGGCAC 21

RESULT 155
US-10-751-736-11161
; Sequence 11161, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11161
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11161

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      635 GAGGCACAAACTGTTCCTCA 655
Db      1 GAGGCACAAACTGTTCCTCA 21

RESULT 156
US-10-751-736-11164
; Sequence 11164, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11164
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11164

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      667 GAGATTGGCCATTCCTTAGGT 687
Db      1 GAGATTGGCCATTCCTTAGGT 21

RESULT 157
US-10-751-736-11167
; Sequence 11167, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```



Matches	21;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

QY 604 GATGAGGACGAATTCTGGACT 624  
 |||||  
 Db 1 GATGAGGACGAATTCTGGACT 21

RESULT 151  
 US-10-751-736-11149  
 ; Sequence 11149, Application US/10751736  
 ; Publication No. US20040265230A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Martinez, Robert  
 ; APPLICANT: Brown, Eugene  
 ; APPLICANT: Liu, Wei  
 ; TITLE OF INVENTION: CANCERS  
 ; FILE REFERENCE: AM100927 (031896-002000)  
 ; CURRENT APPLICATION NUMBER: US/10/751,736  
 ; CURRENT FILING DATE: 2003-01-06  
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
 ; PRIOR FILING DATE: 2003-01-06  
 ; NUMBER OF SEQ ID NOS: 54873  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 11149  
 ; LENGTH: 21  
 ; TYPE: DNA  
 ; ORGANISM: homo sapiens  
 US-10-751-736-11149

Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;

QY 607 GAGGACGAATTCTGGACTACA 627  
 |||||  
 Db 1 GAGGACGAATTCTGGACTACA 21

RESULT 152  
 US-10-751-736-11152  
 ; Sequence 11152, Application US/10751736  
 ; Publication No. US20040265230A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Martinez, Robert  
 ; APPLICANT: Brown, Eugene  
 ; APPLICANT: Liu, Wei  
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
 ; TITLE OF INVENTION: CANCERS  
 ; FILE REFERENCE: AM100927 (031896-002000)  
 ; CURRENT APPLICATION NUMBER: US/10/751,736  
 ; CURRENT FILING DATE: 2003-01-06  
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
 ; PRIOR FILING DATE: 2003-01-06  
 ; NUMBER OF SEQ ID NOS: 54873  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 11152  
 ; LENGTH: 21  
 ; TYPE: DNA  
 ; ORGANISM: homo sapiens  
 US-10-751-736-11152

Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;

QY 610 GACGAATTCGGACTACACAT 630  
 |||||  
 Db 1 GACGAATTCGGACTACACAT 21

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11128
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11128

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      453 GAAATTGAGCAAGATTAAACAC 473
Db      1 GAAATTGAGCAAGATTAAACAC 21

RESULT 145
US-10-751-736-11131
; Sequence 11131, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11131
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11131

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      465 GATTAACACAGGCGTGTGA 485
Db      1 GATTAACACAGGCGTGTGA 21

RESULT 146
US-10-751-736-11134
; Sequence 11134, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
```

```
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11134
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11134

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      509 GAGCTCATGGAGACTTCCATG 529
Db      1 GAGCTCATGGAGACTTCCATG 21

RESULT 147
US-10-751-736-11137
; Sequence 11137, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11137
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11137

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      535 GATGGCAAAGGTGGAATCCTA 555
Db      1 GATGGCAAAGGTGGAATCCTA 21

RESULT 148
US-10-751-736-11140
; Sequence 11140, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11140
```

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 394 GAGGATGTTGACTACGCAATC 414  
Db 1 GAGGATGTTGACTACGCAATC 21

RESULT 140  
US-10-751-736-11119  
; Sequence 11119, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11119  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11119

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 397 GATGTTGACTACGCAATCCGG 417  
Db 1 GATGTTGACTACGCAATCCGG 21

RESULT 141  
US-10-751-736-11122  
; Sequence 11122, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11122  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11122

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 403 GACTACGCAATCCGGAAGCT 423  
Db 1 GACTACGCAATCCGGAAGCT 21

RESULT 142  
US-10-751-736-11123  
; Sequence 11123, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11123  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-11123

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 76.2%; Pred. No. 65;  
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 405 CTACGCAATCCGGAAGCTTT 425  
Db 1 CUACGCAAUCCGGAAGCUUU 21

RESULT 143  
US-10-751-736-11125  
; Sequence 11125, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11125  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11125

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GAAAGCTTTCGAAGTATGGAG 437  
Db 1 GAAAGCTTTCGAAGTATGGAG 21

RESULT 144  
US-10-751-736-11128  
; Sequence 11128, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:

; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11104  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11104

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 342 GAAACATTATATCACCTACAG 362  
|||||  
Db 1 GAAACATTATATCACCTACAG 21

RESULT 136  
US-10-751-736-11107  
; Sequence 11107, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11107  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11107

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 362 GAATCAATAATTACACACCTG 382  
|||||  
Db 1 GAATCAATAATTACACACCTG 21

RESULT 137  
US-10-751-736-11110  
; Sequence 11110, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11110  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11110

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 382 GACATGAACCGTGAGGATGTT 402  
|||||  
Db 1 GACATGAACCGTGAGGATGTT 21

RESULT 138  
US-10-751-736-11113  
; Sequence 11113, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11113  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11113

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 GAACCGTGAGGATGTTGACTA 407  
|||||  
Db 1 GAACCGTGAGGATGTTGACTA 21

RESULT 139  
US-10-751-736-11116  
; Sequence 11116, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11116  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11116



Db1GATAAACAACTTCCAGTGAC21

RESULT 131

US-10-751-736-11092

US-10-751-736-11092, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11092

LENGTH: 21

TYPE: DNA

ORGANISM: homo sapiens

US-10-751-736-11092

Query Match1.2%; Score 21; DB 1; Length 21;

Best Local Similarity100.0%; Pred. No. 65;

Matches21; Conservative0; Mismatches0; Indels0; Gaps0;

QY265GAGATGATGCACGCACCTCGA285

Db1GAGATGATGCACGCACCTCGA21

RESULT 132

US-10-751-736-11095

US-10-751-736-11095, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11095

LENGTH: 21

TYPE: DNA

ORGANISM: homo sapiens

US-10-751-736-11095

Query Match1.2%; Score 21; DB 1; Length 21;

Best Local Similarity100.0%; Pred. No. 65;

Matches21; Conservative0; Mismatches0; Indels0; Gaps0;

QY267GATGATGCACGCACCTCGATG287

Db1GATGATGCACGCACCTCGATG21

RESULT 133

US-10-751-736-11098

US-10-751-736-11098, Application US/10751736

Sequence 11098, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11098

LENGTH: 21

TYPE: DNA

ORGANISM: homo sapiens

US-10-751-736-11098

Query Match1.2%; Score 21; DB 1; Length 21;

Best Local Similarity100.0%; Pred. No. 65;

Matches21; Conservative0; Mismatches0; Indels0; Gaps0;

QY270GATGCACGCACCTCGATGCG290

Db1GATGCACGCACCTCGATGCG21

RESULT 134

US-10-751-736-11101

US-10-751-736-11101, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11101

LENGTH: 21

TYPE: DNA

ORGANISM: homo sapiens

US-10-751-736-11101

Query Match1.2%; Score 21; DB 1; Length 21;

Best Local Similarity100.0%; Pred. No. 65;

Matches21; Conservative0; Mismatches0; Indels0; Gaps0;

QY339GAGGAAACATTATATCACCTA359

Db1GAGGAAACATTATATCACCTA21

RESULT 135

US-10-751-736-11104

US-10-751-736-11104, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11104

LENGTH: 21

TYPE: DNA

ORGANISM: homo sapiens

US-10-751-736-11104

Query Match1.2%; Score 21; DB 1; Length 21;

Best Local Similarity100.0%; Pred. No. 65;

Matches21; Conservative0; Mismatches0; Indels0; Gaps0;

QY339GAGGAAACATTATATCACCTA359

Db1GAGGAAACATTATATCACCTA21

```

; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11077
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11077

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1701 CATCCTTGGACTGAGAAATTA 1721
      |||||||
Db      1 CATCCTTGGACTGAGAAATTA 21

RESULT 127
US-10-751-736-11080
; Sequence 11080, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11080
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11080

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      15 GAAGTTTCTTCTTAATCTGCT 35
      |||||||
Db      1 GAAGTTTCTTCTTAATCTGCT 21

RESULT 128
US-10-751-736-11083
; Sequence 11083, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11083
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens

```

```

US-10-751-736-11083

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      69 GAACAGCTCTACAAGCCTGGA 89
      |||||||
Db      1 GAACAGCTCTACAAGCCTGGA 21

RESULT 129
US-10-751-736-11086
; Sequence 11086, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11086
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11086

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      142 GAGATAAACAAACTTCCAGTG 162
      |||||||
Db      1 GAGATAAACAAACTTCCAGTG 21

RESULT 130
US-10-751-736-11089
; Sequence 11089, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11089
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11089

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      144 GATAAACAAACTTCCAGTGAC 164

```

```
US-10-751-736-11068
; Sequence 11068, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11068
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11068

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1507 CACTACTTAGAGATATGTATC 1527
Db 1 CACTACTTAGAGATATGTATC 21

RESULT 123
US-10-751-736-11071
; Sequence 11071, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11071
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11071

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1608 CATTCTTGCTTGACTCTACTA 1628
Db 1 CATTCTTGCTTGACTCTACTA 21

RESULT 124
US-10-751-736-11072
; Sequence 11072, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
```

```
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11072
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11072

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 65;
Matches 10; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

QY 1610 TTCTTGCTTGACTCTACTATT 1630
Db 1 UUCUGGCUUGACUCUACUAAU 21

RESULT 125
US-10-751-736-11074
; Sequence 11074, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11074
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11074

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1677 CATGCTCTGTAAGTTGCTTCC 1697
Db 1 CATGCTCTGTAAGTTGCTTCC 21

RESULT 126
US-10-751-736-11077
; Sequence 11077, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
```

```
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11053

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1269 CAAGAACTTCCAAGGAATCGG 1289
Db      1 CAAGAACTTCCAAGGAATCGG 21

RESULT 118
US-10-751-736-11056
; Sequence 11056, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11056
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11056

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1342 CAAGGATCTAACCATTGAA 1362
Db      1 CAAGGATCTAACCATTGAA 21

RESULT 119
US-10-751-736-11059
; Sequence 11059, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11059
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11059

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1404 CAATAGCTGGTTGGTTGTTA 1424
Db      1 CAATAGCTGGTTGGTTGTTA 21

RESULT 120
US-10-751-736-11062
; Sequence 11062, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11062
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11062

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1482 CATATTTGCTATGTCCTCAGT 1502
Db      1 CATATTTGCTATGTCCTCAGT 21

RESULT 121
US-10-751-736-11065
; Sequence 11065, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11065
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11065

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1499 CAGTGTAACCACTACTTAGAGA 1519
Db      1 CAGTGTAACCACTACTTAGAGA 21

RESULT 122
```



```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11044
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11044

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1080 CAATTGAAGACCAGAGCCAAA 1100
Db      1 CAATTGAAGACCAGAGCCAAA 21

RESULT 114
US-10-751-736-11045
; Sequence 11045, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11045
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11045

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 65;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1082 ATTTAAGACCAGAGCCAAATT 1102
Db      1 AUUUAAGACCAGAGCCAAAUU 21

RESULT 115
US-10-751-736-11047
; Sequence 11047, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11047
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11047

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1207 CAGTATTGGAGGTATGATGAA 1227
Db      1 CAGTATTGGAGGTATGATGAA 21

RESULT 116
US-10-751-736-11050
; Sequence 11050, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11050
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11050

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1257 CAAACTGATTACCAAGAACTT 1277
Db      1 CAAACTGATTACCAAGAACTT 21

RESULT 117
US-10-751-736-11053
; Sequence 11053, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11053
; LENGTH: 21
```

```
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 921 CAGGTTCTTCTGGCTGAAGGT 941
Db 1 CAGGTTCTTCTGGCTGAAGGT 21

RESULT 109
US-10-751-736-11033
; Sequence 11033, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11033
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11033

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 65;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 923 GGTTCCTTCTGGCTGAAGGTTT 943
Db 1 GGUUCUUCUGGUGAAGGUUU 21

RESULT 110
US-10-751-736-11035
; Sequence 11035, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11035
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11035

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 989 CAACCTTGCCATCTGGCATTG 1009
Db 1 CAACCTTGCCATCTGGCATTG 21
```

```
RESULT 111
US-10-751-736-11038
; Sequence 11038, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11038
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11038

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 998 CATCTGGCATTGAAGCTGCTT 1018
Db 1 CATCTGGCATTGAAGCTGCTT 21

RESULT 112
US-10-751-736-11041
; Sequence 11041, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11041
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11041

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1005 CATTGAAGCTGCTTATGAAAT 1025
Db 1 CATTGAAGCTGCTTATGAAAT 21

RESULT 113
US-10-751-736-11044
; Sequence 11044, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11020  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11020

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 827 CAAATCCTGACAATTTCAGAAC 847  
Db 1 CAAATCCTGACAATTTCAGAAC 21

RESULT 105

US-10-751-736-11023  
; Sequence 11023, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11023  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11023

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 837 CAAATCAGAACAGCTCTCTG 857  
Db 1 CAAATCAGAACAGCTCTCTG 21

RESULT 106

US-10-751-736-11026  
; Sequence 11026, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 11026  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11026

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 842 CAGAACAGCTCTCTGTGACC 862  
Db 1 CAGAACAGCTCTCTGTGACC 21

RESULT 107

US-10-751-736-11029  
; Sequence 11029, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11029  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11029

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 915 CAAAGACAGGTTCTTCTGGCT 935  
Db 1 CAAAGACAGGTTCTTCTGGCT 21

RESULT 108

US-10-751-736-11032  
; Sequence 11032, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11032  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11032

Query Match 1.2%; Score 21; DB 1; Length 21;

Db 1 CATCAACACATTTCGCCCTCTC 21

RESULT 100

US-10-751-736-11008

; Sequence 11008, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10/751,736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 11008

; LENGTH: 21

; TYPE: DNA

; ORGANISM: homo sapiens

US-10-751-736-11008

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 747 CAACACATTTCGCCCTCTCTGC 767

Db 1 CAACACATTTCGCCCTCTCTGC 21

RESULT 101

US-10-751-736-11011

; Sequence 11011, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10/751,736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 11011

; LENGTH: 21

; TYPE: DNA

; ORGANISM: homo sapiens

US-10-751-736-11011

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CACATTTCGCCCTCTCTGCTGA 770

Db 1 CACATTTCGCCCTCTCTGCTGA 21

RESULT 102

US-10-751-736-11014

; Sequence 11014, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10/751,736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 11014

; LENGTH: 21

; TYPE: DNA

; ORGANISM: homo sapiens

US-10-751-736-11014

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 752 CATTCGCCCTCTCTGCTGATG 772

Db 1 CATTCGCCCTCTCTGCTGATG 21

RESULT 103

US-10-751-736-11017

; Sequence 11017, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10/751,736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 11017

; LENGTH: 21

; TYPE: DNA

; ORGANISM: homo sapiens

US-10-751-736-11017

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 817 CAACGCTTGCCAAATCCTGAC 837

Db 1 CAACGCTTGCCAAATCCTGAC 21

RESULT 104

US-10-751-736-11020

; Sequence 11020, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10751736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 11017

; LENGTH: 21

; TYPE: DNA

; ORGANISM: homo sapiens

US-10-751-736-11017

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;



```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10993
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10993

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      676 CATTCTTAGGCTCTGGCCAT 696
Db      1 CATTCTTAGGCTCTGGCCAT 21

RESULT 96
US-10-751-736-10996
; Sequence 10996, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10996
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10996

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      694 CATTCTAGTGATCCAAAGGCT 714
Db      1 CATTCTAGTGATCCAAAGGCT 21

RESULT 97
US-10-751-736-10999
; Sequence 10999, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10999
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10999
```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      726 CACCTACAAATATGTCGACAT 746
Db      1 CACCTACAAATATGTCGACAT 21

RESULT 98
US-10-751-736-11002
; Sequence 11002, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11002
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11002

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      732 CAAATATGTCGACATCAACAC 752
Db      1 CAAATATGTCGACATCAACAC 21

RESULT 99
US-10-751-736-11005
; Sequence 11005, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11005
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11005

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      744 CATCAACACATTTGCGCTCTC 764
Db      1 CATCAACACATTTGCGCTCTC 764
```

```
; Sequence 10984, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10984
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10984

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      641 CAAACTTGTTCTCTCACTGCTG 661
Db      1 CAAACTTGTTCTCTCACTGCTG 21

RESULT 92
US-10-751-736-10985
; Sequence 10985, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10985
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10985

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 65;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      643 AACTTGTTCTCTCACTGCTGTT 663
Db      1 AACUUGUCCUCACUGCUGUU 21

RESULT 93
US-10-751-736-10987
; Sequence 10987, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
```

```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10987
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10987

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      654 CACTGCTGTTCCACGAGATTGG 674
Db      1 CACTGCTGTTCCACGAGATTGG 21

RESULT 94
US-10-751-736-10990
; Sequence 10990, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10990
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10990

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      664 CACGAGATTGGCCATTCTTA 684
Db      1 CACGAGATTGGCCATTCTTA 21

RESULT 95
US-10-751-736-10993
; Sequence 10993, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```

; ORGANISM: homo sapiens
US-10-751-736-10972

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      626 CACATTCAGGAGGCACAAACT 646
Db      1 CACATTCAGGAGGCACAAACT 21

RESULT 87
US-10-751-736-10975
; Sequence 10975, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10975
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10975

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      628 CATTGAGGAGGCACAACTTG 648
Db      1 CATTGAGGAGGCACAACTTG 21

RESULT 88
US-10-751-736-10976
; Sequence 10976, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10976
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10976

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 65;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      630 TTCAGGAGGCACAACTTGTT 650
Db      1 UUCAGGAGGCACAAACUUGUU 21

RESULT 89
US-10-751-736-10978
; Sequence 10978, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10978
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10978

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      632 CAGGAGGCACAACTTGTTCC 652
Db      1 CAGGAGGCACAACTTGTTCC 21

RESULT 90
US-10-751-736-10981
; Sequence 10981, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10981
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10981

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      639 CACAAACTTGTTCTCACTGC 659
Db      1 CACAAACTTGTTCTCACTGC 21

RESULT 91
US-10-751-736-10984

```

```

; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10960
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10960

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      459 CAGCAAGATTAAACACAGGCAT 479
Db      1 CAGCAAGATTAAACACAGGCAT 21

RESULT 83
US-10-751-736-10963
; Sequence 10963, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10963
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10963

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      462 CAAGATTAAACACAGGCATGCC 482
Db      1 CAAGATTAAACACAGGCATGCC 21

RESULT 84
US-10-751-736-10966
; Sequence 10966, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10966
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10966

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      596 CACATTTTCGATGAGGACGAAT 616
Db      1 CACATTTTCGATGAGGACGAAT 21

RESULT 85
US-10-751-736-10969
; Sequence 10969, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10969
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10969

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      598 CATTTCGATGAGGACGAATTC 618
Db      1 CATTTCGATGAGGACGAATTC 21

RESULT 86
US-10-751-736-10972
; Sequence 10972, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10972
; LENGTH: 21
; TYPE: DNA
```



```
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 375 CACACCTGACATGAACCGTGA 395
Db 1 CACACCTGACATGAACCGTGA 21

RESULT 78
US-10-751-736-10948
; Sequence 10948, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10948
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10948

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 377 CACCTGACATGAACCGTGAGG 397
Db 1 CACCTGACATGAACCGTGAGG 21

RESULT 79
US-10-751-736-10951
; Sequence 10951, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10951
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10951

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 384 CATGAACCGTGAGGATGTTGA 404
Db 1 CATGAACCGTGAGGATGTTGA 21
```

```
RESULT 80
US-10-751-736-10954
; Sequence 10954, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10954
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10954

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 410 CAATCCGGAAAGCTTTCCAAG 430
Db 1 CAATCCGGAAAGCTTTCCAAG 21

RESULT 81
US-10-751-736-10957
; Sequence 10957, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10957
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10957

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 427 CAAGTATGGAGTAATGTTACC 447
Db 1 CAAGTATGGAGTAATGTTACC 21

RESULT 82
US-10-751-736-10960
; Sequence 10960, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10933  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10933

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 CAGCACCTCGATGTGGAGTC 294  
|||||  
Db 1 CAGCACCTCGATGTGGAGTC 21

RESULT 74

US-10-751-736-10936  
; Sequence 10936, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10936  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10936

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 346 CATTATATCACCTACAGAATC 366  
|||||  
Db 1 CATTATATCACCTACAGAATC 21

RESULT 75

US-10-751-736-10939  
; Sequence 10939, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10939

; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10939

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 360 CAGAATCAATAATTACACACC 380  
|||||  
Db 1 CAGAATCAATAATTACACACC 21

RESULT 76

US-10-751-736-10942  
; Sequence 10942, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10942  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10942

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 366 CAATAATTACACACCTGACAT 386  
|||||  
Db 1 CAATAATTACACACCTGACAT 21

RESULT 77

US-10-751-736-10945  
; Sequence 10945, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10945  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10945

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;

```
RESULT 69
US-10-751-736-10921
; Sequence 10921, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10921
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10921

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1699 AACATCCTTGGACTGAGAAAT 1719
Db      1 AACATCCTTGGACTGAGAAAT 21

RESULT 70
US-10-751-736-10924
; Sequence 10924, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10924
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10924

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      40 CAGGCCACTGCTTCTGGAGCT 60
Db      1 CAGGCCACTGCTTCTGGAGCT 21

RESULT 71
US-10-751-736-10927
; Sequence 10927, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10927
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10927

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      45 CACTGCTTCTGGAGCTCTTCC 65
Db      1 CACTGCTTCTGGAGCTCTTCC 21

RESULT 72
US-10-751-736-10930
; Sequence 10930, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10930
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10930

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      205 CAAGAAATGCAGCACTTCTTG 225
Db      1 CAAGAAATGCAGCACTTCTTG 21

RESULT 73
US-10-751-736-10933
; Sequence 10933, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
```

```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10906
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10906

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1601 AATTGTCATTCTTGTGAC 1621
Db      1 AATTGTCATTCTTGTGAC 21

RESULT 65
US-10-751-736-10909
; Sequence 10909, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10909
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10909

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1640 AATAGTTACCTTCAAGCAAG 1660
Db      1 AATAGTTACCTTCAAGCAAG 21

RESULT 66
US-10-751-736-10912
; Sequence 10912, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10912
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10912
```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1663 AATTCTATTGAAGCATGCTC 1683
Db      1 AATTCTATTGAAGCATGCTC 21

RESULT 67
US-10-751-736-10915
; Sequence 10915, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10915
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10915

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1674 AAGCATGCTCTGTAAGTTGCT 1694
Db      1 AAGCATGCTCTGTAAGTTGCT 21

RESULT 68
US-10-751-736-10918
; Sequence 10918, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10918
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10918

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1687 AAGTTGCTTCCTAACATCCTT 1707
Db      1 AAGTTGCTTCCTAACATCCTT 21
```



```
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10897
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-751-736-10897

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1401 AAGCAATAGCTGGTTGGTTG 1421
      |||||
Db      1 AAGCAATAGCTGGTTGGTTG 21

RESULT 61
US-10-751-736-10898
; Sequence 10898, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10898
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
; US-10-751-736-10898

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 65;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      1403 GCAATAGCTGGTTGGTTGTT 1423
      |||||
Db      1 GCAAUAGCUGGUUGGUUGUU 21

RESULT 62
US-10-751-736-10900
; Sequence 10900, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10900
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-751-736-10900

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1405 AATAGCTGGTTGGTTGTTAG 1425
      |||||
Db      1 AATAGCTGGTTGGTTGTTAG 21

RESULT 63
US-10-751-736-10903
; Sequence 10903, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10903
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-751-736-10903

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1595 AACTCTAATTGCCATTCTTG 1615
      |||||
Db      1 AACTCTAATTGCCATTCTTG 21

RESULT 64
US-10-751-736-10906
; Sequence 10906, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

US-10-751-736-10882

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1258 AAAGTATTACCAAGAACTTC 1278  
|||||  
Db 1 AAAGTATTACCAAGAACTTC 21

RESULT 56  
US-10-751-736-10885  
; Sequence 10885, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10885  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10885

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1259 AAAGTATTACCAAGAACTTCC 1279  
|||||  
Db 1 AAAGTATTACCAAGAACTTCC 21

RESULT 57  
US-10-751-736-10888  
; Sequence 10888, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10888  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10888

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1296 AATTGATGCAGTCTTCTATTC 1316

Db 1 AATTGATGCAGTCTTCTATTC 21  
|||||

RESULT 58  
US-10-751-736-10891  
; Sequence 10891, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10891  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10891

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1361 AATATGACTTCCTACTCCAAC 1381  
|||||  
Db 1 AATATGACTTCCTACTCCAAC 21

RESULT 59  
US-10-751-736-10894  
; Sequence 10894, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10894  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10894

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1400 AAAGCAATAGCTGGTTTGGTT 1420  
|||||  
Db 1 AAAGCAATAGCTGGTTTGGTT 21

RESULT 60  
US-10-751-736-10897  
; Sequence 10897, Application US/10751736

; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10870  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10870

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1081 AATTAAAGACCAGGCCAAAT 1101  
Db 1 AATTAAAGACCAGGCCAAAT 21

RESULT 52

US-10-751-736-10873  
; Sequence 10873, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10873  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10873

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1086 AAGACCAGAGCCAAATTATCC 1106  
Db 1 AAGACCAGAGCCAAATTATCC 21

RESULT 53

US-10-751-736-10876  
; Sequence 10876, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10876  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10876

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1204 AACCAGTATTGGAGGTATGAT 1224  
Db 1 AACCAGTATTGGAGGTATGAT 21

RESULT 54

US-10-751-736-10879  
; Sequence 10879, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10879  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10879

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1226 AAAGGAGACAGATGATGGACC 1246  
Db 1 AAAGGAGACAGATGATGGACC 21

RESULT 55

US-10-751-736-10882  
; Sequence 10882, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10882  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens

QY	1010	AAGCTGCTTATGAATTGAAG	1030
Db	1	AAGCTGCTTATGAATTGAAG	21
RESULT 47			
US-10-751-736-10864			
; Sequence 10864, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT APPLICATION NUMBER: US/10/751,736			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: PatentIn version 3.2			
; SEQ ID NO 10864			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-10864			
Query Match 1.2%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 65;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1022	AAATTGAAGCCAGAAATCAAG	1042
Db	1	AAATTGAAGCCAGAAATCAAG	21
RESULT 48			
US-10-751-736-10865			
; Sequence 10865, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT APPLICATION NUMBER: US/10/751,736			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: PatentIn version 3.2			
; SEQ ID NO 10865			
; LENGTH: 21			
; TYPE: RNA			
; ORGANISM: RNAl			
US-10-751-736-10865			
Query Match 1.2%; Score 21; DB 1; Length 21;			
Best Local Similarity 76.2%; Pred. No. 65;			
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;			
QY	1024	ATTGAAGCCAGAAATCAAGTT	1044
Db	1	AUUGAAGCCAGAAAUCAAGUU	21
RESULT 49			



```

; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10849
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10849

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      917 AAGACAGGTTCTTCTGGCTGA 937
Db      1 AAGACAGGTTCTTCTGGCTGA 21

RESULT 43
US-10-751-736-10852
; Sequence 10852, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10852
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10852

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      937 AAGGTTTCTGAGAGACCAAAG 957
Db      1 AAGGTTTCTGAGAGACCAAAG 21

RESULT 44
US-10-751-736-10855
; Sequence 10855, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10855
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10855
```

```

; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10855

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      972 AATTTCCTTCCTTATGGCCAAC 992
Db      1 AATTTCCTTCCTTATGGCCAAC 21

RESULT 45
US-10-751-736-10858
; Sequence 10858, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10858
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10858

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      990 AACCTTGCCATCTGGCATTGA 1010
Db      1 AACCTTGCCATCTGGCATTGA 21

RESULT 46
US-10-751-736-10861
; Sequence 10861, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10861
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10861

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
RESULT 38
US-10-751-736-10837
; Sequence 10837, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10837
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10837

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      828 AATCCTGACAATTGAGAACC 848
      |||
Db      1 AATCCTGACAATTGAGAACC 21

RESULT 39
US-10-751-736-10840
; Sequence 10840, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10840
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10840

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      829 AATCCTGACAATTGAGAACC 849
      |||
Db      1 AATCCTGACAATTGAGAACC 21

RESULT 40
US-10-751-736-10843
; Sequence 10843, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10843
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10843

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      838 AATTCAGAACCGTCTCTGT 858
      |||
Db      1 AATTCAGAACCGTCTCTGT 21

RESULT 41
US-10-751-736-10846
; Sequence 10846, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10846
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10846

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      916 AAAGACAGGTTCTTCTGGCTG 936
      |||
Db      1 AAAGACAGGTTCTTCTGGCTG 21

RESULT 42
US-10-751-736-10849
; Sequence 10849, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```
; SEQ ID NO 10822
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10822

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      748 AACACATTTCGCCTCTCTGCT 768
Db      1 AACACATTTCGCCTCTCTGCT 21

RESULT 34
US-10-751-736-10825
; Sequence 10825, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10825
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10825

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      808 AAAGAGAACCAACGCTTGCCA 828
Db      1 AAAGAGAACCAACGCTTGCCA 21

RESULT 35
US-10-751-736-10828
; Sequence 10828, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10828
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10828

Query Match      1.2%; Score 21; DB 1; Length 21;
```

```
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      809 AAGAGAACCAACGCTTGCCAA 829
Db      1 AAGAGAACCAACGCTTGCCAA 21

RESULT 36
US-10-751-736-10831
; Sequence 10831, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10831
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10831

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      814 AACCAACGCTTGCCAAATCCT 834
Db      1 AACCAACGCTTGCCAAATCCT 21

RESULT 37
US-10-751-736-10834
; Sequence 10834, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10834
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10834

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      818 AACGCTTGCCAAATCCTGACA 838
Db      1 AACGCTTGCCAAATCCTGACA 21
```





Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 469 AACACAGGCGTGGCTGACATT 489  
|||||

Db 1 AACACAGGCGTGGCTGACATT 21

RESULT 25  
US-10-751-736-10805  
; Sequence 10805, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10805  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: Rnai  
US-10-751-736-10805

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 71.4%; Pred. No. 65;  
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 471 CACAGGCGTGGCTGACATTTT 491  
|||||

Db 1 CACAGGCGTGGCTGACATTTT 21

RESULT 26  
US-10-751-736-10807  
; Sequence 10807, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; PRIOR FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10807  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10807

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 614 AATTCTGGACTACACATTCAG 634  
|||||

Db 1 AATTCTGGACTACACATTCAG 21

RESULT 27  
US-10-751-736-10810  
; Sequence 10810, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10810  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10810

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 642 AAACCTGTTCTCACTGCTGT 662  
|||||

Db 1 AAACCTGTTCTCACTGCTGT 21

RESULT 28  
US-10-751-736-10813  
; Sequence 10813, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10813  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-10813

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 643 AAACCTGTTCTCACTGCTGT 663  
|||||

Db 1 AAACCTGTTCTCACTGCTGT 21

RESULT 29  
US-10-751-736-10816  
; Sequence 10816, Application US/10751736  
; Publication No. US20040265230A1

```

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10792
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10792

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 AAAGCTTTCCCAAGTATGGAGT 438
Db 1 AAAGCTTTCCCAAGTATGGAGT 21

RESULT 21
US-10-751-736-10795
; Sequence 10795, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10795
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10795

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 AAGCTTTCCCAAGTATGGAGTA 439
Db 1 AAGCTTTCCCAAGTATGGAGTA 21

RESULT 22
US-10-751-736-10798
; Sequence 10798, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10798
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10798

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 AATTCAGCAAGATTAAACACAG 475
Db 1 AATTCAGCAAGATTAAACACAG 21

RESULT 23
US-10-751-736-10801
; Sequence 10801, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10801
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10801

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 463 AAGATTAAACACAGGCATGGCT 483
Db 1 AAGATTAAACACAGGCATGGCT 21

RESULT 24
US-10-751-736-10804
; Sequence 10804, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10804
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10804
```

QY 206 AAGAAATGCAGCACTTCTTGG 226  
|||  
pb 1 AAGAAATGCAGCACTTCTTGG 21

## RESULT 16

```

US-10-751-736-10780
; Sequence 10780, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10780
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10780

```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 367 AATAATTACACACCTGACATG 387  
|||  
pb 1 AATAATTACACACCTGACATG 21

## RESULT 17

```

RESOLUTION 17
US-10-751-736-10783
; Sequence 10783, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10783
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10783

```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 370 AATTACACACCTGACATGAAC 390  
|||||  
pb 1 AATTACACACCTGACATGAAC 21

RESULT 18  
US-10-751-736-10786

```

; Sequence 10786, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10786
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-751-736-10786

```

```
Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 388 AACCGTGAGGATGTTGACTAC 408  
pb 1 AACCGTGAGGATGTTGACTAC 21

## RESULT 19

```

US-10-751-736-10789
; Sequence 10789, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10789
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10789

```

Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches 21;	Conservative	0;	Mismatches	0;
			Indels	0;
			Gaps	0;

Qy 411 AATCCGGAAGCTTTCCAAGT 431  
|||  
nb 1 AATCCGGAAGCTTTCCAAGT 21

## RESULT 20

RESOLUT 20  
US-10-751-736-10792  
; Sequence 10792, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10765
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10765

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 AATGTGCTATTTGGTGAGAGA 117
| | | | | | | | | | | | | | | | | | | | |
Db 1 AATGTGCTATTTGGTGAGAGA 21

RESULT 12
US-10-751-736-10768
; Sequence 10768, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10768
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10768

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 147 AAACAAACTTCCACTGACAAA 167
| | | | | | | | | | | | | | | | | | | | |
Db 1 AAACAAACTTCCACTGACAAA 21

RESULT 13
US-10-751-736-10771
; Sequence 10771, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10771
; LENGTH: 21
; TYPE: DNA

; ORGANISM: homo sapiens
US-10-751-736-10771
Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 200 AAATCCAAGAAATGCAGCACT 220
| | | | | | | | | | | | | | | | | | | | |
Db 1 AAATCCAAGAAATGCAGCACT 21
RESULT 14
US-10-751-736-10774
; Sequence 10774, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10774
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10774

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 201 AATCCAAGAAATGCAGCACTT 221
| | | | | | | | | | | | | | | | | | | | |
Db 1 AATCCAAGAAATGCAGCACTT 21

RESULT 15
US-10-751-736-10777
; Sequence 10777, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10777
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10777

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;



```
RESULT 7
US-10-751-736-10753
; Sequence 10753, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10753
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10753

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      16 AAGTTTCTTCTAATACTGCTC 36
Db      1 AAGTTTCTTCTAATACTGCTC 21

RESULT 8
US-10-751-736-10756
; Sequence 10756, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10756
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10756

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      27 AATACTGCTCCTGCAGGCCAC 47
Db      1 AATACTGCTCCTGCAGGCCAC 21

RESULT 9
US-10-751-736-10759
; Sequence 10759, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10759
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10759

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      70 AACAGCTCTACAAGCCTGGAA 90
Db      1 AACAGCTCTACAAGCCTGGAA 21

RESULT 10
US-10-751-736-10762
; Sequence 10762, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10762
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10762

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      94 AATAATGTGCTATTGGTGAG 114
Db      1 AATAATGTGCTATTGGTGAG 21

RESULT 11
US-10-751-736-10765
; Sequence 10765, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```

; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(24)
; OTHER INFORMATION: SEQ ID NO. 20; MMP-12 forward primer
US-10-619-906-20

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1366 GACTTCCTACTCCACGATATCACC 1389
Db      1 GACTTCCTACTCCACGATATCACC 24

RESULT 3
US-10-619-906-21/c
; Sequence 21, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(24)
; OTHER INFORMATION: SEQ ID NO. 21; MMP-12 reverse primer
US-10-619-906-21

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1692 GCTTCCTAACATCCTTGGACTGAG 1715
Db      24 GCTTCCTAACATCCTTGGACTGAG 1

RESULT 4
US-10-872-063-161/c
; Sequence 161, Application US/10872063
; Publication No. US20050079518A1
; GENERAL INFORMATION:
; APPLICANT: BAKER, Joffre
; APPLICANT: BRYANT, John L.
; APPLICANT: PAIK, Soonmyung
; APPLICANT: SHAK, Steven
; TITLE OF INVENTION: Prediction of Likelihood of Cancer
; FILE REFERENCE: 39740-0012 US
; CURRENT APPLICATION NUMBER: US/10/872,063
; CURRENT FILING DATE: 2004-06-17
; PRIOR APPLICATION NUMBER: US 60/482,339
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer-probe
US-10-872-063-161
```

```

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      870 GAGTTTGTGATGCTGTCACTACCGT 893
Db      24 GAGTTTGTGATGCTGTCACTACCGT 1

RESULT 5
US-10-872-063-162
; Sequence 162, Application US/10872063
; Publication No. US20050079518A1
; GENERAL INFORMATION:
; APPLICANT: BAKER, Joffre
; APPLICANT: BRYANT, John L.
; APPLICANT: PAIK, Soonmyung
; APPLICANT: SHAK, Steven
; TITLE OF INVENTION: Prediction of Likelihood of Cancer
; FILE REFERENCE: 39740-0012 US
; CURRENT APPLICATION NUMBER: US/10/872,063
; CURRENT FILING DATE: 2004-06-17
; PRIOR APPLICATION NUMBER: US 60/482,339
; PRIOR FILING DATE: 2003-06-24
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 162
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer-probe
US-10-872-063-162

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      845 AACCAAGCTCTCTGTGACCCCAATT 868
Db      1 AACCAAGCTCTCTGTGACCCCAATT 24

RESULT 6
US-10-719-900-174229
; Sequence 174229, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 174229
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-174229

Query Match      1.3%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 65;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1290 GCCTAAATTTGATGCAGTCTTCTA 1313
Db      2 GCCTAAATTTGATGCAGTCTTCTA 25
```

545 14.8 0.8 1 US-10-251-598-193 Sequence 193, App  
c 546 14.8 0.8 1 US-10-388-263-57 Sequence 57, Appl  
c 547 14.8 0.8 1 US-10-698-689-57 Sequence 57, Appl  
548 14.8 0.8 1 US-10-698-689-221 Sequence 221, App  
c 549 14.8 0.8 1 US-10-830-475-57 Sequence 57, Appl  
c 550 14.8 0.8 1 US-10-649-467-57 Sequence 57, Appl  
c 551 14.6 0.8 21 US-10-751-736-10778 Sequence 10778, A  
552 14.4 0.8 1 US-09-866-108-8638 Sequence 8638, Ap  
553 14.4 0.8 17 US-09-866-108-8639 Sequence 8639, Ap  
c 554 14.4 0.8 17 US-09-866-108-10431 Sequence 10431, A  
c 555 14.4 0.8 17 US-09-866-108-10433 Sequence 10433, A  
c 556 14.4 0.8 17 US-09-780-533A-479 Sequence 479, App  
557 14.4 0.8 17 US-09-780-533A-554 Sequence 554, App  
c 558 14.4 0.8 17 US-09-780-533A-1343 Sequence 1343, Ap  
559 14.4 0.8 17 US-09-780-533A-1422 Sequence 1422, Ap  
560 14.4 0.8 17 US-09-927-046-160 Sequence 160, App  
561 14.4 0.8 17 US-09-740-332-2114 Sequence 2114, Ap  
562 14.4 0.8 17 US-09-817-879-2114 Sequence 2114, Ap  
563 14.4 0.8 17 US-10-156-306-526 Sequence 526, App  
564 14.4 0.8 17 US-10-156-306-527 Sequence 527, App  
c 565 14.4 0.8 17 US-10-138-674-1826 Sequence 1826, Ap  
c 566 14.4 0.8 17 US-10-287-949A-1826 Sequence 1826, Ap  
567 14.4 0.8 17 US-10-712-672-382 Sequence 382, App  
568 14.4 0.8 17 US-10-669-841-4707 Sequence 4707, Ap  
569 14.4 0.8 17 US-10-723-361-8638 Sequence 8638, Ap  
570 14.4 0.8 17 US-10-723-361-8639 Sequence 8639, Ap  
c 571 14.4 0.8 17 US-10-723-361-10431 Sequence 10431, A  
c 572 14.4 0.8 17 US-10-723-361-10433 Sequence 10433, A  
c 573 14.4 0.8 18 US-10-079-136-14 Sequence 14, Appl  
c 574 14.4 0.8 18 US-10-807-963-14 Sequence 14, Appl  
575 14.2 0.8 19 US-10-619-906-11 Sequence 11, Appl  
c 576 14.2 0.8 21 US-10-751-736-10931 Sequence 10931, A  
c 577 14.2 0.8 50 US-10-131-827-2299 Sequence 2299, Ap  
578 14 0.8 15 US-10-255-120-58 Sequence 58, Appl  
579 14 0.8 16 US-10-255-120-102 Sequence 102, App  
c 580 14 0.8 17 US-09-866-108-10429 Sequence 10429, A  
c 581 14 0.8 17 US-09-866-108-10430 Sequence 10430, A  
c 582 14 0.8 17 US-09-780-533A-2203 Sequence 2203, Ap  
c 583 14 0.8 17 US-10-723-361-10429 Sequence 10429, A  
c 584 14 0.8 17 US-10-723-361-10430 Sequence 10430, A  
585 13.8 0.8 17 US-09-866-108-6761 Sequence 6761, Ap  
586 13.8 0.8 17 US-09-866-108-8637 Sequence 8637, Ap  
c 587 13.8 0.8 17 US-09-866-108-10428 Sequence 10428, A  
c 588 13.8 0.8 17 US-09-866-108-10434 Sequence 10434, A  
589 13.8 0.8 17 US-09-780-533A-330 Sequence 330, App  
c 590 13.8 0.8 17 US-09-780-533A-480 Sequence 480, App  
c 591 13.8 0.8 17 US-09-927-046-948 Sequence 948, App  
c 592 13.8 0.8 17 US-09-848-754A-731 Sequence 731, App  
c 593 13.8 0.8 17 US-09-848-754A-815 Sequence 815, App  
c 594 13.8 0.8 17 US-09-848-754A-2380 Sequence 2380, Ap  
595 13.8 0.8 17 US-09-780-164-947 Sequence 947, App  
c 596 13.8 0.8 17 US-09-827-395A-229 Sequence 229, App  
c 597 13.8 0.8 17 US-09-827-395A-230 Sequence 230, App  
598 13.8 0.8 17 US-09-827-395A-230 Sequence 230, App  
599 13.8 0.8 17 US-10-060-756A-1176 Sequence 1176, Ap  
600 13.8 0.8 17 US-10-060-756A-1177 Sequence 1177, Ap  
601 13.8 0.8 17 US-10-163-552-344 Sequence 344, App  
c 602 13.8 0.8 17 US-10-156-306-529 Sequence 529, App  
c 603 13.8 0.8 17 US-10-156-306-3602 Sequence 3602, Ap  
c 604 13.8 0.8 17 US-10-238-700-304 Sequence 304, App  
c 605 13.8 0.8 17 US-10-430-882-229 Sequence 229, App  
c 606 13.8 0.8 17 US-10-430-882-230 Sequence 230, App  
c 607 13.8 0.8 17 US-10-322-685-6 Sequence 6, Appl  
c 608 13.8 0.8 17 US-10-138-674-222 Sequence 222, App  
c 609 13.8 0.8 17 US-10-138-674-1868 Sequence 1868, Ap  
c 610 13.8 0.8 17 US-10-138-674-3143 Sequence 3143, Ap  
c 611 13.8 0.8 17 US-10-138-674-3686 Sequence 3686, Ap  
c 612 13.8 0.8 17 US-10-138-674-5572 Sequence 5572, Ap  
c 613 13.8 0.8 17 US-10-138-674-8308 Sequence 8308, Ap  
614 13.8 0.8 17 US-10-287-949A-222 Sequence 222, App  
c 615 13.8 0.8 17 US-10-287-949A-1868 Sequence 1868, Ap  
c 616 13.8 0.8 17 US-10-287-949A-3143 Sequence 3143, Ap  
c 617 13.8 0.8 17 US-10-287-949A-3686 Sequence 3686, Ap  
17 US-10-287-949A-5572 Sequence 5572, Ap

c 618 13.8 0.8 17 US-10-287-949A-8308 Sequence 8308, Ap  
619 13.8 0.8 17 US-10-712-672-81 Sequence 81, Appl  
620 13.8 0.8 17 US-10-712-672-82 Sequence 82, Appl  
621 13.8 0.8 17 US-10-723-361-6761 Sequence 6761, Ap  
622 13.8 0.8 17 US-10-723-361-8637 Sequence 8637, Ap  
c 623 13.8 0.8 17 US-10-723-361-10428 Sequence 10428, A  
c 624 13.8 0.8 17 US-10-723-361-10434 Sequence 10434, A  
c 625 13.8 0.8 17 US-10-712-633-1625 Sequence 1625, Ap  
c 626 13.8 0.8 17 US-10-724-270-304 Sequence 304, App  
c 627 13.8 0.8 17 US-10-724-270-4999 Sequence 4999, Ap  
c 628 13.6 0.8 21 US-10-751-736-10774 Sequence 10774, A  
c 629 13.6 0.8 21 US-10-751-736-11161 Sequence 11161, A  
c 630 13.6 0.8 21 US-10-751-736-10772 Sequence 10772, A  
c 631 13.6 0.8 21 US-10-751-736-10775 Sequence 10775, A  
c 632 13.4 0.8 15 US-09-922-261-460 Sequence 460, App  
633 13.4 0.8 16 US-10-138-674-5744 Sequence 5744, Ap  
634 13.4 0.8 16 US-10-287-949A-5744 Sequence 5744, Ap  
635 13.4 0.8 16 US-10-712-672-1831 Sequence 1831, Ap

ALIGNMENTS

RESULT 1  
US-10-131-827-2299  
; Sequence 2299, Application US/10131827  
; Publication No. US20040009479A1  
; GENERAL INFORMATION:  
; APPLICANT: Wohlgemuth, Jay  
; APPLICANT: Fry, Kirk  
; APPLICANT: Woodward, Robert  
; APPLICANT: Ly, Ngoc  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE  
; TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES  
; FILE REFERENCE: 506612000120  
; CURRENT APPLICATION NUMBER: US/10/131,827  
; CURRENT FILING DATE: 2002-09-06  
; PRIOR APPLICATION NUMBER: US 10/006,290  
; PRIOR FILING DATE: 2001-10-22  
; PRIOR APPLICATION NUMBER: US 60/296,764  
; PRIOR FILING DATE: 2001-06-08  
; NUMBER OF SEQ ID NOS: 9090  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 2299  
; LENGTH: 50  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-131-827-2299

Query Match 2.8%; Score 50; DB 1; Length 50;  
Best Local Similarity 100.0%; Pred. No. 0.048;  
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1687 AAGTTGCTTCCTAACATCCTTGGACTGAGAAATTATCTTACTTCTGGCA 1736  
Db 1 AAGTTGCTTCCTAACATCCTTGGACTGAGAAATTATCTTACTTCTGGCA 50

RESULT 2  
US-10-619-906-20  
; Sequence 20, Application US/10619906  
; Publication No. US20040087533A1  
; GENERAL INFORMATION:  
; APPLICANT: Index Pharmaceuticals  
; TITLE OF INVENTION: New Compound  
; FILE REFERENCE: 50299  
; CURRENT APPLICATION NUMBER: US/10/619,906  
; CURRENT FILING DATE: 2003-07-16  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 20  
; LENGTH: 24  
; TYPE: DNA

399	19	1.1	21	1	US-10-751-736-10787	Sequence 10787, A	472	19	1.1	21	1	US-10-751-736-11222	Sequence 11222, A
400	19	1.1	21	1	US-10-751-736-10793	Sequence 10793, A	473	19	1.1	21	1	US-10-751-736-11225	Sequence 11225, A
401	19	1.1	21	1	US-10-751-736-10799	Sequence 10799, A	474	19	1.1	21	1	US-10-751-736-11228	Sequence 11228, A
402	19	1.1	21	1	US-10-751-736-10802	Sequence 10802, A	475	19	1.1	21	1	US-10-751-736-11231	Sequence 11231, A
403	19	1.1	21	1	US-10-751-736-10808	Sequence 10808, A	476	19	1.1	21	1	US-10-751-736-11234	Sequence 11234, A
404	19	1.1	21	1	US-10-751-736-10814	Sequence 10814, A	477	19	1.1	21	1	US-10-751-736-11237	Sequence 11237, A
405	19	1.1	21	1	US-10-751-736-10823	Sequence 10823, A	478	19	1.1	21	1	US-10-751-736-11240	Sequence 11240, A
406	19	1.1	21	1	US-10-751-736-10826	Sequence 10826, A	479	19	1.1	21	1	US-10-751-736-11258	Sequence 11258, A
407	19	1.1	21	1	US-10-751-736-10832	Sequence 10832, A	480	19	1.1	21	1	US-10-751-736-11264	Sequence 11264, A
408	19	1.1	21	1	US-10-751-736-10838	Sequence 10838, A	481	19	1.1	21	1	US-10-751-736-11267	Sequence 11267, A
409	19	1.1	21	1	US-10-751-736-10841	Sequence 10841, A	482	19	1.1	21	1	US-10-751-736-11270	Sequence 11270, A
410	19	1.1	21	1	US-10-751-736-10844	Sequence 10844, A	483	19	1.1	21	1	US-10-751-736-11273	Sequence 11273, A
411	19	1.1	21	1	US-10-751-736-10847	Sequence 10847, A	484	19	1.1	21	1	US-10-751-736-11276	Sequence 11276, A
412	19	1.1	21	1	US-10-751-736-10850	Sequence 10850, A	485	19	1.1	21	1	US-10-751-736-11291	Sequence 11291, A
413	19	1.1	21	1	US-10-751-736-10853	Sequence 10853, A	486	19	1.1	21	1	US-10-751-736-11294	Sequence 11294, A
414	19	1.1	21	1	US-10-751-736-10859	Sequence 10859, A	487	19	1.1	21	1	US-10-751-736-11297	Sequence 11297, A
415	19	1.1	21	1	US-10-751-736-10862	Sequence 10862, A	488	19	1.1	21	1	US-10-751-736-11300	Sequence 11300, A
416	19	1.1	21	1	US-10-751-736-10874	Sequence 10874, A	489	19	1.1	21	1	US-10-751-736-11303	Sequence 11303, A
417	19	1.1	21	1	US-10-751-736-10877	Sequence 10877, A	490	19	1.1	21	1	US-10-751-736-11306	Sequence 11306, A
418	19	1.1	21	1	US-10-751-736-10883	Sequence 10883, A	491	19	1.1	21	1	US-10-751-736-11309	Sequence 11309, A
419	19	1.1	21	1	US-10-751-736-10886	Sequence 10886, A	492	19	1.1	21	1	US-10-751-736-11324	Sequence 11324, A
420	19	1.1	21	1	US-10-751-736-10901	Sequence 10901, A	493	19	1.1	21	1	US-10-751-736-11330	Sequence 11330, A
421	19	1.1	21	1	US-10-751-736-10919	Sequence 10919, A	494	19	1.1	21	1	US-10-751-736-11336	Sequence 11336, A
422	19	1.1	21	1	US-10-751-736-10928	Sequence 10928, A	495	19	1.1	21	1	US-10-751-736-11339	Sequence 11339, A
423	19	1.1	21	1	US-10-751-736-10931	Sequence 10931, A	496	19	1.1	21	1	US-10-751-736-11351	Sequence 11351, A
424	19	1.1	21	1	US-10-751-736-10934	Sequence 10934, A	497	19	1.1	21	1	US-10-751-736-11363	Sequence 11363, A
425	19	1.1	21	1	US-10-751-736-10937	Sequence 10937, A	498	19	1.1	21	1	US-10-751-736-11378	Sequence 11378, A
426	19	1.1	21	1	US-10-751-736-10943	Sequence 10943, A	499	19	1.1	21	1	US-10-751-736-11381	Sequence 11381, A
427	19	1.1	21	1	US-10-751-736-10946	Sequence 10946, A	500	19	1.1	21	1	US-10-751-736-11387	Sequence 11387, A
428	19	1.1	21	1	US-10-751-736-10958	Sequence 10958, A	501	19	1.1	21	1	US-10-751-736-11393	Sequence 11393, A
429	19	1.1	21	1	US-10-751-736-10961	Sequence 10961, A	502	19	1.1	21	1	US-10-751-736-11399	Sequence 11399, A
430	19	1.1	21	1	US-10-751-736-10988	Sequence 10988, A	503	19	1.1	21	1	US-10-751-736-11402	Sequence 11402, A
431	19	1.1	21	1	US-10-751-736-10991	Sequence 10991, A	504	19	1.1	21	1	US-10-751-736-11408	Sequence 11408, A
432	19	1.1	21	1	US-10-751-736-11000	Sequence 11000, A	505	19	1.1	21	1	US-10-751-736-11411	Sequence 11411, A
433	19	1.1	21	1	US-10-751-736-11015	Sequence 11015, A	506	19	1.1	21	1	US-10-751-736-11426	Sequence 11426, A
434	19	1.1	21	1	US-10-751-736-11018	Sequence 11018, A	507	19	1.1	21	1	US-10-751-736-11438	Sequence 11438, A
435	19	1.1	21	1	US-10-751-736-11021	Sequence 11021, A	508	19	1.1	21	1	US-10-751-736-11441	Sequence 11441, A
436	19	1.1	21	1	US-10-751-736-11027	Sequence 11027, A	509	19	1.1	21	1	US-10-751-736-11444	Sequence 11444, A
437	19	1.1	21	1	US-10-751-736-11030	Sequence 11030, A	510	19	1.1	21	1	US-10-751-736-11450	Sequence 11450, A
438	19	1.1	21	1	US-10-751-736-11036	Sequence 11036, A	511	19	1.1	21	1	US-10-751-736-11453	Sequence 11453, A
439	19	1.1	21	1	US-10-751-736-11048	Sequence 11048, A	512	19	1.1	21	1	US-10-751-736-11456	Sequence 11456, A
440	19	1.1	21	1	US-10-751-736-11051	Sequence 11051, A	513	19	1.1	21	1	US-10-751-736-11468	Sequence 11468, A
441	19	1.1	21	1	US-10-751-736-11054	Sequence 11054, A	514	19	1.1	21	1	US-10-751-736-11480	Sequence 11480, A
442	19	1.1	21	1	US-10-751-736-11060	Sequence 11060, A	515	19	1.1	21	1	US-10-751-736-11483	Sequence 11483, A
443	19	1.1	21	1	US-10-751-736-11081	Sequence 11081, A	516	19	1.1	21	1	US-10-751-736-11483	Sequence 11483, A
444	19	1.1	21	1	US-10-751-736-11084	Sequence 11084, A	517	18.4	1.0	21	1	US-10-751-736-9562	Sequence 9562, Ap
445	19	1.1	21	1	US-10-751-736-11087	Sequence 11087, A	518	18.4	1.0	21	1	US-10-751-736-10009	Sequence 10009, A
446	19	1.1	21	1	US-10-751-736-11090	Sequence 11090, A	519	18.4	1.0	21	1	US-10-751-736-10163	Sequence 10163, A
447	19	1.1	21	1	US-10-751-736-11099	Sequence 11099, A	520	18	1.0	21	1	US-10-751-736-9563	Sequence 9563, Ap
448	19	1.1	21	1	US-10-751-736-11102	Sequence 11102, A	521	18	1.0	21	1	US-10-751-736-10012	Sequence 10012, A
449	19	1.1	21	1	US-10-751-736-11105	Sequence 11105, A	522	17.8	1.0	21	1	US-10-751-736-10058	Sequence 10058, A
450	19	1.1	21	1	US-10-751-736-11108	Sequence 11108, A	523	17.4	1.0	21	1	US-10-751-736-10054	Sequence 10054, A
451	19	1.1	21	1	US-10-751-736-11111	Sequence 11111, A	524	16.8	0.9	21	1	US-10-751-736-8698	Sequence 8698, Ap
452	19	1.1	21	1	US-10-751-736-11114	Sequence 11114, A	525	16.8	0.9	21	1	US-10-751-736-8704	Sequence 8704, Ap
453	19	1.1	21	1	US-10-751-736-11117	Sequence 11117, A	526	16.8	0.9	21	1	US-10-751-736-8707	Sequence 8707, Ap
454	19	1.1	21	1	US-10-751-736-11120	Sequence 11120, A	527	16.8	0.9	21	1	US-10-751-736-10057	Sequence 10057, A
455	19	1.1	21	1	US-10-751-736-11129	Sequence 11129, A	528	16.8	0.9	21	1	US-10-751-736-10162	Sequence 10162, A
456	19	1.1	21	1	US-10-751-736-11132	Sequence 11132, A	529	16.4	0.9	19	1	US-10-349-143-5754	Sequence 5754, Ap
457	19	1.1	21	1	US-10-751-736-11138	Sequence 11138, A	530	16.4	0.9	20	1	US-10-316-755-57	Sequence 57, Appl
458	19	1.1	21	1	US-10-751-736-11141	Sequence 11141, A	531	16.4	0.9	20	1	US-10-316-755-202	Sequence 202, App
459	19	1.1	21	1	US-10-751-736-11144	Sequence 11144, A	532	16.2	0.9	21	1	US-10-751-736-10777	Sequence 10777, A
460	19	1.1	21	1	US-10-751-736-11147	Sequence 11147, A	533	16.2	0.9	21	1	US-10-751-736-10930	Sequence 10930, A
461	19	1.1	21	1	US-10-751-736-11150	Sequence 11150, A	534	16	0.9	20	1	US-10-462-039-25	Sequence 25, Appl
462	19	1.1	21	1	US-10-751-736-11156	Sequence 11156, A	535	16	0.9	20	1	US-10-462-039-26	Sequence 26, Appl
463	19	1.1	21	1	US-10-751-736-11159	Sequence 11159, A	536	15.8	0.9	19	1	US-10-830-569-140	Sequence 140, App
464	19	1.1	21	1	US-10-751-736-11171	Sequence 11171, A	537	15.8	0.9	19	1	US-10-830-569-447	Sequence 447, App
465	19	1.1	21	1	US-10-751-736-11183	Sequence 11183, A	538	15.4	0.9	17	1	US-09-866-108-10432	Sequence 10432, A
466	19	1.1	21	1	US-10-751-736-11195	Sequence 11195, A	539	15.4	0.9	17	1	US-10-052-545-19	Sequence 19, Appl
467	19	1.1	21	1	US-10-751-736-11198	Sequence 11198, A	540	15.4	0.9	17	1	US-10-723-361-10432	Sequence 10432, A
468	19	1.1	21	1	US-10-751-736-11207	Sequence 11207, A	541	15	0.8	17	1	US-09-780-533A-2552	Sequence 2552, Ap
469	19	1.1	21	1	US-10-751-736-11213	Sequence 11213, A	542	14.8	0.8	18	1	US-09-067-638B-57	Sequence 57, Appl
470	19	1.1	21	1	US-10-751-736-11216	Sequence 11216, A	543	14.8	0.8	18	1	US-09-969-373-2034	Sequence 2034, Ap
471	19	1.1	21	1	US-10-751-736-11219	Sequence 11219, A	544	14.8	0.8	18	1	US-10-116-325-57	Sequence 57, Appl



253	21	1.2	21	1	US-10-751-736-11440	Sequence 11440, A	326	20	1.1	21	1	US-10-751-736-11420	Sequence 11420, A
254	21	1.2	21	1	US-10-751-736-11443	Sequence 11443, A	327	20	1.1	21	1	US-10-751-736-11432	Sequence 11432, A
255	21	1.2	21	1	US-10-751-736-11446	Sequence 11446, A	328	20	1.1	21	1	US-10-751-736-11459	Sequence 11459, A
256	21	1.2	21	1	US-10-751-736-11447	Sequence 11447, A	329	20	1.1	21	1	US-10-751-736-11462	Sequence 11462, A
257	21	1.2	21	1	US-10-751-736-11449	Sequence 11449, A	330	20	1.1	21	1	US-10-751-736-11471	Sequence 11471, A
258	21	1.2	21	1	US-10-751-736-11452	Sequence 11452, A	331	20	1.1	21	1	US-10-751-736-11477	Sequence 11477, A
259	21	1.2	21	1	US-10-751-736-11455	Sequence 11455, A	332	19.4	1.1	21	1	US-10-751-736-10754	Sequence 10754, A
260	21	1.2	21	1	US-10-751-736-11458	Sequence 11458, A	333	19.4	1.1	21	1	US-10-751-736-10775	Sequence 10775, A
261	21	1.2	21	1	US-10-751-736-11461	Sequence 11461, A	334	19.4	1.1	21	1	US-10-751-736-10778	Sequence 10778, A
262	21	1.2	21	1	US-10-751-736-11464	Sequence 11464, A	335	19.4	1.1	21	1	US-10-751-736-10790	Sequence 10790, A
263	21	1.2	21	1	US-10-751-736-11467	Sequence 11467, A	336	19.4	1.1	21	1	US-10-751-736-10796	Sequence 10796, A
264	21	1.2	21	1	US-10-751-736-11470	Sequence 11470, A	337	19.4	1.1	21	1	US-10-751-736-10829	Sequence 10829, A
265	21	1.2	21	1	US-10-751-736-11473	Sequence 11473, A	338	19.4	1.1	21	1	US-10-751-736-10835	Sequence 10835, A
266	21	1.2	21	1	US-10-751-736-11474	Sequence 11474, A	339	19.4	1.1	21	1	US-10-751-736-10856	Sequence 10856, A
267	21	1.2	21	1	US-10-751-736-11476	Sequence 11476, A	340	19.4	1.1	21	1	US-10-751-736-10880	Sequence 10880, A
268	21	1.2	21	1	US-10-751-736-11479	Sequence 11479, A	341	19.4	1.1	21	1	US-10-751-736-10892	Sequence 10892, A
269	21	1.2	21	1	US-10-751-736-11482	Sequence 11482, A	342	19.4	1.1	21	1	US-10-751-736-10895	Sequence 10895, A
270	20.8	1.2	25	1	US-10-719-900-174230	Sequence 174230, A	343	19.4	1.1	21	1	US-10-751-736-10904	Sequence 10904, A
271	20.4	1.1	25	1	US-10-809-189-127779	Sequence 127779, A	344	19.4	1.1	21	1	US-10-751-736-10910	Sequence 10910, A
272	20.2	1.1	25	1	US-10-719-900-879471	Sequence 879471, A	345	19.4	1.1	21	1	US-10-751-736-10925	Sequence 10925, A
273	20.2	1.1	25	1	US-10-719-900-908158	Sequence 908158, A	346	19.4	1.1	21	1	US-10-751-736-10949	Sequence 10949, A
274	20.2	1.1	25	1	US-10-719-900-967442	Sequence 967442, A	347	19.4	1.1	21	1	US-10-751-736-10952	Sequence 10952, A
275	20.2	1.1	25	1	US-10-809-189-125366	Sequence 125366, A	348	19.4	1.1	21	1	US-10-751-736-10997	Sequence 10997, A
276	20	1.1	20	1	US-10-274-095-35	Sequence 35, Appl	349	19.4	1.1	21	1	US-10-751-736-11003	Sequence 11003, A
277	20	1.1	20	1	US-10-274-095-36	Sequence 36, Appl	350	19.4	1.1	21	1	US-10-751-736-11039	Sequence 11039, A
278	20	1.1	21	1	US-10-751-736-10757	Sequence 10757, A	351	19.4	1.1	21	1	US-10-751-736-11063	Sequence 11063, A
279	20	1.1	21	1	US-10-751-736-10766	Sequence 10766, A	352	19.4	1.1	21	1	US-10-751-736-11069	Sequence 11069, A
280	20	1.1	21	1	US-10-751-736-10772	Sequence 10772, A	353	19.4	1.1	21	1	US-10-751-736-11135	Sequence 11135, A
281	20	1.1	21	1	US-10-751-736-10811	Sequence 10811, A	354	19.4	1.1	21	1	US-10-751-736-11162	Sequence 11162, A
282	20	1.1	21	1	US-10-751-736-10871	Sequence 10871, A	355	19.4	1.1	21	1	US-10-751-736-11165	Sequence 11165, A
283	20	1.1	21	1	US-10-751-736-10889	Sequence 10889, A	356	19.4	1.1	21	1	US-10-751-736-11180	Sequence 11180, A
284	20	1.1	21	1	US-10-751-736-10907	Sequence 10907, A	357	19.4	1.1	21	1	US-10-751-736-11192	Sequence 11192, A
285	20	1.1	21	1	US-10-751-736-10913	Sequence 10913, A	358	19.4	1.1	21	1	US-10-751-736-11210	Sequence 11210, A
286	20	1.1	21	1	US-10-751-736-10916	Sequence 10916, A	359	19.4	1.1	21	1	US-10-751-736-11246	Sequence 11246, A
287	20	1.1	21	1	US-10-751-736-10922	Sequence 10922, A	360	19.4	1.1	21	1	US-10-751-736-11249	Sequence 11249, A
288	20	1.1	21	1	US-10-751-736-10940	Sequence 10940, A	361	19.4	1.1	21	1	US-10-751-736-11252	Sequence 11252, A
289	20	1.1	21	1	US-10-751-736-10964	Sequence 10964, A	362	19.4	1.1	21	1	US-10-751-736-11255	Sequence 11255, A
290	20	1.1	21	1	US-10-751-736-10967	Sequence 10967, A	363	19.4	1.1	21	1	US-10-751-736-11261	Sequence 11261, A
291	20	1.1	21	1	US-10-751-736-10970	Sequence 10970, A	364	19.4	1.1	21	1	US-10-751-736-11282	Sequence 11282, A
292	20	1.1	21	1	US-10-751-736-10973	Sequence 10973, A	365	19.4	1.1	21	1	US-10-751-736-11285	Sequence 11285, A
293	20	1.1	21	1	US-10-751-736-10979	Sequence 10979, A	366	19.4	1.1	21	1	US-10-751-736-11288	Sequence 11288, A
294	20	1.1	21	1	US-10-751-736-10979	Sequence 10979, A	367	19.4	1.1	21	1	US-10-751-736-11318	Sequence 11318, A
295	20	1.1	21	1	US-10-751-736-10982	Sequence 10982, A	368	19.4	1.1	21	1	US-10-751-736-11327	Sequence 11327, A
296	20	1.1	21	1	US-10-751-736-10994	Sequence 10994, A	369	19.4	1.1	21	1	US-10-751-736-11342	Sequence 11342, A
297	20	1.1	21	1	US-10-751-736-11006	Sequence 11006, A	370	19.4	1.1	21	1	US-10-751-736-11345	Sequence 11345, A
298	20	1.1	21	1	US-10-751-736-11009	Sequence 11009, A	371	19.4	1.1	21	1	US-10-751-736-11354	Sequence 11354, A
299	20	1.1	21	1	US-10-751-736-11012	Sequence 11012, A	372	19.4	1.1	21	1	US-10-751-736-11357	Sequence 11357, A
300	20	1.1	21	1	US-10-751-736-11024	Sequence 11024, A	373	19.4	1.1	21	1	US-10-751-736-11360	Sequence 11360, A
301	20	1.1	21	1	US-10-751-736-11042	Sequence 11042, A	374	19.4	1.1	21	1	US-10-751-736-11366	Sequence 11366, A
302	20	1.1	21	1	US-10-751-736-11057	Sequence 11057, A	375	19.4	1.1	21	1	US-10-751-736-11384	Sequence 11384, A
303	20	1.1	21	1	US-10-751-736-11057	Sequence 11057, A	376	19.4	1.1	21	1	US-10-751-736-11396	Sequence 11396, A
304	20	1.1	21	1	US-10-751-736-11066	Sequence 11066, A	377	19.4	1.1	21	1	US-10-751-736-11405	Sequence 11405, A
305	20	1.1	21	1	US-10-751-736-11075	Sequence 11075, A	378	19.4	1.1	21	1	US-10-751-736-11429	Sequence 11429, A
306	20	1.1	21	1	US-10-751-736-11078	Sequence 11078, A	379	19.4	1.1	21	1	US-10-751-736-11465	Sequence 11465, A
307	20	1.1	21	1	US-10-751-736-11093	Sequence 11093, A	C 380	19	1.1	19	1	US-10-619-906-3	Sequence 3, Appli
308	20	1.1	21	1	US-10-751-736-11096	Sequence 11096, A	C 381	19	1.1	19	1	US-10-619-906-4	Sequence 4, Appli
309	20	1.1	21	1	US-10-751-736-11096	Sequence 11096, A	C 382	19	1.1	19	1	US-10-619-906-5	Sequence 5, Appli
310	20	1.1	21	1	US-10-751-736-11126	Sequence 11126, A	C 383	19	1.1	19	1	US-10-619-906-6	Sequence 6, Appli
311	20	1.1	21	1	US-10-751-736-11153	Sequence 11153, A	C 384	19	1.1	19	1	US-10-619-906-7	Sequence 7, Appli
312	20	1.1	21	1	US-10-751-736-11168	Sequence 11168, A	C 385	19	1.1	19	1	US-10-619-906-8	Sequence 8, Appli
313	20	1.1	21	1	US-10-751-736-11174	Sequence 11174, A	C 386	19	1.1	19	1	US-10-619-906-9	Sequence 9, Appli
314	20	1.1	21	1	US-10-751-736-11177	Sequence 11177, A	C 387	19	1.1	19	1	US-10-619-906-10	Sequence 10, Appl
315	20	1.1	21	1	US-10-751-736-11186	Sequence 11186, A	C 388	19	1.1	19	1	US-10-619-906-11	Sequence 11, Appl
316	20	1.1	21	1	US-10-751-736-11189	Sequence 11189, A	C 389	19	1.1	19	1	US-10-619-906-12	Sequence 12, Appl
317	20	1.1	21	1	US-10-751-736-11204	Sequence 11204, A	C 390	19	1.1	19	1	US-10-619-906-13	Sequence 13, Appl
318	20	1.1	21	1	US-10-751-736-11312	Sequence 11312, A	C 391	19	1.1	19	1	US-10-619-906-14	Sequence 14, Appl
319	20	1.1	21	1	US-10-751-736-11315	Sequence 11315, A	C 392	19	1.1	19	1	US-10-872-063-160	Sequence 160, App
320	20	1.1	21	1	US-10-751-736-11321	Sequence 11321, A	393	19	1.1	21	1	US-10-751-736-10010	Sequence 10010, A
321	20	1.1	21	1	US-10-751-736-11333	Sequence 11333, A	394	19	1.1	21	1	US-10-751-736-10760	Sequence 10760, A
322	20	1.1	21	1	US-10-751-736-11348	Sequence 11348, A	395	19	1.1	21	1	US-10-751-736-10763	Sequence 10763, A
323	20	1.1	21	1	US-10-751-736-11369	Sequence 11369, A	396	19	1.1	21	1	US-10-751-736-10769	Sequence 10769, A
324	20	1.1	21	1	US-10-751-736-11375	Sequence 11375, A	397	19	1.1	21	1	US-10-751-736-10781	Sequence 10781, A
325	20	1.1	21	1	US-10-751-736-11390	Sequence 11390, A	398	19	1.1	21	1	US-10-751-736-10784	Sequence 10784, A
					Sequence 11414, A	Sequence 11414, A							
					Sequence 11417, A	Sequence 11417, A							



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:30:53 ; Search time 11 Seconds  
(without alignments)  
4.138 Million cell updates/sec

Title: US-10-619-906-1  
Perfect score: 1778  
Sequence: 1 tagaagttttacaatgaagtt.....ttttggctcaataaaattg 1778

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 625 seqs, 12799 residues

Total number of hits satisfying chosen parameters: 1250

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 635 summaries

Database : rnpb1.seq:\*

pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	%			Query Match	Length	DB ID	Description
	Score	Match	Length				
1	50	2.8	50	1	US-10-131-827-2299	Sequence 2299, Ap	
2	24	1.3	24	1	US-10-619-906-20	Sequence 20, Appl	
C 3	24	1.3	24	1	US-10-619-906-21	Sequence 21, Appl	
C 4	24	1.3	24	1	US-10-872-063-161	Sequence 161, App	
5	24	1.3	24	1	US-10-872-063-162	Sequence 162, App	
6	22.4	1.3	25	1	US-10-719-900-174229	Sequence 174229, A	
7	21	1.2	21	1	US-10-751-736-10753	Sequence 10753, A	
8	21	1.2	21	1	US-10-751-736-10756	Sequence 10756, A	
9	21	1.2	21	1	US-10-751-736-10759	Sequence 10759, A	
10	21	1.2	21	1	US-10-751-736-10762	Sequence 10762, A	
11	21	1.2	21	1	US-10-751-736-10765	Sequence 10765, A	
12	21	1.2	21	1	US-10-751-736-10768	Sequence 10768, A	
13	21	1.2	21	1	US-10-751-736-10771	Sequence 10771, A	
14	21	1.2	21	1	US-10-751-736-10774	Sequence 10774, A	
15	21	1.2	21	1	US-10-751-736-10777	Sequence 10777, A	
16	21	1.2	21	1	US-10-751-736-10780	Sequence 10780, A	
17	21	1.2	21	1	US-10-751-736-10783	Sequence 10783, A	
18	21	1.2	21	1	US-10-751-736-10786	Sequence 10786, A	
19	21	1.2	21	1	US-10-751-736-10789	Sequence 10789, A	
20	21	1.2	21	1	US-10-751-736-10792	Sequence 10792, A	
21	21	1.2	21	1	US-10-751-736-10795	Sequence 10795, A	
22	21	1.2	21	1	US-10-751-736-10798	Sequence 10798, A	
23	21	1.2	21	1	US-10-751-736-10801	Sequence 10801, A	
24	21	1.2	21	1	US-10-751-736-10804	Sequence 10804, A	
25	21	1.2	21	1	US-10-751-736-10805	Sequence 10805, A	
26	21	1.2	21	1	US-10-751-736-10807	Sequence 10807, A	
27	21	1.2	21	1	US-10-751-736-10810	Sequence 10810, A	
28	21	1.2	21	1	US-10-751-736-10813	Sequence 10813, A	
29	21	1.2	21	1	US-10-751-736-10816	Sequence 10816, A	
30	21	1.2	21	1	US-10-751-736-10817	Sequence 10817, A	
31	21	1.2	21	1	US-10-751-736-10819	Sequence 10819, A	
32	21	1.2	21	1	US-10-751-736-10820	Sequence 10820, A	
33	21	1.2	21	1	US-10-751-736-10822	Sequence 10822, A	

34	21	1.2	21	1	US-10-751-736-10825	Sequence 10825, A
35	21	1.2	21	1	US-10-751-736-10828	Sequence 10828, A
36	21	1.2	21	1	US-10-751-736-10831	Sequence 10831, A
37	21	1.2	21	1	US-10-751-736-10834	Sequence 10834, A
38	21	1.2	21	1	US-10-751-736-10837	Sequence 10837, A
39	21	1.2	21	1	US-10-751-736-10840	Sequence 10840, A
40	21	1.2	21	1	US-10-751-736-10843	Sequence 10843, A
41	21	1.2	21	1	US-10-751-736-10846	Sequence 10846, A
42	21	1.2	21	1	US-10-751-736-10849	Sequence 10849, A
43	21	1.2	21	1	US-10-751-736-10852	Sequence 10852, A
44	21	1.2	21	1	US-10-751-736-10855	Sequence 10855, A
45	21	1.2	21	1	US-10-751-736-10858	Sequence 10858, A
46	21	1.2	21	1	US-10-751-736-10861	Sequence 10861, A
47	21	1.2	21	1	US-10-751-736-10864	Sequence 10864, A
48	21	1.2	21	1	US-10-751-736-10865	Sequence 10865, A
49	21	1.2	21	1	US-10-751-736-10867	Sequence 10867, A
50	21	1.2	21	1	US-10-751-736-10868	Sequence 10868, A
51	21	1.2	21	1	US-10-751-736-10870	Sequence 10870, A
52	21	1.2	21	1	US-10-751-736-10873	Sequence 10873, A
53	21	1.2	21	1	US-10-751-736-10876	Sequence 10876, A
54	21	1.2	21	1	US-10-751-736-10879	Sequence 10879, A
55	21	1.2	21	1	US-10-751-736-10882	Sequence 10882, A
56	21	1.2	21	1	US-10-751-736-10885	Sequence 10885, A
57	21	1.2	21	1	US-10-751-736-10888	Sequence 10888, A
58	21	1.2	21	1	US-10-751-736-10891	Sequence 10891, A
59	21	1.2	21	1	US-10-751-736-10894	Sequence 10894, A
60	21	1.2	21	1	US-10-751-736-10897	Sequence 10897, A
61	21	1.2	21	1	US-10-751-736-10898	Sequence 10898, A
62	21	1.2	21	1	US-10-751-736-10900	Sequence 10900, A
63	21	1.2	21	1	US-10-751-736-10903	Sequence 10903, A
64	21	1.2	21	1	US-10-751-736-10906	Sequence 10906, A
65	21	1.2	21	1	US-10-751-736-10909	Sequence 10909, A
66	21	1.2	21	1	US-10-751-736-10912	Sequence 10912, A
67	21	1.2	21	1	US-10-751-736-10915	Sequence 10915, A
68	21	1.2	21	1	US-10-751-736-10918	Sequence 10918, A
69	21	1.2	21	1	US-10-751-736-10921	Sequence 10921, A
70	21	1.2	21	1	US-10-751-736-10924	Sequence 10924, A
71	21	1.2	21	1	US-10-751-736-10927	Sequence 10927, A
72	21	1.2	21	1	US-10-751-736-10930	Sequence 10930, A
73	21	1.2	21	1	US-10-751-736-10933	Sequence 10933, A
74	21	1.2	21	1	US-10-751-736-10936	Sequence 10936, A
75	21	1.2	21	1	US-10-751-736-10939	Sequence 10939, A
76	21	1.2	21	1	US-10-751-736-10942	Sequence 10942, A
77	21	1.2	21	1	US-10-751-736-10945	Sequence 10945, A
78	21	1.2	21	1	US-10-751-736-10948	Sequence 10948, A
79	21	1.2	21	1	US-10-751-736-10951	Sequence 10951, A
80	21	1.2	21	1	US-10-751-736-10954	Sequence 10954, A
81	21	1.2	21	1	US-10-751-736-10957	Sequence 10957, A
82	21	1.2	21	1	US-10-751-736-10960	Sequence 10960, A
83	21	1.2	21	1	US-10-751-736-10963	Sequence 10963, A
84	21	1.2	21	1	US-10-751-736-10966	Sequence 10966, A
85	21	1.2	21	1	US-10-751-736-10969	Sequence 10969, A
86	21	1.2	21	1	US-10-751-736-10972	Sequence 10972, A
87	21	1.2	21	1	US-10-751-736-10975	Sequence 10975, A
88	21	1.2	21	1	US-10-751-736-10976	Sequence 10976, A
89	21	1.2	21	1	US-10-751-736-10978	Sequence 10978, A
90	21	1.2	21	1	US-10-751-736-10981	Sequence 10981, A
91	21	1.2	21	1	US-10-751-736-10984	Sequence 10984, A
92	21	1.2	21	1	US-10-751-736-10985	Sequence 10985, A
93	21	1.2	21	1	US-10-751-736-10987	Sequence 10987, A
94	21	1.2	21	1	US-10-751-736-10990	Sequence 10990, A
95	21	1.2	21	1	US-10-751-736-10993	Sequence 10993, A
96	21	1.2	21	1	US-10-751-736-10996	Sequence 10996, A
97	21	1.2	21	1	US-10-751-736-10999	Sequence 10999, A
98	21	1.2	21	1	US-10-751-736-11002	Sequence 11002, A
99	21	1.2	21	1	US-10-751-736-11005	Sequence 11005, A
100	21	1.2	21	1	US-10-751-736-11008	Sequence 11008, A
101	21	1.2	21	1	US-10-751-736-11011	Sequence 11011, A
102	21	1.2	21	1	US-10-751-736-11014	Sequence 11014, A
103	21	1.2	21	1	US-10-751-736-11017	Sequence 11017, A
104	21	1.2	21	1	US-10-751-736-11020	Sequence 11020, A
105	21	1.2	21	1	US-10-751-736-11023	Sequence 11023, A
106	21	1.2	21	1	US-10-751-736-11026	Sequence 11026, A

**THIS PAGE BLANK (USPTO)**



ZIP: 98104-7092  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/618,166  
FILING DATE: 17-Jul-2000  
CLASSIFICATION: <Unknown>  
ATTORNEY/AGENT INFORMATION:  
NAME: McMasters, David D.  
REGISTRATION NUMBER: 33,963  
REFERENCE/DOCKET NUMBER: 240052.419C1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206) 622-4900  
TELEFAX: (206) 682-6031  
INFORMATION FOR SEQ ID NO: 64:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 64:

US-09-618-166-64  
Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 40;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 13 ATGAAGTTTCTTCT 26  
| | | | | | | | | |  
Db 1 AAGNAGTTTCTTCT 14

RESULT 100  
US-09-689-012-5  
; Sequence 5, Application US/09689012  
; Patent No. 6670135  
; GENERAL INFORMATION:  
; APPLICANT: Spriggs, Melanie K.  
; TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES  
; FILE REFERENCE: 2634-US  
; CURRENT APPLICATION NUMBER: US/09/689,012  
; CURRENT FILING DATE: 2000-10-12  
; PRIOR APPLICATION NUMBER: PCT/US99/09831  
; PRIOR FILING DATE: 1999-05-05  
; PRIOR APPLICATION NUMBER: US 60/085,497  
; PRIOR FILING DATE: 1998-05-14  
; NUMBER OF SEQ ID NOS: 10  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 5  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: PRIMER  
US-09-689-012-5

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 40;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1329 CTACTATTCTTCC 1342  
| | | | | | | | | |  
Db 2 CTACTACTTCTTCC 15

RESULT 101  
US-09-685-664B-4101/C  
; Sequence 4101, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4101  
; LENGTH: 15  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-4101

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 40;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1562 TATATAAAATACAT 1575  
| | | | | | | | | |  
Db 14 TATACAAAATACAT 1

Search completed: May 13, 2005, 11:28:24  
Job time : 2 secs

```
; Patent No. 6528639
; GENERAL INFORMATION:
; APPLICANT: USMAN, NASSIM
; APPLICANT: BEIGELMAN, LEONID
; APPLICANT: MCSWIGGEN, JAMES
; APPLICANT: KARPEISKI, ALEX
; TITLE OF INVENTION: BASE MODIFIED ENZYMATIC NUCLEIC ACIDS
; FILE REFERENCE: MBHB00-810-F
; CURRENT APPLICATION NUMBER: US/09/034,113
; CURRENT FILING DATE: 1998-03-03
; PRIOR APPLICATION NUMBER: 07/963,322
; PRIOR FILING DATE: 1992-10-15
; PRIOR APPLICATION NUMBER: 08/149,210
; PRIOR FILING DATE: 1993-11-08
; PRIOR APPLICATION NUMBER: 08/435,521
; PRIOR FILING DATE: 1995-05-05
; PRIOR APPLICATION NUMBER: 09/034,113
; PRIOR FILING DATE: 1998-03-03
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target of
; OTHER INFORMATION: Hammerhead Ribozyme to Site C (HHC) .
US-09-034-113-11

Query Match      0.7%;   Score 12.4;   DB 1;   Length 15;
Best Local Similarity 92.9%;   Pred. No. 40;
Matches 13;   Conservative 0;   Mismatches 1;   Indels 0;   Gaps 0;

QY      910 TTCTTCAAGACAG 923
Db      14 TTCTTCAAAACAG 1

RESULT 97
US-08-431-048F-148/c
; Sequence 148, Application US/08431048F
; Patent No. 6531586
; GENERAL INFORMATION:
; APPLICANT: ST. GEORGE-HYSLOP, PETER H
; ROMMENS, JOHANNA M
; FRASER, PAUL E
; TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
; TO ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 155
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARBY & DARBY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: N.Y.
; COUNTRY: U.S.A.
; ZIP: 10022-7513
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/431,048F
; FILING DATE: 28-Apr-1995
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: FEHLNER, PAUL F.
; REGISTRATION NUMBER: 35135
; REFERENCE/DOCKET NUMBER: 1034/0F808
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-527-7700
; TELEFAX: 212-527-6237
; INFORMATION FOR SEQ ID NO: 148:
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 148:
US-08-431-048F-148

Query Match      0.7%;   Score 12.4;   DB 1;   Length 15;
Best Local Similarity 92.9%;   Pred. No. 40;
Matches 13;   Conservative 0;   Mismatches 1;   Indels 0;   Gaps 0;

QY      473 CAGGCATGGCTGAC 486
Db      14 CAGGCATGGATGAC 1

RESULT 98
US-09-371-772B-4101/c
; Sequence 4101, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4101
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-4101

Query Match      0.7%;   Score 12.4;   DB 1;   Length 15;
Best Local Similarity 92.9%;   Pred. No. 40;
Matches 13;   Conservative 0;   Mismatches 1;   Indels 0;   Gaps 0;

QY      1562 TATATAAATACAT 1575
Db      14 TATACAAATACAT 1

RESULT 99
US-09-618-166-64
; Sequence 64, Application US/09618166
; Patent No. 6583112
; GENERAL INFORMATION:
; APPLICANT: Fu, Ying-Hui
; Oshima, Junko
; Mulligan, John T.
; Schellenberg, Gerald D.
; TITLE OF INVENTION: GENE AND GENE PRODUCTS RELATED TO
; WERNER'S SYNDROME
; NUMBER OF SEQUENCES: 209
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed Intellectual Property Law Group
; STREET: 701 Fifth Avenue, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
```

ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 8445:

; Sequence 11, Application US/09034113

QY 13 ATGAAGTTTCTTCT 26  
Db 1 AAGAAGTTTCTTCT 14

RESULT 91  
US-08-873-437-12/c  
; Sequence 12, Application US/08873437  
; Patent No. 6124092  
; GENERAL INFORMATION:  
; APPLICANT: O'Neill, Roger A.  
; APPLICANT: Chen, Jer-Kang  
; APPLICANT: Chiesa, Claudia  
; APPLICANT: Fry, George  
; TITLE OF INVENTION: Multiplex Polynucleotide Capture  
; TITLE OF INVENTION: Methods and Compositions  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PE Applied Biosystems  
; STREET: 850 Lincoln Centre Drive  
; CITY: Foster City  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94404  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/873,437  
; FILING DATE: 12-JUN-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/027,832  
; FILING DATE: 04-OCT-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Bortner, Scott R  
; REGISTRATION NUMBER: 34,298  
; REFERENCE/DOCKET NUMBER: 4294  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 415-638-6245  
; TELEFAX: 415-638-6071  
; INFORMATION FOR SEQ ID NO: 12:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-873-437-12

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 40;  
Matches 13; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 15 GAAGTTTCTTCTAA 28  
Db 15 GAAGCTTCTTCTAA 2

RESULT 92  
US-09-038-073-92  
; Sequence 92, Application US/09038073  
; Patent No. 6194150  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Daniel T.  
; APPLICANT: Jarvis, Thale  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
; NUMBER OF SEQUENCES: 2751  
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/038,073  
; FILING DATE:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/585,684  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/078  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 92:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-09-038-073-92

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 57.1%; Pred. No. 40;  
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 652 CTCACGTGCTGTCA 665  
Db 2 CUCACUUCUGUCCA 15

RESULT 93  
US-09-038-073-93  
; Sequence 93, Application US/09038073  
; Patent No. 6194150  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Daniel T.  
; APPLICANT: Jarvis, Thale  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
; NUMBER OF SEQUENCES: 2751  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/038,073  
; FILING DATE:



```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-93

Query Match      0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 40;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      652 CTCACGTGCTGTTC 665
Db      1 CUCACUUCUGUUA 14

RESULT 88
US-08-863-639A-8/c
; Sequence 8, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel Wordperfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueh
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-8

Query Match      0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1043 TTTTCTTTTAAA 1056
Db      14 TTTTCTTTTAAA 1

RESULT 89
US-08-832-021-17
; Sequence 17, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
```

```

; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 17
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-17

Query Match      0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1043 TTTTCTTTTAAA 1056
Db      2 TTTTCTTTTAAA 15

RESULT 90
US-08-781-891-64
; Sequence 64, Application US/08781891
; Patent No. 6090620
; GENERAL INFORMATION:
; APPLICANT: Fu, Ying-Hui
; APPLICANT: Yu, Chang-En
; APPLICANT: Oshima, Junko
; APPLICANT: Mulligan, John T.
; APPLICANT: Schellenberg, Gerald D.
; TITLE OF INVENTION: GENE AND GENE PRODUCTS RELATED TO
; TITLE OF INVENTION: WERNER'S SYNDROME
; NUMBER OF SEQUENCES: 209
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/781,891
; FILING DATE: 27-DEC-1996
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6090620tenburg Ph.D., Carol
; REGISTRATION NUMBER: 39,317
; REFERENCE/DOCKET NUMBER: 240052.419
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-781-891-64

Query Match      0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,634  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/390,850  
; FILING DATE: February 17, 1995  
; APPLICATION NUMBER: 08/354,920  
; FILING DATE: December 13, 1994  
; APPLICATION NUMBER: 08/152,487  
; FILING DATE: No. 5731295ember 12, 1993  
; APPLICATION NUMBER: 07/989,848  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 211/084  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 1145:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-435-634-1145

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 40;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 910 TTCTTCAAAGACAG 923  
Db 14 TTCTTCAAAGACAG 1

RESULT 86  
US-08-585-684B-92  
; Sequence 92, Application US/08585684B  
; Patent No. 5877021  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Daniel T.  
; APPLICANT: Jarvis, Thale  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
; NUMBER OF SEQUENCES: 2751  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/585,684B  
; FILING DATE: January 16, 1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/000,951  
; FILING DATE: July 7, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/078  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 92:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-585-684B-92

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 57.1%; Pred. No. 40;  
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 652 CTCACCTGCTGTCA 665  
Db 2 CUCACUUCUGUUA 15

RESULT 87  
US-08-585-684B-93  
; Sequence 93, Application US/08585684B  
; Patent No. 5877021  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Daniel T.  
; APPLICANT: Jarvis, Thale  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
; NUMBER OF SEQUENCES: 2751  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/585,684B  
; FILING DATE: January 16, 1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/000,951  
; FILING DATE: July 7, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/078  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 93:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs

US-08-319-492B-165  
Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 42.9%; Pred. No. 40;  
Matches 6; Conservative 7; Mismatches 1; Indels 0; Gaps 0;  
QY 1467 AATAAGTATTATT 1480  
||: ||: ||: ||: ||: ||:  
Db 1 AAUAGUAUUUU 14  
RESULT 83  
US-08-334-847-279/c  
; Sequence 279, Application US/08334847  
; Patent No. 5693532  
; GENERAL INFORMATION:  
; APPLICANT: McSwiggen, James  
; APPLICANT: Draper, Kenneth  
; APPLICANT: Pavco, Pam  
; APPLICANT: Woolf, Tod  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: INHIBITING RESPIRATORY  
; TITLE OF INVENTION: SYNCYTIAL VIRUS  
; NUMBER OF SEQUENCES: 909  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Suite 4700  
; STATE: Los Angeles  
; COUNTRY: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/334,847  
; FILING DATE: No. 5693532ember 4, 1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/032  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 279:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-334-847-279  
Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 40;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1748 AAGTATATATTT 1761  
|||||  
Db 15 AAGTATATATTT 2  
RESULT 84  
US-08-334-847-528/c  
; Sequence 528, Application US/08334847  
; Patent No. 5693532

GENERAL INFORMATION:  
APPLICANT: McSwiggen, James  
APPLICANT: Draper, Kenneth  
APPLICANT: Pavco, Pam  
APPLICANT: Woolf, Tod  
TITLE OF INVENTION: METHOD AND REAGENT FOR  
TITLE OF INVENTION: INHIBITING RESPIRATORY  
TITLE OF INVENTION: SYNCYTIAL VIRUS  
NUMBER OF SEQUENCES: 909  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/334,847  
FILING DATE: No. 5693532ember 4, 1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/032  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 528:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-334-847-528  
Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 40;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1570 ATACATATATTTT 1583  
|||||  
Db 14 ATACATATATTTAT 1  
RESULT 85  
US-08-435-634-1145/c  
; Sequence 1145, Application US/08435634  
; Patent No. 5731295  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California

```

; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc_difference
; LOCATION: one-of(6, 9, 11, 13, 15)
; OTHER INFORMATION: /note= "These positions are T,
; OTHER INFORMATION: 5-(1-propynyl)-2'-deoxyuridine (pdu), or other suitable
; OTHER INFORMATION: pyrimidines."
; FEATURE:
; NAME/KEY: misc_difference
; LOCATION: one-of(1, 2, 3, 4, 5, 7, 10, 12, 14)
; OTHER INFORMATION: /note= "These positions are
; OTHER INFORMATION: 2'-deoxyadenosine."
;
US-08-479-248-9

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1570 ATACATAATATTTT 1584
Db 15 ATATATATATTTT 1

RESULT 81
US-08-390-850-1145/C
; Sequence 1145, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327

```

```

; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1145:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-390-850-1145

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTCAAGACAG 923
Db 14 TTCTTCAAAACAG 1

RESULT 82
US-08-319-492B-165
; Sequence 165, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA:
; APPLICATION DATA: including application
; APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 165:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

```



;; PRIOR FILING DATE: 1998-09-22  
;; PRIOR APPLICATION NUMBER: US 60/059,473  
;; PRIOR FILING DATE: 1997-09-22  
;; NUMBER OF SEQ ID NOS: 1208  
;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO 116  
;; LENGTH: 16  
;; TYPE: RNA  
;; ORGANISM: Homo sapiens  
US-09-479-005A-116

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 40;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 AAATACATAATATTTT 1583  
Db 16 AAAAATATAATATTTT 1

RESULT 78  
PCT-US91-03056-1/c  
; Sequence 1, Application PC/TUS9103056  
; GENERAL INFORMATION:  
; APPLICANT: Vakharia, Vikram  
; TITLE OF INVENTION: SPECIFIC DNA AND RNA SEQUENCES  
; TITLE OF INVENTION: ASSOCIATED WITH US IBDV VARIANTS, VECTOR CARRYING DNA  
; TITLE OF INVENTION: SEQUENCES, HOST CARRYING CLONED VECTOR, DEDUCED AMINO ACID  
; TITLE OF INVENTION: SEQUENCES, VACCINE AND METHOD OF VACCINATION  
; NUMBER OF SEQUENCES: 20  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Viviana Amzel, Ph.D.  
; STREET: 112 East Pecan, 2000 NBC Bank Plaza  
; CITY: San Antonio  
; STATE: Texas  
; COUNTRY: USA  
; ZIP: 78205  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US91/03056  
; FILING DATE: 19910718  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/514,202  
; FILING DATE: 14-MAY-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Amzel Ph.D., Viviana  
; REGISTRATION NUMBER: 30,930  
; REFERENCE/DOCKET NUMBER: U-0125.02  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 512/554-5325  
; TELEFAX: 512/226-8395  
; TELEX: 762609  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 16 base pairs  
; TYPE: NUCLEIC ACID  
; STRANDEDNESS: both  
; TOPOLOGY: linear  
; PUBLICATION INFORMATION:  
; AUTHORS: Hudson, P. J.  
; JOURNAL: Nucleic Acids Res.  
; VOLUME: 14  
; PAGES: 5001-5012  
; DATE: 1986  
PCT-US91-03056-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 40;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 553 CTAGCCCATGCTTTTG 568  
Db 16 CTAGCCCATGCAATTG 1

RESULT 79  
US-09-867-915-10  
; Sequence 10, Application US/09867915  
; Patent No. 6521747  
; GENERAL INFORMATION:  
; APPLICANT: Genaissance Pharmaceuticals, Inc.  
; APPLICANT: Anastasio, Alison E.  
; APPLICANT: Finkel, Kevin  
; APPLICANT: Koshy, Beena  
; APPLICANT: Lee, Helen H.  
; TITLE OF INVENTION: HAPLOTYPES OF THE AGTR1 GENE  
; FILE REFERENCE: AGTR1-1136test  
; CURRENT APPLICATION NUMBER: US/09/867,915  
; CURRENT FILING DATE: 2001-05-30  
; PRIOR APPLICATION NUMBER: 60/228,542  
; PRIOR FILING DATE: 2000-08-28  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 10  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-867-915-10

Query Match 0.7%; Score 12.6; DB 1; Length 15;  
Best Local Similarity 92.3%; Pred. No. 36;  
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1709 GACTGAGAAATTA 1721  
Db 3 GACTGAGAAATKA 15

RESULT 80  
US-08-479-248-9/c  
; Sequence 9, Application US/08479248  
; Patent No. 5594121  
; GENERAL INFORMATION:  
; APPLICANT: FROEHLER, BRIAN  
; APPLICANT: MATTEUCCI, MARK  
; TITLE OF INVENTION: ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX  
; TITLE OF INVENTION: FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: GILEAD SCIENCES INC.  
; STREET: 353 Lakeside Drive  
; CITY: Foster City  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94404  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/479,248  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MUENCHAU, DARYL  
; REGISTRATION NUMBER: 36,616  
; REFERENCE/DOCKET NUMBER: 160.1C  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 574-3000  
; TELEFAX: (415) 573-4899



RESULT 72  
US-09-811-492-25/c  
; Sequence 25, Application US/09811492  
; Patent No. 6638764  
; GENERAL INFORMATION:  
; APPLICANT: SCHREIBER, ALAN D.  
; PARK, JONG-GU  
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: NIXON & VANDERHUYE P.C.  
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
; CITY: ARLINGTON  
; STATE: VIRGINIA  
; COUNTRY: U.S.A.  
; ZIP: 22201-4714  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/811,492  
; FILING DATE: 19-Jul-2001  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/657,884  
; FILING DATE: 07-JUN-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: WILSON, MARY J.  
; REGISTRATION NUMBER: 32,955  
; REFERENCE/DOCKET NUMBER: 555-46  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (703) 816-4000  
; TELEFAX: (703) 816-4100  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-811-492-25  
Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 475 GGCATGGCTGACA 487  
Db 14 GGCATGGCTGACA 2  
RESULT 73  
US-09-811-492-29/c  
; Sequence 29, Application US/09811492  
; Patent No. 6638764  
; GENERAL INFORMATION:  
; APPLICANT: SCHREIBER, ALAN D.  
; PARK, JONG-GU  
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: NIXON & VANDERHUYE P.C.  
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
; CITY: ARLINGTON  
; STATE: VIRGINIA  
; COUNTRY: U.S.A.  
; ZIP: 22201-4714  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/811,492  
; FILING DATE: 19-Jul-2001  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/657,884  
; FILING DATE: 07-JUN-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: WILSON, MARY J.  
; REGISTRATION NUMBER: 32,955  
; REFERENCE/DOCKET NUMBER: 555-46  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (703) 816-4000  
; TELEFAX: (703) 816-4100  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-811-492-25  
Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 475 GGCATGGCTGACA 487  
Db 14 GGCATGGCTGACA 2

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/811,492  
FILING DATE: 19-Jul-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/657,884  
FILING DATE: 07-JUN-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: WILSON, MARY J.  
REGISTRATION NUMBER: 32,955  
REFERENCE/DOCKET NUMBER: 555-46  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 816-4000  
TELEFAX: (703) 816-4100  
INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 29:  
US-09-811-492-29  
Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 475 GGCATGGCTGACA 487  
Db 14 GGCATGGCTGACA 2  
RESULT 74  
US-08-719-593-23/c  
; Sequence 23, Application US/08719593  
; Patent No. 5741706  
; GENERAL INFORMATION:  
; APPLICANT: Leavitt, Markley Carl  
; APPLICANT: Duarte, Elizabeth  
; APPLICANT: Tritz, Richard  
; APPLICANT: Barber, Jack R.  
; APPLICANT: Yu, Mang  
; TITLE OF INVENTION: No. 5741706el Anti-HIV Ribozymes  
; NUMBER OF SEQUENCES: 35  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, Eighth Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94111-3834  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/719,593  
; FILING DATE: No. 5741706 yet assigned  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Weber, Kenneth A.  
; REGISTRATION NUMBER: 31,677  
; REFERENCE/DOCKET NUMBER: 016556-000810US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 23:

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
|||||  
Db 14 GGCATGGCTGACA 2

RESULT 69

US-09-158-980-25/c  
; Sequence 25, Application US/09158980  
; Patent No. 6242427  
; GENERAL INFORMATION:  
; APPLICANT: SCHREIBER, ALAN D.  
; APPLICANT: PARK, JONG-GU  
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: NIXON & VANDERHYE P.C.  
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
; CITY: ARLINGTON  
; STATE: VIRGINIA  
; COUNTRY: U.S.A.  
; ZIP: 22201-4714  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/158,980  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/657,884  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: WILSON, MARY J.  
; REGISTRATION NUMBER: 32,955  
; REFERENCE/DOCKET NUMBER: 555-46  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (703) 816-4000  
; TELEFAX: (703) 816-4100  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; US-09-158-980-25

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
|||||  
Db 14 GGCATGGCTGACA 2

RESULT 70

US-09-158-980-29/c  
; Sequence 29, Application US/09158980  
; Patent No. 6242427  
; GENERAL INFORMATION:  
; APPLICANT: SCHREIBER, ALAN D.  
; APPLICANT: PARK, JONG-GU  
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: NIXON & VANDERHYE P.C.

; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
; CITY: ARLINGTON  
; STATE: VIRGINIA  
; COUNTRY: U.S.A.  
; ZIP: 22201-4714  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/158,980  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/657,884  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: WILSON, MARY J.  
; REGISTRATION NUMBER: 32,955  
; REFERENCE/DOCKET NUMBER: 555-46  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (703) 816-4000  
; TELEFAX: (703) 816-4100  
; INFORMATION FOR SEQ ID NO: 29:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; US-09-158-980-29

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487  
|||||  
Db 14 GGCATGGCTGACA 2

RESULT 71

US-09-081-646-162/c  
; Sequence 162, Application US/09081646  
; Patent No. 6333152  
; GENERAL INFORMATION:  
; APPLICANT: Kinzler, Kenneth  
; APPLICANT: Vogelstein, Bert  
; APPLICANT: Zhang, Lin  
; APPLICANT: Zhou, Wei  
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and  
; TITLE OF INVENTION: Cancer Cells  
; FILE REFERENCE: 01107.74664  
; CURRENT APPLICATION NUMBER: US/09/081,646  
; CURRENT FILING DATE: 1998-05-20  
; EARLIER APPLICATION NUMBER: 60/047,352  
; EARLIER FILING DATE: 1997-05-21  
; NUMBER OF SEQ ID NOS: 871  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 162  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; US-09-081-646-162

Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TTTTGTAGTTCA 1457  
|||||  
Db 15 TTTTGTAGTTCA 3



```

; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 599:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-334-847-599

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1572 ACATAATATTTT 1584
Db 14 ACATAATATTTT 2

US-08-657-884-25/c
; Sequence 25, Application US/08657884
; Patent No. 5858981
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHVE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,884
; FILING DATE: 07-JUN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-657-884-29

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCAATGGCTGACA 487
Db 14 GGCAATGGCTGACA 2

US-08-657-884-25
; Sequence 29, Application US/08657884
; Patent No. 5858981
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHVE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,884
; FILING DATE: 07-JUN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-657-884-29
```

; TITLE OF INVENTION: PRODUCTS
; FILE REFERENCE: 2960.44 (HV)
; CURRENT APPLICATION NUMBER: US/09/344,624
; CURRENT FILING DATE: 1999-06-25
; EARLIER APPLICATION NUMBER: 60/090,747
; EARLIER FILING DATE: 1998-06-26
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 28
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-344-624-28

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 25;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1040 AAGTTTCTTTTAA 1054
|||||||
Db 1 AAGTTTCTTTTAA 15

RESULT 63
US-08-436-145-8
; Sequence 8, Application US/08436145
; Patent No. 5681943
; GENERAL INFORMATION:
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Gryaznov, Sergei M.
; TITLE OF INVENTION: METHOD OF FORMING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Reising, Ethington, Barnard & Perry
; STREET: P.O. Box 4390
; CITY: Troy
; STATE: Michigan
; COUNTRY: USA
; ZIP: 48099
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/436,145
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kohn, Kenneth I.
; REGISTRATION NUMBER: 30,955
; REFERENCE/DOCKET NUMBER: P-323 (NW)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (810) 689-3500
; TELEFAX: (810) 689-4071
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-436-145-8

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 31;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1057 GATGACAAATACTGG 1071
|||||||
Db 2 GATGACAAATAGTGG 16

RESULT 64
US-09-371-772B-5744
; Sequence 5744, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5744
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5744

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 53.3%; Pred. No. 31;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1596 ACTCTAATTGTCAT 1610
||:|:|:|:|:|
Db 2 ACUCUAAUUGUCAAU 16

RESULT 65
US-09-479-005A-396
; Sequence 396, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBHB00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 396
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-396

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 31;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1643 AGTTACCTTCAAAGC 1657
||:|:|:|:|
Db 2 AGUUAACCUUGAAAGC 16

RESULT 66
US-08-334-847-599/c
; Sequence 599, Application US/08334847

Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

QY 527 ATGCTTTTGATGGCAA 543  
 |||||  
 Db 17 ATGCTTTTGATGGTAAA 1

RESULT 60  
 5182195-67/c  
 ;Patent No. 5182195  
 ; APPLICANT: NAKAHAMA, KAZUO;KAISHO, YOSHIHIKO;YOSHIMURA, KOJI  
 ; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE  
 ;DEFICIENT YEASTS  
 ; NUMBER OF SEQUENCES: 71  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/269,140  
 ; FILING DATE: 09-NOV-1988  
 ;SEQ ID NO:67:  
 ; LENGTH: 17  
 5182195-67

Query Match	0.8%;	Score	13.8;	DB	1;	Length	17;
Best Local Similarity	88.2%;	Pred. No.	31;				

Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

QY 933 GCTGAAGGTTTCTGAGA 949  
 |  
 Db 17 GATGAAGGTTTCTGAGA 1

RESULT 61  
 US-09-461-697-460/c  
 ; Sequence 460, Application US/09461697  
 ; Patent No. 6277974  
 ; GENERAL INFORMATION:  
 ; APPLICANT: COGENT NEUROSCIENCE, Inc.  
 ; APPLICANT: Lo, Donald C.  
 ; APPLICANT: Barney, Shawn  
 ; APPLICANT: Thomas, Mary Beth  
 ; APPLICANT: Portbury, Stuart D.  
 ; APPLICANT: Puranam, Kasturi  
 ; APPLICANT: Katz, Lawrence C.  
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING  
 ; TITLE OF INVENTION: AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING  
 ; TITLE OF INVENTION: CELL DEATH  
 ; FILE REFERENCE: 10001-005-999  
 ; CURRENT APPLICATION NUMBER: US/09/461,697  
 ; CURRENT FILING DATE: 1999-12-14  
 ; NUMBER OF SEQ ID NOS: 466  
 ; SOFTWARE: FastSEQ for Windows Version 4.0  
 ; SEQ ID NO 460  
 ; LENGTH: 15  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-09-461-697-460

Query Match	0.8%;	Score	13.4;	DB	1;	Length	15;
Best Local Similarity	93.3%;	Pred. No.	25;				

Matches	14;	Conservative	0;	Mismatches	1;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

QY 1561 TTATATAAATACAT 1575  
 |||||  
 Db 15 TTATATAAATACAT 1

RESULT 62  
 US-09-344-624-28  
 ; Sequence 28, Application US/09344624  
 ; Patent No. 6753154  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Chen, Huei-Mei  
 ; APPLICANT: Bissell, Mina  
 ; TITLE OF INVENTION: HUMAN AZ-1 GENE, VARIANTS THEREOF AND EXPRESSED GENE





```
RESULT 52
US-09-866-108A-6761
; Sequence 6761, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6761

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      506 GTGAGCTCATGGAGAC 522
Db      1 GAGGAGCTCCTGGAGAC 17

RESULT 53
US-09-866-108A-8637
; Sequence 8637, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6761

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      506 GTGAGCTCATGGAGAC 522
Db      1 GAGGAGCTCCTGGAGAC 17

RESULT 54
US-09-866-108A-10428/c
; Sequence 10428, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6761

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      200 AAATCCAAGAAATGCAG 216
Db      1 AGATCCAAGAACTGCAG 17
```

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8637
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8637

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      200 AAATCCAAGAAATGCAG 216
Db      1 AGATCCAAGAACTGCAG 17

RESULT 54
US-09-866-108A-10428/c
; Sequence 10428, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8637
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8637

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      200 AAATCCAAGAAATGCAG 216
Db      1 AGATCCAAGAACTGCAG 17
```

```

; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5572
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5572

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1221 TGATGAAAGGAGACAGA 1237
      | | | | | | | | | | | | | | | |
DB      17 TTATGGAAGGAGACAGA 1

RESULT 50
US-09-401-063-731
; Sequence 731, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 731:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 731:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5572
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5572

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1221 TGATGAAAGGAGACAGA 1237
      | | | | | | | | | | | | | | | |
DB      17 TTATGGAAGGAGACAGA 1

RESULT 51
US-09-401-063-815/c
; Sequence 815, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 815:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 815:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5572
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5572

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1221 TGATGAAAGGAGACAGA 1237
      | | | | | | | | | | | | | | | |
DB      17 TTATGGAAGGAGACAGA 1

RESULT 51
US-09-401-063-815/c
; Sequence 815, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 815:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

```

```

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 222
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-222

Query Match      0.8%;   Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;
Matches          9; Conservative    6; Mismatches    2; Indels    0; Gaps    0;

QY      1066 TACTGGTTAATTAGCAA 1082
       :||: ||:||:|:| |||
Db       1 UACUCGUUAUUAUCA 17

RESULT 46
US-09-371-772B-1868
; Sequence 1868, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1868

Query Match      0.8%;   Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;
Matches          9; Conservative    6; Mismatches    2; Indels    0; Gaps    0;

QY      919 GACAGGTTCTTCTGGCT 935
       | || | |:|:|:|:|
Db       1 GCCAUGUUCUUCUGGC 17

RESULT 47
US-09-371-772B-3143/c
; Sequence 3143, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

```

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-5675

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      919 GACAGGTTCTTCTGGCT 935
Db      1 GCCAUGUUCUCUGGCU 17

RESULT 43
US-08-584-040-7334/c
; Sequence 7334, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7334:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7334

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1679 TGCTCTGTAAGTTGCTT 1695
Db      17 TGCTCTCTTAGTTGCTT 1

US-08-584-040-7903/c
; Sequence 7903, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7903:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7903

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      527 ATGCTTTTGTGATGCAAA 543
Db      17 ATGCTTTTGTGATGATAA 1

RESULT 45
US-09-371-772B-222
; Sequence 222, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
```





QY 416 GGAAGCTTTCCAAGTA 432  
| | | | | : | | | | |  
Db 1 GGAAGCUCUCCAAGAA 17

RESULT 38  
US-08-985-162-731  
; Sequence 731, Application US/08985162  
; Patent No. 6057156  
; GENERAL INFORMATION:  
; APPLICANT: Akhtar, Saghir  
; APPLICANT: Fell, Patricia  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT  
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
; TITLE OF INVENTION: FACTOR RECEPTORS  
; NUMBER OF SEQUENCES: 1877  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ for Windows 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/985,162  
; FILING DATE: 04 December 1997  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/036,476  
; FILING DATE: 31 January 1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 230/107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 731:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-985-162-731

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 31;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1687 AAGTTGCTTCCTAACAT 1703  
| | | | | : | | | | |  
Db 1 AAGUCCUCCUCAAUU 17

RESULT 39  
US-08-985-162-815/c  
; Sequence 815, Application US/08985162  
; Patent No. 6057156  
; GENERAL INFORMATION:  
; APPLICANT: Akhtar, Saghir  
; APPLICANT: Fell, Patricia  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT

; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
; TITLE OF INVENTION: FACTOR RECEPTORS  
; NUMBER OF SEQUENCES: 1877  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ for Windows 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/985,162  
; FILING DATE: 04 December 1997  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/036,476  
; FILING DATE: 31 January 1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 230/107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 815:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-985-162-815

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 31;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GTGACAAAAATGAAATA 176  
| | | | | : | | | | |  
Db 17 GAGACAAAAATCAAATA 1

RESULT 40  
US-08-584-040-1677  
; Sequence 1677, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066

```

; INFORMATION FOR SEQ ID NO: 2029:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-2029

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1571 TACATAATATTTTCA 1587
Db      17 TACATAATACTTTCA 1

RESULT 36
US-08-435-628-2031/c
; Sequence 2031, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2031:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-2031

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1570 ATACATAATATTTTCA 1586
Db      17 ATACATAATACTTTCA 1

RESULT 37
US-08-435-628-2419
; Sequence 2419, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2419:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-2419

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 31;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

; APPLICATION NUMBER: 08/354,920  
; FILING DATE: December 13, 1994  
; APPLICATION NUMBER: 08/152,487  
; FILING DATE: No. 5731295ember 12, 1993  
; APPLICATION NUMBER: 07/989,848  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 211/084  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 598:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-435-634-598

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 31;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1144 AAAAAAATTGATGCAGC 1160  
Db 1 AGAAAAAUUGAUGCUGC 17

RESULT 34  
US-08-435-634-605  
; Sequence 605, Application US/08435634  
; Patent No. 5731295  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,634  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/390,850  
; FILING DATE: February 17, 1995  
; APPLICATION NUMBER: 08/354,920  
; FILING DATE: December 13, 1994  
; APPLICATION NUMBER: 08/152,487  
; FILING DATE: No. 5731295ember 12, 1993  
; APPLICATION NUMBER: 07/989,848  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 211/084  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 605:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-435-634-605

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 31;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 1186 ACCTACTTCTTTGTAGA 1202  
Db 1 ACAUACUUCUUGUGGA 17

RESULT 35  
US-08-435-628-2029/c  
; Sequence 2029, Application US/08435628  
; Patent No. 5817796  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,628  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/373,124  
; FILING DATE: January 13, 1995  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510



STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,634  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5731295ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5731295ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 541:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-634-541

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 31;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 908 TTTTCTTCAAGACAGG 924  
: : : : :  
Db 1 UGUUCUUUAAGACAGG 17

RESULT 32  
US-08-435-634-542  
Sequence 542, Application US/08435634  
Patent No. 5731295  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,634  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5731295ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 542:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-634-542

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 31;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 918 AGACAGGTTCTTCTGGC 934  
: : : : :  
Db 1 AGACAGGUAUUCUGGC 17

RESULT 33  
US-08-435-634-598  
Sequence 598, Application US/08435634  
Patent No. 5731295  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,634  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995

RESULT 29  
US-08-373-124A-2031/c  
; Sequence 2031, Application US/08373124A  
; Patent No. 5646042  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/373,124A  
; FILING DATE: January 13, 1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 2031:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-373-124A-2031  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. NO. 31;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1570.ATACATAATATTTTCA 1586  
Db 17 ATACATAATAACTTTCA 1  
RESULT 30  
US-08-373-124A-2419  
; Sequence 2419, Application US/08373124A  
; Patent No. 5646042  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/373,124A  
; FILING DATE: January 13, 1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 2419:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-373-124A-2419  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 76.5%; Pred. No. 31;  
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
QY 416 GGAAAGCTTTCCAAGTA 432  
Db 1 GGAAAGCTTCCCAAGAA 17  
RESULT 31  
US-08-435-634-541  
; Sequence 541, Application US/08435634  
; Patent No. 5731295  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles

TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 598:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-598

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 31;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1144 AAAAAAATTGATGACG 1160  
Db 1 AGAAAAUUGAUGCUGC 17

RESULT 27

US-08-390-850-605  
Sequence 605, Application US/08390850  
Patent No. 5612215  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,850  
FILING DATE: February 17, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5612215ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 605:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-605

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 31;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1186 ACCTACTTCTTTGTAGA 1202  
Db 1 ACAUACUUCUUUGUGGA 17

RESULT 28

US-08-373-124A-2029/c  
Sequence 2029, Application US/08373124A  
Patent No. 5646042  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth  
APPLICANT: McSwiggen, James  
APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
TITLE OF INVENTION: CANCER USING RIBOZYMES  
NUMBER OF SEQUENCES: 2627  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/373,124A  
FILING DATE: January 13, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/245,466  
FILING DATE: May 18, 1994  
APPLICATION NUMBER: 08/192,943  
FILING DATE: February 7, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
APPLICATION NUMBER: 07/936,422  
FILING DATE: August 26, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/035  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2029:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-373-124A-2029

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 31;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1571 TACATAATATTTTCAA 1587  
Db 17 TACATAATAACTTTCAA 1





TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: /desc = "DNA primer"  
US-08-720-625-8

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 28;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 781 GGCATTTCAGTCCCTGT 796  
Db 1 GGCATTTCAGTCGCTGT 16

RESULT 22

US-09-866-108A-10429/c  
Sequence 10429, Application US/098666108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 10430

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-10430

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 10429

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-10429

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886  
Db 17 TTTTGATGCTGTCA 4

RESULT 23

US-09-866-108A-10430/c

Sequence 10430, Application US/098666108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 10430

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-10430

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886  
Db 16 TTTTGATGCTGTCA 3

RESULT 24

US-08-390-850-541

Sequence 541, Application US/08390850

Patent No. 5612215

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John T.  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.

; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 10431  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-10431

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 24;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 871 AGTTTGTGCTGTCA 886  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 ACTTTGTGCTGTCA 2

RESULT 19  
US-09-866-108A-10433/c  
; Sequence 10433, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 10433  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-10433

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 24;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTGTGCTGTC 885  
| | | | | | | | | | | | | | | | | | | | |  
Db 16 GACTTTGTGCTGTC 1

RESULT 20  
US-09-685-664B-1826/c  
; Sequence 1826, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1826  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-1826

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 24;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 518 GAGACTTCCATGCTTT 533  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 GAGACTTCGATGCTTT 2

RESULT 21  
US-08-720-625-8  
; Sequence 8, Application US/08720625  
; Patent No. 6242587  
; GENERAL INFORMATION:  
; APPLICANT: Naik, Ulhas P.  
; APPLICANT: Parise, Leslie V.  
; TITLE OF INVENTION: CALCIUM-INTEGRIN BINDING PROTEIN  
; NUMBER OF SEQUENCES: 10  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Bell, Seltzer, Park & Gibson  
; STREET: P.O. Drawer 34009  
; CITY: Charlotte  
; STATE: No. 6242587th Carolina  
; COUNTRY: USA  
; ZIP: 28234  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/720,625  
; FILING DATE:  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Sibley, Kenneth D.  
; REGISTRATION NUMBER: 31,665  
; REFERENCE/DOCKET NUMBER: 5470-138  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-420-2200  
; TELEFAX: 919-881-3175  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs

Fri May 13 12:26:37 2005

```
US-09-866-108A-8638
; Sequence 8638, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8638
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8639
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 24;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAAATGCAGC 217
Db 2 ATCCAAGAACTGCAGC 17

RESULT 17
US-09-866-108A-8639
; Sequence 8639, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
```

```
US-09-866-108A-8638
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8639
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8639
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 24;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAAATGCAGC 217
Db 1 ATCCAAGAACTGCAGC 16

RESULT 18
US-09-866-108A-10431/c
; Sequence 10431, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

STATE: CA  
COUNTRY: USA  
ZIP: 94111-3834  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSEQ for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/091,952A  
FILING DATE: 19-Apr-1999  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/029,278  
FILING DATE: 28-OCT-1996  
APPLICATION NUMBER: PCT/US97/19381  
FILING DATE: 28-OCT-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Smith, Timothy L.  
REGISTRATION NUMBER: 35,367  
REFERENCE/DOCKET NUMBER: 015280-297100US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
TELEX: <Unknown>  
INFORMATION FOR SEQ ID NO: 193:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
FEATURE:  
NAME/KEY: -  
LOCATION: 1...18  
OTHER INFORMATION: Clone 47 reverse primer  
SEQUENCE DESCRIPTION: SEQ ID NO: 193:  
US-09-091-952A-193  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 24;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 46 ACTGCTTCTGGAGCTCTT 63  
Db 1 AGTGCTTCTGTAGCTCTT 18  
RESULT 14  
US-08-584-040-4059/c  
Sequence 4059, Application US/08584040  
Patent No. 6346398  
GENERAL INFORMATION:  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: TREATMENT OF DISEASES OR  
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
TITLE OF INVENTION: GROWTH FACTOR  
NUMBER OF SEQUENCES: 8502  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 4059:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-4059  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 24;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 518 GAGACTTCCATGCTTT 533  
Db 17 GAGACTTCGATGCTTT 2  
RESULT 15  
US-09-371-772B-1826/c  
Sequence 1826, Application US/09371772B  
Patent No. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MBH00,876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1826  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-1826  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 24;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 518 GAGACTTCCATGCTTT 533  
Db 17 GAGACTTCGATGCTTT 2  
RESULT 16



chong906-1.rn1

RESULT 11  
US-09-866-108A-10432/c  
; Sequence 10432, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSION  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30

RESULT 13  
US-09-091-952A-193  
; Sequence 193, Application US/09091952A  
; Patent No. 6458532  
; GENERAL INFORMATION:  
; APPLICANT: Detera-Wadleigh, Sevilla D.  
; Gershon, Elliot S.  
; Badner, Judith A.  
; Goldin, Lynn R.  
; Berrettini, Wade H.  
; Yoshikawa, Takeo  
; Sanders, Alan R.  
; Esterling, Lisa E.  
; TITLE OF INVENTION: Chromosomal Markers and Diagnostic  
; Tests for Manic-Depressive Illness  
; NUMBER OF SEQUENCES: 197  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Crew LLP  
; STREET: Two Embarcadero Center, Eighth Floor  
; CITY: San Francisco  
;

US-08-390-850-428  
; Sequence 428, Application US/08390850  
; Patent No. 5612215  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/390,850  
; FILING DATE: February 17, 1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/354,920  
; FILING DATE: December 13, 1994  
; APPLICATION NUMBER: 08/152,487  
; FILING DATE: No. 5612215ember 12, 1993  
; APPLICATION NUMBER: 07/989,848  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 211/084  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 428:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-390-850-428  
Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 11;  
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 197 AAAAAATCCAAGAAAT 212  
Db 2 AAAAAAUCCAAGAAAU 17  
RESULT 9  
US-08-435-634-428  
; Sequence 428, Application US/08435634  
; Patent No. 5731295  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,634  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5731295ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 428:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-634-428  
Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 11;  
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 197 AAAAAATCCAAGAAAT 212  
Db 2 AAAAAAUCCAAGAAAU 17  
RESULT 10  
US-08-387-805-19/c  
; Sequence 19, Application US/08387805  
; Patent No. 6448032  
; GENERAL INFORMATION:  
; APPLICANT:  
; TITLE OF INVENTION: Human Melanocyte stimulating hormone receptor  
; NUMBER OF SEQUENCES: 20  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox  
; STREET: 1100 New York Ave., N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20005  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,850  
FILING DATE: February 17, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5612215ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1070:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-1070

Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 61.1%; Pred. No. 11;  
Matches 11; Conservative 6; Mismatches 1; Indels 1; Gaps 0;

QY 782 GCATTGAGTCCCTGTATG 799  
||||:||||:||||: |||  
Db 1 GCAUUCAGUCCCUAUG 18

RESULT 6  
US-08-435-634-1070  
Sequence 1070, Application US/08435634  
Patent No. 5731295  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John T.  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
OF ARTHRITIC CONDITIONS  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,634  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5731295ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1070:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-634-1070

Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 61.1%; Pred. No. 11;  
Matches 11; Conservative 6; Mismatches 1; Indels 1; Gaps 0;

QY 782 GCATTGAGTCCCTGTATG 799  
||||:||||:||||: |||  
Db 1 GCAUUCAGUCCCUAUG 18

RESULT 7

US-09-422-978-5754/c  
Sequence 5754, Application US/09422978  
Patent No. 6537751  
GENERAL INFORMATION:  
APPLICANT: Cohen, Daniel  
APPLICANT: Blumenfeld, Marta  
APPLICANT: Chumakov, Ilya  
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...  
FILE REFERENCE: GENSET.020CP1  
CURRENT APPLICATION NUMBER: US/09/422,978  
CURRENT FILING DATE: 1999-10-20  
EARLIER APPLICATION NUMBER: US 09/298,850  
EARLIER FILING DATE: 1999-04-21  
EARLIER APPLICATION NUMBER: US 60/109,732  
EARLIER FILING DATE: 1998-11-23  
EARLIER APPLICATION NUMBER: US 60/082,614  
EARLIER FILING DATE: 1998-04-21  
NUMBER OF SEQ ID NOS: 11796  
SEQ ID NO 5754  
LENGTH: 19  
TYPE: DNA  
ORGANISM: Homo Sapiens  
FEATURE:  
NAME/KEY: primer\_bind  
LOCATION: 1..19  
OTHER INFORMATION: upstream amplification primer 99-6628 for SEQ 1820,  
US-09-422-978-5754

Query Match 0.9%; Score 16.4; DB 1; Length 19;  
Best Local Similarity 94.4%; Pred. No. 13;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1190 ACTTCTTTGTAGATAACC 1207  
||||| ||||| ||||| |||||  
Db 18 ACTTCTTTGCAGATAACC 1

RESULT 8

```

RESULT 1
US-09-396-196G-127779
; Sequence 127779, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 127779
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-127779

Query Match      1.1%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 5;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      781 GGCATTCAATCCCTGTATGGAG 802
Db      3 GGCATTCAATCCCTGTATGGAG 24

RESULT 2
US-09-396-196G-125366
; Sequence 125366, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125366
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125366

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 5.5;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1276 TTCCAAGGAATCGGGCCTAAATG 1300
Db      1 TTCCAAGGAATCAAGCCTAAATG 25

RESULT 3
US-09-696-791-4459
; Sequence 4459, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
```

```

; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4459
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; OTHER INFORMATION: MMP-3 ribozyme recognition site
US-09-696-791-4459

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.5;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      781 GGCATTCAATCCCTGTATGGA 801
Db      1 GGCATTCAATCCCTGTATGGA 21

RESULT 4
US-09-696-791-2608/c
; Sequence 2608, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2608
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin G1 ribozyme binding site
US-09-696-791-2608

Query Match      1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.3;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      901 AAGATCTTTTCTTCAAAG 919
Db      19 AAGATCTTTTACTTCAAAG 1

RESULT 5
US-08-390-850-1070
; Sequence 1070, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
```



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:28:21 ; Search time 1 Seconds  
(without alignments)  
5.946 Million cell updates/sec

Title: US-10-619-906-1  
Perfect score: 1778  
Sequence: 1 tagaagtttacaatgaagtt.....ttttggctcaataaaattg 1778

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 101 seqs, 1672 residues

Total number of hits satisfying chosen parameters: 202

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 101 summaries

Database : rni1.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	20.4	1.1	25	1	US-09-396-196G-127779 Sequence 127779,
2	20.2	1.1	25	1	US-09-396-196G-125366 Sequence 125366,
3	19.4	1.1	21	1	US-09-696-791-4459 Sequence 4459, Ap
4	17.4	1.0	19	1	US-09-696-791-2608 Sequence 2608, Ap
5	16.4	0.9	18	1	US-08-390-850-1070 Sequence 1070, Ap
6	16.4	0.9	18	1	US-08-435-634-1070 Sequence 1070, Ap
7	16.4	0.9	19	1	US-09-422-978-5754 Sequence 5754, Ap
8	16	0.9	17	1	US-08-390-850-428 Sequence 428, App
9	16	0.9	17	1	US-08-435-634-428 Sequence 428, App
10	15.4	0.9	17	1	US-08-387-805-19 Sequence 19, Appl
11	15.4	0.9	17	1	US-09-866-108A-10432 Sequence 10432, A
12	14.8	0.8	18	1	US-09-071-433-57 Sequence 57, Appl
13	14.8	0.8	18	1	US-09-091-952A-193 Sequence 193, App
14	14.4	0.8	17	1	US-08-584-040-4059 Sequence 4059, Ap
15	14.4	0.8	17	1	US-09-371-772B-1826 Sequence 1826, Ap
16	14.4	0.8	17	1	US-09-866-108A-8639 Sequence 8639, Ap
17	14.4	0.8	17	1	US-09-866-108A-8639 Sequence 8639, Ap
18	14.4	0.8	17	1	US-09-866-108A-10431 Sequence 10431, A
19	14.4	0.8	17	1	US-09-866-108A-10433 Sequence 10433, A
20	14.4	0.8	17	1	US-09-866-108A-10433 Sequence 10433, A
21	14.4	0.8	17	1	US-09-685-664B-1826 Sequence 1826, Ap
22	14.4	0.8	18	1	US-08-720-625-8 Sequence 8, Appli
23	14	0.8	17	1	US-09-866-108A-10429 Sequence 10429, A
24	13.8	0.8	17	1	US-09-866-108A-10430 Sequence 10430, A
25	13.8	0.8	17	1	US-08-390-850-541 Sequence 541, App
26	13.8	0.8	17	1	US-08-390-850-542 Sequence 542, App
27	13.8	0.8	17	1	US-08-390-850-598 Sequence 598, App
28	13.8	0.8	17	1	US-08-373-124A-2029 Sequence 605, App
29	13.8	0.8	17	1	US-08-373-124A-2031 Sequence 2029, Ap
30	13.8	0.8	17	1	US-08-373-124A-2419 Sequence 2419, Ap
31	13.8	0.8	17	1	US-08-373-124A-2419 Sequence 2419, Ap
32	13.8	0.8	17	1	US-08-435-634-541 Sequence 541, App
33	13.8	0.8	17	1	US-08-435-634-542 Sequence 542, App
					Sequence 598, App

34	13.8	0.8	17	1	US-08-435-634-605 Sequence 605, App
35	13.8	0.8	17	1	US-08-435-628-2029 Sequence 2029, Ap
36	13.8	0.8	17	1	US-08-435-628-2031 Sequence 2031, Ap
37	13.8	0.8	17	1	US-08-435-628-2419 Sequence 2419, Ap
38	13.8	0.8	17	1	US-08-985-162-731 Sequence 731, App
39	13.8	0.8	17	1	US-08-985-162-815 Sequence 815, App
40	13.8	0.8	17	1	US-08-584-040-1677 Sequence 1677, Ap
41	13.8	0.8	17	1	US-08-584-040-4101 Sequence 4101, Ap
42	13.8	0.8	17	1	US-08-584-040-5675 Sequence 5675, Ap
43	13.8	0.8	17	1	US-08-584-040-7334 Sequence 7334, Ap
44	13.8	0.8	17	1	US-08-584-040-7903 Sequence 7903, Ap
45	13.8	0.8	17	1	US-09-371-772B-222 Sequence 222, App
46	13.8	0.8	17	1	US-09-371-772B-1868 Sequence 1868, Ap
47	13.8	0.8	17	1	US-09-371-772B-3143 Sequence 3143, Ap
48	13.8	0.8	17	1	US-09-371-772B-3686 Sequence 3686, Ap
49	13.8	0.8	17	1	US-09-371-772B-5572 Sequence 5572, Ap
50	13.8	0.8	17	1	US-09-401-063-731 Sequence 731, App
51	13.8	0.8	17	1	US-09-401-063-815 Sequence 815, App
52	13.8	0.8	17	1	US-09-866-108A-6761 Sequence 6761, Ap
53	13.8	0.8	17	1	US-09-866-108A-8637 Sequence 8637, Ap
54	13.8	0.8	17	1	US-09-866-108A-10428 Sequence 10428, A
55	13.8	0.8	17	1	US-09-866-108A-10434 Sequence 10434, A
56	13.8	0.8	17	1	US-09-685-664B-222 Sequence 222, App
57	13.8	0.8	17	1	US-09-685-664B-1868 Sequence 1868, Ap
58	13.8	0.8	17	1	US-09-685-664B-3143 Sequence 3143, Ap
59	13.8	0.8	17	1	US-09-685-664B-3686 Sequence 3686, Ap
60	13.8	0.8	17	1	5182195-67 Patent No. 5182195
61	13.4	0.8	15	1	US-09-461-697-460 Sequence 460, App
62	13.4	0.8	15	1	US-09-344-624-28 Sequence 28, Appl
63	13.4	0.8	16	1	US-08-436-145-8 Sequence 8, Appli
64	13.4	0.8	16	1	US-09-371-772B-5744 Sequence 5744, Ap
65	13.4	0.8	16	1	US-09-479-005A-396 Sequence 396, App
66	13	0.7	15	1	US-08-334-847-599 Sequence 599, App
67	13	0.7	15	1	US-08-657-884-25 Sequence 25, Appl
68	13	0.7	15	1	US-08-657-884-29 Sequence 29, Appl
69	13	0.7	15	1	US-09-158-980-25 Sequence 25, Appl
70	13	0.7	15	1	US-09-158-980-29 Sequence 29, Appl
71	13	0.7	15	1	US-09-081-646-162 Sequence 162, App
72	13	0.7	15	1	US-09-811-492-25 Sequence 25, Appl
73	13	0.7	15	1	US-09-811-492-29 Sequence 29, Appl
74	13	0.7	16	1	US-08-719-593-23 Sequence 23, Appl
75	13	0.7	16	1	US-08-753-147-183 Sequence 183, App
76	12.8	0.7	16	1	US-08-719-593-7 Sequence 7, Appli
77	12.8	0.7	16	1	US-09-479-005A-116 Sequence 116, App
78	12.8	0.7	16	1	PCT-US91-03056-1 Sequence 1, Appli
79	12.6	0.7	15	1	US-09-867-915-10 Sequence 9, Appli
80	12.4	0.7	15	1	US-08-479-248-9 Sequence 9, Appli
81	12.4	0.7	15	1	US-08-390-850-1145 Sequence 1145, Ap
82	12.4	0.7	15	1	US-08-319-492B-165 Sequence 165, App
83	12.4	0.7	15	1	US-08-334-847-279 Sequence 279, App
84	12.4	0.7	15	1	US-08-334-847-528 Sequence 528, App
85	12.4	0.7	15	1	US-08-435-634-1145 Sequence 1145, Ap
86	12.4	0.7	15	1	US-08-585-684B-92 Sequence 92, Appl
87	12.4	0.7	15	1	US-08-585-684B-93 Sequence 93, Appl
88	12.4	0.7	15	1	US-08-863-639A-8 Sequence 8, Appli
89	12.4	0.7	15	1	US-08-832-021-17 Sequence 17, Appl
90	12.4	0.7	15	1	US-08-781-891-64 Sequence 64, Appl
91	12.4	0.7	15	1	US-08-873-437-12 Sequence 12, Appl
92	12.4	0.7	15	1	US-09-038-073-92 Sequence 92, Appl
93	12.4	0.7	15	1	US-09-038-073-93 Sequence 93, Appl
94	12.4	0.7	15	1	US-08-584-040-8445 Sequence 8445, Ap
95	12.4	0.7	15	1	US-09-593-312-12 Sequence 12, Appl
96	12.4	0.7	15	1	US-09-034-113-11 Sequence 11, Appl
97	12.4	0.7	15	1	US-08-431-048F-148 Sequence 148, App
98	12.4	0.7	15	1	US-09-371-772B-4101 Sequence 4101, Ap
99	12.4	0.7	15	1	US-09-618-166-64 Sequence 64, Appl
100	12.4	0.7	15	1	US-09-689-012-5 Sequence 5, Appli
101	12.4	0.7	15	1	US-09-685-664B-4101 Sequence 4101, Ap

ALIGNMENTS

**THIS PAGE BLANK (USPTO)**

Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 1000 Std Error: 0.00  
Plate: 0082 row: P column: 18  
Seq primer: CGTTCTAAAACGACGGCCAGT  
Class: plasmid ends  
High quality sequence stop: 24

Query Match	0.7%	Score 12.2;	DB 1;	Length 24;
Best Local Similarity	82.4%	Pred. No. 34;		
Matches 14; Conservative	0;	Mismatches	3;	Indels 0; Gaps 0;

RESULT	27
AJ739036	
LOCUS	AJ739036 12 bp mRNA linear EST 07-OCT-2004
DEFINITION	AJ739036 riken1 Gallus gallus cDNA clone 16p11r3, mRNA sequence.
ACCESSION	AJ739036
VERSION	AJ739036.1 GI:53904414
KEYWORDS	EST.
SOURCE	Gallus gallus (chicken)
ORGANISM	Gallus gallus Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus. 1 (bases 1 to 12) Caldwell,R.B., Kierzek,A.M., Arakawa,H., Bezzubov,Y., Zaim,J., Fiedler,P., Kutter,S., Blagodatski,A., Kostovska,D., Koter,M., Plachy,J., Carninci,P., Hayashizaki,Y. and Buerstedde,J.M. Full-length cDNAs from bursal lymphocytes to facilitate gene function analysis Unpublished (2004) Contact: Caldwell RB GSF - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
COMMENT	

```
/clone="16p11r3"  
/cell_type="bursal lymphocyte"  
/dev_stage="2-3 weeks old"  
/clone_lib="riken1"  
/note="CB inbred strain"
```

Query Match 0.7%; Score 12; DB 1; Length 12;  
Best Local Similarity 100.0%; Pred. No. 14;  
Matches 12: Conservative 0; Mismatches 0; Indels

RESULT	28
AJ656714	
LOCUS	15 bp mRNA linear EST 28-JUN-2004
DEFINITION	AJ656714 KN277 Sus scrofa cDNA clone C0005194_F04, mRNA sequence.
ACCESSION	AJ656714
VERSION	AJ656714.1 GI:49340746
KEYWORDS	EST.
SOURCE	Sus scrofa (pig)
ORGANISM	Sus scrofa Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus. 1 (bases 1 to 15) Anderson,S.I., Finlayson,H.A. and Archibald,A.L. Development of cDNA and EST resources for studying reproduction and embryo development in pigs and cattle Unpublished (2004) Contact: Anderson SI Genomics and Bioinformatics Roslin Institute Roslin, Midlothian, EH25 9PS, UNITED KINGDOM Single pass sequencing. Bases called and trimmed with phred v0.020425.c. Vector identified by cross_match with the -minscore 20 and -minmatch 12 options. Vector:pBlueScriptII(SK+) R. Sitel: EcoRI R. Site2: NotI 5' Seq Primer M13F Normalised library constructed from pooled early embryos, from 8- cell stage to blastocysts. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Instititue, Roslin, Midlothian, UK, EH25 9PS, <a href="http://www.arkgenomics.org">www.arkgenomics.org</a> .
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
COMMENT	

```

Query Match          0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 12: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Search completed: May 13, 2005, 12:26:21  
Job time : 1 secs

```
/mol_type="mRNA"
/db_xref="taxon:129 ola"
/db_xref="taxon:10090"
/clone="A015.B4"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="TIGEM gene trap library"
/note="Vector: pFLiP1"

Query Match      0.7%; Score 12.8; DB 1; Length 26;
Best Local Similarity 70.8%; Pred. No. 32;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1575 TTTTTCACCTTCATTCTATTCTTA 1598
      ||||| || ||||| |||
Db 3 TTTTTCATTTTTCATTTTATTGTTA 26

RESULT 24
CF301021
LOCUS
DEFINITION
7LEAF--05-L10.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
sativa (japonica cultivar-group) cDNA clone 7LEAF--05-L10, mRNA
sequence.
CF301021
CF301021.1 GI:33672782
EST.
SOURCE
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 14)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1..14
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-L10"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH108"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match      0.7%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1762
      ||||| |||||
Db 1 AAAAAATAAAAAAA 14

RESULT 25
CV091538
LOCUS
DEFINITION
NA1103_R cDNA non acclimated Bluecrop library Vaccinium corymbosum
```

```
CDNA 3', mRNA sequence.
CV091538
CV091538.1 GI:51570877
EST.
SOURCE
Vaccinium corymbosum
Vaccinium corymbosum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
asterids; Ericales; Ericaceae; Vaccinioideae; Vaccinieae;
Vaccinium.
1 (bases 1 to 28)
Dhanaraj,A.L., Alkharouf,N.W., Beard,H.S., Chouikha,I.B.,
Matthews,B.F. and Rowland,L.J.
Monitoring gene expression changes during cold acclimation of
blueberry (Vaccinium corymbosum L.) using a cDNA microarray
Unpublished (2004)
Contact: Rowland, L.J.
Fruit Lab
US Department of Agriculture (USDA), ARS, PSI
Bldg 010A, 10300 Baltimore avenue, BARC West, Beltsville, MD
20705-2350, USA
Tel: 301-504-6654
Fax: 301-504-5653
Email: rowlandj@ba.ars.usda.gov.

FEATURES
source
1..28
/organism="Vaccinium corymbosum"
/mol_type="mRNA"
/db_xref="taxon:69266"
/tissue_type="Flower buds including bud scales"
/dev_stage="Mature plants"
/clone_lib="cDNA non acclimated Bluecrop library"
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium
corymbosum cv. Bluecrop, RNA for preparation of library
was extracted from flower buds collected in the fall from
non acclimated plants"

Query Match      0.7%; Score 12.4; DB 1; Length 28;
Best Local Similarity 69.6%; Pred. No. 31;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1715 TGTTCGTTTCTTTAAATAATT 1737
      ||||| ||||| ||| |||
Db 4 TTTTTCATTTTTCATTTTACCTTTT 26

RESULT 26
AZ814559
LOCUS
DEFINITION
2M0082P18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0082P18 F, genomic survey sequence.
AZ814559
AZ814559.1 GI:12984467
GSS.
SOURCE
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 24)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
```





Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.  
Large-scale Sequencing Analysis of Rice ESTs  
Unpublished (2003)  
Contact: Nahm B.H.  
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division  
of Bioscience and Bioinformatics, Myongji University  
Yongin, Kyeonggi, Korea  
Tel: 82 31 330 6193  
Fax: 82 31 321 6355  
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES  
source  
1..15  
/organism="Oryza sativa (japonica cultivar-group)"  
/mol\_type="mRNA"  
/cultivar="Nackdong"  
/db\_xref="taxon:39947"  
/clone="14ROOT--01-E19"  
/tissue\_type="root"  
/dev\_stage="14 days after germination"  
/lab\_host="E.coli DH10B"  
/clone\_lib="Rice root plasmid cDNA library (14ROOT)"  
/note="Vector: PCR4-TOPO; Site 1: ECORI; mRNA was capped  
with oligoribonucleotides and then used as templates for  
RT-PCR."

Query Match 0.7%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 15;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763  
|||||  
Db 1 AAAAAAAAAAAAAA 15

RESULT 19  
CV057897/c  
LOCUS  
DEFINITION  
CV057897 31 bp mRNA linear EST 24-AUG-2004  
BNEL32a8 Barley EST endosperm library Hordeum vulgare subsp.  
vulgare cDNA clone BNEL32a8 5' similar to Unknown Function, mRNA  
sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
CV057897.1 GI:51521036  
EST.  
Hordeum vulgare subsp. vulgare  
Hordeum vulgare subsp. vulgare  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
Pooideae; Triticeae; Hordeum.

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT  
1 (bases 1 to 31)  
Ali,S, Holloway,B. and Taylor,W.C.  
Normalisation of cereal endosperm EST libraries for structural and  
functional genomic analysis  
Plant Mol. Biol. Rep. 18, 123-132 (2000)  
Contact: Bill Taylor  
Commonwealth Scientific and Industrial Research Organisation  
Division of Plant Industry.  
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia  
Tel: 61 2 6246 5223  
Fax: 61 2 6246 5000  
Email: Bill.Taylor@csiro.au  
Seq primer: M13 reverse primer  
High quality sequence stop: 31.  
Location/Qualifiers

FEATURES  
source  
1..31  
/organism="Hordeum vulgare subsp. vulgare"  
/mol\_type="mRNA"  
/cultivar="Himalaya"  
/sub\_species="vulgare"  
/db\_xref="taxon:112509"  
/clone="BNEL32a8"  
/tissue\_type="endosperm"  
/dev\_stage="developing endosperm tissue 10, 12, 15 dpa  
(days post anthesis)"

/lab\_host="DH10B (Life Technology)"  
/clone\_lib="Barley EST endosperm library"  
/note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA  
was prepared from endosperm tissues of the barley cultivar  
Himalaya. cDNA was synthesised from pooled 10, 12, and 15  
dpa endosperm using Not I-oligo(dT)18 primer/adaptor  
(Pharmacia Biotech), and then ligated to the Sal I-Not I  
site of Ziplox vector (Life Technology) after adding a  
Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan  
Ali and Bill Taylor."

Query Match 0.7%; Score 13.4; DB 1; Length 31;  
Best Local Similarity 64.5%; Pred. No. 28;  
Matches 20; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 1571 GAACTTTTTCACCTTCATTCTATTCTTAATT 1601  
|||||  
Db 31 GAATTTTTTTTTTTTTTTTTTTTTTTT 1

RESULT 20  
AJ588201  
LOCUS  
DEFINITION  
AJ588201 14 bp DNA linear GSS 15-JAN-2004  
Arabidopsis thaliana T-DNA flanking sequence, left border, clone  
352C02, genomic survey sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
AJ588201 GI:37937825  
GSS; left border; T-DNA flanking sequence.  
Arabidopsis thaliana (thale cress)

REFERENCE  
AUTHORS  
1  
Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,  
Chauvin,S., Bechtold,N., Cruaud,C., Deroose,R., Pelletier,G.,  
Lepiniec,L., Caboche,M. and Lecharny,A.  
T-DNA integration into the Arabidopsis genome depends on sequences  
of pre-insertion sites  
EMBO Rep. 3 (12), 1152-1157 (2002)

JOURNAL  
MEDLINE  
PUBMED  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT  
2 (bases 1 to 14)  
Balzergue,S.  
Direct Submission  
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue  
Gaston Cremieux, 91057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana  
plants from INRA (Versailles). The DNA fragment(s) resulting from  
the PCR were directly sequenced from the left or the right border  
to determine the genomic sequence flanking the insertion. T-DNA  
derived sequences were removed. Information to order the  
corresponding mutant line and a link to a database providing a  
graphical display of the insertion site are available at  
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has  
been generated in the framework of the French plant genomics  
program 'Genoplante' (http://www.genoplante.com and  
http://genoplante-info.infobiogen.fr).

FEATURES  
source  
1..14  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/cultivar="Wassiljewskija"  
/db\_xref="taxon:3702"  
/clone="352C02"  
/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"  
1..14  
/note="T-DNA flanking sequence  
left border"

Query Match 0.7%; Score 13; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 15;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;











```

/strain="129 ola"
/db_xref="taxon:10090"
/clone="A015.B4"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="TIGEM gene trap library"
/note="Vector: pFLIP1"

Query Match      1.2%; Score 21.8; DB 1; Length 26;
Best Local Similarity 92.0%; Pred. No. 5;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
Db 25 AACATAAAAAAAAAAAAAAAAAA 1

RESULT 8
AZ814559/c
LOCUS
DEFINITION
  AZ814559 24 bp DNA linear GSS 20-FEB-2001
  2M0082P18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
  clone UUGC2M0082P18 F, genomic survey sequence.
ACCESSION
  AZ814559 GI:12984467
VERSION
  AZ814559.1
KEYWORDS
  GSS.
SOURCE
  Mus musculus (house mouse)
ORGANISM
  Mus musculus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
REFERENCE
  1 (bases 1 to 24)
AUTHORS
  Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
  Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
  Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
  Niederhausern,A. and Wright,D.,Weiss,R.
  Mouse whole genome scaffolding with paired end reads from 10kb
  plasmid inserts
  Unpublished (2000)
  Contact: Robert B. Weiss
  University of Utah Genome Center
  University of Utah
  Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
  84112, USA
  Tel: 801 585 5606
  Fax: 801 585 7177
  Email: ddunn@genetics.utah.edu
  Insert Length: 10000 Std Error: 0.00
  Plate: 0082 row: P column: 18
  Seq primer: CGTTGTAAACGACGCGCCAGT
  Class: plasmid ends
  High quality sequence stop: 24.
  Location/Qualifiers
    1..24
      /organism="Mus musculus"
      /mol_type="genomic DNA"
      /strain="C57BL/6J"
      /db_xref="taxon:10090"
      /clone="UUGC2M0082P18"
      /sex="Male"
      /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
      /clone_lib="Mouse 10kb plasmid UUGC1M library"
      /note="Vector: PWD42nv; Purified genomic DNA from M.
      musculus C57BL/6J (male) was obtained from the Jackson
      Laboratory Mouse DNA Resource
      (http://www.jax.org/resources/documents/dnares/). The DNA
      was hydrodynamically sheared by repeated passage through a
      0.005 inch orifice at constant velocity. The sheared DNA
      was blunt end-repaired with T4 DNA polymerase and T4
      polynucleotide kinase. Adaptor oligonucleotides were
      ligated to the blunt ends in high molar excess. The
      adapted DNA was purified and size-selected for a 9.5 to
      10.5 kb range using preparative agarose gel
      electrophoresis. Vector DNA was prepared from a derivative
      of PWD42 (gi|4732114|gb|AF129072.1), a copy-number
```

```

of PWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match      1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 8.6;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAGAAAGAAAAAGAAA 1

RESULT 9
AZ597932/c
LOCUS
DEFINITION
  AZ597932 21 bp DNA linear GSS 13-DEC-2000
  1M0412D23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
  clone UUGC1M0412D23 F, genomic survey sequence.
ACCESSION
  AZ597932
VERSION
  AZ597932.1 GI:11720122
KEYWORDS
  GSS.
SOURCE
  Mus musculus (house mouse)
ORGANISM
  Mus musculus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
REFERENCE
  1 (bases 1 to 21)
AUTHORS
  Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
  Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
  Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
  Niederhausern,A. and Wright,D.,Weiss,R.
  Mouse whole genome scaffolding with paired end reads from 10kb
  plasmid inserts
  Unpublished (2000)
  Contact: Robert B. Weiss
  University of Utah Genome Center
  University of Utah
  Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
  84112, USA
  Tel: 801 585 5606
  Fax: 801 585 7177
  Email: ddunn@genetics.utah.edu
  Insert Length: 10000 Std Error: 0.00
  Plate: 0412 row: D column: 23
  Seq primer: CGTTGTAAACGACGCGCCAGT
  Class: plasmid ends
  High quality sequence stop: 21.
  Location/Qualifiers
    1..21
      /organism="Mus musculus"
      /mol_type="genomic DNA"
      /strain="C57BL/6J"
      /db_xref="taxon:10090"
      /clone="UUGC1M0412D23"
      /sex="Male"
      /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
      /clone_lib="Mouse 10kb plasmid UUGC1M library"
      /note="Vector: PWD42nv; Purified genomic DNA from M.
      musculus C57BL/6J (male) was obtained from the Jackson
      Laboratory Mouse DNA Resource
      (http://www.jax.org/resources/documents/dnares/). The DNA
      was hydrodynamically sheared by repeated passage through a
      0.005 inch orifice at constant velocity. The sheared DNA
      was blunt end-repaired with T4 DNA polymerase and T4
      polynucleotide kinase. Adaptor oligonucleotides were
      ligated to the blunt ends in high molar excess. The
      adapted DNA was purified and size-selected for a 9.5 to
      10.5 kb range using preparative agarose gel
      electrophoresis. Vector DNA was prepared from a derivative
      of PWD42 (gi|4732114|gb|AF129072.1), a copy-number
```

30 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 4

Db

RESULT 5  
CV057897  
LOCUS  
DEFINITION

CV057897 31 bp mRNA linear EST 24-AUG-2004  
BNEL32a8 Barley EST endosperm library Hordeum vulgare subsp. vulgare cDNA clone BNEL32a8 5' similar to Unknown Function, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

CV057897 GI:51521036  
EST.  
Hordeum vulgare subsp. vulgare  
Hordeum vulgare subsp. vulgare  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooideae; Triticeae; Hordeum.

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

1 (bases 1 to 31)  
Ali, S., Holloway, B. and Taylor, W.C.  
Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis  
Plant Mol. Biol. Rep. 18, 123-132 (2000)  
Contact: Bill Taylor  
Commonwealth Scientific and Industrial Research Organisation  
Division of Plant Industry.  
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia  
Tel: 61 2 6246 5223  
Fax: 61 2 6246 5000  
Email: Bill.Taylor@csiro.au  
Seq primer: M13 reverse primer  
High quality sequence stop: 31.  
Location/Qualifiers  
1. .31  
/organism="Hordeum vulgare subsp. vulgare"  
/mol\_type="mRNA"  
/cultivar="Himalaya"  
/sub\_species="vulgare"  
/db\_xref="taxon:112509"  
/clone="BNEL32a8"  
/tissue\_type="endosperm"  
/dev\_stage="developing endosperm tissue 10, 12, 15 dpa (days post anthesis)"  
/lab\_host="DH10B (Life Technology)"  
/clone\_lib="Barley EST endosperm library"  
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 1.5%; Score 27; DB 1; Length 31;  
Best Local Similarity 100.0%; Pred. No. 1.6;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1775  
|||||  
1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 27

Db

RESULT 6  
CV091538/c  
LOCUS  
DEFINITION

CV091538 28 bp mRNA linear EST 26-AUG-2004  
NA1103 R cDNA non acclimated Bluecrop library Vaccinium corymbosum cDNA 3', mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

CV091538 GI:51570877  
EST.  
Vaccinium corymbosum  
Vaccinium corymbosum  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Query Match 1.5%; Score 27; DB 1; Length 31;  
Best Local Similarity 100.0%; Pred. No. 1.6;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1775  
|||||  
1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 27

Db

RESULT 7  
CV020478/c  
LOCUS  
DEFINITION

CV020478 26 bp mRNA linear GSS 28-SEP-2004  
GC0745 TIGEM gene trap library Mus musculus cDNA clone A015.B4, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

CV020478 GI:52789738  
GSS.  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

1 (bases 1 to 26)  
Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.  
Tagging genes with cassette-exchange sites  
Unpublished (2004)  
Contact: TIGEM  
107  
TIGEM  
Via P. Castellino, 111, 80131 NAPOLI, ITALY  
Tel: +390816132205  
Fax: +390815790919  
Email: cobellis@tigem.it  
Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM  
Class: Gene Trap.  
Location/Qualifiers  
1. .26  
/organism="Mus musculus"  
/mol\_type="mRNA"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAAA 1

Db

FEATURES  
source

1. .28  
/organism="Vaccinium corymbosum"  
/mol\_type="mRNA"  
/cultivar="Bluecrop"  
/db\_xref="taxon:69266"  
/tissue\_type="Flower buds including bud scales"  
/dev\_stage="Mature plants"  
/clone\_lib="cDNA non acclimated Bluecrop library"  
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop, RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAAA 1

Db

RESULT 7  
CV020478/c  
LOCUS  
DEFINITION

CV020478 26 bp mRNA linear GSS 28-SEP-2004  
GC0745 TIGEM gene trap library Mus musculus cDNA clone A015.B4, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

CV020478 GI:52789738  
GSS.  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

1 (bases 1 to 26)  
Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.  
Tagging genes with cassette-exchange sites  
Unpublished (2004)  
Contact: TIGEM  
107  
TIGEM  
Via P. Castellino, 111, 80131 NAPOLI, ITALY  
Tel: +390816132205  
Fax: +390815790919  
Email: cobellis@tigem.it  
Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM  
Class: Gene Trap.  
Location/Qualifiers  
1. .26  
/organism="Mus musculus"  
/mol\_type="mRNA"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAAA 1

Db

FEATURES  
source

1. .26  
/organism="Vaccinium corymbosum"  
/mol\_type="mRNA"  
/cultivar="Bluecrop"  
/db\_xref="taxon:69266"  
/tissue\_type="Flower buds including bud scales"  
/dev\_stage="Mature plants"  
/clone\_lib="cDNA non acclimated Bluecrop library"  
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop, RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAAA 1

Db

FEATURES  
source

1. .26  
/organism="Vaccinium corymbosum"  
/mol\_type="mRNA"  
/cultivar="Bluecrop"  
/db\_xref="taxon:69266"  
/tissue\_type="Flower buds including bud scales"  
/dev\_stage="Mature plants"  
/clone\_lib="cDNA non acclimated Bluecrop library"  
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop, RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAAA 1

Db

FEATURES  
source

1. .26  
/organism="Vaccinium corymbosum"  
/mol\_type="mRNA"  
/cultivar="Bluecrop"  
/db\_xref="taxon:69266"  
/tissue\_type="Flower buds including bud scales"  
/dev\_stage="Mature plants"  
/clone\_lib="cDNA non acclimated Bluecrop library"  
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop, RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAAA 1

Db

FEATURES  
source

1. .26  
/organism="Vaccinium corymbosum"  
/mol\_type="mRNA"  
/cultivar="Bluecrop"  
/db\_xref="taxon:69266"  
/tissue\_type="Flower buds including bud scales"  
/dev\_stage="Mature plants"  
/clone\_lib="cDNA non acclimated Bluecrop library"  
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop, RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAAA 1

Db

FEATURES  
source

1. .26  
/organism="Vaccinium corymbosum"  
/mol\_type="mRNA"  
/cultivar="Bluecrop"  
/db\_xref="taxon:69266"  
/tissue\_type="Flower buds including bud scales"  
/dev\_stage="Mature plants"  
/clone\_lib="cDNA non acclimated Bluecrop library"  
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop, RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query

30 AAAAAAAAAAAAAAAAAAAAAA 4

Db

RESULT 5  
CV057897  
LOCUS  
DEFINITION  
CV057897 31 bp mRNA linear EST 24-AUG-2004  
BNEL32a8 Barley EST endosperm library Hordeum vulgare subsp. vulgare cDNA clone BNEL32a8 5' similar to Unknown Function, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Hordeum vulgare subsp. vulgare  
Hordeum vulgare subsp. vulgare  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooideae; Triticeae; Hordeum.

REFERENCE  
1 (bases 1 to 31)  
Ali, S., Holloway, B. and Taylor, W.C.  
Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis  
Plant Mol. Biol. Rep. 18, 123-132 (2000)

JOURNAL  
COMMENT  
Contact: Bill Taylor  
Commonwealth Scientific and Industrial Research Organisation  
Division of Plant Industry.  
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia  
Tel: 61 2 6246 5223  
Fax: 61 2 6246 5000  
Email: Bill.Taylor@csiro.au  
Seq primer: M13 reverse primer  
High quality sequence stop: 31.

FEATURES  
source  
Location/Qualifiers  
1..31  
/organism="Hordeum vulgare subsp. vulgare"  
/mol\_type="mRNA"  
/cultivar="Himalaya"  
/sub\_species="vulgare"  
/db\_xref="taxon:112509"  
/clone="BNEL32a8"  
/tissue\_type="endosperm"  
/dev\_stage="developing endosperm tissue 10, 12, 15 dpa (days post anthesis)"  
/lab\_host="DH10B (Life Technology)"  
/clone\_lib="Barley EST endosperm library"  
/note="Vector: ZipLox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZipLox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 1.5%; Score 27; DB 1; Length 31;  
Best Local Similarity 100.0%; Pred. No. 1.6;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1775  
|||||  
1 AAAAAAAAAAAAAAAAAAAAAA 27

Db

RESULT 6  
CV091538/c  
LOCUS  
DEFINITION  
CV091538 28 bp mRNA linear EST 26-AUG-2004  
NA1103 R cDNA non acclimated Bluecrop library Vaccinium corymbosum cDNA 3', mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Vaccinium corymbosum  
Vaccinium corymbosum  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Query Match 1.5%; Score 27; DB 1; Length 31;  
Best Local Similarity 100.0%; Pred. No. 1.6;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1775  
|||||  
1 AAAAAAAAAAAAAAAAAAAAAA 27

Db

RESULT 7  
CV020478/c  
LOCUS  
DEFINITION  
CV020478 26 bp mRNA linear GSS 28-SEP-2004  
GC0745 TIGEM gene trap library Mus musculus cDNA clone A015.B4, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
1 (bases 1 to 26)  
Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.  
Tagging genes with cassette-exchange sites  
Unpublished (2004)  
Contact: TIGEM  
107

TIGEM  
Via P. Castellino, 111, 80131 NAPOLI, ITALY  
Tel: +390816132205  
Fax: +390815790919  
Email: cobellis@tigem.it  
Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM  
Class: Gene Trap.  
Location/Qualifiers  
1..26  
/organism="Mus musculus"  
/mol\_type="mRNA"

FEATURES  
source  
Location/Qualifiers  
1..26  
/organism="Vaccinium corymbosum"  
/mol\_type="mRNA"  
/cultivar="Bluecrop"  
/db\_xref="taxon:69266"  
/tissue\_type="Flower buds including bud scales"  
/dev\_stage="Mature plants"  
/clone\_lib="cDNA non acclimated Bluecrop library"  
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop, RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAA 1

Db

RESULT 7  
CV020478/c  
LOCUS  
DEFINITION  
CV020478 26 bp mRNA linear GSS 28-SEP-2004  
GC0745 TIGEM gene trap library Mus musculus cDNA clone A015.B4, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
1 (bases 1 to 26)  
Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.  
Tagging genes with cassette-exchange sites  
Unpublished (2004)  
Contact: TIGEM  
107

TIGEM  
Via P. Castellino, 111, 80131 NAPOLI, ITALY  
Tel: +390816132205  
Fax: +390815790919  
Email: cobellis@tigem.it  
Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM  
Class: Gene Trap.  
Location/Qualifiers  
1..26  
/organism="Mus musculus"  
/mol\_type="mRNA"

FEATURES  
source  
Location/Qualifiers  
1..26  
/organism="Vaccinium corymbosum"  
/mol\_type="mRNA"  
/cultivar="Bluecrop"  
/db\_xref="taxon:69266"  
/tissue\_type="Flower buds including bud scales"  
/dev\_stage="Mature plants"  
/clone\_lib="cDNA non acclimated Bluecrop library"  
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium corymbosum cv. Bluecrop, RNA for preparation of library was extracted from flower buds collected in the fall from non acclimated plants"

Query Match 1.4%; Score 24.4; DB 1; Length 28;  
Best Local Similarity 89.3%; Pred. No. 2.8;  
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAAGAAAGTGAAAAAAAAAAAAAAAAA 1766  
|||||  
28 ANAAAAAGTNAAAAAAAAAAAAAAAAAA 1

Db



JOURNAL  
COMMENT functional genomic analysis  
Plant Mol. Biol. Rep. 18, 123-132 (2000)  
Contact: Bill Taylor  
Commonwealth Scientific and Industrial Research Organisation  
Division of Plant Industry.  
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia  
Tel: 61 2 6246 5223  
Fax: 61 2 6246 5000  
Email: Bill.Taylor@csiro.au  
Seq primer: M13 reverse primer  
High quality sequence stop: 36.  
Location/Qualifiers  
1. .36  
/organism="Triticum aestivum"  
/mol\_type="mRNA"  
/cultivar="Hartog"  
/db\_xref="taxon:4565"  
/clone="WNEL7d3"  
/tissue\_type="endosperm"  
/dev\_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"  
/lab\_host="DH10B (Life Technology)"  
/clone\_lib="Wheat EST endosperm library"  
/note="Vector: Ziplox; Site\_1: Sal I; Site\_2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adapter (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 1.7%; Score 30.2; DB 1; Length 36;  
Best Local Similarity 91.4%; Pred. No. 0.91;  
Matches 32; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1750 AAAAAAAAAAAAAAAAAAAAAACGGAATTC 1784  
|||||  
Db 1 AAAAAAAAAAAAAAAAAAAAAATTC 35

RESULT 3  
CV066327  
LOCUS  
DEFINITION CV066327 Wheat EST endosperm library Triticum aestivum cDNA clone  
WNEL32e2 5' similar to Unknown Function, mRNA sequence.  
ACCESSION CV066327.1 GI:51529504  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Triticum aestivum (bread wheat)  
Triticum aestivum  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooideae; Triticeae; Triticum.  
1 (bases 1 to 35)  
Ali, S, Holloway, B. and Taylor, W.C.  
Normalisation of cereal endosperm EST libraries for structural and functional genomic analysis  
Plant Mol. Biol. Rep. 18, 123-132 (2000)  
Contact: Bill Taylor  
Commonwealth Scientific and Industrial Research Organisation  
Division of Plant Industry.  
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia  
Tel: 61 2 6246 5223  
Fax: 61 2 6246 5000  
Email: Bill.Taylor@csiro.au  
Seq primer: M13 reverse primer  
High quality sequence stop: 35.  
Location/Qualifiers  
1. .35  
/organism="Triticum aestivum"  
/mol\_type="mRNA"  
/cultivar="Hartog"

/db\_xref="taxon:4565"  
/clone="WNEL32e2"  
/tissue\_type="endosperm"  
/dev\_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"  
/lab\_host="DH10B (Life Technology)"  
/clone\_lib="Wheat EST endosperm library"  
/note="Vector: Ziplox; Site\_1: Sal I; Site\_2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adapter (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adapter (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 1.6%; Score 29.2; DB 1; Length 35;  
Best Local Similarity 91.2%; Pred. No. 1.1;  
Matches 31; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1751 AAAAAAAAAAAAAAAAAACGGAATTC 1784  
|||||  
Db 1 AAAAAAAAAAAAAAAAAATTC 34

RESULT 4  
CW020481/c  
LOCUS  
DEFINITION CW020481 TIGEM gene trap library Mus musculus cDNA clone A015.C10, mRNA sequence.  
ACCESSION CW020481  
VERSION CW020481.1 GI:52789741  
KEYWORDS  
SOURCE  
ORGANISM  
Mus musculus (house mouse)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
1 (bases 1 to 30)  
Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.  
Tagging genes with cassette-exchange sites  
Unpublished (2004)  
Contact: TIGEM  
107  
TIGEM  
Via P. Castellino, 111, 80131 NAPOLI, ITALY  
Tel: +390816132205  
Fax: +390815790919  
Email: cobellis@tigem.it  
Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM  
Class: Gene Trap.  
Location/Qualifiers  
1. .30  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="129 Ola"  
/db\_xref="taxon:10090"  
/clone="A015.C10"  
/sex="male"  
/cell\_type="Embryonic stem cell"  
/cell\_line="E14"  
/clone\_lib="TIGEM gene trap library"  
/note="Vector: pFLIP1"

Query Match 1.5%; Score 27; DB 1; Length 30;  
Best Local Similarity 100.0%; Pred. No. 1.5;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1775  
|||||



Fri May 13 12:26:39 2005

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM.nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:26:20 ; Search time 1 Seconds  
(without alignments)  
1.615 Million cell updates/sec

Title: US-10-619-906-2  
Perfect score: 1790  
Sequence: 1 atgaaattctcatgatg.....aaaaacggaattcccgggga 1790

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 21 seqs, 451 residues

Total number of hits satisfying chosen parameters: 42

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 28 summaries

Database : rst2.seq.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	31.2	1.7	38	1	CV064759
2	30.2	1.7	36	1	CV066718
3	29.2	1.6	35	1	CV066327
C, 4	27	1.5	30	1	CW020481
	27	1.5	31	1	CV057897
5	27	1.5	31	1	CV091538
C 6	24.4	1.4	28	1	CV091538
C 7	21.8	1.2	26	1	CW020478
C 8	19.2	1.1	24	1	AZ814559
C 9	17.8	1.0	21	1	AZ597932
C 10	17.4	1.0	35	1	CV066327
C 11	17.4	1.0	36	1	CV066718
C 12	17.4	1.0	38	1	CV064759
13	16.4	0.9	18	1	AJ725584
14	16.4	0.9	18	1	CR786637
15	16	0.9	16	1	CR786853
16	15	0.8	16	1	CR786609
17	14	0.8	15	1	CR789161
18	13.4	0.7	15	1	CF291030
C 19	13.4	0.7	31	1	CV057897
20	13	0.7	14	1	AJ588201
21	13	0.7	30	1	CW020481
C 22	12.8	0.7	16	1	AA937877
23	12.8	0.7	26	1	CW020478
24	12.4	0.7	14	1	CF301021
25	12.4	0.7	28	1	CV091538
26	12.2	0.7	24	1	AZ814559
27	12	0.7	12	1	AJ739036
28	12	0.7	15	1	AJ656714

ALIGNMENTS

RESULT 1  
CV064759 38 bp mRNA linear EST 24-AUG-2004  
LOCUS Wheat EST endosperm library Triticum aestivum cDNA clone  
DEFINITION WNEL1498 5' similar to Unknown Function, mRNA sequence.  
ACCESSION CV064759  
VERSION CV064759.1 GI:51527936  
KEYWORDS EST.  
SOURCE Triticum aestivum (bread wheat)  
ORGANISM Triticum aestivum  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
Pooideae; Triticeae; Triticum.  
1 (bases 1 to 38)  
Ali,S, Holloway,B. and Taylor,W.C.  
Normalisation of cereal endosperm EST libraries for structural and  
functional genomic analysis  
Plant Mol. Biol. Rep. 18, 123-132 (2000)  
JOURNAL  
COMMENT Contact: Bill Taylor  
Commonwealth Scientific and Industrial Research Organisation  
Division of Plant Industry.  
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia  
Tel: 61 2 6246 5223  
Fax: 61 2 6246 5000  
Email: Bill.Taylor@csiro.au  
Seq primer: M13 reverse primer  
High quality sequence stop: 38.  
Location/Qualifiers  
1. .38  
/organism="Triticum aestivum"  
/mol\_type="mRNA"  
/cultivar="Hartog"  
/db\_xref="taxon:4565"  
/clone="WNEL1498"  
/tissue\_type="endosperm"  
/dev\_stage="developing endosperm tissue 6, 8, 10 dpa (days post-anthesis)"  
/lab\_host="DH10B (Life Technology)"  
/clone\_lib="Wheat EST endosperm library"  
/note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

FEATURES  
source

Query Match 1.7%; Score 31.2; DB 1; Length 38;  
Best Local Similarity 91.7%; Pred. No. 0.77;  
Matches 33; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAAATTC 1784  
|||||  
Db 2 AAAAAAAAAAAAAAAAAAAAAAAAAAATTC 37

RESULT 2

CV066718 36 bp mRNA linear EST 24-AUG-2004  
LOCUS WNEL7d3 Wheat EST endosperm library Triticum aestivum cDNA clone  
DEFINITION WNEL7d3 5' similar to Unknown Function, mRNA sequence.  
ACCESSION CV066718  
VERSION CV066718.1 GI:51529895  
KEYWORDS EST.  
SOURCE Triticum aestivum (bread wheat)  
ORGANISM Triticum aestivum  
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
Pooideae; Triticeae; Triticum.  
1 (bases 1 to 36)  
Ali,S, Holloway,B. and Taylor,W.C.  
Normalisation of cereal endosperm EST libraries for structural and

REFERENCE  
AUTHORS Ali,S, Holloway,B. and Taylor,W.C.  
TITLE Normalisation of cereal endosperm EST libraries for structural and

**THIS PAGE BLANK (USPTO)**

KW dynein axonemal light polypeptide chain 4; haplotyping; genotyping;  
KW neuroprotective; neurological disorder; allele-specific oligonucleotide;  
KW ASO; primer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200179235-A2.  
XX  
PD 25-OCT-2001.  
XX  
PF 16-APR-2001; 2001WO-US012304.  
XX  
PR 17-APR-2000; 2000US-0197460P.  
XX  
PA (GENA-) GENAISSANCE PHARM INC.  
XX  
PI Bentivegna SC, Chew A, Choi JY, Koshy B;  
XX  
DR WPI; 2002-075065/10.  
XX  
PT Genotyping human dynein, axonemal light polypeptide chain 4 gene of  
PT individual, useful for determining haplotype of individual, comprises  
PT determining identity of nucleotide pair at specific polymorphic sites for  
PT two copies of gene.  
XX  
PS Claim 16; Page 13; 79pp; English.  
XX  
CC The present invention relates to novel single nucleotide polymorphisms  
CC (SNPs) in the human dynein, axonemal light polypeptide chain 4 (DNAL4)  
CC gene located on chromosome 22q13.1, and methods for haplotyping and/or  
CC genotyping the DNAL4 gene. The methods of the invention make use of  
CC allele-specific oligonucleotides (ASOs) as probes and primers and/or  
CC primer-extension oligonucleotides for detecting the DNAL4 gene  
CC polymorphisms. The polynucleotides and screened compounds are useful for  
CC the treatment of diseases associated with DNAL4 activity, such as  
CC neurological disorders. AAS19921-AAS19948 represent ASO primers for  
CC detecting human DNAL4 gene polymorphisms  
XX  
SQ Sequence 15 BP; 5 A; 1 C; 5 G; 3 T; 0 U; 1 Other;  
  
Query Match 0.8%; Score 13.6; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.1e+02;  
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
QY 440 AAGATGAGGCTGAC 453  
Db 1 AAGATGAGGCTGAY 14  
  
Search completed: May 13, 2005, 12:20:44  
Job time : 4 secs

PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-008666108.  
XX  
PA (GUYV/) GU Y.  
PA (JIYY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX  
XX WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 874; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63102  
XX  
SQ Sequence 17 BP; 5 A; 2 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1131 CTTTGACCCACTTCGCC 1147  
Db ||||| |||||  
17 CTTTGACCCCTCCTCGCC 1  
  
RESULT 229  
ACN73532/c  
ID ACN73532 standard; DNA; 17 BP.  
XX  
AC ACN73532;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:10434.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-008666108.  
XX  
PA (GUYV/) GU Y.  
PA (JIYY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX  
XX WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10434; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 835 TTGAGTTTTCATGCTGT 851  
Db ||||| |||||  
17 TCGACTTTTCATGCTGT 1  
  
RESULT 230  
AAS19935  
ID AAS19935 standard; DNA; 15 BP.  
XX  
AC AAS19935;  
XX  
DT 26-MAR-2002 (first entry)  
XX  
DE ASO primer #15 to detect human DNAL4 gene polymorphisms.  
XX  
KW Human; single nucleotide polymorphism; SNP; DNAL4; chromosome 22q13.1;





XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX WPI; 2003-058513/05.  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 9; SEQ ID NO 789; 317pp; English.  
XX  
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human NOGO  
CC receptor zinzyme substrate sequence.  
XX  
SQ Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 1.2e+02;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;  
QY 1208 TGGACCCTGCTTACCC 1224  
:|||::||:|||||  
Db 1 UGGCCCGCUGACCC 17  
RESULT 225  
ADL49748  
ID ADL49748 standard; RNA; 17 BP.  
XX  
AC ADL49748;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human PKR substrate sequence #862.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
OS Unidentified.  
XX  
PN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX  
PF 03-APR-2002; 2002WO-US010512.  
XX  
PR 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX WPI; 2003-058513/05.  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 59; SEQ ID NO 3281; 317pp; English.  
XX  
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human PKR  
CC substrate sequence.  
XX  
SQ Sequence 17 BP; 9 A; 2 C; 2 G; 0 T; 4 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.2e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
QY 594 AAGTTTTCAAGGCACAA 610  
|||:::||| |||  
Db 1 AAGUUUUCAAAGCAAAA 17  
RESULT 226  
ADM60332/c  
ID ADM60332 standard; RNA; 17 BP.  
XX  
AC ADM60332;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Hepatitis B virus (HBV) RNA target sequence #2466.  
XX  
KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;  
KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;  
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;  
KW virucide; hepatotropic; antiinflammatory; cytostatic.  
XX  
OS Hepatitis B virus.  
XX  
PN US2004054156-A1.  
XX  
PD 18-MAR-2004.  
XX  
PF 15-JAN-2003; 2003US-00342902.  
XX  
PR 14-MAY-1992; 92US-00882712.  
PR 07-FEB-1994; 94US-00193627.  
PR 08-NOV-1999; 99US-00436430.  
PR 20-MAR-2000; 2000US-00531025.  
PR 09-AUG-2000; 2000US-00636385.  
PR 24-OCT-2000; 2000US-00696347.  
PR 08-JUN-2001; 2001US-00877478.  
XX  
PA (DRAP/) DRAPER K.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.

KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
XX diagnosis.  
OS Homo sapiens.  
XX  
PN WO2003040369-A2.  
XX  
PD 15-MAY-2003.  
XX  
XX 17-SEP-2002; 2002WO-IB004219.  
PF  
XX 17-SEP-2001; 2001FR-00011981.  
PR  
XX (MOLE-) MOLECULAR ENGINES LAB.  
PA Telerman A, Amson R, Tuijnder M;  
XX WPI; 2003-441574/41.  
DR  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX  
PS Disclosure; Page 392; 771pp; French.  
XX  
CC The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules.  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
SQ Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1120 GATGCAGCTGTCTTGA 1136  
DB 1 GATCCAGCTGTCTCTGA 17  
  
RESULT 223  
ACC53133/C  
ID ACC53133 standard; DNA; 17 BP.  
XX  
AC ACC53133;  
XX  
DT 27-JUN-2003 (first entry)  
XX  
DE Human tumour suppressor sequence #1900.  
XX  
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;  
KW tumour regression; apoptosis; virus resistance; diagnosis;  
KW cellular degeneration.  
XX  
OS Homo sapiens.  
XX

PN FR2826373-A1.  
XX  
PD 27-DEC-2002.  
XX  
PF 20-JUN-2001; 2001FR-00008139.  
XX  
PR 20-JUN-2001; 2001FR-00008139.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB SA.  
XX  
PI Tuijnder M, Telerman A, Amson R;  
XX WPI; 2003-250498/25.  
DR  
XX New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.  
XX  
PS Claim 1; Page 479; 798pp; French.  
XX  
CC This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX  
SQ Sequence 17 BP; 5 A; 2 C; 6 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1297 TACATCTTCCAAGGAGC 1313  
DB 17 TACATCTTCCAGGATC 1  
  
RESULT 224  
ADL47256  
ID ADL47256 standard; RNA; 17 BP.  
XX  
AC ADL47256;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human NOGO receptor zinzyme substrate sequence #243.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis;  
KW NOGO receptor zinzyme; substrate; ds.  
XX  
OS Unidentified.  
XX  
XX WO200281628-A2.  
PN  
XX  
PD 17-OCT-2002.  
XX  
XX 03-APR-2002; 2002WO-US010512.  
PF  
XX 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.

CC carcinoma. The present sequence represents a substrate for one of the HBV  
CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences  
CC disclosed in the present invention

SQ Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 792 GACAAAACCTAGCAGTC 808  
||| ||||| ||||| ||  
Db 17 GATAAAACCTAGCAGGC 1

RESULT 220  
ACC64538/c  
ID ACC64538 standard; DNA; 17 BP.

XX  
AC ACC64538;

DT 01-JUL-2003 (first entry)

DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1785.

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX PD 27-MAR-2003.

PF 17-SEP-2002; 2002WO-IB004210.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.

XX Disclosure; Page 239; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-  
CC ACC68806), which are associated with tumour suppression, tumour  
CC reversion, apoptosis and virus resistance. The oligonucleotides are  
CC useful as (1) as probes and primers for detecting, identifying,  
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
CC recombinant polypeptides. The oligonucleotides are useful for preparation  
CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia

XX Sequence 17 BP; 6 A; 5 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1602 TTGAAAGTGCATGTTTC 1618

Db 17 TTGAAAGTGTATGGATC 1

RESULT 221  
ACC65475  
ID ACC65475 standard; DNA; 17 BP.

XX  
AC ACC65475;

DT 01-JUL-2003 (first entry)

DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2722.

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX PD 27-MAR-2003.

PF 17-SEP-2002; 2002WO-IB004210.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.

XX Disclosure; Page 349; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-  
CC ACC68806), which are associated with tumour suppression, tumour  
CC reversion, apoptosis and virus resistance. The oligonucleotides are  
CC useful as (1) as probes and primers for detecting, identifying,  
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
CC recombinant polypeptides. The oligonucleotides are useful for preparation  
CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia

XX Sequence 17 BP; 7 A; 4 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 330 GATCTATAATTACACTC 346  
||||| ||||| ||||| |||||  
Db 1 GATCGAAAATTACACTC 17

RESULT 222  
ADB42757  
ID ADB42757 standard; DNA; 17 BP.

XX  
AC ADB42757;

XX 18-DEC-2003 (revised)

DT 04-DEC-2003 (first entry)

DE Tumour suppression/reversion associated nucleotide #3080.

XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;



CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX

SQ Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 41 CCTGTGGGGCTGCTCCC 57  
Db 17 CTTGTGGGGCTTCTCCC 1

RESULT 218  
ABZ60033/c  
ID ABZ60033 standard; RNA; 17 BP.

XX AC ABZ60033;

XX DT 21-MAR-2003 (first entry)

XX DE Human K-Ras DNazyme substrate #145.

XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;  
KW anti-rheumatic; cancer; AIDS; ss.

XX OS Homo sapiens.

XX PN WO200297114-A2.

XX PD 05-DEC-2002.

XX PF 29-MAY-2002; 2002WO-US016840.

XX PR 29-MAY-2001; 2001US-0294140P.

XX PR 06-JUN-2001; 2001US-0296249P.

XX PR 10-SEP-2001; 2001US-0318471P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Mcswiggen J;

XX DR WPI; 2003-140484/13.

XX PT Novel short interfering RNA and enzymatic nucleic acid useful for  
PT treating cancer, modulates the expression of a nucleic acid encoding  
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

PS Claim 58; Page 87; 185pp; English.

XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic  
CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-  
CC rheumatic activity. The nucleic acid molecules are useful for reducing  
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,  
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human  
CC ribozymes of the invention

XX SQ Sequence 17 BP; 9 A; 4 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1688 CTCTCTGTGCTTTACTG 1704

Db 17 CTGTCTTGCTTGCTG 1

RESULT 219  
ACD55872/c

ID ACD55872 standard; RNA; 17 BP.

XX AC ACD55872;

XX DT 23-SEP-2003 (first entry)

XX DE HBV amberzyme substrate sequence #271.

XX KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; DNazyme; inozyme; zinzyme;  
KW enzymatic nucleic acid; hammerhead ribozyme; decoy molecule; aptamer;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.

XX OS Hepatitis B virus.

XX PN WO200281494-A1.

XX PD 17-OCT-2002.

XX PF 26-MAR-2002; 2002WO-US009187.

XX PR 26-MAR-2001; 2001US-00817879.

XX PR 08-JUN-2001; 2001US-00877478.

XX PR 08-JUN-2001; 2001US-0296876P.

XX PR 24-OCT-2001; 2001US-0335059P.

XX PR 05-DEC-2001; 2001US-0337055P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (BLAT/) BLATT L.

XX PA (MACE/) MACEJAK D.

XX PA (MCSW/) MCSWIGGEN J.

XX PA (MORR/) MORRISSEY D.

XX PA (PAVC/) PAVCO P.

XX PA (LEEP/) LEE P.

XX PA (DRAP/) DRAPER K.

XX PA (ROBE/) ROBERTS E.

XX PI

PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;

XX Draper K, Roberts E;

XX DR WPI; 2003-229207/22.

XX PT

PT Novel compound useful for treating cirrhosis, liver failure,

PT hepatocellular carcinoma, or condition associated with hepatitis C virus

PT infection.

XX PS

XX Example 1; Page 209; 387pp; English.

The present invention relates to nucleic acid molecules which modulate  
the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
transcriptase and/or HBV reverse transcriptase primer sequences, as well  
as oligonucleotides that specifically bind the Enhancer I region of HBV  
DNA. The nucleic acids may be used to modulate the expression of HBV  
genes and HBV viral replication. Also disclosed is a method for screening  
compounds and/or potential therapies directed against HBV, and compounds  
that modulate the expression and/or replication of HCV. The compounds and  
methods of the invention are useful for the treatment of degenerative and  
disease states related to HBV and HCV infection, replication and gene  
expression such as cirrhosis, liver failure, and hepatocellular



XX 05-FEB-2003.  
PD 30-JUL-2002; 2002EP-00016874.  
XX  
PF 02-AUG-2001; 2001US-00922181.  
XX  
PR (AEOM-) AEOMICA INC.  
XX  
PA Shannon M, Gu Y, Nguyen C;  
XX  
PI WPI; 2003-423107/40.  
XX  
DR New zinc finger-containing proteins and nucleic acids, useful in  
XX manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
PT  
XX  
PS Example 8; SEQ ID NO 6360; 103pp; English.  
XX  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 823 TGTCAACCAAGCTTGAG 839  
Db 1 TGTCAACCAAGCTTCAG 17  
  
RESULT 214  
ADB03207/c  
ID ADB03207 standard; DNA; 17 BP.  
XX  
AC ADB03207;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ4 scanning oligonucleotide SEQ ID 4193.  
DE  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
OS  
XX EP1281758-A2.  
XX  
PN 05-FEB-2003.  
XX  
PD 30-JUL-2002; 2002EP-00016874.  
XX  
PF 02-AUG-2001; 2001US-00922181.  
XX  
PR (AEOM-) AEOMICA INC.  
PA

XX Shannon M, Gu Y, Nguyen C;  
PI WPI; 2003-423107/40.  
XX  
DR New zinc finger-containing proteins and nucleic acids, useful in  
XX manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
PT  
XX  
PS Example 8; SEQ ID NO 4193; 103pp; English.  
XX  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1297 TACATCTTCCAAGGAGC 1313  
Db 17 TACCTGTTCCAAGGAGC 1  
  
RESULT 215  
ADB05375  
ID ADB05375 standard; DNA; 17 BP.  
XX  
AC ADB05375;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human MDZ12 scanning oligonucleotide SEQ ID 6361.  
DE  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
OS Homo sapiens.  
OS  
XX EP1281758-A2.  
XX  
PN 05-FEB-2003.  
XX  
PD 30-JUL-2002; 2002EP-00016874.  
XX  
PF 02-AUG-2001; 2001US-00922181.  
XX  
PR (AEOM-) AEOMICA INC.  
XX  
PI Shannon M, Gu Y, Nguyen C;  
XX  
DR WPI; 2003-423107/40.  
XX  
PT New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 1052; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 2 C; 4 G; 0 T; 6 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.2e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 1467 GTGTAACATATGTGGCAA 1483
|:|:|:|:|:|:|
Db 1 GUGUUAUAUAGGCAA 17
RESULT 212
ABT35227
ID ABT35227 standard; DNA; 17 BP.
XX
AC ABT35227;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 864.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX

XX WO2003025175-A2.
PN
XX 27-MAR-2003.
PD
XX 17-SEP-2002; 2002WO-IB004208.
PF
XX 17-SEP-2001; 2001FR-00011978.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX Telerman A, Amson R, Tuijnder M;
PI
XX WPI; 2003-313353/30.
DR
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 134; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1120 GATGCAGCTGTCTTTGA 1136
||| ||| ||| ||| ||| |||
Db 1 GATCCAGATGTCTTTGA 17
RESULT 213
ADB05374
ID ADB05374 standard; DNA; 17 BP.
XX
AC ADB05374;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MDZ12 scanning oligonucleotide SEQ ID 6360.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MD24; MD27; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EPI281758-A2.
XX



QY 1738 GAAAGAAAGTGAAAAA 1754  
Db 17 GAAAGAGAGAGAAAAA 1

RESULT 209  
ACN08010/c  
ID ACN08010 standard; RNA; 17 BP.  
XX  
AC ACN08010;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8013.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 8013; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1466 GGTGTAACATATGGCA 1482  
Db 17 GGTGTTACTATATGGCA 1

RESULT 210  
ACN08216/c

ID ACN08216 standard; RNA; 17 BP.  
XX  
AC ACN08216;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8219.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 8219; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 10 CTCATGATGATTGTGTT 26  
Db 17 CTCTTGATGATTGTGCT 1

RESULT 211  
ACN01062  
ID ACN01062 standard; RNA; 17 BP.  
XX  
AC ACN01062;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV Hammerhead Ribozyme substrate SEQ ID NO 1052.

CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 3 G; 0 T; 5 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.2e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
  
QY 728 TCTCTGCTGATGACATA 744  
:|: :||:|:|:|:| |  
Db 1 UCUAUGCUGAUGACACA 17  
  
RESULT 207  
ACN07020  
ID ACN07020 standard; RNA; 17 BP.  
XX  
AC ACN07020;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV Amberzyme substrate SEQ ID NO 7023.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 7023; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention

XX  
SQ Sequence 17 BP; 12 A; 0 C; 5 G; 0 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1738 GAAAGAAAGTGAAAAAA 1754  
||||| || |||||  
Db 1 GAAAGAGAGAGAAAAAA 17  
  
RESULT 208  
ACN07773/c  
ID ACN07773 standard; RNA; 17 BP.  
XX  
AC ACN07773;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7776.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 7776; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 0 A; 5 C; 0 G; 0 T; 12 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 2887; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 4 A; 2 C; 5 G; 0 T; 6 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.2e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1466 GGTGTAACATATGTGGCA 1482  
Db 1 GGUGUUAUAUUGGCA 17  
  
RESULT 205  
ACN06635  
ID ACN06635 standard; RNA; 17 BP.  
XX  
AC ACN06635;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV Amberzyme substrate SEQ ID NO 6638.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
XX WPI; 2002-706994/76.  
DR  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 6638; 495pp; English.  
XX

CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 2 A; 3 C; 4 G; 0 T; 8 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.2e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 10 CTCATGATGATTGTGTT 26  
Db 1 CUCUUGAUGAUGUGCU 17  
  
RESULT 206  
ACN07069  
ID ACN07069 standard; RNA; 17 BP.  
XX  
AC ACN07069;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV Amberzyme substrate SEQ ID NO 7072.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
XX WPI; 2002-706994/76.  
DR  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 7072; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention

XX 09-AUG-2000; 2000US-0224383P.  
PR (RIBO-) RIBOZYME PHARM INC.  
XX (SYNT ) SYNTEX USA LLC.  
PA (THOM/) THOMPSON J.  
PA  
XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;  
PI Grupe A;  
XX WPI; 2002-217145/27.  
DR  
XX Enzymatic polynucleotide that down regulates expression of chloride  
PT channel calcium activated gene, useful for treating Chronic obstructive  
PT pulmonary disease (COPD), chronic bronchitis and asthma.  
XX  
PS Claim 4; Page 85; 152pp; English.  
XX  
CC The invention relates to enzymatic nucleic acid molecules that down  
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes  
CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
CC useful as pharmaceutical agents for treating conditions such as chronic  
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
CC that are related to or will respond to the levels of CLCA1 in a cell or  
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
CC hence, are useful for treatment of a patient having a condition  
CC associated with the level of CLCA1, where the invention further comprises  
CC the use of one or more therapies under conditions suitable for the  
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The  
CC nucleic acids of the invention are also used as diagnostic tools to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of CLCA1 RNA in a cell. This sequence represents an  
CC enzymatic nucleic acid molecule of the invention  
XX  
SQ Sequence 17 BP; 10 A; 1 C; 3 G; 0 T; 3 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 7 TTTCTCATGATGATTGT 23  
Db ||||| || |||||  
17 TTTCTCATCATTTATTGT 1  
  
RESULT 203  
ACN07730/C  
ID ACN07730 standard; RNA; 17 BP.  
XX  
AC ACN07730;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7733.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX

PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX WPI; 2002-706994/76.  
DR  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 7733; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 728 TCTCTGCTGATGACATA 744  
Db ||| ||||| ||||| |  
17 TCTATGCTGATGACACA 1  
  
RESULT 204  
ACN02884  
ID ACN02884 standard; RNA; 17 BP.  
XX  
AC ACN02884;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV Inozyme substrate SEQ ID NO 2887.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX WPI; 2002-706994/76.  
DR



XX WO200211674-A2.  
XX 14-FEB-2002.  
PD 09-AUG-2001; 2001WO-US024970.  
XX 09-AUG-2000; 2000US-0224383P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX (SYNT ) SYNTEX USA LLC.  
XX (THOM/) THOMPSON J.  
XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;  
PI Grupe A;  
PI WPI; 2002-217145/27.  
XX Enzymatic polynucleotide that down regulates expression of chloride  
PT channel calcium activated gene, useful for treating Chronic obstructive  
PT pulmonary disease (COPD), chronic bronchitis and asthma.  
XX Claim 4; Page 58; 152pp; English.  
XX The invention relates to enzymatic nucleic acid molecules that down  
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes  
CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
CC useful as pharmaceutical agents for treating conditions such as chronic  
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
CC that are related to or will respond to the levels of CLCA1 in a cell or  
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
CC hence, are useful for treatment of a patient having a condition  
CC associated with the level of CLCA1, where the invention further comprises  
CC the use of one or more therapies under conditions suitable for the  
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The  
CC nucleic acids of the invention are also used as diagnostic tools to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of CLCA1 RNA in a cell. This sequence represents an  
CC enzymatic nucleic acid molecule of the invention  
XX Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 298 TCAAGATGGATGAAGCG 314  
Db. 17 TCAAGCTGGATGGAGCG 1  
RESULT 201  
ABK56290  
ID ABK56290 standard; RNA; 17 BP.  
XX ABK56290;  
AC 02-JUL-2002 (first entry)  
XX Human CLCA1 gene enzymatic nucleic acid #661.  
DT Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;  
XX antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;  
DE chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;  
XX oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;  
KW acetylcysteine.  
KW Homo sapiens.  
XX WO200211674-A2.  
OS 14-FEB-2002.  
XX 09-AUG-2001; 2001WO-US024970.  
XX

PD 14-FEB-2002.  
XX 09-AUG-2001; 2001WO-US024970.  
XX 09-AUG-2000; 2000US-0224383P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX (SYNT ) SYNTEX USA LLC.  
XX (THOM/) THOMPSON J.  
XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;  
PI Grupe A;  
PI WPI; 2002-217145/27.  
XX Enzymatic polynucleotide that down regulates expression of chloride  
PT channel calcium activated gene, useful for treating Chronic obstructive  
PT pulmonary disease (COPD), chronic bronchitis and asthma.  
XX Claim 4; Page 66; 152pp; English.  
XX The invention relates to enzymatic nucleic acid molecules that down  
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes  
CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
CC useful as pharmaceutical agents for treating conditions such as chronic  
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
CC that are related to or will respond to the levels of CLCA1 in a cell or  
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
CC hence, are useful for treatment of a patient having a condition  
CC associated with the level of CLCA1, where the invention further comprises  
CC the use of one or more therapies under conditions suitable for the  
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The  
CC nucleic acids of the invention are also used as diagnostic tools to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of CLCA1 RNA in a cell. This sequence represents an  
CC enzymatic nucleic acid molecule of the invention  
XX Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 1.2e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
QY 1093 GGCTTCTCTGCATCTGT 1109  
Db. 1 GGCAUCUCUGUAUCUGU 17  
RESULT 202  
ABK56882/c  
ID ABK56882 standard; RNA; 17 BP.  
XX ABK56882;  
AC 02-JUL-2002 (first entry)  
XX Human CLCA1 gene enzymatic nucleic acid #1253.  
DE Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;  
XX antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;  
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;  
XX oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;  
KW acetylcysteine.  
XX Homo sapiens.  
OS WO200211674-A2.  
XX 14-FEB-2002.  
XX 09-AUG-2001; 2001WO-US024970.  
XX PF

ID ABS75295 standard; DNA; 17 BP.  
XX AC  
XX ABS75295;  
XX DT 24-DEC-2002 (first entry)  
XX DE Human PAPP-Ea associated 17-mer SEQ ID 821.  
XX DE  
XX KW PAPP-E; human; pregnancy associated plasma protein E; abortive;  
XX KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
XX KW dysgenetic pregnancy; primer; ss.  
XX OS Homo sapiens.  
XX XX US2002102252-A1.  
XX PN  
XX PD 01-AUG-2002.  
XX XX 06-APR-2001; 2001US-00827998.  
XX PF 26-MAY-2000; 2000US-0207456P.  
XX PR (GUYY/) GU Y.  
XX PA (SHAN/) SHANNON M E.  
XX PI Gu Y, Shannon ME;  
XX PI WPI; 2002-697817/75.  
XX DR  
XX XX New isolated nucleic acid encoding an isoform of human pregnancy  
PT associated plasma protein E, for preventing or aborting pregnancy.  
XX PS Example 2; Page 183; 353pp; English.  
XX CC This invention describes a novel isolated nucleic acid that encodes one  
CC of three new isoforms of human pregnancy associated plasma protein E,  
CC hPAPP-E. The products of the invention have abortive and contraceptive  
CC activity and can be used for gene therapy or in a vaccine. The nucleic  
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be  
CC used in pharmaceutical compositions or vaccines for preventing or  
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess  
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
CC antibodies can be used to assess the expression levels of PAPP-E isoform  
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
CC antenatally. This sequence represents an oligomer used in scanning the  
CC human PAPP-E genes described in the disclosure of the invention  
XX  
SQ Sequence 17 BP; 4 A; 1 C; 8 G; 4 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1176 CTACTGGAGGTATGATG 1192  
DB 1 CTAGGGGAGGTATGATG 17  
RESULT 199  
ABK57307/c  
ID ABK57307 standard; RNA; 17 BP.  
XX AC  
XX ABK57307;  
XX DT 02-JUL-2002 (first entry)  
XX DE Human CLCA1 gene enzymatic nucleic acid #1678.  
XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;  
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;  
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;  
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;

KW acetylcysteine.  
XX OS Homo sapiens.  
XX PN WO200211674-A2.  
XX PD 14-FEB-2002.  
XX XX 09-AUG-2001; 2001WO-US024970.  
XX PF 09-AUG-2000; 2000US-0224383P.  
XX PR (RIBO-) RIBOZYME PHARM INC.  
XX PA (SYNT ) SYNTEX USA LLC.  
XX PA (THOM/) THOMPSON J.  
XX PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;  
XX PI Grupe A;  
XX XX WPI; 2002-217145/27.  
XX DR Enzymatic polynucleotide that down regulates expression of chloride  
PT channel calcium activated gene, useful for treating Chronic obstructive  
PT pulmonary disease (COPD), chronic bronchitis and asthma.  
XX PS Claim 4; Page 111; 152pp; English.  
XX XX The invention relates to enzymatic nucleic acid molecules that down  
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes  
CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
CC useful as pharmaceutical agents for treating conditions such as chronic  
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
CC that are related to or will respond to the levels of CLCA1 in a cell or  
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
CC hence, are useful for treatment of a patient having a condition  
CC associated with the level of CLCA1, where the invention further comprises  
CC the use of one or more therapies under conditions suitable for the  
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The  
CC nucleic acids of the invention are also used as diagnostic tools to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of CLCA1 RNA in a cell. This sequence represents an  
CC enzymatic nucleic acid molecule of the invention  
XX  
SQ Sequence 17 BP; 9 A; 1 C; 3 G; 0 T; 4 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 6 ATTTCTCATGATGATG 22  
DB 17 ATTTCTCATGATGATG 1  
RESULT 200  
ABK55934/c  
ID ABK55934 standard; RNA; 17 BP.  
XX AC  
XX ABK55934;  
XX XX 02-JUL-2002 (first entry)  
XX DT  
XX DE Human CLCA1 gene enzymatic nucleic acid #305.  
XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;  
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;  
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;  
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;  
XX acetylcysteine.  
XX OS Homo sapiens.

CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytosstatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1459 TGCTCAGGGTGTAACCTA 1475  
Db 17 TGCTCAGGGTGAACCA 1

RESULT 196  
ABS74897  
ID ABS74897 standard; DNA; 17 BP.  
XX  
AC ABS74897;  
XX  
DT 24-DEC-2002 (first entry)  
XX  
DE Human PAPP-Ea associated 17-mer SEQ ID 423.  
XX  
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;  
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
KW dysgenetic pregnancy; primer; ss.

XX Homo sapiens.  
OS  
XX US2002102252-A1.  
XX  
PN 01-AUG-2002.  
XX  
PD 06-APR-2001; 2001US-00827998.  
XX  
PF 26-MAY-2000; 2000US-0207456P.  
XX  
PR (GUY/ ) GU Y.  
XX (SHAN/ ) SHANNON M E.  
XX  
PI Gu Y, Shannon ME;  
XX WPI; 2002-697817/75.  
XX  
PT New isolated nucleic acid encoding an isoform of human pregnancy  
XX associated plasma protein E, for preventing or aborting pregnancy.  
XX  
PS Example 2; Page 130; 353pp; English.

XX This invention describes a novel isolated nucleic acid that encodes one  
CC of three new isoforms of human pregnancy associated plasma protein E,  
CC hPAPP-E. The products of the invention have abortive and contraceptive  
CC activity and can be used for gene therapy or in a vaccine. The nucleic  
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be  
CC used in pharmaceutical compositions or vaccines for preventing or  
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess  
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
CC antibodies can be used to assess the expression levels of PAPP-E isoform  
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
CC antenatally. This sequence represents an oligomer used in scanning the  
CC human PAPP-E genes described in the disclosure of the invention  
XX  
SQ Sequence 17 BP; 0 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 39 TGCCTGTGGGCTGCTC 55  
Db 1 TGCCTGTGGGCTTCTC 17

RESULT 197  
ABS75296  
ID ABS75296 standard; DNA; 17 BP.  
XX  
AC ABS75296;  
XX  
DT 24-DEC-2002 (first entry)  
XX  
DE Human PAPP-Ea associated 17-mer SEQ ID 822.  
XX  
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;  
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
KW dysgenetic pregnancy; primer; ss.

XX Homo sapiens.  
OS  
XX US2002102252-A1.  
XX  
PD 01-AUG-2002.  
XX  
PF 06-APR-2001; 2001US-00827998.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
XX  
PA (GUY/ ) GU Y.  
PA (SHAN/ ) SHANNON M E.  
XX  
PI Gu Y, Shannon ME;  
XX WPI; 2002-697817/75.  
XX  
PT New isolated nucleic acid encoding an isoform of human pregnancy  
XX associated plasma protein E, for preventing or aborting pregnancy.  
XX  
PS Example 2; Page 183; 353pp; English.

XX This invention describes a novel isolated nucleic acid that encodes one  
CC of three new isoforms of human pregnancy associated plasma protein E,  
CC hPAPP-E. The products of the invention have abortive and contraceptive  
CC activity and can be used for gene therapy or in a vaccine. The nucleic  
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be  
CC used in pharmaceutical compositions or vaccines for preventing or  
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess  
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
CC antibodies can be used to assess the expression levels of PAPP-E isoform  
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
CC antenatally. This sequence represents an oligomer used in scanning the  
CC human PAPP-E genes described in the disclosure of the invention  
XX  
SQ Sequence 17 BP; 4 A; 0 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1177 TACTGGAGGTATGATGT 1193  
Db 1 TAGGGAGGTATGATGT 17

RESULT 198  
ABS75295

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 841 TTTGATGCTGTCAAC 857  
DB 17 TTTGATGCTGTCAAC 1

RESULT 194  
ABN10442/C  
ID ABN10442 standard; DNA; 17 BP.  
XX  
AC ABN10442;  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10434.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 10434; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1

CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 TTGAGTTTTGATGCTGT 851  
DB 17 TCGACTTTTGATGCTGT 1

RESULT 195  
ABQ64223/C  
ID ABQ64223 standard; DNA; 17 BP.  
XX  
AC ABQ64223;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 936.  
XX  
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhang J;  
XX  
DR WPI; 2002-479509/51.  
XX  
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX  
PS Example 2; Page 280; 418pp; English.  
XX  
CC The invention relates to a novel isolated nucleic acid encoding human



XX skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

XX WO200192524-A2.

PN 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 30-JAN-2001; 2001WO-US000670.

XX 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

PA Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

PI WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins, or as specific biomolecule capture probes for surface-enhanced laser desorption ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 874; 214pp; English.

XX The present invention describes a human genome-derived myosin-like protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequence

XX Sequence 17 BP; 5 A; 2 C; 9 G; 1 T; 0 U; 0 Other;

SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 CTTTGACCCACTTCGCC 1147

Db 17 CTTTGACCCCTCTCGCC 1

RESULT 193

ABN10436/c

ID ABN10436 standard; DNA; 17 BP.

XX ABN10436;

AC 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10428.

DE Human; genome-derived myosin-like protein 1; GDMPLP-1; heart; muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease; skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 30-JAN-2001; 2001WO-US000670.

XX 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

PA Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

PI WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins, or as specific biomolecule capture probes for surface-enhanced laser desorption ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 10428; 214pp; English.

XX The present invention describes a human genome-derived myosin-like protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequence

XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1678.  
XX  
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9954459-A2.  
XX  
PD 28-OCT-1999.  
XX  
PF 19-APR-1999; 99WO-US008547.  
XX  
PR 20-APR-1998; 98US-0082404P.  
PR 23-JUN-1998; 98US-00103636.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
PI Matulic-Adamic J;  
XX  
DR WPI; 2000-013248/01.  
XX  
PT New nucleic acids that interact, and optionally cleave, target sequences,  
PT used to treat cancer.  
XX  
PS Claim 77; Page 71; 148pp; English.  
XX  
CC The present invention describes nucleic acids (A) that interact stably  
CC with a target sequence and contain at least one phosphoro(di)thioate  
CC link, having endonuclease activity. (A), and more generally any catalytic  
CC nucleic acid (A') that modulates expression of the oestrogen receptor  
CC gene, are used to treat cancer (particularly of breast or endometrium),  
CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
CC for other conditions associated with levels of oestrogen receptor.  
CC Because of the high selectivity for targeted RNA, (A) can also be used to  
CC correlate inhibition of gene expression with alterations in phenotype,  
CC particularly for identification of therapeutic targets, and as research  
CC reagents (for RNA, in the same way that restriction endonucleases are  
CC used with DNA). The combination of modifications in (A) improves  
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
CC AAA24748 to AAA25992 represent their corresponding target sequences.  
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
CC sequences, and AAA26107 to AAA26218 represent their corresponding target  
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and  
CC antisense oligonucleotides used in the exemplification of the present  
CC invention  
XX  
SQ Sequence 17 BP; 1 A; 0 C; 1 G; 15 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1749 AAAAAAAAAAAAAAAAAA 1765  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 AAAAAATAAACAAAAA 1  
  
RESULT 191  
AAA25555/C  
ID AAA25555 standard; DNA; 17 BP.  
XX  
AC AAA25555;  
XX  
DT 19-JUL-2000 (first entry)  
XX  
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2053.  
XX

KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9954459-A2.  
XX  
PD 28-OCT-1999.  
XX  
PF 19-APR-1999; 99WO-US008547.  
XX  
PR 20-APR-1998; 98US-0082404P.  
PR 23-JUN-1998; 98US-00103636.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
PI Matulic-Adamic J;  
XX  
DR WPI; 2000-013248/01.  
XX  
PT New nucleic acids that interact, and optionally cleave, target sequences,  
PT used to treat cancer.  
XX  
PS Claim 77; Page 83; 148pp; English.  
XX  
CC The present invention describes nucleic acids (A) that interact stably  
CC with a target sequence and contain at least one phosphoro(di)thioate  
CC link, having endonuclease activity. (A), and more generally any catalytic  
CC nucleic acid (A') that modulates expression of the oestrogen receptor  
CC gene, are used to treat cancer (particularly of breast or endometrium),  
CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
CC for other conditions associated with levels of oestrogen receptor.  
CC Because of the high selectivity for targeted RNA, (A) can also be used to  
CC correlate inhibition of gene expression with alterations in phenotype,  
CC particularly for identification of therapeutic targets, and as research  
CC reagents (for RNA, in the same way that restriction endonucleases are  
CC used with DNA). The combination of modifications in (A) improves  
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
CC AAA24748 to AAA25992 represent their corresponding target sequences.  
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
CC sequences, and AAA26107 to AAA26218 represent their corresponding target  
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and  
CC antisense oligonucleotides used in the exemplification of the present  
CC invention  
XX  
SQ Sequence 17 BP; 13 A; 1 C; 0 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1717 TTTTGTTCCTTTTAAAT 1733  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 TTTTGTTCCTTTTAAAT 1  
  
RESULT 192  
ABN00882/C  
ID ABN00882 standard; DNA; 17 BP.  
XX  
AC ABN00882;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:874.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX

AC AAA25585;  
XX 19-JUL-2000 (first entry)  
DT  
DE  
XX  
XX  
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2083.  
XX  
XX  
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9954459-A2.  
XX  
PD 28-OCT-1999.  
XX  
XX 19-APR-1999; 99WO-US008547.  
XX  
PF 20-APR-1998; 98US-0082404P.  
XX  
PR 23-JUN-1998; 98US-00103636.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
PI Matulic-Adamic J;  
XX  
XX WPI; 2000-013248/01.  
DR  
XX  
XX New nucleic acids that interact, and optionally cleave, target sequences,  
PT used to treat cancer.  
PT  
XX  
PS Claim 77; Page 84; 148pp; English.  
XX  
XX The present invention describes nucleic acids (A) that interact stably  
CC with a target sequence and contain at least one phosphoro(di)thioate  
CC link, having endonuclease activity. (A), and more generally any catalytic  
CC nucleic acid (A') that modulates expression of the oestrogen receptor  
CC gene, are used to treat cancer (particularly of breast or endometrium),  
CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
CC for other conditions associated with levels of oestrogen receptor.  
CC Because of the high selectivity for targeted RNA, (A) can also be used to  
CC correlate inhibition of gene expression with alterations in phenotype,  
CC particularly for identification of therapeutic targets, and as research  
CC reagents (for RNA, in the same way that restriction endonucleases are  
CC used with DNA). The combination of modifications in (A) improves  
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
CC AAA24748 to AAA25992 represent their corresponding target sequences.  
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
CC sequences, and AAA26107 to AAA26218 represent their corresponding target  
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and  
CC antisense oligonucleotides used in the exemplification of the present  
CC invention  
XX  
SQ Sequence 17 BP; 7 A; 3 C; 1 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1287 AAGACACTACTACATCT 1303  
DB 1 AAGATACTACTACATT 17  
RESULT 189  
AAA25182/c  
ID AAA25182 standard; DNA; 17 BP.  
XX  
AC AAA25182;  
XX  
XX

DT 19-JUL-2000 (first entry)  
XX  
DE  
XX  
XX  
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9954459-A2.  
XX  
PD 28-OCT-1999.  
XX  
XX 19-APR-1999; 99WO-US008547.  
XX  
PF 20-APR-1998; 98US-0082404P.  
XX  
PR 23-JUN-1998; 98US-00103636.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
PI Matulic-Adamic J;  
XX  
XX WPI; 2000-013248/01.  
DR  
XX  
XX New nucleic acids that interact, and optionally cleave, target sequences,  
PT used to treat cancer.  
PT  
XX  
PS Claim 77; Page 71; 148pp; English.  
XX  
XX The present invention describes nucleic acids (A) that interact stably  
CC with a target sequence and contain at least one phosphoro(di)thioate  
CC link, having endonuclease activity. (A), and more generally any catalytic  
CC nucleic acid (A') that modulates expression of the oestrogen receptor  
CC gene, are used to treat cancer (particularly of breast or endometrium),  
CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
CC for other conditions associated with levels of oestrogen receptor.  
CC Because of the high selectivity for targeted RNA, (A) can also be used to  
CC correlate inhibition of gene expression with alterations in phenotype,  
CC particularly for identification of therapeutic targets, and as research  
CC reagents (for RNA, in the same way that restriction endonucleases are  
CC used with DNA). The combination of modifications in (A) improves  
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
CC AAA24748 to AAA25992 represent their corresponding target sequences.  
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
CC sequences, and AAA26107 to AAA26218 represent their corresponding target  
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and  
CC antisense oligonucleotides used in the exemplification of the present  
CC invention  
XX  
SQ Sequence 17 BP; 1 A; 0 C; 2 G; 14 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 130 ACAAAAACAAAAACCAA 146  
DB 17 ACAAAAATAAAAAACAAA 1  
RESULT 190  
AAA25180/c  
ID AAA25180 standard; DNA; 17 BP.  
XX  
AC AAA25180;  
XX  
DT 19-JUL-2000 (first entry)  
XX



KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9950403-A2.  
XX  
PD 07-OCT-1999.  
XX  
PF 24-MAR-1999; 99WO-US006507.  
XX  
PR 27-MAR-1998; 98US-0079678P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
XX  
DR WPI; 1999-591315/50.  
XX  
PT Novel ribozymes for modulating the synthesis, expression and/or stability  
PT of an mRNA encoding an angiogenic factors.  
XX  
PS Claim 56; Page 134; 305pp; English.  
XX  
CC The present invention describes enzymatic nucleic acid molecules with RNA  
CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 5 A; 0 C; 3 G; 0 T; 9 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.2e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
  
QY 830 AAAGCTTGAGTTTGTAT 846  
Db 1 AAAGUUUUAGUUUUUGAU 17  
  
RESULT 187  
AAA18786/C  
ID AAA18786 standard; RNA; 17 BP.  
XX  
AC AAA18786;  
XX  
DT 19-JUN-2000 (first entry)  
XX  
DE Human TIE-2 substrate sequence SEQ ID NO:2012.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9950403-A2.  
XX  
PD 07-OCT-1999.  
XX  
PF 24-MAR-1999; 99WO-US006507.  
XX  
PR 27-MAR-1998; 98US-0079678P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
XX  
DR WPI; 1999-591315/50.  
XX  
PT Novel ribozymes for modulating the synthesis, expression and/or stability  
PT of an mRNA encoding an angiogenic factors.  
XX  
PS Claim 56; Page 117; 305pp; English.  
XX  
CC The present invention describes enzymatic nucleic acid molecules with RNA  
CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 6 A; 2 C; 3 G; 0 T; 6 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1317 TCAATTGGATATGACC 1333  
Db 17 TCAATTGCAATATGATC 1  
  
RESULT 188  
AAA25585  
ID AAA25585 standard; DNA; 17 BP.  
XX



Best Local Similarity 88.2%; Pred. No. 1.2e+02; Mismatches 2; Indels 0; Gaps 0; Matches 15; Conservative 0;

QY 217 GACAACTCAACTCTGGC 233  
Db 17 GACAACTCAACTCTGGC 1

RESULT 184  
AAV85964/c  
ID AAV85964 standard; DNA; 17 BP.  
XX  
AC AAV85964;  
XX  
DT 10-FEB-1999 (first entry)  
XX  
DE Mouse LRP-3 cDNA PCR primer 83r (mucx 1r).  
XX  
KW LRP5; LDL-receptor related protein; LRP-3; IDDM; diagnosis; endocytosis;  
KW insulin dependent diabetes mellitus; autoimmune disease;  
KW glomerulonephritis; inflammation; viral infection; osteoporosis;  
KW hypercholesterolemia; Alzheimer's disease; low density lipoprotein;  
KW PCR primer; ss.  
XX  
OS Synthetic.  
OS Mus sp.  
XX  
PN WO9846743-A1.  
XX  
PD 22-OCT-1998.  
XX  
PF 15-APR-1998; 98WO-GB001102.  
XX  
PR 15-APR-1997; 97US-0043553P.  
PR 05-JUN-1997; 97US-0048740P.  
XX  
PA (WELL ) WELLCOME TRUST LTD.  
PA (MERI ) MERCK & CO INC.  
XX  
PI Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H;  
PI Hey P, Kawaguchi Y, Merriman TR, Metzker ML, Nakagawa Y;  
PI Phillips MS, Twells RCJ;  
XX  
WPI; 1998-594573/50.  
XX  
New isolated LDL-receptor related protein - used to develop products for  
treating, e.g. elevated triglyceride levels, diabetes, autoimmune  
disorders, inflammation or Alzheimer's disease.  
XX  
Claim 12; Page 117; 200pp; English.  
XX  
The present invention describes LRP5 (low density lipoprotein (LDL)  
receptor related protein, previously designated LRP-3). Nucleic acid  
molecules (NAMS) encoding LRP5 can be used for determining if an  
individual is susceptible to insulin dependent diabetes mellitus (IDDM).  
The NAMS or proteins can be used for reducing triglyceride levels in the  
serum of an individual. Therapies that affect LRP5 may also be useful in  
the treatment of autoimmune diseases such as glomerulonephritis, diseases  
and disorders involving disruption of endocytosis and/or antigen  
presentation, cytokine clearance and/or inflammation, viral infection,  
pathogenic bacterial toxin contamination, elevation of free fatty acids  
or hypercholesterolemia, type 2 diabetes, osteoporosis, Alzheimer's  
disease and cardiovascular disease. Products from the present invention  
can also be used for detection, diagnosis and drug screening. AAV85917 to  
AAV86012 represent PCR primers for obtaining LRP-3 cDNA  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 762 CTATGGAGCCCCAGTGA 778  
Db 17 CCATGGAGCCCCAGTGA 1

RESULT 185  
AAV26749  
ID AAV26749 standard; DNA; 17 BP.  
XX  
AC AAV26749;  
XX  
DT 17-SEP-1998 (first entry)  
XX  
DE Retroviral vector primer EPC5.  
XX  
KW ss; gag; gene delivery; pol; env; murine leukaemia virus; gene therapy;  
KW primer; PCR; amplification.  
XX  
OS Synthetic.  
XX  
PN WO9812338-A1.  
XX  
PD 26-MAR-1998.  
XX  
PF 22-SEP-1997; 97WO-KR000180.  
XX  
PR 21-SEP-1996; 96KR-00041438.  
XX  
PA (VIRO-) VIROMEDICA PACIFIC LTD.  
XX  
PI Kim S, Kim S, Robbins PD;  
XX  
WPI; 1998-217273/19.  
XX  
New retroviral vectors, particularly for gene therapy - which are free of  
the gag coding sequence, to provide for high levels of gene expression,  
viral titre and packaging efficiency.  
XX  
Example 6; Page 32; 79pp; English.  
XX  
The primers AAV26717-V26750 and AAV26752-V26753 were used in the  
production of two retroviral vectors (RV). The first is a RV that has no  
gag coding sequence is capable of delivering a gene of interest to a  
target cell when packaging functions of gag, pol and env are provided.  
The second is a RV based on murine leukaemia virus (MLV) where entire gag  
and env coding sequences are completely deleted. The vectors can be used  
for gene therapy, for example for the delivery of hormones, enzymes,  
receptors or drugs  
XX  
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 CCTTGGGGCTGCAGCAT 663  
Db 1 CCATGGGGCTGCAGAAAT 17

RESULT 186  
AAA19065  
ID AAA19065 standard; RNA; 17 BP.  
XX  
AC AAA19065;  
XX  
DT 19-JUN-2000 (first entry)  
XX  
DE Human TIE-2 substrate sequence SEQ ID NO:2291.  
XX  
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;

DR WPI; 1997-259017/23.  
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
XX Claim 4; Page 149; 218pp; English.  
PS  
XX The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 1 A; 4 C; 4 G; 0 T; 8 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 1.2e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
QY 29 TACAGGTATCTGCCTGT 45  
Db :|||:::|:|:|:|:  
1 UACUGGUUCUGCCUGU 17  
AAX75069;  
XX  
XX 28-JUL-1999 (first entry)  
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #597.  
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
OS Mus sp.  
XX WO9715662-A2.  
PN 01-MAY-1997.  
PD 25-OCT-1996; 96WO-US017480.  
PF 26-OCT-1995; 95US-0005974P.  
XX 11-JAN-1996; 96US-00584040.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
PI WPI; 1997-259017/23.  
DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
PS Claim 4; Page 173; 218pp; English.  
XX The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 0 A; 0 C; 2 G; 0 T; 15 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAA 1765  
Db ||||| ||||| |||||  
17 AAAAAAAAAAACAAAAA 1  
RESULT 183  
AAX69542/c  
ID AAX69542 standard; RNA; 17 BP.  
XX  
XX AAX69542;  
XX 28-JUL-1999 (first entry)  
XX Human flt1 VEGF receptor hammerhead ribozyme substrate #837.  
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
OS Homo sapiens.  
XX WO9715662-A2.  
PN 01-MAY-1997.  
PD 25-OCT-1996; 96WO-US017480.  
PF 26-OCT-1995; 95US-0005974P.  
XX 11-JAN-1996; 96US-00584040.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
PI WPI; 1997-259017/23.  
DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
PS Claim 4; Page 72; 218pp; English.  
XX The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;

KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
OS Mus sp.  
XX  
XX  
PN WO9715662-A2.  
XX  
XX  
PD  
XX  
XX  
PF 25-OCT-1996; 96WO-US017480.  
XX  
XX  
PR 26-OCT-1995; 95US-0005974P.  
PR 11-JAN-1996; 96US-00584040.  
XX  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX  
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
PI  
XX  
XX WPI; 1997-259017/23.  
DR  
XX  
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
XX  
XX  
PS Claim 4; Page 149; 218pp; English.  
XX  
XX The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 1 A; 4 C; 5 G; 0 T; 7 U; 0 Other;  
XX  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.2e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 30 ACAGGTATCTGCCTGTG 46  
DB 1 ACUGGUUUCUGCCUGUG 17  
XX  
RESULT 180  
AAX75068/c  
ID AAX75068 standard; RNA; 17 BP.  
XX  
AC AAX75068;  
XX  
XX 28-JUL-1999 (first entry)  
DT  
XX  
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #596.  
XX  
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
XX Mus sp.  
OS  
XX  
XX WO9715662-A2.  
PN  
XX  
PD 01-MAY-1997.

XX 25-OCT-1996; 96WO-US017480.  
PF  
XX  
XX 26-OCT-1995; 95US-0005974P.  
PR 11-JAN-1996; 96US-00584040.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX  
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
PI  
XX  
XX WPI; 1997-259017/23.  
DR  
XX  
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
XX  
XX  
PS Claim 4; Page 173; 218pp; English.  
XX  
XX The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 0 A; 0 C; 2 G; 0 T; 15 U; 0 Other;  
XX  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAA 1765  
DB 17 AACACAAAAACAAAAA 1  
XX  
RESULT 181  
AAX73377  
ID AAX73377 standard; RNA; 17 BP.  
XX  
XX  
AC AAX73377;  
XX  
XX 28-JUL-1999 (first entry)  
DT  
XX  
XX Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #810.  
DE  
XX  
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
XX Mus sp.  
OS  
XX  
XX WO9715662-A2.  
PN  
XX  
XX 01-MAY-1997.  
PD  
XX  
XX 25-OCT-1996; 96WO-US017480.  
PF  
XX  
XX 26-OCT-1995; 95US-0005974P.  
PR 11-JAN-1996; 96US-00584040.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX  
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
PI  
XX  
XX WO9715662-A2.  
PN  
XX  
PD 01-MAY-1997.

```
AAV25258
ID  AAV25258 standard; DNA; 17 BP.
XX  AC
XX  AAV25258;
XX  DT 11-JUN-1998 (first entry)
XX  DE Primer R3 for H.pylori MurC gene.
XX  KW Cytoplasmic; vaccine; prevention; treatment; infection; envelope;
KW  identification; binding compound; bacteria; life cycle; activator;
KW  inhibitor; duodenal ulcer disease; chronic gastritis; diagnosis;
KW  PCR primer; ss.
XX  OS Synthetic.
OS  OS Helicobacter pylori.
XX  PN WO9737044-A1.
XX  PD 09-OCT-1997.
XX  PF 27-MAR-1997; 97WO-US005223.
XX  PR 29-MAR-1996; 96US-00625811.
PR  02-APR-1996; 96US-00758731.
PR  25-OCT-1996; 96US-00736905.
PR  28-OCT-1996; 96US-00738859.
PR  06-DEC-1996; 96US-00761318.
XX  PA (ASTR ) ASTRA AB.
XX  PI Smith D, Alm RA;
XX  DR WPI; 1997-503122/46.
XX  PT Helicobacter pylori nucleic acid sequences and encoded polypeptide(s) -
PT  useful in vaccines to treat or prevent H. pylori infection and for
PT  diagnosis of H. pylori infection.
XX  PS Example; Page 108; 1145pp; English.
XX  CC This sequence represents a primer for the H.pylori MurC gene. The
CC  amplified sequence was used to compare homology of the coding sequences
CC  of the invention with other known proteins. The protein encoded by the
CC  DNA of the invention may be used in a vaccine to prevent or treat
CC  H.pylori infection or to identify H.pylori polypeptide binding compounds,
CC  useful as potential H.pylori life cycle activators or inhibitors. The DNA
CC  and probes derived from it may be used for the identification of H.pylori
CC  in a sample and the diagnosis of H.pylori infection. Nucleic acid
CC  sequences complementary to the DNA act as antisense sequences and can be
CC  used to prevent the translation of H.pylori mRNA. Antibodies against the
CC  protein can be used in immunoassays to evaluate the abundance and
CC  distribution of H.pylori-specific antigens. The genomic sequence of
CC  H.pylori (ATCC 55679) was determined from overlapping contigs generated
CC  by mechanically shearing the bacterial DNA. The sequences were analysed
CC  for ORF of at least 180 nucleotides, and the predicted coding regions
CC  defined by computer evaluation. To identify likely H.pylori antigens for
CC  vaccine development, the amino acid sequences predicted from various ORF
CC  were analysed for significant homology to other known or exported
CC  membrane proteins. Having identified and determined the sequences of
CC  interest, particular regions can be isolated from H.pylori by PCR
CC  amplification for recombinant polypeptide production, e.g. in E. coli
XX  hosts
XX  SQ Sequence 17 BP; 3 A; 7 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 713 CCAGCACATTTCGCCTC 729
Db 1 CCATTACATTTCGCCTC 17
```

```
RESULT 178
AAT60238/c
ID  AAT60238 standard; DNA; 17 BP.
XX  AC
XX  AAT60238;
XX  DT 19-OCT-1997 (first entry)
XX  DE ASO Q493XM representing known cystic fibrosis mutation.
XX  KW Multiplex allele-specific diagnostic assay; MASDA;
KW  allele-specific oligonucleotide; ASO; polymorphism; genetic disease;
KW  diagnosis; cystic fibrosis; ss.
XX  OS Synthetic.
OS  OS WO9710366-A2.
XX  PN WO9710366-A2.
XX  PD 20-MAR-1997.
XX  PF 13-SEP-1996; 96WO-US014842.
XX  PR 15-SEP-1995; 95US-0003788P.
XX  PA (GENZ ) GENZYME CORP.
XX  PI Shuber AP;
XX  DR WPI; 1997-202258/18.
XX  PT Identifying genetic alterations or target sequences in nucleic acid
PT  samples - useful for detecting genetic alterations associated with a
PT  disease, e.g. cystic fibrosis and sickle cell anaemia.
XX  PS Example 2; Page 40; 85pp; English.
XX  CC Allele-specific oligonucleotides (ASOs) (AAT60210-41) representing known
CC  cystic fibrosis mutations, and corresponding ASOs (AAT60242-70)
CC  representing wild-type sequences, are examples of ASOs that can be used
CC  in a multiplex allele-specific diagnostic assay (MASDA) that has the
CC  capacity to analyse over 500 samples of a large number of mutations (over
CC  100) in a single assay. Target DNA is immobilised to a solid support and
CC  interrogated in combinatorial fashion with a mixture of mutation-specific
CC  ASOs in solution. The ASO(s) corresponding to the specific mutation(s)
CC  present in the sample is hybrid-selected from the pool, and the
CC  mutation(s) is identified. MASDA can be used to detect genetic
CC  alterations associated with genetic disorders, to identify genetic
CC  polymorphisms, to determine the molecular basis of genetic diseases, or
CC  for high-resolution identification of disease-causing microorganisms
XX  SQ Sequence 17 BP; 10 A; 2 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1584 TTCATTCTATTCTTAAT 1600
Db 17 TTCATTCTGTCTTAGT 1

RESULT 179
AAX73378
ID  AAX73378 standard; RNA; 17 BP.
XX  AC
XX  AAX73378;
XX  DT 28-JUL-1999 (first entry)
XX  DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #811.
XX  XX
```



XX OS Oryctolagus cuniculus.  
XX PN WO9618736-A2.  
XX PD 20-JUN-1996.  
XX PF 22-NOV-1995; 95WO-US015516.  
XX PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX PA (RIBO-) RIBOZYME PHARM INC.  
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX DR WPI; 1996-300653/30.  
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX PS Example 1; Page 154; 307pp; English.  
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX SQ Sequence 17 BP; 5 A; 2 C; 2 G; 0 T; 8 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.2e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
QY 870 AATCCTTTTCTTTAAAG 886  
Db 1 AAUUCUGUCUUUAAAG 17  
RESULT 176  
AAX63884  
ID AAX63884 standard; RNA; 17 BP.  
XX AC AAX63884;  
XX DT 20-JUL-1999 (first entry)  
XX

DE XX Rabbit stromelysin hammerhead target SEQ ID NO:516.  
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX OS Oryctolagus cuniculus.  
XX PN WO9618736-A2.  
XX PD 20-JUN-1996.  
XX PF 22-NOV-1995; 95WO-US015516.  
XX PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX PA (RIBO-) RIBOZYME PHARM INC.  
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX DR WPI; 1996-300653/30.  
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX PS Example 1; Page 154; 307pp; English.  
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX SQ Sequence 17 BP; 4 A; 7 C; 1 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.2e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 750 CATTTCAGTCCCTCTATG 766  
Db 1 CAUCCAAUCCCUUAUG 17  
RESULT 177

PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
PS Example 1; Page 154; 307pp; English.  
XX  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 5 A; 3 C; 3 G; 0 T; 6 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 1.2e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
  
QY 874 CTTTCTCTTTAAAGACTG 890  
| : : : : :  
Db 1 CUGUUCUUUAAAGACAG 17  
  
RESULT 174  
AAX63864  
ID AAX63864 standard; RNA; 17 BP.  
XX  
AC AAX63864;  
XX  
DT 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hammerhead target SEQ ID NO:496.  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
PN WO9618736-A2.  
XX  
PD 20-JUN-1996.  
XX

PF 22-NOV-1995; 95WO-US015516.  
XX  
PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
PS Example 1; Page 154; 307pp; English.  
XX  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.2e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
  
QY 623 TTGCTGTTTCATGAAC TT 639  
: : : : :  
Db 1 UUGCUGCUCAUGAGCUU 17  
  
RESULT 175  
AAX63905  
ID AAX63905 standard; RNA; 17 BP.  
XX  
AC AAX63905;  
XX  
DT 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hammerhead target SEQ ID NO:537.  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.





CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention

XX  
SQ Sequence 17 BP; 4 A; 1 C; 7 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.2e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1179 CTGGAGGTATGATGTA 1195  
Db |:|||||: |||: ||  
1 CUGGAGGUUGAUGAGA 17

RESULT 170  
AAX64062/c  
ID AAX64062 standard; RNA; 17 BP.

XX AC AAX64062;

XX DT 20-JUL-1999 (first entry)

XX DE Rabbit stromelysin hammerhead target SEQ ID NO:694.

XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.

XX OS Oryctolagus cuniculus.

XX PN WO9618736-A2.

XX PD 20-JUN-1996.

XX PF 22-NOV-1995; 95WO-US015516.

XX PR 13-DEC-1994; 94US-00354920.

XX PR 23-DEC-1994; 94US-00363253.

XX PR 23-DEC-1994; 94US-00363254.

XX PR 17-FEB-1995; 95US-00390850.

XX PR 20-APR-1995; 95US-00426124.

XX PR 02-MAY-1995; 95US-00432874.

XX PR 04-MAY-1995; 95US-00434509.

XX PR 07-JUL-1995; 95US-0000951P.

XX PR 07-JUL-1995; 95US-0000974P.

XX PR 07-AUG-1995; 95US-00512861.

XX PR 05-OCT-1995; 95US-00541365.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;

XX PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;

XX PI Karpeisky A, Thompson JD, Modak A, Burgin A;

XX DR WPI; 1996-300653/30.

CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention

XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 896 TCTGGTGGAGCTTCCT 912  
Db ||| ||||| |||  
17 TCTCGTGGAGCTCCCT 1

RESULT 171

AAX63909

ID AAX63909 standard; RNA; 17 BP.

XX AC AAX63909;

XX DT 20-JUL-1999 (first entry)

XX DE Rabbit stromelysin hammerhead target SEQ ID NO:541.

XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.

XX OS Oryctolagus cuniculus.

XX PN WO9618736-A2.

XX PD 20-JUN-1996.

XX PF 22-NOV-1995; 95WO-US015516.

XX PR 13-DEC-1994; 94US-00354920.

XX PR 23-DEC-1994; 94US-00363253.

XX PR 23-DEC-1994; 94US-00363254.

XX PR 17-FEB-1995; 95US-00390850.

XX PR 20-APR-1995; 95US-00426124.

XX PR 02-MAY-1995; 95US-00432874.

XX PR 04-MAY-1995; 95US-00434509.

XX PR 07-JUL-1995; 95US-0000951P.

XX PR 07-JUL-1995; 95US-0000974P.

XX PR 07-AUG-1995; 95US-00512861.

XX PR 05-OCT-1995; 95US-00541365.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;

XX PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;

XX PI Karpeisky A, Thompson JD, Modak A, Burgin A;

XX DR WPI; 1996-300653/30.



Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. NO. 1.2e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 631 CATGAACCTTGCCATTC 647  
Db 1 CAUGAGCUUGGCCACUC 17

RESULT 168  
AAX63906  
ID AAX63906 standard; RNA; 17 BP.  
XX  
AC AAX63906;  
XX  
DT 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hammerhead target SEQ ID NO:538.  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
PN WO9618736-A2.  
XX  
PD 20-JUN-1996.  
XX  
PF 22-NOV-1995; 95WO-US015516.  
XX  
PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
PS Example 1; Page 154; 307pp; English.  
XX  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.

The concentration of ribozyme required to affect a therapeutic treatment  
is lower than that required of antisense molecules, and is highly  
specific. The present sequence is used in the exemplification of the  
present invention

Sequence 17 BP; 5 A; 2 C; 2 G; 0 T; 8 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. NO. 1.2e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 871 ATCCTTTTCTTTAAAGA 887  
Db 1 AUUCUGUUCUUUAAGA 17

RESULT 169  
AAX63977  
ID AAX63977 standard; RNA; 17 BP.  
XX  
AC AAX63977;  
XX  
DT 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hammerhead target SEQ ID NO:609.  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
PN WO9618736-A2.  
XX  
PD 20-JUN-1996.  
XX  
PF 22-NOV-1995; 95WO-US015516.  
XX  
PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
PS Example 1; Page 155; 307pp; English.  
XX  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also

Db 16 TTTTGATGCTGTCA 3  
|||||  
RESULT 166  
AAQ20006/c  
ID AAQ20006 standard; DNA; 17 BP.  
XX  
AC AAQ20006;  
XX  
DT 01-APR-1992 (first entry)  
XX  
DE Oligonucleotide #2 able to covalently cross-link to target DNA.  
XX  
KW deoxyribonucleic acid; major groove; ethanoino group;  
KW aziridinylcytosine; cross-linking group; ss.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 8 /\*tag= b  
FT /mod\_base= m5c  
FT modified\_base 14  
FT /\*tag= c  
FT /mod\_base= m5c  
FT modified\_base 17  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "N4N4-ethanocytosine"  
XX  
PN W09118997-A.  
XX  
PD 12-DEC-1991.  
XX  
PF 25-MAY-1990; 90US-00529346.  
XX  
PR 25-MAY-1990; 90US-00529346.  
PR 14-JAN-1991; 91US-00640654.  
XX  
PA (GILE-) GILEAD SCIE INC.  
XX  
PI Matteucci MD, Krawczyk S;  
XX  
DR WPI; 1992-007480/01.  
XX  
PT New sequence-specific non-photo-activated crosslinking agents - bind to  
PT the major groove of duplex DNA and are esp. useful for treating latent  
PT infections e.g. HIV.  
XX  
PS Example 2; Page 20; 42pp; English.  
XX  
CC The 3' end of this oligonucleotide carries 1,3-propanediol. The oligo is  
CC one of four oligonucleotides which were designed to specifically bind and  
CC cross-link to the duplex target sequence AAQ20004. Oligo #2 has the  
CC covalent cross-linking group, i.e. N4N4-ethanocytosine, at its 3' end. An  
CC assay for crosslinked triple helix showed considerable reaction with  
CC Oligo #2 and with Oligo #1 (see AAQ20005) which has the crosslinking  
CC group at the 5' end. The most complete reaction was seen with Oligo #3  
CC (see AAQ20007) having N4N4-ethanocytosine at both the 5' and 3' termini.  
CC A control oligo with no cross-linking group showed no reaction. The half-  
CC life of the cross-linking reaction for Oligo #2 was ca. 1 hr (1 microm);  
CC Oligo #1 showed a rate four times slower. See also AAQ20008  
XX  
SQ Sequence 17 BP; 0 A; 3 C; 0 G; 14 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1748 GAAAAAAAAAAAAAAAAA 1764  
||| ||||| |||||  
Db 17 GAAGAAAAAGAAAAAAAAA 1

RESULT 167  
AAX63865  
ID AAX63865 standard; RNA; 17 BP.  
XX  
AC AAX63865;  
XX  
DT 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hammerhead target SEQ ID NO:497.  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
PN W09618736-A2.  
XX  
PD 20-JUN-1996.  
XX  
PF 22-NOV-1995; 95WO-US015516.  
XX  
PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
PS Example 1; Page 154; 307pp; English.  
XX  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

KW skeletal muscle function.  
XX Homo sapiens.  
OS  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10429; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 840 TTTTGATGCTGTCA 853  
Db |||||  
17 TTTTGATGCTGTCA 4  
  
RESULT 165  
ACN73528/c  
ID ACN73528 standard; DNA; 17 BP.  
XX

AC ACN73528;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPLP-1 probe SEQ ID NO:10430.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10430; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 840 TTTTGATGCTGTCA 853

```

ID  ABZ61010 standard; RNA; 17 BP.
XX  AC
XX  ABZ61010;
XX  DT 21-MAR-2003 (first entry)
XX  DE Human K-Ras DNazyme substrate #1122.
XX  KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX  OS Homo sapiens.
XX  PN WO200297114-A2.
XX  PD 05-DEC-2002.
XX  PF 29-MAY-2002; 2002WO-US016840.
XX  PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX  PA (RIBO-) RIBOZYME PHARM INC.
XX  PI Mcswiggen J;
XX  DR WPI; 2003-140484/13.
XX  PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX  PS Claim 58; Page 106; 185pp; English.
XX  CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX  SQ Sequence 17 BP; 6 A; 1 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.2e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1706 AATGTAACATGTTT 1719
Db ||:|||||:|::
3 AAUGUAACAUGUUU 16

RESULT 163
AAD48153
ID AAD48153 standard; DNA; 17 BP.
XX AC
XX AAD48153;
XX DT 24-FEB-2003 (first entry)
XX DE PCR primer #1 used for single nucleotide polymorphism (SNP) analysis.
XX KW Peptide nucleic acid; PNA; nucleic acid zygosity; genetic analysis;
KW scientific investigation; pharmacogenomic; pharmacogenetic; epigenomic;
KW PCR; primer; ss.
```

```

XX OS Unidentified.
XX PN WO200272865-A2.
XX PD 19-SEP-2002.
XX PF 09-MAR-2002; 2002WO-US007050.
XX PR 09-MAR-2001; 2001US-0274547P.
XX PA (BOST-) BOSTON PROBES INC.
XX PI Coull JM, Fiandaca MJ, Kristjanson MD, Hyldig-Nielsen JJ;
XX PI Creasey TM;
XX DR WPI; 2003-018741/01.
XX PT Composition for determining target sequence of contiguous nucleobases,
PT comprises polynucleobase strand and combination oligomer comprising first
PT and second oligomer blocks that are covalently linked to each other.
XX PS Example 5; Page 70; 149pp; English.
XX CC The present invention relates to combination oligomers, including block
CC synthesis of combination of oligomers in the absence of a template. The
CC invention relates to a composition comprising a polynucleobase strand and
CC a combination oligomer comprising first and second oligomer blocks that
CC are each independently a peptide nucleic acid (PNA) covalently linked to.
CC each other by a linker of at least three atoms in length, where the
CC oligomer blocks are sequences specifically hybridised to a target
CC sequence of contiguous nucleobases in the polynucleobase strand, to form
CC a double stranded target sequence-oligomer complex. The composition is
CC used for determining a target sequence of contiguous nucleobases and for
CC determining the zygosity of a nucleic acid for a single nucleotide
CC polymorphism (SNP). The methods are useful in scientific investigation,
CC e.g., for detection, identification and/or enumeration of bacteria,
CC viruses and pathogens in food, beverages, water, pharmaceutical products,
CC personal care products, dairy products, in clinical samples or in samples
CC of plant, animal, human or environmental origin. They are also useful for
CC the analysis of raw materials, equipment, products or processes used to
CC manufacture or store food, beverages, water, pharmaceutical products,
CC personal care products dairy products or environmental samples. The
CC methods and materials are useful in areas such as expression analysis,
CC SNP analysis, genetic analysis of humans, animals, fungi, yeast viruses
CC and plants, therapy monitoring, pharmacogenomics, pharmacogenetics,
CC epigenomics and high throughput screening operations. The present
CC sequence is a PCR primer used for single nucleotide polymorphism (SNP)
CC analysis
XX  SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 394 CAAGTCTGGAGTGA 407
Db |||||:|||||
2 CAAGTCTGGAGTGA 15

RESULT 164
ACN73527/c
ID ACN73527 standard; DNA; 17 BP.
XX AC
XX ACN73527;
XX DT 02-DEC-2004 (first entry)
XX DE Human GDMLP-1 probe SEQ ID NO:10429.
XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
```





PN US2002102252-A1.  
XX  
PD 01-AUG-2002.  
XX  
XX  
PF 06-APR-2001; 2001US-00827998.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
XX  
PA (GUY/ ) GU Y.  
PA (SHAN/ ) SHANNON M E.  
XX  
PI Gu Y, Shannon ME;  
XX  
DR WPI; 2002-697817/75.  
XX  
XX  
PT New isolated nucleic acid encoding an isoform of human pregnancy  
associated plasma protein E, for preventing or aborting pregnancy.  
XX  
PS Example 2; Page 183; 353pp; English.  
XX  
CC This invention describes a novel isolated nucleic acid that encodes one  
of three new isoforms of human pregnancy associated plasma protein E,  
hPAPP-E. The products of the invention have abortive and contraceptive  
activity and can be used for gene therapy or in a vaccine. The nucleic  
acid, polypeptide encoded by it, or antibody to the polypeptide can be  
used in pharmaceutical compositions or vaccines for preventing or  
aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
dysgenetic pregnancies. The nucleic acids are used as probes to assess  
the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
antibodies can be used to assess the expression levels of PAPP-E isoform  
proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
antenatally. This sequence represents an oligomer used in scanning the  
human PAPP-E genes described in the disclosure of the invention  
XX  
SQ Sequence 17 BP; 4 A; 0 C; 9 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1181 GGAGGTATGATGTG 1194  
Db 4 GGAGGTATGATGTG 17  
  
RESULT 158  
ABS75299  
ID ABS75299 standard; DNA; 17 BP.  
XX  
AC ABS75299;  
XX  
XX 24-DEC-2002 (first entry)  
XX  
DE Human PAPP-Ea associated 17-mer SEQ ID 825.  
XX  
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;  
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
KW dysgenetic pregnancy; primer; ss.  
XX  
OS Homo sapiens.  
XX  
XX US2002102252-A1.  
XX  
PD 01-AUG-2002.  
XX  
XX 06-APR-2001; 2001US-00827998.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
XX  
PA (GUY/ ) GU Y.  
PA (SHAN/ ) SHANNON M E.  
XX  
PI Gu Y, Shannon ME;

XX  
DR WPI; 2002-697817/75.  
XX  
XX  
PT New isolated nucleic acid encoding an isoform of human pregnancy  
associated plasma protein E, for preventing or aborting pregnancy.  
XX  
XX  
PS Example 2; Page 183; 353pp; English.  
XX  
CC This invention describes a novel isolated nucleic acid that encodes one  
of three new isoforms of human pregnancy associated plasma protein E,  
hPAPP-E. The products of the invention have abortive and contraceptive  
activity and can be used for gene therapy or in a vaccine. The nucleic  
acid, polypeptide encoded by it, or antibody to the polypeptide can be  
used in pharmaceutical compositions or vaccines for preventing or  
aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
dysgenetic pregnancies. The nucleic acids are used as probes to assess  
the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
antibodies can be used to assess the expression levels of PAPP-E isoform  
proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
antenatally. This sequence represents an oligomer used in scanning the  
human PAPP-E genes described in the disclosure of the invention  
XX  
SQ Sequence 17 BP; 3 A; 1 C; 8 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1181 GGAGGTATGATGTG 1194  
Db 2 GGAGGTATGATGTG 15  
  
RESULT 159  
ABS75298  
ID ABS75298 standard; DNA; 17 BP.  
XX  
AC ABS75298;  
XX  
XX 24-DEC-2002 (first entry)  
XX  
DE Human PAPP-Ea associated 17-mer SEQ ID 824.  
XX  
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;  
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
KW dysgenetic pregnancy; primer; ss.  
XX  
OS Homo sapiens.  
XX  
XX US2002102252-A1.  
XX  
PD 01-AUG-2002.  
XX  
PF 06-APR-2001; 2001US-00827998.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
XX  
PA (GUY/ ) GU Y.  
PA (SHAN/ ) SHANNON M E.  
XX  
PI Gu Y, Shannon ME;  
XX  
XX WPI; 2002-697817/75.  
XX  
XX  
PT New isolated nucleic acid encoding an isoform of human pregnancy  
associated plasma protein E, for preventing or aborting pregnancy.  
XX  
XX  
PS Example 2; Page 183; 353pp; English.  
XX  
CC This invention describes a novel isolated nucleic acid that encodes one  
of three new isoforms of human pregnancy associated plasma protein E,  
hPAPP-E. The products of the invention have abortive and contraceptive  
activity and can be used for gene therapy or in a vaccine. The nucleic  
acid, polypeptide encoded by it, or antibody to the polypeptide can be  
used in pharmaceutical compositions or vaccines for preventing or  
aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
dysgenetic pregnancies. The nucleic acids are used as probes to assess  
the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
antibodies can be used to assess the expression levels of PAPP-E isoform  
proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
antenatally. This sequence represents an oligomer used in scanning the  
human PAPP-E genes described in the disclosure of the invention  
XX  
PI

XX 28-JAN-2002; 2002EP-00001167.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 23-MAY-2001; 2001US-00864761.  
PR 09-OCT-2001; 2001US-0327898P.  
XX (AEOM-) AEOMICA INC.  
XX Zhan J;  
XX WPI; 2002-676582/73.  
DR Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX Example 2; Page 241; 718pp; English.  
XX The present invention relates to human testis expressed Patched like  
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX Sequence 17 BP; 1 A; 3 C; 3 G; 10 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 994 GAAAGCAGAAATCA 1007  
Db ||||||||||||  
14 GAAAGCAGAAATCA 1  
RESULT 156  
ABV80108/c  
ID ABV80108 standard; DNA; 17 BP.  
XX  
AC ABV80108;  
XX  
DT 03-JAN-2003 (first entry)  
XX Human HTPL scanning oligonucleotide SEQ ID 1354.  
DE  
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1229046-A2.

XX 07-AUG-2002.  
XX 28-JAN-2002; 2002EP-00001167.  
XX 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 23-MAY-2001; 2001US-00864761.  
PR 09-OCT-2001; 2001US-0327898P.  
XX (AEOM-) AEOMICA INC.  
XX Zhan J;  
XX WPI; 2002-676582/73.  
DR Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX Example 2; Page 241; 718pp; English.  
XX The present invention relates to human testis expressed Patched like  
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX Sequence 17 BP; 2 A; 3 C; 3 G; 9 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 994 GAAAGCAGAAATCA 1007  
Db ||||||||||||  
16 GAAAGCAGAAATCA 3  
RESULT 157  
ABS75297  
ID ABS75297 standard; DNA; 17 BP.  
XX  
AC ABS75297;  
XX  
DT 24-DEC-2002 (first entry)  
XX Human PAPP-Ea associated 17-mer SEQ ID 823.  
DE  
XX PAPP-E; human; pregnancy associated plasma protein E; abortive;  
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
KW dysgenetic pregnancy; primer; ss.  
XX  
OS Homo sapiens.  
XX

```
PR 30-JAN-2001; 2001WO-US0000664.
PR 30-JAN-2001; 2001WO-US0000665.
PR 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
XX Zhan J;
PI
XX WPI; 2002-676582/73.
DR
XX
XX Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 241; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
XX example from the invention
SQ Sequence 17 BP; 1 A; 3 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
Db |||||
15 GAAAGCAGAAATCA 2

RESULT 154
ABV80107/C
ID ABV80107 standard; DNA; 17 BP.
XX
AC ABV80107;
XX
XX 03-JAN-2003 (first entry)
XX
XX Human HTPL scanning oligonucleotide SEQ ID 1353.
DE
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
XX Homo sapiens.
XX
XX EP1229046-A2.
PN
XX 07-AUG-2002.
XX
XX 28-JAN-2002; 2002EP-00001167.
PF
```

```
XX 30-JAN-2001; 2001WO-US0000663.
PR 30-JAN-2001; 2001WO-US0000664.
PR 30-JAN-2001; 2001WO-US0000665.
PR 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhan J;
PI
XX WPI; 2002-676582/73.
DR
XX
XX Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 241; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
XX example from the invention
SQ Sequence 17 BP; 2 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
Db |||||
17 GAAAGCAGAAATCA 4

RESULT 155
ABV80110/C
ID ABV80110 standard; DNA; 17 BP.
XX
AC ABV80110;
XX
XX 03-JAN-2003 (first entry)
XX
XX Human HTPL scanning oligonucleotide SEQ ID 1356.
DE
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
XX Homo sapiens.
XX
XX EP1229046-A2.
PN
XX 07-AUG-2002.
XX
XX 07-AUG-2002.
PD
```



PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 10429; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 840 TTTTGATGCTGTCA 853  
DB 17 TTTTGATGCTGTCA 4  
  
RESULT 152  
ABN10438/c  
ID ABN10438 standard; DNA; 17 BP.  
XX  
AC ABN10438;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10430.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR

PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0256860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 10430; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 840 TTTTGATGCTGTCA 853  
DB 16 TTTTGATGCTGTCA 3  
  
RESULT 153  
ABV80109/c  
ID ABV80109 standard; DNA; 17 BP.  
XX  
AC ABV80109;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 1355.  
XX  
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1229046-A2.  
XX  
PD 07-AUG-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001167.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
PR

CC oligonucleotide has at least one mismatch compared with the genomic  
CC sequence to be altered. In particular, these sequences are directed at  
CC the following genes: adenosine deaminase, p53, beta-globin,  
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus  
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
CC various syndromes. The present sequence is one of the gene correcting  
CC oligonucleotides of the invention  
XX  
SQ Sequence 17 BP; 4 A; 5 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331  
|||||  
Db 15 CAATTGGAATATGA 2

RESULT 150  
ABA78617  
ID ABA78617 standard; DNA; 17 BP.  
XX  
AC ABA78617;

XX  
DT 24-JAN-2002 (first entry)

XX  
DE APC mutation correcting oligonucleotide SEQ ID NO: 1463.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
KW Alzheimer's disease; cytostatic; antisludging; antianaemic; haemostatic;  
KW antilipemic; ss.

XX Homo sapiens.

OS  
XX WO200173002-A2.

PN  
XX 04-OCT-2001.

PD  
XX 27-MAR-2001; 2001WO-US009761.

XX  
PR 27-MAR-2000; 2000US-0192176P.

PR 27-MAR-2000; 2000US-0192179P.

PR 01-JUN-2000; 2000US-0208538P.

PR 30-OCT-2000; 2000US-0244989P.

XX (UYDE ) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for  
PT treating cystic fibrosis, comprises at least one mismatch and chemical  
PT modification.

XX Claim 7; Page 133; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can

CC be used for the targeted alteration of genomic sequences, where the  
CC oligonucleotide has at least one mismatch compared with the genomic  
CC sequence to be altered. In particular, these sequences are directed at  
CC the following genes: adenosine deaminase, p53, beta-globin,  
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus  
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
CC various syndromes. The present sequence is one of the gene correcting  
CC oligonucleotides of the invention  
XX

SQ Sequence 17 BP; 7 A; 1 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331  
|||||  
Db 3 CAATTGGAATATGA 16

RESULT 151  
ABN10437/c  
ID ABN10437 standard; DNA; 17 BP.  
XX  
AC ABN10437;

XX  
DT 29-MAY-2002 (first entry)

XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10429.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y., Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser

XX 06-APR-2000.  
PD  
XX  
XX 24-SEP-1999; 99WO-US022283.  
PF  
XX  
XX 25-SEP-1998; 98US-0101757P.  
PR  
XX  
XX (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
PA  
XX  
XX Landers JE, Jordan B, Housman DE, Charest A;  
PI  
XX WPI; 2000-293181/25.  
DR  
XX  
XX Detection of single nucleotide polymorphisms in genomes by preparation  
PT and analysis of reduced complexity genomes, useful for genotyping,  
PT fingerprinting and determining allele frequency of SNPs.  
XX  
XX Disclosure; Page 60; 111pp; English.  
PS  
XX A method has been developed for detecting the presence or absence of a  
CC single nucleotide polymorphism (SNP) allele in a genomic sample. The  
CC method comprises preparing a reduced complexity genome (RCG) from the  
CC genomic sample and analysing the RCG for the presence or absence of a SNP  
CC allele. The method can be used to characterise a tumour, to generate a  
CC genomic pattern for an individual genome or to generate a genomic  
CC classification code for a genome. The method can be used to assess  
CC whether a subject is at risk for developing a disease or to identify a  
CC set of SNP alleles associated with a disease. The method can also be used  
CC to perform linkage analysis. AAA35944 to AAA35947 represent sequences  
CC used in the exemplification of the present invention. AAA35948 to  
CC AAA36632 represent nucleotide sequences containing SNPs  
XX  
XX Sequence 17 BP; 9 A; 1 C; 3 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1483 ATAAATGTAACAGGA 1496  
Db 4 ATAAATGTAACAGGA 17  
RESULT 148  
AAAF02752/c  
ID AAF02752 standard; DNA; 17 BP.  
XX  
XX AAF02752;  
AC  
XX 16-FEB-2001 (first entry)  
DT  
XX Hammerhead ribozyme substrate #1047.  
DE  
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
KW interferon alpha; ss.  
KW  
XX Homo sapiens.  
OS  
XX WO200061729-A2.  
PN  
XX 19-OCT-2000.  
PD  
XX 11-APR-2000; 2000WO-US009721.  
PF  
XX 12-APR-1999; 99US-0129390P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;  
PI  
XX WPI; 2000-647423/62.  
DR  
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
PT

PT useful for producing e.g. granulocyte colony stimulating factor protein,  
PT interferon alpha and erythropoietin.  
XX  
XX Claim 37; Page 79; 164pp; English.  
PS  
XX The present invention relates to enzymatic and antisense nucleic acid  
CC molecules that act as inhibitors of the expression of repressor genes  
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).  
XX Inhibition of the repressors removes prevents inhibition (and  
CC consequently increases expression of) genes involved in the production of  
CC erythropoietin, granulocyte colony stimulating factor protein and  
CC interferon alpha  
XX  
XX Sequence 17 BP; 7 A; 5 C; 2 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 565 CATTTTGATGAGGC 578  
Db 15 CATTTTGATGAGGC 2  
RESULT 149  
ABA78618/c  
ID ABA78618 standard; DNA; 17 BP.  
XX  
XX ABA78618;  
AC  
XX 24-JAN-2002 (first entry)  
DT  
XX APC mutation correcting oligonucleotide SEQ ID NO: 1464.  
DE  
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;  
KW antilipemic; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO200173002-A2.  
PN  
XX 04-OCT-2001.  
PD  
XX 27-MAR-2001; 2001WO-US009761.  
PF  
XX 27-MAR-2000; 2000US-0192176P.  
XX 27-MAR-2000; 2000US-0192179P.  
PR  
XX 01-JUN-2000; 2000US-0208538P.  
PR  
XX 30-OCT-2000; 2000US-0244989P.  
PR  
XX (UYDE ) UNIV DELAWARE.  
PA  
XX Kmiec EB, Gamper HB, Rice MC;  
XX WPI; 2001-639230/73.  
PI  
XX Oligonucleotide for targeted alterations of genetic sequences and for  
PT treating cystic fibrosis, comprises at least one mismatch and chemical  
PT modification.  
XX  
XX Claim 7; Page 133; 294pp; English.  
PS  
XX The present invention provides single-stranded oligonucleotides which can  
CC be used for the targeted alteration of genomic sequences, where the



```
OS Synthetic.
XX WO200130362-A2.
PN
XX
XX
PD 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
PF
XX
PR 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
PA
XX Robbins JM, Tritz R;
PI
XX WPI; 2001-300427/31.
DR
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 20; 408pp; English.
PS
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnery, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
XX exemplification of the present invention
SQ Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTGCACCAA 832
Db 1 TTTCTGTGCACCAA 14

RESULT 146
AAH61946
ID AAH61946 standard; DNA; 16 BP.
XX
AC AAH61946;
XX
DT 10-SEP-2001 (first entry)
XX
DE PCNA hammerhead ribozyme recognition site SEQ ID NO:4370.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnery;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
```

```
XX Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
XX 03-MAY-2001.
PD
XX
XX 26-OCT-2000; 2000WO-US029500.
PF
XX
XX 26-OCT-1999; 99US-0161532P.
PR (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
PI
XX WPI; 2001-300427/31.
DR
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Disclosure; Page 394; 408pp; English.
PS
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnery, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
XX exemplification of the present invention
SQ Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTGCACCAA 832
Db 1 TTTCTGTGCACCAA 14

RESULT 147
AAA36162
ID AAA36162 standard; DNA; 17 BP.
XX
AC AAA36162;
XX
DT 26-JUL-2000 (first entry)
XX
DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:219.
XX
KW Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW genomic classification; identification; DNA fingerprinting;
KW tumour characterisation; hybridisation; ss.
XX
OS Homo sapiens.
XX
PN WO200018960-A2.
```



CC smooth muscle cell (SMC) proliferation in vascular tissue leading to  
CC restenosis. The ribozymes can also directly block the production of  
CC oncogenes and cell regulatory factors involved with SMC growth following  
CC vascular injury

XX Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTCACCAAA 832  
|||||  
Db 1 TTTCTGTCACCAAA 14

RESULT 143  
AAA86559  
ID AAA86559 standard; DNA; 16 BP.

XX AAA86559;

DT 04-DEC-2000 (first entry)

DE PCNA hairpin ribozyme recognition site #7.

XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.

OS Mammalia.

XX WO200032765-A2.

PD 08-JUN-2000.

PF 06-DEC-1999; 99WO-US028772.

PR 04-DEC-1998; 98US-0110954P.

PA (IMMU-) IMMUSOL INC.

PI Tritz R, Welch PJ, Barber JR, Robbins JM;

DR WPI; 2000-412314/35.

XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.

XX Example 1; Page 16; 109pp; English.

XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
CC Representative examples of ribozyme recognition sites are given in  
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for  
CC inhibiting restenosis by introduction of the ribozyme into cells. The  
CC ribozyme is resistant to endonuclease activity and hence is efficient in  
CC restenosis treatment

XX Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTCACCAAA 832  
|||||  
Db 1 TTTCTGTCACCAAA 14

RESULT 144  
AAA86780  
ID AAA86780 standard; DNA; 16 BP.

XX AAA86780;  
AC 04-DEC-2000 (first entry)  
DT PCNA hammerhead ribozyme recognition site #5.  
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.

OS Mammalia.

XX WO200032765-A2.

PD 08-JUN-2000.

PF 06-DEC-1999; 99WO-US028772.

PR 04-DEC-1998; 98US-0110954P.

XX (IMMU-) IMMUSOL INC.

PI Tritz R, Welch PJ, Barber JR, Robbins JM;

XX WPI; 2000-412314/35.

XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.

XX Example 1; Page 24; 109pp; English.

XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
CC Representative examples of ribozyme recognition sites are given in  
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for  
CC inhibiting restenosis by introduction of the ribozyme into cells. The  
CC ribozyme is resistant to endonuclease activity and hence is efficient in  
CC restenosis treatment

XX Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTCACCAAA 832  
|||||  
Db 1 TTTCTGTCACCAAA 14

RESULT 145  
AAH61725  
ID AAH61725 standard; DNA; 16 BP.

XX AAH61725;

DT 10-SEP-2001 (first entry)

XX PCNA hairpin/hammerhead ribozyme recognition site SEQ ID NO:4149.

XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
KW recognition site; target; ribozyme binding site; eye disease; vulnery;  
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;  
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;

XX sickle cell retinopathy; ss.

OS Homo sapiens.

CC orientation, respectively, to target sequences on alternate strands of  
CC the double helical nucleic acid. The method has therapeutic applications,  
CC where gene expression is controlled by selective triple-helix formation  
CC within expression regulatory sequences of a target gene. The  
CC oligonucleotides can be used to form triple-helices, and are useful to  
CC detect the presence or absence of specific sequences within genomic DNA  
CC for diagnostic and therapeutic purposes. The oligonucleotides can be  
CC selected to specifically bind to pathogenic double-stranded DNA including  
CC specific sequences required by pathogenic bacteria or viruses for  
CC replication or virulence, reducing their pathogenicity. Alternatively,  
CC the oligonucleotide can be chosen to target a unique sequence of the  
CC pathogen which is not found in the genome of pathogen's host. The  
CC oligonucleotides can be used in cancer treatment by way of triple-helix  
CC suppression of specific oncogenes including those of endogenous or viral  
CC origin. Such therapeutic oligonucleotides are capable of forming triple-  
CC helices with such sequences in cancerous cells containing the activated  
CC oncogene, so preferentially killing or repressing the cancer causing  
CC cell. The present sequence represents an oligonucleotide used in the  
CC methods of the present invention  
XX  
SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 96;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763  
||||| |||||  
Db 15 AAAAAAAAAAAAAA 1

RESULT 141  
ABK98186/c  
ID ABK98186 standard; DNA; 15 BP.  
XX  
AC ABK98186;  
XX  
DT 07-OCT-2002 (first entry)  
XX  
DE Triple helix forming associated oligonucleotide #50.

XX Triple-helix formation; purine-rich target sequence; double-helix DNA;  
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;  
KW pathogenic bacteria; virus; replication; virulence; cancer;  
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.

OS Synthetic.  
XX  
PN US6403302-B1.  
XX  
PD 11-JUN-2002.  
XX  
PF 16-DEC-1993; 93US-00168920.  
XX  
PR 17-SEP-1992; 92US-00946976.  
XX  
PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.

PI Dervan PB, Beal PA;  
XX  
DR WPI; 2002-536030/57.

XX A triple-helix comprising a double helical nucleic acid (DHNA) and an  
PT oligonucleotide which binds in parallel and antiparallel orientation,  
PT respectively, for targeting sequences on alternate strands of DHNA to  
PT control gene expression.

PS Example 7; Fig 24A; 108pp; English.

XX The present invention relates to methods and oligonucleotides for forming  
CC a triple-helix comprising a double helical nucleic acid comprising first  
CC and second substantially complementary strands, and an oligonucleotide  
CC bound to a purine-rich target sequence within the double helical nucleic

CC acid, where the oligonucleotide binds in a parallel and antiparallel  
CC orientation, respectively, to target sequences on alternate strands of  
CC the double helical nucleic acid. The method has therapeutic applications,  
CC where gene expression is controlled by selective triple-helix formation  
CC within expression regulatory sequences of a target gene. The  
CC oligonucleotides can be used to form triple-helices, and are useful to  
CC detect the presence or absence of specific sequences within genomic DNA  
CC for diagnostic and therapeutic purposes. The oligonucleotides can be  
CC selected to specifically bind to pathogenic double-stranded DNA including  
CC specific sequences required by pathogenic bacteria or viruses for  
CC replication or virulence, reducing their pathogenicity. Alternatively,  
CC the oligonucleotide can be chosen to target a unique sequence of the  
CC pathogen which is not found in the genome of pathogen's host. The  
CC oligonucleotides can be used in cancer treatment by way of triple-helix  
CC suppression of specific oncogenes including those of endogenous or viral  
CC origin. Such therapeutic oligonucleotides are capable of forming triple-  
CC helices with such sequences in cancerous cells containing the activated  
CC oncogene, so preferentially killing or repressing the cancer causing  
CC cell. The present sequence represents an oligonucleotide used in the  
CC methods of the present invention  
XX

SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 96;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763  
||||| |||||  
Db 15 AAAAAAAAAAAAAA 1

RESULT 142  
AAT60192  
ID AAT60192 standard; DNA; 16 BP.

XX  
AC AAT60192;

XX  
DT 03-FEB-1998 (first entry)

XX Synthetic PCNA ribozyme recognition site #4.

XX Ribozyme; hairpin; hammerhead; proliferating cell nuclear antigen;  
KW growth factor; oncogene; vascular tissue; SMC; PCNA; recognition site;  
KW restenosis; smooth muscle cell proliferation; ss.

OS Synthetic.

XX  
PN WO9710334-A2.

XX  
PD 20-MAR-1997.

XX  
PF 12-SEP-1996; 96WO-US014838.

XX  
PR 12-SEP-1995; 95US-00527060.

XX (IMMU-) IMMUSOL INC.

XX Goldenberg T, Tritz R;

XX  
DR WPI; 1997-202230/18.

XX New hairpin and hammer:head ribozyme(s) - which inhibit abnormal smooth  
PT muscle cell proliferation in vascular tissue, partic. for preventing or  
PT treating restenosis.

PS Example 1; Page 15; 50pp; English.

XX This sequence represents a ribozyme recognition site for the  
CC proliferating cell nuclear antigen (PCNA) gene which is cleaved by a  
CC hairpin ribozyme at position 867 and by a hammerhead ribozyme at position  
CC 869. Novel ribozymes are being investigated for their ability to inhibit  
CC the activity of a growth factor (e.g. PCNA) responsible for abnormal

CC where gene expression is controlled by selective triple-helix formation  
CC within expression regulatory sequences of a target gene. The  
CC oligonucleotides can be used to form triple-helices, and are useful to  
CC detect the presence or absence of specific sequences within genomic DNA  
CC for diagnostic and therapeutic purposes. The oligonucleotides can be  
CC selected to specifically bind to pathogenic double-stranded DNA including  
CC specific sequences required by pathogenic bacteria or viruses for  
CC replication or virulence, reducing their pathogenicity. Alternatively,  
CC the oligonucleotide can be chosen to target a unique sequence of the  
CC pathogen which is not found in the genome of pathogen's host. The  
CC oligonucleotides can be used in cancer treatment by way of triple-helix  
CC suppression of specific oncogenes including those of endogenous or viral  
CC origin. Such therapeutic oligonucleotides are capable of forming triple-  
CC helices with such sequences in cancerous cells containing the activated  
CC oncogene, so preferentially killing or repressing the cancer causing  
CC cell. The present sequence represents an oligonucleotide used in the  
CC methods of the present invention  
XX  
SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 96;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763  
|||||||  
Db 15 AAAAAAAAAAAAAA 1

RESULT 139  
ABK98168/c  
ID ABK98168 standard; DNA; 15 BP.

AC ABK98168;

DT 07-OCT-2002 (first entry)

DE Triple helix forming associated oligonucleotide #38.

XX Triple-helix formation; purine-rich target sequence; double-helix DNA;  
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;  
KW pathogenic bacteria; virus; replication; virulence; cancer;  
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.

XX Synthetic.

XX US6403302-B1.

XX 11-JUN-2002.

XX 16-DEC-1993; 93US-00168920.

XX 17-SEP-1992; 92US-00946976.

XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.

XX Dervan PB, Beal PA;

XX WPI; 2002-536030/57.

XX A triple-helix comprising a double helical nucleic acid (DHNA) and an  
PT oligonucleotide which binds in parallel and antiparallel orientation,  
PT respectively, for targeting sequences on alternate strands of DHNA to  
PT control gene expression.

XX Example 6; Fig 20A; 108pp; English.

XX The present invention relates to methods and oligonucleotides for forming  
CC a triple-helix comprising a double helical nucleic acid comprising first  
CC and second substantially complementary strands, and an oligonucleotide  
CC bound to a purine-rich target sequence within the double helical nucleic  
CC acid, where the oligonucleotide binds in a parallel and antiparallel  
CC orientation, respectively, to target sequences on alternate strands of

CC the double helical nucleic acid. The method has therapeutic applications,  
CC where gene expression is controlled by selective triple-helix formation  
CC within expression regulatory sequences of a target gene. The  
CC oligonucleotides can be used to form triple-helices, and are useful to  
CC detect the presence or absence of specific sequences within genomic DNA  
CC for diagnostic and therapeutic purposes. The oligonucleotides can be  
CC selected to specifically bind to pathogenic double-stranded DNA including  
CC specific sequences required by pathogenic bacteria or viruses for  
CC replication or virulence, reducing their pathogenicity. Alternatively,  
CC the oligonucleotide can be chosen to target a unique sequence of the  
CC pathogen which is not found in the genome of pathogen's host. The  
CC oligonucleotides can be used in cancer treatment by way of triple-helix  
CC suppression of specific oncogenes including those of endogenous or viral  
CC origin. Such therapeutic oligonucleotides are capable of forming triple-  
CC helices with such sequences in cancerous cells containing the activated  
CC oncogene, so preferentially killing or repressing the cancer causing  
CC cell. The present sequence represents an oligonucleotide used in the  
CC methods of the present invention  
XX

SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 96;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763  
|||||||  
Db 15 AAAAAAAAAAAAAA 1

RESULT 140

ABK98167/c

ID ABK98167 standard; DNA; 15 BP.

AC ABK98167;

DT 07-OCT-2002 (first entry)

DE Triple helix forming associated oligonucleotide #37.

XX Triple-helix formation; purine-rich target sequence; double-helix DNA;  
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;  
KW pathogenic bacteria; virus; replication; virulence; cancer;  
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.

XX Synthetic.

XX US6403302-B1.

XX 11-JUN-2002.

XX 16-DEC-1993; 93US-00168920.

XX 17-SEP-1992; 92US-00946976.

XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.

XX Dervan PB, Beal PA;

XX WPI; 2002-536030/57.

XX A triple-helix comprising a double helical nucleic acid (DHNA) and an  
PT oligonucleotide which binds in parallel and antiparallel orientation,  
PT respectively, for targeting sequences on alternate strands of DHNA to  
PT control gene expression.

XX Example 6; Fig 20A; 108pp; English.

XX The present invention relates to methods and oligonucleotides for forming  
CC a triple-helix comprising a double helical nucleic acid comprising first  
CC and second substantially complementary strands, and an oligonucleotide  
CC bound to a purine-rich target sequence within the double helical nucleic  
CC acid, where the oligonucleotide binds in a parallel and antiparallel



CC which represents hybridisation conditions, and calculating HT including  
CC net HT based on the hybridisation information, TP, the correction data  
CC and the first set of data. Also described are: (1) a computer-readable  
CC storage medium having stored in it, a database of TP and a computer  
CC program which executes the above method; and (2) a system for predicting  
CC nucleic acid HT, comprising a database of TP, units for receiving  
CC hybridisation information which represents at least one sequence and for  
CC receiving correction data, receiving a first set of data which represents  
CC hybridisation conditions and unit for calculating HT. The method and  
CC system are useful to optimise and predict probe-target hybridisation. The  
CC method and system takes into account of single strand folding  
CC thermodynamics to calculate effective hybridisation thermodynamics not  
CC taken into account by prior art methods. ABL42498 to ABL42626 represent  
CC oligonucleotide sequences which are used in the exemplification of the  
CC present invention

XX SQ Sequence 15 BP; 0 A; 0 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. NO. 96;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 131 CAAAAACAAAACC 144  
| | | | | | | | | | | | | | | | |  
Db 14 CAAAAACAAAACC 1

RESULT 137  
ABK98169/C  
ID ABK98169 standard; DNA; 15 BP.

XX AC ABK98169;

XX DT 07-OCT-2002 (first entry)

XX DE Triple helix forming associated oligonucleotide #39.

XX KW Triple-helix formation; purine-rich target sequence; double-helix DNA;  
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;  
KW pathogenic bacteria; virus; replication; virulence; cancer;  
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.

XX OS Synthetic.

XX PN US6403302-B1.

XX PD 11-JUN-2002.

XX PF 16-DEC-1993; 93US-00168920.

XX PR 17-SEP-1992; 92US-00946976.

XX PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.

XX PI Dervan PB, Beal PA;

XX DR WPI; 2002-536030/57.

XX PT A triple-helix comprising a double helical nucleic acid (DHNA) and an  
PT oligonucleotide which binds in parallel and antiparallel orientation,  
PT respectively, for targeting sequences on alternate strands of DHNA to  
PT control gene expression.

XX PS Example 6; Fig 20A; 108pp; English.

XX CC The present invention relates to methods and oligonucleotides for forming  
CC a triple-helix comprising a double helical nucleic acid comprising first  
CC and second substantially complementary strands, and an oligonucleotide  
CC bound to a purine-rich target sequence within the double helical nucleic  
CC acid, where the oligonucleotide binds in a parallel and antiparallel  
CC orientation, respectively, to target sequences on alternate strands of  
CC the double helical nucleic acid. The method has therapeutic applications,  
CC where gene expression is controlled by selective triple-helix formation

CC within expression regulatory sequences of a target gene. The  
CC oligonucleotides can be used to form triple-helices, and are useful to  
CC detect the presence or absence of specific sequences within genomic DNA  
CC for diagnostic and therapeutic purposes. The oligonucleotides can be  
CC selected to specifically bind to pathogenic double-stranded DNA including  
CC specific sequences required by pathogenic bacteria or viruses for  
CC replication or virulence, reducing their pathogenicity. Alternatively,  
CC the oligonucleotide can be chosen to target a unique sequence of the  
CC pathogen which is not found in the genome of pathogen's host. The  
CC oligonucleotides can be used in cancer treatment by way of triple-helix  
CC suppression of specific oncogenes including those of endogenous or viral  
CC origin. Such therapeutic oligonucleotides are capable of forming triple-  
CC helices with such sequences in cancerous cells containing the activated  
CC oncogene, so preferentially killing or repressing the cancer causing  
CC cell. The present sequence represents an oligonucleotide used in the  
CC methods of the present invention

XX SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 96;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763  
| | | | | | | | | | | | | | | | |  
Db 15 AAAAAAAAAAAAAA 1

RESULT 138

ABK98187/C

ID ABK98187 standard; DNA; 15 BP.

XX AC ABK98187;

XX DT 07-OCT-2002 (first entry)

XX DE Triple helix forming associated oligonucleotide #51.

XX KW Triple-helix formation; purine-rich target sequence; double-helix DNA;  
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;  
KW pathogenic bacteria; virus; replication; virulence; cancer;  
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.

XX OS Synthetic.

XX PN US6403302-B1.

XX PD 11-JUN-2002.

XX PF 16-DEC-1993; 93US-00168920.

XX PR 17-SEP-1992; 92US-00946976.

XX PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.

XX PI Dervan PB, Beal PA;

XX DR WPI; 2002-536030/57.

XX PT A triple-helix comprising a double helical nucleic acid (DHNA) and an  
PT oligonucleotide which binds in parallel and antiparallel orientation,  
PT respectively, for targeting sequences on alternate strands of DHNA to  
PT control gene expression.

XX PS Example 7; Fig 24A; 108pp; English.

XX CC The present invention relates to methods and oligonucleotides for forming  
CC a triple-helix comprising a double helical nucleic acid comprising first  
CC and second substantially complementary strands, and an oligonucleotide  
CC bound to a purine-rich target sequence within the double helical nucleic  
CC acid, where the oligonucleotide binds in a parallel and antiparallel  
CC orientation, respectively, to target sequences on alternate strands of  
CC the double helical nucleic acid. The method has therapeutic applications,



Best Local Similarity 100.0%; Pred. No. 96;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 917 GTCCAGCCACCAAC 930  
Db 2 GTCCAGCCACCAAC 15

RESULT 135  
ABS97730  
ID ABS97730 standard; DNA; 15 BP.  
XX  
AC ABS97730;  
XX  
DT 23-DEC-2002 (first entry)  
XX  
DE Human kelleikrin 2 (KLK2) gene sequencing primer #5.  
XX  
KW Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;  
KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;  
KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;  
KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;  
KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;  
KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;  
KW glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;  
KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;  
KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;  
KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;  
KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;  
KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;  
KW multidrug resistance associated protein 3; cancer; prostate;  
KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;  
KW altered drug metabolism; cardiovascular function; colorectal tumour;  
KW central nervous system; pulmonary; immunological; sequencing.

XX  
OS Homo sapiens.  
XX  
PN WO200257410-A2.  
XX  
PD 25-JUL-2002.  
XX  
PF 28-NOV-2001; 2001WO-US044838.  
XX  
PR 28-NOV-2000; 2000US-00724389.  
XX  
PA (DNAS-) DNA SCI LAB INC.  
XX  
XX Guida M, Hall J;  
PI  
XX WPI; 2002-698522/75.  
DR  
XX Isolated nucleic acid molecules having polymorphisms in known human genes  
PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers  
PT for locating, identifying and characterizing the genes responsible for  
PT disorder-related traits.  
XX  
PS Example 14; Page 126; 714pp; English.

XX  
CC This invention relates to the sequence of an isolated nucleic acid  
CC molecule comprising at least one base variation from that of a known  
CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),  
CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),  
CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator  
CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding  
CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating  
CC protein (FLAP), glutathione-S-transferase 12 (GSTI2), histamine-N-methyl  
CC transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl  
CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),  
CC sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4  
CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl  
CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1  
CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3  
CC (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic

receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.  
The polymorphisms in the human genes cited in the invention are useful as  
genetic linkage markers for locating and characterising the genes that  
are responsible for specific traits within the genome and eventually  
identifying the genes responsible for a variety of disorder-related  
traits as a result of their e.g., overexpression, constitutive  
expression, mutation or underexpression, which may be used in diagnosing  
and/or treating the disorders. The nucleic acid molecules comprising the  
polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,  
ARNT, EPHX2, GSTI2, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,  
MDR1 and/or MDR3 are useful for screening individuals for altered drug  
metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,  
AHR, MDR1 and/or MDR3 may also be used to screen individuals for  
susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are  
used to screen for altered cardiovascular function, in COX2 for altered  
susceptibility to colorectal tumours, in DBI or CHMR1 for altered central  
nervous system function, in FLAP and HNMT for altered pulmonary,  
immunological or haematological function, in KLK2 for altered serine  
protease activity in the prostate, in LTF for altered immunological or  
haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and  
peripheral nervous system function. The present sequence represents a  
sequencing primer used to sequence the polymorphic genes of the invention

XX  
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 96;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 917 GTCCAGCCACCAAC 930  
Db 2 GTCCAGCCACCAAC 15

RESULT 136  
ABL42626/c  
ID ABL42626 standard; DNA; 15 BP.  
XX  
AC ABL42626;  
XX  
DT 11-APR-2002 (first entry)  
XX  
DE Hairpin beacon target hybridisation oligonucleotide #5.  
XX  
KW Hybridisation; thermodynamic; computer readable storage medium; probe;  
KW target; molecular beacon; duplex; hairpin; ss.  
XX  
OS Synthetic.  
XX  
PN WO200194611-A2.  
XX  
PD 13-DEC-2001.  
XX  
PF 07-JUN-2001; 2001WO-US018424.  
XX  
PR 07-JUN-2000; 2000US-0209778P.  
XX  
PA (UYWA-) UNIV WAYNE STATE.  
XX  
PI Santalucia J, Peyret N;  
XX  
DR WPI; 2002-122125/16.  
XX  
PT Predicting nucleic acid hybridization thermodynamics based on  
PT hybridization information, thermodynamic parameter, correction data and  
PT first set of data which represents hybridization conditions.  
XX  
PS Disclosure; Fig 8; 100pp; English.

XX  
CC The present invention describes a method for predicting nucleic acid  
CC hybridisation thermodynamics (HT) comprising providing a database of  
CC thermodynamic parameters (TP), receiving hybridisation information which  
CC represents a sequence, receiving correction data, and a first set of data

PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers  
PT for locating, identifying and characterizing the genes responsible for  
PT disorder-related traits.  
XX  
PS Example 14; Page 125; 714pp; English.  
XX  
CC This invention relates to the sequence of an isolated nucleic acid  
CC molecule comprising at least one base variation from that of a known  
CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),  
CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor betal (ADBR1),  
CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator  
CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding  
CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating  
CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl  
CC transferase (HNMT), (kallikrein 2) KLK2, nicotineamide -N-methyl  
CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),  
CC sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4  
CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl  
CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1  
CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3  
CC (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic  
CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.  
CC The polymorphisms in the human genes cited in the invention are useful as  
CC genetic linkage markers for locating and characterising the genes that  
CC are responsible for specific traits within the genome and eventually  
CC identifying the genes responsible for a variety of disorder-related  
CC traits as a result of their e.g., overexpression, constitutive  
CC expression, mutation or underexpression, which may be used in diagnosing  
CC and/or treating the disorders. The nucleic acid molecules comprising the  
CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,  
CC ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,  
CC MDR1 and/or MDR3 are useful for screening individuals for altered drug  
CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,  
CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for  
CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are  
CC used to screen for altered cardiovascular function, in COX2 for altered  
CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central  
CC nervous system function, in FLAP and HNMT for altered pulmonary,  
CC immunological or haematological function, in KLK2 for altered serine  
CC protease activity in the prostate, in LTF for altered immunological or  
CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and  
CC peripheral nervous system function. The present sequence represents a PCR  
CC primer used to amplify the sequences of the invention  
XX  
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 96;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 917 GTCCAGCCACCAAC 930  
DB |||||||  
2 GTCCAGCCACCAAC 15

RESULT 134  
ABS97731  
ID ABS97731 standard; DNA; 15 BP.  
XX  
AC ABS97731;  
XX  
DT 23-DEC-2002 (first entry)  
XX  
DE Human kelleikrin 2 (KLK2) gene sequencing primer #6.  
XX  
KW Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;  
KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;  
KW adrenergic receptor betal; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;  
KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;  
KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;  
KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;  
KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;  
KW HNMT; kallikrein 2; KLK2; nicotineamide-N-methyl transferase; NNMT;

KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;  
KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;  
KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;  
KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;  
KW multidrug resistance associated protein 3; cancer; prostate;  
KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;  
KW altered drug metabolism; cardiovascular function; colorectal tumour;  
KW central nervous system; pulmonary; immunological; sequencing.  
XX Homo sapiens.  
OS WO200257410-A2.  
XX 25-JUL-2002.  
PF 28-NOV-2001; 2001WO-US044838.  
XX 28-NOV-2000; 2000US-00724389.  
PR (DNAS-) DNA SCI LAB INC.  
XX Guida M, Hall J;  
WPI; 2002-698522/75.  
PT Isolated nucleic acid molecules having polymorphisms in known human genes  
PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers  
PT for locating, identifying and characterizing the genes responsible for  
PT disorder-related traits.  
XX Example 14; Page 126; 714pp; English.  
PS This invention relates to the sequence of an isolated nucleic acid  
XX molecule comprising at least one base variation from that of a known  
CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),  
CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor betal (ADBR1),  
CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator  
CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding  
CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating  
CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl  
CC transferase (HNMT), (kallikrein 2) KLK2, nicotineamide -N-methyl  
CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),  
CC sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4  
CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl  
CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1  
CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3  
CC (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic  
CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.  
CC The polymorphisms in the human genes cited in the invention are useful as  
CC genetic linkage markers for locating and characterising the genes that  
CC are responsible for specific traits within the genome and eventually  
CC identifying the genes responsible for a variety of disorder-related  
CC traits as a result of their e.g., overexpression, constitutive  
CC expression, mutation or underexpression, which may be used in diagnosing  
CC and/or treating the disorders. The nucleic acid molecules comprising the  
CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,  
CC ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,  
CC MDR1 and/or MDR3 are useful for screening individuals for altered drug  
CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,  
CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for  
CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are  
CC used to screen for altered cardiovascular function, in COX2 for altered  
CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central  
CC nervous system function, in FLAP and HNMT for altered pulmonary,  
CC immunological or haematological function, in KLK2 for altered serine  
CC protease activity in the prostate, in LTF for altered immunological or  
CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and  
CC peripheral nervous system function. The present sequence represents a  
XX sequencing primer used to sequence the polymorphic genes of the invention  
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;

```
CC      that can be dispense or administer a composition comprising (I). (I) is
CC      useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC      is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC      The subject is suffering from a disorder characterised by elevated or
CC      otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC      levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC      disorder is chosen from the HDL/LDL cholesterol imbalance,
CC      dyslipidaemias, hypercholesterolaemia, statin-resistant
CC      hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC      disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC      inhibit hepatic glucose production or for treating glucose-metabolism-
CC      related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC      treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC      lung cancer), neurological disease (e.g., Huntington disease or
CC      spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC      represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC      can be used to control ApoB gene expression.
XX      Sequence 19 BP; 9 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
SQ
      Query Match      0.8%;      Score 14.2;      DB 1;      Length 19;
      Best Local Similarity      84.2%;      Pred. No. 1.3e+02;
      Matches 16;      Conservative      0;      Mismatches      3;      Indels      0;      Gaps      0;

QY      1723 TTTCTTTAAATAATTGAAA 1741
Db      ||||| ||||| ||||| |||||
      19 TTTCTTTCAACAATTATAA 1

RESULT 133
ADR78853/c
ID      ADR78853 standard; DNA; 19 BP.
XX
AC      ADR78853;
XX
DT      16-DEC-2004 (first entry)
XX
DE      Human apolipoprotein B (ApoB) oligonucleotide seqid 3338.
XX
KW      antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW      cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW      RNA interference; iRNA; antisense technology; lipid metabolism;
KW      cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW      coronary artery disease; CAD; coronary heart disease; CHD;
KW      atherosclerosis; hepatic glucose production;
KW      glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW      colon cancer; lung cancer; neurological disease; Huntington disease;
KW      spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
OS      Homo sapiens.
XX
PN      WO2004080406-A2.
XX
PD      23-SEP-2004.
XX
PF      08-MAR-2004; 2004WO-US007070.
XX
PR      07-MAR-2003; 2003US-0452682P.
PR      12-MAR-2003; 2003US-0454265P.
PR      13-MAR-2003; 2003US-0454962P.
PR      13-MAR-2003; 2003US-0455050P.
PR      14-APR-2003; 2003US-0462894P.
PR      17-APR-2003; 2003US-0463772P.
PR      25-APR-2003; 2003US-0465665P.
PR      25-APR-2003; 2003US-0465802P.
PR      09-MAY-2003; 2003US-0469612P.
PR      08-AUG-2003; 2003US-0493986P.
PR      11-AUG-2003; 2003US-0506341P.
PR      26-SEP-2003; 2003US-0494597P.
PR      09-OCT-2003; 2003US-0510246P.
PR      10-OCT-2003; 2003US-0510318P.
PR      07-NOV-2003; 2003US-0518453P.
XX
PA      (ALNY-) ALNYLAM PHARM.
XX
PI      Manoharan M, Bumcrot D;
XX
DR      WPI; 2004-677362/66.
XX
PT      Interference RNA agent useful for treating dyslipidemias, coronary artery
PT      disease, diabetes, cancer or neurological disease, comprises sense
PT      sequence and antisense sequence which has specific modifications.
XX
PS      Example 5; SEQ ID NO 3338; 378pp; English.
XX
CC      The invention describes a RNA interference (iRNA) agent (I) comprising a
CC      sense sequence and an antisense sequence, where the sense sequences have
CC      one or more asymmetrical 2'-O alkyl modifications, the antisense
CC      sequences have one or more asymmetrical phosphorothioate modifications
CC      and the antisense sequence targets a human gene sequence. Also described
CC      are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC      levels or glucose-6-phosphatase levels in a subject; producing (I);
CC      stabilising (I), involves selecting a sequence with activity and
CC      introducing one or more asymmetrical modification in the sequence, where
CC      the modification decreases nuclease sensitivity while not decreasing its
CC      activity; a kit comprising (I) and instruction for its use; and a device
```

```
CC      that can be dispense or administer a composition comprising (I). (I) is
CC      useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC      is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC      The subject is suffering from a disorder characterised by elevated or
CC      otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC      levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC      disorder is chosen from the HDL/LDL cholesterol imbalance,
CC      dyslipidaemias, hypercholesterolaemia, statin-resistant
CC      hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC      disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC      inhibit hepatic glucose production or for treating glucose-metabolism-
CC      related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC      treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC      lung cancer), neurological disease (e.g., Huntington disease or
CC      spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC      represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC      can be used to control ApoB gene expression.
XX      Sequence 19 BP; 9 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
SQ
      Query Match      0.8%;      Score 14.2;      DB 1;      Length 19;
      Best Local Similarity      84.2%;      Pred. No. 1.3e+02;
      Matches 16;      Conservative      0;      Mismatches      3;      Indels      0;      Gaps      0;

QY      1723 TTTCTTTAAATAATTGAAA 1741
Db      ||||| ||||| ||||| |||||
      19 TTTCTTTCAACAATTATAA 1

RESULT 133
ABS97718
ID      ABS97718 standard; DNA; 15 BP.
XX
AC      ABS97718;
XX
DT      23-DEC-2002 (first entry)
XX
DE      Human kelleikrin 2 (KLK2) gene PCR primer #3.
XX
KW      Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
KW      cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW      adrenergic receptor betal; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW      aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW      cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW      epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW      glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;
KW      HNM1; kallikrein 2; KLK2; nicotineamide-N-methyl transferase; NNMT;
KW      NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
KW      UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW      UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW      multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW      multidrug resistance associated protein 3; cancer; prostate;
KW      acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW      altered drug metabolism; cardiovascular function; colorectal tumour;
KW      central nervous system; pulmonary; immunological.
XX
OS      Homo sapiens.
XX
PN      WO200257410-A2.
XX
PD      25-JUL-2002.
XX
PF      28-NOV-2001; 2001WO-US044838.
XX
PR      28-NOV-2000; 2000US-00724389.
XX
PA      (DNAS-) DNA SCI LAB INC.
XX
PI      Guida M, Hall J;
XX
DR      WPI; 2002-698522/75.
XX
PT      Isolated nucleic acid molecules having polymorphisms in known human genes
```



KW ss; cell proliferative disorder; breast; methylation; cytostatic;  
KW gene therapy; single nucleotide polymorphism; SNP.  
XX Unidentified.  
XX WO2004035803-A2.  
XX PD 29-APR-2004.  
XX PF 01-OCT-2003; 2003WO-EP010881.  
XX PR 01-OCT-2002; 2002DE-01045779.  
XX PR 07-JAN-2003; 2003DE-01000096.  
XX PR 17-APR-2003; 2003DE-01017955.  
XX PA (EPIG-) EPIGENOMICS AG.  
XX PI Foekens J, Harbeck N, Koenig T, Maier S, Martens J, Model F;  
PI Nimmrich I, Rujan T, Schmitt A, Schmitt M, Look MP, Marx A;  
XX WPI; 2004-348468/32.  
XX Predicting responsiveness of a subject with breast cell proliferative  
PT disorder, useful for treating or differentiating breast cell  
PT proliferative disorders comprises analyzing methylation pattern of a  
PT genomic DNA from the subject.  
XX Disclosure; SEQ ID NO 1108; 104pp; English.  
XX The invention relates to a novel method for predicting the responsiveness  
CC of a subject with a cell proliferative disorder of the breast tissues to  
CC a therapy comprising analysing the methylation pattern of a target  
CC nucleic acid by contacting at least one of the target nucleic acids in a  
CC biological sample obtained from the subject prior to or during treatment.  
CC The method of the invention has cytostatic activity, and may have a use  
CC in gene therapy. The set of oligonucleotides comprising at least two of  
CC the oligomers are useful for detecting the cytosine methylation state  
CC and/or single nucleotide polymorphisms (SNPs) within the sequences. The  
CC methods, nucleic acid, oligonucleotide, and kit are useful for the  
CC treatment, characterisation, classification and/or differentiation, of  
CC breast cell proliferative disorders. The method is also useful for  
CC predicting the responsiveness of a subject with a cell proliferative  
CC disorder of the breast tissues to a therapy. The present sequence is used  
CC in the exemplification of the invention.  
XX SQ Sequence 18 BP; 3 A; 0 C; 7 G; 8 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1376 GGTTTGGTTGTTAGGA 1391  
Db | | | | | | | | | |  
2 GATTGGTTGTTAGGA 17  
RESULT 131  
ADR76235/c  
ID ADR76235 standard; DNA; 19 BP.  
XX  
AC ADR76235;  
XX  
DT 16-DEC-2004 (first entry)  
XX  
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 720.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;

KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.  
XX Homo sapiens.  
XX WO2004080406-A2.  
XX PD 23-SEP-2004.  
XX PF 08-MAR-2004; 2004WO-US007070.  
XX PR 07-MAR-2003; 2003US-0452682P.  
XX PR 12-MAR-2003; 2003US-0454265P.  
XX PR 13-MAR-2003; 2003US-0454962P.  
XX PR 13-MAR-2003; 2003US-0455050P.  
XX PR 14-APR-2003; 2003US-0462894P.  
XX PR 17-APR-2003; 2003US-0463772P.  
XX PR 25-APR-2003; 2003US-0465665P.  
XX PR 25-APR-2003; 2003US-0465802P.  
XX PR 09-MAY-2003; 2003US-0469612P.  
XX PR 08-AUG-2003; 2003US-0493986P.  
XX PR 11-AUG-2003; 2003US-0494597P.  
XX PR 26-SEP-2003; 2003US-0506341P.  
XX PR 09-OCT-2003; 2003US-0510246P.  
XX PR 10-OCT-2003; 2003US-0510318P.  
XX PR 07-NOV-2003; 2003US-0518453P.  
XX (ALNY-) ALNYLAM PHARM.  
XX PA Manoharan M, Bumcrot D;  
XX WPI; 2004-677362/66.  
XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX Example 5; SEQ ID NO 720; 378pp; English.  
XX The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that  
CC can be used to control ApoB gene expression.  
XX SQ Sequence 19 BP; 9 A; 0 C; 3 G; 7 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.2; DB 1; Length 19;  
Best Local Similarity 84.2%; Pred. No. 1.3e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;



XX Synthetic.

OS Key Location/Qualifiers

XX misc\_feature 17..18

FT /\*tag= a

FT /note= "2 deoxynucleotide overhang"

XX

XX WO2004063331-A2.

XX

XX 29-JUL-2004.

XX

XX 05-JAN-2004; 2004WO-US000128.

XX

XX 03-JAN-2003; 2003US-0437842P.

XX

XX (GENC-) GENCIA CORP.

XX

XX Kahn S;

XX

XX WPI; 2004-561892/54.

XX

XX Inhibitory nucleic acid that inhibits expression of an androgen signal transduction pathway protein useful for treating hair loss, comprises a double stranded RNA having a partial sequence encoding a pathway protein in one strand.

XX

XX Claim 11; Page 59; 92pp; English.

XX

XX The present invention relates to novel small interfering RNAs (siRNAs), comprising a double stranded RNA, where one strand comprises a partial nucleic acid sequence of an androgen signal transduction pathway protein, and where the double-stranded RNA inhibits translation of mRNA encoding the nucleic acid sequence of the androgen signal transduction pathway protein thereby blocking the androgen signal transduction pathway. The androgen signal transduction pathway protein is chosen from isozymes I and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-hydroxysteroiddehydrogenase (ADQ93182), 3-beta-hydroxysteroiddehydrogenase (ADQ93360), 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-hydroxysteroiddehydrogenase (ADQ93722), and steroid sulfatase (ADQ93770). The siRNAs of the invention are useful for reducing hair loss in a mammal which involves contacting several mammal's hair cells with the siRNA, where the siRNA interferes with the translation of mRNA of the androgen signal transduction protein. The siRNAs are useful for treating hyperandrogenic conditions of androgenic alopecia, including male pattern alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic hypertrophy. The present sequence is the antisense strand for one such siRNA of the invention.

XX.

SQ Sequence 18 BP; 3 A; 4 C; 5 G; 2 T; 4 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 68.8%; Pred. No. 1.1e+02;

Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 387 AGCTTTCCCAAGTCTGG 402

||||:||||| |:|

Db 1 AGCUUUCCAAGGCGG 16

RESULT 129

ADQ93225/c

ID ADQ93225 standard; DNA; 18 BP.

XX

XX ADQ93225;

XX

XX 21-OCT-2004 (first entry)

XX

XX 3-alpha-hydroxysteroiddehydrogenase target oligonucleotide, SEQ ID 801.

DE

XX Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;

KW small interfering RNA; siRNA;

KW androgen signal transduction pathway protein;

KW androgen signal transduction; 3-alpha-hydroxysteroiddehydrogenase;

KW hair loss; hyperandrogenic condition; androgenic alopecia;

KW male pattern alopecia; acne vulgaris; seborrhea; female hirsutism;

KW prostatic hypertrophy; human; ss.

XX

OS Homo sapiens.

XX

XX WO2004063331-A2.

XX

XX 29-JUL-2004.

XX

XX 05-JAN-2004; 2004WO-US000128.

XX

XX 03-JAN-2003; 2003US-0437842P.

XX

XX (GENC-) GENCIA CORP.

XX

XX Kahn S;

XX

XX WPI; 2004-561892/54.

XX

XX Inhibitory nucleic acid that inhibits expression of an androgen signal transduction pathway protein useful for treating hair loss, comprises a double stranded RNA having a partial sequence encoding a pathway protein in one strand.

XX

XX Claim 11; Page 59; 92pp; English.

XX

XX The present invention relates to novel small interfering RNAs (siRNAs), comprising a double stranded RNA, where one strand comprises a partial nucleic acid sequence of an androgen signal transduction pathway protein, and where the double-stranded RNA inhibits translation of mRNA encoding the nucleic acid sequence of the androgen signal transduction pathway protein thereby blocking the androgen signal transduction pathway. The androgen signal transduction pathway protein is chosen from isozymes I and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-hydroxysteroiddehydrogenase (ADQ93182), 3-beta-hydroxysteroiddehydrogenase (ADQ93360), 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-hydroxysteroiddehydrogenase (ADQ93722), and steroid sulfatase (ADQ93770). The siRNAs of the invention are useful for reducing hair loss in a mammal which involves contacting several mammal's hair cells with the siRNA, where the siRNA interferes with the translation of mRNA of the androgen signal transduction protein. The siRNAs are useful for treating hyperandrogenic conditions of androgenic alopecia, including male pattern alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic hypertrophy. The present sequence is a target sequence which was used to generate the siRNAs of the invention.

XX

SQ Sequence 18 BP; 6 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.1e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 387 AGCTTTCCCAAGTCTGG 402

||||:||||| |:|

Db 18 AGCTTTCCCAAGGCTGG 3

RESULT 130

ADS90092

ID ADS90092 standard; DNA; 18 BP.

XX

XX ADS90092;

XX

XX 18-NOV-2004 (first entry)

XX

XX Oligonucleotide of the invention SEQ ID NO:1108.

DE

XX

KW hybrid polypeptide/polyketide metabolite; Lnm production; cytostatic;  
KW PCR; primer; ss.  
XX  
OS Streptomyces atroolivaceus.  
XX  
PN WO200277179-A2.  
XX  
PD 03-OCT-2002.  
XX  
PP 22-MAR-2002; 2002WO-US008937.  
XX  
PR 26-MAR-2001; 2001US-0278935P.  
XX  
PA (REGC ) UNIV CALIFORNIA.  
PA (KYOW ) KYOWA HAKKO KOGYO KK.  
XX  
PI Shen B, Cheng Y, Tang G;  
XX  
DR WPI; 2003-018907/01.  
XX  
PT Novel gene cluster responsible for synthesis of leinamycin in  
PT Streptomyces atroolivaceus useful for making various peptide and/or  
PT polyketide, and/or hybrid polypeptide/polyketide metabolites.  
XX  
PS Claim 1; Page 29; 185pp; English.  
XX  
CC The present invention relates to the isolation of the Streptomyces  
CC atroolivaceus leinamycin (Lnm) biosynthesis gene cluster containing 71  
CC open reading frames (ORFs) (ORFs -35 through -1, ORFs lnmA through lnmZ,  
CC and ORFs +1 through +9). Leinamycin is a novel anti-tumour antibiotic  
CC produced by several Streptomyces species. It exhibits broad spectrum  
CC antimicrobial activity against Gram-positive and Gram-negative bacteria,  
CC but not against fungi. The polypeptides encoded by the Lnm biosynthesis  
CC gene cluster ORFs are useful for chemically modifying a molecule in a  
CC host cell. The host cell is a bacterium or eukaryotic cell, including a  
CC mammalian, yeast, plant, fungal, or insect cell. The molecule is an  
CC endogenous metabolite produced by the host cell or exogenously supplied  
CC metabolite, or an amino acid, and the polypeptide is a peptide synthetase  
CC or amino transferase. The polypeptides encoded by the Lnm gene cluster  
CC are useful for converting an apo-carrier protein to a holo-carrier  
CC protein. Lnm shows potent antitumour activity in tumour models in vivo.  
CC The Lnm gene cluster modules and/or catalytic domains are useful for  
CC making various peptide and/or polyketide, and/or hybrid  
CC polypeptide/polyketide metabolites. The proteins encoded by the ORFs are  
CC useful alone, or in combination with other active domains to modify  
CC various target substrates. The Lnm gene cluster is useful to upregulate  
CC endogenous Lnm production to permit Lnm production in cells and/or to  
CC make various modified Lnm. Lnm, its analogue, or other polyketide,  
CC peptide or hybrid polyketide/peptide metabolites are useful as  
CC therapeutic agents, to treat a number of disorders, depending upon the  
CC type of metabolites. ABX34290-ABX34431 represent PCR primers used to  
CC amplify individual ORFs of the S. atroolivaceus leinamycin biosynthesis  
CC gene cluster  
XX  
SQ Sequence 18 BP; 5 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 600 TCAAGGCACAAACCTC 615  
Db 1 TCAAGGCACGAACCTC 16

RESULT 127  
ADK82331/c  
ID ADK82331 standard; DNA; 18 BP.  
XX  
AC ADK82331;  
XX  
DT 03-JUN-2004 (first entry)  
XX

DE Nucleic acid analysis method spacer oligonucleotide seqid 108.  
XX  
KW nucleic acid analysis; hepatitis C virus;  
KW non-contiguous single-stranded region; NCSR; cleavage structure;  
KW clinical; diagnostic; microorganism detection;  
KW microorganism identification; ss.  
XX  
OS Synthetic.  
XX  
PN US6709815-B1.  
XX  
PD 23-MAR-2004.  
XX  
PF 18-JUL-2000; 2000US-00402618.  
XX  
PR 05-MAY-1997; 97US-00851588.  
PR 19-SEP-1997; 97US-00934097.  
PR 03-MAR-1998; 98US-00034205.  
XX  
PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX  
PI Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;  
PI Anderson TA, Dahlberg JE;  
XX  
DR WPI; 2004-256067/24.  
XX  
PT Analyzing nucleic acids, comprises mixing target nucleic acid such as  
PT hepatitis C virus nucleic acid, bridging oligonucleotide, second  
PT oligonucleotide and cleavage agent to form cleavage structure.  
XX  
PS Example 13; SEQ ID NO 108; 143pp; English.  
XX  
CC The invention describes a method of analysing nucleic acids comprising  
CC providing a target nucleic acid, e.g. hepatitis C virus nucleic acid  
CC having non-contiguous single-stranded regions (NCSR) separated by an  
CC intervening region, a bridging oligonucleotide capable of binding to the  
CC first and second NCSR; a second oligonucleotide binding to a portion of  
CC the first NCSR and a cleavage agent, and mixing the contents to form a  
CC cleavage structure. The method is useful for analysing nucleic acids,  
CC e.g. hepatitis C virus nucleic acid useful for clinical diagnostic  
CC purposes and detection and identification of pathogenic microorganisms  
CC such as hepatitis C virus. This sequence represents a spacer  
CC oligonucleotide associated with the nucleic acid analysis method of the  
CC invention.  
XX  
SQ Sequence 18 BP; 5 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTTCTGTCTCAC 828  
Db 16 AACAACTTTCTGTCTCAC 1

RESULT 128  
ADQ93227  
ID ADQ93227 standard; RNA; 18 BP.  
XX  
AC ADQ93227;  
XX  
DT 21-OCT-2004 (first entry)  
XX  
DE 3-alpha-hydroxysteroiddehydrogenase siRNA antisense strand, SEQ ID 803.  
XX  
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;  
KW small interfering RNA; siRNA;  
KW androgen signal transduction pathway protein;  
KW androgen signal transduction; 3-alpha-hydroxysteroiddehydrogenase;  
KW hair loss; hyperandrogenic condition; androgenic alopecia;  
KW male pattern alopecia; acne vulgaris; seborrhea; female hirsutism;  
KW prostatic hypertrophy; ds.

KW multidrug resistance associated protein 3; cancer; prostate;  
KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;  
KW altered drug metabolism; cardiovascular function; colorectal tumour;  
KW central nervous system; pulmonary; immunological; sequencing.  
XX  
OS Homo sapiens.  
XX WO200257410-A2.  
PN  
XX  
XX  
PD 25-JUL-2002.  
XX  
XX 28-NOV-2001; 2001WO-US044838.  
PF  
XX 28-NOV-2000; 2000US-00724389.  
PR  
XX (DNAS-) DNA SCI LAB INC.  
PA  
XX Guida M, Hall J;  
PI  
XX WPI; 2002-698522/75.  
DR  
XX Isolated nucleic acid molecules having polymorphisms in known human genes  
PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers  
PT for locating, identifying and characterizing the genes responsible for  
PT disorder-related traits.  
XX  
PS Example 2; Page 101; 714pp; English.  
XX  
CC This invention relates to the sequence of an isolated nucleic acid  
CC molecule comprising at least one base variation from that of a known  
CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),  
CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),  
CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator  
CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding  
CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating  
CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl  
CC transferase (HNMT), kallikrein 2) KLK2, nicotineamide -N-methyl  
CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),  
CC sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4  
CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl  
CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1  
CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3  
CC (MRP3), orphan nuclear receptor (NRI12), or acetylcholine muscarinic  
CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.  
CC The polymorphisms in the human genes cited in the invention are useful as  
CC genetic linkage markers for locating and characterising the genes that  
CC are responsible for specific traits within the genome and eventually  
CC identifying the genes responsible for a variety of disorder-related  
CC traits as a result of their e.g., overexpression, constitutive  
CC expression, mutation or underexpression, which may be used in diagnosing  
CC and/or treating the disorders. The nucleic acid molecules comprising the  
CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,  
CC ARNT, EPHX2, GST12, NNMT, NQO2, NRI12, STM, UGT2B4, UGT2B7, UGT2B15, AHR,  
CC MDR1 and/or MDR3 are useful for screening individuals for altered drug  
CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,  
CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for  
CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are  
CC used to screen for altered cardiovascular function, in COX2 for altered  
CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central  
CC nervous system function, in FLAP and HNMT for altered pulmonary,  
CC immunological or haematological function, in KLK2 for altered serine  
CC protease activity in the prostate, in LTF for altered immunological or  
CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and  
CC peripheral nervous system function. The present sequence represents a  
CC sequencing primer used to sequence the polymorphic genes of the invention  
XX  
SQ Sequence 18 BP; 4 A; 1 C; 10 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1504 GGAGGTGTACAGGTCA 1519

|||||  
Db 1 GGAGGTGTAGAGGTCA 16  
RESULT 125  
ABN83386  
ID ABN83386 standard; DNA; 18 BP.  
XX  
XX ABN83386;  
AC  
XX 15-AUG-2002 (first entry)  
DT  
XX Hepatocyte growth factor, HGF, sense RT-PCR primer.  
DE  
XX RT-PCR; primer; hepatotropic; antifibrotic; vulnerary; fibrosis;  
KW hepatocyte growth factor; HGF; ss.  
KW  
XX Unidentified.  
OS  
XX WO200244393-A1.  
PN  
XX 06-JUN-2002.  
PD  
XX 30-NOV-2000; 2000WO-MX000050.  
PF  
XX 28-NOV-2000; 2000MX-00011713.  
PR  
XX (TGTT-) TGT LAB SA DE CV.  
PA  
XX Armendariz Borunda J, Aguilar Cordova E;  
PI  
XX WPI; 2002-471834/50.  
DR  
XX Preparing recombinant vector containing reporter and therapeutic genes,  
PT useful for treatment of fibrosis, particularly of liver, by inducing  
PT degradation of collagen.  
PT  
XX Example; Page 41; 75pp; Spanish.  
PS  
XX The present invention relates to a method for preparing recombinant  
CC vectors (A) by cloning a reporter gene, and modified cDNA of a  
CC therapeutic gene that encodes a protein useful for treating fibrosis  
CC (hepatic, pulmonary, renal, cardiac or pancreatic), keloids and  
CC hypertrophic scars. (A) are used to treat fibrosis in the cirrhotic  
CC liver, but more generally fibrosis in any organ. The present sequence is  
CC a RT-PCR primer for hepatocyte growth factor (HGF), which was used in the  
CC examples from the invention  
XX  
SQ Sequence 18 BP; 3 A; 5 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1203 GCTCATGGACCCCTGCT 1218  
|||||  
Db 3 GCTCATGGACCCCTGCT 18  
RESULT 126  
ABX34397  
ID ABX34397 standard; DNA; 18 BP.  
XX  
XX ABX34397;  
AC  
XX 11-FEB-2003 (first entry)  
DT  
XX PCR primer #2 for S. atroolivaceus leinamycin gene cluster ORF lnms.  
DE  
XX Leinamycin biosynthesis gene cluster; lmn; open reading frame; ORF;  
KW anti-tumour antibiotic; broad spectrum antimicrobial activity;  
KW Gram-positive; Gram-negative bacteria; chemical modification; metabolite;  
KW apo-carrier protein; holo-carrier protein; tumour; polyketide;



XX ABL44181;  
AC  
XX  
DT 11-APR-2002 (first entry)  
XX  
DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1225.  
XX  
KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;  
KW PCR primer; ss.  
XX  
OS Homo sapiens.  
XX  
PN JP2001321190-A.  
XX  
PD 20-NOV-2001.  
XX  
PF 12-MAR-2001; 2001JP-00068285.  
XX  
PR 10-MAR-2000; 2000JP-00066716.  
XX  
PA (RIKA ) RIKAGAKU KENKYUSHO.  
PA (GENO-) GENOTEX YG.  
XX  
DR WPI; 2002-144136/19.  
XX  
PT Arraying genome clones.  
XX  
PS Claim 4; Page 29; 528pp; Japanese.  
XX  
CC The present invention describes a method of arraying genome clones. The  
CC method comprises: (a) clones of the genomic libraries contained in  
CC multiwell plates numbered for discrimination are mixed in each of the  
CC multiwell plates; (b) a primer designed based on the chromosome marker  
CC sequence is added to the mixture to carry out an amplification reaction;  
CC (c) a signal corresponding to the marker is detected from the resultant  
CC amplified product to specify the discrimination Nos. of the multiwell  
CC plates containing the clones having said marker sequence; (d) the order  
CC of the markers is changed so that the same discrimination Nos. succeed to  
CC the maximum in the specified discrimination Nos. to array the multiwell  
CC plates; (e) the clones in the multiwell plates of the specified  
CC discrimination Nos. are mixed respectively in each wells of longitudinal  
CC and lateral directions; (f) the mixed clones are cultured and the  
CC resultant cultures are amplified by using the above primer; (g) signals  
CC are detected from the amplified products; (h) the clones in the multiwell  
CC plates are specified from the detected result; and (i) the clones are  
CC reconstituted as the positions on the chromosome and arrayed. The  
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent  
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634  
CC represent PCR primers for human chromosome 21q22.1, which are  
CC specifically claimed for use in the present invention  
XX  
SQ Sequence 18 BP; 4 A; 5 C; 5 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1243 TTCCCAGGAATCAAGC 1258  
DB 1 TTCCCAGGAATCAGGC 16  
  
RESULT 123  
ABL46141/C  
ID ABL46141 standard; DNA; 18 BP.  
XX  
AC ABL46141;  
XX  
DT 26-APR-2002 (first entry)  
XX  
DE Mycobacterium tuberculosis rpoB gene bridging probe SEQ ID NO:108.  
XX  
KW Nucleic acid accessible hybridisation site; detection; hybridisation;

KW characterisation; identification; nucleic acid structure; diagnosis;  
KW PCR primer; probe; ss.  
XX  
OS Mycobacterium tuberculosis.  
OS Synthetic.  
XX  
PN WO200198537-A2.  
XX  
PD 27-DEC-2001.  
XX  
PF 15-JUN-2001; 2001WO-US019401.  
XX  
PR 17-JUN-2000; 2000US-0212308P.  
PR 15-JUN-2001; 2001US-00212308.  
XX  
PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX  
PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;  
XX WPI; 2002-049698/06.  
DR  
XX Identifying oligonucleotides hybridizing to nucleic acids containing  
PT secondary structure, useful in clinical diagnosis, comprises identifying  
PT primers that interact with the target to form an extension product under  
PT amplification conditions.  
XX  
PS Example 13; Fig 37C; 409pp; English.  
XX  
CC The present invention describes a method for identifying oligonucleotides  
CC with desired hybridisation properties to nucleic acid targets containing  
CC secondary structure. The method comprises amplifying a target nucleic  
CC acid having at least one accessible and one inaccessible site. Primers  
CC that form an extension product are identified as the oligonucleotides  
CC which can interact with the folded target nucleic acid. Oligonucleotides  
CC from the present invention can be used in novel detection methods for  
CC clinical diagnostic purposes, including the detection and identification  
CC of pathogenic organisms (e.g. HIV). The method allows the ability to  
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
CC sequences used in the exemplification of the present invention  
XX  
SQ Sequence 18 BP; 5 A; 2 C; 5 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 813 ATCAACTTTCTGTCTCAC 828  
DB 16 AACCAACTTTCTGTCTCAC 1  
  
RESULT 124  
ABS97172  
ID ABS97172 standard; DNA; 18 BP.  
XX  
AC ABS97172;  
XX  
DT 23-DEC-2002 (first entry)  
XX  
DE Human CYP4501A2 Exon 2 sequencing primer #2.  
XX  
KW Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;  
KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;  
KW adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;  
KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;  
KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;  
KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;  
KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;  
KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;  
KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;  
KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;  
KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;  
KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;



Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTTCGTGCAC 828  
| | | | | | | | | | | | | | | |  
Db 16 AACAACTTTCGTGCAC 1

RESULT 120  
AAS06835  
ID' AAS06835 standard; DNA; 18 BP.  
XX  
AC AAS06835;  
XX  
DT 12-SEP-2001 (first entry)  
XX  
DE SNP containing protein kinase DNA sequence #4.  
XX  
KW Human; protein kinase; PTK; STK; cancer; cardiovascular disease; SNP;  
KW metabolic disorder; immune related disease; neurological disorder;  
KW neurodegenerative disorder; inflammatory disorder; infectious disease;  
KW reproductive disorder; gene therapy; single nucleotide polymorphism; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO200138503-A2.  
XX  
PD 31-MAY-2001.  
XX  
PF 22-NOV-2000; 2000WO-US032085.  
XX  
PR 24-NOV-1999; 99US-0167482P.  
XX  
PA (SUGE-) SUGEN INC.  
XX  
PI Plowman GD, Whyte D, Manning G, Sudarsanam S, Martinez R;  
PI Flanagan P, Clary D;  
XX  
DR WPI; 2001-343950/36.  
XX  
PT Nucleic acids encoding human kinase polypeptides, useful for preventing  
PT diagnosing and/or treating e.g. cancer, immune, cardiovascular and  
PT neuronal-associated diseases, and microbial infections.  
XX  
PS Example 8B; Page 329; 433pp; English.  
XX  
CC AAS06832-AAS06897 represent part of a polynucleotide sequence encoding  
CC for novel human protein kinases where a single nucleotide polymorphism  
CC (SNP) has been identified. The SNP occurs at the last position of the  
CC present sequence. The sequences are described relating to the invention  
CC of novel human protein kinases #1-57 (AAU03501-AAU03557). The novel  
CC protein kinases have been identified as members of the tyrosine or  
CC serine/threonine kinase (PTK and STK) families. The polynucleotides  
CC encoding protein kinases and the polypeptides may be used in the  
CC prevention, diagnosis and treatment of diseases associated with  
CC inappropriate kinase expression. For example, they may be used to treat  
CC cancers (especially cancers of haematopoietic origin), cardiovascular  
CC disease (e.g. atherosclerosis), metabolic disorders (e.g. diabetes),  
CC immune related diseases (e.g. rheumatoid arthritis), neurological  
CC disorders (e.g. schizophrenia), neurodegenerative disorders (e.g.  
CC Parkinson's disease), inflammatory disorders (e.g. asthma), infectious  
CC disease (e.g. HIV) and reproductive disorders (e.g. infertility).  
CC Additionally, polynucleotides encoding protein kinases may be used for  
CC gene therapy and as DNA probes in diagnostic assays. The protein kinase  
CC polypeptides may be used as antigens in the production of antibodies  
CC against the protein kinases and in assays to identify modulators of  
CC protein kinase expression and activity  
XX  
SQ Sequence 18 BP; 6 A; 3 C; 5 G; 3 T; 0 U; 1 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 83.3%; Pred. No. 1.1e+02;

Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 351 CATGAAGCGTGAGGATGT 368  
| | | | | | | | | | | | | | | |  
Db 1 CATGAAGCCTGAGAATGK 18

RESULT 121  
ABK40971  
ID ABK40971 standard; DNA; 18 BP.  
XX  
AC ABK40971;  
XX  
DT 21-MAY-2002 (first entry)  
XX  
DE Human obesity-associated biallelic marker upstream PCR primer #48.  
XX  
KW Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;  
KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;  
KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;  
KW insulin disorder; atheromatous disease; cardiac insufficiency; primer.  
XX  
OS Homo sapiens.  
XX  
PN WO200206525-A2.  
XX  
PD 24-JAN-2002.  
XX  
PF 28-JUN-2001; 2001WO-IB001477.  
XX  
PR 18-JUL-2000; 2000US-0219704P.  
XX  
PA (GEST ) GENSET.  
XX  
PI Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;  
XX  
DR WPI; 2002-155043/20.  
XX  
PT Set of novel map-related biallelic markers, preferably located on obesity  
PT disorder-associated chromosomal regions on chromosomes 3, 10 and 19,  
PT useful, for e.g. detecting statistical correlations between marker allele  
PT and a phenotype.  
XX  
PS Example 2; Page 237; 311pp; English.  
XX  
CC The invention relates to a set of novel map-related biallelic markers,  
CC preferably located on obesity disorder-associated chromosomal regions on  
CC chromosomes 3, 10 and 19. The markers are useful for genotyping or  
CC estimating the frequency of an allele in a population, for detecting an  
CC association between a genotype or haplotype and a phenotype, e.g. a  
CC disease involving drug responses, obesity or disorders related to  
CC obesity, such as hyperuricaemia, digestive pathology, hepatic function  
CC disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,  
CC insulin disorders, atheromatous disease and cardiac insufficiency. The  
CC markers are useful for detecting a statistical correlation between a  
CC biallelic marker allele and a phenotype and/or between a biallelic marker  
CC haplotype and a phenotype. This sequence represents a PCR primer used to  
CC amplify a human obesity-associated biallelic marker  
XX  
SQ Sequence 18 BP; 5 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1238 CACACTTCCCAGGAAT 1253  
| | | | | | | | | | | | | | | |  
Db 1 CACACTTCCCTGGAAT 16

RESULT 122  
ABL44181  
ID ABL44181 standard; DNA; 18 BP.



AC ADN45011;  
XX  
DT 15-JUL-2004 (first entry)  
XX  
DE Mutant cell identification-related mutagenic oligonucleotide SeqID1680.  
XX  
KW cell identification; oligonucleotide-directed sequence alteration;  
KW selectable phenotype; transgenic plant; herbicide resistance;  
KW sterile plant; abiotic stress tolerance; albino plant;  
KW amino acid production; ss.  
XX  
OS Solanum tuberosum.  
OS Synthetic.  
XX  
PN WO2004033708-A2.  
XX  
PD 22-APR-2004.  
XX  
PF 07-OCT-2003; 2003WO-US031862.  
XX  
PR 07-OCT-2002; 2002US-0416983P.  
PR 07-MAR-2003; 2003US-0453360P.  
XX  
PA (UYDE ) UNIV DELAWARE.  
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.  
XX  
XX Kmiec EB, Van Brabant A;  
PI  
XX WPI; 2004-340941/31.  
DR  
XX Identifying a cell with a desired oligonucleotide-directed sequence  
PT alteration at a nucleic acid target site within the cell by identifying  
PT the desired sequence alteration in cells selected for the presence of a  
PT selectable phenotype.  
XX  
PS Example 28; SEQ ID NO 1680; 303pp; English.  
XX  
CC This invention relates to a novel method of identifying a cell having a  
CC desired oligonucleotide-directed sequence alteration at a first nucleic  
CC acid target site within the cell. The method comprises identifying the  
CC desired sequence alteration in cells that have been selected for the  
CC presence of a selectable phenotype conferred by a concurrent  
CC oligonucleotide-directed sequence alteration at a second nucleic acid  
CC target site within the cells. The method is useful in identifying a cell  
CC having a desired oligonucleotide-directed sequence alteration at a first  
CC nucleic acid target site within the cell. The method may be useful for  
CC the production of plants with herbicide resistance, male or female  
CC sterile plants, abiotic stress tolerance, albino plants or plants with  
CC altered amino acid production as well as for use in mammalian cell lines.  
CC The present sequence is that of a mutagenic oligonucleotide which was  
CC used in the exemplification of the invention.  
XX  
SQ Sequence 17 BP; 5 A; 3 C; 3 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1478 TGGCAATAATGTAACA 1493  
DB 17 TGGCAATAATGTCACA 2  
  
RESULT 117  
ACN73529/c  
ID ACN73529 standard; DNA; 17 BP.  
XX  
AC ACN73529;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:10431.  
XX

KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 10431; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 838 AGTTTGTGATGCTGTCA 853  
DB 17 ACTTTGTGATGCTGTCA 2  
  
RESULT 118  
ACN73531/c

RESULT 114  
ADL50592/c  
ID ADL50592 standard; RNA; 17 BP.  
XX  
AC ADL50592;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human PKR substrate sequence #1706.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
OS Unidentified.  
XX  
PN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX  
PF 03-APR-2002; 2002WO-US010512.  
XX  
PR 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX  
DR WPI; 2003-058513/05.  
XX  
PT Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 59; SEQ ID NO 4125; 317pp; English.  
XX  
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune-  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human PKR  
CC substrate sequence.  
XX  
SQ Sequence 17 BP; 10 A; 0 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 ATTACTTCTATTCTT 946  
|||||  
Db 16 ATTAATCTATTCTT 1

RESULT 115  
ADN45010  
ID ADN45010 standard; DNA; 17 BP.  
XX  
AC ADN45010;  
XX  
DT 15-JUL-2004 (first entry)  
XX  
DE Mutant cell identification-related mutagenic oligonucleotide SeqID1679.  
XX  
KW cell identification; oligonucleotide-directed sequence alteration;  
KW selectable phenotype; transgenic plant; herbicide resistance;  
KW sterile plant; abiotic stress tolerance; albino plant;  
KW amino acid production; ss.  
XX  
OS Solanum tuberosum.  
OS Synthetic.  
XX  
PN WO2004033708-A2.  
XX  
PD 22-APR-2004.  
XX  
PF 07-OCT-2003; 2003WO-US031862.  
XX  
PR 07-OCT-2002; 2002US-0416983P.  
PR 07-MAR-2003; 2003US-0453360P.  
XX  
PA (UYDE ) UNIV DELAWARE.  
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.  
XX  
PI Kmiec EB, Van Brabant A;  
XX  
DR WPI; 2004-340941/31.  
XX  
PT Identifying a cell with a desired oligonucleotide-directed sequence  
PT alteration at a nucleic acid target site within the cell by identifying  
PT the desired sequence alteration in cells selected for the presence of a  
PT selectable phenotype.  
XX  
PS Example 28; SEQ ID NO 1679; 303pp; English.  
XX  
CC This invention relates to a novel method of identifying a cell having a  
CC desired oligonucleotide-directed sequence alteration at a first nucleic  
CC acid target site within the cell. The method comprises identifying the  
CC desired sequence alteration in cells that have been selected for the  
CC presence of a selectable phenotype conferred by a concurrent  
CC oligonucleotide-directed sequence alteration at a second nucleic acid  
CC target site within the cells. The method is useful in identifying a cell  
CC having a desired oligonucleotide-directed sequence alteration at a first  
CC nucleic acid target site within the cell. The method may be useful for  
CC the production of plants with herbicide resistance, male or female  
CC sterile plants, abiotic stress tolerance, albino plants or plants with  
CC altered amino acid production as well as for use in mammalian cell lines.  
CC The present sequence is that of a mutagenic oligonucleotide which was  
CC used in the exemplification of the invention.  
XX  
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAAACA 1493  
|||||  
Db 1 TGGCAATAATGTCAACA 16

RESULT 116  
ADN45011/c  
ID ADN45011 standard; DNA; 17 BP.  
XX



RESULT 112  
ADL49538  
ID ADL49538 standard; RNA; 17 BP.  
XX  
AC ADL49538;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human PKR substrate sequence #652.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
OS Unidentified.  
XX  
PN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX  
PF 03-APR-2002; 2002WO-US010512.  
XX  
PR 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX  
DR WPI; 2003-058513/05.  
XX  
PT Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 59; SEQ ID NO 3071; 317pp; English.  
XX  
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human PKR  
CC substrate sequence.  
XX  
SQ Sequence 17 BP; 9 A; 4 C; 1 G; 0 T; 3 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 75.0%; Pred. No. 1e+02;  
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
QY 146 ATAGAAACTTCCTAAA 161  
|:|||||:|:|  
Db 1 AUAGAAACAUCCUAAA 16

RESULT 113  
ADL49154/c  
ID ADL49154 standard; RNA; 17 BP.  
XX  
AC ADL49154;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Human PKR substrate sequence #268.  
XX  
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
OS Unidentified.  
XX  
PN WO200281628-A2.  
XX  
PD 17-OCT-2002.  
XX  
PF 03-APR-2002; 2002WO-US010512.  
XX  
PR 05-APR-2001; 2001US-00827395.  
PR 29-MAY-2001; 2001US-0294412P.  
PR 28-AUG-2001; 2001US-0315315P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX  
DR WPI; 2003-058513/05.  
XX  
PT Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
PS Claim 59; SEQ ID NO 2687; 317pp; English.  
XX  
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human PKR  
CC substrate sequence.  
XX  
SQ Sequence 17 BP; 11 A; 0 C; 2 G; 0 T; 4 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 931 ATTACTTCTATTTCTT 946  
|:|||||:|:|  
Db 17 ATTAATTCTATTTCTT 2

CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, identifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
XX  
SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 2 TGAATTTCTCATGAT 17  
Db 17 TGAATTTCTCATGAT 2  
  
RESULT 110  
ADI49691  
ID ADI49691 standard; DNA; 17 BP.  
XX  
AC ADI49691;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human tumour suppression/reversion-related DNA sequence SeqID2194.  
XX  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;  
KW primer; PCR; gene chip; antisense; viral disease; tumour;  
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025177-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313354/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; SEQ ID NO 2194; 30pp; French.  
XX  
CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, identifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 871 ATCCTTTTCTTTAAAG 886  
Db 2 ATCCTTTTCTTGAAG 17  
  
RESULT 111  
ACC51935/c  
ID ACC51935 standard; DNA; 17 BP.  
XX  
AC ACC51935;  
XX  
DT 27-JUN-2003 (first entry)  
XX  
DE Human tumour suppressor sequence #702.  
XX  
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;  
KW tumour regression; apoptosis; virus resistance; diagnosis;  
KW cellular degeneration.  
XX  
OS Homo sapiens.  
XX  
PN FR2826373-A1.  
XX  
PD 27-DEC-2002.  
XX  
PF 20-JUN-2001; 2001FR-00008139.  
XX  
PR 20-JUN-2001; 2001FR-00008139.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB SA.  
XX  
PI Tuijnder M, Telerman A, Amson R;  
XX  
DR WPI; 2003-250498/25.  
XX  
PT New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.  
XX  
PS Claim 1; Page 202; 798pp; French.  
XX  
CC This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX  
SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 2 TGAATTTCTCATGAT 17  
Db 17 TGAATTTCTCATGAT 2

PR 06-JUN-2001; 2001US-0296249P.  
PR 10-SEP-2001; 2001US-0318471P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Mcswiggen J;  
XX  
DR WPI; 2003-140484/13.  
XX  
XX Novel short interfering RNA and enzymatic nucleic acid useful for  
PT treating cancer, modulates the expression of a nucleic acid encoding  
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
XX  
PS Claim 58; Page 93; 185pp; English.  
XX  
CC The invention relates to a novel short interfering RNA (siRNA) nucleic  
CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-  
CC rheumatic activity. The nucleic acid molecules are useful for reducing  
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,  
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human  
CC ribozymes of the invention  
XX  
SQ Sequence 17 BP; 10 A; 1 C; 4 G; 0 T; 2 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1576 TTTTCACTTCATTCT 1591  
Db 16 TTTTCACTTCATTGT 1  
RESULT 108  
ADB40294  
ID ADB40294 standard; DNA; 17 BP.  
XX  
AC ADB40294;  
XX  
DT 18-DEC-2003 (revised)  
DT 04-DEC-2003 (first entry)  
XX  
DE Tumour suppression/reversion associated nucleotide #617.  
XX  
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX  
OS Homo sapiens.  
XX  
PN WO2003040369-A2.  
XX  
PD 15-MAY-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004219.  
XX  
PR 17-SEP-2001; 2001FR-00011981.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-441574/41.  
XX  
PT New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related

PT polypeptide and antibodies.  
XX  
PS Disclosure; Page 104; 771pp; French.  
XX  
CC The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
SQ Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1316 ATCAATTGGAATATGA 1331  
Db 2 ATCAATTGGAATATGA 17  
RESULT 109  
ADI48529/c  
ID ADI48529 standard; DNA; 17 BP.  
XX  
AC ADI48529;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human tumour suppression/reversion-related DNA sequence SeqID1032.  
XX  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;  
KW primer; PCR; gene chip; antisense; viral disease; tumour;  
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025177-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313354/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; SEQ ID NO 1032; 30pp; French.  
XX

KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
XX WPI; 2002-706994/76.  
DR  
XX  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 8220; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 9 A; 3 C; 3 G; 0 T; 2 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 8 TTCTCATGATGATTGT 23  
|||||  
Db 16 TTCTCTTGATGATTGT 1  
  
RESULT 106  
ABT34768  
ID ABT34768 standard; DNA; 17 BP.  
XX  
AC ABT34768;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
DE Tumour suppression related human fukutin oligo SEQ ID No 405.  
XX  
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025175-A2.  
XX  
PD 27-MAR-2003.  
XX

PF 17-SEP-2002; 2002WO-IB004208.  
XX  
PR 17-SEP-2001; 2001FR-00011978.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313353/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; Page 81; 720pp; French.  
XX  
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
CC given in the specification, a sequence containing at least 15 consecutive  
CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
CC hybridizes to them under highly stringent conditions, or the complement  
CC of any of them, or the corresponding RNA. The novel isolated nucleic  
CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 871 ATCCTTTTCTTTAAAG 886  
|||||  
Db 2 ATCCTTTTCTTGAAAG 17  
  
RESULT 107  
ABZ60344/c  
ID ABZ60344 standard; RNA; 17 BP.  
XX  
AC ABZ60344;  
XX  
DT 21-MAR-2003 (first entry)  
XX  
DE Human K-Ras DNazyme substrate #456.  
XX  
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;  
KW anti-rheumatic; cancer; AIDS; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200297114-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 29-MAY-2002; 2002WO-US016840.  
XX  
PR 29-MAY-2001; 2001US-0294140P.



RESULT 103  
ACN06634  
ID ACN06634 standard; RNA; 17 BP.  
XX  
AC ACN06634;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV Amberzyme substrate SEQ ID NO 6637.  
XX  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 6637; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 2 A; 3 C; 3 G; 0 T; 9 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 43.8%; Pred. NO. 1e+02;  
Matches 7; Conservative 8; Mismatches 1; Indels 0; Gaps 0;  
  
QY 8 TTCTCATGATGATTGT 23  
Db ::|:|:|:|:|:|:  
2 UUCUCUUGAUGAUUGU 17  
  
RESULT 104  
ACN10573/c  
ID ACN10573 standard; RNA; 17 BP.  
XX  
AC ACN10573;  
XX  
DT 22-APR-2004 (first entry)

XX WNV minus strand Inozyme substrate SEQ ID NO 10576.  
DE  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 10576; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 0 T; 2 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. NO. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 9 TCTCATGATGATTGTG 24  
Db ||||| ||||| ||||| |||||  
17 TCTCTTGATGATTGTG 2  
  
RESULT 105  
ACN08217/c  
ID ACN08217 standard; RNA; 17 BP.  
XX  
AC ACN08217;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8220.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;

KW increased stearate production; reduced linolenic acid production;  
KW photosynthetic process.  
XX  
OS Solanum tuberosum.  
OS Synthetic.  
XX  
PN WO200192512-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 01-JUN-2001; 2001WO-US017672.  
XX  
PR 01-JUN-2000; 2000US-0208538P.  
PR 30-OCT-2000; 2000US-0244989P.  
PR 27-MAR-2001; 2001US-00818875.  
XX  
PA (UYDE ) UNIV DELAWARE.  
XX  
PI Kmiec EB, Gamper HB, Rice MC, Kim J;  
XX  
DR WPI; 2002-106307/14.  
XX  
PT New oligonucleotides with modified nuclease-resistant termini, useful for  
PT creating plants with desired phenotypes, e.g. stress tolerance, improved  
PT nutritional value, herbicide or disease resistance, or modified oil  
PT production.  
XX  
PS Claim 7; Page 144; 220pp; English.  
XX  
CC The invention relates to an oligonucleotide for targeted alteration of a  
CC genetic sequence, which comprises a single-stranded oligonucleotide  
CC having a DNA domain. The DNA domain has at least one mismatch with  
CC respect to the genetic sequence to be altered and further comprises  
CC chemical modifications of the oligonucleotide. The chemical modifications  
CC consist of o-methyl modification, an LNA modification, two or more  
CC phosphorothioate linkages on a terminus, or a combination of any two or  
CC more of these modifications. The oligonucleotides are useful for  
CC directing repair or alteration of plant genetic information. The  
CC oligonucleotides are particularly useful for creating plants with desired  
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved  
CC nutritional value (e.g. altering amino acid content of plants or  
CC conferring amino acid over production), herbicide resistance (e.g.  
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide  
CC resistance, porphyrin herbicide resistance or triazine resistance),  
CC disease resistance, modified oil production, modified starch production  
CC (e.g. increased starch or production of waxy starch), altered floral  
CC morphology (e.g. male-sterile plants) or modified fatty acid content  
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).  
CC The oligonucleotides are also useful for producing albino mutants for the  
CC analysis of photosynthetic processes. This sequence represents a genome  
CC altering oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1478 TGGCAATAATGTAACA 1493  
DB 1 TGGCAATAATGTCACA 16  
  
RESULT 102  
ABK26320/c  
ID ABK26320 standard; DNA; 17 BP.  
XX  
AC ABK26320;  
XX  
DT 09-APR-2002 (first entry)  
XX  
DE Increased starch production genome altering oligonucleotide #172.  
XX

KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;  
KW o-methyl modification; LNA modification; phosphorothioate linkage;  
KW DNA repair; DNA alteration; improved nutritional tolerance; hygromycin-B;  
KW abiotic stress tolerance; improved nutritional value; hygromycin-B;  
KW amino acid over production; herbicide resistance; glyphosate resistance;  
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;  
KW porphyrin herbicide resistance; triazine resistance; disease resistance;  
KW modified oil production; modified starch production; waxy starch;  
KW altered floral morphology; male-sterile plant; albino mutant;  
KW modified fatty acid content; reduced palmitate production; albino plant;  
KW increased stearate production; reduced linolenic acid production;  
KW photosynthetic process.  
XX  
OS Solanum tuberosum.  
OS Synthetic.  
XX  
PN WO200192512-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 01-JUN-2001; 2001WO-US017672.  
XX  
PR 01-JUN-2000; 2000US-0208538P.  
PR 30-OCT-2000; 2000US-0244989P.  
PR 27-MAR-2001; 2001US-00818875.  
XX  
PA (UYDE ) UNIV DELAWARE.  
XX  
PI Kmiec EB, Gamper HB, Rice MC, Kim J;  
XX  
DR WPI; 2002-106307/14.  
XX  
PT New oligonucleotides with modified nuclease-resistant termini, useful for  
PT creating plants with desired phenotypes, e.g. stress tolerance, improved  
PT nutritional value, herbicide or disease resistance, or modified oil  
PT production.  
XX  
PS Claim 7; Page 144; 220pp; English.  
XX  
CC The invention relates to an oligonucleotide for targeted alteration of a  
CC genetic sequence, which comprises a single-stranded oligonucleotide  
CC having a DNA domain. The DNA domain has at least one mismatch with  
CC respect to the genetic sequence to be altered and further comprises  
CC chemical modifications of the oligonucleotide. The chemical modifications  
CC consist of o-methyl modification, an LNA modification, two or more  
CC phosphorothioate linkages on a terminus, or a combination of any two or  
CC more of these modifications. The oligonucleotides are useful for  
CC directing repair or alteration of plant genetic information. The  
CC oligonucleotides are particularly useful for creating plants with desired  
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved  
CC nutritional value (e.g. altering amino acid content of plants or  
CC conferring amino acid over production), herbicide resistance (e.g.  
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide  
CC resistance, porphyrin herbicide resistance or triazine resistance),  
CC disease resistance, modified oil production, modified starch production  
CC (e.g. increased starch or production of waxy starch), altered floral  
CC morphology (e.g. male-sterile plants) or modified fatty acid content  
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).  
CC The oligonucleotides are also useful for producing albino mutants for the  
CC analysis of photosynthetic processes. This sequence represents a genome  
CC altering oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 5 A; 3 C; 3 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1478 TGGCAATAATGTAACA 1493  
DB 17 TGGCAATAATGTCACA 2  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DR WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption ionization, comprises human myosin-like protein hGDMLP-1.

XX

PS Disclosure; SEQ ID NO 10433; 214pp; English.

XX

CC The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequence

XX

SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTGTGCTGTC 852

DB 16 GACTTTGTGCTGTC 1

RESULT 100

ABN10439/c

ID ABN10439 standard; DNA; 17 BP.

XX

AC ABN10439;

XX

DT 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10431.

XX

KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.

XX

OS Homo sapiens.

XX

PN WO200192524-A2.

XX

PD 06-DEC-2001.

XX

PF 25-MAY-2001; 2001WO-US016981.

XX

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

XX

PA (AEOM-) AEOMICA INC.

XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

DR

XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption ionization, comprises human myosin-like protein hGDMLP-1.

XX

PS Disclosure; SEQ ID NO 10431; 214pp; English.

XX

CC The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequence

XX

SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 838 AGTTTGTGCTGTCA 853

DB 17 ACTTTGTGCTGTCA 2

RESULT 101

ABK26319

ID ABK26319 standard; DNA; 17 BP.

XX

AC ABK26319;

XX

DT 09-APR-2002 (first entry)

XX

DE Increased starch production genome altering oligonucleotide #171.

XX

KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;

KW o-methyl modification; LNA modification; phosphorothioate linkage;

KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;

KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;

KW amino acid over production; herbicide resistance; glyphosate resistance;

KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;

KW porphyrin herbicide resistance; triazine resistance; disease resistance;

KW modified oil production; modified starch production; waxy starch;

KW altered floral morphology; male-sterile plant; albino mutant;

KW modified fatty acid content; reduced palmitate production; albino plant;







CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention

XX  
SQ Sequence 17 BP; 6 A; 4 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 1e+02;  
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 317 ACCTCACTTACAGGAT 332  
|||: |||: |||: |||:  
DB 1 ACCUACUUACAGGAU 16

RESULT 96  
AAX73080  
ID AAX73080 standard; RNA; 17 BP.  
XX  
AC AAX73080;  
XX  
DT 28-JUL-1999 (first entry)  
XX  
DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #513.  
XX  
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
KW foetal liver kinase 1; ss.  
XX  
OS Mus sp.  
XX  
PN WO9715662-A2.  
XX  
PD 01-MAY-1997.  
XX  
PF 25-OCT-1996; 96WO-US017480.  
XX  
PR 26-OCT-1995; 95US-0005974P.  
PR 11-JAN-1996; 96US-00584040.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (CHIR ) CHIRON CORP.  
XX  
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;  
XX  
XX WPI; 1997-259017/23.  
DR  
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
PT rheumatoid arthritis, etc., in a human patient.  
XX  
PS Claim 4; Page 139; 218pp; English.  
XX  
CC The present invention describes nucleic acid molecules which modulate the  
CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
CC receptors of vascular endothelial growth factor (VEGF). A patient  
CC (preferably human) having a condition associated with the level of the  
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
CC treated by administering the nucleic acid molecule or the expression  
CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
CC of nucleic acid molecules from the present invention  
XX  
SQ Sequence 17 BP; 7 A; 1 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 75.0%; Pred. No. 1e+02;  
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 297 GTCAGATGGATGAAG 312

Db |||: |||: |||: |||:  
1 GUCAAGAUUGAUGAAG 16

RESULT 97  
AAA21150  
ID AAA21150 standard; RNA; 17 BP.  
XX  
AC AAA21150;  
XX  
DT 19-JUN-2000 (first entry)  
XX  
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4376.  
XX  
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9950403-A2.  
XX  
PD 07-OCT-1999.  
XX  
PF 24-MAR-1999; 99WO-US006507.  
XX  
PR 27-MAR-1998; 98US-0079678P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
XX  
XX WPI; 1999-591315/50.  
DR  
XX Novel ribozymes for modulating the synthesis, expression and/or stability  
PT of an mRNA encoding an angiogenic factors.  
PT  
XX Claim 55; Page 190; 305pp; English.  
PS  
XX The present invention describes enzymatic nucleic acid molecules with RNA  
CC cleaving activity, which specifically cleave RNA encoded by an aryl  
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberos scleriosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

CC macromolecules are specifically bound. The method of the invention may be  
CC used to detect hybridisation of RNA or, particularly DNA, especially for  
CC detecting the presence of particular sequences in samples, but also for  
CC studying reaction kinetics. The method allows the use of molecular  
CC beacons that are simple to prepare or synthesise, particularly because  
CC they do not require incorporation of a quencher. The current sequence is  
CC that of the control probe of the invention which is targeted to the  
CC fluorescent-labelled and bound DNA oligonucleotide in the binding  
CC analysis method.

SQ . Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 95;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAA 1763  
DB 1 GAAAAAAAAACAAAAAAAA 16

RESULT 94

AAT81521/c  
ID AAT81521 standard; RNA; 17 BP.

XX AC AAT81521;

XX DT 14-DEC-1997 (first entry)

XX DE Human c-myb hammerhead ribozyme target sequence (nt. position 2738).

XX KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;

XX KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;  
XX KW coronary angioplasty; ss.

OS Homo sapiens.

XX PN WO9531541-A2.

XX PD 23-NOV-1995.

XX PF 18-MAY-1995; 95WO-US006368.

XX PR 18-MAY-1994; 94US-00245466.

XX PR 13-JAN-1995; 95US-00373124.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;

XX DR WPI; 1996-010927/01.

XX PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,  
XX PT for treating restenosis or cancer.

XX PS Claim 1; Page 77; 128pp; English.

XX CC The present sequence represents the preferred target sequence for an  
XX CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves  
XX CC the human c-myb sequence at the base position indicated in the descriptor  
XX CC line. The c-myb sequence was screened for optimal ribozyme target sites  
XX CC using a computer folding algorithm, and regions of the mRNA which did not  
XX CC form secondary folding structures and contained potential ribozyme  
XX CC cleavage sites were identified. Ribozymes were synthesised and their  
XX CC activities optimised by either varying the length of the binding arms or  
XX CC by modification to prevent degradation by nucleases. The ribozymes cleave  
XX CC the c-myb sequence and can be used to prevent smooth muscle cell  
XX CC hyperproliferation in restenosis, especially after coronary angioplasty,  
XX CC and in cancers

SQ Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTTTTACAAATTAA 1560  
DB 17 GCATTTACAAATTAA 2

RESULT 95

AAX63814

ID AAX63814 standard; RNA; 17 BP.

XX AC AAX63814;

XX DT 20-JUL-1999 (first entry)

XX DE Rabbit stromelysin hammerhead target SEQ ID NO:446.

XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
XX KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
XX KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
XX KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
XX KW diagnosis; ss.

XX OS Oryctolagus cuniculus.

XX PN WO9618736-A2.

XX PD 20-JUN-1996.

XX PF 22-NOV-1995; 95WO-US015516.

XX PR 13-DEC-1994; 94US-00354920.

XX PR 23-DEC-1994; 94US-00363253.

XX PR 23-DEC-1994; 94US-00363254.

XX PR 17-FEB-1995; 95US-00390850.

XX PR 20-APR-1995; 95US-00426124.

XX PR 02-MAY-1995; 95US-00432874.

XX PR 04-MAY-1995; 95US-00434509.

XX PR 07-JUL-1995; 95US-0000951P.

XX PR 07-JUL-1995; 95US-0000974P.

XX PR 07-AUG-1995; 95US-00512861.

XX PR 05-OCT-1995; 95US-00541365.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;

XX PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;

XX PI Karpeisky A, Thompson JD, Modak A, Burgin A;

XX DR WPI; 1996-300653/30.

XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
XX PT the treatment of arthritis, induction of graft tolerance or treatment of  
XX PT auto-immune diseases.

XX PS Example 1; Page 153; 307pp; English.

XX CC The present invention describes a novel enzymatic nucleic acid (ENA)  
XX CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
XX CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
XX CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
XX CC can inhibit collagenase and stromelysin production in the synovial  
XX CC membrane of joints for the treatment or prevention of arthritis,  
XX CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
XX CC be used to treat antigen presenting cells of a donor to induce tolerance  
XX CC in a recipient to an alloantigen of a donor. They can also be used for  
XX CC enhancing graft tolerance or for treating autoimmune disease, and for  
XX CC treating allergies and other inflammatory conditions. The ENA's can also  
XX CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
XX CC stromelysin without introducing the non-specific effects upon gene  
XX CC expression which accompany treatment with retinoids and dexamethasone.  
XX CC The concentration of ribozyme required to affect a therapeutic treatment

KW Nonlinear optical technique; screening; ss.  
XX  
OS Unidentified.  
XX  
XX WO2003064991-A2.  
PN  
XX 07-AUG-2003.  
PD  
XX 17-JUL-2002; 2002WO-US022681.  
PF  
XX 17-JUL-2001; 2001US-0306040P.  
PR 23-OCT-2001; 2001US-0347821P.  
PR 06-FEB-2002; 2002US-0354668P.  
XX  
XX (SALA/) SALAFSKY J S.  
PA  
XX Salafsky JS;  
PI  
XX WPI; 2003-646172/61.  
DR  
XX Screening candidate binding partner(s) for binding to test molecule by  
PT applying external force field to sample in homogeneous phase,  
PT illuminating sample with light beam(s) at fundamental frequencies, and  
PT measuring physical properties.  
XX  
XX Disclosure; Fig 20-B; 146pp; English.  
PS  
XX The present invention relates to a method for detecting interactions  
CC between biological components using a nonlinear optical technique. The  
CC invention is used for screening candidate binding partner(s) for binding  
CC to test molecule. It can also be used to detect changes in orientation or  
CC conformation of the probe and/or target. The present sequence is a target  
CC oligonucleotide used in nonlinear optical technique  
XX  
SQ Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 95;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1748 GAAAAAAAAAAAAAAAAA 1763  
Db 1 GAAAAAAAAACAAAAAAAA 16  
|||||  
  
RESULT 92  
ADF23332  
ID ADF23332 standard; DNA; 16 BP.  
XX  
AC ADF23332;  
XX  
DT 12-FEB-2004 (first entry)  
XX  
DE Binding partner sceening method molecular beacon analogue #3.  
XX  
KW binding partner screening; light beam; nonlinear optical light beam; ss;  
KW molecular beacon analogue.  
XX  
OS Synthetic.  
XX  
XX US2003148391-A1.  
PN  
XX 07-AUG-2003.  
PD  
XX 06-JUN-2002; 2002US-00164915.  
PF  
XX 24-JAN-2002; 2002US-0351879P.  
PR 06-FEB-2002; 2002US-0354668P.  
PR 06-FEB-2002; 2002US-0354679P.  
PR 05-MAR-2002; 2002US-0362003P.  
XX  
XX (SALA/) SALAFSKY J S.  
PA  
XX

PI Salafsky JS;  
XX  
DR WPI; 2003-897567/82.  
XX  
PT Screening of candidate binding partners for binding to test molecule  
PT comprises illuminating sample with light beams and measuring physical  
PT properties of nonlinear optical light beam emanating from sample.  
XX  
PS Disclosure; SEQ ID NO 3; 58pp; English.  
XX  
CC The invention describes screening a candidate binding partner by  
CC illuminating the sample with light beams at fundamental frequencies to  
CC binding partners, and measuring physical properties of a nonlinear  
CC optical light beam emanating from sample. On binding to the test molecule  
CC the properties change relative to that in absence of exposure of the test  
CC molecule. The invention is used in the screening of candidate binding  
CC partners for binding to test molecule. This sequence represents a  
CC molecular beacon analogue, an exemplary test molecule of the invention.  
XX  
SQ Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 95;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1748 GAAAAAAAAAAAAAAAAA 1763  
Db 1 GAAAAAAAAACAAAAAAAA 16  
|||||  
  
RESULT 93  
ADS15827  
ID ADS15827 standard; DNA; 16 BP.  
XX  
AC ADS15827;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Control probe targeted to labelled/bound oligo in binding analysis.  
XX  
KW binding; sequence detection; reaction kinetics; ss; probe.  
XX  
OS Synthetic.  
XX  
PN DE10307801-A1.  
XX  
PD 09-SEP-2004.  
XX  
PF 24-FEB-2003; 2003DE-01007801.  
XX  
PR 24-FEB-2003; 2003DE-01007801.  
XX  
PA (ADVA-) ADVALYTIX AG.  
XX  
PI Kirchner R, Gauer C;  
XX  
DR WPI; 2004-654186/64.  
XX  
XX Analyzing binding between macromolecules, useful for detecting nucleic  
PT acids by hybridization, where a labeled detector molecule is immobilized  
PT and becomes fluorescent only after specific binding.  
XX  
PS Example; Page 6; 11pp; German.  
XX  
CC The invention relates to a novel analytical method for examining binding  
CC events between first and second macromolecules. The method comprises  
CC preparing a surface on which a fluorescently-labelled first macromolecule  
CC is bound and which is at least partly fitted with a fluorescence-  
CC suppressing layer. A sample liquid containing the second macromolecule is  
CC applied and fluorescence is measured. The first macromolecule has a  
CC secondary structure such that its fluorescence is suppressed by the  
CC suppressing layer when it is not specifically bound to the second  
CC macromolecule, but fluorescence is not suppressed when the two

```

XX
DT
XX
DE
XX
XX
KW
XX
XX
OS
XX
FH
FT
FT
XX
PN
XX
PD
XX
PF
XX
PR
PR
XX
PA
XX
PI
XX
DR
XX
PT
PT
PT
XX
PS
XX
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
SQ
    Query Match      0.8%; Score 14.8; DB 1; Length 18;
    Best Local Similarity 88.9%; Pred. No. 1e+02;
    Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1042 ATAAACAACCTTAGTACCA 1059
      |||||
Db      18 ATAAACAACCTCAATACCA 1

RESULT 90
ABLS7076
ID      ABL57076 standard; DNA; 16 BP.
XX
AC      ABL57076;
```

```

XX
DT
XX
DE
XX
XX
KW
XX
XX
OS
XX
FH
FT
FT
XX
PN
XX
PD
XX
PF
XX
PR
PR
XX
PA
XX
PI
XX
DR
XX
PT
PT
PT
XX
PS
XX
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
SQ
    Query Match      0.8%; Score 14.4; DB 1; Length 16;
    Best Local Similarity 93.8%; Pred. No. 95;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1748 GAAAAA
      |||||
Db      1 GAAAAAACAAAAAA 16

RESULT 91
AAD57846
ID      AAD57846 standard; DNA; 16 BP.
XX
AC      AAD57846;
XX
DT      20-NOV-2003 (first entry)
XX
DE      Target oligonucleotide #3 used in nonlinear optical technique.
XX
```

```

RESULT 89
ADS90796/c
ID      ADS90796 standard; DNA; 18 BP.
XX
AC      ADS90796;
XX
DT      18-NOV-2004 (first entry)
XX
DE      Oligonucleotide of the invention SEQ ID NO:1812.
XX
KW      ss; cell proliferative disorder; breast; methylation; cytostatic;
KW      gene therapy; single nucleotide polymorphism; SNP.
XX
OS      Unidentified.
XX
PN      WO2004035803-A2.
XX
PD      29-APR-2004.
XX
PF      01-OCT-2003; 2003WO-EP010881.
XX
PR      01-OCT-2002; 2002DE-01045779.
PR      07-JAN-2003; 2003DE-01000096.
PR      17-APR-2003; 2003DE-01017955.
XX
PA      (EPIG-) EPIGENOMICS AG.
XX
```

```

PI      Foekens J, Harbeck N, Koenig T, Maier S, Martens J, Model F;
PI      Nimmrich I, Rujan T, Schmitt A, Schmitt M, Look MP, Marx A;
XX
DR      WPI; 2004-348468/32.
XX
```

```

PT      Predicting responsiveness of a subject with breast cell proliferative
PT      disorder, useful for treating or differentiating breast cell
PT      proliferative disorders comprises analyzing methylation pattern of a
PT      genomic DNA from the subject.
XX
```

```

PS      Disclosure; SEQ ID NO 1812; 104pp; English.
XX
```

```

CC      The invention relates to a novel method for predicting the responsiveness
CC      of a subject with a cell proliferative disorder of the breast tissues to
CC      a therapy comprising analysing the methylation pattern of a target
CC      nucleic acid by contacting at least one of the target nucleic acids in a
CC      biological sample obtained from the subject prior to or during treatment.
CC      The method of the invention has cytostatic activity, and may have a use
CC      in gene therapy. The set of oligonucleotides comprising at least two of
CC      the oligomers are useful for detecting the cytosine methylation state
CC      and/or single nucleotide polymorphisms (SNPs) within the sequences. The
CC      methods, nucleic acid, oligonucleotide, and kit are useful for the
CC      treatment, characterisation, classification and/or differentiation, of
CC      breast cell proliferative disorders. The method is also useful for
CC      predicting the responsiveness of a subject with a cell proliferative
CC      disorder of the breast tissues to a therapy. The present sequence is used
CC      in the exemplification of the invention.
```

```

SQ      Sequence 18 BP; 3 A; 0 C; 5 G; 10 T; 0 U; 0 Other;
```

```

    Query Match      0.8%; Score 14.8; DB 1; Length 18;
    Best Local Similarity 88.9%; Pred. No. 1e+02;
    Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      1042 ATAAACAACCTTAGTACCA 1059
      |||||
Db      18 ATAAACAACCTCAATACCA 1
```

```

RESULT 90
ABLS7076
ID      ABL57076 standard; DNA; 16 BP.
XX
AC      ABL57076;
```

```

22-JUL-2002 (first entry)
Molecular beacon target sequence (single mismatch).
Molecular beacon; fluorophore; nanoparticle; nucleic acid detection; ss.
Synthetic.
Key      Location/Qualifiers
misc_feature 9
      /*tag= a
      /note= "mismatch site"
WO200218951-A2.
07-MAR-2002.
29-AUG-2001; 2001WO-US041941.
29-AUG-2000; 2000US-0228728P.
30-MAR-2001; 2001US-0280350P.
(UYRQ ) UNIV ROCKEFELLER.
Dubertret B, Calame M, Libchaber A;
WPI; 2002-404569/43.
```

```

Sensitively detecting proximity changes in a system that utilizes an
interacting fluorophore and quencher, for high sensitivity applications,
involves utilizing a metal surface as quencher.
```

```

Example 3; Page 30; 62pp; English.
```

```

The present sequence is that of a single mismatch target sequence for a
molecular beacon comprising an oligonucleotide probe (see ABL57069)
covalently attached at the 3' end to fluorescent dye and at the 5' end to
a nanoparticle. In the native state, the probe forms a hairpin
conformation with hybridised termini. The proximity of the fluorophore
and quencher (gold nanoparticle) in the molecular beacon results in
little or no detectable fluorescence. Upon hybridisation of the central
complementary stretch of the probe to a target sequence, such as the
present sequence, the hairpin undergoes a conformational change resulting
in an increase in fluorescence, the extent of which is proportional to
the amount of target sequence present. Experiments with the present
sequence and a perfectly-matched target (see ABL57071) showed that
hybridisation was very specific to the matched target. The invention
relates generally to the use of metal surface quenchers such as particles
or films for high sensitivity applications in, for example, detection and
diagnostic systems
```

```

SQ      Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;
```

```

    Query Match      0.8%; Score 14.4; DB 1; Length 16;
    Best Local Similarity 93.8%; Pred. No. 95;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```

QY      1748 GAAAAA
      |||||
Db      1 GAAAAAACAAAAAA 16
```

```

RESULT 91
AAD57846
ID      AAD57846 standard; DNA; 16 BP.
XX
AC      AAD57846;
```

```

DT      20-NOV-2003 (first entry)
XX
DE      Target oligonucleotide #3 used in nonlinear optical technique.
XX
```



CC untranslated region of the PLA2 group IV nucleotide sequence. The  
CC antisense compound inhibits the expression of PLA2 group IV. The PLA2  
CC group IV antisense compounds are used to inhibit the expression of  
CC cytosolic PLA2 in cells and tissues in vitro. The antisense molecules can  
CC also be used to treat or prevent PLA2-associated diseases, particularly  
CC infection, inflammation and tumours. The antisense compound can also be  
CC used for research or diagnosis, e.g. to study gene function or in  
CC hybridization assays  
XX  
SQ Sequence 18 BP; 2 A; 6 C; 2 G; 8 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 577 GCAGAAACGTGGACTAAA 594  
Db 18 GCAGAAAGTGGGCTAAA 1  
  
RESULT 87  
AAZ71138/c  
ID AAZ71138 standard; DNA; 18 BP.  
XX  
AC AAZ71138;  
XX  
DT 10-SEP-2001 (first entry)  
XX  
DE Human biallelic marker upstream amplification primer SEQ ID NO:5494.  
XX  
KW Human genome; biallelic marker; high density disequilibrium map;  
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;  
KW haplotyping; hybridisation; identification; characterisation;  
KW amplification; single nucleotide polymorphism; SNP; PCR primer;  
KW diagnosis; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9954500-A2.  
XX  
PD 28-OCT-1999.  
XX  
PF 21-APR-1999; 99WO-IB000822.  
XX  
PR 21-APR-1998; 98US-0082614P.  
XX  
PR 23-NOV-1998; 98US-0109732P.  
XX  
PA (GEST ) GENSET.  
XX  
PI Cohen D, Blumenfeld M, Chumakov I;  
XX  
DR WPI; 2000-013267/01.  
XX  
PT Novel biallelic markers used to construct a high density disequilibrium  
PT map of the human genome.  
XX  
PS Claim 8; Page 1402; 2745pp; English.  
XX  
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present  
CC invention, which contain a polymorphic base at position 24 of their  
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification  
CC primers for the biallelic markers. The biallelic markers of the invention  
CC have a variety of uses: they can be used for high density mapping of the  
CC human genome, and in complex association studies and haplotyping studies  
CC which are useful in determining the genetic basis for disease states.  
CC Compositions and methods of the invention can also be useful for the  
CC identification of the targets for the development of pharmaceutical  
CC agents and diagnostic methods, as well as the characterisation of the  
CC differential efficacious responses to and side effects from  
CC pharmaceutical agents acting on a disease as well as other treatment.  
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and  
CC 3367, are not actually given a sequence in the Sequence Listing from the  
CC present invention

XX  
SQ Sequence 18 BP; 5 A; 2 C; 7 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 691 CCCACCTACAGATACCTT 708  
Db 18 CCCACCTTGAGATACCTT 1  
  
RESULT 88  
ADQ78196/c  
ID ADQ78196 standard; DNA; 18 BP.  
XX  
AC ADQ78196;  
XX  
DT 09-SEP-2004 (first entry)  
XX  
DE PCR primer used to amplify cancer related genes for biochip SeqID 878.  
XX  
KW mini-sequencing; CpG island; methylation specific PCR; MSP;  
KW multiplex MSP PCR; cancer; PCR; primer; ss; microarray chip.  
XX  
OS Unidentified.  
XX  
PN KR2003069752-A.  
XX  
PD 27-AUG-2003.  
XX  
PF 07-MAY-2002; 2002KR-00025108.  
XX  
PR 20-FEB-2002; 2002KR-00009132.  
XX  
PA (GOOD-) GOODGENE INC.  
XX  
PI Choi HI, Eom TH, Jun BI, Kim OH, Mun UC, Oh MY, Song MG;  
XX  
DR WPI; 2004-095256/10.  
XX  
PT Minisequencing type oligonucleotide chip for detecting methylation of  
PT promoter CpG islands of multiple genes, useful for detecting cancer.  
XX  
PS Claim 13; SEQ ID NO 878; 248pp; Korean.  
XX  
CC This invention relates to a novel mini-sequencing type DNA  
CC oligonucleotide chip. Specifically, it refers to a chip that is useful  
CC for detecting methylation of promoter CpG islands occurring in multiple  
CC genes. The present invention describes using oligonucleotide primers to  
CC determine the position of a target gene and promoter CpG islands, this  
CC constitutes treating DNA of the target gene with sodium bisulfite in  
CC order to carry out methylation specific (MSP) PCR or multiplex MSP PCR to  
CC amplify the sodium bisulfite treated DNA and sequencing the PCR product  
CC to confirm the hypomethylation site of the promoter CpG islands of  
CC multiple genes. Accordingly, the chip comprises primer sequences designed  
CC from these PCR products that have amine linkers of 12 carbons attached to  
CC the 5'-terminal, which are spotted onto the glass slide coated with 3-  
CC aminopropyltrimethoxylan and 1,4-diisothiocyanate using an array robot.  
CC The resulting minisequencing chip is useful for detecting cancer, thereby  
CC accurately and rapidly detecting methylation of CpG islands of multiple  
CC genes. This oligonucleotide sequence is a PCR primer given in an  
CC exemplification of the invention.  
XX  
SQ Sequence 18 BP; 1 A; 0 C; 1 G; 16 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAACCAATAAAAA 1



XX DE Human stromelysin hairpin target sequence SEQ ID NO:1068.  
XX DE  
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX OS Homo sapiens.  
XX KW WO9618736-A2.  
XX PN  
XX PD 20-JUN-1996.  
XX PF 22-NOV-1995; 95WO-US015516.  
XX PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX PA (RIBO-) RIBOZYME PHARM INC.  
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX DR WPI; 1996-300653/30.  
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX PS Example 1; Page 164; 307pp; English.  
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX SQ Sequence 18 BP; 7 A; 3 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 55.6%; Pred. No. 1e+02;  
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886  
|||:|:|:|:|:|:|  
Db 1 AAAUCCUGAUCUUUAAAG 18

RESULT 84  
AAX64464  
ID AAX64464 standard; RNA; 18 BP.  
XX AC AAX64464;  
XX DT 20-JUL-1999 (first entry)  
XX DE Rabbit stromelysin hairpin target sequence SEQ ID NO:1096.  
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX OS Oryctolagus cuniculus.  
XX PN WO9618736-A2.  
XX PD 20-JUN-1996.  
XX PF 22-NOV-1995; 95WO-US015516.  
XX PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX PA (RIBO-) RIBOZYME PHARM INC.  
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX DR WPI; 1996-300653/30.  
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX PS Example 1; Page 165; 307pp; English.  
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX SQ Sequence 18 BP; 2 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 50.0%; Pred. No. 1e+02;



XX 22-NOV-1995; 95WO-US015516.  
PF 13-DEC-1994; 94US-00354920.  
XX 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX WPI; 1996-300653/30.  
XX Enzymatic nucleic acid molecules having a hammer-head motif : used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX Example 1; Page 165; 307pp; English.  
XX The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX Sequence 18 BP; 6 A; 2 C; 2 G; 0 T; 8 U; 0 Other;  
SQ Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 50.0%; Pred. No. 1e+02;  
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
OY 869 AAATCCTTTTCTTTAAAG 886  
Db |||: |: :|::|||  
1 AAUUCUGUUCUUUAAG 18  
RESULT 82  
AA63389  
ID AAX63389 standard; RNA; 18 BP.  
XX  
AC AAX63389;  
XX  
DT 20-JUL-1999 (first entry)  
XX Human stromelysin hammerhead target SEQ ID NO:21.  
DE  
XX Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;

KW diagnosis; ss.  
XX Homo sapiens.  
PN WO9618736-A2.  
XX 20-JUN-1996.  
XX 22-NOV-1995; 95WO-US015516.  
XX 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX WPI; 1996-300653/30.  
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX Example 1; Page 139; 307pp; English.  
XX The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX Sequence 18 BP; 7 A; 3 C; 2 G; 0 T; 6 U; 0 Other;  
SQ Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 55.6%; Pred. No. 1e+02;  
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
OY 870 AATCCTTTTCTTTAAAGA 887  
Db |||: |: :|::|||  
1 AAUCCUGAUCUUUAAAGA 18  
RESULT 83  
AAX64436  
ID AAX64436 standard; RNA; 18 BP.  
XX  
AC AAX64436;  
XX  
DT 20-JUL-1999 (first entry)



Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 73.3%; Pred. No. 87;  
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 629 TTCATGAAC TTGGCC 643  
Db. 1 UUCAUGAAC UTGGCC 15

RESULT 79  
AAQ57225  
ID AAQ57225 standard; mRNA; 18 BP.  
XX  
AC AAQ57225;  
XX  
DT 25-MAR-2003 (revised)  
DT 26-JUL-1994 (first entry)  
XX  
DE Enzymatic RNA molecule stromelysin mRNA target sequence.  
XX  
KW Specific; cleavage; target RNA; protein; prophylaxis; expression;  
KW inhibitor; inhibition; ribozyme; treatment; prevention; psoriasis;  
KW asthma; inflammatory diseases; restenosis; cardiovascular condition;  
KW hypertension; arthritis; ss.  
XX  
OS Synthetic.  
XX  
PN WO9402595-A1.  
XX  
PD 03-FEB-1994.  
XX  
PF 02-JUL-1993; 93WO-US006316.  
XX  
PR 17-JUL-1992; 92US-00916763.  
PR 07-DEC-1992; 92US-00987132.  
PR 07-DEC-1992; 92US-00989848.  
PR 07-DEC-1992; 92US-00989849.  
PR 19-JAN-1993; 93US-00008895.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Sullivan SM, Draper KG;  
XX  
DR WPI; 1994-048853/06.  
XX  
PT Enzymatic RNA molecules which cleave mRNA - used to treat or prevent  
PT inflammatory, arthritic, stenotic or cardiovascular diseases or  
PT conditions.  
XX  
PS Claim 3; Page 18; 65pp; English.  
XX  
CC This is a stromelysin mRNA target sequence (nucleotide no. 958) of an  
CC enzymatic RNA molecule (ribozyme) which cleaves mRNA associated with the  
CC development or maintenance of osteoarthritis or other pathological  
CC conditions which are mediated by metalloproteinase activation. The concn.  
CC of the ribozyme necessary to effect a therapeutic treatment is lower than  
CC that of an antisense oligonucleotide and the specificity of action is  
CC higher. (Updated on 25-MAR-2003 to correct PN field.)  
XX  
SQ Sequence 18 BP; 7 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTTCTTTAAAGA 887  
Db 1 AATCCTGATCTTTAAAGA 18

RESULT 80  
AAQ93482  
ID AAQ93482 standard; RNA; 18 BP.

XX AAQ93482;  
AC  
XX 25-MAR-2003 (revised)  
DT 06-DEC-1995 (first entry)  
XX  
DE Hammerhead ribozyme target sequence #21.  
XX  
KW Hammerhead ribozyme motif; arthritis; cancer; angiogenesis; hairpin;  
KW hepatitis delta virus; group 1 intron; RNase P RNA; stromelysin; ss.  
XX  
OS Synthetic.  
XX  
PN WO9513380-A2.  
XX  
PD 18-MAY-1995.  
XX  
PF 10-NOV-1994; 94WO-US013129.  
XX  
PR 12-NOV-1993; 93US-00152487.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Draper KG, Pavco P, Mcswiggen J, Gustofson J;  
XX  
DR WPI; 1995-194099/25.  
XX  
PT New enzymatic RNA molecules - which cleave mRNA of a gene encoding a  
PT matrix metalloproteinase, for treating arthritis, cancer or angiogenesis.  
XX  
PS Disclosure; Page 18; 70pp; English.  
XX  
CC The sequences AAQ93462-Q93494 are examples of target cleavage sequences  
CC for a hammerhead ribozyme with sequence motif AAQ90453. A ribozyme, pref.  
CC hammerhead, hairpin, hepatitis delta virus, group 1 intron or RNase P RNA  
CC motif can be used in a composition for the treatment of arthritis, cancer  
CC or angiogenesis. The ribozyme comprises between 5-45 bases complementary  
CC to the target mRNA. The ribozymes (see AAQ93830-51 for examples) were  
CC synthesised based on putative stromelysin mRNA target cleavage sequences  
CC (AAQ93496-Q93829). (Updated on 25-MAR-2003 to correct PN field.)  
XX  
SQ Sequence 18 BP; 7 A; 3 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 55.6%; Pred. No. 1e+02;  
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTTCTTTAAAGA 887  
Db 1 AAUCCUGAUCUUUAAAGA 18

RESULT 81  
AAQ64488  
ID AAX64488 standard; RNA; 18 BP.  
XX  
AC AAX64488;  
XX  
DT 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hairpin target sequence SEQ ID NO:1120.  
XX  
KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
PN WO9618736-A2.  
XX  
PD 20-JUN-1996.

RESULT 77  
ABK03571  
ID ABK03571 standard; RNA; 17 BP.  
XX  
AC ABK03571;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human CD20 DNazyme #25.  
XX  
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX  
WPI; 2001-607195/69.  
XX  
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
PS Claim 30; Page 159; 200pp; English.  
XX  
CC The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the

CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a DNazyme molecule of the invention  
XX  
SQ Sequence 17 BP; 8 A; 3 C; 5 G; 0 T; 1 U; 0 Other;  
Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 87;  
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 162 AGAAAAAAGCTCCAGGA 176  
Db 3 AGAAAAAACUCCAGGA 17  
|||||:|||||  
RESULT 78  
ADI83540  
ID ADI83540 standard; RNA; 17 BP.  
XX  
AC ADI83540;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE HCV DNazyme substrate sequence #786.  
XX  
KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
KW HCV infection; type I interferon; DNazyme.  
XX  
OS Hepatitis C virus.  
XX  
PN US2003125270-A1.  
XX  
PD 03-JUL-2003.  
XX  
PF 18-DEC-2000; 2000US-00740332.  
XX  
PR 18-DEC-2000; 2000US-00740332.  
XX  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (ROBE/) ROBERTS E.  
PA (PAVC/) PAVCO P A.  
PA (MACE/) MACEJACK D.  
XX  
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
XX  
WPI; 2004-031273/03.  
XX  
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived  
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
PT especially in combination with type I interferon therapy.  
XX  
PS Claim 1; SEQ ID NO 786; 198pp; English.  
XX  
CC The invention relates to an enzymatic nucleic acid molecule which  
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
CC the binding arms of the enzymatic nucleic acid molecule comprises  
CC sequences complementary to any of the defined substrate sequences given  
CC in the specification. The nucleic acid molecule may be administered for  
CC the treatment of HCV infections, especially in combination with type I  
CC interferons. The present sequence represents a HCV DNazyme substrate  
CC sequence.  
XX  
SQ Sequence 17 BP; 4 A; 5 C; 3 G; 1 T; 4 U; 0 Other;

PT pancreatic cancer.

XX

PS Claim 13; Page 56; 120pp; English.

XX

CC AAX30947-31815 represent tag sequences of transcripts that are

CC differentially expressed in colorectal cancer, in pancreatic cancer, or

CC in both. The tag sequences can be used to identify genes by matching the

CC tag to a gen data base member, or by using the tag sequences as probes to

CC isolate unidentified genes from cDNA libraries. The tag sequences can

CC also be used in a method for diagnosing colon or pancreatic cancer in a

CC sample suspected of being neoplastic. The method comprises comparing the

CC level of at least one transcript in a first sample of a tissue to a

CC second sample, where the first sample is a colonic tissue suspected of

CC being neoplastic and the second sample is a normal human colonic tissue.

CC The transcript is identified by a tag selected from AAX30947-31815. The

CC methods of the invention can be used in the diagnosis, prognosis and

CC treatment of cancer

XX

SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 71;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 CATGAACCTGGCCAT 645

Db 1 CATGAACCTGGCCAT 15

RESULT 75

ABK32457

ID ABK32457 standard; DNA; 15 BP.

XX

AC ABK32457;

XX

DT 23-APR-2002 (first entry)

XX

DE Human pancreatic cancer SAGE tag #9.

XX

KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;

KW serial analysis of gene expression; diagnostic; prognostic; probe;

KW cancer marker; ss.

XX

OS Homo sapiens.

XX

PN US6333152-B1.

XX

PD 25-DEC-2001.

XX

PF 20-MAY-1998; 98US-00081646.

XX

PR 20-MAY-1998; 98US-00081646.

XX

PA (UYJO ) UNIV JOHNS HOPKINS.

XX

PI Vogelstein B, Kinzler KW, Zhang L, Zhou W;

XX

DR WPI; 2002-153821/20.

XX

PT New human nucleic acid containing specific SAGE tags, useful as

PT diagnostic markers for cancer, also derived probes.

XX

PS Disclosure; Col 62; 161pp; English.

XX

CC The invention relates to an isolated, purified human nucleic acid (I)

CC that has the same sequence as a mRNA found in humans and is a SAGE

CC (serial analysis of gene expression) tag comprising a single stranded

CC probe containing at least 10 consecutive nucleotides. SAGE tags, are

CC diagnostic and prognostic markers of cancer, especially of the colon and

CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer

CC SAGE tags of the invention

XX

SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 71;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 CATGAACCTGGCCAT 645

Db 1 CATGAACCTGGCCAT 15

RESULT 76

ADQ81798/c

ID ADQ81798 standard; DNA; 15 BP.

XX

AC ADQ81798;

XX

DT 07-OCT-2004 (first entry)

XX

DE Oligonucleotide synthesis method polynucleotide #2.

XX

KW ss; primer; DNA synthesis; nucleotide chemistry.

XX

OS Synthetic.

XX

PN WO2004058794-A1.

XX

PD 15-JUL-2004.

XX

PF 31-DEC-2002; 2002WO-EP014905.

XX

PR 31-DEC-2002; 2002WO-EP014905.

XX

PA (PROL-) PROLIGO LLC.

XX

PI Arar K;

XX

DR WPI; 2004-553145/53.

XX

PT Synthesis of oligonucleotides in nucleotide chemistry involves providing

PT solid support of anchor group protected by orthogonal protective group,

PT removing the protective group, synthesizing an oligonucleotide followed

PT by capping and cleaving.

XX

PS Example 9; SEQ ID NO 13; 77pp; English.

XX

CC The present invention relates to a method for the synthesis of at least

CC two different oligonucleotides, which involves providing a solid support

CC comprising anchor groups that are protected by at least two orthogonal

CC protective groups, removing one of the protective groups from the anchor

CC groups, synthesizing an oligonucleotide on the deprotected anchor groups,

CC capping the synthesized oligonucleotide, repeating these steps until all

CC of anchor groups are deprotected, and cleaving the synthesized

CC oligonucleotides. The method can be used for the synthesis of at least

CC two different oligonucleotides, in the field of nucleotide chemistry, in

CC applying the required pairs of oligonucleotide primers, several probes at

CC a time, duplexed nuclei acid fragments (including PCR, sequencing,

CC multiplexed genotyping, cloning and RNA interference), for applying to

CC any known methods for the solid phase synthesis of oligonucleotides

CC (including phosphoramidite chemistry, H-phosphonate chemistry,

CC phosphotriester chemistry, or any other synthetic chemistry used to

CC prepare oligonucleotides on solid supports). The present sequence is a

CC polynucleotide used to demonstrate the method of the invention.

XX

SQ Sequence 15 BP; 0 A; 0 C; 0 G; 15 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 71;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763

Db 15 AAAAAAAAAAAAAA 1





XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 5198; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 2 A; 2 C; 4 G; 0 T; 9 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 77;  
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;  
  
QY 8 TTCTCATGATGATTGTG 24  
Db 1 UUCUCUUGAUGAUUGUG 17  
  
RESULT 71  
ABZ222228  
ID ABZ222228 standard; DNA; 17 BP.  
XX  
AC ABZ222228;  
XX  
DT 18-MAR-2003 (first entry)  
XX  
DE Transposon insertion site related oligonucleotide #4.  
XX  
KW Mouse; chromosome; transposon; transposon insertion site; adenovirus;  
KW helper-dependent adenoviral vector; restriction endonuclease site;  
KW stuffer region; packaging sequence; cytosstatic; gene therapy;  
KW genetic defect-based disease; cancer; ss.  
XX  
OS Synthetic.  
XX  
PN WO200292786-A2.  
XX  
PD 21-NOV-2002.  
XX  
PF 25-MAR-2002; 2002WO-US009125.  
XX  
PR 26-MAR-2001; 2001US-0278972P.  
PR 16-APR-2001; 2001US-0284335P.  
XX  
PA (STRD ) UNIV LELAND STANFORD JUNIOR.  
XX  
PI Ehrhardt A, Kay M;  
XX  
DR WPI; 2003-129286/12.  
XX  
PT New helper-dependent adenoviral vector for integrating endogenous or  
PT exogenous nucleic acids into a target cell, comprises a restriction  
PT endonuclease site, stuffer region and packaging sequence flanked by  
PT adenoviral ITR sequences.  
XX  
PS Disclosure; Fig 18; 58pp; English.  
XX  
CC The present invention describes a helper-dependent adenoviral vector (I)

CC comprising at least one restriction endonuclease site, a stuffer region  
CC and a packaging sequence, that are flanked by adenoviral ITR sequences.  
CC Also described: (1) an adenoviral helper vector comprising an adenoviral  
CC vector coding sequence or its portion, positioned in a first region  
CC between first and second recombinase recognition sites that recombine  
CC with each other, and at least one endonuclease recognition site not found  
CC in mammalian genomic sequences and that is located in a region that is  
CC other than the first region; (2) a mammalian cell or a collection of  
CC mammalian cells that stably expresses a recombinase, an endonuclease that  
CC recognises a sequence not found in mammalian cells, an adenoviral  
CC preterminal protein, and an adenoviral polymerase; and (3) a system for  
CC use in producing an adenoviral vector, comprising the helper-dependent  
CC adenoviral vector, the adenoviral helper vector, and the mammalian cell.  
CC (f) has cytosstatic activity and can be used in gene therapy. The helper-  
CC dependent adenoviral vector and/or the adenoviral helper vector are  
CC useful in integrating a wide variety of endogenous and/or exogenous  
CC nucleic acids into a target cell. The vectors and methods from the  
CC present invention may also be used in research applications, in synthesis  
CC of polypeptides, and in therapeutic applications (e.g. in treating  
CC genetic defect-based disease conditions or cancers). The present sequence  
CC represents a transposon insertion site related oligonucleotide which is  
CC used in the exemplification of the present invention  
XX  
SQ Sequence 17 BP; 3 A; 4 C; 1 G; 9 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1576 TTTTTCAC TTCATTCTA 1592  
Db 1 TTTTTCAC TGCATTCTA 17  
  
RESULT 72  
ADR053333/c  
ID ADR05333 standard; DNA; 17 BP.  
XX  
AC ADR05333;  
XX  
DT 21-OCT-2004 (first entry)  
XX  
DE Silkworm juvenile hormone acid transmethylase cDNA PCR primer FP1.  
XX  
KW ss; primer; insect repellent; insect attractant;  
KW reproductive maturation regulator; imago; diapause inducer;  
KW diapause inhibitor; larva; transformation regulator; pupa;  
KW juvenile hormone acid transmethylase; silkworm; Bombyx mori;  
KW Drosophila melanogaster; mosquito; Anopheles gambia; Spodoptera litura;  
KW Helicoverpa armigera; molting; transformation; diapause; blastogenesis;  
KW polymorphism; arthropod; cotton bollworm; PCR primer.  
XX  
OS Bombyx mori.  
XX  
PN WO2004065604-A1.  
XX  
PD 05-AUG-2004.  
XX  
PF 20-JAN-2003; 2003WO-JP000415.  
XX  
PR 20-JAN-2003; 2003WO-JP000415.  
XX  
PA (NAAG-) NAT AGRIC RES ORG JAPAN.  
XX  
PI Shinoda T, Itoyama K, Hamamura T;  
XX  
DR WPI; 2004-580727/56.  
XX  
PT New DNA encoding protein having juvenile-hormone acid transmethylase  
PT activity, useful for screening for a compound controlling the expression  
PT level of juvenile-hormone acid transmethylase DNA.  
XX  
PS Example 1; SEQ ID NO 11; 118pp; Japanese.

CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a hammerhead ribozyme of the invention  
XX  
SQ Sequence 17 BP; 8 A; 3 C; 4 G; 0 T; 2 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 77;  
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
  
QY 163 GAAAAACTCCAGGAAT 179  
Db 1 GAAAAACUCCAGGAAGU 17  
|||||:|||||:  
  
RESULT 69  
ABN10440/c  
ID ABN10440 standard; DNA; 17 BP.  
XX  
AC ABN10440;  
XX  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10432.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 10432; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 837 GAGTTTTGATGCTGTCA 853  
Db 17 GACTTTTGATGCTGTCA 1  
|||||:|||||:  
  
RESULT 70  
ACN05195  
ID ACN05195 standard; RNA; 17 BP.  
XX  
AC ACN05195;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV DNAzyme substrate SEQ ID NO 5198.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX WPI; 2002-706994/76.  
DR

KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytooma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
DR  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
PS Claim 30; Page 147; 200pp; English.  
XX  
CC The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytooma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is an inozyme of the invention  
XX  
SQ Sequence 17 BP; 8 A; 3 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 77;

Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
OY 164 AAAAAGCTCCAGGAATG 180  
Db 1 AAAAACUCCAGGAAGUG 17  
RESULT 68  
ABK02767  
ID ABK02767 standard; RNA; 17 BP.  
XX  
AC ABK02767;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human CD20 Hammerhead ribozyme #66.  
XX  
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytooma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
DR  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
PS Claim 30; Page 141; 200pp; English.  
XX  
CC The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-



XX Manoharan M, Bumcrot D;  
PI WPI; 2004-677362/66.  
XX  
XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
XX Example 5; SEQ ID NO 3338; 378pp; English.  
PS  
XX The invention describes a RNA interference (irna) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that  
CC can be used to control ApoB gene expression.  
XX  
SQ Sequence 19 BP; 9 A; 0 C; 3 G; 7 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 81;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1727 TTTAAATAATTGAAAGAAA 1745  
Db 1 TTTAAATTGTTGAAAGAAA 19  
  
RESULT 66  
AAX63863  
ID AAX63863 standard; RNA; 17 BP.  
XX  
AC AAX63863;  
XX  
XX 20-JUL-1999 (first entry)  
XX  
DE Rabbit stromelysin hammerhead target SEQ ID NO:495.  
XX  
XX Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
OS Oryctolagus cuniculus.  
XX  
PN WO9618736-A2.  
XX  
XX 20-JUN-1996.  
PD  
XX

PF 22-NOV-1995; 95WO-US015516.  
XX  
PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
DR WPI; 1996-300653/30.  
XX  
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
PS Example 1; Page 154; 307pp; English.  
XX  
CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 1 A; 5 C; 3 G; 0 T; 8 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 77;  
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;  
  
QY 616 TTCCTTGTGCTGTCA 632  
Db 1 UUCCUUGUGUGUCUCA 17  
  
RESULT 67  
ABK03147  
ID ABK03147 standard; RNA; 17 BP.  
XX  
AC ABK03147;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human CD20 Inozyme #98.  
XX  
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;



QY 175 GAAATGCAGCAGTCTTTG 193  
Db 19 GAAATGCAGCAGTCTTTG 1

RESULT 64  
ADR76235  
ID ADR76235 standard; DNA; 19 BP.  
XX  
AC ADR76235;  
XX  
DT 16-DEC-2004 (first entry)  
XX  
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 720.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
XX WPI; 2004-677362/66.  
DR  
XX  
PT Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 720; 378pp; English.  
XX  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is

CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that  
CC can be used to control ApoB gene expression.  
XX  
SQ Sequence 19 BP; 9 A; 0 C; 3 G; 7 T; 0 U; 0 Other;  
Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 81;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1727 TTAAATAATTGAAAGAAA 1745  
Db 1 TTAAATTGTTGAAAGAAA 19

RESULT 65  
ADR78853  
ID ADR78853 standard; DNA; 19 BP.  
XX  
AC ADR78853;  
XX  
DT 16-DEC-2004 (first entry)  
XX  
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 3338.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
XX WPI; 2004-677362/66.  
DR  
XX  
PT Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 720; 378pp; English.  
XX  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is

CC The invention relates to an isolated and purified protein of the  
CC hepatitis C virus (HCV) that is formed by expression of an overlapping  
CC open reading frame in the core protein gene sequence through an RNA frame  
CC shifting mechanism. The protein is termed p17 (the full length, unshifted  
CC protein being p21c). Also included are a vaccine (including a DNA  
CC vaccine) for immunising a mammal against hepatitis C (producing a  
CC protective antibody) comprising at least 1 protein of p17 (or a nucleic  
CC acid encoding p17), an anti-viral composition (used to treat hepatitis C)  
CC comprising a compound that binds to p17, antibodies directed against an  
CC HCV core protein which are elicited by immunising an animal using the  
CC partially purified protein p17, a method for analysing an HCV antigen in  
CC a sample using the anti-p17 antibodies and detection of anti-HCV  
CC antibodies in a sample using the p17 proteins. The HCV p17 and the DNA  
CC sequences that encode it may be used as vaccines for immunising patients  
CC against HCV infection. The antibodies and the antiviral compound may also  
CC be used for treating HCV infections. HCV p17 and the antibodies may also  
CC be used in immunoassays for detecting HCV antigens and/or antibodies in  
CC samples for the diagnosis of HCV infections. The present sequence  
CC represents part of the an HCV core protein DNA from the frameshift region  
XX  
SQ Sequence 19 BP; 15 A; 2 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 81;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 134 AAACAAAAACCAATAGAAA 152  
||| ||||| ||||| |||||  
Db 1 AAAGAAAAACCAAAAGAAA 19

RESULT 62  
ADI53700/c  
ID ADI53700 standard; DNA; 19 BP.  
XX  
AC ADI53700;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 13.

XX Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004009098-A1.

XX  
PD 29-JAN-2004.  
XX  
PF 17-JUL-2003; 2003WO-SE001223.  
XX  
PR 18-JUL-2002; 2002SE-00002253.  
PR 04-SEP-2002; 2002US-0407680P.  
XX  
PA (INDE-) INDEX PHARM AB.  
XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
DR WPI; 2004-123288/12.  
XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.  
XX  
PS Claim 7; SEQ ID NO 13; 55pp; English.

XX The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and

CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.  
XX  
SQ Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 81;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 880 TTAAAGACTGGTTCTTCT 898  
|| ||||| ||||| |||||  
Db 19 TTCAAAGACAGGTTCTTCT 1

RESULT 63  
ADI53698/c  
ID ADI53698 standard; DNA; 19 BP.  
XX

AC ADI53698;

DT 22-APR-2004 (first entry)

DE Human MMP-12 antisense oligonucleotide, SEQ ID 11.

XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;  
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;  
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;  
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.

OS Homo sapiens.  
OS Synthetic.

PN WO2004009098-A1.

PD 29-JAN-2004.

PF 17-JUL-2003; 2003WO-SE001223.

PR 18-JUL-2002; 2002SE-00002253.

PR 04-SEP-2002; 2002US-0407680P.

PA (INDE-) INDEX PHARM AB.

XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;  
XX  
DR WPI; 2004-123288/12.

XX  
PT New compound having a sequence targeted to a nucleic acid encoding  
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for  
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,  
PT asthma or psoriasis.

PS Claim 7; SEQ ID NO 11; 55pp; English.

XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-  
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and  
CC ADI53689), which specifically hybridise with the nucleic acid encoding  
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense  
CC oligonucleotides are useful for preparing a composition for treating or  
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory  
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid  
CC arthritis, psoriasis, emphysema or asthma.

XX  
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 81;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Fri May 13 12:26:39 2005

PT 04-DEC-1998; 98US-0110954P.  
XX (IMMU-) IMMUSOL INC.  
XX Tritz R, Welch PJ, Barber JR, Robbins JM;  
PI WPI; 2000-412314/35.  
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.  
XX Disclosure; Page 108; 109pp; English.  
XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
CC Representative examples of ribozyme recognition sites are given in  
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for  
CC inhibiting restenosis by introduction of the ribozyme into cells. The  
CC ribozyme is resistant to endonuclease activity and hence is efficient in  
CC restenosis treatment  
XX Sequence 19 BP; 6 A; 1 C; 2 G; 10 T; 0 U; 0 Other;  
SQ Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 81;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1717 TTTTGTTCCTTTAAATAA 1735  
Db 1 TATTGTTTCTGTAATAA 19  
RESULT 60  
AAH61620  
ID AAH61620 standard; DNA; 19 BP.  
XX AAH61620;  
AC 10-SEP-2001 (first entry)  
XX PCNA HH ribozyme binding site SEQ ID NO:4044.  
DE Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
XX recognition site; target; ribozyme binding site; eye disease; vulnery;  
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
KW atopic dermatitis; actinic keratosis; keratolytic; gene therapy; viral wart;  
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
KW sickle cell retinopathy; ss.  
XX Homo sapiens.  
OS Synthetic.  
OS WO200130362-A2.  
XX 03-MAY-2001.  
XX 26-OCT-2000; 2000WO-US029500.  
PF 26-OCT-1999; 99US-0161532P.  
XX (IMMU-) IMMUSOL INC.  
PA Robbins JM, Tritz R;  
XX WPI; 2001-300427/31.  
XX Treating proliferative skin or eye diseases and scarring, using ribozymes

PT that cleave RNA encoding cytokines involved in inflammation, matrix  
PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
XX Example 1; Page 366; 408pp; English.  
XX The present invention describes a method for treating a proliferative  
CC skin or eye disease and scarring. The method involves administering a  
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
CC dependent kinase, growth factor or a reductase, or administering a  
CC nucleic acid molecule (II) comprising a promoter operably linked to a  
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antickling,  
CC ophthalmological, vulnery, keratolytic and virucide activities, and  
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
CC also be used for treating proliferative eye diseases such as diabetic  
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
CC prematurity and retinal detachment, and for treating and preventing  
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
CC scar. AAH57577 to AAH62099 represent sequences used in the  
CC exemplification of the present invention  
XX Sequence 19 BP; 6 A; 1 C; 2 G; 10 T; 0 U; 0 Other;  
SQ Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 81;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1717 TTTTGTTCCTTTAAATAA 1735  
Db 1 TATTGTTTCTGTAATAA 19  
RESULT 61  
ACA62442  
ID ACA62442 standard; DNA; 19 BP.  
XX ACA62442;  
AC 14-AUG-2003 (first entry)  
XX HCV core protein frameshift region DNA #4.  
DE HCV; hepatitis C infection; RNA frameshift; core protein; p17; virucide;  
XX hepatotropic; overlapping open reading frame; p21c; vaccine; ds.  
KW Hepatitis C virus.  
XX US2002076415-A1.  
XX 20-JUN-2002.  
XX 14-DEC-2000; 2000US-00736959.  
XX 14-DEC-1999; 99US-0170835P.  
XX (OUJJ/) OU J.  
PA (XUZZ/) XU Z.  
XX Ou J, Xu Z;  
PI WPI; 2003-479366/45.  
XX Isolated hepatitis C virus (HCV) proteins formed by expression of  
PT overlapping open reading frames in the core protein gene sequence through  
PT a frame shifting mechanism, useful for vaccinating against, and detecting  
PT HCV infections.  
XX Example 5; Fig 6B; 37pp; English.  
PS



PI Cooper DN, Procter AM, Gregory J, Millar DS, Lewis M, Ulled A;  
XX WPI; 2003-449559/42.  
XX  
PT New polynucleotide comprising a variant of the human growth hormone  
PT nucleic acid sequence, GH1, useful for diagnosing or treating obesity,  
PT diabetes, infection, cancer or cardiac conditions.  
XX  
PS Example 3; Page 33; 62pp; English.  
XX  
CC The present sequence is that of primer GH2DF, which is one of a set of  
CC primers (see ACC58404-17) used for the denaturing high-pressure liquid  
CC chromatography (DHPLC) analysis and DNA sequencing of human growth  
CC hormone GH1 genes from a cohort of short stature patients. The primer  
CC corresponds to nucleotides -59 to -40 of the GH1 gene (see ACC58424).  
CC Novel GH1 gene mutations and polymorphisms were identified. The invention  
CC provides methods for detecting these variants of the GH1 gene, for  
CC screening patients for growth hormone irregularities, and for producing  
CC variant proteins for use in therapeutic, diagnostic or detection methods,  
CC e.g. for determination of susceptibility of an individual to diabetes,  
CC obesity, infection, cancer or a cardiac condition, and in gene therapy  
XX  
SQ Sequence 20 BP; 7 A; 2 C; 10 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 83;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 854 CAACAGTGGGAGAGAA 869  
Db |||||  
4 CAACAGTGGGAGAGAA 19  
  
RESULT 58  
ADP19711  
ID ADP19711 standard; DNA; 20 BP.  
XX  
AC ADP19711;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human GH1 gene PCR primer GH2DF.  
XX  
KW human; growth hormone; growth hormone variant; GH; GH1;  
KW receptor-mediated cell signaling pathway activator;  
KW growth hormone dysfunction; growth hormone irregularity; chromosome 17;  
KW PCR; primer; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2004044002-A1.  
XX  
PD 27-MAY-2004.  
XX  
PF 04-NOV-2003; 2003WO-GB004775.  
XX  
PR 12-NOV-2002; 2002GB-00026441.  
PR 12-NOV-2002; 2002WO-GB005112.  
PR 10-APR-2003; 2003GB-00008242.  
XX  
PA (UYWA-) UNIV WALES COLLEGE OF MEDICINE.  
XX  
PI Cooper DN, Procter AM, Gregory J, Millar DS, Lewis M, Ulled A;  
XX WPI; 2004-411699/38.  
XX  
PT Isolated variant of human growth hormone nucleic acid molecule, GH1  
PT useful for diagnosing growth hormone dysfunction or development of  
PT suitable therapies, comprises altered nitrogenous bases.  
XX  
PS Example 3; Page 28; 66pp; English.  
XX

CC The present invention describes an isolated variant of a human growth  
CC hormone (GH) nucleic acid molecule (I), GH1, comprising the substitution:  
CC +1491 cytosine substituted by guanine, wherein 1491 refers to the  
CC position of the nucleotide with respect to this transcription initiation  
CC site which is designated 1 or comprises a nucleic acid molecule that  
CC encodes a protein, i.e. a GH protein, including the substitution  
CC Ile179Met. Also described: (1) a transcript of (I); (2) an isolated  
CC polypeptide encoded by (I); (3) an isolated polypeptide which is a  
CC variant of the growth hormone protein, GH, and which includes the  
CC substitution Ile179Met; (4) screening (M1) an individual suspected of  
CC having dysfunctional GH, involving: (a) obtaining a test sample  
CC comprising a nucleic acid molecule of human GH1 gene from an individual,  
CC sequencing the molecule, examining the sequence for a+1491 cytosine  
CC substituted by guanine, and where the substitution exists concluding  
CC there is GH dysfunction; (b) obtaining a test sample comprising a growth  
CC hormone, GH, polypeptide from the individual, sequencing the polypeptide,  
CC examining the sequence for a Ile179Met substitution, and where the  
CC substitution exists concluding there is a GH dysfunction; or (c)  
CC obtaining a test sample from the individual comprising the individual's  
CC endogenous growth mitogen-activated protein kinases (MAPK) hormone,  
CC examining the growth hormone to determine whether and to what extent it  
CC will activate the receptor-mediated cell signaling pathway, and where  
CC there is a reduction in MAPK cell signaling, with respect to wild-type  
CC GH, concluding there is a GH dysfunction; (5) a kit suitable for carrying  
CC out M1; (6) an oligonucleotide suitable for use in (M1) and optionally,  
CC provided in the kit; (7) an isolated growth hormone polypeptide or  
CC protein (II), containing an Ile179Met substitution and which further  
CC provides for differential activation of receptor-mediated cell signaling  
CC pathways or possessing a reduced ability to activate the MAP kinase  
CC pathway; (8) an antibody specific for (II); (9) pharmaceutical  
CC composition comprising (I) or (II) with a carrier; (10) vector (III)  
CC comprising (I); (11) host cell (IV) comprising (III); and (12) a  
CC polypeptide or protein produced by using (IV). (I) activates receptor-  
CC mediated cell signaling pathway. (I) and (II) are useful for the  
CC diagnosis of growth hormone dysfunction or the development of suitable  
CC therapies. (I) or (II) is useful as a pharmaceutical composition for  
CC treating growth hormone irregularities. (IV) is useful for preparing  
CC (II), by culturing (IV) and recovering from the culture medium the  
CC polypeptide or protein produced by the cell. The present sequence  
CC represents a PCR primer for human GH1, which is used in an example from  
CC the present invention. Human GH1 is located on chromosome 17q23.  
XX  
SQ Sequence 20 BP; 7 A; 2 C; 10 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 83;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 854 CAACAGTGGGAGAGAA 869  
Db |||||  
4 CAACAGTGGGAGAGAA 19  
  
RESULT 59  
AAA86458  
ID AAA86458 standard; DNA; 19 BP.  
XX  
AC AAA86458;  
XX  
DT 04-DEC-2000 (first entry)  
XX  
DE PCBA HH ribozyme binding site #190.  
XX  
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
XX Mammalia.  
XX  
PN WO200032765-A2.  
XX  
PD 08-JUN-2000.  
XX  
PF 06-DEC-1999; 99WO-US028772.  
XX



Db ||||||| 4 CAACAGTGGGAGAGAA 19

RESULT 55  
ABT15831  
ID ABT15831 standard; DNA; 20 BP.  
XX  
AC ABT15831;  
XX  
DT 28-MAR-2003 (first entry)  
XX  
DE Human GU protein antisense oligonucleotide, SEQ ID No 80.  
XX  
KW Human; gene therapy; antisense therapy; antisense oligonucleotide;  
KW GU protein; autoimmune disorder; connective tissue disorder; ss;  
KW hyperproliferative disorder; cancer; phosphorothioate backbone; 2-MOE;  
KW 2'-methoxyethyl.  
XX  
OS Homo sapiens.  
XX  
PN WO200288392-A1.  
XX  
PD 07-NOV-2002.  
XX  
PF 22-APR-2002; 2002WO-US012904.  
XX  
PR 27-APR-2001; 2001US-00844521.  
XX  
PA (ISIS-) ISIS PHARM INC.  
PA (BAYU ) BAYLOR COLLEGE MEDICINE.  
XX  
XX Bennett FC, Busch H, Wyatt JR;  
PI  
XX WPI; 2003-111899/10.  
DR  
XX New antisense compound, particularly antisense oligonucleotide targeted  
PT to a nucleic acid molecule that encodes GU Protein, useful for treating  
PT autoimmune, connective tissue or hyperproliferative disorder, e.g. cancer  
PT in animal.  
XX  
PS Claim 3; Page 83; 112pp; English.  
XX  
CC The invention comprises antisense oligonucleotides designed to inhibit  
CC expression of the human GU protein. The antisense oligonucleotides are  
CC useful for treating autoimmune disorders, connective tissue disorders and  
CC hyperproliferative disorders (e.g. cancer). The present DNA sequence  
CC represents an antisense oligonucleotide of the invention. NOTE: The  
CC present DNA sequence contains a phosphorothioate backbone, nucleotides 1-  
CC 5 and 16-20 are 2'-methoxyethyl (2'-MOE) residues  
XX  
SQ Sequence 20 BP; 8 A; 6 C; 1 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 83;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1294 TACTACATCTTCCAAG 1309  
DB ||||||| 5 TACTACATCTTCCAAG 20  
  
RESULT 56  
ADC61334  
ID ADC61334 standard; DNA; 20 BP.  
XX  
AC ADC61334;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human Growth Hormone 1, GH1, PCR primer GH2DF.  
XX  
KW Growth Hormone; GH1; human; PCR; primer; ss.

XX Homo sapiens.  
OS  
XX WO2003042408-A2.  
PN  
XX 22-MAY-2003.  
PD  
XX 12-NOV-2002; 2002WO-GB005103.  
PF  
XX 12-NOV-2001; 2001GB-00027213.  
PR  
XX (UYWA-) UNIV WALES COLLEGE OF MEDICINE.  
PA  
XX Cooper DN, Procter AM, Gregory J, Millar DS;  
PI  
XX WPI; 2003-449578/42.  
DR  
XX Detecting a variation in pituitary-expressed growth hormone (GH1), useful  
PT as an indicator of growth hormone (GH) dysfunction comprises comparing  
PT the sequence obtained from the test sample with a standard sequence of  
PT the human GHI gene.  
XX  
PS Example 3; Page 40; 70pp; English.  
XX  
CC The present invention relates to a method for detecting a variation in  
CC pituitary-expressed Growth Hormone (GH1) effective to act as an indicator  
CC of Growth Hormone (GH) dysfunction in an individual. The method comprises  
CC comparing the sequence obtained from the test sample with a standard  
CC sequence of the human GH1 gene. The detection comprises PCR amplification  
CC of the GH1 gene of the individual using a GH1 gene-specific fragment that  
CC is unique to the GH1 gene whose sequence is not found in the four  
CC paralogous (non-GH1) genes in the GH cluster, and one or more GH1-gene  
CC specific primers that cannot bind to the homologous flanking regions in  
CC the four other paralogous (non-GH1) genes in the GH cluster (ADC61308-  
CC ADC61343).  
XX  
SQ Sequence 20 BP; 7 A; 2 C; 10 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 83;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 854 CAACAGTGGGAGAGAA 869  
DB ||||||| 4 CAACAGTGGGAGAGAA 19  
  
RESULT 57  
ACC58406  
ID ACC58406 standard; DNA; 20 BP.  
XX  
AC ACC58406;  
XX  
DT 26-AUG-2003 (first entry)  
XX  
DE Human growth hormone GH1 gene PCR primer GH2DF.  
XX  
KW Growth hormone; GH1 gene; human; cytostatic; antidiabetic; anorectic;  
KW antimicrobial; cardiant; gene therapy; PCR; primer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2003042245-A2.  
XX  
PD 22-MAY-2003.  
XX  
PF 12-NOV-2002; 2002WO-GB005112.  
XX  
PR 12-NOV-2001; 2001GB-00027214.  
PR 14-NOV-2001; 2001GB-00027328.  
XX  
XX (UYWA-) UNIV WALES COLLEGE OF MEDICINE.  
PA  
XX

OS Synthetic.  
PN WO200159103-A2.  
XX  
PD 16-AUG-2001.  
XX  
PF 09-FEB-2001; 2001WO-US004273.  
XX  
PR 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
PI Blatt L, Mcswiggen J, Chowrira BM;  
XX  
DR WPI; 2001-607195/69.  
XX  
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
PS Claim 30; Page 147; 200pp; English.  
XX  
CC The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN motif) pr  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targetting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is an inozyme of the invention  
XX  
SQ Sequence 17 BP; 9 A; 3 C; 4 G; 0 T; 1 U; 0 Other;  
  
Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 64;  
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
QY 162 AGAAAAAATCCAGGAA 177  
Db |||||:|||||  
1 AGAAAAACUCCAGGAA 16  
  
RESULT 54  
AAS18855

ID AAS18855 standard; DNA; 20 BP.  
XX  
AC AAS18855;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Growth hormone 1 gene (GH1), specific primer GH2DF.  
XX  
KW Growth hormone 1; GH1; osteopathic; gene therapy; protein therapy;  
KW diabetes; obesity; infection; acromegaly; gigantism; sodium retention;  
KW water retention; metabolic syndrome; mood disorder; sleep disorder;  
KW Growth hormone dysfunction; familial growth hormone deficiency;  
KW short stature; pituitary storage defect; human; primer; GH2DF;  
KW denaturing high performance liquid chromatography; DHPLC; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200185993-A2.  
XX  
PD 15-NOV-2001.  
XX  
PF 14-MAY-2001; 2001WO-GB002126.  
XX  
PR 12-MAY-2000; 2000GB-00011459.  
PR 14-JUL-2000; 2000EP-00306004.  
XX  
PA (UYWA-) UNIV WALES COLLEGE OF MEDICINE.  
XX  
PI Cooper DN, Procter AM, Gregory J, Millar DS;  
XX WPI; 2002-089798/12.  
XX  
PT Detecting growth hormone variants (GH1), useful in screening patients for  
PT growth hormone irregularities, comprises comparing the nucleotide  
PT sequence of a GH1 gene from a test sample with that of a standard  
PT sequence of the human GH1.  
XX  
PS Claim 11; Page 76; 95pp; English.  
XX  
CC The invention described a method of detecting variation in growth hormone  
CC 1 (GH1), and therefore GH dysfunction in an individual. The method  
CC comprises comparing the nucleotide sequence of GH1 gene obtained from the  
CC test sample with a standard human GH1 gene sequence, in order to identify  
CC variation (GH1 variant). The method is useful in screening patients for  
CC growth hormone irregularities or producing variant proteins for treating  
CC irregularities, and for the early detection and appropriate clinical  
CC management of familial GH deficiency. The GH1 variants are useful in  
CC therapeutic, diagnostic or detection method, particularly for determining  
CC binding defects and susceptibility to a disease such as diabetes, obesity  
CC or infection; for treating acromegaly or gigantism conditions associated  
CC with lactogenic, diabetogenic, lipolytic and protein anabolic effects,  
CC conditions associated with sodium and water retention, metabolic  
CC syndromes, mood and sleep disorders; diagnosing GH dysfunction and  
CC determining pituitary storage defects. The GH1 variants are especially  
CC useful in gene therapy or protein therapy. The GH1 or GH variant may also  
CC be used in the preparation of a medicament, diagnostics composition or  
CC kit, or detection kit. The method has the advantage of: expanding the  
CC know spectrum of GH1 gene mutations; evaluating the role of GH1 gene  
CC mutations in the etiology of short stature; identifying of the mode of  
CC inheritance of novel lesions; evaluation the effects of GH1 mutations on  
CC the structure and function of the GH molecule and development of rapid  
CC diagnostic tests for inherited GH deficiency. This sequence is the GH1  
CC gene specific primer, GH2DF, used in the denaturing high performance  
CC liquid chromatography (DHPLC) analysis of the GH1 gene to identify  
CC sequence variants, described in the method of the invention  
XX  
SQ Sequence 20 BP; 7 A; 2 C; 10 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 83;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 854 CAACAGTGGGAGAGAA 869

```

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 74;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      251 GATGTGGAGTCCCCGATG 268
      |||||
Db      3 GATGTGGAGTCCAGATG 20

RESULT 51
ACC57867/c
ID ACC57867 standard; DNA; 20 BP.
XX
AC ACC57867;
XX
DT 11-AUG-2003 (first entry)
XX
DE Matrix metalloproteinase 12 antisense PCR primer.
XX
KW Matrix metalloproteinase 12; MMP-12; human; transcription;
KW cis-acting element; transcription factor; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003033679-A2.
XX
PD 24-APR-2003.
XX
PF 17-OCT-2002; 2002WO-US033579.
XX
PR 17-OCT-2001; 2001US-0329961P.
XX
PA (ADRE-) ADVANCED RES & TECHNOLOGY INST.
XX
PI Yokota H, Sun HB;
XX
DR WPI; 2003-393526/37.
XX
PT Predicting an expression level of a target gene or gene family comprises
PT experimentally determining the number and type of cis-acting elements
PT provided in 5' untranslated regulatory regions of the target gene.
XX
PS Example 4; Page 36; 78pp; English.
XX
CC The present sequence is an antisense primer for the PCR amplification of
CC human matrix metalloproteinase 12 (MMP-12) cDNA. A 369 bp product is
CC obtained using this antisense primer with the sense primer given in
CC ACC57866. RT-PCR was performed in an example from the invention to
CC determine expression profiles of MMP genes in human synovial cells in
CC response to mechanical shear. A model-based analysis was used to identify
CC the role of transcription factor binding motifs in gene regulation. The
CC results provide an example of the method of the invention for determining
CC expression levels of target genes based on sequence elements present in
CC untranslated regulatory regions
XX
SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 74;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      358 CGTGAGGATGTAGACTAC 375
      |||||
Db      20 CGTGAGGATGTTGACTAC 3

RESULT 52
ADH14321/c
ID ADH14321 standard; DNA; 20 BP.
XX
AC ADH14321;
XX
DT 11-MAR-2004 (first entry)
OS
```

```

XX Human retinoblastoma 1 (RB1CC1) cDNA PCR primer RB1CC-RS5.
DE cell nucleus; transcription; gene expression; retinoblastoma-1; RB1CC1;
XX diagnosis; cancer; primer; ss.
KW Homo sapiens.
XX WO2003102028-A1.
XX 11-DEC-2003.
XX 30-JAN-2003; 2003WO-JP000882.
XX 03-JUN-2002; 2002JP-00161400.
XX 24-JUL-2002; 2002JP-00214978.
XX (OKAB/) OKABE H.
XX (IKEG/) IKEGAWA S.
XX (CHAN/) CHANO T.
XX Chano T;
XX WPI; 2004-081932/08.
XX Protein in the nuclei of human and animal cells associated with
XX expression of retinoblastoma-1 gene for diagnosis of cancer.
XX Example 1; SEQ ID NO 35; 113pp; Japanese.
XX The invention relates to a protein or polypeptide found in the nuclei of
XX human and animal cells that are associated with transcription and/or
XX induction of expression of retinoblastoma-1 gene (RB1CC1). The detection
XX of RB1CC1 gene and its protein is useful for the diagnosis of cancer. The
XX human RB1CC1 cDNA is 6.6 kb containing a 4782 bp ORF, encoding a 180 kD
XX 1594 amino acid protein. This sequence corresponds to a PCR primer used
XX to amplify and isolate the human RB1CC1 cDNA sequence (ADH14289).
XX
SQ Sequence 20 BP; 5 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 74;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1238 CACACTTCCCAGGAATCA 1255
      |||||
Db      18 CACACTTCCCAGCAATCA 1

RESULT 53
ABK03146
ID ABK03146 standard; RNA; 17 BP.
XX
AC ABK03146;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CD20 Inozyme #97.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscar; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
```

CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo  
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors  
CC that express siNA; and (5) single-stranded siNA with similar properties.  
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,  
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and  
CC gynaecological activities. The siNA are useful for modulating  
CC (downregulating) the expression of VEGFR genes. The siNA are potentially  
CC useful for treating a wide range of angiogenesis-associated conditions,  
CC particularly cancers, diabetic retinopathy, macular degeneration,  
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,  
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,  
CC drug screening, target identification and validation, genetic  
CC engineering, studying gene function, and also for gene mapping (e.g. of  
CC single-nucleotide polymorphisms). The present sequence is used in the  
CC exemplification of the present invention.

XX  
SQ Sequence 19 BP; 9 A; 7 C; 1 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 19;  
Best Local Similarity 83.3%; Pred. No. 68;  
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACACATAGTTACA 1535  
|||||  
Db 2 CACACACACACAGUUA 19

RESULT 49  
AAQ95937/c  
ID AAQ95937 standard; DNA; 20 BP.  
XX  
AC AAQ95937;  
XX  
DT 21-FEB-1996 (first entry)  
XX  
DE Primer A (Group 13, set C) for marker D19S218, chromosome 19.  
XX  
KW primer; polymerase chain reaction; PCR; linkage study; locus;  
KW microsatellite marker sequence; automated genotyping; allele;  
KW polymorphism; detection; Homo sapiens; ss.

XX Synthetic.  
XX WO9515400-A1.  
XX  
PD 08-JUN-1995.  
XX  
PF 05-DEC-1994; 94WO-US013945.  
XX  
PR 03-DEC-1993; 93US-00160837.  
XX

PA (UYJO ) UNIV JOHNS HOPKINS.

PI Levitt RC;

XX WPI; 1995-215278/28.

PT Kit for automated genotyping contg. pairs of PCR primers - designed to  
PT amplify polymorphic nucleotide repeat sequences, arranged in sets each  
PT with a characteristic fluorescence label, useful e.g. in detection of  
PT disease related genetic rearrangement.

XX  
PS Disclosure; Fig 7M-2; 104pp; English.

XX  
CC The method aims to provide a collection of highly reproducible  
CC microsatellite marker sequences (MMS) at approx. 10-50 cm intervals  
CC throughout the human genome which can be detectably labelled. The MMS are  
CC polymorphic, simple sequence repeats and can be used in automated  
CC genotyping. esp. fluorescence-based. The primers correspond to the unique  
CC DNA sequence surrounding each marker, and PCR is used to detect each  
CC polymorphism. When the MMS show considerable polymorphism (ie. a  
CC difference in the number of repeats) between individuals, the markers can  
CC be particularly informative. The MMS can be ideal for linkage studies.

CC Kits comprise at least 4 groups, of at least 3 sets, each comprising  
CC labelled primers for PCR amplification of the DNA. Group 13 primer pairs  
CC are shown in AAQ95915-46. The published size range of the D19S218 allele  
CC is 240-256 bp, and the degree of heterozygosity in the population is  
CC about 60%

XX  
SQ Sequence 20 BP; 2 A; 2 C; 4 G; 12 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 74;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 165 AAAAATCCAGGAATGCA 182  
|||||  
Db 20 AAAAATCCAGGAATGCA 3

RESULT 50  
AAX78290  
ID AAX78290 standard; DNA; 20 BP.  
XX  
AC AAX78290;

XX  
DT 24-AUG-1999 (first entry)  
XX  
DE Human matrilysin PCR primer 1.

XX  
KW Transplanted cell survival; transplantation; injection; anti-LFA-1;  
KW antibody; anti-inflammatory; pro-inflammatory cell; anti-ICAM-1;  
KW treatment; Duchenne muscular dystrophy; Becker muscular dystrophy;  
KW inflammatory disease; arthritis; sporiasis; heart insufficiency; nanism;  
KW hemophilia; Parkinson's disease; matrilysin; PCR primer; ss.

XX Synthetic.  
OS Homo sapiens.  
XX  
PN WO9930730-A1.

XX  
PD 24-JUN-1999.

XX  
PF 15-DEC-1998; 98WO-CA001176.

PR 15-DEC-1997; 97CA-02224768.

XX  
PR 24-DEC-1997; 97CA-02225837.

XX (UYLA-) UNIV LAVAL.

XX Tremblay JP;

XX  
DR WPI; 1999-395091/33.

PT New compositions for increasing survival of transplanted cells.

XX  
PS Example 3; Page 27; 90pp; English.

XX  
CC This invention describes a novel composition for increasing the survival  
CC of transplanted cells upon their transplantation or injection into a  
CC host. The composition contains an anti-inflammatory agent which  
CC interferes with the recruitment, the binding or the activation of pro-  
CC inflammatory cells of the host toward the cells, so as to prevent the  
CC destruction of the transplanted cells by the host, with the proviso that  
CC the composition does not consist of an anti-LFA-1 antibody or anti-ICAM-1  
CC antibody fragment, and a carrier. The anti-inflammatory agents hinder the  
CC binding of pro-inflammatory cells to transplanted cells or inhibit the  
CC recruitment of pro-inflammatory cells on the transplanted cells. The  
CC compositions can be used to treat e.g. Duchenne or Becker muscular  
CC dystrophy, inflammatory disease such as arthritis or sporiasis, heart  
CC insufficiency, nanism, hemophilia or Parkinson's disease. This sequence  
CC represents a PCR primer used to amplify human matrilysin which is used in  
CC the method of the invention

XX  
SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;



Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 385 AAAGCTTTTCCAAGTCTGG 402  
| | | | | | | | | | | | | | | | | | | | |  
Db 18 AAAGCTTTTCCAAGGCTGG 1

RESULT 47  
ADF36099/C  
ID ADF36099 standard; RNA; 19 BP.  
XX  
AC ADF36099;  
XX  
DT 12-FEB-2004 (first entry)  
XX  
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:388.  
XX  
KW double-stranded short interfering nucleic acid;  
KW short interfering nucleic acid; siNA; downregulation;  
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;  
KW cytosstatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;  
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;  
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;  
KW arthritis; psoriasis; endometriosis; angiofibroma;  
KW polycystic kidney disease; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO2003070910-A2.  
XX  
PD 28-AUG-2003.  
XX  
PF 20-FEB-2003; 2003WO-US005022.  
XX  
PR 20-FEB-2002; 2002US-0358580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 29-MAY-2002; 2002WO-US017674.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 03-JUL-2002; 2002US-0393796P.  
PR 29-JUL-2002; 2002US-0399348P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 04-NOV-2002; 2002US-00287949.  
PR 27-NOV-2002; 2002US-00306747.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Mcswiggen J, Beigelman L, Pavco P;  
XX  
XX WPI; 2003-679876/64.  
XX  
DR  
XX  
PT New double-stranded interfering nucleic acid, useful e.g. for treatment  
PT and diagnosis of cancer, downregulates the vascular endothelial growth  
PT factor receptor gene.  
XX  
PS Example 3; SEQ ID NO 388; 207pp; English.  
XX  
CC The present invention describes a double-stranded short interfering  
CC nucleic acid (siNA) that downregulates expression of the vascular  
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a  
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo  
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors  
CC that express siNA; and (5) single-stranded siNA with similar properties.  
CC The siNAs have antiangiogenic, cytosstatic, antidiabetic,  
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and  
CC gynaecological activities. The siNA are useful for modulating  
CC (downregulating) the expression of VEGFR genes. The siNA are potentially  
CC useful for treating a wide range of angiogenesis-associated conditions,  
CC particularly cancers, diabetic retinopathy, macular degeneration,  
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,

CC and polycystic kidney disease. The siNA may also be useful for diagnosis,  
CC drug screening, target identification and validation, genetic  
CC engineering, studying gene function, and also for gene mapping (e.g. of  
CC single-nucleotide polymorphisms). The present sequence is used in the  
CC exemplification of the present invention.  
XX  
SQ Sequence 19 BP; 2 A; 1 C; 7 G; 0 T; 9 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 19;  
Best Local Similarity 94.4%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACACATAGTTACA 1535  
| | | | | | | | | | | | | | | | | | | | |  
Db 18 CACACACACACAGTTACA 1

RESULT 48  
ADF36526  
ID ADF36526 standard; RNA; 19 BP.  
XX  
AC ADF36526;  
XX  
DT 12-FEB-2004 (first entry)  
XX  
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:815.  
XX  
KW double-stranded short interfering nucleic acid;  
KW short interfering nucleic acid; siNA; downregulation;  
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;  
KW cytosstatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;  
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;  
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;  
KW arthritis; psoriasis; endometriosis; angiofibroma;  
KW polycystic kidney disease; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO2003070910-A2.  
XX  
PD 28-AUG-2003.  
XX  
PF 20-FEB-2003; 2003WO-US005022.  
XX  
PR 20-FEB-2002; 2002US-0358580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 29-MAY-2002; 2002WO-US017674.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 03-JUL-2002; 2002US-0393796P.  
PR 29-JUL-2002; 2002US-0399348P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 04-NOV-2002; 2002US-00287949.  
PR 27-NOV-2002; 2002US-00306747.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Mcswiggen J, Beigelman L, Pavco P;  
XX  
XX WPI; 2003-679876/64.  
XX  
PT New double-stranded interfering nucleic acid, useful e.g. for treatment  
PT and diagnosis of cancer, downregulates the vascular endothelial growth  
PT factor receptor gene.  
XX  
PS Example 3; SEQ ID NO 815; 207pp; English.  
XX  
CC The present invention describes a double-stranded short interfering  
CC nucleic acid (siNA) that downregulates expression of the vascular  
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a

CC developing Alzheimer's disease. Transgenic animals containing sequences  
CC from the CP2/LSF/LBP-1 gene are useful for screening for drugs capable of  
CC reducing or treating symptoms associated with Alzheimer's disease  
XX  
SQ Sequence 21 BP; 8 A; 2 C; 8 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 71;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 354 GAAGCGTGAGGATGTAGACT 373  
Db 2 GAAGCATGAGGATGGAGACT 21  
  
RESULT 45  
ACF04639  
ID ACF04639 standard; DNA; 21 BP.  
XX  
AC ACF04639;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Murine tumour chromatin immunoprecipitation promoter PCR primer #2.  
XX  
KW Mouse; tumour chromatin; immunoprecipitation; heterologous gene;  
KW transcription amplification system; molecular imaging; PCR; primer; ss.  
XX  
OS Mus sp.  
XX  
PN WO2003066883-A2.  
XX  
PD 14-AUG-2003.  
XX  
PF 07-FEB-2003; 2003WO-US003847.  
XX  
PR 08-FEB-2002; 2002US-0355300P.  
XX  
PA (REGC ) UNIV CALIFORNIA.  
XX  
PI Carey MF, Wu L, Gambhir S, Iyer M, Zhang J;  
XX  
DR WPI; 2003-731506/69.  
XX  
PT Expression vector comprising an effector nucleotide sequence having a  
PT modified tissue specific enhancer and promoter sequences, and a sequence  
PT encoding a chimeric transactivator, useful for detecting heterologous  
PT gene product.  
XX  
PS Example 5; Page 103; Opp; English.  
XX  
CC The present invention relates to an expression vector comprising an  
CC effector nucleotide sequence comprising a modified tissue specific  
CC enhancer sequence, a tissue specific promoter sequence, and a nucleotide  
CC sequence encoding a chimeric transactivator operably linked to the  
CC modified tissue specific promoter sequence, where the encoded  
CC transactivator comprises a DNA binding domain and at least one viral  
CC transcription activation domain. The expression vector and vector system  
CC can be used for producing, detecting, imaging, and monitoring the  
CC heterologous gene product in a cell or in a subject. The present sequence  
CC is a PCR primer used to monitor the gene activity in a murine tumour cell  
CC in the exemplification of the invention  
XX  
SQ Sequence 21 BP; 5 A; 5 C; 5 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 71;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 478 GCTCAGGAGACTTCACTA 497  
Db 1 GCTCATGGAGACTTCATCTA 20

RESULT 46  
ADQ93226/c  
ID ADQ93226 standard; RNA; 18 BP.  
XX  
AC ADQ93226;  
XX  
DT 21-OCT-2004 (first entry)  
XX  
DE 3-alpha-hydroxysteroiddehydrogenase siRNA sense strand, SEQ ID 802.  
XX  
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;  
KW small interfering RNA; siRNA;  
KW androgen signal transduction pathway protein;  
KW androgen signal transduction; 3-alpha-hydroxysteroiddehydrogenase;  
KW hair loss; hyperandrogenic condition; androgenic alopecia;  
KW male pattern alopecia; acne vulgaris; seborrhea; female hirsutism;  
KW prostatic hypertrophy; ds.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT misc\_feature 17..18  
FT /\*tag= a  
FT /note= "2 deoxynucleotide overhang"  
XX  
PN WO2004063331-A2.  
XX  
PD 29-JUL-2004.  
XX  
PF 05-JAN-2004; 2004WO-US000128.  
XX  
PR 03-JAN-2003; 2003US-0437842P.  
XX  
PA (GENC-) GENCIA CORP.  
XX  
PI Kahn S;  
XX  
DR WPI; 2004-561892/54.  
XX  
PT Inhibitory nucleic acid that inhibits expression of an androgen signal  
PT transduction pathway protein useful for treating hair loss, comprises a  
PT double stranded RNA having a partial sequence encoding a pathway protein  
PT in one strand.  
XX  
PS Claim 11; Page 59; 92pp; English.  
XX  
CC The present invention relates to novel small interfering RNAs (siRNAs),  
CC comprising a double stranded RNA, where one strand comprises a partial  
CC nucleic acid sequence of an androgen signal transduction pathway protein,  
CC and where the double-stranded RNA inhibits translation of mRNA encoding  
CC the nucleic acid sequence of the androgen signal transduction pathway  
CC protein thereby blocking the androgen signal transduction pathway. The  
CC androgen signal transduction pathway protein is chosen from isoymes I  
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen  
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-  
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-  
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-  
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-  
CC hydroxysteroidoxidoreductase (ADQ93722), and steroid sulfatase  
CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss  
CC in a mammal which involves contacting several mammal's hair cells with  
CC the siRNA, where the siRNA interferes with the translation of mRNA of the  
CC androgen signal transduction protein. The siRNAs are useful for treating  
CC hyperandrogenic conditions of androgenic alopecia, including male pattern  
CC alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic  
CC hypertrophy. The present sequence is the sense strand for one such siRNA  
CC of the invention.  
XX  
SQ Sequence 18 BP; 4 A; 5 C; 4 G; 2 T; 3 U; 0 Other;  
  
Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 94.4%; Pred. No. 62;

XX PR 14-AUG-2002; 2002US-0403416P.  
XX PA (PHAA ) PHARMACIA CORP.  
XX PI Roberds SL;  
XX DR WPI; 2004-203785/19.  
XX PT New antisense compound targeted to a nucleic acid molecule encoding  
PT Nav1.3, useful for treating a disease or condition associated  
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure  
PT disorder, or ataxia.  
XX PS Claim 4; SEQ ID NO 8124; 417pp; English.  
XX CC The present invention relates to an antisense compound targeted to a  
CC nucleic acid molecule encoding Nav1.3, where the antisense compound  
CC specifically hybridizes with and inhibits the expression of Nav1.3. The  
CC compound and composition are useful for treating a disease or condition  
CC associated with Nav1.3, e.g. pain including but not limited to  
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,  
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,  
CC pain from burns, migraine headache, cluster headache, mild-to-moderate  
CC headache; seizure disorder such as childhood seizure disorder, including  
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present  
CC sequence represents a chimeric phosphorothioate oligonucleotide with  
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of  
CC human Nav1.3 expression, the oligonucleotides are designed to target  
CC different regions of the human Nav1.3 RNA.  
XX SQ Sequence 20 BP; 17 A; 3 C; 0 G; 0 T; 0 U; 0 Other;  
Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 65;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1757 AAAAAAAAAAAAAAAAAAAC 1776  
Db 1 AAAAAAAAAAAAAAAAAAAC 20  
RESULT 43  
AAQ65723  
ID AAQ65723 standard; DNA; 21 BP.  
XX AC AAQ65723;  
XX DT 25-MAR-2003 (revised)  
DT 18-JAN-1995 (first entry)  
XX DE HIV-1 antisense RNA expression vector PCR primer.  
XX KW PCR; polymerase chain reaction amplification; hybrid promoter;  
KW expression vector; antisense sequence; anti-viral; HIV-1;  
KW human immunodeficiency virus; inhibition; viral replication; ss.  
XX OS Synthetic.  
XX PN EP598935-A1.  
XX PD 01-JUN-1994.  
XX PF 24-NOV-1992; 92EP-00119963.  
XX PR 24-NOV-1992; 92EP-00119963.  
XX PA (FARB ) BAYER AG.  
XX PI Kretschmer A, Antonicek H, Baumgarten J, Loebberding A, Mielke B;  
PI Springer W, Stropp U, Struck M, Biesert L, Ruebsamen-Waigmann H;  
PI Suhartono H, Hausner T;  
XX

DR WPI; 1994-169331/21.  
XX Vectors for expressing anti:sense RNA for HIV-1 pro-viral DNA - in  
PT haematopoietic cells, providing complete blockage of HIV-1 replication.  
XX Example 9; Page 9; 28pp; German.  
XX PS Expression vectors were prepared for the expression of HIV-1 antisense  
XX RNA. The antisense sequences are designed to hybridise to proviral RNA  
CC and to thereby inhibit (block) viral replication. The vector constructs  
CC contain a constitutive promoter or a promoter which is inducible in  
CC haematopoietic cells. The promoter may be fused to a sequence which  
CC enhances expression following exposure to the virus, e.g. cytomegalovirus  
CC immediate early promoter/ metallothionein promoter fragment and the HIV-1  
CC long terminal repeat. Polyadenylation signals are also included in the  
CC constructs to ensure stability of antisense transcripts. Primers AAQ65721  
CC -Q65725 were used to amplify regions of expression vector constructs to  
CC verify the cloning procedure. (Updated on 25-MAR-2003 to correct PN  
CC field.)  
XX SQ Sequence 21 BP; 3 A; 5 C; 1 G; 12 T; 0 U; 0 Other;  
Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 71;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1575 TTTTTCACCTTCATTCTATT 1594  
Db 1 TTTTTCACCTGCATTCTACT 20  
RESULT 44  
AAF87025  
ID AAF87025 standard; DNA; 21 BP.  
XX AC AAF87025;  
XX DT 18-SEP-2001 (first entry)  
XX DE Sequencing primer for Human CP2/LSF/LBP-1 ARNm sequence.  
XX KW LBP-1; human; intron; Alzheimer's disease; diagnosis; ADN sequence;  
KW CP2/LSF/LBP-1 gene; sequencing primer; ss.  
XX OS Homo sapiens.  
XX PN EP1113081-A1.  
XX PD 04-JUL-2001.  
XX PF 28-DEC-1999; 99EP-00403304.  
XX PR 28-DEC-1999; 99EP-00403304.  
XX PA (INSP ) INST PASTEUR LILLE.  
PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.  
XX PI Chartier-Harlin M, Amouyel P, Lambert J;  
XX DR WPI; 2001-427121/46.  
XX PT Predicting increased risk of human developing Alzheimer's disease,  
PT comprises identifying polymorphisms located at untranslated regions of  
PT CP2/LSF/LBP-1 gene.  
XX PS Example 1; Page 10; 35pp; English.  
XX CC This sequence is a sequencing primer for the human CP2/LSF/LBP-1 gene  
CC ARNm. The invention relates to a method for predicting an increased risk  
CC of a human subject of developing Alzheimer's disease, comprising assaying  
CC for a mutation within the ADN sequence of the CP2/LSF/LBP-1 gene  
CC including the region controlling the expression of the gene. The method  
CC is useful for predicting an increased risk of a human subject of

```
FT      /*tag= a
FT      /note= "phosphorothioate linkage"
XX
PN      WO200144455-A2.
XX
XX      21-JUN-2001.
XX
XX      12-DEC-2000; 2000WO-GB004741.
XX
XX      15-DEC-1999; 99GB-00029487.
XX
XX      (ASTR ) ASTRAZENECA AB.
XX      (ASTR ) ASTRAZENECA UK LTD.
XX
XX      Beri R;
XX
XX      WPI; 2001-398145/42.
XX
XX      Novel antisense DNA oligonucleotide useful for inhibiting the expression
PT      of wild type COL1A1 gene, for treating, reducing the risk of, and
PT      preventing collagen disorders.
XX
XX      Claim 10; Page 8; 30pp; English.
XX
XX      The present sequence is that of 1 of 12 claimed antisense
CC      oligonucleotides (ASOs, see AAF90492-503) of the invention. These ASOs
CC      are complementary to regions of the human gene (see AAF90491) for the pro
CC      -alpha-1 chain of type I procollagen. They are capable of inhibiting the
CC      expression of type I procollagen pro-alpha-1 chain in a cell that
CC      expresses it. The ASO, or a pharmaceutical composition including it, is
CC      used in a claimed method of treating, or reducing a risk of, a collagen
CC      disorder. Such disorders may include those caused by overproduction of
CC      collagen fibres, such as liver cirrhosis, kidney, liver and heart
CC      fibrosis, scleroderma, hypertrophic scars and keloids. The present ASO,
CC      when administered to human WI-26 cells, inhibited type I collagen
CC      production by 50%
XX
XX      Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
SQ
      Query Match      0.9%; Score 16.8; DB 1; Length 20;
      Best Local Similarity 90.0%; Pred. No. 65;
      Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1194 GAGGCAGGAGCTCATGGACC 1213
      ||||| ||||| ||||| |||||
DB      20 GAGGCTGGAGCTCAGGGACC 1

RESULT 41
ADI27533
ID      ADI27533 standard; DNA; 20 BP.
XX
XX      ADI27533;
XX
XX      22-APR-2004 (first entry)
XX
XX      Human DRAK1 DNA, antisense oligonucleotide #11.
XX
KW      Antisense therapy; human;
KW      death-associated protein kinase-related apoptosis-inducing;
KW      protein kinase 1; DRAK1; hyperproliferative disorder; cancer;
KW      neurological disorder; infection; inflammation; tumour formation;
KW      cytostatic; antiinflammatory; neuroprotective; antimicrobial;
KW      phosphorothioate; ss.
XX
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
FH      modified_base 1. .20
FT      /tag= a
FT      /mod_base= OTHER
FT      /note= "This oligonucleotide has a phosphorothioate
FT      backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
```

```
FT      and 3' ends, which are 5 nucleotides in length at each
FT      end. All cytidine residues are 5-methylcytidines"
XX
XX      US2003232773-A1.
XX
XX      18-DEC-2003.
XX
XX      17-JUN-2002; 2002US-00174559.
XX
XX      17-JUN-2002; 2002US-00174559.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Bennett CF, Freier SM, Dobie KW;
XX
XX      WPI; 2004-061310/06.
XX
XX      New antisense compound targeted to a nucleic acid molecule encoding death
PT      -associated protein kinase-related apoptosis-inducing protein kinase 1
PT      (DRAK1), useful for modulating expression of DRAK1 or for treating
PT      cancer.
XX
XX      Example 15; SEQ ID NO 25; 56pp; English.
XX
XX      The present invention relates to antisense compounds targeted to a
CC      nucleic acid encoding death-associated protein kinase-related apoptosis-
CC      inducing protein kinase 1 (DRAK1). The antisense compound comprises an
CC      antisense oligonucleotide that specifically hybridises with the nucleic
CC      acid and inhibits the expression of DRAK1. The antisense oligonucleotide
CC      is a chimeric oligonucleotide. The antisense oligonucleotide comprises at
CC      least one modified internucleoside linkage, preferably a phosphorothioate
CC      linkage. It also comprises at least one modified sugar moiety, preferably
CC      a 2'-O-methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide
CC      further comprises at least one modified nucleobase, preferably a 5-
CC      methylcytosine. The antisense oligonucleotides are useful for the
CC      treatment of diseases such as hyperproliferative disorders, preferably
CC      cancer, and neurological disorders. The antisense compound can also be
CC      used as prophylaxis, e.g. to prevent or delay infection, inflammation or
CC      tumour formation. The present sequence represents an antisense
CC      oligonucleotide used in the examples of the present invention.
XX
XX      Sequence 20 BP; 6 A; 3 C; 2 G; 9 T; 0 U; 0 Other;
SQ
      Query Match      0.9%; Score 16.8; DB 1; Length 20;
      Best Local Similarity 90.0%; Pred. No. 65;
      Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      867 GAAAATCCTTTTCTTTAAAG 886
      ||| ||| ||||| |||||
DB      1 GAACATCTTTTCTTTAAAG 20

RESULT 42
ADK80790
ID      ADK80790 standard; DNA; 20 BP.
XX
XX      ADK80790;
XX
XX      20-MAY-2004 (first entry)
XX
XX      Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8124.
XX
KW      Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW      diabetic neuropathy; arthritic pain; migraine headache;
KW      infantile epilepsy; ataxia; ss.
XX
XX      Synthetic.
XX
XX      WO2004016754-A2.
XX
XX      26-FEB-2004.
XX
XX      14-AUG-2003; 2003WO-US025465.
```



```
XX 18-JAN-2000.
PD
XX
XX PF 06-JUL-1998; 98JP-00190869.
XX
XX PR 06-JUL-1998; 98JP-00190869.
XX
XX (TAKA/) TAKAHASHI T.
PA (SDIS-) SDI KK.
XX
XX WPI; 2000-154341/14.
DR
XX
XX A new metalloprotease and a DNA coding it.
PT
XX
XX Example 3; Page 8; 21pp; Japanese.
PS
XX
XX This sequence represents a PCR primer corresponding to the preservative
CC amino acid sequence of the matrix metalloprotease MMP family of proteins.
CC The PCR primer is used in the detection of the MMP of the invention. The
CC invention relates to the human metalloprotease in the female reproductive
CC tract (MIFR) protein which is 390 amino acids in length. A recombinant
CC vector containing the MIFR gene can be used to create transformants which
CC produce the metalloprotease in culture
XX
XX Sequence 20 BP; 4 A; 3 C; 6 G; 3 T; 0 U; 4 Other;
SQ
Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 65;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 631 CATGAACCTTGGCCATTCCTT 650
Db |||||:|||||:|||||
20 CATGARYTTGGCCAYKCCCT 1

RESULT 38
AAZ88394
ID AAZ88394 standard; DNA; 20 BP.
XX
AC AAZ88394;
XX
XX 05-MAY-2000 (first entry)
DT
XX Metalloprotease sense primer SEQ ID NO:5.
DE
XX Rat; metalloprotease; metalloprotease; MMP; primer; ss.
XX
XX Rattus norvegicus.
OS
XX JP2000014386-A.
PN
XX 18-JAN-2000.
PD
XX
XX 06-JUL-1998; 98JP-00190868.
PF
XX
XX 06-JUL-1998; 98JP-00190868.
PR
XX (TAKA/) TAKAHASHI T.
PA (SDIS-) SDI KK.
XX
XX WPI; 2000-154340/14.
DR
XX
XX A new metalloprotease and a DNA coding it.
PT
XX
XX Example 3; Page 8; 17pp; Japanese.
PS
XX The present invention describes a metalloprotease (MMP) isolated from
CC rat. MMP has metalloprotease activity. The present sequence represents a
CC MMP sense primer, used in the exemplification of the present invention
XX
XX Sequence 20 BP; 1 A; 2 C; 7 G; 5 T; 0 U; 5 Other;
SQ
Query Match 0.9%; Score 16.8; DB 1; Length 20;
```

```
Best Local Similarity 75.0%; Pred. No. 65;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 250 CGATGTGGAGTCCCCGATGT 269
Db |||||:|||||:|||||
1 MGVTTGGWGTBCCCHGATGT 20

RESULT 39
AAZ88395/c
ID AAZ88395 standard; DNA; 20 BP.
XX
AC AAZ88395;
XX
XX 05-MAY-2000 (first entry)
DT
XX Metalloprotease antisense primer SEQ ID NO:6.
DE
XX Rat; metalloprotease; metalloprotease; MMP; primer; ss.
XX
XX Rattus norvegicus.
OS
XX JP2000014386-A.
PN
XX 18-JAN-2000.
PD
XX
XX 06-JUL-1998; 98JP-00190868.
PF
XX
XX 06-JUL-1998; 98JP-00190868.
PR
XX (TAKA/) TAKAHASHI T.
PA (SDIS-) SDI KK.
XX
XX WPI; 2000-154340/14.
DR
XX
XX A new metalloprotease and a DNA coding it.
PT
XX
XX Example 3; Page 8; 17pp; Japanese.
PS
XX The present invention describes a metalloprotease (MMP) isolated from
CC rat. MMP has metalloprotease activity. The present sequence represents a
CC MMP antisense primer, used in the exemplification of the present
CC invention
XX
XX Sequence 20 BP; 4 A; 3 C; 6 G; 3 T; 0 U; 4 Other;
SQ
Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 65;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 631 CATGAACCTTGGCCATTCCTT 650
Db |||||:|||||:|||||
20 CATGARYTTGGCCAYKCCCT 1

RESULT 40
AAF90500/c
ID AAF90500 standard; DNA; 20 BP.
XX
AC AAF90500;
XX
XX 22-AUG-2001 (first entry)
DT
XX COL1A1 gene antisense oligonucleotide 9.
DE
XX COL1A1 gene; collagen; procollagen; human; antisense; vulneryary;
KW dermatological; scar; keloid; scleroderma; cirrhosis; fibrosis; therapy;
KW ss.
XX
XX Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT
```

KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX Hepatitis C virus.  
OS  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
XX 08-MAR-2004; 2004WO-US007070.  
PF  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
XX Manoharan M, Bumcrot D;  
PI  
XX WPI; 2004-677362/66.  
DR  
XX  
PT Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 6180; 378pp; English.  
PS  
CC The invention describes a RNA interference (irna) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 2 G; 17 T; 0 U; 0 Other;

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 56;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1760 AAAAAAAAAAAAAAAC 1776  
Db 19 AAAAAAAAAAAAAAAC 3

RESULT 36

AAZ90012  
ID AAZ90012 standard; DNA; 20 BP.

XX AC AAZ90012;

XX DT 05-MAY-2000 (first entry)

XX DE PCR primer corresponding to MMP preservative amino acid sequence.

XX KW Metalloprotease in the female reproductive tract; MIFR; MMP; PCR primer;

XX KW matrix metalloprotease; ss.

XX OS Synthetic.

XX PN JP2000014387-A.

XX PD 18-JAN-2000.

XX PF 06-JUL-1998; 98JP-00190869.

XX PR 06-JUL-1998; 98JP-00190869.

XX PA (TAKA/) TAKAHASHI T.

XX PA (SDIS-) SDI KK.

XX DR WPI; 2000-154341/14.

XX PT A new metalloprotease and a DNA coding it.

XX PS Example 3; Page 8; 21pp; Japanese.

XX CC This sequence represents a PCR primer corresponding to the preservative  
CC amino acid sequence of the matrix metalloprotease MMP family of proteins.  
CC The PCR primer is used in the detection of the MMP of the invention. The  
CC invention relates to the human metalloprotease in the female reproductive  
CC tract (MIFR) protein which is 390 amino acids in length. A recombinant  
CC vector containing the MIFR gene can be used to create transformants which  
CC produce the metalloprotease in culture

XX SQ Sequence 20 BP; 1 A; 2 C; 7 G; 5 T; 0 U; 5 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 75.0%; Pred. No. 65;  
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 250 CGATGTGGAGTGCCCGATGT 269

Db 1 MGVGTGGWGTBCCHGATGT 20

RESULT 37

AAZ90013/c

ID AAZ90013 standard; DNA; 20 BP.

XX AC AAZ90013;

XX DT 05-MAY-2000 (first entry)

XX DE PCR primer corresponding to MMP preservative amino acid sequence.

XX KW Metalloprotease in the female reproductive tract; MIFR; MMP; PCR primer;

XX KW matrix metalloprotease; ss.

XX OS Synthetic.

XX PN JP2000014387-A.

XX 03-JAN-2003; 2003US-0437842P.  
XX (GENC-) GENCIA CORP.  
XX Kahn S;  
XX WPI; 2004-561892/54.  
XX Inhibitory nucleic acid that inhibits expression of an androgen signal  
PT transduction pathway protein useful for treating hair loss, comprises a  
PT double stranded RNA having a partial sequence encoding a pathway protein  
PT in one strand.  
XX Claim 11; Page 70; 92pp; English.  
XX The present invention relates to novel small interfering RNAs (siRNAs),  
CC comprising a double stranded RNA, where one strand comprises a partial  
CC nucleic acid sequence of an androgen signal transduction pathway protein,  
CC and where the double-stranded RNA inhibits translation of mRNA encoding  
CC the nucleic acid sequence of the androgen signal transduction pathway  
CC protein thereby blocking the androgen signal transduction pathway. The  
CC androgen signal transduction pathway protein is chosen from isoymes I  
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen  
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-  
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-  
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-  
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-  
CC hydroxysteroidoxidoreductase (ADQ93722), and steroid sulfatase  
CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss  
CC in a mammal which involves contacting several mammal's hair cells with  
CC the siRNA, where the siRNA interferes with the translation of mRNA of the  
CC androgen signal transduction protein. The siRNAs are useful for treating  
CC hyperandrogenic conditions of androgenic alopecia, including male pattern  
CC alopecia, acne vulgaris, seborrhoea, and female hirsutism and prostatic  
CC hypertrophy. The present sequence is the antisense strand for one such  
CC siRNA of the invention.  
XX Sequence 21 BP; 3 A; 4 C; 5 G; 2 T; 7 U; 0 Other;  
SQ Query Match 1.0%; Score 17.8; DB 1; Length 21;  
Best Local Similarity 61.9%; Pred. No. 52;  
Matches 13; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
QY 1454 CTCATGCTCAGGGTGTAACT 1474  
Db 1 CUCUUUGCUCAGGGUGUAATT 21  
RESULT 34  
AAX64428  
ID AAX64428 standard; RNA; 18 BP.  
XX  
AC AAX64428;  
XX 20-JUL-1999 (first entry)  
DT Human stromelysin hairpin target sequence SEQ ID NO:1060.  
XX Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX Homo sapiens.  
OS WO9618736-A2.  
XX 20-JUN-1996.  
PD 22-NOV-1995; 95WO-US015516.  
XX

PR 13-DEC-1994; 94US-00354920.  
PR 23-DEC-1994; 94US-00363253.  
PR 23-DEC-1994; 94US-00363254.  
PR 17-FEB-1995; 95US-00390850.  
PR 20-APR-1995; 95US-00426124.  
PR 02-MAY-1995; 95US-00432874.  
PR 04-MAY-1995; 95US-00434509.  
PR 07-JUL-1995; 95US-0000951P.  
PR 07-JUL-1995; 95US-0000974P.  
PR 07-AUG-1995; 95US-00512861.  
PR 05-OCT-1995; 95US-00541365.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX WPI; 1996-300653/30.  
DR Enzymatic nucleic acid molecules having a hammer-head motif - used for  
XX the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
PT Example 1; Page 164; 307pp; English.  
XX The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor. They can also be used for  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX Sequence 18 BP; 3 A; 6 C; 3 G; 0 T; 6 U; 0 Other;  
SQ Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 64.7%; Pred. No. 51;  
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 750 CATTGAGTCCCTCTATG 766  
Db 2 CAUUCAGUCCCUAUG 18  
RESULT 35  
ADR81681/c  
ID ADR81681 standard; DNA; 19 BP.  
XX  
AC ADR81681;  
XX 16-DEC-2004 (first entry)  
DT Hepatitis C virus (HCV) oligonucleotide seqid 6180.  
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytosstatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;

XX Inhibitory nucleic acid that inhibits expression of an androgen signal  
PT transduction pathway protein useful for treating hair loss, comprises a  
PT double stranded RNA having a partial sequence encoding a pathway protein  
PT in one strand.  
XX  
PS Claim 11; Page 77; 92pp; English.  
XX  
CC The present invention relates to novel small interfering RNAs (siRNAs),  
CC comprising a double stranded RNA, where one strand comprises a partial  
CC nucleic acid sequence of an androgen signal transduction pathway protein,  
CC and where the double-stranded RNA inhibits translation of mRNA encoding  
CC the nucleic acid sequence of the androgen signal transduction pathway  
CC protein thereby blocking the androgen signal transduction pathway. The  
CC androgen signal transduction pathway protein is chosen from isozyms I  
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen  
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-  
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-  
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-  
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-  
CC hydroxysteroidoxidoreductase (ADQ93722), and steroid sulfatase  
CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss  
CC in a mammal which involves contacting several mammal's hair cells with  
CC the siRNA, where the siRNA interferes with the translation of mRNA of the  
CC androgen signal transduction protein. The siRNAs are useful for treating  
CC hyperandrogenic conditions of androgenic alopecia, including male pattern  
CC alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic  
CC hypertrophy. The present sequence, SEQ ID 1258, is the antisense strand  
CC for one such siRNA of the invention.  
XX  
SQ Sequence 21 BP; 3 A; 4 C; 5 G; 2 T; 7 U; 0 Other;

Query Match 1.0%; Score 17.8; DB 1; Length 21;  
Best Local Similarity 61.9%; Pred. No. 52;  
Matches 13; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1454 CTCTATGCTCAGGGTGTAACT 1474  
|:|:|:|:|:|:|:|:|:|:|:|:|:|  
Db 1 CUCUUUGCUCAGGGUGUAATT 21

RESULT 32  
ADQ93680/c  
ID ADQ93680 standard; DNA; 21 BP.  
XX  
AC ADQ93680;  
XX  
XX 21-OCT-2004 (first entry)  
XX  
DE 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase target oligonucleotide.  
XX  
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;  
KW small interfering RNA; siRNA;  
KW androgen signal transduction pathway protein;  
KW androgen signal transduction;  
KW 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase; hair loss;  
KW hyperandrogenic condition; androgenic alopecia; male pattern alopecia;  
KW acne vulgaris; seborrhea; female hirsutism; prostatic hypertrophy;  
KW human; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004063331-A2.  
XX  
PD 29-JUL-2004.  
XX  
PF 05-JAN-2004; 2004WO-US000128.  
XX  
PR 03-JAN-2003; 2003US-0437842P.  
XX  
PA (GENC-) GENCIA CORP.  
XX  
PI Kahn S;

XX WPI; 2004-561892/54.  
XX  
XX Inhibitory nucleic acid that inhibits expression of an androgen signal  
PT transduction pathway protein useful for treating hair loss, comprises a  
PT double stranded RNA having a partial sequence encoding a pathway protein  
PT in one strand.  
XX  
PS Claim 11; Page 77; 92pp; English.  
XX  
CC The present invention relates to novel small interfering RNAs (siRNAs),  
CC comprising a double stranded RNA, where one strand comprises a partial  
CC nucleic acid sequence of an androgen signal transduction pathway protein,  
CC and where the double-stranded RNA inhibits translation of mRNA encoding  
CC the nucleic acid sequence of the androgen signal transduction pathway  
CC protein thereby blocking the androgen signal transduction pathway. The  
CC androgen signal transduction pathway protein is chosen from isozyms I  
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen  
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-  
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-  
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-  
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-  
CC hydroxysteroidoxidoreductase (ADQ93722), and steroid sulfatase  
CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss  
CC in a mammal which involves contacting several mammal's hair cells with  
CC the siRNA, where the siRNA interferes with the translation of mRNA of the  
CC androgen signal transduction protein. The siRNAs are useful for treating  
CC hyperandrogenic conditions of androgenic alopecia, including male pattern  
CC alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic  
CC hypertrophy. The present sequence, SEQ ID 1256, is a target sequence  
CC which was used to generate the siRNAs of the invention.  
XX  
SQ Sequence 21 BP; 9 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 17.8; DB 1; Length 21;  
Best Local Similarity 90.5%; Pred. No. 52;  
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1454 CTCTATGCTCAGGGTGTAACT 1474  
|:|:|:|:|:|:|:|:|:|:|:|:|:|  
Db 21 CTCTTTGCTCAGGGTGTAAATT 1

RESULT 33  
ADQ93501  
ID ADQ93501 standard; RNA; 21 BP.  
XX  
AC ADQ93501;  
XX  
XX 21-OCT-2004 (first entry)  
DT  
DE 3-beta-hydroxysteroiddehydrogenase siRNA antisense strand, SEQ ID 1077.  
XX  
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;  
KW small interfering RNA; siRNA;  
KW androgen signal transduction pathway protein;  
KW androgen signal transduction; 3-beta-hydroxysteroiddehydrogenase;  
KW hair loss; hyperandrogenic condition; androgenic alopecia;  
KW male pattern alopecia; acne vulgaris; seborrhea; female hirsutism;  
KW prostatic hypertrophy; ds.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT misc\_feature 20..21  
FT /\*tag= a  
FT /note= "2 deoxynucleotide overhang"  
XX  
PN WO2004063331-A2.  
XX  
PD 29-JUL-2004.  
XX  
PF 05-JAN-2004; 2004WO-US000128.





KW 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase; hair loss;  
KW hyperandrogenic condition; androgenic alopecia; male pattern alopecia;  
KW acne vulgaris; seborrhoea; female hirsutism; prostatic hypertrophy; ds.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT misc\_feature 20..21  
FT /\*tag= a  
FT /note= "2 deoxynucleotide overhang"  
XX  
PN WO2004063331-A2.  
XX  
XX  
PD 29-JUL-2004.  
XX  
XX  
PF 05-JAN-2004; 2004WO-US000128.  
XX  
XX 03-JAN-2003; 2003US-0437842P.  
PR  
XX (GENC-) GENCIA CORP.  
PA  
XX  
XX Kahn S;  
PI  
XX  
XX  
DR WPI; 2004-561892/54.  
XX  
XX Inhibitory nucleic acid that inhibits expression of an androgen signal  
PT transduction pathway protein useful for treating hair loss, comprises a  
PT double stranded RNA having a partial sequence encoding a pathway protein  
PT in one strand.  
XX  
XX Claim 11; Page 77; 92pp; English.  
PS  
XX The present invention relates to novel small interfering RNAs (siRNAs),  
CC comprising a double stranded RNA, where one strand comprises a partial  
CC nucleic acid sequence of an androgen signal transduction pathway protein,  
CC and where the double-stranded RNA inhibits translation of mRNA encoding  
CC the nucleic acid sequence of the androgen signal transduction pathway  
CC protein thereby blocking the androgen signal transduction pathway. The  
CC androgen signal transduction pathway protein is chosen from isozyms I  
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen  
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-  
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-  
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-  
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-  
CC hydroxysteroidoxidoreductase (ADQ93722), and steroid sulfatase  
CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss  
CC in a mammal which involves contacting several mammal's hair cells with  
CC the siRNA, where the siRNA interferes with the translation of mRNA of the  
CC androgen signal transduction protein. The siRNAs are useful for treating  
CC hyperandrogenic conditions of androgenic alopecia, including male pattern  
CC alopecia, acne vulgaris, seborrhoea, and female hirsutism and prostatic  
CC hypertrophy. The present sequence, SEQ ID 1257, is the sense strand for  
CC one such siRNA of the invention.  
XX  
SQ Sequence 21 BP; 7 A; 5 C; 4 G; 2 T; 3 U; 0 Other;  
  
Query Match 1.0%; Score 18.4; DB 1; Length 21;  
Best Local Similarity 95.0%; Pred. No. 43;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1453 ACTCTATGCTCAGGGTGTA 1472  
Db 20 ACTCTTTGCTCAGGGTGTA 1  
  
RESULT 28  
ADR32355/c  
ID ADR32355 standard; DNA; 18 BP.  
XX  
AC ADR32355;  
XX  
DT 04-NOV-2004 (first entry)  
XX

DE Rat KDR cytosolic domain cloning RT-PCR primer.  
XX  
KW Rat; receptor tyrosine kinase; KDR; therapy; cancer;  
KW ischaemic ocular disease; proliferative retinopathy; inflammation;  
KW reverse transcription; RT; PCR; primer; ss.  
XX  
OS Rattus norvegicus.  
XX  
PN WO2004070004-A2.  
XX  
PD 19-AUG-2004.  
XX  
PF 23-JAN-2004; 2004WO-US001928.  
XX  
XX 29-JAN-2003; 2003US-0443335P.  
PR  
PA (MERI ) MERCK & CO INC.  
XX  
XX Thomas RA, Pan B, Mcgaughey GB;  
PI  
XX WPI; 2004-604429/58.  
DR  
XX  
XX New nucleic acid molecules encoding rat KDR protein, useful for  
PT identifying inhibitors of KDR activity for treating cancer, ischemic  
PT ocular diseases, and inflammation.  
XX  
XX Example 2; Page 30; 77pp; English.  
PS  
XX The invention relates to rat receptor tyrosine kinase (KDR) and its  
CC corresponding nucleic acid sequence. The nucleic acid molecules of the  
CC invention are useful for identifying compounds that modulate wild-type  
CC rat KDR activity to evaluate the safety and efficacy of specific  
CC inhibitors of KDR in rats. KDR inhibitors are useful for treating cancer,  
CC ischaemic ocular diseases such as proliferative retinopathy and  
CC inflammation. The present sequence is a reverse transcription (RT) PCR  
CC primer used for cloning rat KDR cytosolic domain. This sequence is used  
CC in the exemplification of the invention.  
XX  
SQ Sequence 18 BP; 0 A; 0 C; 0 G; 18 T; 0 U; 0 Other;  
  
Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1  
  
RESULT 29  
ADR57967/c  
ID ADR57967 standard; DNA; 18 BP.  
XX  
AC ADR57967;  
XX  
DT 18-NOV-2004 (first entry)  
XX  
XX Nucleotide #4 for signal amplification method.  
DE  
XX ss; signal amplification method; gene expression; reverse transcription;  
KW self-assembly reaction; DNA chip.  
XX  
XX Unidentified.  
OS  
XX WO2004072302-A1.  
PN  
XX 26-AUG-2004.  
PD  
XX 13-FEB-2004; 2004WO-JP001588.  
XX  
PF 14-FEB-2003; 2003JP-00037212.  
XX  
XX (PALM-) PALMA BEEZ RES INST CO LTD.  
PA

DE Antisense primer to amplify DNA encoding human IQGAP1.  
XX  
KW IQGAP1; human GTPase-activating protein; IQ motif; diagnosis; treatment;  
KW tumour; suppressor; ras; cancer; p21-ras; neoplastic cell; primer; PCR;  
KW polymerase chain reaction; matrix metalloproteinase; ss.  
XX  
OS Synthetic.  
XX  
PN US5639651-A.  
XX  
PD 17-JUN-1997.  
XX  
PF 09-AUG-1994; 94US-00287959.  
XX  
PR 09-AUG-1994; 94US-00287959.  
XX  
PA (GEO ) GEN HOSPITAL CORP.  
XX  
PI Settleman J, Weissbach L, Bernards A;  
XX  
XX WPI; 1997-332049/30.  
DR  
XX DNA encoding GTPase-activating protein IQGAP1 - for producing recombinant  
PT protein useful for tumour diagnosis and therapy.  
XX  
XX Disclosure; Col 4; 35pp; English.  
PS  
XX AAT58682 and AAT70486 are degenerate primers designed based on conserved  
CC peptides in matrix metalloproteinases. They were used to amplify a human  
CC IQGAP1 (a GTPase-activating protein) DNA probe using total RNA from human  
CC metastatic osteosarcoma tissue as a template. IQGAP1 (AAW18822) has an  
CC "IQ motif" which is defined as an amino acid sequence of 20-40 amino  
CC acids in length containing an isoleucine residue immediately followed by  
CC a glutamine residue which has at least 50 percent sequence similarity to  
CC the consensus sequence shown in AAW18823. The DNA sequence (AAT58681) is  
CC used for production of recombinant IQGAP1, which is useful in the  
CC diagnosis and treatment of tumours characterised by aberrant ras  
CC expression. Detection of mutations in the IQGAP1 gene is diagnostic of  
CC cancer. The IQGAP1 protein can be used for treatment of cancer to reduce  
CC the activity of p21-ras. Detection of neoplastic cells can be achieved by  
CC measuring IQGAP1 expression  
XX  
SQ Sequence 23 BP; 4 A; 6 C; 4 G; 4 T; 0 U; 5 Other;  
  
Query Match 1.0%; Score 18.6; DB 1; Length 23;  
Best Local Similarity 73.9%; Pred. No. 47;  
Matches 17; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
  
QY 631 CATGAACCTTGGCCATTCCTTGGG 653  
Db 23 CATGAATTTGGCCAYKYBCTGGG 1  
  
RESULT 26  
ADQ93500/c  
ID ADQ93500 standard; RNA; 21 BP.  
XX  
AC ADQ93500;  
XX  
DT 21-OCT-2004 (first entry)  
XX  
DE 3-beta-hydroxysteroiddehydrogenase siRNA sense strand, SEQ ID 1076.  
XX  
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;  
KW small interfering RNA; siRNA;  
KW androgen signal transduction pathway protein;  
KW androgen signal transduction; 3-beta-hydroxysteroiddehydrogenase;  
KW hair loss; hyperandrogenic condition; androgenic alopecia;  
KW male pattern alopecia; acne vulgaris; seborrhoea; female hirsutism;  
KW prostatic hypertrophy; ds.  
XX  
OS Synthetic.  
XX

PH Key Location/Qualifiers  
FT misc\_feature 20..21  
FT /\*tag= a  
FT /note= "2 deoxynucleotide overhang"  
XX  
PN WO2004063331-A2.  
XX  
XX 29-JUL-2004.  
XX  
XX 05-JAN-2004; 2004WO-US000128.  
PF  
XX 03-JAN-2003; 2003US-0437842P.  
PR  
XX (GENC-) GENCIA CORP.  
PA  
XX Kahn S;  
PI  
XX WPI; 2004-561892/54.  
DR  
XX Inhibitory nucleic acid that inhibits expression of an androgen signal  
PT transduction pathway protein useful for treating hair loss, comprises a  
PT double stranded RNA having a partial sequence encoding a pathway protein  
PT in one strand.  
XX  
PS Claim 11; Page 70; 92pp; English.  
XX  
CC The present invention relates to novel small interfering RNAs (siRNAs),  
CC comprising a double stranded RNA, where one strand comprises a partial  
CC nucleic acid sequence of an androgen signal transduction pathway protein,  
CC and where the double-stranded RNA inhibits translation of mRNA encoding  
CC the nucleic acid sequence of the androgen signal transduction pathway  
CC protein thereby blocking the androgen signal transduction pathway. The  
CC androgen signal transduction pathway protein is chosen from isozyms I  
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen  
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-  
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-  
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-  
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-  
CC hydroxysteroiddehydrogenase (ADQ93722), and steroid sulfatase  
CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss  
CC in a mammal which involves contacting several mammal's hair cells with  
CC the siRNA, where the siRNA interferes with the translation of mRNA of the  
CC androgen signal transduction protein. The siRNAs are useful for treating  
CC hyperandrogenic conditions of androgenic alopecia, including male pattern  
CC alopecia, acne vulgaris, seborrhoea, and female hirsutism and prostatic  
CC hypertrophy. The present sequence is the sense strand for one such siRNA  
CC of the invention.  
XX  
SQ Sequence 21 BP; 7 A; 5 C; 4 G; 2 T; 3 U; 0 Other;  
  
Query Match 1.0%; Score 18.4; DB 1; Length 21;  
Best Local Similarity 95.0%; Pred. No. 43;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1453 ACTCTATGCTCAGGGTGTA 1472  
Db 20 ACTCTTTGCTCAGGGTGTA 1  
  
RESULT 27  
ADQ93681/c  
ID ADQ93681 standard; RNA; 21 BP.  
XX  
AC ADQ93681;  
XX  
DT 21-OCT-2004 (first entry)  
XX  
DE 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase siRNA sense strand.  
XX  
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;  
KW small interfering RNA; siRNA;  
KW androgen signal transduction pathway protein;  
KW androgen signal transduction;  
XX



PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
XX WPI; 2004-677362/66.  
XX  
PT Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 6758; 378pp; English.  
XX  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767  
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1  
  
RESULT 24  
AAH62035  
ID AAH62035 standard; DNA; 21 BP.  
XX  
AC AAH62035;  
XX  
DT 10-SEP-2001 (first entry)  
XX  
DE MMP3 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4459.  
XX

KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
KW recognition site; target; ribozyme binding site; eye disease; vulneryary;  
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
KW antisklicking; ophthalmological; keratolytic; gene therapy; viral wart;  
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
KW sickle cell retinopathy; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200130362-A2.  
XX  
PD 03-MAY-2001.  
XX  
PF 26-OCT-2000; 2000WO-US029500.  
XX  
PR 26-OCT-1999; 99US-0161532P.  
XX  
PA (IMMU-) IMMUSOL INC.  
XX  
PI Robbins JM, Tritz R;  
XX  
XX WPI; 2001-300427/31.  
XX  
PT Treating proliferative skin or eye diseases and scarring, using ribozymes  
PT that cleave RNA encoding cytokines involved in inflammation, matrix  
PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
XX  
PS Example 1; Page 23; 408pp; English.  
XX  
CC The present invention describes a method for treating a proliferative  
CC skin or eye disease and scarring. The method involves administering a  
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
CC dependent kinase, growth factor or a reductase, or administering a  
CC nucleic acid molecule (II) comprising a promoter operably linked to a  
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisklicking,  
CC ophthalmological, vulneryary, keratolytic and virucide activities, and  
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
CC also be used for treating proliferative eye diseases such as diabetic  
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
CC prematurity and retinal detachment, and for treating and preventing  
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
CC scar. AAH57577 to AAH62099 represent sequences used in the  
CC exemplification of the present invention  
XX  
SQ Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 36;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 750 CATTGAGTCCCTCTATGGA 768  
Db 3 CATTGAGTCCCTCTATGGA 21  
  
RESULT 25  
AAAT70486/c  
ID AAAT70486 standard; DNA; 23 BP.  
XX  
AC AAAT70486;  
XX  
DT 05-JAN-1998 (first entry)  
XX



CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAA 1767  
Db 19 AAAAAAAAAAAAAAAAAA 1  
  
RESULT 22  
ADR82256/c  
ID ADR82256 standard; DNA; 19 BP.  
XX  
AC ADR82256;  
XX  
DT 16-DEC-2004 (first entry)  
XX  
DE Hepatitis C virus (HCV) oligonucleotide seqid 6755.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
XX WPI; 2004-677362/66.  
XX  
PT Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 6755; 378pp; English.  
XX

CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAA 1767  
Db 19 AAAAAAAAAAAAAAAAAA 1  
  
RESULT 23  
ADR82259/c  
ID ADR82259 standard; DNA; 19 BP.  
XX  
AC ADR82259;  
XX  
DT 16-DEC-2004 (first entry)  
XX  
DE Hepatitis C virus (HCV) oligonucleotide seqid 6758.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.

PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
XX WPI; 2004-677362/66.  
DR  
XX  
XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 6760; 378pp; English.  
XX  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1749 AAAAAAAAAAAAAAAAAA 1767  
Db 19 AAAAAAAAAAAAAAAAAA 1  
  
RESULT 21  
ADR82258/c  
ID ADR82258 standard; DNA; 19 BP.  
XX  
AC ADR82258;  
XX

DT 16-DEC-2004 (first entry)  
XX  
DE Hepatitis C virus (HCV) oligonucleotide seqid 6757.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytotstatic; anticonvulsant; nootropic; muscula; anti-Hiv;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
OS Hepatitis C virus.  
XX  
XX WO2004080406-A2.  
XX  
XX 23-SEP-2004.  
XX  
XX 08-MAR-2004; 2004WO-US007070.  
PF  
XX 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
XX (ALNY-) ALNYLAM PHARM.  
PA  
XX Manoharan M, Bumcrot D;  
XX  
PI WPI; 2004-677362/66.  
XX  
XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
XX Example 5; SEQ ID NO 6757; 378pp; English.  
PT  
PT The invention describes a RNA interference (iRNA) agent (I) comprising a  
XX sense sequence and an antisense sequence, where the sense sequences have  
XX one or more asymmetrical 2'-O alkyl modifications, the antisense  
XX sequences have one or more asymmetrical phosphorothioate modifications  
XX and the antisense sequence targets a human gene sequence. Also described  
XX are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
XX levels or glucose-6-phosphatase levels in a subject; producing (I);  
XX stabilising (I), involves selecting a sequence with activity and  
XX introducing one or more asymmetrical modification in the sequence, where  
XX the modification decreases nuclease sensitivity while not decreasing its  
XX activity; a kit comprising (I) and instruction for its use; and a device  
XX that can be dispense or administer a composition comprising (I). (I) is  
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
XX The subject is suffering from a disorder characterised by elevated or  
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The  
XX disorder is chosen from the HDL/LDL cholesterol imbalance,  
XX dyslipidaemias, hypercholesterolaemia, statin-resistant  
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to  
XX inhibit hepatic glucose production or for treating glucose-metabolism-  
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or  
XX lung cancer), neurological disease (e.g., Huntington disease or  
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
XX represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
XX be used to control HCV gene expression.

CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAA 1767  
Db 19 AAAAAAAAAAAAAAAAAA 1  
  
RESULT 19  
ADR82257/c  
ID ADR82257 standard; DNA; 19 BP.  
XX  
AC ADR82257;  
XX  
DT 16-DEC-2004 (first entry)  
XX  
DE Hepatitis C virus (HCV) oligonucleotide seqid 6756.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
XX WPI; 2004-677362/66.  
DR  
XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense

PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 6756; 378pp; English.  
XX  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAA 1767  
Db 19 AAAAAAAAAAAAAAAAAA 1  
  
RESULT 20  
ADR82261/c  
ID ADR82261 standard; DNA; 19 BP.  
XX  
AC ADR82261;  
XX  
DT 16-DEC-2004 (first entry)  
XX  
DE Hepatitis C virus (HCV) oligonucleotide seqid 6760.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.



SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. NO. 42;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
| | | | | | | | | | | | | | | | | |  
Db 24 AAAAAAAAAAAAAACAAAAAACAA 1

RESULT 17  
ADI53690/c

ID ADI53690 standard; DNA; 19 BP.

XX  
AC ADI53690;

XX  
DT 22-APR-2004 (first entry)

XX  
DE Human MMP-12 antisense oligonucleotide, SEQ ID 3.

XX  
KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;

KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;

KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;

KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.

XX  
OS Homo sapiens.

OS Synthetic.

XX  
PN WO2004009098-A1.

XX  
PD 29-JAN-2004.

XX  
PF 17-JUL-2003; 2003WO-SE001223.

XX  
PR 18-JUL-2002; 2002SE-00002253.

PR 04-SEP-2002; 2002US-0407680P.

XX  
PA (INDE-) INDEX PHARM AB.

XX  
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;

XX  
DR WPI; 2004-123288/12.

XX  
PT New compound having a sequence targeted to a nucleic acid encoding

PT metalloproteinase 12 (MMP-12), useful for preparing a composition for

PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,

PT asthma or psoriasis.

XX  
PS Claim 7; SEQ ID NO 3; 55pp; English.

XX  
CC The present invention relates to antisense oligonucleotides (ADI53690-

CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and

CC ADI53689), which specifically hybridise with the nucleic acid encoding

CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense

CC oligonucleotides are useful for preparing a composition for treating or

CC preventing MMP-12 dependant disorder in a human patient e.g. inflammatory

CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid

CC arthritis, psoriasis, emphysema or asthma.

XX  
SQ Sequence 19 BP; 7 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. NO. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 ACATTTCGCCTCTCTGCTG 736  
| | | | | | | | | | | | | | | | | |  
Db 19 ACATTTCGCCTCTCTGCTG 1

RESULT 18  
ADR82260/c

ID  
XX  
AC ADR82260 standard; DNA; 19 BP.  
XX  
DT 16-DEC-2004 (first entry)  
XX  
DE Hepatitis C virus (HCV) oligonucleotide seqid 6759.  
XX  
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2004080406-A2.  
XX  
PD 23-SEP-2004.  
XX  
PF 08-MAR-2004; 2004WO-US0007070.  
XX  
PR 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.  
PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX  
PA (ALNY-) ALNYLAM PHARM.  
XX  
PI Manoharan M, Bumcrot D;  
XX  
DR WPI; 2004-677362/66.  
XX  
PT Interference RNA agent useful for treating dyslipidemias, coronary artery

PT disease, diabetes, cancer or neurological disease, comprises sense

PT sequence and antisense sequence which has specific modifications.

XX  
PS Example 5; SEQ ID NO 6759; 378pp; English.

XX  
CC The invention describes a RNA interference (iRNA) agent (I) comprising a

CC sense sequence and an antisense sequence, where the sense sequences have

CC one or more asymmetrical 2'-O alkyl modifications, the antisense

CC sequences have one or more asymmetrical phosphorothioate modifications

CC and the antisense sequence targets a human gene sequence. Also described

CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100

CC levels or glucose-6-phosphatase levels in a subject; producing (I);

CC stabilising (I), involves selecting a sequence with activity and

CC introducing one or more asymmetrical modification in the sequence, where

CC the modification decreases nuclease sensitivity while not decreasing its

CC activity; a kit comprising (I) and instruction for its use; and a device

CC that can be dispense or administer a composition comprising (I). (I) is

CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)

CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.

CC The subject is suffering from a disorder characterised by elevated or

CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted

CC levels of cholesterol, and/or dysregulation of lipid metabolism. The

CC disorder is chosen from the HDL/LDL cholesterol imbalance,

CC dyslipidaemias, hypercholesterolaemia, statin-resistant



XX The present invention describes a method for predicting, diagnosing or  
CC prognosing chronic lung disease by detecting a chronic obstructive  
CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to  
CC ACC46777, which encode the COPD related proteins in ABP96779 to  
CC ABP96806). The method is useful for predicting, diagnosing or prognosing  
CC chronic lung disease in a biological sample. The COPD genes and proteins  
CC encoded by them from the present invention (I) can be used for treating  
CC or preventing chronic lung disease in a mammal. (I) can be used in an  
CC animal model for determining the efficacy, toxicity, or side effects of  
CC treatment with (I), and determining the mechanism of action of (I).  
CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used  
CC in an example from the present invention  
XX  
SQ Sequence 24 BP; 6 A; 5 C; 3 G; 10 T; 0 U; 0 Other;  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 42;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 981 TGCTTACGAAATTGAAAGCAGAAA 1004  
Db 24 TGCTTATGAAATTGAAGCCAGAAA 1  
RESULT 15  
ADG76001/c  
ID ADG76001 standard; DNA; 24 BP.  
XX  
AC ADG76001;  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Non-CpG DNA oligonucleotide 2.  
XX  
KW ss; non-CpG; immunostimulatory; non-palindromic; immune response;  
KW proliferation; differentiation; cytokine; antibody production; B-cell;  
KW plasmacytoid dendritic cell; immunomodulator; gene therapy;  
KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;  
KW renal cell carcinoma.  
XX  
OS Synthetic.  
XX  
PN WO2003101375-A2.  
XX  
PD 11-DEC-2003.  
XX  
PF 30-MAY-2003; 2003WO-EP005691.  
XX  
PR 30-MAY-2002; 2002CA-02388049.  
XX  
PA (IMMU-) IMMUNOTECH SA.  
XX  
PI Lopez RA;  
XX  
DR WPI; 2004-053333/05.  
XX  
PT New immunostimulatory oligonucleotide comprising non-palindromic nucleic  
PT acid sequence motif, useful for inducing B-cell activation, treating,  
PT preventing or ameliorating immune system disorder or tumoral disease e.g.  
PT melanoma.  
XX  
PS Example 17; Page 80; 139pp; English.  
XX  
CC This invention relates to novel immunostimulatory oligonucleotides that  
CC contain a non-palindromic sequence motif. Specifically, it refers to DNA  
CC oligonucleotides (without a CpG motif), which can stimulate an immune  
CC response in animals of the order of primate, including humans. The immune  
CC response is characterised by the proliferation, differentiation, cytokine  
CC and antibody production in B-cells, as well as cell differentiation and  
CC cytokine production in plasmacytoid dendritic cells. The present  
CC invention describes immunomodulator compositions that also comprise an  
CC antigen selected from, for example, viruses, bacteria, parasites, tumour  
CC cells and glycolipids. As such, these DNA oligos can be used in gene  
CC therapy for inducing B-cell activation, treating, preventing or  
CC ameliorating an immune system disorder or a tumoural disease including  
CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell  
CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the  
CC invention.

CC cells and glycolipids. As such, these DNA oligos can be used in gene  
CC therapy for inducing B-cell activation, treating, preventing or  
CC ameliorating an immune system disorder or a tumoural disease including  
CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell  
CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the  
CC invention.  
XX  
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 42;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAA 1772  
Db 24 AAAAAAAAAAAAAAAAAACAAAAAACAA 1  
RESULT 16  
ADG76035/c  
ID ADG76035 standard; DNA; 24 BP.  
XX  
AC ADG76035;  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Non-CpG DNA oligonucleotide 36.  
XX  
KW ss; non-CpG; immunostimulatory; non-palindromic; immune response;  
KW proliferation; differentiation; cytokine; antibody production; B-cell;  
KW plasmacytoid dendritic cell; immunomodulator; gene therapy;  
KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;  
KW renal cell carcinoma.  
XX  
OS Synthetic.  
XX  
PN WO2003101375-A2.  
XX  
PD 11-DEC-2003.  
XX  
PF 30-MAY-2003; 2003WO-EP005691.  
XX  
PR 30-MAY-2002; 2002CA-02388049.  
XX  
PA (IMMU-) IMMUNOTECH SA.  
XX  
PI Lopez RA;  
XX  
DR WPI; 2004-053333/05.  
XX  
PT New immunostimulatory oligonucleotide comprising non-palindromic nucleic  
PT acid sequence motif, useful for inducing B-cell activation, treating,  
PT preventing or ameliorating immune system disorder or tumoral disease e.g.  
PT melanoma.  
XX  
PS Example 17; Page 81; 139pp; English.  
XX  
CC This invention relates to novel immunostimulatory oligonucleotides that  
CC contain a non-palindromic sequence motif. Specifically, it refers to DNA  
CC oligonucleotides (without a CpG motif), which can stimulate an immune  
CC response in animals of the order of primate, including humans. The immune  
CC response is characterised by the proliferation, differentiation, cytokine  
CC and antibody production in B-cells, as well as cell differentiation and  
CC cytokine production in plasmacytoid dendritic cells. The present  
CC invention describes immunomodulator compositions that also comprise an  
CC antigen selected from, for example, viruses, bacteria, parasites, tumour  
CC cells and glycolipids. As such, these DNA oligos can be used in gene  
CC therapy for inducing B-cell activation, treating, preventing or  
CC ameliorating an immune system disorder or a tumoural disease including  
CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell  
CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the  
CC invention.

RESULT 12  
ACD99368/c  
ID . ACD99368 standard; DNA; 24 BP.  
XX  
AC ACD99368;  
XX  
DT 25-SEP-2003 (first entry)  
XX  
DE Immunostimulatory nucleic acid #54.  
XX  
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;  
KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;  
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;  
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.  
XX  
OS Synthetic.  
XX  
PN US2003050268-A1.  
XX  
PD 13-MAR-2003.  
XX  
PF 29-MAR-2002; 2002US-00112653.  
XX  
PR 29-MAR-2001; 2001US-0279642P.  
XX  
PA (KRIE/) KRIEG A M.  
PA (BERG/) BERG D J.  
XX  
PI Krieg AM, Berg DJ;  
XX  
DR WPI; 2003-521815/49.  
XX  
PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,  
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel  
PT disease by administering an immunostimulatory nucleic acid.  
XX  
PS Disclosure; Page 10; 229pp; English.  
XX  
CC The invention describes a method of treating non-allergic inflammatory  
CC disease comprising administering to a subject having or at risk of  
CC developing a non-allergic inflammatory disease an immunostimulatory  
CC nucleic acid for prevention or treatment of the disease. The method is  
CC useful for treating non-allergic inflammatory diseases, such as  
CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or  
CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.  
CC This sequence represents an immunostimulatory nucleic acid  
XX  
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 42;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
Db ||||| ||||| ||||| ||||| ||  
24 AAAAAACAAAAAACAAAAAACAA 1  
  
RESULT 13  
ADB36437/c  
ID ADB36437 standard; DNA; 24 BP.  
XX  
AC ADB36437;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Immunostimulatory nucleic acid #51.  
XX  
KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;  
KW hypo-responsive subject; immunostimulatory.  
XX  
OS Synthetic.  
XX

PN US2003087848-A1.  
XX  
PD 08-MAY-2003.  
XX  
PF 02-FEB-2001; 2001US-00776479.  
XX  
PR 03-FEB-2000; 2000US-0179991P.  
XX  
PA (BRAT/) BRATZLER R L.  
PA (PETE/) PETERSEN D M.  
PA (FOUR/) FOURON Y.  
XX  
PI Bratzler RL, Petersen DM, Fouron Y;  
XX  
DR WPI; 2003-657977/62.  
XX  
PT Treating and/or preventing allergy or asthma using an immunostimulatory  
PT nucleic acid alone or in combination with an asthma/allergy medicament.  
XX  
PS Disclosure; Page 6; 221pp; English.  
XX  
CC The invention relates to a method of treating or preventing allergy or  
CC asthma which comprises administering to a subject a poly-G nucleic acid  
CC in an aerosol formulation. The methods and compositions of the present  
CC invention are useful for diagnosing and/or treating asthma and allergy  
CC especially in a hypo-responsive subject. The present sequence represents  
CC an immunostimulatory nucleic acid of the invention.  
XX  
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 42;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
Db ||||| ||||| ||||| ||||| ||  
24 AAAAAACAAAAAACAAAAAACAA 1  
  
RESULT 14  
ACC46843/c  
ID ACC46843 standard; DNA; 24 BP.  
XX  
AC ACC46843;  
XX  
DT 05-JUN-2003 (first entry)  
XX  
DE Human COPD related gene reverse PCR primer SEQ ID NO:122.  
XX  
KW Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;  
KW PCR primer; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200297127-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 28-MAY-2002; 2002WO-EP005835.  
XX  
PR 31-MAY-2001; 2001GB-00013266.  
XX  
PA (FARB ) BAYER AG.  
XX  
PI Oellers N, Gehrman M, Kallabis H, Hall R, Schulze T, Kroegel C;  
XX  
DR WPI; 2003-140492/13.  
XX  
PT Predicting, diagnosing or prognosing chronic lung disease, by detecting a  
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.  
XX  
PS Example 1; Page 212; 214pp; English.

CC behaviour in a non turbulent flow, in a micro flow path, where a large  
CC number of samples can be processed. This polynucleotide sequence  
CC represents an oligo used in the exemplification of the invention.  
XX  
SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
|||||  
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20  
  
RESULT 10  
AAF98935/c  
ID AAF98935 standard; DNA; 24 BP.  
XX  
AC AAF98935;  
XX  
DT 12-JUN-2001 (first entry)  
XX  
DE Immunostimulatory nucleic acid #51.  
XX  
KW Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;  
KW immunostimulatory; tumour; viral infection; bacterial infection;  
KW fungal infection; parasitic infection; cancer; asthma;  
KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.  
XX  
OS Synthetic.  
XX  
PN WO200122972-A2.  
XX  
PD 05-APR-2001.  
XX  
PF 25-SEP-2000; 2000WO-US026383.  
XX  
PR 25-SEP-1999; 99US-0156113P.  
PR 27-SEP-1999; 99US-0156135P.  
PR 23-AUG-2000; 2000US-0227436P.  
XX  
PA (IOWA ) UNIV IOWA RES FOUND.  
PA (COLE-) COLEY PHARM GMBH.  
XX  
PI Krieg AM, Schetter C, Vollmer J;  
XX  
DR WPI; 2001-273485/28.  
XX  
PT Vaccinating against tumors, infectious diseases, allergies and asthma  
PT using immunostimulatory Py-rich and TG nucleic acids.  
XX  
PS Disclosure; Page 39; 338pp; English.  
XX  
CC The present invention relates to a method for stimulating an immune  
CC response. The method comprises administering an immunostimulatory nucleic  
CC acid to a non-rodent subject in sufficient quantity to stimulate an  
CC immune response. The present sequence is one such immunostimulatory  
CC nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich  
CC (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects  
CC against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae  
CC and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,  
CC haemophilus, campylobacter, clostridium, Escherichia coli and/or  
CC staphylococcus), fungal antigens and/or parasitic antigens. The method is  
CC also useful for preventing cancer, asthma, infectious disease, allergy or  
CC immune deficiency. The present sequence can also be used to redirect a  
CC Th2 to a Th1 immune response and to activate immune cells. Note: the  
CC present sequence may have a phosphorothioate backbone  
XX  
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 42;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
|||||  
Db 24 AAAAAACAAAAAAACAAAAAACAA 1  
  
RESULT 11  
ABS77576/c  
ID ABS77576 standard; DNA; 24 BP.  
XX  
AC ABS77576;  
XX  
DT 13-DEC-2002 (first entry)  
XX  
DE Angiogenesis inhibitory oligonucleotide #60.  
XX  
KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;  
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;  
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;  
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;  
KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;  
KW plaque neovascularisation; telangiectasia; haemophilic joint;  
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;  
KW scleroderma; hypertrophic scar.  
XX  
OS Synthetic.  
XX  
PN WO200253141-A2.  
XX  
PD 11-JUL-2002.  
XX  
PF 14-DEC-2001; 2001WO-US048458.  
XX  
PR 14-DEC-2000; 2000US-0255534P.  
XX  
PA (COLE-) COLEY PHARM GROUP INC.  
XX  
PI Bratzler RL;  
XX  
DR WPI; 2002-566690/60.  
XX  
PT Inhibiting angiogenesis in a subject, involves administering at least one  
PT antiangiogenic nucleic acid molecule to the subject.  
XX  
PS Claim 2; Page 20; 276pp; English.  
XX  
CC The invention relates to inhibiting angiogenesis in a subject, comprising  
CC administering at least one antiangiogenic nucleic acid molecule. Also  
CC included is a kit comprising a first container housing the antiangiogenic  
CC nucleic acids, and instructions for administering them to a subject  
CC having a condition characterised by unwanted angiogenesis. The method is  
CC useful for inhibiting angiogenesis associated with solid tumour growth,  
CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,  
CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,  
CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,  
CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque  
CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma, and  
CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and  
CC hypertrophic scars. The present sequence is an antiangiogenic nucleic  
CC acid of the invention  
XX  
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 42;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
|||||  
Db 24 AAAAAACAAAAAAACAAAAAACAA 1







CC from the genes corresponding to the partial sequences given in ABZ82842  
CC to ABZ84764, or their fragments of at least 20 nucleotides, or homologues  
CC ; and (2) determining if a gene putatively identified to be a toxic  
CC response gene plays a role on toxic response pathways by determining the  
CC expression profile of the gene after exposure of cells or a human subject  
CC to a known toxic pharmaceutical or industrial agent, comprising: (a)  
CC exposing cells to an agent or isolating cells from a human subject who  
CC was exposed to an agent; (b) obtaining the test gene expression profile  
CC for a putatively identified toxic response gene after exposure to a known  
CC toxic pharmaceutical or industrial agent; and (c) comparing the test  
CC profile to the expression profile of a gene with a similar function or  
CC comparing the test profile to the expression profile of that gene after  
CC exposure to other known toxic compounds. The methods are useful for  
CC predicting and determining toxicological responses on a cellular, organ  
CC or system level. The arrays comprising the human genes are useful for  
CC toxicological screening of drugs, pharmaceutical compounds and chemicals  
XX  
SQ Sequence 26 BP; 7 A; 10 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.3%; Score 22.8; DB 1; Length 26;  
Best Local Similarity 92.3%; Pred. No. 15;  
Matches 24; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1370 CAAGCTGGTTGGTTGTTAGGAAGAA 1395  
Db | | | | | | | | | | | | | | | | | | | |  
26 CGAGCTGGTTCGGTTGTTAGGAAGAA 1

RESULT 6  
ADR44220  
ID ADR44220 standard; DNA; 25 BP.  
XX  
AC ADR44220;  
XX  
DT 04-NOV-2004 (first entry)  
XX  
DE Caenorhabditis elegans heat-shock promoter DNA #1.  
XX  
KW Nematode; gene therapy; tumour; cancer; heat-shock promoter; ss.  
XX  
OS Caenorhabditis elegans.

FH Key Location/Qualifiers  
FT misc\_feature 4 /tag= a  
FT /note= "N can be repeated X times"  
FT misc\_feature 22  
FT /tag= b  
FT /note= "N can be repeated Y times"

XX US2004161782-A1.  
PN  
XX  
XX  
PD 19-AUG-2004.  
XX  
XX  
PF 21-NOV-2003; 2003US-00719995.  
XX  
XX  
PR 22-MAY-2001; 2001EP-00201936.  
PR 22-MAY-2002; 2002WO-NL000322.  
PR 28-NOV-2002; 2002WO-WO095071.

XX (TIJS/) TIJSTERMAN M.  
PA (PLAS/) PLASTERK R H A.  
XX  
XX  
PI Tijsterman M, Plasterk RHA;  
XX  
XX WPI; 2004-603554/58.

XX Determining if a gene product/compound is involved in preventing  
PT replication error in a cell, useful for treating cancer, comprises  
PT determining expression level of a marker gene in a cell treated with a  
PT gene product inhibitor/compound.  
XX  
PS Disclosure; Fig 3; 25pp; English.

XX The present invention relates to a method for determining if a gene  
CC product or compound is involved in preventing replication error in a  
CC cell. The method involves providing a cell with a specific inhibitor for  
CC a gene product or with a compound and determining the expression level of  
CC a marker gene in the cell, where the expression level of the marker gene  
CC is dependent on the occurrence of a replication error. The invention is  
CC useful in gene therapy and for treating a subject having tumours or  
CC cancer. The present sequence is a Caenorhabditis elegans heat-shock  
CC promoter DNA. This sequence is used to illustrate the method of  
CC invention.

SQ Sequence 25 BP; 21 A; 0 C; 1 G; 1 T; 0 U; 2 Other;  
Query Match 1.2%; Score 22; DB 1; Length 25;  
Best Local Similarity 91.7%; Pred. No. 18;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1747 TGAAGAAAAAAGAAAAAAGAAAAA 1770  
Db | | | | | | | | | | | | | | | | | | | |  
2 TGAAGAAAAAAGAAAAAAGAAAAA 25

RESULT 7  
ADR44221  
ID ADR44221 standard; DNA; 24 BP.  
XX  
AC ADR44221;  
XX  
DT 04-NOV-2004 (first entry)

XX Caenorhabditis elegans heat-shock promoter DNA #2.  
XX  
KW Nematode; gene therapy; tumour; cancer; heat-shock promoter; ss.  
XX  
OS Caenorhabditis elegans.

FH Key Location/Qualifiers  
FT misc\_feature 4 /tag= a  
FT /note= "N can be repeated X times"  
FT misc\_feature 21  
FT /tag= b  
FT /note= "N can be repeated Y times"

XX US2004161782-A1.  
PN  
XX  
XX  
PD 19-AUG-2004.  
XX  
XX  
PF 21-NOV-2003; 2003US-00719995.  
XX  
XX  
PR 22-MAY-2001; 2001EP-00201936.  
PR 22-MAY-2002; 2002WO-NL000322.  
PR 28-NOV-2002; 2002WO-WO095071.

XX (TIJS/) TIJSTERMAN M.  
PA (PLAS/) PLASTERK R H A.  
XX  
XX  
PI Tijsterman M, Plasterk RHA;  
XX  
XX WPI; 2004-603554/58.

XX Determining if a gene product/compound is involved in preventing  
PT replication error in a cell, useful for treating cancer, comprises  
PT determining expression level of a marker gene in a cell treated with a  
PT gene product inhibitor/compound.  
XX  
PS Disclosure; Fig 3; 25pp; English.

XX The present invention relates to a method for determining if a gene  
CC product or compound is involved in preventing replication error in a  
CC cell. The method involves providing a cell with a specific inhibitor for  
CC a gene product or with a compound and determining the expression level of

PA (KRON/) KRONICK M N.  
XX  
PI Leproust EM, Amorese DA, Kronick MN;  
XX  
DR WPI; 2004-634540/61.  
XX  
PT Detection of deposition unit misalignment of in situ polymeric array  
PT synthesis device, by contacting test probe feature with different  
PT distinguishably labeled targets, and evaluating binding of labeled  
PT targets to test probe feature.  
XX  
PS Example 2; Page 16; 36pp; English.  
XX  
CC The invention relates to a method of detection of deposition unit  
CC misalignment of an in situ polymeric array synthesis device which  
CC comprises synthesising test probe feature(s) on substrate using in situ  
CC polymeric array synthesis device, contacting test probe feature with at  
CC least two different distinguishably labelled targets and evaluating  
CC binding of labelled targets to test probe feature to detect any pulse jet  
CC misalignment of polymeric array synthesis device. The method is useful  
CC for detecting deposition unit misalignment e.g. printhead misalignment,  
CC of an in situ polymeric, e.g. nucleic acid, array synthesis device. The  
CC method is easy to use, cost effective. effective at detecting printhead  
CC misalignments and may enable immediate detection and/or adjustments of  
CC one or more printheads of an in situ nucleic acid array synthesis fluid  
CC deposition device if misalignment is detected. The present sequence  
CC represents an oligonucleotide synthesised on a microarray.  
XX  
SQ Sequence 24 BP; 24 A; 0 C; 0 G; 0 T; 0 U; 0 Other;  
  
Query Match 1.3%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 8.8;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAA 1772  
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAA 24  
  
RESULT 4  
ADR48249/C  
ID ADR48249 standard; DNA; 24 BP.  
XX  
AC ADR48249;  
XX  
DT 18-NOV-2004 (first entry)  
XX  
DE Microarray synthesised oligonucleotide #13.  
XX  
KW ss; deposition unit misalignment; polymeric array synthesis;  
KW pulse jet misalignment; printhead misalignment; microarray.  
XX  
OS Synthetic.  
XX  
PN US2004170984-A1.  
XX  
PD 02-SEP-2004.  
XX  
PF 25-FEB-2003; 2003US-00374307.  
XX  
PR 25-FEB-2003; 2003US-00374307.  
XX  
PA (LEPR/) LEPROUST E M.  
PA (AMOR/) AMORESE D A.  
PA (KRON/) KRONICK M N.  
XX  
PI Leproust EM, Amorese DA, Kronick MN;  
XX  
DR WPI; 2004-634540/61.  
XX  
PT Detection of deposition unit misalignment of in situ polymeric array  
PT synthesis device, by contacting test probe feature with different  
PT distinguishably labeled targets, and evaluating binding of labeled

PT targets to test probe feature.  
XX  
PS Example 2; Page 16; 36pp; English.  
XX  
CC The invention relates to a method of detection of deposition unit  
CC misalignment of an in situ polymeric array synthesis device which  
CC comprises synthesising test probe feature(s) on substrate using in situ  
CC polymeric array synthesis device, contacting test probe feature with at  
CC least two different distinguishably labelled targets and evaluating  
CC binding of labelled targets to test probe feature to detect any pulse jet  
CC misalignment of polymeric array synthesis device. The method is useful  
CC for detecting deposition unit misalignment e.g. printhead misalignment,  
CC of an in situ polymeric, e.g. nucleic acid, array synthesis device. The  
CC method is easy to use, cost effective. effective at detecting printhead  
CC misalignments and may enable immediate detection and/or adjustments of  
CC one or more printheads of an in situ nucleic acid array synthesis fluid  
CC deposition device if misalignment is detected. The present sequence  
CC represents an oligonucleotide synthesised on a microarray.  
XX  
SQ Sequence 24 BP; 0 A; 0 C; 0 G; 24 T; 0 U; 0 Other;  
  
Query Match 1.3%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 8.8;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAA 1772  
Db 24 AAAAAAAAAAAAAAAAAAAAAAAAAA 1  
  
RESULT 5  
ABZ84111/c  
ID ABZ84111 standard; DNA; 26 BP.  
XX  
AC ABZ84111;  
XX  
DT 14-MAY-2003 (first entry)  
XX  
DE Toxicologically relevant rat PCR primer #1270.  
XX  
KW Toxicologically relevant gene; toxicological response; PCR primer; ss.  
XX  
OS Rattus sp.  
OS Synthetic.  
XX  
PN WO2003016500-A2.  
XX  
PD 27-FEB-2003.  
XX  
PF 16-AUG-2002; 2002WO-US026514.  
XX  
PR 16-AUG-2001; 2001US-0313080P.  
XX  
PA (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.  
XX  
PI Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schmeiser K;  
PI Alen P;  
XX  
DR WPI; 2003-268322/26.  
XX  
PT Determining a toxicological response to an agent, useful for screening of  
PT drugs, comprises comparing the expression profile of one or more human  
PT toxic response genes to a reference gene expression profile indicative of  
PT toxicity.  
XX  
PS Claim 1; Page 332; 455pp; English.  
XX  
CC The present invention describes a method (M1) for determining a  
CC toxicological response to an agent, which comprises comparing the  
CC expression profile of one or more human toxic response genes to a  
CC reference gene expression profile indicative of toxicity, and so  
CC determining the presence of a toxic response to the agent. Also  
CC described: (1) an array comprising one or more polynucleotides selected

PD 27-FEB-2003.  
XX  
PF 16-AUG-2002; 2002WO-US026514.  
XX  
XX 16-AUG-2001; 2001US-0313080P.  
PR  
XX (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.  
PA  
XX Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schmeiser K;  
PI Alen P;  
PI  
XX WPI; 2003-268322/26.  
DR  
XX Determining a toxicological response to an agent, useful for screening of  
XX drugs, comprises comparing the expression profile of one or more human  
PT toxic response genes to a reference gene expression profile indicative of  
PT toxicity.  
PT  
XX  
PS Claim 1; Page 332; 455pp; English.  
XX  
XX The present invention describes a method (M1) for determining a  
CC toxicological response to an agent, which comprises comparing the  
CC expression profile of one or more human toxic response genes to a  
CC reference gene expression profile indicative of toxicity, and so  
CC determining the presence of a toxic response to the agent. Also  
CC described: (1) an array comprising one or more polynucleotides selected  
CC from the genes corresponding to the partial sequences given in ABZ82842  
CC to ABZ84764, or their fragments of at least 20 nucleotides, or homologues  
CC ; and (2) determining if a gene putatively identified to be a toxic  
CC response gene plays a role on toxic response pathways by determining the  
CC expression profile of the gene after exposure of cells or a human subject  
CC to a known toxic pharmaceutical or industrial agent, comprising: (a)  
CC exposing cells to an agent or isolating cells from a human subject who  
CC was exposed to an agent; (b) obtaining the test gene expression profile  
CC for a putatively identified toxic response gene after exposure to a known  
CC toxic pharmaceutical or industrial agent; and (c) comparing the test  
CC profile to the expression profile of a gene with a similar function or  
CC comparing the test profile to the expression profile of that gene after  
CC exposure to other known toxic compounds. The methods are useful for  
CC predicting and determining toxicological responses on a cellular, organ  
CC or system level. The arrays comprising the human genes are useful for  
CC toxicological screening of drugs, pharmaceutical compounds and chemicals  
XX  
SQ Sequence 26 BP; 7 A; 8 C; 5 G; 6 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 5.3;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 912 TGGGAGTCCAGCCACCACTTACTT 937  
Db 1 TGGGAGTCCAGCCACCACTTACTT 26  
  
RESULT 2  
ADR51048/c  
ID ADR51048 standard; DNA; 27 BP.  
XX  
AC ADR51048;  
XX  
DT 21-OCT-2004 (first entry)  
XX  
DE Duo binding moiety multivalent compound associated primer #1.  
XX  
KW ss; primer; antiarthritic; cytostatic; ophthalmological;  
KW angiogenesis inhibitor; Kdr tyrosine kinase inhibitor; VEGF antagonist;  
KW hepatocyte growth factor antagonist; multivalent compound;  
KW binding moiety; euplastic tumour growth; angiogenesis;  
KW hyperproliferation; arthritis; atherosclerotic plaque;  
KW corneal graft neovascularization; ocular disease.  
XX  
OS Synthetic.  
XX

PN WO2004064595-A2.  
XX  
PD 05-AUG-2004.  
XX  
PF 11-SEP-2003; 2003WO-US028838.  
XX  
PR 15-JAN-2003; 2003US-0440201P.  
PR 03-MAR-2003; 2003US-00379287.  
XX  
PA (BRAC ) BRACCO INT BV.  
PA (DYAX-) DYAX CORP.  
XX  
PI Arbogast C, Bussat P, Dransfield DT, Fan H, Linder K;  
PI Marinelli ER, Nanjappan P, Nunn A, Pillai R, Pochon S, Ramalingam K;  
PI Sato A, Shrivastava A, Song B, Swenson RE, Von Wronski MA;  
PI Walker SM;  
XX  
DR WPI; 2004-593275/57.  
XX  
PT Multivalent compounds with at least two binding moities having  
PT specificity for different binding sites on the same target, useful for  
PT treating and diagnosing, e.g. angiogenic and hyperproliferative  
PT disorders.  
XX  
PS Example 6; SEQ ID NO 72; 320pp; English.  
XX  
CC The invention relates to a multivalent compound (C) comprising at least  
CC two binding moities having specificity for different binding sites on  
CC the same target. (C) is useful for treating euplastic tumour growth and  
CC disease associated with angiogenesis or hyperproliferation (claimed). (C)  
CC is useful for treating diseases such as arthritis, atherosclerotic  
CC plaques, corneal graft neovascularization or ocular diseases. (C) is  
CC small and can more easily reach a target. (C) localizes more effectively  
CC to the target site than other targeting compounds due to its binding to  
CC more than one site on the same target. This sequence represents a DNA  
CC oligonucleotide used in the invention.  
XX  
SQ Sequence 27 BP; 0 A; 1 C; 1 G; 25 T; 0 U; 0 Other;  
  
Query Match 1.4%; Score 25.4; DB 1; Length 27;  
Best Local Similarity 96.3%; Pred. No. 6.9;  
Matches 26; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1748 GAAAAA  
Db 27 GCAAAAAA  
  
RESULT 3  
ADR48246  
ID ADR48246 standard; DNA; 24 BP.  
XX  
AC ADR48246;  
XX  
DT 18-NOV-2004 (first entry)  
XX  
DE Microarray synthesised oligonucleotide #10.  
XX  
KW ss; deposition unit misalignment; polymeric array synthesis;  
KW pulse jet misalignment; printhead misalignment; microarray.  
XX  
OS Synthetic.  
XX  
PN US2004170984-A1.  
XX  
XX 02-SEP-2004.  
XX  
PF 25-FEB-2003; 2003US-00374307.  
XX  
PR 25-FEB-2003; 2003US-00374307.  
XX  
PA (LEPR/) LEPROUST E M.  
PA (AMOR/) AMORESE D A.

C 107	14.4	0.8	17	1	ABZ60344	Human K-Ras DNazym
C 108	14.4	0.8	17	1	ADB40294	Tumour suppression
C 109	14.4	0.8	17	1	ADI48529	Human tumour suppr
C 110	14.4	0.8	17	1	ADI49691	Human tumour suppr
C 111	14.4	0.8	17	1	ACC51935	Human tumour suppr
C 112	14.4	0.8	17	1	ADL49154	Human PKR substrat
C 113	14.4	0.8	17	1	ADL49154	Human PKR substrat
C 114	14.4	0.8	17	1	ADL50592	Human PKR substrat
C 115	14.4	0.8	17	1	ADN45010	Mutant cell identi
C 116	14.4	0.8	17	1	ADN45011	Mutant cell identi
C 117	14.4	0.8	17	1	ACN73529	Human GDMPLP-1 prob
C 118	14.4	0.8	17	1	ACN73531	Human GDMPLP-1 prob
C 119	14.4	0.8	18	1	AAV70530	rpoB binding captu
C 120	14.4	0.8	18	1	AAS06835	SNP containing pro
C 121	14.4	0.8	18	1	ABK40971	Human obesity-asso
C 122	14.4	0.8	18	1	ABL44181	Human chromosome 1
C 123	14.4	0.8	18	1	ABL46141	Mycobacterium tube
C 124	14.4	0.8	18	1	ABS97172	Human CYP4501A2 Ex
C 125	14.4	0.8	18	1	ABN83386	Hepatocyte growth
C 126	14.4	0.8	18	1	ABX34397	PCR primer #2 for
C 127	14.4	0.8	18	1	ADK82331	Nucleic acid analy
C 128	14.4	0.8	18	1	ADQ93227	3-alpha-hydroxyste
C 129	14.4	0.8	18	1	ADQ93225	3-alpha-hydroxyste
C 130	14.4	0.8	18	1	ADS90092	Oligonucleotide of
C 131	14.2	0.8	19	1	ADR76235	Human apolipoprote
C 132	14.2	0.8	19	1	ABS97718	Human apolipoprote
C 133	14	0.8	15	1	ABS97731	Human kelleikrin 2
C 134	14	0.8	15	1	ABS97730	Human kelleikrin 2
C 135	14	0.8	15	1	ABL42626	Human kelleikrin 2
C 136	14	0.8	15	1	ABK98169	Hairpin beacon tar
C 137	14	0.8	15	1	ABK98187	Triple helix formi
C 138	14	0.8	15	1	ABK98167	Triple helix formi
C 139	14	0.8	15	1	ABK98168	Triple helix formi
C 140	14	0.8	15	1	ABK98167	Triple helix formi
C 141	14	0.8	15	1	ABK98186	Triple helix formi
C 142	14	0.8	16	1	AAT60192	Synthetic PCNA rib
C 143	14	0.8	16	1	AAA86559	PCNA hairpin riboz
C 144	14	0.8	16	1	AAA86780	PCNA hammerhead ri
C 145	14	0.8	16	1	AAH61725	PCNA hairpin/hamme
C 146	14	0.8	16	1	AAH61946	PCNA hammerhead ri
C 147	14	0.8	17	1	AAA36162	Human genomic SNP
C 148	14	0.8	17	1	AAF02752	Hammerhead ribozym
C 149	14	0.8	17	1	ABA78618	APC mutation corre
C 150	14	0.8	17	1	ABA78617	APC mutation corre
C 151	14	0.8	17	1	ABN10437	Human GDMPLP-1 17-m
C 152	14	0.8	17	1	ABN10438	Human GDMPLP-1 17-m
C 153	14	0.8	17	1	ABV80109	Human HTPL scannin
C 154	14	0.8	17	1	ABV80107	Human HTPL scannin
C 155	14	0.8	17	1	ABV80110	Human HTPL scannin
C 156	14	0.8	17	1	ABV80108	Human HTPL scannin
C 157	14	0.8	17	1	ABS75297	Human PAPP-Ea asso
C 158	14	0.8	17	1	ABS75299	Human PAPP-Ea asso
C 159	14	0.8	17	1	ABS75298	Human PAPP-Ea asso
C 160	14	0.8	17	1	ABS75300	Human PAPP-Ea asso
C 161	14	0.8	17	1	ABZ61011	Human K-Ras DNazym
C 162	14	0.8	17	1	ABZ61010	Human K-Ras DNazym
C 163	14	0.8	17	1	AAD48153	PCR primer #1 used
C 164	14	0.8	17	1	ACN73527	Human GDMPLP-1 prob
C 165	14	0.8	17	1	ACN73528	Human GDMPLP-1 prob
C 166	13.8	0.8	17	1	AAQ20006	Oligonucleotide #2
C 167	13.8	0.8	17	1	AAX63865	Rabbit stromelysin
C 168	13.8	0.8	17	1	AAX63906	Rabbit stromelysin
C 169	13.8	0.8	17	1	AAX63977	Rabbit stromelysin
C 170	13.8	0.8	17	1	AAX64062	Rabbit stromelysin
C 171	13.8	0.8	17	1	AAX63909	Rabbit stromelysin
C 172	13.8	0.8	17	1	AAX63885	Rabbit stromelysin
C 173	13.8	0.8	17	1	AAX63908	Rabbit stromelysin
C 174	13.8	0.8	17	1	AAX63864	Rabbit stromelysin
C 175	13.8	0.8	17	1	AAX63905	Rabbit stromelysin
C 176	13.8	0.8	17	1	AAX63884	Rabbit stromelysin
C 177	13.8	0.8	17	1	AAV25258	Primer R3 for H.py
C 178	13.8	0.8	17	1	AAT60238	ASO Q493XM represe
C 179	13.8	0.8	17	1	AAX73378	Mouse flk-1 VEGF r

C 180	13.8	0.8	17	1	AAAX75068	Mouse flt-1 VEGF r
C 181	13.8	0.8	17	1	AAAX73377	Mouse flk-1 VEGF r
C 182	13.8	0.8	17	1	AAAX75069	Mouse flt-1 VEGF r
C 183	13.8	0.8	17	1	AAAX69542	Human flt1 VEGF re
C 184	13.8	0.8	17	1	AAV85964	Mouse LRP-3 CDNA P
C 185	13.8	0.8	17	1	AAV26749	Retroviral vector
C 186	13.8	0.8	17	1	AAA19065	Human TIE-2 substr
C 187	13.8	0.8	17	1	AAA18786	Human TIE-2 substr
C 188	13.8	0.8	17	1	AAA25585	Oestrogen receptor
C 189	13.8	0.8	17	1	AAA25182	Oestrogen receptor
C 190	13.8	0.8	17	1	AAA25180	Oestrogen receptor
C 191	13.8	0.8	17	1	AAA25555	Oestrogen receptor
C 192	13.8	0.8	17	1	ABN00882	Human GDMPLP-1 17-m
C 193	13.8	0.8	17	1	ABN10436	Human GDMPLP-1 17-m
C 194	13.8	0.8	17	1	ABN10442	Human GDMPLP-1 17-m
C 195	13.8	0.8	17	1	ABQ64223	Human KTOM1a porti
C 196	13.8	0.8	17	1	ABS74897	Human PAPP-Ea asso
C 197	13.8	0.8	17	1	ABS75296	Human PAPP-Ea asso
C 198	13.8	0.8	17	1	ABS75295	Human PAPP-Ea asso
C 199	13.8	0.8	17	1	ABK57307	Human CLCA1 gene e
C 200	13.8	0.8	17	1	ABK55934	Human CLCA1 gene e
C 201	13.8	0.8	17	1	ABK56290	Human CLCA1 gene e
C 202	13.8	0.8	17	1	ABK56882	Human CLCA1 gene e
C 203	13.8	0.8	17	1	ACN07730	WNV minus strand H
C 204	13.8	0.8	17	1	ACN02884	WNV Inozyme substr
C 205	13.8	0.8	17	1	ACN06635	WNV Amberzyme subs
C 206	13.8	0.8	17	1	ACN07069	WNV Amberzyme subs
C 207	13.8	0.8	17	1	ACN07020	WNV Amberzyme subs
C 208	13.8	0.8	17	1	ACN07773	WNV minus strand H
C 209	13.8	0.8	17	1	ACN08010	WNV minus strand H
C 210	13.8	0.8	17	1	ACN08216	WNV minus strand H
C 211	13.8	0.8	17	1	ACN01062	WNV Hammerhead Rib
C 212	13.8	0.8	17	1	ABT35227	Tumour suppression
C 213	13.8	0.8	17	1	ADB05374	Human MDZ12 scanni
C 214	13.8	0.8	17	1	ADB03207	Human MDZ4 scanni
C 215	13.8	0.8	17	1	ADB05375	Human MDZ12 scanni
C 216	13.8	0.8	17	1	ADB03208	Human MDZ4 scanni
C 217	13.8	0.8	17	1	ADB00428	Human MDZ3 scanni
C 218	13.8	0.8	17	1	ADBZ60033	Human K-Ras DNazym
C 219	13.8	0.8	17	1	ACD55872	HBV amberzyme subs
C 220	13.8	0.8	17	1	ACC64538	Murine oligonucleo
C 221	13.8	0.8	17	1	ACC65475	Murine oligonucleo
C 222	13.8	0.8	17	1	ADB42757	Tumour suppression
C 223	13.8	0.8	17	1	ACC53133	Human tumour suppr
C 224	13.8	0.8	17	1	ADL47256	Human NOGO recepto
C 225	13.8	0.8	17	1	ADL49748	Human PKR substrat
C 226	13.8	0.8	17	1	ADM60332	Hepatitis B virus
C 227	13.8	0.8	17	1	ACN73526	Human GDMPLP-1 prob
C 228	13.8	0.8	17	1	ACN63972	Human GDMPLP-1 prob
C 229	13.8	0.8	17	1	ACN73532	Human GDMPLP-1 prob
C 230	13.6	0.8	15	1	AAS19935	ASO primer #15 to

## ALIGNMENTS

RESULT 1  
ABZ84116  
ID ABZ84116 standard; DNA; 26 BP.  
XX  
AC ABZ84116;  
XX  
DT 14-MAY-2003 (first entry)  
XX  
DE Toxicologically relevant rat PCR primer #1275.  
KW Toxicologically relevant gene; toxicological response; PCR primer; ss.  
XX Rattus sp.  
OS Synthetic.  
XX  
PN WO2003016500-A2.  
XX



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:20:39 ; Search time 3 Seconds  
(without alignments)  
4.905 Million cell updates/sec

Title: US-10-619-906-2  
Perfect score: 1790  
Sequence: 1 atgaaatttctcatgatg.....aaaaacggaattcccgggga 1790

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 228 seqs, 4110 residues

Total number of hits satisfying chosen parameters: 456

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 230 summaries

Database : rng2.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	26	1.5	26	1	ABZ84116
2	25.4	1.4	27	1	ADR51048
3	24	1.3	24	1	ADR48246
4	24	1.3	24	1	ADR48249
5	22.8	1.3	26	1	ABZ84111
6	22	1.2	25	1	ADR44220
7	21	1.2	24	1	ADR44221
8	20.2	1.1	22	1	ADS13095
9	20	1.1	20	1	ADR69805
10	19.2	1.1	24	1	AAF98935
11	19.2	1.1	24	1	ABS77576
12	19.2	1.1	24	1	ACD99368
13	19.2	1.1	24	1	ADB36437
14	19.2	1.1	24	1	ACC46843
15	19.2	1.1	24	1	ADG76001
16	19.2	1.1	24	1	ADG76035
17	19	1.1	19	1	ADI53690
18	19	1.1	19	1	ADR82260
19	19	1.1	19	1	ADR82257
20	19	1.1	19	1	ADR82261
21	19	1.1	19	1	ADR82258
22	19	1.1	19	1	ADR82256
23	19	1.1	19	1	ADR82255
24	19	1.1	21	1	AAH62035
25	18.6	1.0	23	1	AAT70486
26	18.4	1.0	21	1	ADQ93500
27	18.4	1.0	21	1	ADQ93681
28	18	1.0	18	1	ADR32355
29	18	1.0	18	1	ADR57967
30	17.8	1.0	21	1	ADQ93499
31	17.8	1.0	21	1	ADQ93682
32	17.8	1.0	21	1	ADQ93680
33	17.8	1.0	21	1	ADQ93501

34	17	0.9	18	1	AAZ64428	Human stromelysin
35	17	0.9	19	1	ADR81681	Hepatitis C virus
36	16.8	0.9	20	1	AAZ90012	PCR primer corres
37	16.8	0.9	20	1	AAZ90013	PCR primer corres
38	16.8	0.9	20	1	AAZ88394	Metalloproteinase
39	16.8	0.9	20	1	AAZ88395	Metalloproteinase
40	16.8	0.9	20	1	AAF90500	COL1A1 gene antise
41	16.8	0.9	20	1	ADI27533	Human DRAK1 DNA, a
42	16.8	0.9	20	1	ADK80790	Chimeric phosphoro
43	16.8	0.9	21	1	AAQ65723	HIV-1 antisense RN
44	16.8	0.9	21	1	AAF87025	Sequencing primer
45	16.8	0.9	21	1	ACF04639	Murine tumour chro
46	16.4	0.9	18	1	ADQ93226	3-alpha-hydroxyste
47	16.4	0.9	19	1	ADF36099	Human VEGFR1 short
48	16.4	0.9	19	1	ADF36526	Human VEGFR1 short
49	16.4	0.9	20	1	AAQ95937	Primer A (Group 13
50	16.4	0.9	20	1	AAZ78290	Human matrilysin P
51	16.4	0.9	20	1	ACC57867	Matrix metalloprot
52	16.4	0.9	20	1	ADH14321	Human retinoblasto
53	16	0.9	17	1	ABK03146	Human CD20 Inozyme
54	16	0.9	20	1	AAZ18855	Growth hormone 1 g
55	16	0.9	20	1	ABT15831	Human GU protein a
56	16	0.9	20	1	ADC61334	Human Growth Hormo
57	16	0.9	20	1	ACC58406	Human growth hormo
58	16	0.9	20	1	ADP19711	Human GH1 gene PCR
59	15.8	0.9	19	1	AAZ86458	PCBA HH ribozyme b
60	15.8	0.9	19	1	AAH61620	PCNA HH ribozyme b
61	15.8	0.9	19	1	ACA62442	HCV core protein f
62	15.8	0.9	19	1	ADI53700	Human MMP-12 antise
63	15.8	0.9	19	1	ADI53698	Human MMP-12 antise
64	15.8	0.9	19	1	ADR76235	Human apolipoprote
65	15.8	0.9	19	1	ADR78853	Human apolipoprote
66	15.4	0.9	17	1	AAZ63863	Rabbit stromelysin
67	15.4	0.9	17	1	ABK03147	Human CD20 Inozyme
68	15.4	0.9	17	1	ABK02767	Human CD20 Hammerh
69	15.4	0.9	17	1	ABN10440	Human GDMLP-1 17-m
70	15.4	0.9	17	1	ACN05195	WNV DNAzyme substr
71	15.4	0.9	17	1	ABZ22228	Transposon inserti
72	15.4	0.9	17	1	ADR05333	Silkworm juvenile
73	15.4	0.9	17	1	ACN73530	Human GDMLP-1 prob
74	15	0.8	15	1	AAZ31503	Tag sequence of a
75	15	0.8	15	1	ABK32457	Human pancreatic c
76	15	0.8	15	1	ADQ81798	Oligonucleotide sy
77	15	0.8	17	1	ABK03571	Human CD20 DNAzyme
78	15	0.8	17	1	ADI83540	HCV DNAzyme substr
79	14.8	0.8	18	1	AAQ57225	Enzymatic RNA mole
80	14.8	0.8	18	1	AAQ93482	Hammerhead ribozym
81	14.8	0.8	18	1	AAZ64488	Rabbit stromelysin
82	14.8	0.8	18	1	AAZ63389	Rabbit stromelysin
83	14.8	0.8	18	1	AAZ64436	Human stromelysin
84	14.8	0.8	18	1	AAZ64464	Human stromelysin
85	14.8	0.8	18	1	AAV33107	Rabbit stromelysin
86	14.8	0.8	18	1	AAZ56071	Stromelysin primer
87	14.8	0.8	18	1	AAZ71138	Phospholipase A2 g
88	14.8	0.8	18	1	ADQ78196	Human biallelic ma
89	14.8	0.8	18	1	ADS90796	PCR primer used to
90	14.4	0.8	16	1	ABL57076	Oligonucleotide of
91	14.4	0.8	16	1	AAD57846	Molecular beacon t
92	14.4	0.8	16	1	ADF23332	Target oligonucleo
93	14.4	0.8	16	1	ADF23332	Binding partner sc
94	14.4	0.8	16	1	ADS15827	Control probe targ
95	14.4	0.8	17	1	AAT81521	Human c-myb hamme
96	14.4	0.8	17	1	AAZ63814	Rabbit stromelysin
97	14.4	0.8	17	1	AAZ73080	Mouse flk-1 VEGF r
98	14.4	0.8	17	1	AAA21150	Integrin alpha 6 s
99	14.4	0.8	17	1	ABK03148	Human CD20 Inozyme
100	14.4	0.8	17	1	ABN10441	Human GDMLP-1 17-m
101	14.4	0.8	17	1	ABN10439	Human GDMLP-1 17-m
102	14.4	0.8	17	1	ABK26319	Increased starch p
103	14.4	0.8	17	1	ABK26320	Increased starch p
104	14.4	0.8	17	1	ACN06634	WNV Amberzyme subs
105	14.4	0.8	17	1	ACN10573	WNV minus strand I
106	14.4	0.8	17	1	ACN08217	WNV minus strand H
	14.4	0.8	17	1	ABT34768	Tumour suppression

Job time : 3 secs

---

```

FEATURES
  source
    /organism='Artificial Sequence'.
    Location/Qualifiers
      1..15
        /organism="synthetic construct"
        /mol_type="genomic DNA"
        /db_xref="taxon:32630"

  Query Match
    0.7%; Score 13.4; DB 1; Length 15;
  Best Local Similarity
    93.3%; Pred. No. 84;
  Matches
    14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 1 AAAAAAAAAAAAAA 15

RESULT 180
AX632930
LOCUS
  AX632930
  Sequence 69 from Patent EP1260586.
  15 bp RNA
  linear PAT 21-FEB-2003
ACCESSION
  AX632930
VERSION
  AX632930.1 GI:28468544
KEYWORDS
  unidentified
SOURCE
  unidentified
  unclassified.
REFERENCE
  1
  Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
  Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL
  Patent: EP 1260586-A 69 27-NOV-2002;
  RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    /organism="unidentified"
    /mol_type="unassigned RNA"
    /db_xref="taxon:32644"

  Query Match
    0.7%; Score 13.4; DB 1; Length 15;
  Best Local Similarity
    93.3%; Pred. No. 84;
  Matches
    14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 969 TGCTATTCAAGCTGC 983
Db 1 TGCTATTCAAACTGC 15

RESULT 181
CQ831855
LOCUS
  CQ831855
  Sequence 30 from Patent WO2004057029.
  16 bp DNA
  linear PAT 29-JUL-2004
ACCESSION
  CQ831855
VERSION
  CQ831855.1 GI:50831730
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Cooper,D.N., Krawczak,M. and Hedderich,J.
  Haplotype partitioning
  Patent: WO 2004057029-A 30 08-JUL-2004;
  University of Wales College of Medicine (GB)
FEATURES
  source
    Location/Qualifiers
      1..16
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

  misc_feature
    3
```

```

/note="n may be any nucleotide"

  Query Match
    0.7%; Score 13.4; DB 1; Length 16;
  Best Local Similarity
    87.5%; Pred. No. 94;
  Matches
    14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1381 GGTTGTTAGGAAGAAT 1396
Db 1 GGNGGTTAGGAAGAAT 16

RESULT 182
AR328665/c
LOCUS
  AR328665
  Sequence 6067 from patent US 6566127.
  16 bp RNA
  linear PAT 17-AUG-2003
DEFINITION
  AR328665
ACCESSION
  AR328665
VERSION
  AR328665.1 GI:33714473
KEYWORDS
  Unknown.
SOURCE
  Unknown.
  Unclassified.
REFERENCE
  1 (bases 1 to 16)
  Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  Method and reagent for the treatment of diseases or conditions
  related to levels of vascular endothelial growth factor receptor
  Patent: US 6566127-A 6067 20-MAY-2003;
JOURNAL
  Patent: US 6566127-A 6067 20-MAY-2003;
FEATURES
  source
    Location/Qualifiers
      1..16
        /organism="unknown"
        /mol_type="unassigned RNA"

  Query Match
    0.7%; Score 13.4; DB 1; Length 16;
  Best Local Similarity
    93.3%; Pred. No. 94;
  Matches
    14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACACATAGTT 1532
Db 15 CACACACACACAGTT 1

RESULT 183
AX458441/c
LOCUS
  AX458441
  Sequence 26 from Patent WO0246457.
  16 bp DNA
  linear PAT 08-JUL-2002
DEFINITION
  AX458441
ACCESSION
  AX458441.1 GI:21725107
VERSION
  AX458441.1 GI:21725107
KEYWORDS
  synthetic construct
SOURCE
  synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1
  Fischer,A. and Newrzella,D.
  Method for encoding hybridization probes
  Patent: WO 0246457-A 26 13-JUN-2002;
  Axaron Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..16
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Oligonukleotid 1-TACG- zur Herstellung des Encoders
        1-TACG (Beispiel 2)"

  Query Match
    0.7%; Score 13.4; DB 1; Length 16;
  Best Local Similarity
    93.3%; Pred. No. 94;
  Matches
    14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1402 GAAGGGTGCTTGCTG 1416
Db 15 GAAGGATGCTTGCTG 1

Search completed: May 13, 2005, 12:18:38
```

JOURNAL Patent: JP 2002501376-A 326 15-JAN-2002;  
THE WELLCOME TRUST LTD AS TRUSTEE TO THE WELLCOME TRUST, MERCK & CO  
INC  
COMMENT PN JP 2002501376-A/326  
PD 15-JAN-2002  
PF 15-APR-1998 JP 1998543635  
PR 15-APR-1997 US 60/043553,05-JUN-1997 US 60/048740 PI  
JOHN ANDREW TODD,JOHN WILFRED HESS,CHARLES  
THOMAS CASKEY,ROGER  
PI DAVID COX,  
PI DAVID GERHOLD,HOLLY HAMMOND,PATRICIA HEY  
PC C12N15/12,C12N15/11,C12Q1/68,C07K14/705,C07K16/28,A61K38/17,  
PC A61K39/395,  
PC A61K48/00  
CC Strandedness: Single;  
CC Topology: Linear;  
FH Key Location/Qualifiers.  
FEATURES  
source  
1..17  
/organism="Chlamydia sp."  
/mol\_type="genomic DNA"  
/db\_xref="taxon:35827"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 762 CTATGGAGCCCCAGTGA 778  
Db 17 CCATGGAGCCCGAGTGA 1  
RESULT 176  
AR055837  
LOCUS AR055837 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 41 from patent US 5837542.  
ACCESSION AR055837  
VERSION AR055837.1 GI:5981414  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 41 17-NOV-1998;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.7%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 84;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 969 TGCTATTCAAGCTGC 983  
Db 1 TGCTATTCAAACCTGC 15  
RESULT 177  
AR113595  
LOCUS AR113595 15 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 41 from patent US 6132967.  
ACCESSION AR113595  
VERSION AR113595.1 GI:14093917  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and

Draper,K.G.  
Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)  
Patent: US 6132967-A 41 17-OCT-2000;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.7%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 84;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 969 TGCTATTCAAGCTGC 983  
Db 1 TGCTATTCAAACCTGC 15  
RESULT 178  
AR133315  
LOCUS AR133315 15 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1740 from patent US 6194150.  
ACCESSION AR133315  
VERSION AR133315.1 GI:14122220  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.,  
TITLE Nucleic acid based inhibition of CD40  
JOURNAL Patent: US 6194150-A 1740 27-FEB-2001;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.7%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 84;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1483 ATAATGTAAACAGGAA 1497  
Db 1 AGAATGTAAACAGGAA 15  
RESULT 179  
BD244856  
LOCUS BD244856 15 bp DNA linear PAT 17-JUL-2003  
DEFINITION Oligonucleotide primer capable of making the non-specific double strand formation unstable.  
ACCESSION BD244856  
VERSION BD244856.1 GI:33054626  
KEYWORDS JP 2002532063-A/1.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Pelletier,J. and Das,M.  
TITLE Oligonucleotide primer capable of making the non-specific double strand formation unstable  
JOURNAL Patent: JP 2002532063-A 1 02-OCT-2002;  
MCGILL UNIVERSITY  
COMMENT OS Artificial Sequence  
PN JP 2002532063-A/1  
PD 02-OCT-2002  
PF 06-OCT-1999 JP 2000574722  
PR 07-OCT-1998 CA 2246623  
PI JERRY PELLETIER,MANJULA DAS  
PC C12N15/09,C12Q1/68,C12N15/00  
CC Description of Artificial Sequence: synthetic oligonucleotide  
FH Key Location/Qualifiers  
FT source 1..15



RESULT 171  
AX724098/c  
LOCUS AX724098 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 1785 from Patent WO03025176.  
ACCESSION AX724098  
VERSION AX724098.1 GI:30503441  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025176-A 1785 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1602 TTGAAAGTGCATGCTC 1618  
Db |||||  
17 TTGAAAGTGATGGATC 1  
RESULT 172  
AX725035  
LOCUS AX725035 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 2722 from Patent WO03025176.  
ACCESSION AX725035  
VERSION AX725035.1 GI:30504378  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025176-A 2722 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 330 GATCTATAATTACACTC 346  
Db |||||  
1 GATCGAAATTAATCACTC 17  
RESULT 173  
AX729230  
LOCUS AX729230 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 864 from Patent WO03025175.  
ACCESSION AX729230  
VERSION AX729230.1 GI:30508573  
KEYWORDS

SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 864 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1120 GATGCAGCTGTCTTTGA 1136  
Db |||||  
1 GATCCAGATGTCTTTGA 17  
RESULT 174  
AX759759  
LOCUS AX759759 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 3080 from Patent WO03040369.  
ACCESSION AX759759  
VERSION AX759759.1 GI:32254375  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion,  
apoptosis and/or viral resistance phenomena and their use as  
medicines  
JOURNAL Patent: WO 03040369-A 3080 15-MAY-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1120 GATGCAGCTGTCTTTGA 1136  
Db |||||  
1 GATCCAGCTGTCTCTGA 17  
RESULT 175  
BD106311/c  
LOCUS BD106311 17 bp DNA linear PAT 18-SEP-2002  
DEFINITION Novel LDL-receptor.  
ACCESSION BD106311  
VERSION BD106311.1 GI:23201129  
KEYWORDS JP 2002501376-A/326.  
SOURCE Chlamydia sp.  
ORGANISM Chlamydia sp.  
Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.  
1 (bases 1 to 17)  
REFERENCE  
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D., Hammond,H.  
and Hey,P.  
TITLE Novel LDL-receptor

mdz12  
JOURNAL Patent: EP 1281758-A 1414 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 41 CCTGTGGGGCTGCTCCC 57  
| | | | | | | | | | | | | | |  
Db 17 CTTGTGGGGCTTCTCCC 1

RESULT 167  
AX691461/c 17 bp DNA linear PAT 31-MAR-2003  
LOCUS  
DEFINITION Sequence 4193 from Patent EP1281758.  
ACCESSION AX691461  
VERSION AX691461.1 GI:29414397  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 4193 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1297 TACATCTTCCAAGGAGC 1313  
| | | | | | | | | | | | | | |  
Db 17 TACCTGTTCCAAGGAGC 1

RESULT 168  
AX691462/c 17 bp DNA linear PAT 31-MAR-2003  
LOCUS  
DEFINITION Sequence 4194 from Patent EP1281758.  
ACCESSION AX691462  
VERSION AX691462.1 GI:29414398  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 4194 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1296 CTACATCTTCCAAGGAG 1312  
| | | | | | | | | | | | | | |  
Db 17 CTACCTGTTCCAAGGAG 1

RESULT 169  
AX693628 17 bp DNA linear PAT 31-MAR-2003  
LOCUS  
DEFINITION Sequence 6360 from Patent EP1281758.  
ACCESSION AX693628  
VERSION AX693628.1 GI:29416677  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 6360 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 TGTCAACCAAGCTTGAG 839  
| | | | | | | | | | | | | | |  
Db 1 TGTCACAAAAGCTTCAG 17

RESULT 170  
AX693629 17 bp DNA linear PAT 31-MAR-2003  
LOCUS  
DEFINITION Sequence 6361 from Patent EP1281758.  
ACCESSION AX693629  
VERSION AX693629.1 GI:29416678  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 6361 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 824 GTCACCAAAAGCTTGAGT 840  
| | | | | | | | | | | | | | |  
Db 1 GTCACAAAGCTTCAGT 17

DEFINITION Sequence 661 from Patent WO0211674.  
ACCESSION AX578823  
VERSION AX578823.1 GI:27648025  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.  
and Grupe,A.  
TITLE Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
JOURNAL Patent: WO 0211674-A 661 14-FEB-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1093 GGCTTCTCTGCATCTGT 1109  
Db 1 GGCATCTCTGTATCTGT 17  
RESULT 163  
AX579415/c  
LOCUS AX579415 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 1253 from Patent WO0211674.  
ACCESSION AX579415  
VERSION AX579415.1 GI:27648617  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.  
and Grupe,A.  
TITLE Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
JOURNAL Patent: WO 0211674-A 1253 14-FEB-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 7 TTTCTCATGATGATTGT 23  
Db 17 TTTCTCATGATGATTGT 1  
RESULT 164  
AX579840/c  
LOCUS AX579840 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 1678 from Patent WO0211674.  
ACCESSION AX579840  
VERSION AX579840.1 GI:27649042  
KEYWORDS  
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.  
and Grupe,A.  
TITLE Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
JOURNAL Patent: WO 0211674-A 1678 14-FEB-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 6 ATTTCTCATGATGATTG 22  
Db 17 ATTTCTCATGATGATTG 1  
RESULT 165  
AX673455/c  
LOCUS AX673455 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 1900 from Patent WO03004526.  
ACCESSION AX673455  
VERSION AX673455.1 GI:29331803  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 1900 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1297 TACATCTTCCAGGAGC 1313  
Db 17 TACATCTTCCAGGATC 1  
RESULT 166  
AX688682/c  
LOCUS AX688682 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1414 from Patent EP1281758.  
ACCESSION AX688682  
VERSION AX688682.1 GI:29411384  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

JOURNAL FEATURES source	predominantly in heart and muscle Patent: US 6686188-A 10428 03-FEB-2004; Location/Qualifiers 1. .17 /organism="unknown" /mol_type="genomic DNA"									
	Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;					
	Best Local Similarity	88.2%;	Pred. No. 93;							
	Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;					
QY	841 TTTGATGCTGTCAAC 857									
Db	17 TTTGATGCTGTCAAC 1									
RESULT 158										
AR466757/c										
LOCUS	AR466757		17 bp	DNA	linear	PAT 20-FEB-2004				
DEFINITION	Sequence 10434 from patent US 6686188.									
ACCESSION	AR466757									
VERSION	AR466757.1	GI:42701814								
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.									
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle									
JOURNAL	Patent: US 6686188-A 10434 03-FEB-2004;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="genomic DNA"									
Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;						
Best Local Similarity	88.2%;	Pred. No. 93;								
Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;						
QY	835 TTGAGTTTGTGCTGT 851									
Db	17 TCGACTTTTGTGCTGT 1									
RESULT 159										
AX166715										
LOCUS	AX166715		17 bp	DNA	linear	PAT 22-JUN-2001				
DEFINITION	Sequence 206 from Patent WO0138503.									
ACCESSION	AX166715									
VERSION	AX166715.1	GI:14546990								
KEYWORDS										
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	1									
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.									
TITLE	Flowman,G.D., Whyte,D., Manning,G.S., Sudarsanam,S.S., Martinez,R., Planagan,P. and Clary,D.S.									
JOURNAL	Novel human protein kinases and protein kinase-like enzymes									
FEATURES	Patent: WO 0138503-A 206 31-MAY-2001; Sugen, Inc. (US)									
source	Location/Qualifiers 1. .17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"									
Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;						
Best Local Similarity	88.2%;	Pred. No. 93;								
Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;						
QY	835 TTTGATGCTGTGCTGT 851									
Db	17 TCGACTTTTGTGCTGT 1									
RESULT 160										
AX475778/c										
LOCUS	AX475778		17 bp	DNA	linear	PAT 12-AUG-2002				
DEFINITION	Sequence 999 from Patent WO0224750.									
ACCESSION	AX475778									
VERSION	AX475778.1	GI:22215063								
KEYWORDS										
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	1									
AUTHORS	Zhang,J.									
TITLE	Human kidney tumor overexpressed membrane protein 1									
JOURNAL	Patent: WO 0224750-A 999 28-MAR-2002;									
FEATURES	Aeomica, Inc. (US) Location/Qualifiers 1. .17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"									
source										
Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;						
Best Local Similarity	88.2%;	Pred. No. 93;								
Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;						
QY	1459 TGCTCAGGCTGTAAC 1475									
Db	17 TGCTCAGGCTGGAAC 1									
RESULT 161										
AX578467/c										
LOCUS	AX578467		17 bp	RNA	linear	PAT 10-JAN-2003				
DEFINITION	Sequence 305 from Patent WO0211674.									
ACCESSION	AX578467									
VERSION	AX578467.1	GI:27647669								
KEYWORDS										
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	1									
AUTHORS	Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E. and Grupe,A.									
TITLE	Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)									
JOURNAL	Patent: WO 0211674-A 305 14-FEB-2002; RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ; Thompson, James (US)									
FEATURES	Location/Qualifiers 1. .17 /organism="Homo sapiens" /mol_type="unassigned RNA" /db_xref="taxon:9606"									
source										
Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;						
Best Local Similarity	88.2%;	Pred. No. 93;								
Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;						
QY	298 TCAAGATGGATGAAGCG 314									
Db	17 TCAAGCTGGATGGAGCG 1									
RESULT 162										
AX578823										
LOCUS	AX578823		17 bp	RNA	linear	PAT 10-JAN-2003				



AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 3603 20-MAY-2003;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1749 AAAAAAAAAAAAAAAAAA 1765  
Db 17 AAAAAAAAAACAAAAA 1

RESULT 153  
AR434000  
LOCUS AR434000 17 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 423 from patent US 6656700.  
ACCESSION AR434000  
VERSION AR434000.1 GI:40196843  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
TITLE Isoforms of human pregnancy-associated protein-E  
JOURNAL Patent: US 6656700-A 423 02-DEC-2003;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 39 TGCCCTGTGGGGTGCTC 55  
Db 1 TGCCCTGTGGGTCTTCTC 17

RESULT 154  
AR434398  
LOCUS AR434398 17 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 821 from patent US 6656700.  
ACCESSION AR434398  
VERSION AR434398.1 GI:40197241  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
TITLE Isoforms of human pregnancy-associated protein-E  
JOURNAL Patent: US 6656700-A 821 02-DEC-2003;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1176 CTACTGGAGGTATGATG 1192  
Db 1 CTAGGGGAGGTATGATG 17

RESULT 155  
AR434399  
LOCUS AR434399 17 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 822 from patent US 6656700.  
ACCESSION AR434399  
VERSION AR434399.1 GI:40197242  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
TITLE Isoforms of human pregnancy-associated protein-E  
JOURNAL Patent: US 6656700-A 822 02-DEC-2003;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1177 TACTGGAGGTATGATG 1193  
Db 1 TAGGGGAGGTATGATG 17

RESULT 156  
AR457197/c  
LOCUS AR457197 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 874 from patent US 6686188.  
ACCESSION AR457197  
VERSION AR457197.1 GI:42692254  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 874 03-FEB-2004;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1131 CTTTGACCCACTTCGCC 1147  
Db 17 CTTTGACCCCTCCTCGCC 1

RESULT 157  
AR466751/c  
LOCUS AR466751 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 10428 from patent US 6686188.  
ACCESSION AR466751  
VERSION AR466751.1 GI:42701808  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed

AUTHORS Todd, J.A., Hess, J.W., Caskey, C.T., Cox, R.D., Gerhold, D., Hammond, H., Hey, P., Kawaguchi, Y., Merriman, T.R., Metzker, M.L., Nakagawa, Y., Phillips, M.S. and Twells, R.C.J.

TITLE LDL-receptor

JOURNAL Patent: US 6555654-A 354 29-APR-2003;

FEATURES Location/Qualifiers

source 1. .17 /organism="unknown" /mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 93; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 762 CTATGGAGCCCCAGTGA 778

Db 17 CCATGGAGCCCCGAGTGA 1

RESULT 148

AR323435/c

LOCUS AR323435 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 837 from patent US 6566127.

ACCESSION AR323435

VERSION AR323435.1 GI:33709243

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 837 20-MAY-2003;

FEATURES Location/Qualifiers

source 1. .17 /organism="unknown" /mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 93; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 217 GACAACTCAACTCTGGC 233

Db 17 GACAACTCAACTCTGGC 1

RESULT 149

AR325562

LOCUS AR325562 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 2964 from patent US 6566127.

ACCESSION AR325562

VERSION AR325562.1 GI:33711370

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 2964 20-MAY-2003;

FEATURES Location/Qualifiers

source 1. .17 /organism="unknown" /mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 93; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 TACAGGTATCTGCCTGT 45

Db 1 TACTGGTTTCTGCCTGT 17

RESULT 150

AR325563

LOCUS AR325563 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 2965 from patent US 6566127.

ACCESSION AR325563

VERSION AR325563.1 GI:33711371

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 2965 20-MAY-2003;

FEATURES Location/Qualifiers

source 1. .17 /organism="unknown" /mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 93; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 ACAGGTATCTGCCTGTG 46

Db 1 ACTGGTTTCTGCCTGTG 17

RESULT 151

AR326200/c

LOCUS AR326200 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 3602 from patent US 6566127.

ACCESSION AR326200

VERSION AR326200.1 GI:33712008

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 3602 20-MAY-2003;

FEATURES Location/Qualifiers

source 1. .17 /organism="unknown" /mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 93; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1765

Db 17 AAACAAAAAAAAACAAAAAA 1

RESULT 152

AR326201/c

LOCUS AR326201 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 3603 from patent US 6566127.

ACCESSION AR326201

VERSION AR326201.1 GI:33712009

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 6127 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 29 TACAGGTATCTGCCTGT 45  
|||||  
Db 1 TACTGGTTTCTGCCCTGT 17  
RESULT 143  
AR190640  
LOCUS AR190640 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 6128 from patent US 6346398.  
ACCESSION AR190640  
VERSION AR190640.1 GI:20236605  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 6128 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 30 ACAGGTATCTGCCTGTG 46  
|||||  
Db 1 ACTGGTTTCTGCCTGTG 17  
RESULT 144  
AR192330/c  
LOCUS AR192330 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 7818 from patent US 6346398.  
ACCESSION AR192330  
VERSION AR192330.1 GI:20238295  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 7818 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAA 1765  
|||||

Db 17 AAAAAAAAAACAAAAA 1  
RESULT 145  
AR192331/c  
LOCUS AR192331 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 7819 from patent US 6346398.  
ACCESSION AR192331  
VERSION AR192331.1 GI:20238296  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 7819 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAA 1765  
|||||  
Db 17 AAAAAAAAAACAAAAA 1  
RESULT 146  
AR305400/c  
LOCUS AR305400 17 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 354 from patent US 6545137.  
ACCESSION AR305400  
VERSION AR305400.1 GI:31694710  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D., Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L., Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.  
TITLE Receptor  
JOURNAL Patent: US 6545137-A 354 08-APR-2003;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 762 CTATGGAGCCCCAGTGA 778  
|  
Db 17 CCATGGAGCCCCAGTGA 1  
RESULT 147  
AR309504/c  
LOCUS AR309504 17 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 354 from patent US 6555654.  
ACCESSION AR309504  
VERSION AR309504.1 GI:31701509  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)

REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 540 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 874 CTTTCTTTTAAAGACTG 890  
Db 1 CTGTTCTTTAAAGACAG 17  
RESULT 138  
I94378  
LOCUS 194378 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 541 from patent US 5731295.  
ACCESSION I94378  
VERSION I94378.1 GI:3938848  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 541 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 875 TTTTCTTTTAAAGACTGG 891  
Db 1 TGTCTCTTTAAAGACAG 17  
RESULT 139  
I94446  
LOCUS I94446 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 609 from patent US 5731295.  
ACCESSION I94446  
VERSION I94446.1 GI:3938916  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 609 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1179 CTGAGGTATGATGTGA 1195

Db 1 CTGGAGGTTTGATGAGA 17  
RESULT 140  
I94531/c  
LOCUS I94531 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 694 from patent US 5731295.  
ACCESSION I94531  
VERSION I94531.1 GI:3939001  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 694 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 896 TCTGGTGGAGCTTCCT 912  
Db 17 TCTCGTGGAGCTCCCT 1  
RESULT 141  
AR186804/c  
LOCUS AR186804 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 2292 from patent US 6346398.  
ACCESSION AR186804  
VERSION AR186804.1 GI:20232769  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2292 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 217 GACAACTCAACTCTGGC 233  
Db 17 GACAACTCAACTCTGGC 1  
RESULT 142  
AR190639  
LOCUS AR190639 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 6127 from patent US 6346398.  
ACCESSION AR190639  
VERSION AR190639.1 GI:20236604  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)



Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 497 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 631 CATGAACCTTGGCCATTC 647  
Db 1 CATGAGCTTGGCCACTC 17  
RESULT 133  
I94353  
LOCUS I94353 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 516 from patent US 5731295.  
ACCESSION I94353  
VERSION I94353.1 GI:3938823  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 516 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 750 CATTGAGTCCCTCTATG 766  
Db 1 CATCCAATCCCTCTATG 17  
RESULT 134  
I94354  
LOCUS I94354 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 517 from patent US 5731295.  
ACCESSION I94354  
VERSION I94354.1 GI:3938824  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 517 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 754 CAGTCCCTCTATGGAGC 770  
Db 1 CAATCCCTCTATGGACC 17  
RESULT 135  
I94374  
LOCUS I94374 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 537 from patent US 5731295.  
ACCESSION I94374  
VERSION I94374.1 GI:3938844  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 537 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 870 AATCCTTTTCTTTAAAG 886  
Db 1 AATTCTGTTCTTTAAAG 17  
RESULT 136  
I94375  
LOCUS I94375 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 538 from patent US 5731295.  
ACCESSION I94375  
VERSION I94375.1 GI:3938845  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 538 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 871 ATCCTTTTCTTTAAAGA 887  
Db 1 ATTCTGTTCTTTAAAGA 17  
RESULT 137  
I94377  
LOCUS I94377 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 540 from patent US 5731295.  
ACCESSION I94377  
VERSION I94377.1 GI:3938847  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 540 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	874	CTTTCTTTAAAGACTG	890							
Db	1	CTGTTCTTTAAAGACAG	17							
RESULT 128										
LOCUS	I37528									
DEFINITION	Sequence 541 from patent US 5612215.									
ACCESSION	I37528									
VERSION	I37528.1 GI:2085488									
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 541 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	875	TTTTCTTTAAAGACTGG	891							
Db	1	TGTTCTTTAAAGACAGG	17							
RESULT 129										
LOCUS	I37596									
DEFINITION	Sequence 609 from patent US 5612215.									
ACCESSION	I37596									
VERSION	I37596.1 GI:2085556									
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 609 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	876	TTTGTGTTCAAGCTT	639							
Db	1	TTGCTGCTCATGAGCTT	17							
RESULT 132										
LOCUS	I94334									
DEFINITION	Sequence 497 from patent US 5731295.									
ACCESSION	I94334									
VERSION	I94334.1 GI:3938804									
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 609 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	1179	CTGGAGGTATGATGTA	1195							
Db	1	CTGGAGGTTTGATGAGA	17							
RESULT 130										
I37681/c	I37681									
LOCUS	Sequence 694 from patent US 5612215.									
DEFINITION	I37681									
ACCESSION	I37681.1 GI:2085641									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 694 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	896	TCTGCTGGAAGCTTCCT	912							
Db	17	TCTCGTGGAGCTCCCT	1							
RESULT 131										
I94333	I94333									
LOCUS	Sequence 496 from patent US 5731295.									
DEFINITION	I94333									
ACCESSION	I94333.1 GI:3938803									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Method of reducing stromelysin RNA via ribozymes									
JOURNAL	Patent: US 5731295-A 496 24-MAR-1998;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	623	TTGCTGTTTCATGAAC	639							
Db	1	TTGCTGCTCATGAGCTT	17							
RESULT 132										
I94334	I94334									
LOCUS	Sequence 497 from patent US 5731295.									
DEFINITION	I94334									
ACCESSION	I94334.1 GI:3938804									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 609 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	1179	CTGGAGGTATGATGTA	1195							
Db	1	CTGGAGGTTTGATGAGA	17							
RESULT 130										
I37681/c	I37681									
LOCUS	Sequence 694 from patent US 5612215.									
DEFINITION	I37681									
ACCESSION	I37681.1 GI:2085641									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 694 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	896	TCTGCTGGAAGCTTCCT	912							
Db	17	TCTCGTGGAGCTCCCT	1							
RESULT 131										
I94333	I94333									
LOCUS	Sequence 496 from patent US 5731295.									
DEFINITION	I94333									
ACCESSION	I94333.1 GI:3938803									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Method of reducing stromelysin RNA via ribozymes									
JOURNAL	Patent: US 5731295-A 496 24-MAR-1998;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	623	TTGCTGTTTCATGAAC	639							
Db	1	TTGCTGCTCATGAGCTT	17							
RESULT 132										
I94334	I94334									
LOCUS	Sequence 497 from patent US 5731295.									
DEFINITION	I94334									
ACCESSION	I94334.1 GI:3938804									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 609 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	1179	CTGGAGGTATGATGTA	1195							
Db	1	CTGGAGGTTTGATGAGA	17							
RESULT 130										
I37681/c	I37681									
LOCUS	Sequence 694 from patent US 5612215.									
DEFINITION	I37681									
ACCESSION	I37681.1 GI:2085641									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 694 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	896	TCTGCTGGAAGCTTCCT	912							
Db	17	TCTCGTGGAGCTCCCT	1							
RESULT 131										
I94333	I94333									
LOCUS	Sequence 496 from patent US 5731295.									
DEFINITION	I94333									
ACCESSION	I94333.1 GI:3938803									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Method of reducing stromelysin RNA via ribozymes									
JOURNAL	Patent: US 5731295-A 496 24-MAR-1998;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	623	TTGCTGTTTCATGAAC	639							
Db	1	TTGCTGCTCATGAGCTT	17							
RESULT 132										
I94334	I94334									
LOCUS	Sequence 497 from patent US 5731295.									
DEFINITION	I94334									
ACCESSION	I94334.1 GI:3938804									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 609 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	1179	CTGGAGGTATGATGTA	1195							
Db	1	CTGGAGGTTTGATGAGA	17							
RESULT 130										
I37681/c	I37681									
LOCUS	Sequence 694 from patent US 5612215.									
DEFINITION	I37681									
ACCESSION	I37681.1 GI:2085641									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 694 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	896	TCTGCTGGAAGCTTCCT	912							
Db	17	TCTCGTGGAGCTCCCT	1							
RESULT 131										
I94333	I94333									
LOCUS	Sequence 496 from patent US 5731295.									
DEFINITION	I94333									
ACCESSION	I94333.1 GI:3938803									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Method of reducing stromelysin RNA via ribozymes									
JOURNAL	Patent: US 5731295-A 496 24-MAR-1998;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	623	TTGCTGTTTCATGAAC	639							
Db	1	TTGCTGCTCATGAGCTT	17							
RESULT 132										
I94334	I94334									
LOCUS	Sequence 497 from patent US 5731295.									
DEFINITION	I94334									
ACCESSION	I94334.1 GI:3938804									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 609 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	1179	CTGGAGGTATGATGTA	1195							
Db	1	CTGGAGGTTTGATGAGA	17							
RESULT 130										
I37681/c	I37681									
LOCUS	Sequence 694 from patent US 5612215.									
DEFINITION	I37681									
ACCESSION	I37681.1 GI:2085641									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Stromelysin targeted ribozymes									
JOURNAL	Patent: US 5612215-A 694 18-MAR-1997;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	896	TCTGCTGGAAGCTTCCT	912							
Db	17	TCTCGTGGAGCTCCCT	1							
RESULT 131										
I94333	I94333									
LOCUS	Sequence 496 from patent US 5731295.									
DEFINITION	I94333									
ACCESSION	I94333.1 GI:3938803									
VERSION										
KEYWORDS										
SOURCE	Unknown.									
ORGANISM	Unknown.									
REFERENCE	Unclassified.									
AUTHORS	1 (bases 1 to 17) Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.									
TITLE	Method of reducing stromelysin RNA via ribozymes									
JOURNAL	Patent: US 5731295-A 496 24-MAR-1998;									
FEATURES	Location/Qualifiers									
source	1. .17 /organism="unknown" /mol_type="unassigned DNA"									
Query Match	0.8%; Score 13.8; DB 1; Length 17;									
Best Local Similarity	88.2%; Pred. No. 93;									
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	623	TTGCTGTTTCATGAAC	639							
Db	1	TTGCTGCTCATGAGCTT	17							
RESULT 132										
I94334	I94334									
LOCUS	Sequence 497 from patent US 573									

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
TITLE Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and  
JOURNAL Stinchcomb,D.T.  
FEATURES Stromelysin targeted ribozymes  
Patent: US 5612215-A 497 18-MAR-1997;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 631 CATGAACCTGGCCATTC 647  
Db 1 CATGAGCTTGGCCACTC 17

RESULT 123  
I37503  
LOCUS I37503 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 516 from patent US 5612215.  
ACCESSION I37503  
VERSION I37503.1 GI:2085463  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
TITLE Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and  
JOURNAL Stinchcomb,D.T.  
FEATURES Stromelysin targeted ribozymes  
Patent: US 5612215-A 516 18-MAR-1997;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 750 CATTCAGTCCCTCTATG 766  
Db 1 CATCCAATCCCTCTATG 17

RESULT 124  
I37504  
LOCUS I37504 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 517 from patent US 5612215.  
ACCESSION I37504  
VERSION I37504.1 GI:2085464  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
TITLE Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and  
JOURNAL Stinchcomb,D.T.  
FEATURES Stromelysin targeted ribozymes  
Patent: US 5612215-A 517 18-MAR-1997;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 754 CAGTCCCTCTATGGAGC 770  
Db 1 CAATCCCTCTATGGACC 17

RESULT 125  
I37524  
LOCUS I37524 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 537 from patent US 5612215.  
ACCESSION I37524  
VERSION I37524.1 GI:2085484  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
TITLE Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and  
JOURNAL Stinchcomb,D.T.  
FEATURES Stromelysin targeted ribozymes  
Patent: US 5612215-A 537 18-MAR-1997;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTCTTTAAAG 886  
Db 1 AATCTGTTCTTTAAAG 17

RESULT 126  
I37525  
LOCUS I37525 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 538 from patent US 5612215.  
ACCESSION I37525  
VERSION I37525.1 GI:2085485  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
TITLE Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and  
JOURNAL Stinchcomb,D.T.  
FEATURES Stromelysin targeted ribozymes  
Patent: US 5612215-A 538 18-MAR-1997;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 871 ATCCTTTTCTTTAAAGA 887  
Db 1 ATTCTGTTCTTTAAAGA 17

RESULT 127  
I37527  
LOCUS I37527 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 540 from patent US 5612215.  
ACCESSION I37527  
VERSION I37527.1 GI:2085487  
KEYWORDS  
SOURCE Unknown.

FEATURES  
source Aeomica, Inc. (US)  
Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 CTTTGACCCACTTCGCC 1147  
|||||  
Db 17 CTTTGACCCCTCCTCGCC 1

RESULT 118  
CQ625688/c  
LOCUS CQ625688 17 bp DNA PAT 02-FEB-2004  
DEFINITION Sequence 10428 from Patent WO0192524.  
ACCESSION CQ625688  
VERSION CQ625688.1 GI:41675906  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10428 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 841 TTTGATGCTGTCAAC 857  
|||||  
Db 17 TTTGATGCTGTCAAC 1

RESULT 119  
CQ625694/c  
LOCUS CQ625694 17 bp DNA PAT 02-FEB-2004  
DEFINITION Sequence 10434 from Patent WO0192524.  
ACCESSION CQ625694  
VERSION CQ625694.1 GI:41675912  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10434 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 TTGAGTTTGATGCTGT 851  
|||||  
Db 17 TCGACTTTTGATGCTGT 1

RESULT 120  
I32565/c  
LOCUS I32565 17 bp DNA PAT 06-FEB-1997  
DEFINITION Sequence 29 from patent US 5589330.  
ACCESSION I32565  
VERSION I32565.1 GI:1823356  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Shuber,A.P.  
TITLE High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides  
JOURNAL Patent: US 5589330-A 29 31-DEC-1996;  
FEATURES  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1584 TTCATTCTATTCTTAAT 1600  
|||||  
Db 17 TTCATTCTGTCTTAGT 1

RESULT 121  
I37483  
LOCUS I37483 17 bp DNA PAT 13-MAY-1997  
DEFINITION Sequence 496 from patent US 5612215.  
ACCESSION I37483  
VERSION I37483.1 GI:2085443  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 496 18-MAR-1997;  
FEATURES  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 623 TTGCTGTCATGAACCTT 639  
|||||  
Db 1 TTGCTGTCATGAGCTT 17

RESULT 122  
I37484  
LOCUS I37484 17 bp DNA PAT 13-MAY-1997  
DEFINITION Sequence 497 from patent US 5612215.  
ACCESSION I37484  
VERSION I37484.1 GI:2085444  
KEYWORDS



RESULT 114  
ARI131042  
LOCUS  
DEFINITION Sequence 35 from patent US 6190907.  
ACCESSION ARI131042  
VERSION ARI131042.1 GI:14119367  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Kim,S.-Y., Kim,S.-H. and Robbins,P.D.  
TITLE Retroviral vectors for gene therapy  
JOURNAL Patent: US 6190907-A 35 20-FEB-2001;  
FEATURES  
    source  
        1..17  
            /organism="unknown"  
            /mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 647 CCTGGGGCTGCAGCAT 663  
Db 1 CCATGGGGCTGCAGAAAT 17  
RESULT 115  
BD198986/c  
LOCUS  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD198986  
VERSION BD198986.1 GI:33008756  
KEYWORDS JP 2002509721-A/2012.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 2012 02-APR-2002;  
COMMENT RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/2012  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00  
CC Method and reagent for treating diseases or conditions concerning molecule  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1..17  
FT /organism='Homo sapiens (human)'.  
FEATURES  
    source  
        1..17  
            /organism="Homo sapiens"  
            /mol\_type="genomic RNA"  
            /db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 830 AAAGCTTGAGTTTGTAT 846  
Db 1 AAAGTTTGTAGTTTGTAT 17  
RESULT 117  
CQ616134/c  
LOCUS  
DEFINITION Sequence 874 from Patent WO0192524.  
ACCESSION CQ616134  
VERSION CQ616134.1 GI:41666352  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 874 06-DEC-2001;

QY 1317 TCAATTGGAATATGACC 1333  
Db 17 TCAATTGCAATATGATC 1  
RESULT 116  
BD199265  
LOCUS  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD199265  
VERSION BD199265.1 GI:33009035  
KEYWORDS JP 2002509721-A/2291.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 2291 02-APR-2002;  
COMMENT RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/2291  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00  
CC Method and reagent for treating diseases or conditions concerning molecule  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1..17  
FT /organism='Homo sapiens (human)'.  
FEATURES  
    source  
        1..17  
            /organism="Homo sapiens"  
            /mol\_type="genomic RNA"  
            /db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 830 AAAGCTTGAGTTTGTAT 846  
Db 1 AAAGTTTGTAGTTTGTAT 17  
RESULT 117  
CQ616134/c  
LOCUS  
DEFINITION Sequence 874 from Patent WO0192524.  
ACCESSION CQ616134  
VERSION CQ616134.1 GI:41666352  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 874 06-DEC-2001;

VERSION AX500047.1 GI:23382340  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1354 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 994 GAAAGCAGAAATCA 1007  
Db 16 GAAAGCAGAAATCA 3  
RESULT 110  
AX500048/c  
LOCUS AX500048 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1355 from Patent EP1229046.  
ACCESSION AX500048  
VERSION AX500048.1 GI:23382341  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1355 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 994 GAAAGCAGAAATCA 1007  
Db 15 GAAAGCAGAAATCA 2  
RESULT 111  
AX500049/c  
LOCUS AX500049 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1356 from Patent EP1229046.  
ACCESSION AX500049  
VERSION AX500049.1 GI:23382342  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1356 07-AUG-2002;  
Aeomica, Inc. (US)

FEATURES  
source 1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 994 GAAAGCAGAAATCA 1007  
Db 14 GAAAGCAGAAATCA 1  
RESULT 112  
AR053059/c  
LOCUS AR053059 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 29 from patent US 5834181.  
ACCESSION AR053059  
VERSION AR053059.1 GI:5977921  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Shuber,A.P.  
TITLE High throughput screening method for sequences or genetic alterations in nucleic acids  
JOURNAL Patent: US 5834181-A 29 10-NOV-1998;  
FEATURES  
source 1. .17  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1584 TTCATTCTATTCTTAAT 1600  
Db 17 TTCATTCTGTCTTAGT 1  
RESULT 113  
AR065020/c  
LOCUS AR065020 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 29 from patent US 5849483.  
ACCESSION AR065020  
VERSION AR065020.1 GI:5995236  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Shuber,A.P.  
TITLE High throughput screening method for sequences or genetic alterations in nucleic acids  
JOURNAL Patent: US 5849483-A 29 15-DEC-1998;  
FEATURES  
source 1. .17  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1584 TTCATTCTATTCTTAAT 1600  
Db 17 TTCATTCTGTCTTAGT 1

Shannon,M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 10430 03-FEB-2004;  
Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 840 TTTTGATGCTGTCA 853  
Db 16 TTTTGATGCTGTCA 3

RESULT 105  
AR482773  
LOCUS AR482773 17 bp DNA linear PAT 14-MAY-2004  
DEFINITION Sequence 219 from patent US 6703228.  
ACCESSION AR482773  
VERSION AR482773.1 GI:47245296  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Landers,J.; Jordan,B.; Housman,D.E. and Charest,A.  
TITLE Methods and products related to genotyping and DNA analysis  
JOURNAL Patent: US 6703228-A 219 09-MAR-2004;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1483 ATAATGTAACAGGA 1496  
Db 4 ATAATGTAACAGGA 17

RESULT 106  
AX264072  
LOCUS AX264072 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 1463 from Patent WO0173002.  
ACCESSION AX264072  
VERSION AX264072.1 GI:16512871  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 1463 04-OCT-2001;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1318 CAATTGGAATATGA 1331  
Db 3 CAATTGGAATATGA 16

RESULT 107  
AX264073/c  
LOCUS AX264073 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 1464 from Patent WO0173002.  
ACCESSION AX264073  
VERSION AX264073.1 GI:16512872  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 1464 04-OCT-2001;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1318 CAATTGGAATATGA 1331  
Db 15 CAATTGGAATATGA 2

RESULT 108  
AX500046/c  
LOCUS AX500046 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1353 from Patent EPI229046.  
ACCESSION AX500046  
VERSION AX500046.1 GI:23382339  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1353 07-AUG-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 994 GAAAGCAGAAATCA 1007  
Db 17 GAAAGCAGAAATCA 4

RESULT 109  
AX500047/c  
LOCUS AX500047 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1354 from Patent EPI229046.  
ACCESSION AX500047

ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
TITLE Isoforms of human pregnancy-associated protein-E  
JOURNAL Patent: US 6656700-A 823 02-DEC-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194  
|||||  
Db 4 GGAGGTATGATGTG 17

RESULT 100  
AR434401  
LOCUS AR434401 linear PAT 18-DEC-2003  
DEFINITION Sequence 824 from patent US 6656700.  
ACCESSION AR434401  
VERSION AR434401.1 GI:40197244  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
TITLE Isoforms of human pregnancy-associated protein-E  
JOURNAL Patent: US 6656700-A 824 02-DEC-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194  
|||||  
Db 3 GGAGGTATGATGTG 16

RESULT 101  
AR434402  
LOCUS AR434402 linear PAT 18-DEC-2003  
DEFINITION Sequence 825 from patent US 6656700.  
ACCESSION AR434402  
VERSION AR434402.1 GI:40197245  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
TITLE Isoforms of human pregnancy-associated protein-E  
JOURNAL Patent: US 6656700-A 825 02-DEC-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194  
|||||  
Db 4 GGAGGTATGATGTG 17

Db 2 GGAGGTATGATGTG 15

RESULT 102  
AR434403  
LOCUS AR434403 linear PAT 18-DEC-2003  
DEFINITION Sequence 826 from patent US 6656700.  
ACCESSION AR434403  
VERSION AR434403.1 GI:40197246  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
TITLE Isoforms of human pregnancy-associated protein-E  
JOURNAL Patent: US 6656700-A 826 02-DEC-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194  
|||||  
Db 1 GGAGGTATGATGTG 14

RESULT 103  
AR466752/c  
LOCUS AR466752 linear PAT 20-FEB-2004  
DEFINITION Sequence 10429 from patent US 6686188.  
ACCESSION AR466752  
VERSION AR466752.1 GI:42701809  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10429 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853  
|||||  
Db 17 TTTTGATGCTGTCA 4

RESULT 104  
AR466753/c  
LOCUS AR466753 linear PAT 20-FEB-2004  
DEFINITION Sequence 10430 from patent US 6686188.  
ACCESSION AR466753  
VERSION AR466753.1 GI:42701810  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and



PD 13-AUG-2002  
PF 24-SEP-1999 JP 2000572407  
PR 25-SEP-1998 US 60/101757  
PI JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSMAN, ALAIN CHAREST PC  
G01N37/00, C12N15/09, C12Q1/68, G01N33/53, G01N33/566, G01N37/00, PC  
PC C12N15/00  
CC Methods and products related to genotyping and DNA analysis FH  
Key Location/Qualifiers  
FT source 1. .17  
FT Location/Qualifiers  
1. .17  
/organism='Homo sapiens (human)'.  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1483 ATAATGTAACAGGA 1496  
Db 4 ATAATGTAACAGGA 17  
|||||

RESULT 96  
BD254950/c  
LOCUS 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Regulation of repressor genes using nucleic acid molecules.  
ACCESSION BD254950  
VERSION BD254950.1 GI:33064720  
KEYWORDS JP 2002541795-A/2743.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.  
TITLE Regulation of repressor genes using nucleic acid molecules  
JOURNAL Patent: JP 2002541795-A 2743 10-DEC-2002;  
RIBOZYME PHARMACEUTICALS INC  
OS Eukaryote  
PN JP 2002541795-A/2743  
PD 10-DEC-2002  
PF 11-APR-2000 JP 2000611654  
PR 12-APR-1999 US 60/129390  
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC  
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC  
C12R1:91),  
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,  
PC A61K37/02,  
PC (C12N5/00, C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1. .17  
FT Location/Qualifiers  
1. .17  
/organism='Eukaryote'.  
FEATURES  
source  
1. .17  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 CATTTTGATGAGGC 578  
Db 15 CATTTTGATGAGGC 2  
|||||

RESULT 97  
CQ625689/c  
LOCUS 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10429 from Patent WO0192524.  
ACCESSION CQ625689  
VERSION CQ625689.1 GI:41675907  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10429 06-DEC-2001;  
FEATURES  
source  
1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853  
Db 17 TTTTGATGCTGTCA 4  
|||||

RESULT 98  
CQ625690/c  
LOCUS 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10430 from Patent WO0192524.  
ACCESSION CQ625690  
VERSION CQ625690.1 GI:41675908  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10430 06-DEC-2001;  
FEATURES  
source  
1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853  
Db 16 TTTTGATGCTGTCA 3  
|||||

RESULT 99  
AR434400  
LOCUS 17 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 823 from patent US 6656700.  
ACCESSION AR434400  
VERSION AR434400.1 GI:40197243  
KEYWORDS  
SOURCE Unknown.

QY 1243 TTCCCAGGAATCAAGC 1258  
|||||  
Db 1 TTCCCAGGAATCAGGC 16

RESULT 91  
AR054087  
LOCUS AR054087 16 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 14 from patent US 5834440.  
ACCESSION AR054087  
VERSION AR054087.1 GI:5978949  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Goldenberg,T. and Tritz,R.  
TITLE Ribozyme therapy for the inhibition of restenosis  
JOURNAL Patent: US 5834440-A 14 10-NOV-1998;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 79;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTCCACAAA 832  
|||||  
Db 1 TTTCTGTCCACAAA 14

RESULT 92  
AR436182  
LOCUS AR436182 16 bp RNA linear PAT 18-DEC-2003  
DEFINITION Sequence 441 from patent US 6656731.  
ACCESSION AR436182  
VERSION AR436182.1 GI:40199266  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.  
TITLE Nucleic acid catalysts with endonuclease activity  
JOURNAL Patent: US 6656731-A 441 02-DEC-2003;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 79;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1706 AATGTAACATGTTT 1719  
|||||  
Db 1 AATGTAACATGTTT 14

RESULT 93  
AX132931  
LOCUS AX132931 16 bp DNA linear PAT 15-MAY-2001  
DEFINITION Sequence 4149 from Patent WO0130362.  
ACCESSION AX132931  
VERSION AX132931.1 GI:14139241  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.  
TITLE Methods and products related to genotyping and DNA analysis  
JOURNAL Patent: JP 2002525127-A 219 13-AUG-2002;  
COMMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY  
OS Homo sapiens (human)  
PN JP 2002525127-A/219

REFERENCE 1  
AUTHORS Robbins,J.M. and Tritz,R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 4149 03-MAY-2001;  
FEATURES IMMUSOL, INC. (US)  
source Location/Qualifiers  
1..16  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Hairpin ribozyme recognition site for PCNA"

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 79;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTCCACAAA 832  
|||||  
Db 1 TTTCTGTCCACAAA 14

RESULT 94  
AX133152  
LOCUS AX133152 16 bp DNA linear PAT 15-MAY-2001  
DEFINITION Sequence 4370 from Patent WO0130362.  
ACCESSION AX133152  
VERSION AX133152.1 GI:14139462  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Robbins,J.M. and Tritz,R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 4370 03-MAY-2001;  
FEATURES IMMUSOL, INC. (US)  
source Location/Qualifiers  
1..16  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Hammerhead ribozyme recognition site for PCNA"

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 79;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTCCACAAA 832  
|||||  
Db 1 TTTCTGTCCACAAA 14

RESULT 95  
BD241272  
LOCUS BD241272 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Methods and products related to genotyping and DNA analysis.  
ACCESSION BD241272  
VERSION BD241272.1 GI:33051042  
KEYWORDS JP 2002525127-A/219.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.  
TITLE Methods and products related to genotyping and DNA analysis  
JOURNAL Patent: JP 2002525127-A 219 13-AUG-2002;  
COMMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY  
OS Homo sapiens (human)  
PN JP 2002525127-A/219

AUTHORS		Soeda,E.	
TITLE		A method of arraying genome clone	
JOURNAL		Patent: JP 2001321190-A 1225 20-NOV-2001; THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA	
COMMENT		GENOTECHS OS Artificial Sequence PN JP 2001321190-A/1225 PD 20-NOV-2001 PF 12-MAR-2001 JP 2001068285 PI EIICHI SOEDA PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC C12N15/00, PC C12N15/00 CC Description of Artificial Sequence:Synthetic DNA FH Key Location/Qualifiers FT source 1..18 FT /organism='Artificial Sequence'.	
FEATURES		Location/Qualifiers source 1..18 /organism="synthetic construct" /mol_type="genomic DNA" /db_xref="taxon:32630"	
Query Match		0.8%; Score 14.4; DB 1; Length 18;	
Best Local Similarity		93.8%; Pred. No. 86;	
Matches		15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1243	TTCCCAGGAATCAAGC	1258
Db	1	TTCCCAGGAATCAGGC	16
RESULT 90			
AB068916			
LOCUS		AB068916 18 bp DNA linear SYN 21-MAY-2003	
DEFINITION		Synthetic construct DNA, forward primer for human STS sts-R164D21F at 1p36.	
ACCESSION		AB068916	
VERSION		AB068916.1 GI:15129720	
KEYWORDS		synthetic construct	
SOURCE		synthetic construct	
ORGANISM		other sequences; artificial sequences.	
REFERENCE		1	
AUTHORS		Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K., Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H., Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A. and Soeda,E.	
TITLE		A BAC-based STS-content map spanning a 35-Mb region of human chromosome 1p35-p36	
JOURNAL		Genomics 74 (1), 55-70 (2001)	
MEDLINE		21269192	
PUBMED		11374902	
REFERENCE		2 (bases 1 to 18)	
AUTHORS		Horii,A.	
TITLE		Direct Submission	
JOURNAL		Submitted (04-AUG-2001) Akira Horii, Tohoku University School of Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp, Tel:81-22-717-8042, Fax:81-22-717-8047)	
FEATURES		Location/Qualifiers source 1..18 /organism="synthetic construct" /mol_type="genomic DNA" /db_xref="taxon:32630"	
misc_feature		1..18 /note="forward primer for human STS sts-R164D21F at 1p36 sts-R164D21F obtained from clones B331A4, B354N13, B330C5, 260O18, B145C4, B164D21, B27A6, Human BAC library RPCI-11"	
Query Match		0.8%; Score 14.4; DB 1; Length 18;	
Best Local Similarity		93.8%; Pred. No. 86;	
Matches		15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	

AUTHORS		Soeda,E.	
TITLE		A method of arraying genome clone	
JOURNAL		Patent: JP 2001321190-A 1225 20-NOV-2001; THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA	
COMMENT		GENOTECHS OS Artificial Sequence PN JP 2001321190-A/1225 PD 20-NOV-2001 PF 12-MAR-2001 JP 2001068285 PI EIICHI SOEDA PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC C12N15/00, PC C12N15/00 CC Description of Artificial Sequence:Synthetic DNA FH Key Location/Qualifiers FT source 1..18 FT /organism='Artificial Sequence'.	
FEATURES		Location/Qualifiers source 1..18 /organism="synthetic construct" /mol_type="genomic DNA" /db_xref="taxon:32630"	
Query Match		0.8%; Score 14.4; DB 1; Length 18;	
Best Local Similarity		93.8%; Pred. No. 86;	
Matches		15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1243	TTCCCAGGAATCAAGC	1258
Db	1	TTCCCAGGAATCAGGC	16
RESULT 90			
AB068916			
LOCUS		AB068916 18 bp DNA linear SYN 21-MAY-2003	
DEFINITION		Synthetic construct DNA, forward primer for human STS sts-R164D21F at 1p36.	
ACCESSION		AB068916	
VERSION		AB068916.1 GI:15129720	
KEYWORDS		synthetic construct	
SOURCE		synthetic construct	
ORGANISM		other sequences; artificial sequences.	
REFERENCE		1	
AUTHORS		Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K., Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H., Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A. and Soeda,E.	
TITLE		A BAC-based STS-content map spanning a 35-Mb region of human chromosome 1p35-p36	
JOURNAL		Genomics 74 (1), 55-70 (2001)	
MEDLINE		21269192	
PUBMED		11374902	
REFERENCE		2 (bases 1 to 18)	
AUTHORS		Horii,A.	
TITLE		Direct Submission	
JOURNAL		Submitted (04-AUG-2001) Akira Horii, Tohoku University School of Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp, Tel:81-22-717-8042, Fax:81-22-717-8047)	
FEATURES		Location/Qualifiers source 1..18 /organism="synthetic construct" /mol_type="genomic DNA" /db_xref="taxon:32630"	
misc_feature		1..18 /note="forward primer for human STS sts-R164D21F at 1p36 sts-R164D21F obtained from clones B331A4, B354N13, B330C5, 260O18, B145C4, B164D21, B27A6, Human BAC library RPCI-11"	
Query Match		0.8%; Score 14.4; DB 1; Length 18;	
Best Local Similarity		93.8%; Pred. No. 86;	
Matches		15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	

/organism="synthetic construct"		/mol_type="unassigned DNA"		/db_xref="taxon:32630"	
Query Match		0.8%; Score 14.4; DB 1; Length 18;			
Best Local Similarity		93.8%; Pred. No. 86;			
Matches		15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
QY	813	ATCAACTTCTGTGCAC	828		
Db	16	AACAACTTCTGTGCAC	1		
RESULT 88					
BD085033/c					
LOCUS		BD085033 18 bp DNA linear PAT 27-AUG-2002			
DEFINITION		Target-dependent reactions using structure-bridging oligonucleotides.			
ACCESSION		BD085033			
VERSION		BD085033.1 GI:22630643			
KEYWORDS		JP 2001523111-A/108.			
SOURCE		unidentified			
ORGANISM		unidentified			
REFERENCE		1 (bases 1 to 18)			
AUTHORS		Dong,F., Lyamichev			

AX757296  
LOCUS AX757296 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 617 from Patent WO03040369.  
ACCESSION AX757296  
VERSION AX757296.1 GI:32251912  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 617 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1316 ATCAATTGGAATATGA 1331  
||||| |||||||||  
Db 2 ATCAATGGAATATGA 17  
RESULT 84  
CQ807658  
LOCUS CQ807658 18 bp DNA linear PAT 10-MAY-2004  
DEFINITION Sequence 1108 from Patent WO2004035803.  
ACCESSION CQ807658  
VERSION CQ807658.1 GI:47113052  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F., Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and Marx,A.  
TITLE Method and nucleic acids for the improved treatment of breast cell proliferative disorders  
JOURNAL Patent: WO 2004035803-A 1108 29-APR-2004;  
FEATURES Epigenomics AG (DE)  
source Location/Qualifiers  
1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Detection oligonucleotide for BCL2"  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 86;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1376 GGTTTGGTTGTTAGGA 1391  
||||| |||||||||  
Db 2 GATTGGTTGTTAGGA 17  
RESULT 85  
AR488779/c  
LOCUS AR488779 18 bp DNA linear PAT 15-MAY-2004  
DEFINITION Sequence 108 from patent US 6709815.  
ACCESSION AR488779  
VERSION AR488779.1 GI:47254977  
KEYWORDS

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Dong,F., Lyamichev,V.I., Prudent,J.R., Fors,L., Neri,B.P., Brow,M.A.D., Anderson,T.A. and Dahlberg,J.E.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6709815-A 108 23-MAR-2004;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 86;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 813 ATCAACTTTCTGTCTCAC 828  
| ||||| ||||| |||||  
Db 16 AACAACTTTCTGTCTCAC 1  
RESULT 86  
AX378430  
LOCUS AX378430 18 bp DNA linear PAT 18-MAR-2002  
DEFINITION Sequence 219 from Patent WO0206525.  
ACCESSION AX378430  
VERSION AX378430.1 GI:19574283  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Cohen,D., Blumenfeld,M., Chumakov,I., Abderrahim,H. and Bihain,B.  
TITLE Obesity associated biallelic marker maps  
JOURNAL Patent: WO 0206525-A 219 24-JAN-2002;  
FEATURES GENSET (FR)  
source Location/Qualifiers  
1. .18  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
primer\_bind 1. .18  
/note="upstream amplification primer 99-32165 for SEQ 48"  
Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 86;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1238 CACACTTCCCAGGAAT 1253  
||||| ||||| |||||  
Db 1 CACACTTCCCCTGGAAT 16  
RESULT 87  
AX419771/c  
LOCUS AX419771 18 bp DNA linear PAT 18-JUN-2002  
DEFINITION Sequence 108 from Patent WO0198537.  
ACCESSION AX419771  
VERSION AX419771.1 GI:21524138  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.  
TITLE Nucleic acid accessible hybridization sites  
JOURNAL Patent: WO 0198537-A 108 27-DEC-2001;  
FEATURES THIRD WAVE TECHNOLOGIES, INC. (US)  
source Location/Qualifiers  
1. .18



Qy	871 ATCCTTTTCTTTAAAG 886 
Db	2 ATCCTTTTCTTGAAAG 17
RESULT 81	
AX735442/c	
LOCUS	AX735442 linear DNA 17 bp PAT 08-MAY-2003
DEFINITION	Sequence 1032 from Patent WO03025177.
ACCESSION	AX735442
VERSION	AX735442.1 GI:30514719
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 1032 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers 1. .17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
AUTHORS	
TITLE	
JOURNAL	
FEATURES	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No. 78; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
source	
1. .17	
/organism="Homo sapiens"	
/mol_type="unassigned DNA"	
/db_xref="taxon:9606"	
Qy	2 TGAATTTCTCATGAT 17 
Db	17 TGAATTTCTCATGAT 2
RESULT 82	
AX736604	
LOCUS	AX736604 linear DNA 17 bp PAT 08-MAY-2003
DEFINITION	Sequence 2194 from Patent WO03025177.
ACCESSION	AX736604
VERSION	AX736604.1 GI:30515892
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 2194 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers 1. .17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
AUTHORS	
TITLE	
JOURNAL	
FEATURES	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No. 78; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
source	
1. .17	
/organism="Homo sapiens"	
/mol_type="unassigned DNA"	
/db_xref="taxon:9606"	
Qy	871 ATCCTTTTCTTTAAAG 886 
Db	2 ATCCTTTTCTTGAAAG 17
RESULT 83	

```
RESULT 74
AR466754/c
LOCUS AR466754 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10431 from patent US 6686188.
ACCESSION AR466754
VERSION AR466754.1 GI:42701811
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10431 03-FEB-2004;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 838 AGTTTGTGATGCTGTCA 853
Db 17 ACTTTGTGATGCTGTCA 2

RESULT 75
AR466756/c
LOCUS AR466756 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10433 from patent US 6686188.
ACCESSION AR466756
VERSION AR466756.1 GI:42701813
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10433 03-FEB-2004;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTGTGATGCTGTC 852
Db 16 GACTTTTGTGATGCTGTC 1

RESULT 76
AX217706
LOCUS AX217706 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3148 from Patent WO0159103.
ACCESSION AX217706
VERSION AX217706.1 GI:15527767
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
```

```
nogo gene expression
Patent: WO 0159103-A 3148 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)

JOURNAL Location/Qualifiers
1. .17
FEATURES
source
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 165 AAAACTCCAGGAATG 180
Db 1 AAAACTCCAGGAAGTG 16

RESULT 77
AX325541
LOCUS AX325541 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1679 from Patent WO0192512.
ACCESSION AX325541
VERSION AX325541.1 GI:18096298
KEYWORDS
SOURCE Solanum tuberosum (potato)
ORGANISM Solanum tuberosum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
asterids; lamiids; Solanales; Solanaceae; Solanum.
REFERENCE
AUTHORS Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides
JOURNAL Patent: WO 0192512-A 1679 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .17
/organism="Solanum tuberosum"
/mol_type="unassigned DNA"
/db_xref="taxon:4113"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAACA 1493
Db 1 TGGCAATAATGTCACA 16

RESULT 78
AX325542/c
LOCUS AX325542 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1680 from Patent WO0192512.
ACCESSION AX325542
VERSION AX325542.1 GI:18096299
KEYWORDS
SOURCE Solanum tuberosum (potato)
ORGANISM Solanum tuberosum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
asterids; lamiids; Solanales; Solanaceae; Solanum.
REFERENCE
AUTHORS Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides
JOURNAL Patent: WO 0192512-A 1680 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .17
Location/Qualifiers
```

RESULT 69  
I54342/c  
LOCUS I54342 17 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 2083 from patent US 5646042.  
ACCESSION I54342  
VERSION I54342.1 GI:2475545  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 2083 08-JUL-1997;  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1545 GCTTTTACAAAATTAA 1560  
||| ||||| ||||| |||||  
Db 17 GCATTACAAAATTAA 2  
RESULT 70  
I94283  
LOCUS I94283 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 446 from patent US 5731295.  
ACCESSION I94283  
VERSION I94283.1 GI:3938753  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 446 24-MAR-1998;  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 317 ACCTCACTTACAGGAT 332  
||| ||||| ||||| |||||  
Db 1 ACCTAACTTACAGGAT 16  
RESULT 71  
AR190342  
LOCUS AR190342 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 5830 from patent US 6346398.  
ACCESSION AR190342  
VERSION AR190342.1 GI:20236307  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6346398-A 5830 12-FEB-2002;  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 297 GTCAAGATGGATGAAG 312  
||| ||||| ||||| |||||  
Db 1 GTCAAGATTGATGAAG 16  
RESULT 72  
AR325288  
LOCUS AR325288 17 bp RNA linear PAT 17-AUG-2003  
DEFINITION Sequence 2690 from patent US 6566127.  
ACCESSION AR325288  
VERSION AR325288.1 GI:33711096  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 2690 20-MAY-2003;  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 297 GTCAAGATGGATGAAG 312  
||| ||||| ||||| |||||  
Db 1 GTCAAGATTGATGAAG 16  
RESULT 73  
AR328139/c  
LOCUS AR328139 17 bp RNA linear PAT 17-AUG-2003  
DEFINITION Sequence 5541 from patent US 6566127.  
ACCESSION AR328139  
VERSION AR328139.1 GI:33713947  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 5541 20-MAY-2003;  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1521 ACACACATAGTTACAC 1536  
||| ||||| ||||| |||||  
Db 17 ACACACACAGTTACAC 2

PI JAMES A MCSWIGGEN  
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00  
CC Method and reagent for treating diseases or conditions CC concerning molecule  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1. .17  
FT /organism='Homo sapiens (human)'.  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1672 ATTAGAATTAGATTAA 1687  
||| ||||| ||||| |||||  
Db 1 ATCAGAATTAGATTAA 16  
RESULT 65  
LOCUS CQ625691/c 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10431 from Patent WO0192524.  
ACCESSION CQ625691  
VERSION CQ625691.1 GI:41675909  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10431 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 838 AGTTTGTGCTGTCA 853  
| | | | | | | | | | | | | | | |  
Db 17 ACTTTTGTGCTGTCA 2  
RESULT 66  
LOCUS CQ625693/c 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10433 from Patent WO0192524.  
ACCESSION CQ625693  
VERSION CQ625693.1 GI:41675911  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10433 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 837 GAGTTTGTGCTGTC 852  
||| ||||| ||||| |||||  
Db 16 GACTTTTGTGCTGTC 1  
RESULT 67  
LOCUS I37433 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 446 from patent US 5612215.  
ACCESSION I37433  
VERSION I37433.1 GI:2085393  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 446 18-MAR-1997;  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 317 ACCTCACATTACAGGAT 332  
||| ||||| ||||| |||||  
Db 1 ACCTAACTTACAGGAT 16  
RESULT 68  
LOCUS I53259/c 17 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 1000 from patent US 5646042.  
ACCESSION I53259  
VERSION I53259.1 GI:2474462  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 1000 08-JUL-1997;  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1545 GCTTTTACAAAATTAA 1560  
||| ||||| ||||| |||||  
Db 17 GCATTTTACAAAATTAA 2



Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 70;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1521 ACACACATAGTTACAC 1536  
Db 16 ACACACACAGTTACAC 1

RESULT 60  
AR328664/c  
LOCUS AR328664 16 bp RNA linear PAT 17-AUG-2003  
DEFINITION Sequence 6066 from patent US 6566127.  
ACCESSION AR328664  
VERSION AR328664.1 GI:33714472  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 6066 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 70;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1519 ACACACACATAGTTAC 1534  
Db 16 ACACACACAGTTAC 1

RESULT 61  
AR435918/c  
LOCUS AR435918 16 bp RNA linear PAT 18-DEC-2003  
DEFINITION Sequence 177 from patent US 6656731.  
ACCESSION AR435918  
VERSION AR435918.1 GI:40199002  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.  
TITLE Nucleic acid catalysts with endonuclease activity  
JOURNAL Patent: US 6656731-A 177 02-DEC-2003;  
FEATURES Location/Qualifiers  
source 1..16  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 70;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTTCACCTTCATTCT 1591  
Db 16 TTTTTCACCTTCATTGT 1

RESULT 62  
AR046207/c  
LOCUS AR046207 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 1000 from patent US 5817796.  
ACCESSION AR046207  
VERSION AR046207.1 GI:5967672  
KEYWORDS

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues  
JOURNAL Patent: US 5817796-A 1000 06-OCT-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTTTTACAAAATTAA 1560  
Db 17 GCATTTACAAAATTAA 2

RESULT 63  
AR047290/c  
LOCUS AR047290 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 2083 from patent US 5817796.  
ACCESSION AR047290  
VERSION AR047290.1 GI:5968755  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues  
JOURNAL Patent: US 5817796-A 2083 06-OCT-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 78;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTTTTACAAAATTAA 1560  
Db 17 GCATTTACAAAATTAA 2

RESULT 64  
BD201350  
LOCUS BD201350 17 bp RNA linear PAT 17-JUL-2003  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD201350  
VERSION BD201350.1 GI:33011120  
KEYWORDS JP 2002509721-A/4376.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 4376 02-APR-2002;  
COMMENT RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/4376  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTTCTTTAAAGA 887  
Db 1 AATCCTGATCTTTAAAGA 18

RESULT 55  
194911  
LOCUS 18 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 1074 from patent US 5731295.  
ACCESSION 194911  
VERSION 194911.1 GI:3939381  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 1074 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886  
Db 1 AAATCCTGATCTTTAAAG 18

RESULT 56  
194954  
LOCUS 18 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 1117 from patent US 5731295.  
ACCESSION 194954  
VERSION 194954.1 GI:3939424  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 1117 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 621 TGTGCTGTTTCATGAAC 638  
Db 1 TGTGCTGCTCATGAGCT 18

RESULT 57  
194966  
LOCUS 18 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 1129 from patent US 5731295.  
ACCESSION 194966

VERSION 194966.1 GI:3939436  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 1129 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886  
Db 1 AAATTCGTCTCTTTAAAG 18

RESULT 58  
AR293759/c  
LOCUS 18 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 5494 from patent US 6537751.  
ACCESSION AR293759  
VERSION AR293759.1 GI:31681043  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.  
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome  
JOURNAL Patent: US 6537751-A 5494 25-MAR-2003;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 CCCACCTACGATACCTT 708  
Db 18 CCCACCTTGAGATACCTT 1

RESULT 59  
AR328663/c  
LOCUS 16 bp RNA linear PAT 17-AUG-2003  
DEFINITION Sequence 6065 from patent US 6566127.  
ACCESSION AR328663  
VERSION AR328663.1 GI:33714471  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 6065 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1. .16  
/organism="unknown"  
/mol\_type="unassigned RNA"

RESULT 52				
I38104				
LOCUS	I38104	18 bp	DNA	linear
DEFINITION	Sequence 1117 from patent US 5612215.			PAT 13-MAY-1997

RESULT 45  
AX217705  
LOCUS AX217705 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 3147 from Patent WO0159103.  
ACCESSION AX217705  
VERSION AX217705.1 GI:15527766  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source 1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 58;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 164 AAAAAGTCCAGGAATG 180  
|||||  
Db 1 AAAAAGTCCAGGAAGTG 17  
RESULT 46  
AR180490  
LOCUS AR180490 15 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 558 from patent US 6333152.  
ACCESSION AR180490  
VERSION AR180490.1 GI:20222523  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.  
TITLE Gene expression profiles in normal and cancer cells  
JOURNAL Patent: US 6333152-A 558 25-DEC-2001;  
FEATURES  
source 1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 631 CATGAAGTGGCCAT 645  
|||||  
Db 1 CATGAAGTGGCCAT 15  
RESULT 47  
AX218129  
LOCUS AX218129 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 3571 from Patent WO0159103.  
ACCESSION AX218129  
VERSION AX218129.1 GI:15528190  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1

AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 3571 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
Location/Qualifiers  
source 1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 65;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 162 AGAAAACTCCAGGA 176  
|||||  
Db 3 AGAAAACTCCAGGA 17  
RESULT 48  
AR096838/c  
LOCUS AR096838 18 bp DNA linear PAT 08-SEP-2000  
DEFINITION Sequence 36 from patent US 6008344.  
ACCESSION AR096838  
VERSION AR096838.1 GI:10025996  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Bennett,C.Frank. and Cowser,L.M.  
TITLE Antisense modulation of phospholipase A2 group IV expression  
JOURNAL Patent: US 6008344-A 36 28-DEC-1999;  
FEATURES  
Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 577 GCAGAAACGTGGACTAAA 594  
|||||  
Db 18 GCAGAAAGTGGCTAAA 1  
RESULT 49  
CQ808362/c  
LOCUS CQ808362 18 bp DNA linear PAT 10-MAY-2004  
DEFINITION Sequence 1812 from Patent WO2004035803.  
ACCESSION CQ808362  
VERSION CQ808362.1 GI:47113756  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F., Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and Marx,A.  
TITLE Method and nucleic acids for the improved treatment of breast cell proliferative disorders  
JOURNAL Patent: WO 2004035803-A 1812 29-APR-2004;  
FEATURES  
Location/Qualifiers  
source 1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"





```
FEATURES
source      Location/Qualifiers
1. .16
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1764
Db 16 AAAAAAAAAAAAAAAAAA 1

RESULT 36
AX217704
LOCUS      AX217704      17 bp      RNA      linear      PAT 07-SEP-2001
DEFINITION Sequence 3146 from Patent WO0159103.
ACCESSION  AX217704
VERSION     AX217704.1 GI:15527765
KEYWORDS
SOURCE      synthetic construct
ORGANISM    synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS     Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE       Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
JOURNAL     Patent: WO 0159103-A 3146 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source      Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match      0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 162 AGAAAAAATCCAGGAA 177
Db 1 AGAAAAAATCCAGGAA 16

RESULT 37
AR266181
LOCUS      AR266181      20 bp      DNA      linear      PAT 10-APR-2003
DEFINITION Sequence 80 from patent US 6492172.
ACCESSION  AR266181
VERSION     AR266181.1 GI:29695027
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS     Bennett,C.F., Busch,H. and Wyatt,J.
TITLE       Antisense modulation of GU protein expression
JOURNAL     Patent: US 6492172-A 80 10-DEC-2002;
FEATURES
source      Location/Qualifiers
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1294 TACTACATCTTCCAAG 1309
Db 5 TACTACATCTTCCAAG 20

FEATURES
source      Location/Qualifiers
1. .16
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1764
Db 16 AAAAAAAAAAAAAAAAAA 1

RESULT 38
AX300803
LOCUS      AX300803      20 bp      DNA      linear      PAT 30-NOV-2001
DEFINITION Sequence 5 from Patent WO0185993.
ACCESSION  AX300803
VERSION     AX300803.1 GI:17382083
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS     Cooper,D.N., Procter,A.M., Gregory,J.D. and Millar,D.S.
TITLE       Method for detecting growth hormone variations in humans, the
            variations and their uses
JOURNAL     Patent: WO 0185993-A 5 15-NOV-2001;
            University of Wales College of Medicine (GB)
FEATURES
source      Location/Qualifiers
1. .20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 854 CAACAGTGGGAGAGAA 869
Db 4 CAACAGTGGGAGAGAA 19

RESULT 39
AX132826
LOCUS      AX132826      19 bp      DNA      linear      PAT 15-MAY-2001
DEFINITION Sequence 4044 from Patent WO0130362.
ACCESSION  AX132826
VERSION     AX132826.1 GI:14139136
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS     Robbins,J.M. and Tritz,R.
TITLE       Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
JOURNAL     Patent: WO 0130362-A 4044 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES
source      Location/Qualifiers
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="PCNA HH ribozyme binding site"

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 63;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1717 TTTTGTTCCTTTAAATAA 1735
Db 1 TATTGTTTCCTGTAATAA 19

RESULT 40
CQ625692/c
LOCUS      CQ625692      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 10432 from Patent WO0192524.
ACCESSION  CQ625692
VERSION     CQ625692.1 GI:41675910
```

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAAGCGTGAGGATGTAGACT 373  
||||| ||||||| |||||

Db 2 GAAGCATGAGGATGGAGACT 21

RESULT 31  
AX189740  
LOCUS  
DEFINITION Sequence 42 from Patent WO0148240.  
ACCESSION AX189740  
VERSION AX189740.1 GI:15143116  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Chartier-Harlin,M.C., Amouyel,P., Lambert,J.C. and Araria,L.  
TITLE Implication of a known gene named cp2/lstf-lbp-1 in Alzheimer's  
disease  
JOURNAL Patent: WO 0148240-A 42 05-JUL-2001;  
INSTITUT PASTEUR DE LILLE (FR) ; INSTITUT NATIONAL DE LA SANTE ET  
DE LA RECHERCHE MEDICALE (INSERM) (FR)  
FEATURES  
source Location/Qualifiers  
1. .21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 56;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAAGCGTGAGGATGTAGACT 373  
||||| ||||||| |||||

Db 2 GAAGCATGAGGATGGAGACT 21

RESULT 32  
AX021121  
LOCUS  
DEFINITION Sequence 5 from Patent WO9930730.  
ACCESSION AX021121  
VERSION AX021121.1 GI:10044774  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Tremblay,J.P.  
TITLE Methods and compositions for improving the success of cell  
transplantation in a host  
JOURNAL Patent: WO 9930730-A 5 24-JUN-1999;  
UNIV LAVAL (CA); TREMBLAY JACQUES P (CA)  
FEATURES  
source Location/Qualifiers  
1. .20  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Oligonucleotide"

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 58;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATG 268  
||||| ||||||| |||||

Db 3 GATGTGGAGTGCCAGATG 20

RESULT 33

AX613732/c  
LOCUS  
DEFINITION Sequence 4757 from Patent WO02072882.  
ACCESSION AX613732  
VERSION AX613732.1 GI:28409161  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Cullen,P. and Seedorf,U.  
TITLE Coronary chip  
JOURNAL Patent: WO 02072882-A 4757 19-SEP-2002;  
OGHAM GmbH (DE)  
FEATURES  
source Location/Qualifiers  
1. .20  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 58;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 799 CCTAGCAGTCCACCATCA 816  
||||| ||||||| |||||

Db 20 CCTTGCAGTCCACCATCA 3

RESULT 34  
AR561628  
LOCUS  
DEFINITION Sequence 1 from patent US 6756492.  
ACCESSION AR561628  
VERSION AR561628.1 GI:53974736  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Beier,M. and Honeisel,J.  
TITLE Nucleoside derivatives with photo-unstable protective groups  
JOURNAL Patent: US 6756492-A 1 29-JUN-2004;  
FEATURES  
source Location/Qualifiers  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAA 1764  
||||| ||||||| |||||

Db 1 AAAAAAAAAAAAAAAA 16

RESULT 35  
AR561693/c  
LOCUS  
DEFINITION Sequence 9 from patent US 6759039.  
ACCESSION AR561693  
VERSION AR561693.1 GI:53974843  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Tsang,W.-G., Zheng,T. and Huang,C.J.  
TITLE Culturing pancreatic stem cells having a specified, intermediate  
stage of development  
JOURNAL Patent: US 6759039-A 9 06-JUL-2004;

FEATURES  
source  
Location/Qualifiers  
1. .20  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 75.0%; Pred. No. 51;  
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 250 CGATGTGGAGTGCCCGATGT 269  
:|||||:|||||:|||||  
Db 1 MGVGTGGWGTBCCHGATGT 20

RESULT 27  
E31766/c  
LOCUS E31766 20 bp DNA linear PAT 18-JUN-2001  
DEFINITION Novel metaprotease and DNA encoding the same.  
ACCESSION E31766  
VERSION E31766.1 GI:13018615  
KEYWORDS JP 2000014387-A/4.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Yoshiyuki,O. and Takayuki,T.  
TITLE Novel metaprotease and DNA encoding the same  
JOURNAL Patent: JP 2000014387-A 4 18-JAN-2000;  
TAKAYUKI TAKAHASHI,KK SDI  
COMMENT OS Artificial Sequence  
PN JP 2000014387-A/4  
PD 18-JAN-2000  
PF 06-JUL-1998 JP 1998190869  
PR  
PI YOSHIYUKI ONISHI,TAKAYUKI TAKAHASHI  
PC C12N15/09,C12N1/21,C12N9/50/(C12N1/21,C12R1:19),(C12N9/50, PC  
C12R1:19),  
PC C12N15/00  
CC  
FH Key Location/Qualifiers  
FT source 1. .20  
FT /organism='Artificial Sequence'.  
FEATURES  
source  
Location/Qualifiers  
1. .20  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 75.0%; Pred. No. 51;  
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 631 CATGAACCTGGCCATCCTT 650  
|||||:|||||:|||||  
Db 20 CATGARYTTGGCCAYKCCCT 1

RESULT 28  
AX167124/c  
LOCUS AX167124 20 bp DNA linear PAT 03-JUL-2001  
DEFINITION Sequence 11 from Patent WO0144455.  
ACCESSION AX167124  
VERSION AX167124.1 GI:14596612  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Beri,R.  
TITLE Antisense oligonucleotides  
JOURNAL Patent: WO 0144455-A 11 21-JUN-2001;

FEATURES  
source  
AstraZeneca AB (SE)  
Location/Qualifiers  
1. .20  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Antisense oligonucleotide"

Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 51;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1194 GAGGCAGGAGCTCATGGACC 1213  
|||||:|||||:|||||  
Db 20 GAGGCTGGAGCTCAGGGACC 1

RESULT 29  
I31840  
LOCUS I31840 21 bp DNA linear PAT 06-FEB-1997  
DEFINITION Sequence 3 from patent US 5583035.  
ACCESSION I31840  
VERSION I31840.1 GI:1822631  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Kretschmer,A., Antonicek,H.-P., Baumgarten,J., Loebberding,A.,  
Mielke,B., Springer,W., Stropp,U., Struck,M.-M., Biesert,L.,  
Rubsamen-Waigmann,H., Suhartono,H. and Hausner,T.-P.  
TITLE HIV antisense expression vectors  
JOURNAL Patent: US 5583035-A 3 10-DEC-1996;  
FEATURES  
source  
Location/Qualifiers  
1. .21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 56;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1575 TTTTTCACCTTCATTCATT 1594  
|||||:|||||:|||||  
Db 1 TTTTTCACCTGCATTCTACT 20

RESULT 30  
AX134131  
LOCUS AX134131 21 bp DNA linear PAT 29-MAY-2001  
DEFINITION Sequence 42 from Patent EP1113081.  
ACCESSION AX134131  
VERSION AX134131.1 GI:14270895  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Chartier-Harlin,M.C., Amouyel,P. and Lambert,J.C.  
TITLE Implication of a known gene named cp2/lstf/lbp-1 in alzheimer's  
disease  
JOURNAL Patent: EP 1113081-A 42 04-JUL-2001;  
INSTITUT PASTEUR DE LILLE (FR); INSTITUT NATIONAL DE LA SANTE ET  
DE LA RECHERCHE MEDICALE (INSERM) (FR)  
FEATURES  
source  
Location/Qualifiers  
1. .21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 56;



I94907  
LOCUS I94907 18 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 1070 from patent US 5731295.  
ACCESSION I94907  
VERSION I94907.1 GI:3939377  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 1070 24-MAR-1998;  
FEATURES  
source  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 750 CATTGAGTCCCTCTATG 766  
|||||  
Db 2 CATTGAGTCCCTCTATG 18  
|||||  
RESULT 24  
E31760  
LOCUS E31760 20 bp DNA linear PAT 18-JUN-2001  
DEFINITION Novel metaprotease and DNA encoding the same.  
ACCESSION E31760  
VERSION E31760.1 GI:13018609  
KEYWORDS JP 2000014386-A/2.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Takayuki,T. and Yoshiyuki,O.  
TITLE Novel metaprotease and DNA encoding the same  
JOURNAL Patent: JP 2000014386-A 2 18-JAN-2000;  
COMMENT TAKAYUKI TAKAHASHI,KK SDI  
OS Artificial Sequence  
PN JP 2000014386-A/2  
PD 18-JAN-2000  
PF 06-JUL-1998 JP 1998190868  
PR  
PI TAKAYUKI TAKAHASHI,YOSHIYUKI ONISHI  
PC C12N15/09,C12N1/21,C12N5/10,C12N9/50,C12P21/08//(C12N15/09, PC C12R1:91), (C12N5/10,C12R1:91), (C12N9/50,C12R1:19), (C12P21/08,C12R1:91), (C12N15/00,C12N5/00,C12R1:91), (C12N5/00,C12R1:91)  
CC  
FH Key Location/Qualifiers  
FT source 1. .20  
/organism='Artificial Sequence'.  
FEATURES  
source  
1. .20  
Location/Qualifiers  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 75.0%; Pred. No. 51;  
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
Qy 631 CATGAAC TTGCCATTCCCTT 650  
|||||:::|||||:::|  
Db 20 CATGARYTTGCCCAKCCCT 1  
|||||:::|||||:::|  
RESULT 26  
E31765  
LOCUS E31765 20 bp DNA linear PAT 18-JUN-2001  
DEFINITION Novel metaprotease and DNA encoding the same.  
ACCESSION E31765  
VERSION E31765.1 GI:13018614  
KEYWORDS JP 2000014387-A/3.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Yoshiyuki,O. and Takayuki,T.  
TITLE Novel metaprotease and DNA encoding the same  
JOURNAL Patent: JP 2000014387-A 3 18-JAN-2000;  
COMMENT TAKAYUKI TAKAHASHI,KK SDI  
OS Artificial Sequence  
PN JP 2000014387-A/3  
PD 18-JAN-2000  
PF 06-JUL-1998 JP 1998190869  
PR  
PI YOSHIYUKI ONISHI,TAKAYUKI TAKAHASHI  
PC C12N15/09,C12N1/21,C12N9/50//(C12N1/21,C12R1:19), (C12N9/50, PC C12R1:19), (C12N15/00,C12R1:91), (C12N5/00,C12R1:91)  
CC  
FH Key Location/Qualifiers  
FT source 1. .20  
/organism='Artificial Sequence'.  
FEATURES  
source  
1. .20  
Location/Qualifiers  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 75.0%; Pred. No. 51;  
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;  
Qy 250 CGATGTGGAGTGCCTGATGT 269  
:|||||:::|||||  
Db 1 MGVGTGGWGTBCCHGATGT 20  
|||||:::|||||:::|

RESULT 25  
E31761/c  
LOCUS E31761 20 bp DNA linear PAT 18-JUN-2001  
DEFINITION Novel metaprotease and DNA encoding the same.  
ACCESSION E31761  
VERSION E31761.1 GI:13018610  
KEYWORDS JP 2000014386-A/3.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Takayuki,T. and Yoshiyuki,O.  
TITLE Novel metaprotease and DNA encoding the same  
JOURNAL Patent: JP 2000014386-A 3 18-JAN-2000;  
COMMENT TAKAYUKI TAKAHASHI,KK SDI  
OS Artificial Sequence  
PN JP 2000014386-A/3  
PD 18-JAN-2000  
PF 06-JUL-1998 JP 1998190868  
PR  
PI TAKAYUKI TAKAHASHI,YOSHIYUKI ONISHI  
PC C12N15/09,C12N1/21,C12N5/10,C12N9/50,C12P21/08//(C12N15/09, PC C12R1:91), (C12N5/10,C12R1:91), (C12N9/50,C12R1:19), (C12P21/08,C12R1:91), (C12N15/00,C12N5/00,C12R1:91), (C12N5/00,C12R1:91)  
CC  
FH Key Location/Qualifiers  
FT source 1. .20  
/organism='Artificial Sequence'.  
FEATURES  
source  
1. .20  
Location/Qualifiers  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 75.0%; Pred. No. 51;  
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
Qy 631 CATGAAC TTGCCATTCCCTT 650  
|||||:::|||||:::|  
Db 20 CATGARYTTGCCCAKCCCT 1  
|||||:::|||||:::|  
RESULT 26  
E31765  
LOCUS E31765 20 bp DNA linear PAT 18-JUN-2001  
DEFINITION Novel metaprotease and DNA encoding the same.  
ACCESSION E31765  
VERSION E31765.1 GI:13018614  
KEYWORDS JP 2000014387-A/3.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Yoshiyuki,O. and Takayuki,T.  
TITLE Novel metaprotease and DNA encoding the same  
JOURNAL Patent: JP 2000014387-A 3 18-JAN-2000;  
COMMENT TAKAYUKI TAKAHASHI,KK SDI  
OS Artificial Sequence  
PN JP 2000014387-A/3  
PD 18-JAN-2000  
PF 06-JUL-1998 JP 1998190869  
PR  
PI YOSHIYUKI ONISHI,TAKAYUKI TAKAHASHI  
PC C12N15/09,C12N1/21,C12N9/50//(C12N1/21,C12R1:19), (C12N9/50, PC C12R1:19), (C12N15/00,C12R1:91), (C12N5/00,C12R1:91)  
CC  
FH Key Location/Qualifiers  
FT source 1. .20  
/organism='Artificial Sequence'.  
FEATURES  
source  
1. .20  
Location/Qualifiers  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"



```
RESULT 13
AR541352/c
LOCUS AR541352 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 17 from patent US 6737520.
ACCESSION AR541352
VERSION AR541352.1 GI:53932999
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 17 18-MAY-2004;
FEATURES
source
Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767
|||||
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 14
AR541353/c
LOCUS AR541353 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 18 from patent US 6737520.
ACCESSION AR541353
VERSION AR541353.1 GI:53933000
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 18 18-MAY-2004;
FEATURES
source
Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767
|||||
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 15
AR541361/c
LOCUS AR541361 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 26 from patent US 6737520.
ACCESSION AR541361
VERSION AR541361.1 GI:53933008
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
```

```
JOURNAL Patent: US 6737520-A 26 18-MAY-2004;
FEATURES
source
Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767
|||||
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 16
AR562158/c
LOCUS AR562158 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 34 from patent US 6759215.
ACCESSION AR562158
VERSION AR562158.1 GI:53976021
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
AUTHORS Zsebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 34 06-JUL-2004;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.1%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAAAAAA 1766
|||||
Db 19 GAAAAAAAAAAAAAAAAAAAAA 1

RESULT 17
AX133241
LOCUS AX133241 21 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 4459 from Patent WO0130362.
ACCESSION AX133241
VERSION AX133241.1 GI:14139551
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 4459 03-MAY-2001;
FEATURES
source
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="MMP-3 ribozyme recognition site"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTGAGTCCCTCTATGGA 768
|||||
```

KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Krieg,A.M., Schetter,C. and Vollmer,J.C.  
TITLE Immunostimulatory nucleic acids  
JOURNAL Patent: WO 0122972-A 60 05-APR-2001;  
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical  
GmbH (DE)  
FEATURES  
source Location/Qualifiers  
1. .24  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 35;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
||||| ||||||| ||||||| ||  
Db 24 AAAAACAAAAAACAAAAACAA 1  
RESULT 9  
AX546921/c  
LOCUS AX546921 24 bp DNA linear PAT 01-MAR-2003  
DEFINITION Sequence 60 from Patent WO02053141.  
ACCESSION AX546921  
VERSION AX546921.1 GI:25812065  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Bratzler,R.L.  
TITLE Inhibition of angiogenesis by nucleic acids  
JOURNAL Patent: WO 02053141-A 60 11-JUL-2002;  
Coley Pharmaceutical Group, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1. .24  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Synthetic Sequence"  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 35;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
||||| ||||||| ||||||| ||  
Db 24 AAAAACAAAAAACAAAAACAA 1  
RESULT 10  
AX663747/c  
LOCUS AX663747 24 bp DNA linear PAT 22-MAR-2003  
DEFINITION Sequence 122 from Patent WO02097127.  
ACCESSION AX663747  
VERSION AX663747.1 GI:29163927  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Oellers,N., Gehrmann,M., Kallabis,H., Hall,R., Schulze,T. and  
Kroegel,C.  
TITLE Genes and proteins for prevention, prediction, diagnosis, prognosis  
and treatment of chronic lung disease  
JOURNAL Patent: WO 02097127-A 122 05-DEC-2002;  
Bayer Aktiengesellschaft (DE)

FEATURES  
source Location/Qualifiers  
1. .24  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="L23808 reverse primer"  
Query Match 1.1%; Score 19.2; DB 1; Length 24;  
Best Local Similarity 87.5%; Pred. No. 35;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 981 TGCTTACGAAATTGAAAGCAGAAA 1004  
||||| ||||||| ||||||| ||  
Db 24 TGCTTATGAAATTGAAGCCAGAAA 1  
RESULT 11  
AR541350/c  
LOCUS AR541350 19 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 15 from patent US 6737520.  
ACCESSION AR541350  
VERSION AR541350.1 GI:53932997  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Manoharan,M. and Mohan,V.  
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational  
geometry  
JOURNAL Patent: US 6737520-A 15 18-MAY-2004;  
FEATURES  
source Location/Qualifiers  
1. .19  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 23;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767  
||||| ||||||| ||||||| ||  
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1  
RESULT 12  
AR541351/c  
LOCUS AR541351 19 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 16 from patent US 6737520.  
ACCESSION AR541351  
VERSION AR541351.1 GI:53932998  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Manoharan,M. and Mohan,V.  
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational  
geometry  
JOURNAL Patent: US 6737520-A 16 18-MAY-2004;  
FEATURES  
source Location/Qualifiers  
1. .19  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 1.1%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 23;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767  
||||| ||||||| ||||||| ||  
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1



ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,  
Elghanian,R. and Taton,T.A.  
TITLE Nanoparticles having oligonucleotides attached thereto and uses  
therefor  
JOURNAL Patent: US 6730269-A 55 04-MAY-2004;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20  
RESULT 4  
AR559396  
LOCUS AR559396 20 bp DNA PAT 08-OCT-2004  
DEFINITION Sequence 55 from patent US 6750016.  
ACCESSION AR559396  
VERSION AR559396.1 GI:53968812  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Mirkin,C.A., Letsinger,R.L. and Park,S.-J.  
TITLE Nanoparticles having oligonucleotides attached thereto and uses  
therefor  
JOURNAL Patent: US 6750016-A 55 15-JUN-2004;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20  
RESULT 5  
AR559411  
LOCUS AR559411 20 bp DNA PAT 08-OCT-2004  
DEFINITION Sequence 70 from patent US 6750016.  
ACCESSION AR559411  
VERSION AR559411.1 GI:53968827  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Mirkin,C.A., Letsinger,R.L. and Park,S.-J.  
TITLE Nanoparticles having oligonucleotides attached thereto and uses  
therefor  
JOURNAL Patent: US 6750016-A 70 15-JUN-2004;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20  
RESULT 6  
AR561993  
LOCUS AR561993 20 bp DNA PAT 08-OCT-2004  
DEFINITION Sequence 55 from patent US 6759199.  
ACCESSION AR561993  
VERSION AR561993.1 GI:53975645  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,  
Elghanian,R. and Taton,T.A.  
TITLE Nanoparticles having oligonucleotides attached thereto and uses  
therefor  
JOURNAL Patent: US 6759199-A 55 06-JUL-2004;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20  
RESULT 7  
AR565165  
LOCUS AR565165 20 bp DNA PAT 08-OCT-2004  
DEFINITION Sequence 55 from patent US 6767702.  
ACCESSION AR565165  
VERSION AR565165.1 GI:53981003  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,  
Elghanian,R., Taton,T.A., Garimella,V. and Li,Z.  
TITLE Nanoparticles having oligonucleotides attached thereto and uses  
therefor  
JOURNAL Patent: US 6767702-A 55 27-JUL-2004;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20  
RESULT 8  
AX103868/c  
LOCUS AX103868 24 bp DNA PAT 30-APR-2001  
DEFINITION Sequence 60 from Patent WO0122972.  
ACCESSION AX103868  
VERSION AX103868.1 GI:13920065

ACCESSION:AX264073  
ACCESSION:AX500046  
ACCESSION:AX500047  
ACCESSION:AX500048  
ACCESSION:AX500049  
ACCESSION:AR053059  
ACCESSION:AR065020  
ACCESSION:AR131042  
ACCESSION:BD198986  
ACCESSION:BD199265  
ACCESSION:CQ616134  
ACCESSION:CQ625688  
ACCESSION:CQ625694  
ACCESSION:I32565  
ACCESSION:I37483  
ACCESSION:I37484  
ACCESSION:I37503  
ACCESSION:I37504  
ACCESSION:I37524  
ACCESSION:I37525  
ACCESSION:I37527  
ACCESSION:I37528  
ACCESSION:I37596  
ACCESSION:I37681  
ACCESSION:I94333  
ACCESSION:I94334  
ACCESSION:I94353  
ACCESSION:I94354  
ACCESSION:I94374  
ACCESSION:I94375  
ACCESSION:I94377  
ACCESSION:I94378  
ACCESSION:I94446  
ACCESSION:I94531  
ACCESSION:AR186804  
ACCESSION:AR190639  
ACCESSION:AR190640  
ACCESSION:AR192330  
ACCESSION:AR192331  
ACCESSION:AR305400  
ACCESSION:AR309504  
ACCESSION:AR323435  
ACCESSION:AR325562  
ACCESSION:AR325563  
ACCESSION:AR326200  
ACCESSION:AR326201  
ACCESSION:AR434000  
ACCESSION:AR434398  
ACCESSION:AR434399  
ACCESSION:AR457197  
ACCESSION:AR466751  
ACCESSION:AR466757  
ACCESSION:AX166715  
ACCESSION:AX475778  
ACCESSION:AX578467  
ACCESSION:AX578823  
ACCESSION:AX579415  
ACCESSION:AX579840  
ACCESSION:AX673455  
ACCESSION:AX688682  
ACCESSION:AX691461  
ACCESSION:AX691462  
ACCESSION:AX693628  
ACCESSION:AX693629  
ACCESSION:AX724098  
ACCESSION:AX725035  
ACCESSION:AX729230  
ACCESSION:AX759759  
ACCESSION:BD106311  
ACCESSION:AR055837  
ACCESSION:AR113595  
ACCESSION:AR133315  
ACCESSION:BD244856

14 0.8 17 1 AX264073  
14 0.8 17 1 AX500046  
14 0.8 17 1 AX500047  
14 0.8 17 1 AX500048  
14 0.8 17 1 AX500049  
13.8 0.8 17 1 AR053059  
13.8 0.8 17 1 AR065020  
13.8 0.8 17 1 AR131042  
13.8 0.8 17 1 BD198986  
13.8 0.8 17 1 BD199265  
13.8 0.8 17 1 CQ616134  
13.8 0.8 17 1 CQ625688  
13.8 0.8 17 1 CQ625694  
13.8 0.8 17 1 I32565  
13.8 0.8 17 1 I37483  
13.8 0.8 17 1 I37484  
13.8 0.8 17 1 I37503  
13.8 0.8 17 1 I37504  
13.8 0.8 17 1 I37524  
13.8 0.8 17 1 I37525  
13.8 0.8 17 1 I37527  
13.8 0.8 17 1 I37528  
13.8 0.8 17 1 I37596  
13.8 0.8 17 1 I37681  
13.8 0.8 17 1 I94333  
13.8 0.8 17 1 I94334  
13.8 0.8 17 1 I94353  
13.8 0.8 17 1 I94354  
13.8 0.8 17 1 I94374  
13.8 0.8 17 1 I94375  
13.8 0.8 17 1 I94377  
13.8 0.8 17 1 I94378  
13.8 0.8 17 1 I94446  
13.8 0.8 17 1 I94531  
13.8 0.8 17 1 AR186804  
13.8 0.8 17 1 AR190639  
13.8 0.8 17 1 AR190640  
13.8 0.8 17 1 AR192330  
13.8 0.8 17 1 AR192331  
13.8 0.8 17 1 AR305400  
13.8 0.8 17 1 AR309504  
13.8 0.8 17 1 AR323435  
13.8 0.8 17 1 AR325562  
13.8 0.8 17 1 AR325563  
13.8 0.8 17 1 AR326200  
13.8 0.8 17 1 AR326201  
13.8 0.8 17 1 AR434000  
13.8 0.8 17 1 AR434398  
13.8 0.8 17 1 AR434399  
13.8 0.8 17 1 AR457197  
13.8 0.8 17 1 AR466751  
13.8 0.8 17 1 AR466757  
13.8 0.8 17 1 AX166715  
13.8 0.8 17 1 AX475778  
13.8 0.8 17 1 AX578467  
13.8 0.8 17 1 AX578823  
13.8 0.8 17 1 AX579415  
13.8 0.8 17 1 AX579840  
13.8 0.8 17 1 AX673455  
13.8 0.8 17 1 AX688682  
13.8 0.8 17 1 AX691461  
13.8 0.8 17 1 AX691462  
13.8 0.8 17 1 AX693628  
13.8 0.8 17 1 AX693629  
13.8 0.8 17 1 AX724098  
13.8 0.8 17 1 AX725035  
13.8 0.8 17 1 AX729230  
13.8 0.8 17 1 AX759759  
13.8 0.8 17 1 BD106311  
13.4 0.7 15 1 AR055837  
13.4 0.7 15 1 AR113595  
13.4 0.7 15 1 AR133315  
13.4 0.7 15 1 BD244856

180 13.4 0.7 15 1 AX632930  
181 13.4 0.7 16 1 CQ831855  
182 13.4 0.7 16 1 AR328665  
183 13.4 0.7 16 1 AX458441  
ACCESSION:AX632930  
ACCESSION:CQ831855  
ACCESSION:AR328665  
ACCESSION:AX458441

RESULT 1  
AR541545/c  
LOCUS AR541545 30 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 1 from patent US 6743588.  
ACCESSION AR541545  
VERSION AR541545.1 GI:539333523  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 30)  
AUTHORS Tokunaga,T., Ishiguro,T. and Horie,R.  
TITLE Fluorescent dye and method of measuring nucleic acid  
JOURNAL Patent: US 6743588-A 1 01-JUN-2004;  
FEATURES  
Location/Qualifiers  
source  
1..30  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.5%; Score 27; DB 1; Length 30;  
Best Local Similarity 100.0%; Pred. No. 4.4;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1775  
|||||  
Db 30 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 4

RESULT 2  
AR541546  
LOCUS AR541546 30 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 2 from patent US 6743588.  
ACCESSION AR541546  
VERSION AR541546.1 GI:539333524  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 30)  
AUTHORS Tokunaga,T., Ishiguro,T. and Horie,R.  
TITLE Fluorescent dye and method of measuring nucleic acid  
JOURNAL Patent: US 6743588-A 2 01-JUN-2004;  
FEATURES  
Location/Qualifiers  
source  
1..30  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.5%; Score 27; DB 1; Length 30;  
Best Local Similarity 100.0%; Pred. No. 4.4;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1775  
|||||  
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 27

RESULT 3  
AR532682  
LOCUS AR532682 20 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 55 from patent US 6730269.  
ACCESSION AR532682  
VERSION AR532682.1 GI:53922053  
KEYWORDS  
SOURCE Unknown.

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:18:34 ; Search time 3 Seconds  
(without alignments)  
3.868 Million cell updates/sec

Title: US-10-619-906-2  
Perfect score: 1790  
Sequence: 1 atgaatttctcatgatg.....aaaaacggaattcccgaggga 1790

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 183 seqs, 3241 residues

Total number of hits satisfying chosen parameters: 366

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 183 summaries

Database : rge2.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	27	1.5	30	1	AR541545
2	27	1.5	30	1	AR541546
3	20	1.1	20	1	AR532682
4	20	1.1	20	1	AR559396
5	20	1.1	20	1	AR559411
6	20	1.1	20	1	AR561993
7	20	1.1	20	1	AR565165
8	19.2	1.1	24	1	AX103868
9	19.2	1.1	24	1	AX546921
10	19.2	1.1	24	1	AX663747
11	19	1.1	19	1	AR541350
12	19	1.1	19	1	AR541351
13	19	1.1	19	1	AR541352
14	19	1.1	19	1	AR541353
15	19	1.1	19	1	AR541361
16	19	1.1	20	1	AR562158
17	19	1.1	21	1	AX133241
18	18.6	1.0	23	1	I46905
19	18.2	1.0	19	1	AR528447
20	18	1.0	20	1	AR562156
21	18	1.0	20	1	AR562157
22	17	0.9	18	1	I38057
23	17	0.9	18	1	I94907
24	16.8	0.9	20	1	E31760
25	16.8	0.9	20	1	E31761
26	16.8	0.9	20	1	E31765
27	16.8	0.9	20	1	E31766
28	16.8	0.9	20	1	AX167124
29	16.8	0.9	21	1	I31840
30	16.8	0.9	21	1	AX134131
31	16.8	0.9	21	1	AX189740
32	16.4	0.9	20	1	AX021121
33	16.4	0.9	20	1	AX613732

34	16	0.9	16	1	AR561628	ACCESSION:AR561628
C 35	16	0.9	16	1	AR561693	ACCESSION:AR561693
36	16	0.9	16	1	AX217704	ACCESSION:AX217704
37	16	0.9	16	1	AR266181	ACCESSION:AR266181
38	16	0.9	16	1	AX300803	ACCESSION:AX300803
39	15.8	0.9	15.8	1	AX132826	ACCESSION:AX132826
C 40	15.4	0.9	15.4	1	CQ625692	ACCESSION:CQ625692
41	15.4	0.9	15.4	1	I37482	ACCESSION:I37482
42	15.4	0.9	15.4	1	I94332	ACCESSION:I94332
C 43	15.4	0.9	15.4	1	AR466755	ACCESSION:AR466755
44	15.4	0.9	15.4	1	AX217325	ACCESSION:AX217325
45	15.4	0.9	15.4	1	AX217705	ACCESSION:AX217705
46	15	0.8	15	1	AR180490	ACCESSION:AR180490
47	15	0.8	15	1	AX218129	ACCESSION:AX218129
C 48	14.8	0.8	14.8	1	AR096838	ACCESSION:AR096838
C 49	14.8	0.8	14.8	1	CQ808362	ACCESSION:CQ808362
50	14.8	0.8	14.8	1	I37008	ACCESSION:I37008
51	14.8	0.8	14.8	1	I38061	ACCESSION:I38061
52	14.8	0.8	14.8	1	I38104	ACCESSION:I38104
53	14.8	0.8	14.8	1	I38116	ACCESSION:I38116
54	14.8	0.8	14.8	1	I93858	ACCESSION:I93858
55	14.8	0.8	14.8	1	I94911	ACCESSION:I94911
56	14.8	0.8	14.8	1	I94954	ACCESSION:I94954
57	14.8	0.8	14.8	1	I94966	ACCESSION:I94966
C 58	14.8	0.8	14.8	1	AR293759	ACCESSION:AR293759
C 59	14.4	0.8	14.4	1	AR328663	ACCESSION:AR328663
C 60	14.4	0.8	14.4	1	AR328664	ACCESSION:AR328664
C 61	14.4	0.8	14.4	1	AR435918	ACCESSION:AR435918
C 62	14.4	0.8	14.4	1	AR046207	ACCESSION:AR046207
C 63	14.4	0.8	14.4	1	AR047290	ACCESSION:AR047290
64	14.4	0.8	14.4	1	BD201350	ACCESSION:BD201350
C 65	14.4	0.8	14.4	1	CQ625691	ACCESSION:CQ625691
C 66	14.4	0.8	14.4	1	CQ625693	ACCESSION:CQ625693
67	14.4	0.8	14.4	1	I37433	ACCESSION:I37433
C 68	14.4	0.8	14.4	1	I53259	ACCESSION:I53259
C 69	14.4	0.8	14.4	1	I54342	ACCESSION:I54342
70	14.4	0.8	14.4	1	I94283	ACCESSION:I94283
71	14.4	0.8	14.4	1	AR190342	ACCESSION:AR190342
72	14.4	0.8	14.4	1	AR325288	ACCESSION:AR325288
C 73	14.4	0.8	14.4	1	AR328139	ACCESSION:AR328139
C 74	14.4	0.8	14.4	1	AR466754	ACCESSION:AR466754
C 75	14.4	0.8	14.4	1	AR466756	ACCESSION:AR466756
76	14.4	0.8	14.4	1	AX217706	ACCESSION:AX217706
77	14.4	0.8	14.4	1	AX325541	ACCESSION:AX325541
C 78	14.4	0.8	14.4	1	AX325542	ACCESSION:AX325542
C 79	14.4	0.8	14.4	1	AX672257	ACCESSION:AX672257
80	14.4	0.8	14.4	1	AX728771	ACCESSION:AX728771
C 81	14.4	0.8	14.4	1	AX735442	ACCESSION:AX735442
82	14.4	0.8	14.4	1	AX736604	ACCESSION:AX736604
83	14.4	0.8	14.4	1	AX757296	ACCESSION:AX757296
84	14.4	0.8	14.4	1	CQ807658	ACCESSION:CQ807658
C 85	14.4	0.8	14.4	1	AR488779	ACCESSION:AR488779
86	14.4	0.8	14.4	1	AX378430	ACCESSION:AX378430
C 87	14.4	0.8	14.4	1	AX419771	ACCESSION:AX419771
C 88	14.4	0.8	14.4	1	BD085033	ACCESSION:BD085033
89	14.4	0.8	14.4	1	BD088981	ACCESSION:BD088981
90	14.4	0.8	14.4	1	AB068916	ACCESSION:AB068916
91	14	0.8	14	1	AR054087	ACCESSION:AR054087
92	14	0.8	14	1	AR436182	ACCESSION:AR436182
93	14	0.8	14	1	AX132931	ACCESSION:AX132931
94	14	0.8	14	1	AX133152	ACCESSION:AX133152
95	14	0.8	14	1	BD241272	ACCESSION:BD241272
C 96	14	0.8	14	1	BD254950	ACCESSION:BD254950
C 97	14	0.8	14	1	CQ625689	ACCESSION:CQ625689
C 98	14	0.8	14	1	CQ625690	ACCESSION:CQ625690
99	14	0.8	14	1	AR434400	ACCESSION:AR434400
100	14	0.8	14	1	AR434401	ACCESSION:AR434401
101	14	0.8	14	1	AR434402	ACCESSION:AR434402
102	14	0.8	14	1	AR434403	ACCESSION:AR434403
C 103	14	0.8	14	1	AR466752	ACCESSION:AR466752
C 104	14	0.8	14	1	AR466753	ACCESSION:AR466753
105	14	0.8	14	1	AR482773	ACCESSION:AR482773
106	14	0.8	14	1	AX264072	ACCESSION:AX264072

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10434

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      835 TTGAGTTTGTGCTGT 851
Db      17 TCGACTTTGTGCTGT 1

RESULT 372
US-10-724-270-145/c
; Sequence 145, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; TITLE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MEHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 145
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-145

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1688 CTCTCTTGCTTTACTG 1704
Db      17 CTGCTTGCTTTGCTG 1

Search completed: May 13, 2005, 12:24:30
Job time : 6 secs
```



```
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 874
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-874
```

```
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1131 CTTTGACCCACTTCGCC 1147
Db 17 CTTTGACCCCTCTCGCC 1

RESULT 370
US-10-723-361-10428/c
; Sequence 10428, Application US/107233361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
```

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10428
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10428
```

```
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 841 TTTGATGCTGTCAAC 857
Db 17 TTTGATGCTGTCAAC 1
```

RESULT 371

```
US-10-723-361-10434/c
; Sequence 10434, Application US/107233361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10434
; LENGTH: 17
```

```

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2965
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2965

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 30 ACAGGTATCTGCCTGTG 46
Db 1 ACUGGUUUCUGCCUGUG 17

RESULT 366
US-10-287-949A-3602/c
; Sequence 3602, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3602

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1765
Db 17 AAACAAACCAACAAAAA 1

RESULT 367
US-10-287-949A-3603/c
; Sequence 3603, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3603
```

```

; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3603

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1765
Db 17 AAACAAACCAACAAAAA 1

RESULT 368
US-10-669-841-2269/c
; Sequence 2269, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2269
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-2269

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 792 GACAAACCTAGCAGTC 808
Db 17 GATAAACCTAGCAGGC 1

RESULT 369
US-10-723-361-874/c
; Sequence 874, Application US/10723361
```

Best Local Similarity 58.8%; Pred. No. 2.5e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 30 ACAGGTATCTGCCTGTG 46  
||| |:|:|:|:|:  
Db 1 ACUGGUUUCUGCCUG 17

RESULT 361  
US-10-138-674-3602/c  
; Sequence 3602, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3602  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-138-674-3602

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1765  
||| ||||| |||||  
Db 17 AAACAAAAAACAAAAA 1

RESULT 362  
US-10-138-674-3603/c  
; Sequence 3603, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3603  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-138-674-3603

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1765  
||| ||||| |||||  
Db 17 AAACAAAAAACAAAAA 1

RESULT 363

US-10-287-949A-837/c  
; Sequence 837, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 837  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-837

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 217 GACAACTCAACTCTGGC 233  
||||| ||||| |||||  
Db 17 GACAACTCAACTCTGGC 1

RESULT 364  
US-10-287-949A-2964  
; Sequence 2964, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2964  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-287-949A-2964

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 2.5e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 29 TACAGGTATCTGCCTGT 45  
:|:|:|:|:|:|:  
Db 1 UACUGGUUUCUGCCUG 17

RESULT 365  
US-10-287-949A-2965  
; Sequence 2965, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime

```

; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 821
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-821

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1176 CTACTGGAGGTATGATG 1192
Db      1 CTAGGGGAGGTATGATG 17

RESULT 357
US-10-675-685-822
; Sequence 822, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-822

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1177 TACTGGAGGTATGATGT 1193
Db      1 TAGGGGAGGTATGATGT 17

RESULT 358
US-10-138-674-837/c
; Sequence 837, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
```

```

; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-837

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      217 GACAACTCAAACTCTGGC 233
Db      17 GACAACTTAACCTCTGGC 1

RESULT 359
US-10-138-674-2964
; Sequence 2964, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2964
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2964

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.5e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      29 TACAGGTATCTGCCTGT 45
Db      1 UACUGGUUUCUGCCUGU 17

RESULT 360
US-10-138-674-2965
; Sequence 2965, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2965
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2965

Query Match      0.8%; Score 13.8; DB 1; Length 17;
```





Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.5e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 594 AAGTTTTCAGGCACAA 610  
|||:::|||||  
Db 1 AAGUUUUCAAAGCAAAA 17

RESULT 350  
US-10-238-700-145/c  
; Sequence 145, Application US/10238700  
; Publication No. US20030153521A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level  
; FILE REFERENCE: 400/057 (MBHB01-1158-A)  
; CURRENT APPLICATION NUMBER: US/10/238,700  
; CURRENT FILING DATE: 2002-09-18  
; PRIOR APPLICATION NUMBER: PCT/US 02/16840  
; PRIOR FILING DATE: 2002-05-29  
; PRIOR APPLICATION NUMBER: US 60/318,471  
; PRIOR FILING DATE: 2001-09-10  
; NUMBER OF SEQ ID NOS: 4666  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 145  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-238-700-145

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1688 CTCTCTTGCTTTACTG 1704  
||| ||||| |||||  
Db 17 CTGCTTGCTTTGCTG 1

RESULT 351  
US-10-331-907-354/c  
; Sequence 354, Application US/10331907  
; Publication No. US20030181660A1  
; GENERAL INFORMATION:  
; APPLICANT: Todd, John A  
; Hess, John W  
; Caskey, Charles T  
; Cox, Roger D  
; Gerhold, David  
; Hammond, Holly  
; Hey, Patricia  
; Kawaguchi, Yoshihiko  
; Merriman, Tony R  
; Metzker, Michael L  
; TITLE OF INVENTION: No. US20030181660A1e1 LDL-Receptor  
; NUMBER OF SEQUENCES: 455  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Nixon and Vanderhye  
; STREET: 1100 No. US20030181660A1th Glebe Road, Eighth Floor  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: US  
; ZIP: VA 22201-4714  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/331,907  
; FILING DATE: 31-Dec-2002

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/402,923A  
FILING DATE: 14-Feb-2001  
APPLICATION NUMBER: PCT/GB98/01102  
FILING DATE: 15-APR-1998  
APPLICATION NUMBER: US 60/043,553  
FILING DATE: 15-APR-1997  
APPLICATION NUMBER: US 60/048,740  
FILING DATE: 05-JUN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: B.J.Sadoff  
REGISTRATION NUMBER: 36,663  
REFERENCE/DOCKET NUMBER: 620-81  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703)816-4091  
TELEFAX: (703)816-4100  
INFORMATION FOR SEQ ID NO: 354:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 354:  
US-10-331-907-354

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 762 CTATGGAGCCCCAGTGA 778  
| ||||| |||||  
Db 17 CCATGGAGCCCGAGTGA 1

RESULT 352  
US-10-430-882-789  
; Sequence 789, Application US/10430882  
; Publication No. US20030203870A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowrira  
; APPLICANT: Peter Haerberli  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G  
; FILE REFERENCE: MBHB00-878-H (400/112)  
; CURRENT APPLICATION NUMBER: US/10/430,882  
; CURRENT FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 09/827,395  
; PRIOR FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: PCT/US01/04273  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: PCT/US02/10512  
; PRIOR FILING DATE: 2002-04-03  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 789  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-430-882-789

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 2.5e+02;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1208 TGGACCCCTGCTTACCCC 1224  
: ||| ||| : |||  
Db 1 UGGGCCCCUGCUGACCCC 17

QY 1254 CAAGCCTAAATTTGATG 1270  
|||||:||||:|  
Db 1 CAAGCCUAACAUUGGUG 17  
  
RESULT 345  
US-09-827-395A-789  
; Sequence 789, Application US/09827395A  
; Publication No. US20030113891A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowrira  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor  
; FILE REFERENCE: MBHB00-878-C (400/017)  
; CURRENT APPLICATION NUMBER: US/09/827,395A  
; CURRENT FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 789  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-827-395A-789

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 2.5e+02;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1208 TGGACCCCTGCTTACCCC 1224  
:|||:||||:|  
Db 1 UGGGCCCCUGCUGACCCC 17

RESULT 346  
US-09-745-237A-952  
; Sequence 952, Application US/09745237A  
; Publication No. US20030143708A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: 400/007 (MBHB00-918-A)  
; CURRENT APPLICATION NUMBER: US/09/745,237A  
; CURRENT FILING DATE: 2002-04-15  
; NUMBER OF SEQ ID NOS: 4550  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 952  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-745-237A-952

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 2.5e+02;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1251 AATCAAGCCTAAATTTG 1267  
|||:||||:|  
Db 1 AAACAAGCCUAACAUUG 17

RESULT 347  
US-09-745-237A-954  
; Sequence 954, Application US/09745237A  
; Publication No. US20030143708A1  
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: 400/007 (MBHB00-918-A)  
; CURRENT APPLICATION NUMBER: US/09/745,237A  
; CURRENT FILING DATE: 2002-04-15  
; NUMBER OF SEQ ID NOS: 4550  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 954  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-745-237A-954

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.5e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1256 AGCCTAAATTTGATGCA 1272  
|||||:||||:|  
Db 1 AGCCUACAUUGGUGCA 17

RESULT 348  
US-09-745-237A-1445  
; Sequence 1445, Application US/09745237A  
; Publication No. US20030143708A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: 400/007 (MBHB00-918-A)  
; CURRENT APPLICATION NUMBER: US/09/745,237A  
; CURRENT FILING DATE: 2002-04-15  
; NUMBER OF SEQ ID NOS: 4550  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1445  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-745-237A-1445

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.5e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1254 CAAGCCTAAATTTGATG 1270  
|||||:||||:|  
Db 1 CAAGCCUAACAUUGGUG 17

RESULT 349  
US-10-156-306-1493  
; Sequence 1493, Application US/10156306  
; Publication No. US20030119017A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: MBHB01-664-A (400/050)  
; CURRENT APPLICATION NUMBER: US/10/156,306  
; CURRENT FILING DATE: 2002-05-28  
; NUMBER OF SEQ ID NOS: 8013  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1493  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-156-306-1493

Best Local Similarity 88.2%; Pred. No. 2.5e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 502 GATGGCAAAGGTGGTAC 518  
|||||  
Db 17 GATGGCACAGGTGGCAC 1

RESULT 340  
US-09-848-754A-2380/c  
; Sequence 2380, Application US/09848754A  
; Publication No. US20030073207A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors  
; FILE REFERENCE: MBHB00-958-I (400/018)  
; CURRENT APPLICATION NUMBER: US/09/848,754A  
; CURRENT FILING DATE: 2001-05-03  
; NUMBER OF SEQ ID NOS: 9645  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2380  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-848-754A-2380

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 499 TTGTATGGCAAAGGTGG 515  
|||||  
Db 17 TTGTATGGCACAGGTGG 1

RESULT 341  
US-09-848-754A-2718/c  
; Sequence 2718, Application US/09848754A  
; Publication No. US20030073207A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors  
; FILE REFERENCE: MBHB00-958-I (400/018)  
; CURRENT APPLICATION NUMBER: US/09/848,754A  
; CURRENT FILING DATE: 2001-05-03  
; NUMBER OF SEQ ID NOS: 9645  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2718  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-848-754A-2718

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1512 ACAGGTCACACACAT 1528  
|||||  
Db 17 ACAGGTCACACACAT 1

RESULT 342  
US-09-930-423-952  
; Sequence 952, Application US/09930423  
; Publication No. US20030092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease

; FILE REFERENCE: MBHB00,918-A 400/027  
; CURRENT APPLICATION NUMBER: US/09/930,423  
; CURRENT FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 4553  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 952  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-09-930-423-952

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 2.5e+02; Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1251 AATCAAGCCTAAAATTG 1267  
|||  
Db 1 AAACAAGCCUAACAUG 17

RESULT 343  
US-09-930-423-954  
; Sequence 954, Application US/09930423  
; Publication No. US20030092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: MBHB00,918-A 400/027  
; CURRENT APPLICATION NUMBER: US/09/930,423  
; CURRENT FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 4553  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 954  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-09-930-423-954

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.5e+02; Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 AGCCTAAAATTGATGCA 1272  
|||||  
Db 1 AGCCUAACAUGGUGCA 17

RESULT 344  
US-09-930-423-1445  
; Sequence 1445, Application US/09930423  
; Publication No. US20030092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: MBHB00,918-A 400/027  
; CURRENT APPLICATION NUMBER: US/09/930,423  
; CURRENT FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 4553  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1445  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-09-930-423-1445

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.5e+02; Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;



; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1253
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1253

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 7 TTTCTCATGATGATTGT 23
Db 17 TTTCTCATCATATTGT 1

RESULT 336
US-09-927-046-1678/c
; Sequence 1678, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1678
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1678

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 ATTTCTCATGATGATTG 22
Db 17 ATTTCTCATCATATTG 1

RESULT 337
US-09-877-478-2466/c
; Sequence 2466, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrisey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24

; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2466
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2466

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 792 GACAAAACCTAGCAGTC 808
Db 17 GATAAAACCTAGCAGGC 1

RESULT 338
US-09-848-754A-1292/c
; Sequence 1292, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1292
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1292

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 503 ATGGCAAAGGTGGTACA 519
Db 17 ATGGCACAGGTGGCAC A 1

RESULT 339
US-09-848-754A-1293/c
; Sequence 1293, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1293
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1293

Query Match 0.8%; Score 13.8; DB 1; Length 17;

```
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 821
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-821

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1176 CTACTGGAGGTATGATG 1192
Db      1 CTAGGGGAGGTATGATG 17

RESULT 332
US-09-827-998-822
; Sequence 822, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-822

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1177 TACTGGAGGTATGATGT 1193
Db      1 TAGGGGAGGTATGATGT 17

RESULT 333
US-09-927-046-305/c
; Sequence 305, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
```

```
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 305
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-305

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      298 TCAAGATGGATGAAGCG 314
Db      17 TCAAGCTGGATGGAGCG 1

RESULT 334
US-09-927-046-661
; Sequence 661, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 661
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-661

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.5e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy      1093 GGCTTCTCTGCATCTGT 1109
Db      1 GGCAUCUCUGUAUCUGU 17

RESULT 335
US-09-927-046-1253/c
; Sequence 1253, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
```

; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 10428  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-10428

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 841 TTTGATGCTGTCAAC 857  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 TTTGATGCTGTCAAC 1

RESULT 329  
US-09-866-108-10434/c  
; Sequence 10434, Application US/09866108  
; Patent No. US2002048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 10434  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-10434

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 TTGAGTTTGATGCTGT 851  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 TCGACTTTTGATGCTGT 1

RESULT 330  
US-09-827-998-423  
; Sequence 423, Application US/09827998  
; Patent No. US20020102252A1  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; APPLICANT: Shannon, Mark  
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
; FILE REFERENCE: MDHMORF-8  
; CURRENT APPLICATION NUMBER: US/09/827,998  
; CURRENT FILING DATE: 2001-04-06  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; NUMBER OF SEQ ID NOS: 1881  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 423  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-827-998-423

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 TGCCTGTGGGGCTGCTC 55  
| | | | | | | | | | | | | | | | | | | | |  
Db 1 TGCCTGTGGGGCTGCTC 17

RESULT 331  
US-09-827-998-821  
; Sequence 821, Application US/09827998

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1122
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1122

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 2.4e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      1706 AATGTACATGTTT 1719
Db      3 AAUGUACAUGUUU 16

RESULT 326
US-10-724-270-1123
; Sequence 1123, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1123
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1123

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 2.4e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      1706 AATGTACATGTTT 1719
Db      1 AAUGUACAUGUUU 14

RESULT 327
US-09-866-108-874/c
; Sequence 874, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 874
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-874

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1131 CTTTGACCCACTTCGCC 1147
Db      17 CTTTGACCCCTCCTCGCC 1

RESULT 328
US-09-866-108-10428/c
; Sequence 10428, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```



; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10430
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10430

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853
Db 16 TTTTGATGCTGTCA 3

RESULT 323
US-10-681-074-1463
; Sequence 1463, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1463
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-1463

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 15 CAATTGGAATATGA 2

RESULT 325
US-10-724-270-1122
; Sequence 1122, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; TITLE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16

Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 3 CAATTGGAATATGA 16

RESULT 324
US-10-681-074-1464/c
; Sequence 1464, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-1464

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 15 CAATTGGAATATGA 2

RESULT 325
US-10-724-270-1122
; Sequence 1122, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; TITLE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 825
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-825

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1181 GGAGGTATGATGTG 1194
Db 2 GGAGGTATGATGTG 15

RESULT 319
US-10-675-685-826
; Sequence 826, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 826
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-826

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1181 GGAGGTATGATGTG 1194
Db 1 GGAGGTATGATGTG 14

RESULT 320
US-10-676-154-219
; Sequence 219, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/676,154
; CURRENT FILING DATE: 2003-09-29
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 219
; LENGTH: 17

; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-676-154-219

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1483 ATAAATGTAACAGGA 1496
Db 4 ATAAATGTAACAGGA 17

RESULT 321
US-10-723-361-10429/c
; Sequence 10429, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10429
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10429

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 840 TTTTGATGCTGTCA 853
Db 17 TTTTGATGCTGTCA 4

RESULT 322
US-10-723-361-10430/c
; Sequence 10430, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

```

; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1463
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1463

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 3 CAATTGGAATATGA 16

RESULT 315
US-10-261-185-1464/c
; Sequence 1464, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1464

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 15 CAATTGGAATATGA 2

RESULT 316
US-10-675-685-823
; Sequence 823, Application US/10675685
; Publication No. US20040063134A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-823

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 4 GGAGGTATGATGTG 17

RESULT 317
US-10-675-685-824
; Sequence 824, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-824

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 3 GGAGGTATGATGTG 16

RESULT 318
US-10-675-685-825
; Sequence 825, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

; CURRENT APPLICATION NUMBER: US/10/238,700  
; CURRENT FILING DATE: 2002-09-18  
; PRIOR APPLICATION NUMBER: PCT/US 02/16840  
; PRIOR FILING DATE: 2002-05-29  
; PRIOR APPLICATION NUMBER: US 60/318,471  
; PRIOR FILING DATE: 2001-09-10  
; NUMBER OF SEQ ID NOS: 4666  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1122  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-238-700-1122

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 57.1%; Pred. No. 2.4e+02;  
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1706 AATGTAACATGTTT 1719  
||:|||||:|:  
Db 3 AAUGUACAUGUUU 16

RESULT 311

US-10-238-700-1123  
; Sequence 1123, Application US/10238700  
; Publication No. US20030153521A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level  
; FILE REFERENCE: 400/057 (MBHB01-1158-A)  
; CURRENT APPLICATION NUMBER: US/10/238,700  
; CURRENT FILING DATE: 2002-09-18  
; PRIOR APPLICATION NUMBER: PCT/US 02/16840  
; PRIOR FILING DATE: 2002-05-29  
; PRIOR APPLICATION NUMBER: US 60/318,471  
; PRIOR FILING DATE: 2001-09-10  
; NUMBER OF SEQ ID NOS: 4666  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1123.  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-238-700-1123

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 57.1%; Pred. No. 2.4e+02;  
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1706 AATGTAACATGTTT 1719  
||:|||||:|:  
Db 1 AAUGUACAUGUUU 14

RESULT 312

US-10-209-787-1463  
; Sequence 1463, Application US/10209787  
; Publication No. US20030217377A1  
; GENERAL INFORMATION:  
; APPLICANT: Kmiec, Eric B.  
; APPLICANT: Gamper, Howard B.  
; APPLICANT: Rice, Michael C.  
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
; TITLE OF INVENTION: Stranded Oligonucleotides  
; FILE REFERENCE: Napro-4  
; CURRENT APPLICATION NUMBER: US/10/209,787  
; CURRENT FILING DATE: 2002-07-30  
; PRIOR APPLICATION NUMBER: US 09/818,875  
; PRIOR FILING DATE: 2001-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,176  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,179

; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/208,538  
; PRIOR FILING DATE: 2000-06-01  
; PRIOR APPLICATION NUMBER: US 60/244,989  
; PRIOR FILING DATE: 2000-10-30  
; NUMBER OF SEQ ID NOS: 4385  
; SOFTWARE: Friedman macro Napro4  
; SEQ ID NO 1463  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-209-787-1463

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1318 CAATTGGAATATGA 1331  
|||||||:  
Db 3 CAATTGGAATATGA 16

RESULT 313

US-10-209-787-1464/c  
; Sequence 1464, Application US/10209787  
; Publication No. US20030217377A1  
; GENERAL INFORMATION:  
; APPLICANT: Kmiec, Eric B.  
; APPLICANT: Gamper, Howard B.  
; APPLICANT: Rice, Michael C.  
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
; TITLE OF INVENTION: Stranded Oligonucleotides  
; FILE REFERENCE: Napro-4  
; CURRENT APPLICATION NUMBER: US/10/209,787  
; CURRENT FILING DATE: 2002-07-30  
; PRIOR APPLICATION NUMBER: US 09/818,875  
; PRIOR FILING DATE: 2001-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,176  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,179  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/208,538  
; PRIOR FILING DATE: 2000-06-01  
; PRIOR APPLICATION NUMBER: US 60/244,989  
; PRIOR FILING DATE: 2000-10-30  
; NUMBER OF SEQ ID NOS: 4385  
; SOFTWARE: Friedman macro Napro4  
; SEQ ID NO 1464  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-209-787-1464

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1318 CAATTGGAATATGA 1331  
|||||||:  
Db 15 CAATTGGAATATGA 2

RESULT 314

US-10-261-185-1463  
; Sequence 1463, Application US/10261185  
; Publication No. US20040014057A1  
; GENERAL INFORMATION:  
; APPLICANT: Kmiec, Eric B.  
; APPLICANT: Gamper, Howard B.  
; APPLICANT: Rice, Michael C.  
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
; TITLE OF INVENTION: Stranded Oligonucleotides  
; FILE REFERENCE: Napro-4CON



```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1354

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
Db 16 GAAAGCAGAAATCA 3

RESULT 307
US-10-060-756A-1355/c
; Sequence 1355, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1355

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
Db 15 GAAAGCAGAAATCA 2

RESULT 308
US-10-060-756A-1356/c
; Sequence 1356, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1356
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1356

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
Db 14 GAAAGCAGAAATCA 1

RESULT 309
US-10-096-125-8
; Sequence 8, Application US/10096125
; Publication No. US20030077608A1
; GENERAL INFORMATION:
; APPLICANT: Coull, James M.
; APPLICANT: Fiandaca, Mark J.
; APPLICANT: Kristjanson, Mark D.
; APPLICANT: Hyldig-Nielsen, Jens J.
; APPLICANT: Creasey, Theresa S.
; TITLE OF INVENTION: Methods, Kits And Compositions Pertaining To
; TITLE OF INVENTION: Combination Oligomers And Libraries For Their
; TITLE OF INVENTION: Preparation
; FILE REFERENCE: BP0102-US
; CURRENT APPLICATION NUMBER: US/10/096,125
; CURRENT FILING DATE: 2002-03-09
; PRIOR APPLICATION NUMBER: 60/274,547
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide Primer
US-10-096-125-8

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 394 CAAGTCTGGAGTGA 407
Db 2 CAAGTCTGGAGTGA 15

RESULT 310
US-10-238-700-1122
; Sequence 1122, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; FILE REFERENCE: 400/057 (MEHB01-1158-A)
```

```

; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1464

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 15 CAATTGGAATATGA 2

RESULT 303
US-09-848-754A-2095
; Sequence 2095, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2095
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2095

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1516 GTCACACACACATA 1529
Db 4 GUCACACACACAU 17

RESULT 304
US-09-848-754A-2096
; Sequence 2096, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2096
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2096

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1516 GTCACACACACATA 1529
Db 2 GUCACACACACAU 15
```

```

RESULT 305
US-10-060-756A-1353/c
; Sequence 1353, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1353

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
Db 17 GAAAGCAGAAATCA 4

RESULT 306
US-10-060-756A-1354/c
; Sequence 1354, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1354
; LENGTH: 17
```

; CURRENT APPLICATION NUMBER: US/09/827,998  
; CURRENT FILING DATE: 2001-04-06  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; NUMBER OF SEQ ID NOS: 1881.  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 824  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-827-998-824

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194  
|||||  
Db 3 GGAGGTATGATGTG 16

RESULT 299  
US-09-827-998-825  
; Sequence 825, Application US/09827998  
; Patent No. US20020102252A1  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
; FILE REFERENCE: MDhMORF-8  
; CURRENT APPLICATION NUMBER: US/09/827,998  
; CURRENT FILING DATE: 2001-04-06  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; NUMBER OF SEQ ID NOS: 1881  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 825  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-827-998-825

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194  
|||||  
Db 2 GGAGGTATGATGTG 15

RESULT 300  
US-09-827-998-826  
; Sequence 826, Application US/09827998  
; Patent No. US20020102252A1  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
; FILE REFERENCE: MDhMORF-8  
; CURRENT APPLICATION NUMBER: US/09/827,998  
; CURRENT FILING DATE: 2001-04-06  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; NUMBER OF SEQ ID NOS: 1881  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 826

; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-827-998-826

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194  
|||||  
Db 1 GGAGGTATGATGTG 14

RESULT 301  
US-09-818-875-1463  
; Sequence 1463, Application US/09818875  
; Publication No. US20030051270A1  
; GENERAL INFORMATION:  
; APPLICANT: Kmiec, Eric B.  
; APPLICANT: Gamper, Howard B.  
; APPLICANT: Rice, Michael C.  
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
; TITLE OF INVENTION: Stranded Oligonucleotides  
; FILE REFERENCE: Napro-4  
; CURRENT APPLICATION NUMBER: US/09/818,875  
; CURRENT FILING DATE: 2001-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,176  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,179  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/208,538  
; PRIOR FILING DATE: 2000-06-01  
; PRIOR APPLICATION NUMBER: US 60/244,989  
; PRIOR FILING DATE: 2000-10-30  
; NUMBER OF SEQ ID NOS: 4385  
; SOFTWARE: Friedman macro Napro4  
; SEQ ID NO 1463  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-818-875-1463

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331  
|||||  
Db 3 CAATTGGAATATGA 16

RESULT 302  
US-09-818-875-1464/c  
; Sequence 1464, Application US/09818875  
; Publication No. US20030051270A1  
; GENERAL INFORMATION:  
; APPLICANT: Kmiec, Eric B.  
; APPLICANT: Gamper, Howard B.  
; APPLICANT: Rice, Michael C.  
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
; TITLE OF INVENTION: Stranded Oligonucleotides  
; FILE REFERENCE: Napro-4  
; CURRENT APPLICATION NUMBER: US/09/818,875  
; CURRENT FILING DATE: 2001-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,176  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,179  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/208,538  
; PRIOR FILING DATE: 2000-06-01  
; PRIOR APPLICATION NUMBER: US 60/244,989  
; PRIOR FILING DATE: 2000-10-30

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10429
; .LENGTH: 17
; .TYPE: DNA
; .ORGANISM: Homo sapiens
; US-09-866-108-10429

```

```
Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 840 TTTTGATGCTGTCA 853  
Db 17 TTTTGATGCTGTCA 4

RESULT 296  
US-09-866-108-10430/c  
; Sequence 10430, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10430
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10430

```

Query Match	0.8%;	Score 14;	DB 1;	Length 17;
Best Local Similarity	100.0%;	Pred. No. 2.4e+02;		
Matches 14;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	840	TTTTGATGCTGTCA	853	
db	16	TTTTGATGCTGTCA	3	

## RESULT 297

```

US-09-827
; Sequence 823, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMA
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-823

```

Query Match	0.8%;	Score 14;	DB 1;	Length 17;
Best Local Similarity	100.0%;	Pred. No. 2.4e+02;		
Matches 14;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1181	GGAGGTATGATGTG	1194	
Db	4	GGAGGTATGATGTG	17	

RESULT 298

US-09-827-998-824  
; Sequence 824,, Application US/09827998  
; Patent No. US20020102252A1  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; APPLICANT: Shannon, Mark  
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
; FILE REFERENCE: MDMORF-8



```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/855,532
; FILING DATE: 28-May-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/668,482
; FILING DATE: 25-Sep-2000
; APPLICATION NUMBER: 08/882,164
; FILING DATE: June 25, 1997
; APPLICATION NUMBER: 08/667,546
; FILING DATE: June 21, 1996
; APPLICATION NUMBER: 08/724,466
; FILING DATE: October 1, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunt, John C.
; REGISTRATION NUMBER: 36,424
; REFERENCE/DOCKET NUMBER: 50767/00010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 863-4344
; TELEFAX: (416) 863-2653
; INFORMATION FOR SEQ ID NO: 21
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 21
US-10-855-532-21

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1747 TGAAGAAAAA 1760
Db      14 TGAAGAAAAA 1

RESULT 293
US-10-764-388-11
; Sequence 11, Application US/10764388
; Publication No. US20050004350A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,388
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-388-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAA 1762
Db      1 AAAAAA 14

RESULT 294
US-10-601-140A-21/c
```

```
; Sequence 21, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 21
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; OTHER INFORMATION: LNA monomer
US-10-601-140A-21

Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1763 AAAAAA 1776
Db      14 AAAAAA 1

RESULT 295
US-09-866-108-10429/c
; Sequence 10429, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

US-10-764-389-11  
; Sequence 11, Application US/10764389  
; Publication No. US20040230036A1  
; GENERAL INFORMATION:  
; APPLICANT: STAVRIANOPOULOS, JANNIS G.  
; APPLICANT: RABBANI, ELAZAR  
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING  
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC  
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES  
; FILE REFERENCE: ENZ-61  
; CURRENT APPLICATION NUMBER: US/10/764,389  
; CURRENT FILING DATE: 2004-01-23  
; PRIOR APPLICATION NUMBER: US/10/096,075  
; PRIOR FILING DATE: 2002-03-12  
; NUMBER OF SEQ ID NOS: 12  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 11  
; LENGTH: 14  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-764-389-11  
  
Query Match 0.8%; Score 14; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1749 AAAAAAAAAAAAAA 1762  
Db 1 AAAAAAAAAAAAAA 14  
| | | | | | | | | | | | | | | |  
  
RESULT 290  
US-10-855-595-21/c  
; Sequence 21, Application US/10855595  
; Publication No. US20040235057A1  
; GENERAL INFORMATION:  
; APPLICANT: Petkovich, P. Martin, White, Jay A.,  
Beckett, Barbara R., Jones, Glenville  
; TITLE OF INVENTION: Retinoid Metabolizing Protein  
; NUMBER OF SEQUENCES: 43  
; CORRESPONDENCE ADDRESS:  
ADDRESSEE: Blake, Cassels & Graydon  
STREET: Box 25, Commerce Court West  
CITY: Toronto  
STATE: Ontario  
COUNTRY: Canada  
ZIP: M5L 1A9  
; COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage  
COMPUTER: COMPAQ, IBM PC compatible  
OPERATING SYSTEM: MS-DOS 5.1  
SOFTWARE: WORD PERFECT  
; CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/855,595  
FILING DATE: 28-May-2004  
; PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/668,482  
FILING DATE: 25-Sep-2000  
APPLICATION NUMBER: 08/882,164  
FILING DATE: June 25, 1997  
APPLICATION NUMBER: 08/667,546  
FILING DATE: June 21, 1996  
APPLICATION NUMBER: 08/724,466  
FILING DATE: October 1, 1996  
; ATTORNEY/AGENT INFORMATION:  
NAME: Hunt, John C.  
REGISTRATION NUMBER: 36,424  
REFERENCE/DOCKET NUMBER: 50767/00010  
; TELECOMMUNICATION INFORMATION:  
TELEPHONE: (416) 863-4344  
TELEFAX: (416) 863-2653

; INFORMATION FOR SEQ ID NO: 21  
; SEQUENCE CHARACTERISTICS:  
LENGTH: 14 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
; SEQUENCE DESCRIPTION: SEQ ID NO: 21  
US-10-855-595-21  
  
Query Match 0.8%; Score 14; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1747 TCAAAAAAAAAAAAA 1760  
Db 14 TCAAAAAAAAAAAAAA 1  
| | | | | | | | | | | | | | | |  
  
RESULT 291  
US-10-763-076-11  
; Sequence 11, Application US/10763076  
; Publication No. US20040254355A1  
; GENERAL INFORMATION:  
; APPLICANT: STAVRIANOPOULOS, JANNIS G.  
; APPLICANT: RABBANI, ELAZAR  
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING  
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC  
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES  
; FILE REFERENCE: ENZ-61  
; CURRENT APPLICATION NUMBER: US/10/763,076  
; CURRENT FILING DATE: 2004-01-22  
; PRIOR APPLICATION NUMBER: US/10/096,075  
; PRIOR FILING DATE: 2002-03-12  
; NUMBER OF SEQ ID NOS: 12  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 11  
; LENGTH: 14  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-763-076-11  
  
Query Match 0.8%; Score 14; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1749 AAAAAAAAAAAAAA 1762  
Db 1 AAAAAAAAAAAAAA 14  
| | | | | | | | | | | | | | | |  
  
RESULT 292  
US-10-855-532-21/c  
; Sequence 21, Application US/10855532  
; Publication No. US20040259074A1  
; GENERAL INFORMATION:  
; APPLICANT: Petkovich, P. Martin, White, Jay A.,  
Beckett, Barbara R., Jones, Glenville  
; TITLE OF INVENTION: Retinoid Metabolizing Protein  
; NUMBER OF SEQUENCES: 43  
; CORRESPONDENCE ADDRESS:  
ADDRESSEE: Blake, Cassels & Graydon  
STREET: Box 25, Commerce Court West  
CITY: Toronto  
STATE: Ontario  
COUNTRY: Canada  
ZIP: M5L 1A9  
; COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage  
COMPUTER: COMPAQ, IBM PC compatible  
OPERATING SYSTEM: MS-DOS 5.1  
SOFTWARE: WORD PERFECT

US-10-655-362-108/c  
 ; Sequence 108, Application US/10655362  
 ; Publication No. US20050014163A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Dong, Fang  
 ; APPLICANT: Lyamichev, Victor  
 ; APPLICANT: Prudent, James  
 ; APPLICANT: Fors, Lance  
 ; APPLICANT: Neri, Bruce  
 ; APPLICANT: Brow, Mary Ann  
 ; APPLICANT: Anderson, Todd  
 ; APPLICANT: Dahlberg, James  
 ; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides  
 ; FILE REFERENCE: FORS-04012  
 ; CURRENT APPLICATION NUMBER: US/10/655,362  
 ; CURRENT FILING DATE: 2003-09-04  
 ; PRIOR APPLICATION NUMBER: US/09/402,618B  
 ; PRIOR FILING DATE: 2000-07-18  
 ; PRIOR APPLICATION NUMBER: PCT/US98/03194  
 ; PRIOR FILING DATE: 1998-05-05  
 ; NUMBER OF SEQ ID NOS: 128  
 ; SOFTWARE: PatentIn version 3.0  
 ; SEQ ID NO 108  
 ; LENGTH: 18  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic  
 US-10-655-362-108

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 813 ATCAACTTCTGTCTAC 828  
 | | | | | | | | | | | | | | | |  
 Db 16 AACAACTTCTGTCTAC 1

RESULT 286  
 US-10-473-193-180  
 ; Sequence 180, Application US/10473193  
 ; Publication No. US20050080247A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: SHEN, BEN  
 ; APPLICANT: CHEN, YI-QIANG  
 ; APPLICANT: TANG, GONG-LI  
 ; TITLE OF INVENTION: LEINAMYCIN BIOSYNTHESIS GENE CLUSTER AND ITS COMPONENTS AND THEIR  
 ; FILE REFERENCE: 309T-000110US  
 ; CURRENT APPLICATION NUMBER: US/10/473,193  
 ; CURRENT FILING DATE: 2003-09-24  
 ; PRIOR APPLICATION NUMBER: US 60/278,935  
 ; PRIOR FILING DATE: 2001-03-26  
 ; PRIOR APPLICATION NUMBER: PCT/US02/08937  
 ; PRIOR FILING DATE: 2002-03-22  
 ; NUMBER OF SEQ ID NOS: 222  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 180  
 ; LENGTH: 18  
 ; TYPE: DNA  
 ; ORGANISM: Artificial  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic oligonucleotide PCR primer.  
 US-10-473-193-180

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 600 TCAAGGCACAAACCTC 615  
 | | | | | | | | | | | | | | | |  
 Db 1 TCAAGGCACGAACCTC 16

RESULT 287  
 US-10-830-484-3/c  
 ; Sequence 3, Application US/10830484  
 ; Publication No. US20040220397A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Leuck, Michael  
 ; APPLICANT: Wolter, Andreas  
 ; TITLE OF INVENTION: Solid Support For The Synthesis Of 3' Amino Oligonucleotides  
 ; FILE REFERENCE: PRO13  
 ; CURRENT APPLICATION NUMBER: US/10/830,484  
 ; CURRENT FILING DATE: 2004-04-21  
 ; PRIOR APPLICATION NUMBER: 60/464,269  
 ; PRIOR FILING DATE: 2003-04-21  
 ; NUMBER OF SEQ ID NOS: 4  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 3  
 ; LENGTH: 14  
 ; TYPE: DNA  
 ; ORGANISM: Artificial  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic Nucleic Acid Ligand  
 ; NAME/KEY: misc\_feature  
 ; LOCATION: (1)..(14)  
 ; OTHER INFORMATION: 3' NH2  
 US-10-830-484-3

Query Match 0.8%; Score 14; DB 1; Length 14;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1762  
 | | | | | | | | | | | | | | | |  
 Db 14 AAAAAAAAAAAAAA 1

RESULT 288  
 US-10-764-393-11  
 ; Sequence 11, Application US/10764393  
 ; Publication No. US20040229248A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: STAVRIANOPOULOS, JANNIS G.  
 ; APPLICANT: RABBANI, ELAZAR  
 ; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING  
 ; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC  
 ; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES  
 ; FILE REFERENCE: ENZ-61  
 ; CURRENT APPLICATION NUMBER: US/10/764,393  
 ; CURRENT FILING DATE: 2004-01-23  
 ; PRIOR APPLICATION NUMBER: US/10/096,075  
 ; PRIOR FILING DATE: 2002-03-12  
 ; NUMBER OF SEQ ID NOS: 12  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 11  
 ; LENGTH: 14  
 ; TYPE: RNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Primer  
 US-10-764-393-11

Query Match 0.8%; Score 14; DB 1; Length 14;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1762  
 | | | | | | | | | | | | | | | |  
 Db 1 AAAAAAAAAAAAAA 14

RESULT 289

Best Local Similarity 93.8%; Pred. No. 2.4e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1;

QY 1191 TGTGAGGCAGGAGCTC 1206  
| | | | | | | | | | | | | | | |  
Db 1 TGTGAGGCAGGAATC 16

RESULT 281  
US-09-882-945A-108/c  
; Sequence 108, Application US/09882945A  
; Publication No. US20030143535A1  
; GENERAL INFORMATION:  
; APPLICANT: Lyamichev, Victor  
; APPLICANT: Allawi, Hatim  
; APPLICANT: Dong, Fang  
; APPLICANT: Neri, Bruce  
; APPLICANT: Vener, Tatiana  
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites  
; FILE REFERENCE: FORS-04586  
; CURRENT APPLICATION NUMBER: US/09/882,945A  
; CURRENT FILING DATE: 2001-06-15  
; NUMBER OF SEQ ID NOS: 334  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 108  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-882-945A-108

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTCTGTGCAC 828  
| | | | | | | | | | | | | | | |  
Db 16 AACAACTTCTGTGCAC 1

RESULT 282  
US-10-314-657-180  
; Sequence 180, Application US/10314657  
; Publication No. US20030175888A1  
; GENERAL INFORMATION:  
; APPLICANT: SHEN, Ben  
; APPLICANT: CHENG, Yi-Qiang  
; APPLICANT: TANG, Gong-Li  
; TITLE OF INVENTION: Discrete Acyltransferases Associated with Type I Polyketide  
; TITLE OF INVENTION: Synthases and Methods of Use  
; FILE REFERENCE: 054030-0021  
; CURRENT APPLICATION NUMBER: US/10/314,657  
; CURRENT FILING DATE: 2002-12-09  
; PRIOR APPLICATION NUMBER: PCT/US02/08937  
; PRIOR FILING DATE: 2002-03-22  
; PRIOR APPLICATION NUMBER: US 60/278,935  
; PRIOR FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 214  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 180  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Streptomyces atroolivaceus  
US-10-314-657-180

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 600 TCAAGGCACAAACCTC 615  
| | | | | | | | | | | | | | | |  
Db 1 TCAAGGCACGAACCTC 16

RESULT 283  
US-10-333-429-219  
; Sequence 219, Application US/10333429  
; Publication No. US20040048265A1  
; GENERAL INFORMATION:  
; APPLICANT: GENSET  
; TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps  
; FILE REFERENCE: G-083US02PCT  
; CURRENT APPLICATION NUMBER: US/10/333,429  
; CURRENT FILING DATE: 2003-01-17  
; PRIOR APPLICATION NUMBER: PCT/IB01/01477  
; PRIOR FILING DATE: 2001-06-28  
; PRIOR APPLICATION NUMBER: US 60/219,704  
; PRIOR FILING DATE: 2000-07-18  
; NUMBER OF SEQ ID NOS: 579  
; SOFTWARE: Patent.pm  
; SEQ ID NO 219  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Homo Sapiens  
; FEATURE:  
; NAME/KEY: primer\_bind  
; LOCATION: 1..18  
; OTHER INFORMATION: upstream amplification primer 99-32165 for SEQ 48,  
US-10-333-429-219

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1238 CACACTTCCCAGGAAT 1253  
| | | | | | | | | | | | | | | |  
Db 1 CACACTTCCCTGGAAT 16

RESULT 284  
US-10-807-114-108/c  
; Sequence 108, Application US/10807114  
; Publication No. US20040235024A1  
; GENERAL INFORMATION:  
; APPLICANT: Lyamichev, Victor  
; APPLICANT: Allawi, Hatim  
; APPLICANT: Dong, Fang  
; APPLICANT: Neri, Bruce  
; APPLICANT: Vener, Tatiana  
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites  
; FILE REFERENCE: FORS-04586  
; CURRENT APPLICATION NUMBER: US/10/807,114  
; CURRENT FILING DATE: 2004-03-23  
; PRIOR APPLICATION NUMBER: US/09/882,945  
; PRIOR FILING DATE: 2001-06-15  
; NUMBER OF SEQ ID NOS: 334  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 108  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-807-114-108

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTCTGTGCAC 828  
| | | | | | | | | | | | | | | |  
Db 16 AACAACTTCTGTGCAC 1

RESULT 285



; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 10431  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-723-361-10431

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 838 AGTTTGTGCTGCTCA 853  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 ACTTTGTGCTGCTCA 2

RESULT 278  
US-10-723-361-10433/c  
; Sequence 10433, Application US/107233361  
; Publication No. US20040137589A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
; FILE REFERENCE: PB0105  
; CURRENT APPLICATION NUMBER: US/10/723,361  
; CURRENT FILING DATE: 2003-11-26  
; PRIOR APPLICATION NUMBER: US 09/866,108  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 10433  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-723-361-10433

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTGTGCTGTC 852  
| | | | | | | | | | | | | | | | | | | | |  
Db 16 GACTTTTGTGCTGTC 1

RESULT 279  
US-10-724-270-456/c

; Sequence 456, Application US/10724270  
; Publication No. US20050080031A1  
; GENERAL INFORMATION:  
; APPLICANT: Sirna Therapeutics, Inc.  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels  
; TITLE OF INVENTION: RAS, HER2 and HIV  
; FILE REFERENCE: 400/046-US (MBHB02-326-A)  
; CURRENT APPLICATION NUMBER: US/10/724,270  
; CURRENT FILING DATE: 2003-11-26  
; PRIOR APPLICATION NUMBER: PCT/US02/16840  
; PRIOR FILING DATE: 2002-05-29  
; PRIOR APPLICATION NUMBER: US 60/318,471  
; PRIOR FILING DATE: 2001-09-10  
; PRIOR APPLICATION NUMBER: US 60/296,249  
; PRIOR FILING DATE: 2001-06-06  
; PRIOR APPLICATION NUMBER: US 60/294,140  
; PRIOR FILING DATE: 2001-05-29  
; PRIOR APPLICATION NUMBER: US 10/238,700  
; PRIOR FILING DATE: 2002-09-10  
; PRIOR APPLICATION NUMBER: US 10/163,552  
; PRIOR FILING DATE: 2002-06-06  
; PRIOR APPLICATION NUMBER: US 10/157,580  
; PRIOR FILING DATE: 2002-05-29  
; PRIOR APPLICATION NUMBER: US 10/693,059  
; PRIOR FILING DATE: 2002-10-23  
; PRIOR APPLICATION NUMBER: US 10/444,853  
; PRIOR FILING DATE: 2003-05-23  
; PRIOR APPLICATION NUMBER: US 10/417,012  
; PRIOR FILING DATE: 2003-04-16  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 6810  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 456  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-724-270-456

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTCACTTCATTCT 1591  
| | | | | | | | | | | | | | | | | | | | |  
Db 16 TTTTCACTTCATTGT 1

RESULT 280  
US-09-969-373-1693  
; Sequence 1693, Application US/09969373  
; Patent No. US20020133852A1  
; GENERAL INFORMATION:  
; APPLICANT: Effertz, Roger J.  
; APPLICANT: Hauge, Brian M.  
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping  
; FILE REFERENCE: 38-10(52679)A  
; CURRENT APPLICATION NUMBER: US/09/969,373  
; CURRENT FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: US 09/754,853  
; PRIOR FILING DATE: 2001-01-05  
; PRIOR APPLICATION NUMBER: US 09/760,427  
; PRIOR FILING DATE: 2001-01-13  
; PRIOR APPLICATION NUMBER: US 09/855,768  
; PRIOR FILING DATE: 2001-05-15  
; NUMBER OF SEQ ID NOS: 4593  
; SEQ ID NO 1693  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Glycine max  
US-09-969-373-1693

Query Match 0.8%; Score 14.4; DB 1; Length 18;

```

; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2690

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      297 GTCAAGATGGATGAAG 312
Db      1 GUCAAGAUGAUGAAG 16
      |:|||||: |:|||||

RESULT 274
US-10-138-674-5541/c
; Sequence 5541, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5541

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1521 ACACACATAGTTACAC 1536
Db      17 ACACACACAGTTACAC 2
      ||||||| |||||||

RESULT 275
US-10-287-949A-2690
; Sequence 2690, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2690

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      297 GTCAAGATGGATGAAG 312
```

```

      |:|||||: |:|||||
Db      1 GUCAAGAUGAUGAAG 16

RESULT 276
US-10-287-949A-5541/c
; Sequence 5541, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5541

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1521 ACACACATAGTTACAC 1536
Db      17 ACACACACAGTTACAC 2
      ||||||| |||||||

RESULT 277
US-10-723-361-10431/c
; Sequence 10431, Application US/107233361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```

; SEQ ID NO 3637
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3637

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 ATTACTTCTATTCTT 946
    ||||| ||||| |||||
Db 16 ATTAATTCATTCTT 1

RESULT 270
US-10-238-700-456/c
; Sequence 456, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 456
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-456

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTTCACCTTCATTCT 1591
    ||||| ||||| |||||
Db 16 TTTTTCACCTTCATTGT 1

RESULT 271
US-10-307-005-1679
; Sequence 1679, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1679
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Solanum tuberosum
US-10-307-005-1680

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAACA 1493
    ||||| ||||| |||||
Db 17 TGGCAATAATGTCACA 2

RESULT 273
US-10-138-674-2690
; Sequence 2690, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Solanum tuberosum
US-10-307-005-1680
```

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Solanum tuberosum
US-10-307-005-1679

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAACA 1493
    ||||| ||||| |||||
Db 1 TGGCAATAATGTCACA 16

RESULT 272
US-10-307-005-1680/c
; Sequence 1680, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1680
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Solanum tuberosum
US-10-307-005-1680

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAACA 1493
    ||||| ||||| |||||
Db 17 TGGCAATAATGTCACA 2

RESULT 273
US-10-138-674-2690
; Sequence 2690, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Solanum tuberosum
US-10-307-005-1680
```

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10433
; . LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10433

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 837 GAGTTTGATGCTGTC 852
||| ||||| ||||| |||
Db 16 GACTTTTGATGCTGTC 1

RESULT 266
US-09-780-164-447
; Sequence 447, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 447
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-447

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 165 AAAAAGTCCAGGAATG 180
|||||:|||||:|
Db 1 AAAACUCCAGGAAGUG 16

RESULT 267
US-10-156-306-268/c
; Sequence 268, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 268
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-268

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 ATTACTTCTATTCTT 946
||||| ||||| ||||| |||
Db 17 ATTAATCTATTCTT 2

RESULT 268
US-10-156-306-1283
; Sequence 1283, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1283
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1283

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 146 ATAGAACTTCCTAAA 161
|:|||||:|:|
Db 1 AUAGAAACAUCUAAA 16

RESULT 269
US-10-156-306-3637/c
; Sequence 3637, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0



US-10-287-949A-6065/c  
; Sequence 6065, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6065  
; LENGTH: 16  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-6065  
  
Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1521 ACACACATAGTTACAC 1536  
Db 16 ACACACACAGTTACAC 1  
  
RESULT 263  
US-10-287-949A-6066/c  
; Sequence 6066, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6066  
; LENGTH: 16  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-6066  
  
Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1519 ACACACACATAGTTAC 1534  
Db 16 ACACACACACAGTTAC 1  
  
RESULT 264  
US-09-866-108-10431/c  
; Sequence 10431, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 10431  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-10431

; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 10431  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-10431  
  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 838 AGTTTGTGATGCTGTCA 853  
Db 17 ACTTTGTGATGCTGTCA 2  
  
RESULT 265  
US-09-866-108-10433/c  
; Sequence 10433, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04

Db 3 AGAAAAACUCCAGGA 17

RESULT 258

US-10-349-143-5494/c

; Sequence 5494, Application US/10349143

; Publication No. US20040005584A1

; GENERAL INFORMATION:

; APPLICANT: Cohen, Daniel

; APPLICANT: Blumenfeld, Marta

; APPLICANT: Chumakov, Ilya

; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

; FILE REFERENCE: GENSET.020CP1

; CURRENT FILING DATE: 2003-01-21

; PRIOR FILING DATE: 2003-01-21

; PRIOR FILING DATE: 1999-10-20

; PRIOR FILING DATE: 1999-10-20

; PRIOR FILING DATE: 1999-04-21

; PRIOR FILING DATE: 1999-04-21

; PRIOR FILING DATE: 1998-11-23

; PRIOR FILING DATE: 1998-11-23

; PRIOR FILING DATE: 1998-04-21

; PRIOR FILING DATE: 1998-04-21

; NUMBER OF SEQ ID NOS: 11796

; SEQ ID NO 5494

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Homo Sapiens

; FEATURE:

; NAME/KEY: primer\_bind

; LOCATION: 1..18

; OTHER INFORMATION: upstream amplification primer 99-4676 for SEQ 1560,

US-10-349-143-5494

Query Match 0.8%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 2.2e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 CCCACCTACGATACCTT 708

Db 18 CCCACCTTGAGATACCTT 1

RESULT 259

US-10-164-915-3

; Sequence 3, Application US/10164915

; Publication No. US20030148391A1

; GENERAL INFORMATION:

; APPLICANT: Salafsky, Joshua S.

; TITLE OF INVENTION: Method Using a Surface-Selective No. US20030148391A1linear Optica

; TITLE OF INVENTION: for Detection of Interactions Involving a Conformational Change

; FILE REFERENCE: 11100-035-999

; CURRENT APPLICATION NUMBER: US/10/164,915

; CURRENT FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: 60/253,862

; PRIOR FILING DATE: 2000-11-29

; PRIOR APPLICATION NUMBER: 60/260,249

; PRIOR FILING DATE: 2001-01-08

; PRIOR APPLICATION NUMBER: 60/265,775

; PRIOR FILING DATE: 2001-02-01

; PRIOR APPLICATION NUMBER: 60/278,941

; PRIOR FILING DATE: 2001-01-27

; NUMBER OF SEQ ID NOS: 6

; SEQ ID NO 3

; LENGTH: 16

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Aritificial Sequence: Oligonucleotide structure fo

; OTHER INFORMATION: molecular beacon

US-10-164-915-3

Query Match 0.8%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAA 1763

Db 1 GAAAAAAAAACAAAAA 16

RESULT 260

US-10-138-674-6065/c

; Sequence 6065, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MHB00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6065

; LENGTH: 16

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-6065

Query Match 0.8%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1521 ACACACATAGTTACAC 1536

Db 16 ACACACACAGTTACAC 1

RESULT 261

US-10-138-674-6066/c

; Sequence 6066, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MHB00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6066

; LENGTH: 16

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-6066

Query Match 0.8%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1519 ACACACATAGTTAC 1534

Db 16 ACACACACAGTTAC 1

RESULT 262



```

; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-54

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 251
US-10-939-214-55/c
; Sequence 55, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 55
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-55

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 252
US-10-239-919A-4/c
; Sequence 4, Application US/10239919A
; Publication No. US20050054831A1

```

```

; GENERAL INFORMATION:
; APPLICANT: HWANG, IN-HWAN
; APPLICANT: LIM, JEONG-HWA
; APPLICANT: PIH, KYOUNG-TAE
; TITLE OF INVENTION: AN OSMOTIC STRESS-INDUCIBLE PROTEIN FUNCTIONING AS A
; TITLE OF INVENTION: NEGATIVE REGULATOR IN OSMOTIC STRESS SIGNALING PATHWAY
; TITLE OF INVENTION: OF PLANTS
; FILE REFERENCE: 7022-0004
; CURRENT APPLICATION NUMBER: US/10/239,919A
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/KR02/00152
; PRIOR FILING DATE: 2002-02-01
; PRIOR APPLICATION NUMBER: KR 2001/5097
; PRIOR FILING DATE: 2001-02-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-239-919A-4

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 253
US-10-601-140A-5/c
; Sequence 5, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)..(15)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-5

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 254
US-10-601-140A-16/c

```



```
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 247
US-10-755-118-49/c
; Sequence 49, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Clz)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
; US-10-755-118-49

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 248
US-10-770-989-9/c
; Sequence 9, Application US/10770989
; Publication No. US20050019789A1
; GENERAL INFORMATION:
; APPLICANT: Ankenbauer, Waltraud
; APPLICANT: Schmitz-Agheguian, Gudrun
; APPLICANT: Bonch-Osmolovskaya, Elizaveta
; APPLICANT: Svetlichny, Vitaly
; APPLICANT: Markau, Ursula
```

```
; APPLICANT: Angerer, Bernard
; APPLICANT: Reiser, Astrid
; APPLICANT: Roche Molecular Systems, Inc.
; TITLE OF INVENTION: Thermostable DNA Polymerase from Anaerocellum
; TITLE OF INVENTION: thermophilum
; FILE REFERENCE: 022101-000610US
; CURRENT APPLICATION NUMBER: US/10/770,989
; CURRENT FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: EP 96115877.1
; PRIOR FILING DATE: 1996-10-03
; PRIOR APPLICATION NUMBER: WO PCT/EP97/05390
; PRIOR FILING DATE: 1997-10-01
; PRIOR APPLICATION NUMBER: US 09/269,858
; PRIOR FILING DATE: 1999-06-10
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:(dt)-15,
US-10-770-989-9

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 249
US-10-833-502-9/c
; Sequence 9, Application US/10833502
; Publication No. US20050026279A1
; GENERAL INFORMATION:
; APPLICANT: TSENG, SCHEFFER C.G.
; APPLICANT: ESPANA, EDGAR M.
; TITLE OF INVENTION: SURGICAL GRAFTS AND METHODS OF PREPARATION
; FILE REFERENCE: TIS-107
; CURRENT APPLICATION NUMBER: US/10/833,502
; CURRENT FILING DATE: 2002-04-28
; PRIOR APPLICATION NUMBER: 60/465,989
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/473,007
; PRIOR FILING DATE: 2003-05-22
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-833-502-9

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 250
US-10-939-214-54/c
; Sequence 54, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:
```



; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (1)..(15)  
; OTHER INFORMATION: (2'-aminoethyl)glycine  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (15)..(15)  
; OTHER INFORMATION: Acr1  
US-10-755-118-39

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763  
|||  
Db 15 AAAAAAAAAAAAAA 1

RESULT 242  
US-10-755-118-40/c  
; Sequence 40, Application US/10755118  
; Publication No. US20050009041A1  
; GENERAL INFORMATION:  
; APPLICANT: Buchardt, Ole  
; APPLICANT: Egholm, Michael  
; APPLICANT: Nielsen, Peter Eigil  
; APPLICANT: Berg, Rolf Henrik  
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR  
; FILE REFERENCE: ISIS-5427  
; CURRENT APPLICATION NUMBER: US/10/755,118  
; CURRENT FILING DATE: 2004-01-09  
; PRIOR APPLICATION NUMBER: US 08/462,977  
; PRIOR FILING DATE: 1995-06-05  
; PRIOR APPLICATION NUMBER: US 08/108,591  
; PRIOR FILING DATE: 1993-11-22  
; PRIOR APPLICATION NUMBER: PCT/EP92/01219  
; PRIOR FILING DATE: 1992-05-22  
; PRIOR APPLICATION NUMBER: DN 510/92  
; PRIOR FILING DATE: 1991-05-24  
; PRIOR APPLICATION NUMBER: DN 987/91  
; PRIOR FILING DATE: 1991-05-24  
; PRIOR APPLICATION NUMBER: DN 986/91  
; NUMBER OF SEQ ID NOS: 157  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 40  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Construct

; NAME/KEY: misc feature  
; LOCATION: (1)..(1)  
; OTHER INFORMATION: BHA resin  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (1)..(15)  
; OTHER INFORMATION: (2'-aminoethyl)glycine  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (15)..(15)  
; OTHER INFORMATION: Hydrogen  
US-10-755-118-40

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763  
|||  
Db 15 AAAAAAAAAAAAAA 1

RESULT 243  
US-10-755-118-43/c  
; Sequence 43, Application US/10755118  
; Publication No. US20050009041A1  
; GENERAL INFORMATION:  
; APPLICANT: Buchardt, Ole  
; APPLICANT: Egholm, Michael  
; APPLICANT: Nielsen, Peter Eigil  
; APPLICANT: Berg, Rolf Henrik  
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR  
; FILE REFERENCE: ISIS-5427  
; CURRENT APPLICATION NUMBER: US/10/755,118  
; CURRENT FILING DATE: 2004-01-09  
; PRIOR APPLICATION NUMBER: US 08/462,977  
; PRIOR FILING DATE: 1995-06-05  
; PRIOR APPLICATION NUMBER: US 08/108,591  
; PRIOR FILING DATE: 1993-11-22  
; PRIOR APPLICATION NUMBER: PCT/EP92/01219  
; PRIOR FILING DATE: 1992-05-22  
; PRIOR APPLICATION NUMBER: DN 510/92  
; PRIOR FILING DATE: 1992-04-15  
; PRIOR APPLICATION NUMBER: DN 987/91  
; PRIOR FILING DATE: 1991-05-24  
; PRIOR APPLICATION NUMBER: DN 986/91  
; PRIOR FILING DATE: 1991-05-24  
; NUMBER OF SEQ ID NOS: 157  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 43  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Construct

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763  
|||  
Db 15 AAAAAAAAAAAAAA 1

RESULT 244  
US-10-755-118-44/c  
; Sequence 44, Application US/10755118  
; Publication No. US20050009041A1  
; GENERAL INFORMATION:  
; APPLICANT: Buchardt, Ole  
; APPLICANT: Egholm, Michael  
; APPLICANT: Nielsen, Peter Eigil  
; APPLICANT: Berg, Rolf Henrik  
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR  
; FILE REFERENCE: ISIS-5427  
; CURRENT APPLICATION NUMBER: US/10/755,118  
; CURRENT FILING DATE: 2004-01-09  
; PRIOR APPLICATION NUMBER: US 08/462,977  
; PRIOR FILING DATE: 1995-06-05

```
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: tert-butoxycarbonyl
; SEQ ID NO 36
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: tert-butoxycarbonyl
; US-10-755-118-36

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAA 1763
        |||||
Db       15 AAAAAAAAAAAAAA 1

RESULT 240
US-10-755-118-39/c
; Sequence 39, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin
; OTHER INFORMATION: BHA resin
```

```
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resins
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: tert-butoxycarbonyl
; US-10-755-118-38

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAA 1763
        |||||
Db       15 AAAAAAAAAAAAAA 1

RESULT 241
US-10-755-118-39/c
; Sequence 39, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin
; OTHER INFORMATION: BHA resin
```





; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1533
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1533

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1518 CACACACACATAGTTAC 1534
Db 17 CACACACACACAGTTAC 1

RESULT 233
US-10-848-922-98/c
; Sequence 98, Application US/10848922
; Publication No. US20040235138A1
; GENERAL INFORMATION:
; APPLICANT: Weisburg, William G.
; APPLICANT: Bungo, Jennifer J.
; TITLE OF INVENTION: Compositions, Methods and Kits for Determining the Presence of
; TITLE OF INVENTION: Trichomonas vaginalis in a Test Sample
; FILE REFERENCE: GP142-02.UT
; CURRENT APPLICATION NUMBER: US/10/848,922
; CURRENT FILING DATE: 2004-05-18
; PRIOR APPLICATION NUMBER: 60/472,028
; PRIOR FILING DATE: 2003-05-19
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 98
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Polynucleotide having a 3' poly (dA)30 tail and a 5' poly (dT)3
; OTHER INFORMATION: flexible linker for use in a capture probe
US-10-848-922-98

Query Match 0.9%; Score 15.4; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.7e+02;
Matches 22; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 1575 TTTTTCACATTCATTCTTCTTAATTTTGA 1607
Db 33 TTTTTCATTCATTCATTCTTCTTAATTTTGA 1

RESULT 234
US-10-830-484-4/c
; Sequence 4, Application US/10830484
; Publication No. US20040220397A1
; GENERAL INFORMATION:
; APPLICANT: Leuck, Michael
; APPLICANT: Wolter, Andreas
; TITLE OF INVENTION: Solid Support For The Synthesis Of 3' Amino Oligonucleotides

; FILE REFERENCE: PRO13
; CURRENT APPLICATION NUMBER: US/10/830,484
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,269
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Nucleic Acid Ligand
US-10-830-484-4

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 235
US-10-755-118-3/c
; Sequence 3, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
US-10-755-118-3

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10432
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10432

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTGTGCTGTCA 853
Db 17 GACTTTGTGCTGTCA 1

RESULT 230
US-10-753-962-23
; Sequence 23, Application US/10753962
; Publication No. US20040203133A1
; GENERAL INFORMATION:
; APPLICANT: Ehrhardt, Anja
; APPLICANT: Kay, Mark
; TITLE OF INVENTION: Helper Dependent Adenoviral Vector
; TITLE OF INVENTION: System and Methods for Using the Same
; FILE REFERENCE: STAN-215US2
; CURRENT APPLICATION NUMBER: US/10/753,962
; CURRENT FILING DATE: 2004-01-07
; PRIOR APPLICATION NUMBER: 60/438,715
; PRIOR FILING DATE: 2003-01-07
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-753-962-23

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTTCATTCATTCTA 1592
Db 1 TTTTTCATTCATTCTA 17

RESULT 231
US-10-712-633-1532/c
; Sequence 1532, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND C
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1532
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1532

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1520 CACACACATAGTTACAC 1536
Db 17 CACACACACAGTTACAC 1

RESULT 232
US-10-712-633-1533/c
; Sequence 1533, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND C
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-106-831-23

```

Query Match	0.9%	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	94.1%	Pred. No. 1.7e+02;		
Matches 16;	Conservative	0;	Mismatches 1;	Indels 0;
				Gaps 0;

Qy 1576 TTTTTCACCTTCATTCTA 1592  
|||  
Db 1 TTTTTCACCTGCATTCTA 17

## RESULT 225

RES001 223  
US-10-138-674-8254/c  
; Sequence 8254, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1520 CACACACATAGTTACAC 1536  
|||  
pb 17 CACACACACAGTTACAC 1

## RESULT 226

RESOL 228  
US-10-138-674-8255/c  
; Sequence 8255, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

Query Match	0.9%	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	94.1%	Pred. No. 1.7e+02;		
Matches 16:	Conservative	0;	Mismatches 1;	Indels 0; Gaps 0;

Qy 1518 CACACACACATAGTTAC 1534  
|||  
Db 17 CACACACACACAGTTAC 1

## RESULT 227

US-10-287-949A-8254/c  
; Sequence 8254, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```
Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 1520 CACACACATAGTTACAC 1536  
|||  
Db 17 CACACACACAGTTACAC 1

**RESULT 228**

REG-10-287-949A-8255/c  
; Sequence 8255, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

Query Match	0.9%;	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	94.1%;	Pred. No. 1.7e+02;		
Matches 16:	Conservative	0;	Mismatches 1;	Indels 0;
				Gaps 0;

Qy 1518 CACACACATAGTTAC 1534  
|||  
Db 17 CACACACACAGTTAC 1

RESULT 229  
US-10-723-361-10432/c  
; Sequence 10432, Application US/10723361  
; Publication No. US20040137589A1



```
RESULT 221
US-09-866-108-10432/c
; Sequence 10432, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10432
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10432

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      837 GAGTTTGTGCTGTCA 853
Db      17 GACTTTTGTGCTGTCA 1

RESULT 222
US-09-780-164-66
; Sequence 66, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
```

```
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 66
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-66

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.7e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      163 GAAAAACTCCAGAAAT 179
Db      1 GAAAAACUCCAGGAAGU 17

RESULT 223
US-09-780-164-446
; Sequence 446, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-446

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.7e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      164 AAAAATCCAGAAATG 180
Db      1 AAAAACUCCAGGAAGUG 17

RESULT 224
US-10-106-831-23
; Sequence 23, Application US/10106831
; Publication No. US2003002378A1
; GENERAL INFORMATION:
; APPLICANT: Ehrhardt, Anja
; APPLICANT: Kay, Mark
; TITLE OF INVENTION: Helper Dependent Adenoviral Vector
; TITLE OF INVENTION: System and Methods for Using the Same
; FILE REFERENCE: STAN-215
; CURRENT APPLICATION NUMBER: US/10/106,831
; CURRENT FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: 60/278,972
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: 60/284,335
; PRIOR FILING DATE: 2001-04-16
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 17
; TYPE: DNA
```

```

; CURRENT APPLICATION NUMBER: US/09/853,688
; CURRENT FILING DATE: 2001-05-14
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-853-688-39

Query Match      0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      854 CAACAGTGGGAGAGAA 869
Db      4 CAACAGTGGGAGAGAA 19
      |||||
RESULT 217
US-10-788-318-39
; Sequence 39, Application US/10788318
; Publication No. US20040137510A1
; GENERAL INFORMATION:
; APPLICANT: COOPER, DAVID N.
; APPLICANT: PROCTER, ANNIE M.
; APPLICANT: GREGORY, JOHN
; APPLICANT: MILLAR, DAVID S.
; TITLE OF INVENTION: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN
; TITLE OF INVENTION: HUMANS, THE VARIATIONS AND THEIR USES
; FILE REFERENCE: WCM78
; CURRENT APPLICATION NUMBER: US/10/788,318
; CURRENT FILING DATE: 2004-03-01
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-788-318-39

Query Match      0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      854 CAACAGTGGGAGAGAA 869
Db      4 CAACAGTGGGAGAGAA 19
      |||||
US-10-831-778-431
; Sequence 431, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 431
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence

US-10-831-778-431
; Sequence 431, Application US/10831778
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 13, antisense oligonucleotide
US-10-619-906-13

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      175 GAAATGCAGCAGTCTCTTG 193
Db      19 GAAATGCAGCAGTCTCTTG 1
      |||||
US-10-619-906-11/c
; Sequence 11, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 11, antisense oligonucleotide
US-10-619-906-11

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      175 GAAATGCAGCAGTCTCTTG 193
Db      19 GAAATGCAGCAGTCTCTTG 1
      |||||
US-10-619-906-13/c
; Sequence 13, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 13, antisense oligonucleotide
US-10-619-906-13

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      880 TTTAAAGACTGGTCTTCT 898
Db      19 TTCAAGACAGAGTCTTCT 1
      |||||
US-10-619-906-11/c
; Sequence 11, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 11, antisense oligonucleotide
US-10-619-906-11

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      880 TTTAAAGACTGGTCTTCT 898
Db      19 TTCAAGACAGAGTCTTCT 1
      |||||
```

; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 445
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-445

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 162 AGAAAACTCCAGAA 177
|||||||:|||||
Db 1 AGAAAAACUCCAGAA 16

RESULT 213
US-10-608-863-3/c
; Sequence 3, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREATING ALLERGIC DISEASES
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608,863
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially Synthesized Primer Sequence
US-10-608-863-3

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAC 1776
|||||||:|||||
Db 16 AAAAAAAAAAAAAAC 1

RESULT 214
US-10-608-863-4/c
; Sequence 4, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREATING ALLERGIC DISEASES
; FILE REFERENCE: 3462.1003-000

; CURRENT APPLICATION NUMBER: US/10/608,863
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially Synthesized Primer Sequence
US-10-608-863-4

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAA 1763
|||||||:|||||
Db 17 GAAAAAAAAAAAAA 2

RESULT 215
US-10-608-863-5/c
; Sequence 5, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREATING ALLERGIC DISEASES
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608,863
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially Synthesized Primer Sequence
US-10-608-863-5

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAC 1776
|||||||:|||||
Db 16 AAAAAAAAAAAAAAC 1

RESULT 216
US-09-853-688-39
; Sequence 39, Application US/09853688
; Patent No. US20020081605A1
; GENERAL INFORMATION:
; APPLICANT: COOPER, DAVID N.
; APPLICANT: PROCTER, ANNIE M.
; APPLICANT: GREGORY, JOHN
; APPLICANT: MILLAR, DAVID S.
; TITLE OF INVENTION: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN HUMANS, THE VARIATIONS AND THEIR USES
; FILE REFERENCE: WCM78

```
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 815
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-758-155-815

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1518 CACACACACATAGTTACA 1535
Db      2 CACACACACACAGUUA 19
|||||
|::|

RESULT 209
US-10-238-011-36
; Sequence 36, Application US/10238011
; Publication No. US20030091568A1
; GENERAL INFORMATION:
; APPLICANT: Frey Jorgen
; APPLICANT: Frey, Jorgen
; TITLE OF INVENTION: Inhibitors for the Formation of Soluble Human CD23
; FILE REFERENCE: 516326-2002
; CURRENT APPLICATION NUMBER: US/10/238,011
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: EP 00 107 515.9
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/827,406
; PRIOR FILING DATE: 2000-04-05
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-238-011-36

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 251 GATGTGAGTGCCCGATG 268
Db      3 GATGTGAGTGCCAGATG 20
|||||
|::|

RESULT 210
US-10-274-095-36/c
; Sequence 36, Application US/10274095
; Publication No. US20030120433A1
; GENERAL INFORMATION:
; APPLICANT: Yokota, Hiroki
; APPLICANT: Sun, Hui Bin
; TITLE OF INVENTION: Methods for Predicting Transcription
; TITLE OF INVENTION: Levels
; FILE REFERENCE: ARTI.0137US
; CURRENT APPLICATION NUMBER: US/10/274,095
; CURRENT FILING DATE: 2002-10-17
```

```
; PRIOR APPLICATION NUMBER: 60/329,961
; PRIOR FILING DATE: 2001-10-17
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-274-095-36

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 358 CGTGAGGATGTAGACTAC 375
Db      20 CGTGAGGATGTTGACTAC 3
|||||
|::|

RESULT 211
US-10-755-118-94/c
; Sequence 94, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Bigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 94
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-755-118-94

Query Match      0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAA 1764
Db      16 AAAAAAAAAAAAAAAA 1
|||||
|::|

RESULT 212
US-09-780-164-445
; Sequence 445, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
```



```
Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1518 CACACACACATAGTTACA 1535
      ||||||||| |||||
Db      18 CACACACACACAGTTACA 1

RESULT 206
US-10-665-951-815
; Sequence 815, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 815
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

US-10-665-951-815

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1518 CACACACACATAGTTACA 1535
      ||||||||| ||::|||
Db      2 CACACACACACAGUACA 19

RESULT 207
US-10-758-155-388/c
; Sequence 388, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
```

```
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 388
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re

US-10-758-155-388

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1518 CACACACACATAGTTACA 1535
      ||||||||| |||||
Db      18 CACACACACACAGTTACA 1

RESULT 208
US-10-758-155-815
; Sequence 815, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
```

APPLICANT: Martinez, Robert  
APPLICANT: Brown, Eugene  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
TITLE OF INVENTION: CANCERS  
FILE REFERENCE: AM100927 (031896-002000)  
CURRENT APPLICATION NUMBER: US/10/751,736  
CURRENT FILING DATE: 2003-01-06  
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
PRIOR FILING DATE: 2003-01-06  
NUMBER OF SEQ ID NOS: 54873  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 12929  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAi  
US-10-751-736-12929

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 1.7e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1687 ACTCTCTGTCTTTACTGAA 1706  
||||| ||||||| |||||  
Db 20 ACTCTGTGTCTTTGCTGAA 1

RESULT 203  
US-10-872-984-5/c  
Sequence 5, Application US/10872984  
Publication No. US20040265888A1  
GENERAL INFORMATION:  
APPLICANT: Kaufman, Joseph C.  
APPLICANT: Roth, Matthew E.  
APPLICANT: Lizardi, Paul M.  
APPLICANT: Feng, Li  
APPLICANT: Latimer, Darin R.  
TITLE OF INVENTION: Binary Encoded Sequence Tags  
FILE REFERENCE: AGL 100  
CURRENT APPLICATION NUMBER: US/10/872,984  
CURRENT FILING DATE: 2004-06-21  
PRIOR APPLICATION NUMBER: US/09/994,311  
PRIOR FILING DATE: 2001-11-26  
PRIOR APPLICATION NUMBER: US/09/637,751  
PRIOR FILING DATE: 2000-08-11  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 5  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-872-984-5

Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 94.4%; Pred. No. 1.4e+02;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAA 1765  
| ||||||| |||||  
Db 18 GCAAAAAAAAAAAAAAAAAA 1

RESULT 204  
US-10-872-984-6/c  
Sequence 6, Application US/10872984  
Publication No. US20040265888A1  
GENERAL INFORMATION:  
APPLICANT: Kaufman, Joseph C.  
APPLICANT: Roth, Matthew E.  
APPLICANT: Lizardi, Paul M.  
APPLICANT: Feng, Li

APPLICANT: Latimer, Darin R.  
TITLE OF INVENTION: Binary Encoded Sequence Tags  
FILE REFERENCE: AGL 100  
CURRENT APPLICATION NUMBER: US/10/872,984  
CURRENT FILING DATE: 2004-06-21  
PRIOR APPLICATION NUMBER: US/09/994,311  
PRIOR FILING DATE: 2001-11-26  
PRIOR APPLICATION NUMBER: US/09/637,751  
PRIOR FILING DATE: 2000-08-11  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 6  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-872-984-6

Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 94.4%; Pred. No. 1.4e+02;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766  
| ||||||| |||||  
Db 18 ACAAAAAAAAAAAAAAAAAA 1

RESULT 205  
US-10-665-951-388/c  
Sequence 388, Application US/10665951  
Publication No. US20040138163A1  
GENERAL INFORMATION:  
APPLICANT: Sirna Therapeutics, Inc.  
APPLICANT: McSwiggen, James  
APPLICANT: Beigelman, Leonid  
APPLICANT: Pavco, Pamela  
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial  
TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor  
TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)  
FILE REFERENCE: 400/131 (MBHB02-742-F)  
CURRENT APPLICATION NUMBER: US/10/665,951  
CURRENT FILING DATE: 2003-09-18  
PRIOR APPLICATION NUMBER: US 10/664,668  
PRIOR FILING DATE: 2003-09-18  
PRIOR APPLICATION NUMBER: PCT/US 03/05022  
PRIOR FILING DATE: 2003-02-20  
PRIOR APPLICATION NUMBER: US 60/399,348  
PRIOR FILING DATE: 2002-07-29  
PRIOR APPLICATION NUMBER: US 60/393,796  
PRIOR FILING DATE: 2002-07-03  
PRIOR APPLICATION NUMBER: US 10/287,949  
PRIOR FILING DATE: 2002-11-04  
PRIOR APPLICATION NUMBER: US 10/306,747  
PRIOR FILING DATE: 2002-11-27  
PRIOR APPLICATION NUMBER: PCT/US 02/17674  
PRIOR FILING DATE: 2002-05-29  
PRIOR APPLICATION NUMBER: US 60/358,580  
PRIOR FILING DATE: 2002-02-20  
PRIOR APPLICATION NUMBER: US 60/363,124  
PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 60/386,782  
PRIOR FILING DATE: 2002-06-06  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 2455  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 388  
LENGTH: 19  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re  
US-10-665-951-388

Best Local Similarity 90.0%; Pred. No. 1.7e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 973 ATTCAAGCTGCTTACGAAAT 992  
||| ||||| ||||| |||||  
Db 2 ATTGAAGCTGCTTATGAAAT 21

RESULT 198  
US-10-751-736-11042  
; Sequence 11042, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11042  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11042

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 55.0%; Pred. No. 1.7e+02;  
Matches 11; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 974 TTCAAGCTGCTTACGAAATT 993  
:: ||||: ||: ||||: ||:  
Db 1 UUGAAGCUGCUAUGAAAUU 20

RESULT 199  
US-10-751-736-11177  
; Sequence 11177, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11177  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11177

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 60.0%; Pred. No. 1.7e+02;  
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 738 TGACATACGTAACATTTCAGT 757  
: ||||: ||: ||||: ||:  
Db 1 UGACAUACGUGGCAUUCAGU 20

RESULT 200  
US-10-751-736-11332  
; Sequence 11332, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11332  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11332

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 1.7e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1292 ACTACTACATCTTCCAAGGA 1311  
||||| ||||| ||||| |||||  
Db 2 ACTACTATTCTTCCAAGGA 21

RESULT 201  
US-10-751-736-11381  
; Sequence 11381, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11381  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-11381

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 65.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 358 CGTGAGGATGTAGACTACAT 377  
||: ||||: ||: ||||: ||:  
Db 2 CGUGAGGAUGUGACUACUU 21

RESULT 202  
US-10-751-736-12929/c  
; Sequence 12929, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth

```

; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10783
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10783

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      337 AATTACACTCCGGACATGAA 356
Db      1 AATTACACACCTGACATGAA 20

RESULT 194
US-10-751-736-10787
; Sequence 10787, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10787
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-10787

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      358 CGTGAGGATGTAGACTACAT 377
Db      2 CGUGAGGAUGUUGACUACUU 21

RESULT 195
US-10-751-736-10864
; Sequence 10864, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
```

```

; SEQ ID NO 10864
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10864

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      989 AAATTGAAAGCAGAAATCAA 1008
Db      1 AAATTGAAGCCAGAAATCAA 20

RESULT 196
US-10-751-736-10930
; Sequence 10930, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10930
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10930

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      172 CAGGAAATGCAGCAGTTCCTT 191
Db      1 CAAGAAATGCAGCACITTCCTT 20

RESULT 197
US-10-751-736-11041
; Sequence 11041, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11041
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11041

Query Match          0.9%; Score 16.8; DB 1; Length 21;
```



```
Db      21 AATGACAAGGAATTGCTGA 2

RESULT 189
US-10-751-736-8632
; Sequence 8632, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8632
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8632

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      386 AAGCTTTCCAAGTCTGGAGT 405
      ||||| ||||| ||||| |||||
Db      1 AAGCCTTCCAACACTCTGGAGT 20

RESULT 190
US-10-751-736-9055
; Sequence 9055, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9055
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9055

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      383 AGAAAGCTTTCCAAGTCTGG 402
      ||||| ||||| ||||| |||||
Db      2 AGAAAGCCTTCCAACACTCTGG 21

RESULT 191
US-10-751-736-9059
; Sequence 9059, Application US/10751736
; Publication No. US20040265230A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9059
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-9059

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      386 AAGCTTTCCAAGTCTGGAGT 405
      ||||| :||| :||| :||| :||| :
Db      1 AAGCCUCCAAACUCUGGAGU 20

RESULT 192
US-10-751-736-10780
; Sequence 10780, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10780
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10780

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      335 ATAATTACACTCCGGACATG 354
      ||||| ||||| ||||| |||||
Db      2 ATAATTACACACCTGACATG 21

RESULT 193
US-10-751-736-10783
; Sequence 10783, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
```

ORGANISM: Homo sapiens  
US-10-168-989-42

Query Match  
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 1.7e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 354 GAAGCGTGAGGATGTAGACT 373  
Db 2 GAAGCATGAGGATGGAGACT 21

RESULT 185  
US-10-842-142-10  
; Sequence 10, Application US/10842142  
; Publication No. US20040259136A1  
; GENERAL INFORMATION:  
; APPLICANT: LaVallie, Edward R.  
; APPLICANT: Collins-Racie, Lisa A.  
; APPLICANT: Arai, Maya  
; TITLE OF INVENTION: PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER  
; TITLE OF INVENTION: INFLAMMATORY DISEASES  
; FILE REFERENCE: 01997.026800  
; CURRENT APPLICATION NUMBER: US/10/842,142  
; CURRENT FILING DATE: 2004-05-10  
; PRIOR APPLICATION NUMBER: US 60/468,987  
; PRIOR FILING DATE: 2003-05-08  
; PRIOR APPLICATION NUMBER: US 60/491,274  
; PRIOR FILING DATE: 2003-07-31  
; NUMBER OF SEQ ID NOS: 164  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 10  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-842-142-10

Query Match  
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 1.7e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 300 AAGATGGATGAAGCGGTACC 319  
Db 1 AAGATGGAGGAAGCTGTACC 20

RESULT 186  
US-10-842-142-94  
; Sequence 94, Application US/10842142  
; Publication No. US20040259136A1  
; GENERAL INFORMATION:  
; APPLICANT: LaVallie, Edward R.  
; APPLICANT: Collins-Racie, Lisa A.  
; APPLICANT: Arai, Maya  
; TITLE OF INVENTION: PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER  
; TITLE OF INVENTION: INFLAMMATORY DISEASES  
; FILE REFERENCE: 01997.026800  
; CURRENT APPLICATION NUMBER: US/10/842,142  
; CURRENT FILING DATE: 2004-05-10  
; PRIOR APPLICATION NUMBER: US 60/468,987  
; PRIOR FILING DATE: 2003-05-08  
; PRIOR APPLICATION NUMBER: US 60/491,274  
; PRIOR FILING DATE: 2003-07-31  
; NUMBER OF SEQ ID NOS: 164  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 94  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-842-142-94

Query Match  
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 1.7e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 300 AAGATGGATGAAGCGGTACC 319  
Db 2 AAGATGGAGGAAGCTGTACC 21

RESULT 187  
US-10-842-142-114  
; Sequence 114, Application US/10842142  
; Publication No. US20040259136A1  
; GENERAL INFORMATION:  
; APPLICANT: LaVallie, Edward R.  
; APPLICANT: Collins-Racie, Lisa A.  
; APPLICANT: Arai, Maya  
; TITLE OF INVENTION: PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER  
; TITLE OF INVENTION: INFLAMMATORY DISEASES  
; FILE REFERENCE: 01997.026800  
; CURRENT APPLICATION NUMBER: US/10/842,142  
; CURRENT FILING DATE: 2004-05-10  
; PRIOR APPLICATION NUMBER: US 60/468,987  
; PRIOR FILING DATE: 2003-05-08  
; PRIOR APPLICATION NUMBER: US 60/491,274  
; PRIOR FILING DATE: 2003-07-31  
; NUMBER OF SEQ ID NOS: 164  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 114  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: siRNA polynucleotide, synthesized  
US-10-842-142-114

Query Match  
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 75.0%; Pred. No. 1.7e+02;  
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 301 AGATGGATGAAGCGGTACCT 320  
Db 1 AGAUGGAGGAAGCUGUACCU 20

RESULT 188  
US-10-751-736-2282/c  
; Sequence 2282, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; TITLE OF INVENTION: CANCERS  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 2282  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-2282

Query Match  
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 1.7e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 61 AATGACAGTGAATTTGCTGA 80

```
RESULT 180
US-10-751-736-11059
; Sequence 11059, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11059
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11059

Query Match          0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1372 AGCTGGTTTGGTTGTTA 1388
Db 5 AGCTGGTTTGGTTGTTA 21

RESULT 181
US-10-751-736-11060
; Sequence 11060, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11060
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11060

Query Match          0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 52.9%; Pred. No. 1.7e+02;
Matches 9; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1372 AGCTGGTTTGGTTGTTA 1388
Db 3 AGCUGGUUUGGUUGUUA 19

RESULT 182
US-10-149-352-11/c
; Sequence 11, Application US/10149352
; Publication No. US20030105050A1
; GENERAL INFORMATION:
; APPLICANT: Beri, Rajinder
```

```
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES
; FILE REFERENCE: 06275-254US1
; CURRENT APPLICATION NUMBER: US/10/149,352
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/GB00/04741
; PRIOR FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: GB 9929487.8
; PRIOR FILING DATE: 1999-12-15
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 4.0
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-149-352-11

Query Match          0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1194 GAGGCAGGAGCTCATGGACC 1213
Db 20 GAGGCTGGAGCTCAGGGACC 1

RESULT 183
US-10-174-559-25
; Sequence 25, Application US/10174559
; Publication No. US20030232773A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF DRAK1 EXPRESSION
; FILE REFERENCE: PTS-0006
; CURRENT APPLICATION NUMBER: US/10/174,559
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 112
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-559-25

Query Match          0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 GAAATCCTTTTCTTTAAAG 886
Db 1 GAACATCTTTTCTTTAAAG 20

RESULT 184
US-10-168-989-42
; Sequence 42, Application US/10168989
; Publication No. US20030190631A1
; GENERAL INFORMATION:
; APPLICANT: Chartier-Harlin et al.
; TITLE OF INVENTION: Implication of a known gene named CP2/LSF-LBP-1 in
; TITLE OF INVENTION: Alzheimer's disease
; FILE REFERENCE: P07666US00/BAS
; CURRENT APPLICATION NUMBER: US/10/168,989
; CURRENT FILING DATE: 2002-06-26
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 21
; TYPE: DNA
```

```
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAA 1764
Db 19 GAAAAAAAAAAAAAAAAA 3

RESULT 177
US-10-800-487-328
; Sequence 328, Application US/108000487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-328

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAA 1764
Db 1 GAAAAAAAAAAAAAAAAA 17

RESULT 178
US-10-644-052A-376/c
; Sequence 376, Application US/10644052A
; Publication No. US20050059619A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M
; APPLICANT: Samulowitz, Ulrike
; APPLICANT: Vollmer, Joerg
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Jurk, Marion
; APPLICANT: Lipford, Grayson
; APPLICANT: Rankin, Robert
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
; FILE REFERENCE: C1037.70048US00
; CURRENT APPLICATION NUMBER: US/10/644,052A
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/404,820
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: US 60/447,377
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 376
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-377

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAAG 1777
Db 20 AAAAAAAAAAAAAAAG 4
```

```
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
; FILE REFERENCE: C1037.70048US00
; CURRENT APPLICATION NUMBER: US/10/644,052A
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/404,820
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/429,701
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: US 60/447,377
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 376
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-376

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAAG 1777
Db 20 AAAAAAAAAAAAAAAG 4

RESULT 179
US-10-644-052A-377/c
; Sequence 377, Application US/10644052A
; Publication No. US20050059619A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M
; APPLICANT: Samulowitz, Ulrike
; APPLICANT: Vollmer, Joerg
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Jurk, Marion
; APPLICANT: Lipford, Grayson
; APPLICANT: Rankin, Robert
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
; FILE REFERENCE: C1037.70048US00
; CURRENT APPLICATION NUMBER: US/10/644,052A
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/404,820
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/429,701
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: US 60/447,377
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 377
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-377

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAAG 1777
Db 20 AAAAAAAAAAAAAAAG 4
```



```

; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11449
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11449

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      559 GATGCACATTTTCATGAGG 577
Db      1 GATGCACATTTTCATGAGG 19

RESULT 174
US-10-669-962-27/c
; Sequence 27, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Brugliera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-27

Query Match      0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAA 1765
Db      17 AAAAAAAAAAAAAAAAAA 1

RESULT 175
US-10-669-962-29/c
; Sequence 29, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Brugliera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.

```

```

; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-29

Query Match      0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAA 1765
Db      17 AAAAAAAAAAAAAAAAAA 1

RESULT 176
US-10-800-487-162/c
; Sequence 162, Application US/108000487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-800-487-162

Query Match      0.9%; Score 17; DB 1; Length 19;

```

Query Match 1.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.5e+02;  
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 978 AGCTGCTTACGAAATTGAA 996  
|||:||||:||||:||||  
Db 1 AGCUGCUUAUGAAAUUGAA 19

RESULT 169  
US-10-751-736-11296  
; Sequence 11296, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11296  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-11296

Query Match 1.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 94.7%; Pred. No. 1.5e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 940 ATTTCTTCATATGGCCAA 958  
|||||  
Db 3 ATTTCTTCATATGGCCAA 21

RESULT 170  
US-10-751-736-11297  
; Sequence 11297, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11297  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-11297

Query Match 1.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 57.9%; Pred. No. 1.5e+02;  
Matches 11; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 940 ATTTCTTCATATGGCCAA 958  
|:::|:::|:::|:::|:::|

Db 1 AUUUCUCCUUAUGGCCAA 19

RESULT 171  
US-10-751-736-11345  
; Sequence 11345, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11345  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-11345

Query Match 1.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 52.6%; Pred. No. 1.5e+02;  
Matches 10; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 1373 GCTGGTTTGGTTGTTAGGA 1391  
||:||||:|::|::|::|  
Db 1 GCGGUGUUGGUGUUGAAGAA 19

RESULT 172  
US-10-751-736-11432  
; Sequence 11432, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11432  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi  
US-10-751-736-11432

Query Match 1.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 63.2%; Pred. No. 1.5e+02;  
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 714 CAGCACATTTGCGCTCTCT 732  
||| ||||:|::|::|::|  
Db 2 CAACACAUUUGCCUCUCU 20

RESULT 173  
US-10-751-736-11449  
; Sequence 11449, Application US/10751736  
; Publication No. US20040265230A1

```

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10793
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10793

Query Match          1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.5e+02;
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 387 AGCTTTCCTCAAGTCTGGAGT 405
      |||:::|||||: |||||:
Db 1 AGCUUCCACGUAUGGAGU 19

RESULT 165
US-10-751-736-10855
; Sequence 10855, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10855
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10855

Query Match          1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 940 ATTTCTTCATATGGCCAA 958
      ||||||||| |||||||
Db 2 ATTTCTTCATATGGCCAA 20

RESULT 166
US-10-751-736-11006
; Sequence 11006, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11006
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11006

Query Match          1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.5e+02;
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 714 CAGCACATTTGCGCTCTCT 732
      |||||||: |||||: |||:
Db 2 CAACACAUUUGCCUCUCU 20

RESULT 167
US-10-751-736-11143
; Sequence 11143, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11143
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11143

Query Match          1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 559 GATGCACATTTTGATGAGG 577
      ||||||| |||||||
Db 1 GATGCACATTTGATGAGG 19

RESULT 168
US-10-751-736-11207
; Sequence 11207, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11207
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11207
```

QY 739 GACATACGTAACATTGAGTCC 759  
Db 1 GACATACGTGGCATTGAGTCC 21

RESULT 160  
US-10-238-011-32  
; Sequence 32, Application US/10238011  
; Publication No. US20030091568A1  
; GENERAL INFORMATION:  
; APPLICANT: Frey Jorgen  
; APPLICANT: Frey, Jorgen  
; TITLE OF INVENTION: Inhibitors for the Formation of Soluble Human CD23  
; FILE REFERENCE: 516326-2002  
; CURRENT APPLICATION NUMBER: US/10/238,011  
; CURRENT FILING DATE: 2002-09-09  
; PRIOR APPLICATION NUMBER: EP 00 107 515.9  
; PRIOR FILING DATE: 2000-04-07  
; PRIOR APPLICATION NUMBER: 09/827,406  
; PRIOR FILING DATE: 2000-04-05  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 32  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-238-011-32

Query Match 1.0%; Score 17.4; DB 1; Length 20;  
Best Local Similarity 94.7%; Pred. No. 1.4e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATGT 269  
Db 1 GATGTGGAGTGCCTGATGT 19

RESULT 161  
US-10-751-736-8824  
; Sequence 8824, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 8824  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-8824

Query Match 1.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 94.7%; Pred. No. 1.5e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATGT 269  
Db 3 GATGTGGAGTGCCTGATGT 21

RESULT 162  
US-10-751-736-8825

; Sequence 8825, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 8825  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAl  
US-10-751-736-8825

Query Match 1.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 1.5e+02;  
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATGT 269  
Db 1 GAUGUGGAGUGCCUGAUGU 19

RESULT 163  
US-10-751-736-9031  
; Sequence 9031, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 9031  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-9031

Query Match 1.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 94.7%; Pred. No. 1.5e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATGT 269  
Db 1 GATGTGGAGTGCCTGATGT 19

RESULT 164  
US-10-751-736-10793  
; Sequence 10793, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei



```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11269
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11269

Query Match          1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 336 TAATTACACTCCGACATGAA 356
Db 1 TAATTACACACCTGACATGAA 21

RESULT 156
US-10-751-736-11380
; Sequence 11380, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11380
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11380

Query Match          1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 355 AAGCGTGAGGATGTAGACTAC 375
Db 1 AACCGTGAGGATGTGACTAC 21

RESULT 157
US-10-751-736-11404
; Sequence 11404, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11404
; LENGTH: 21
```

```
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11404

Query Match          1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 351 CATGAACCGTGAGGATGTAGA 371
Db 1 CATGAACCGTGAGGATGTTGA 21

RESULT 158
US-10-751-736-11437
; Sequence 11437, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11437
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11437

Query Match          1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAAGCGTGAGGATGTAGACTA 374
Db 1 GAACCGTGAGGATGTTGACTA 21

RESULT 159
US-10-751-736-11464
; Sequence 11464, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11464
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11464

Query Match          1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
RESULT 151
US-10-751-736-11113
; Sequence 11113, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11113
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11113

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      354 GAAGCGTGAGGATGTAGACTA 374
      ||| ||||| ||||| |||||
Db      1 GAACCGTGAGGATGTTGACTA 21

RESULT 152
US-10-751-736-11176
; Sequence 11176, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11176
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11176

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      736 GATGACATACGTAAACATTTCAG 756
      ||||| ||||| ||||| |||||
Db      1 GATGACATACGTGGCATTTCAG 21

RESULT 153
US-10-751-736-11179
; Sequence 11179, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11179
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11179

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      739 GACATACGTAAACATTTCAGTCC 759
      ||||| ||||| ||||| |||||
Db      1 GACATACGTGGCATTTCAGTCC 21

RESULT 154
US-10-751-736-11209
; Sequence 11209, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11209
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11209

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      988 GAAATTGAAAGCAGAAATCAA 1008
      ||||| ||||| ||||| |||||
Db      1 GAAATTGAAGCCAGAAATCAA 21

RESULT 155
US-10-751-736-11269
; Sequence 11269, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```
; SEQ ID NO 10901
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10901

Query Match      1.0%; Score 18; DB 1; Length 21;
Best Local Similarity 55.6%; Pred. No. 1.3e+02;
Matches 10; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1372 AGCTGGTTTGGTTGTTAG 1389
Db      2 AGCUGGUUUGGUUGUAG 19

RESULT 147
US-10-751-736-8629
; Sequence 8629, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8629
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8629

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      385 AAAGCTTTCCAAGTCTGGAGT 405
Db      1 AAAGCCTTCCAAGTCTGGAGT 21

RESULT 148
US-10-751-736-9058
; Sequence 9058, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9058
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9058

Query Match      1.0%; Score 17.8; DB 1; Length 21;
```

```
; SEQ ID NO 10901
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10901

Query Match      1.0%; Score 18; DB 1; Length 21;
Best Local Similarity 55.6%; Pred. No. 1.3e+02;
Matches 10; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1372 AGCTGGTTTGGTTGTTAG 1389
Db      2 AGCUGGUUUGGUUGUAG 19

RESULT 147
US-10-751-736-8629
; Sequence 8629, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8629
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8629

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      385 AAAGCTTTCCAAGTCTGGAGT 405
Db      1 AAAGCCTTCCAAGTCTGGAGT 21

RESULT 148
US-10-751-736-9058
; Sequence 9058, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9058
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9058

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      385 AAAGCTTTCCAAGTCTGGAGT 405
Db      1 AAAGCCTTCCAAGTCTGGAGT 21

RESULT 149
US-10-751-736-10786
; Sequence 10786, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10786
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10786

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      355 AAGCGTGAGGATGTAGACTAC 375
Db      1 AACCGTGAGGATGTTGACTAC 21

RESULT 150
US-10-751-736-10951
; Sequence 10951, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10951
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10951

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      351 CATGAAGCGTGAGGATGTAGA 371
Db      1 CATGAACCGTGAGGATGTTGA 21
```

```

;
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-10-620-642-32

Query Match      1.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 144
US-10-620-642-33/c
; Sequence 33, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:

```

```

;
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-620-642-33

Query Match      1.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 145
US-10-751-736-10900
; Sequence 10900, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10900
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10900

Query Match      1.0%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1372 AGCTGGTTTGGTTGTAG 1389
Db 4 AGCTGGTTTGGTTGTAG 21

RESULT 146
US-10-751-736-10901
; Sequence 10901, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2

```



```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-28

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAA 1765
Db 18 GAAAAAAAAAAAAAAAAA 1

RESULT 141
US-10-913-246-22
; Sequence 22, Application US/10913246
; Publication No. US2005003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; PRIOR FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-22

Query Match      1.0%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 2 AAAAAAAAAAAAAAAAAA 19

RESULT 142
US-10-934-890-22
; Sequence 22, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA

```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-22

Query Match      1.0%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 2 AAAAAAAAAAAAAAAAAA 19

RESULT 143
US-10-620-642-32/c
; Sequence 32, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448

```

RESULT 137  
US-10-776-934-741/c  
; Sequence 741, Application US/10776934  
; Publication No. US20050014712A1  
; GENERAL INFORMATION:  
; APPLICANT: HANSEN, BO  
; APPLICANT: THRUE, CHARLOTTE ALBAEK  
; APPLICANT: WESTERGAARD, MAJKEN  
; APPLICANT: PETERSEN, KAMILLE DUMONG  
; APPLICANT: WISSENBACH, MARGIT  
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION  
; FILE REFERENCE: 58610(71432)  
; CURRENT APPLICATION NUMBER: US/10/776,934  
; CURRENT FILING DATE: 2004-02-10  
; PRIOR APPLICATION NUMBER: 60/446,372  
; PRIOR FILING DATE: 2003-02-10  
; PRIOR APPLICATION NUMBER: 60/523,591  
; PRIOR FILING DATE: 2003-11-19  
; NUMBER OF SEQ ID NOS: 741  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 741  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: poly-T oligonucleotide  
; FEATURE:  
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the  
; OTHER INFORMATION: specification as filed  
US-10-776-934-741

Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 138  
US-10-601-140A-24/c  
; Sequence 24, Application US/10601140A  
; Publication No. US20050053942A1  
; GENERAL INFORMATION:  
; APPLICANT: KAUPPINEN, SAKARI  
; APPLICANT: JACOBSEN, NANA  
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE  
; FILE REFERENCE: 57764(71994)  
; CURRENT APPLICATION NUMBER: US/10/601,140A  
; CURRENT FILING DATE: 2003-06-20  
; PRIOR APPLICATION NUMBER: US 60/390,928  
; PRIOR FILING DATE: 2002-06-24  
; NUMBER OF SEQ ID NOS: 45  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 24  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: (1)..(18)  
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides  
US-10-601-140A-24

Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 139  
US-10-884-617-2/c  
; Sequence 2, Application US/10884617  
; Publication No. US20050054730A1  
; GENERAL INFORMATION:  
; APPLICANT: Fu, Jin  
; APPLICANT: Gaetani, Silvana  
; APPLICANT: Piomelli, Daniele  
; APPLICANT: The Regents of the University of California  
; TITLE OF INVENTION: Compounds, Compositions and Treatments of  
; TITLE OF INVENTION: Oleoylethanolamide-Like Modulators of PPARalpha  
; FILE REFERENCE: 02307E-133310US  
; CURRENT APPLICATION NUMBER: US/10/884,617  
; CURRENT FILING DATE: 2004-07-01  
; PRIOR APPLICATION NUMBER: US 60/279,542  
; PRIOR FILING DATE: 2001-03-27  
; PRIOR APPLICATION NUMBER: US 60/336,289  
; PRIOR FILING DATE: 2001-10-31  
; PRIOR APPLICATION NUMBER: US 10/112,509  
; PRIOR FILING DATE: 2002-03-27  
; PRIOR APPLICATION NUMBER: US 60/485,062  
; PRIOR FILING DATE: 2003-07-02  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:Oligo(dT)-12-18  
; OTHER INFORMATION: primer for reverse transcription of total RNA  
; FEATURE:  
; NAME/KEY: modified base  
; LOCATION: (13)..(18)  
; OTHER INFORMATION: t at positions 13-18 may be present or absent  
US-10-884-617-2

Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 140  
US-10-669-962-28/c  
; Sequence 28, Application US/10669962  
; Publication No. US20050081264A1  
; GENERAL INFORMATION:  
; APPLICANT: Brugliera, Filippa  
; APPLICANT: Holton, Timothy A.  
; APPLICANT: Michael, Michael Z.  
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES  
; TITLE OF INVENTION: AND USES THEREFOR  
; FILE REFERENCE: 11658  
; CURRENT APPLICATION NUMBER: US/10/669,962  
; CURRENT FILING DATE: 2003-09-24  
; PRIOR APPLICATION NUMBER: US/09/142,108C  
; PRIOR FILING DATE: 1998-09-01  
; PRIOR APPLICATION NUMBER: PN8386  
; PRIOR FILING DATE: 1996-03-01  
; NUMBER OF SEQ ID NOS: 45  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 28  
; LENGTH: 18

FEATURE:  
OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the  
OTHER INFORMATION: specification as filed  
US-10-776-917-141

Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 134  
US-10-766-096-9/c  
Sequence 9, Application US/10766096  
Publication No. US20040265786A1  
GENERAL INFORMATION:  
APPLICANT: Lin, Ching-I Patsy  
Wallace, Robert Bruce  
Cossman, Jeffrey  
French, Cynthia  
TITLE OF INVENTION: Lyophilization of Cultured Human Cells  
to Preserve RNA and DNA  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, Eighth Floor  
CITY: San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94111-3834  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/766,096  
FILING DATE: 27-Jan-2004  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/884,029  
FILING DATE: 27-JUN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Parent, Annette S.  
REGISTRATION NUMBER: 42,058  
REFERENCE/DOCKET NUMBER: 02558B-059100US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: 13..18  
OTHER INFORMATION: /mod\_base= OTHER  
/note= "t at positions 13-18 may be  
present or absent"  
SEQUENCE DESCRIPTION: SEQ ID NO: 9:

US-10-766-096-9  
Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1

Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 135  
US-10-872-984-7/c  
Sequence 7, Application US/10872984  
Publication No. US20040265888A1  
GENERAL INFORMATION:  
APPLICANT: Kaufman, Joseph C.  
APPLICANT: Roth, Matthew E.  
APPLICANT: Lizardi, Paul M.  
APPLICANT: Feng, Li  
APPLICANT: Latimer, Darin R.  
TITLE OF INVENTION: Binary Encoded Sequence Tags  
FILE REFERENCE: AGL 100  
CURRENT APPLICATION NUMBER: US/10/872,984  
PRIOR FILING DATE: 2004-06-21  
PRIOR APPLICATION NUMBER: US/09/994,311  
PRIOR FILING DATE: 2001-11-26  
PRIOR APPLICATION NUMBER: US/09/637,751  
PRIOR FILING DATE: 2000-08-11  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 7  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-872-984-7

Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1747 TGAATAAAAAAAAAAAAAA 1764  
Db 18 TGAATAAAAAAAAAAAAAA 1

RESULT 136  
US-10-638-141-10/c  
Sequence 10, Application US/10638141  
Publication No. US20050003364A1  
GENERAL INFORMATION:  
APPLICANT: Stanton, Lawrence W.  
APPLICANT: Kapoun, Ann Marie  
TITLE OF INVENTION: SECRETED FACTORS  
FILE REFERENCE: SCIOS.013A  
CURRENT APPLICATION NUMBER: US/10/638,141  
CURRENT FILING DATE: 2003-08-07  
PRIOR APPLICATION NUMBER: US/09/665,728  
PRIOR FILING DATE: 2000-09-20  
PRIOR APPLICATION NUMBER: 60/156,277  
PRIOR FILING DATE: 1999-09-27  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 10  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: synthetic  
US-10-638-141-10

Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-913

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 130
US-10-831-778-939/c
; Sequence 939, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fourn, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 939
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-939

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 131
US-10-776-933-150/c
; Sequence 150, Application US/10776933
; Publication No. US20040241717A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRUE, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 58614(71432)
; CURRENT APPLICATION NUMBER: US/10/776,933
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,374
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 150
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: poly-T oligonucleotide

```

```

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: poly-T oligonucleotide
; FEATURE:
; OTHER INFORMATION: This sequence may encompass 12-18 nucleotides
; OTHER INFORMATION: according to the specification as filed
US-10-776-933-150

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 132
US-10-674-159A-112/c
; Sequence 112, Application US/10674159A
; Publication No. US20040242518A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Jianzhu
; APPLICANT: Ge, Qing
; APPLICANT: Eisen, Herman
; TITLE OF INVENTION: Influenza Therapeutic
; FILE REFERENCE: 0492611-0506
; CURRENT APPLICATION NUMBER: US/10/674,159A
; CURRENT FILING DATE: 2003-09-29
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 112
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: mRNA
US-10-674-159A-112

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 133
US-10-776-917-141/c
; Sequence 141, Application US/10776917
; Publication No. US20040248840A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRUE, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION
; FILE REFERENCE: 58609(71432)
; CURRENT APPLICATION NUMBER: US/10/776,917
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,363
; PRIOR FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: DK 2003-01539
; PRIOR FILING DATE: 2003-10-20
; NUMBER OF SEQ ID NOS: 201
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 141
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: poly-T oligonucleotide

```



```
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11383
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11383

Query Match          1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 386 AAGCTTCCAAAGTCTGGAGT 405
Db 1 AAGCTTCCAAAGTATGGAGT 20
|||||
RESULT 126
US-10-751-736-11434
; Sequence 11434, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11434
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11434

Query Match          1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 349 GACATGAAGCGTGAGGATGT 368
Db 1 GACATGAACCGTGAGGATGT 20
|||||
RESULT 127
US-10-849-072-21
; Sequence 21, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; FILE REFERENCE: 4780/00/WO
```

```
; CURRENT APPLICATION NUMBER: US/10/849,072
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-21

Query Match          1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 1 AAAAAAAAAAAAAAAAAA 18
|||||
RESULT 128
US-10-849-072-23/c
; Sequence 23, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; TITLE OF INVENTION: used
; FILE REFERENCE: 4780/00/WO
; CURRENT APPLICATION NUMBER: US/10/849,072
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-23

Query Match          1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1
|||||
RESULT 129
US-10-831-778-913/c
; Sequence 913, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 913
; LENGTH: 18
```

```
US-10-751-736-10888
Query Match      1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1263 AATTGATGCAGTCTCTATT 1282
Db 1 AATTGATGCAGTCTCTATT 20

RESULT 121
US-10-751-736-11110
; Sequence 11110, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11110
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11110

Query Match      1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 349 GACATGAAGCGTGGAGTGT 368
Db 1 GACATGAACCGTGGAGTGT 20

RESULT 122
US-10-751-736-11126
; Sequence 11126, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11126
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11126

Query Match      1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 386 AAGCTTTCCAAGTCTGGAGT 405
```

```
Db 1 AAGCUUCCAAUGAUGAGU 20

RESULT 123
US-10-751-736-11206
; Sequence 11206, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11206
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11206

Query Match      1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 977 AAGCTGCTTACGAAATTGAA 996
Db 2 AAGCTGCTTATGAAATTGAA 21

RESULT 124
US-10-751-736-11344
; Sequence 11344, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11344
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11344

Query Match      1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1372 AGCTGTTTGGTTGTAGGA 1391
Db 2 AGCTGTTTGGTTGTAGGA 21

RESULT 125
US-10-751-736-11383
; Sequence 11383, Application US/10751736
```

```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11015
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11015

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 99;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      721 TTTGCGCTCTCTGCTGATG 739
      :::|||||:::|:::|:::|:::|
Db      1 UUUCGCCUCUCUCUGCUGAUG 19

RESULT 117
US-10-831-778-61/c
; Sequence 61, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 61
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-61

Query Match          1.1%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1770
      ||||| ||||| ||||| ||||| |||||
Db      22 AAAAAACAAAAAAAAACAAAAAAA 1

RESULT 118
US-10-751-736-10795
; Sequence 10795, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
```

```
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10795
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10795

Query Match          1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      386 AAGCTTTCCAAGTCTGGAGT 405
      ||||| ||||| ||||| |||||
Db      1 AAGCTTTCCAAGTATGGAGT 20

RESULT 119
US-10-751-736-10861
; Sequence 10861, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10861
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10861

Query Match          1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      977 AAGCTGCTTACGAAATTGAA 996
      ||||| ||||| ||||| |||||
Db      1 AAGCTGCTTATGAAATTGAA 20

RESULT 120
US-10-751-736-10888
; Sequence 10888, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10888
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
```

; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-620-642-34

Query Match 1.1%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAA 1766
. |||||
Db 19 GAAAAAAAAAAAAAAAAA 1

RESULT 114
US-10-751-736-10823

; Sequence 10823, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10823
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
; US-10-751-736-10823

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 99;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 717 CACATTTGCGCTCTCTGCT 735
|||||
Db 1 CACAUUUGCCUCUCUGCU 19

RESULT 115

US-10-751-736-11009
; Sequence 11009, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11009
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
; US-10-751-736-11009

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 99;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 717 CACATTTGCGCTCTCTGCT 735
|||||
Db 2 CACAUUUGCCUCUCUGCU 20

RESULT 116

US-10-751-736-11015
; Sequence 11015, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei



```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-913-246-24

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1767
      |||
Db      1 AAAAAAAAAAAAAAAAAAAAAA 19

RESULT 110
US-10-934-890-24
; Sequence 24, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-934-890-24

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1767
      |||
Db      1 AAAAAAAAAAAAAAAAAAAAAA 19

RESULT 111
US-10-700-884-23/c
; Sequence 23, Application US/10700884
; Publication No. US20050037370A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Eldrup, Anne B.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bhat, Balkrishen
; APPLICANT: Griffey, Richard
; APPLICANT: Swayze, Eric E.
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Prakash, Thazha P.
; APPLICANT: Rajeev, Kallanthottathil G.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE
; TITLE OF INVENTION: AND GUANINE AND THEIR USE IN GENE MODULATION
; FILE REFERENCE: ISIS-5317
; CURRENT APPLICATION NUMBER: US/10/700,884
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: US 10/635,380
; PRIOR FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: US 60/423,760
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 10/078,949
; PRIOR FILING DATE: 2002-02-20
```

```
; PRIOR APPLICATION NUMBER: US 09/479,783
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 08/870,608
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: US 08/659,440
; PRIOR FILING DATE: 1996-06-06
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-O-[2-(methoxy)ethyl]-2-thio-5-methyluridine
US-10-700-884-23

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1767
      |||
Db      19 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 112
US-10-728-078-14
; Sequence 14, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Puromycin linker oligonucleotide
US-10-728-078-14

Query Match      1.1%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1758 AAAAAAAAAAAAAAAAAAAC 1776
      |||
Db      1 AAAAAAAAAAAAAAAAAAAC 19

RESULT 113
US-10-620-642-34/c
; Sequence 34, Application US/10620642
; Publication No. US20050080250A1
```

; PRIOR APPLICATION NUMBER: US 60/227,436  
 ; PRIOR FILING DATE: 2000-08-23  
 ; NUMBER OF SEQ ID NOS: 1145  
 ; SOFTWARE: FastSEQ for Windows Version 3.0  
 ; SEQ ID NO 60  
 ; LENGTH: 24  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic Sequence  
 US-10-314-578-60

Query Match 1.1%; Score 19.2; DB 1; Length 24;  
 Best Local Similarity 87.5%; Pred. No. 1.2e+02;  
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
 Db 24 AAAAAAAAAACAAAAAACAA 1

RESULT 106  
 US-10-831-778-60/c  
 ; Sequence 60, Application US/10831778  
 ; Publication No. US20040235774A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Bratzler, Robert L.  
 ; APPLICANT: Petersen, Deanna M.  
 ; APPLICANT: Fourn, Yves  
 ; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the  
 ; TITLE OF INVENTION: Treatment of Asthma and Allergy  
 ; FILE REFERENCE: C1037/7013 (HCL/MAT)  
 ; CURRENT APPLICATION NUMBER: US/10/831,778  
 ; CURRENT FILING DATE: 2004-04-23  
 ; PRIOR APPLICATION NUMBER: US 60/179,991  
 ; PRIOR FILING DATE: 2000-02-03  
 ; NUMBER OF SEQ ID NOS: 1093  
 ; SOFTWARE: FastSEQ for Windows Version 3.0  
 ; SEQ ID NO 60  
 ; LENGTH: 24  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic Sequence  
 US-10-831-778-60

Query Match 1.1%; Score 19.2; DB 1; Length 24;  
 Best Local Similarity 87.5%; Pred. No. 1.2e+02;  
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
 Db 24 AAAAAAAAAACAAAAAACAA 1

RESULT 107  
 US-10-619-906-3/c  
 ; Sequence 3, Application US/10619906  
 ; Publication No. US20040087533A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Index Pharmaceuticals  
 ; TITLE OF INVENTION: New Compound  
 ; FILE REFERENCE: 50299  
 ; CURRENT APPLICATION NUMBER: US/10/619,906  
 ; CURRENT FILING DATE: 2003-07-16  
 ; NUMBER OF SEQ ID NOS: 23  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 3  
 ; LENGTH: 19  
 ; TYPE: DNA  
 ; ORGANISM: Artificial  
 ; FEATURE:  
 ; NAME/KEY: misc\_feature

; LOCATION: (1)..(19)  
 ; OTHER INFORMATION: SEQ ID NO.3, antisense oligonucleotide  
 US-10-619-906-3

Query Match 1.1%; Score 19; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 81;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 718 ACATTTCGCCTCTCTGCTG 736  
 Db 19 ACATTTCGCCTCTCTGCTG 1

RESULT 108  
 US-10-760-940-1/c  
 ; Sequence 1, Application US/10760940  
 ; Publication No. US20040219577A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ravikumar, Vasulinga  
 ; APPLICANT: Manoharan, Muthiah  
 ; APPLICANT: Capaldi, Daniel C.  
 ; APPLICANT: Krotz, Achim  
 ; APPLICANT: Cole, Douglas L.  
 ; APPLICANT: Guzaev, Andrei  
 ; TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS  
 ; FILE REFERENCE: ISIS-5422  
 ; CURRENT APPLICATION NUMBER: US/10/760,940  
 ; CURRENT FILING DATE: 2004-01-20  
 ; PRIOR APPLICATION NUMBER: US 10/232,881  
 ; PRIOR FILING DATE: 2002-08-30  
 ; PRIOR APPLICATION NUMBER: US 09/288,679  
 ; PRIOR FILING DATE: 1999-04-09  
 ; PRIOR APPLICATION NUMBER: US 60/118,564  
 ; PRIOR FILING DATE: 1999-02-04  
 ; NUMBER OF SEQ ID NOS: 5  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 1  
 ; LENGTH: 19  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic Construct  
 US-10-760-940-1

Query Match 1.1%; Score 19; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 81;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAA 1767  
 Db 19 AAAAAAAAAAAAAAAAAAAA 1

RESULT 109  
 US-10-913-246-24  
 ; Sequence 24, Application US/10913246  
 ; Publication No. US20050003441A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Kurn, Nurith  
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
 ; TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES  
 ; FILE REFERENCE: 4926200500  
 ; CURRENT APPLICATION NUMBER: US/10/913,246  
 ; CURRENT FILING DATE: 2004-08-05  
 ; PRIOR APPLICATION NUMBER: US/10/100,321  
 ; PRIOR FILING DATE: 2002-03-11  
 ; PRIOR APPLICATION NUMBER: US 60/274,550  
 ; PRIOR FILING DATE: 2001-03-09  
 ; NUMBER OF SEQ ID NOS: 25  
 ; SOFTWARE: FastSEQ for Windows Version 4.0  
 ; SEQ ID NO 24  
 ; LENGTH: 19  
 ; TYPE: DNA

```
; Sequence 60, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence.
US-09-776-479-60
```

```
Query Match 1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
||||| ||||||| ||||||| ||
Db 24 AAAAAACAAAAAAACAAAAAACAA 1
```

```
RESULT 102
US-09-776-479-60/c
; Sequence 60, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-60
```

```
Query Match 1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
||||| ||||||| ||||||| ||
Db 24 AAAAAACAAAAAAACAAAAAACAA 1
```

```
RESULT 103
US-10-112-653-54/c
; Sequence 54, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Berg, Daniel J.
```

```
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
; TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
; FILE REFERENCE: C01039/70060(AWS)
; CURRENT APPLICATION NUMBER: US/10/112,653
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/279,642
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 54
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-54
```

```
Query Match 1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
||||| ||||||| ||||||| ||
Db 24 AAAAAACAAAAAAACAAAAAACAA 1
```

```
RESULT 104
US-10-017-995-60/c
; Sequence 60, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-60
```

```
Query Match 1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
||||| ||||||| ||||||| ||
Db 24 AAAAAACAAAAAAACAAAAAACAA 1
```

```
RESULT 105
US-10-314-578-60/c
; Sequence 60, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jorg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
```

```
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-23

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 2 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 97
US-10-751-736-10792
; Sequence 10792, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10792
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10792

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 89;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 385 AAAGCTTCCAAGTCTGGAGT 405
Db 1 AAAGCTTCCAAGTATGGAGT 21

RESULT 98
US-10-751-736-10822
; Sequence 10822, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10822
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10822

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 89;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 715 AGCACATTTGGCCTCTCTGCT 735
Db 1 AACACATTTGGCCTCTCTGCT 21

RESULT 99
US-10-751-736-11008
; Sequence 11008, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11008
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11008

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 89;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 714 CAGCACATTTGGCCTCTCTGC 734
Db 1 CAACACATTTGGCCTCTCTGC 21

RESULT 100
US-10-751-736-11125
; Sequence 11125, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11125
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11125

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 89;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 384 GAAAGCTTTCCAAGTCTGGAG 404
Db 1 GAAAGCTTTCCAAGTATGGAG 21

RESULT 101
US-09-776-479-60/c
```



```

; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide
US-10-601-140A-44

Query Match          1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 93
US-10-876-086-49/c
; Sequence 49, Application US/10876086
; Publication No. US20050066389A1
; GENERAL INFORMATION:
; APPLICANT: Gallie, Daniel R.
; APPLICANT: Young, Todd E.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Genes Which Produce Staygreen Characteristics in Maize
; FILE REFERENCE: 023070-137010US
; CURRENT APPLICATION NUMBER: US/10/876,086
; CURRENT FILING DATE: 2004-06-23
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligo-dT(20)
; OTHER INFORMATION: primer
US-10-876-086-49

Query Match          1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 94
US-10-751-736-11012
; Sequence 11012, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11012
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-11012
```

```

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 76;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 719 CATTCGCCTCTCTGCTGAT 738
Db 1 CAUUCGCCUCUCUGCUGAU 20

RESULT 95
US-10-913-246-23
; Sequence 23, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-23

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 2 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 96
US-10-934-890-23
; Sequence 23, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
```

```
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide capture probe
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; OTHER INFORMATION: LNA monomer
US-10-601-140A-23

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 90
US-10-601-140A-34
; Sequence 34, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 44
; LENGTH: 20
```

```
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide linker
US-10-601-140A-34

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db      1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 91
US-10-601-140A-40/c
; Sequence 40, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-40

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 92
US-10-601-140A-44
; Sequence 44, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 44
; LENGTH: 20
```

```

RESULT 86
US-10-601-140A-8/c
; Sequence 8, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-8

```

```

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
      |||||
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

```

```

RESULT 87
US-10-601-140A-9/c
; Sequence 9, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)..(4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (8)..(9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base

```

```

; LOCATION: (13)..(14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (18)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-9

```

```

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
      |||||
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

```

```

RESULT 88
US-10-601-140A-10/c
; Sequence 10, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)..(5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)..(12)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-10

```

```

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
      |||||
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

```

```

RESULT 89
US-10-601-140A-23/c
; Sequence 23, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)

```

```
;
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (16)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-4
```

```
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1
```

```
RESULT 84
US-10-601-140A-6/c
; Sequence 6, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
;
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-6
```

```
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1
```

```
RESULT 85
US-10-601-140A-7/c
; Sequence 7, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-7
```

```
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1
```



```

; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-1

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 81
US-10-601-140A-2/c
; Sequence 2, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base

```

```

; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-2

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 82
US-10-601-140A-3/c
; Sequence 3, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-3

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 83
US-10-601-140A-4/c
; Sequence 4, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 4
; LENGTH: 20

```

; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-226

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 77
US-10-831-778-556/c
; Sequence 556, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 556
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-556

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 78
US-10-831-778-560
; Sequence 560, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23

; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 560
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-560

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 79
US-10-728-078-23/c
; Sequence 23, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-728-078-23

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 80
US-10-601-140A-1/c
; Sequence 1, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24

```
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (22)
; OTHER INFORMATION: a, t, c or g
US-10-601-140A-45

Query Match      1.1%; Score 20.2; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 79;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAAAAAA 1768
Db 21 BAAAAAAAAAAAAAAAAAAAAA 1

RESULT 73
US-09-976-900A-55
; Sequence 55, Application US/09976900A
; Publication No. US20040219520A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-713-123
; CURRENT APPLICATION NUMBER: US/09/976,900A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-09-976-900A-55

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 74
US-10-661-415-12
; Sequence 12, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
```

```
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-12

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 75
US-10-661-415-15/c
; Sequence 15, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-15

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 76
US-10-831-778-226/c
; Sequence 226, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
```

Db 24 GAGTTTGTGCTGTCACTACCGT 1

RESULT 70

US-10-664-000-3/c  
; Sequence 3, Application US/10664000  
; Publication No. US20040248144A1  
; GENERAL INFORMATION:  
; APPLICANT: Mir, Kalim  
; TITLE OF INVENTION: Arrays and Methods of Use  
; FILE REFERENCE: 8654/2182  
; CURRENT APPLICATION NUMBER: US/10/664,000  
; CURRENT FILING DATE: 2003-09-16  
; PRIOR APPLICATION NUMBER: PCT/GB02/01245  
; PRIOR FILING DATE: 2002-03-18  
; PRIOR APPLICATION NUMBER: GB0106635.6  
; PRIOR FILING DATE: 2001-03-16  
; PRIOR APPLICATION NUMBER: GB0118879.6  
; PRIOR FILING DATE: 2001-08-02  
; NUMBER OF SEQ ID NOS: 3  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 3  
; LENGTH: 22  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Anchored capture oligonucleotide  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (22)..(22)  
; OTHER INFORMATION: n is a, c, g, or t  
US-10-664-000-3

Query Match 1.1%; Score 20.2; DB 1; Length 22;  
Best Local Similarity 95.2%; Pred. No. 79;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAAAAAA 1768  
:|||||  
Db 21 BAAAAAAAAAAAAAAAAAAAAA 1

RESULT 71

US-10-601-140A-32/c  
; Sequence 32, Application US/10601140A  
; Publication No. US20050053942A1  
; GENERAL INFORMATION:  
; APPLICANT: KAUPPINEN, SAKARI  
; APPLICANT: JACOBSEN, NANA  
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE  
; FILE REFERENCE: 57764(71994)  
; CURRENT APPLICATION NUMBER: US/10/601,140A  
; CURRENT FILING DATE: 2003-06-20  
; PRIOR APPLICATION NUMBER: US 60/390,928  
; PRIOR FILING DATE: 2002-06-24  
; NUMBER OF SEQ ID NOS: 45  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 32  
; LENGTH: 22  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: oligonucleotide  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (1)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (3)  
; OTHER INFORMATION: LNA monomer

; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (5)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (7)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (9)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (11)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (13)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (15)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (17)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (19)  
; OTHER INFORMATION: LNA monomer  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (22)  
; OTHER INFORMATION: a, t, c or g  
US-10-601-140A-32

Query Match 1.1%; Score 20.2; DB 1; Length 22;  
Best Local Similarity 95.2%; Pred. No. 79;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAAAAAA 1768  
:|||||  
Db 21 BAAAAAAAAAAAAAAAAAAAAA 1

RESULT 72

US-10-601-140A-45/c  
; Sequence 45, Application US/10601140A  
; Publication No. US20050053942A1  
; GENERAL INFORMATION:  
; APPLICANT: KAUPPINEN, SAKARI  
; APPLICANT: JACOBSEN, NANA  
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE  
; FILE REFERENCE: 57764(71994)  
; CURRENT APPLICATION NUMBER: US/10/601,140A  
; CURRENT FILING DATE: 2003-06-20  
; PRIOR APPLICATION NUMBER: US 60/390,928  
; PRIOR FILING DATE: 2002-06-24  
; NUMBER OF SEQ ID NOS: 45  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 45  
; LENGTH: 22  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: oligonucleotide  
; FEATURE:  
; NAME/KEY: modified\_base  
; LOCATION: (1)..(20)



; SEQ ID NO 11011
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11011

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 717 CACATTTCGCCCTCTCTGCTGA 737
Db 1 CACATTTCGCCCTCTCTGCTGA 21

RESULT 66
US-10-751-736-11014
; Sequence 11014, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11014
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11014

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 719 CATTTCGCCCTCTCTGCTGATG 739
Db 1 CATTTCGCCCTCTCTGCTGATG 21

RESULT 67
US-10-830-287A-7/c
; Sequence 7, Application US/10830287A
; Publication No. US20050038238A1
; GENERAL INFORMATION:
; APPLICANT: Kriesel, John D.
; APPLICANT: Jones, Brandt B.
; APPLICANT: Grissom, Charles B.
; APPLICANT: Herpin, Geoff
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: OLIGONUCLEOTIDE COMPLEXES FOR USE AS ANTI-VIRAL THERAPEUTICS
; FILE REFERENCE: 007180-19
; CURRENT APPLICATION NUMBER: US/10/830,287A
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,270
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Variola virus
US-10-830-287A-7

Query Match
1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1769
Db 21 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 68
US-10-601-140A-43
; Sequence 43, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 43
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-601-140A-43

Query Match
1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1769
Db 1 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 69
US-10-872-063-161/c
; Sequence 161, Application US/10872063
; Publication No. US20050079518A1
; GENERAL INFORMATION:
; APPLICANT: BAKER, Joffre
; APPLICANT: BRYANT, John L.
; APPLICANT: PRAK, Soonmyung
; APPLICANT: SHAK, Steven
; TITLE OF INVENTION: Prediction of Likelihood of Cancer
; FILE REFERENCE: 39740-0012 US
; CURRENT APPLICATION NUMBER: US/10/872,063
; CURRENT FILING DATE: 2004-06-17
; PRIOR APPLICATION NUMBER: US 60/482,339
; PRIOR FILING DATE: 2003-06-24
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer-probe
US-10-872-063-161

Query Match
1.2%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 80;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 837 GAGTTTGTGCTGTCTCAACAGT 860

```
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 908158
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-908158

Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1164 TGTGATAAACACTACTGGAGGTAT 1188
      |||||
Db 1 TGTGATAAACAGTACTGGAGGTAT 25

RESULT 62
US-10-719-900-962530
; Sequence 962530, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 962530
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus.
US-10-719-900-962530

Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1644 TTGTTTCTAACACCTTCAAGTAG 1668
      |||||
Db 1 TTGTTTCTAACTACCTTCAAGTAG 25

RESULT 63
US-10-721-793-285/c
; Sequence 285, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerril Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; TITLE OF INVENTION: Venom of Scorpions of the Genus Centruroides
; FILE REFERENCE: 2099.0070001
; CURRENT APPLICATION NUMBER: US/10/721,793
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 285
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PCR Reverse oligonucleotide primer
; NAME/KEY: misc_feature
```

```
; LOCATION: (23)..(23)
; OTHER INFORMATION: n is a, t, g, or c
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: (1)..(24)
; OTHER INFORMATION: oligonucleotide T22NN
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (24)..(24)
; OTHER INFORMATION: n is a, t, g, or c
US-10-721-793-285

Query Match      1.2%; Score 22; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1770
      |||||
Db 22 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 64
US-10-831-778-912/c
; Sequence 912, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 912
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-912

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1769
      |||||
Db 21 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 65
US-10-751-736-11011
; Sequence 11011, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
```

```

; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 512976
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-512976

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1267 GATGCAGTCCTCTATTTCAAAAGAC 1291
|||||
Db 1 GATGCAGTCCTCAATTTCAAAAGAC 25

RESULT 57
US-10-719-900-611610
; Sequence 611610, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 611610
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-611610

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1196 GGCAGGAGCTCATGGACCCTGCTTA 1220
|||||
Db 1 GGCAGGAGCTCAAGGACCCTGCTTA 25

RESULT 58
US-10-719-900-761328
; Sequence 761328, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 761328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-761328

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1297 TACATCTTCCAAAGGAGCCTATCAAT 1321
|||||
Db 1 TACATCTTCCAAAGGAGCCTATCAAT 25

; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 512976
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-512976

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1267 GATGCAGTCCTCTATTTCAAAAGAC 1291
|||||
Db 1 GATGCAGTCCTCAATTTCAAAAGAC 25

RESULT 59
US-10-719-900-860596
; Sequence 860596, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 860596
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-860596

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1229 TGATTTCCACACACTTCCCAGGAAT 1253
|||||
Db 1 TGATTTCCACACTTCCCAGGAAT 25

RESULT 60
US-10-719-900-879472
; Sequence 879472, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 879472
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-879472

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1208 TGGACCCCTGCTTACCCCAAGCTGAT 1232
|||||
Db 1 TGGACCCCTGCTTACCCCAAGCTGAT 25

RESULT 61
US-10-719-900-908158
; Sequence 908158, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914

```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-3

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
      |||
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 52
US-10-719-900-174230
; Sequence 174230, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 174230
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-174230

Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 AGCCTAAATTCAGTCCTCTA 1280
      |||
Db 1 AGCCTAAATTCAGTCCTCTA 25

RESULT 53
US-10-719-900-309853
; Sequence 309853, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 309853
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-309853

Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1240 CACTTCCCAGGAATCAAGCCTAAAA 1264
      |||
```

```
Db 1 CACTTCCCAGGATTCAAGCCTAAAA 25

RESULT 54
US-10-719-900-446212
; Sequence 446212, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 446212
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-446212

Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1289 GACACTACTACATCTTCCCAAGGAGC 1313
      |||
Db 1 GACACTACTACAACTTCCCAAGGAGC 25

RESULT 55
US-10-719-900-480520
; Sequence 480520, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 480520
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-480520

Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1310 GAGCCTATCAATTGGAATATGACCC 1334
      |||
Db 1 GAGCCTATCAATAGGAATATGACCC 25

RESULT 56
US-10-719-900-512976
; Sequence 512976, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
```



```
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 433
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-433

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 48
US-10-831-778-961/c
; Sequence 961, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 961
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-961

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 49
US-10-831-778-962
; Sequence 962, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 962
; LENGTH: 24
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-962

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 1 AAAAAAAAAAAAAAAAAAAAAA 24

RESULT 50
US-10-357-930-14833/c
; Sequence 14833, Application US/10357930
; Publication No. US20040259086A1
; GENERAL INFORMATION:
; APPLICANT: Schlegel, Robert
; APPLICANT: Endege, Wilson
; APPLICANT: Monahan, John
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR
; TITLE OF INVENTION: IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF
; TITLE OF INVENTION: HUMAN PROSTATE CANCER
; FILE REFERENCE: MRI-007BCN
; CURRENT APPLICATION NUMBER: US/10/357,930
; CURRENT FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: 09/785,276
; PRIOR FILING DATE: 2003-02-16
; PRIOR APPLICATION NUMBER: 60/183,319
; PRIOR FILING DATE: 2000-02-17
; PRIOR APPLICATION NUMBER: 60/189,862
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/207,454
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 60/211,314
; PRIOR FILING DATE: 2000-06-09
; PRIOR APPLICATION NUMBER: 60/219,007
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: 60/255,281
; PRIOR FILING DATE: 2000-12-13
; NUMBER OF SEQ ID NOS: 62232
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14833
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-357-930-14833

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 51
US-10-942-251-3/c
; Sequence 3, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; TITLE OF INVENTION: NUCLEIC ACIDS INTO CIRCULAR VECTORS
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
```

```

RESULT 43
US-10-969-164-7/c
; Sequence 7, Application US/10969164
; Publication No. US20050065322A1
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/10/969,164
; CURRENT FILING DATE: 2004-10-20
; PRIOR APPLICATION NUMBER: US/09/527,345
; PRIOR FILING DATE: 1999-03-17
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764a
US-10-969-164-7

```

```

Query Match      1.4%; Score 25; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1749 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1773
Db 25 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

```

```

RESULT 44
US-10-942-251-8/c
; Sequence 8, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-8

```

```

Query Match      1.4%; Score 25; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1752 AAAAAAAAAAAAAAAAAAAAAAAAAAAC 1776
Db 28 AAAAAAAAAAAAAAAAAAAAAAAAAAAC 4

```

```

RESULT 45
US-10-942-251-9/c
; Sequence 9, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri

```

```

; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-9

```

```

Query Match      1.4%; Score 24.6; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 31;
Matches 24; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1752 AAAAAAAAAAAAAAAAAAAAAAAAAAAC 1776
Db 25 AAAAAAAAAAAAAAAAAAAAAAAAAAAY 1

```

```

RESULT 46
US-10-942-251-12/c
; Sequence 12, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-12

```

```

Query Match      1.4%; Score 24.4; DB 1; Length 28;
Best Local Similarity 96.2%; Pred. No. 42;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 1752 AAAAAAAAAAAAAAAAAAAAAAAAAACG 1777
Db 28 AAAAAAAAAAAAAAAAAAAAAAAAAAGG 3

```

```

RESULT 47
US-10-831-778-433/c
; Sequence 433, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03

```

US-10-809-189-125382  
; Sequence 125382, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125382  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125382

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1324 GAATATGACCCCTGTTCCGTCGTG 1348  
|||||  
Db 1 GAATATGACCCCTGTTCCGTCGTG 25

RESULT 40  
US-10-809-189-125383  
; Sequence 125383, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125383  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125383

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1336 CTGTTCCGTCGTGTACCAAAACAT 1360  
|||||  
Db 1 CTGTTCCGTCGTGTACCAAAACAT 25

RESULT 41  
US-10-809-189-125384  
; Sequence 125384, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann

; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125384  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125384

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1339 TTCCGTCGTGTACCAAAACATTGA 1363  
|||||  
Db 1 TTCCGTCGTGTACCAAAACATTGA 25

RESULT 42  
US-10-787-442-38/c  
; Sequence 38, Application US/10787442  
; Publication No. US20040260065A1  
; GENERAL INFORMATION:  
; APPLICANT: Novak, Julia E.  
; APPLICANT: Presnell, Scott R.  
; APPLICANT: Sprecher, Cindy A.  
; APPLICANT: Foster, Donald C.  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Gross, Jane A.  
; APPLICANT: Johnston, Janet V.  
; APPLICANT: Nelson, Andrew J.  
; APPLICANT: Dillon, Stacey R.  
; APPLICANT: Hammond, Angela K.  
; TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND  
; FILE REFERENCE: 99-16  
; CURRENT APPLICATION NUMBER: US/10/787,442  
; CURRENT FILING DATE: 2004-02-26  
; PRIOR APPLICATION NUMBER: US/09/522,217  
; PRIOR FILING DATE: 2000-03-09  
; PRIOR APPLICATION NUMBER: US 60/123,547  
; PRIOR FILING DATE: 1999-03-09  
; PRIOR APPLICATION NUMBER: US 60/123,904  
; PRIOR FILING DATE: 1999-03-11  
; PRIOR APPLICATION NUMBER: US 60/142,013  
; PRIOR FILING DATE: 1999-07-01  
; NUMBER OF SEQ ID NOS: 115  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 38  
; LENGTH: 26  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Oligonucleotide primer ZC7764a  
US-10-787-442-38

Query Match 1.4%; Score 25; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773  
|||||  
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1273 GTCCTCTATTTCAAAAGACACTACT 1297  
Db 1 GTCCTCTATTTCAAAAGACACTACT 25

RESULT 35  
US-10-809-189-125378  
; Sequence 125378, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125378  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125378

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1276 CTCTATTTCAAAAGACACTACTACA 1300  
Db 1 CTCTATTTCAAAAGACACTACTACA 25

RESULT 36  
US-10-809-189-125379  
; Sequence 125379, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125379  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125379

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1279 TATTTCAAAGACACTACTACTATCT 1303

Db 1 TATTTCAAAGACACTACTACTATCT 25

RESULT 37  
US-10-809-189-125380  
; Sequence 125380, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125380  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125380

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1297 TACATCTTCCAAGGAGCCTATCAAT 1321  
Db 1 TACATCTTCCAAGGAGCCTATCAAT 25

RESULT 38  
US-10-809-189-125381  
; Sequence 125381, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125381  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125381

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1303 TTCCAAGGAGCCTATCAATTGGAAT 1327  
Db 1 TTCCAAGGAGCCTATCAATTGGAAT 25

RESULT 39



; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 125373  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125373

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1588 TTCTATTCTTAATTTTGAAAGTGCA 1612  
|||||  
Db 1 TTCTATTCTTAATTTTGAAAGTGCA 25

RESULT 31  
US-10-809-189-125374  
; Sequence 125374, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 125374  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125374

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1612 ATGGTTCAGAGGCCAACTGGTTTAT 1636  
|||||  
Db 1 ATGGTTCAGAGGCCAACTGGTTTAT 25

RESULT 32  
US-10-809-189-125375  
; Sequence 125375, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 125375

; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125375

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1681 AGAATTACTCTTGTCTTTACTGA 1705  
|||||  
Db 1 AGAATTACTCTTGTCTTTACTGA 25

RESULT 33  
US-10-809-189-125376  
; Sequence 125376, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 125376  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125376

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1684 ATTACTCTTGTCTTTACTGAAAT 1708  
|||||  
Db 1 ATTACTCTTGTCTTTACTGAAAT 25

RESULT 34  
US-10-809-189-125377  
; Sequence 125377, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 125377  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125377

```
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125369
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125369

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1447 ATATTCTCTATGCTCAGGGTGTA 1471
Db      1 ATATTCTCTATGCTCAGGGTGTA 25

RESULT 27
US-10-809-189-125370
; Sequence 125370, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125370
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125370

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1453 ACTCTATGCTCAGGGTGTAATG 1477
Db      1 ACTCTATGCTCAGGGTGTAATG 25

RESULT 28
US-10-809-189-125371
; Sequence 125371, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
```

```
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125371
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125371

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1513 CAGGTCACACACACATAGTTACACA 1537
Db      1 CAGGTCACACACACATAGTTACACA 25

RESULT 29
US-10-809-189-125372
; Sequence 125372, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125372
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125372

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1516 GTCACACACACATAGTTACACAGAA 1540
Db      1 GTCACACACACATAGTTACACAGAA 25

RESULT 30
US-10-809-189-125373
; Sequence 125373, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
```

QY 1644 TTGTTTTCTAACACCTTCAAGTAG 1668  
Db 1 TTGTTTTCTAACACCTTCAAGTAG 25

RESULT 22  
US-10-809-189-125365  
; Sequence 125365, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125365  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125365

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1237 ACACACTTCCAGGAATCAAGCCTA 1261  
Db 1 ACACACTTCCAGGAATCAAGCCTA 25

RESULT 23  
US-10-809-189-125366  
; Sequence 125366, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125366  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125366

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1243 TTCCCAGGAATCAAGCCTAAATG 1267  
Db 1 TTCCCAGGAATCAAGCCTAAATG 25

RESULT 24  
US-10-809-189-125367  
; Sequence 125367, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125367  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125367

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1441 TATTACATATTCACCTCTATGCTCAG 1465  
Db 1 TATTACATATTCACCTCTATGCTCAG 25

RESULT 25  
US-10-809-189-125368  
; Sequence 125368, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/10/809,189  
; CURRENT FILING DATE: 2004-03-25  
; PRIOR APPLICATION NUMBER: US/09/396,196  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125368  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-10-809-189-125368

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1444 TACATATTCACCTCTATGCTCAGGGT 1468  
Db 1 TACATATTCACCTCTATGCTCAGGGT 25

RESULT 26  
US-10-809-189-125369  
; Sequence 125369, Application US/10809189  
; Publication No. US20050048531A1  
; GENERAL INFORMATION:

QY 1196 GGCAGGAGCTCATGGACCCCTGCTTA 1220  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 GGCAGGAGCTCATGGACCCCTGCTTA 25

RESULT 17  
US-10-719-900-761329  
; Sequence 761329, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 761329  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-761329

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1297 TACATCTTCCAAGGAGCCTATCAAT 1321  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 TACATCTTCCAAGGAGCCTATCAAT 25

RESULT 18  
US-10-719-900-860595  
; Sequence 860595, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 860595  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-860595

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1229 TGATTCCACACACTTCCCAGGAAT 1253  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 TGATTCCACACACTTCCCAGGAAT 25

RESULT 19  
US-10-719-900-879471  
; Sequence 879471, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 879471  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-879471

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1208 TGGACCCCTGCTTACCCCAAGCTGAT 1232  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 TGGACCCCTGCTTACCCCAAGCTGAT 25

RESULT 20  
US-10-719-900-908157  
; Sequence 908157, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 908157  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-908157

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1164 TGTGGATAAACACTACTGGAGGTAT 1188  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 TGTGGATAAACACTACTGGAGGTAT 25

RESULT 21  
US-10-719-900-962529  
; Sequence 962529, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 962529  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-962529

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;



Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1256 AGCTAAATGATGTCAGTCTCTA 1280  
 Db 1 AGCTAAATGATGTCAGTCTCTA 25

RESULT 12  
 US-10-719-900-309852  
 ; Sequence 309852, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1  
 ; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002 11 20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 309852  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-719-900-309852

Query Match 1.4%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 28;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1240 CACTTCCCAGGAATCAAGCCTAAAA 1264  
 Db 1 CACTTCCCAGGAATCAAGCCTAAAA 25

RESULT 13  
 US-10-719-900-446213  
 ; Sequence 446213, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1  
 ; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002 11 20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 446213  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-719-900-446213

Query Match 1.4%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 28;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1289 GACACTACTACATCTTCCAAGGAGC 1313  
 Db 1 GACACTACTACATCTTCCAAGGAGC 25

RESULT 14  
 US-10-719-900-480521  
 ; Sequence 480521, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002 11 20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 480521  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-719-900-480521

Query Match 1.4%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 28;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1310 GAGCCTATCAATTGGAATATGACCC 1334  
 Db 1 GAGCCTATCAATTGGAATATGACCC 25

RESULT 15  
 US-10-719-900-512977  
 ; Sequence 512977, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1  
 ; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002 11 20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 512977  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-719-900-512977

Query Match 1.4%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 28;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1267 GATGCAGTCTCTATTTCAAAAGAC 1291  
 Db 1 GATGCAGTCTCTATTTCAAAAGAC 25

RESULT 16  
 US-10-719-900-611611  
 ; Sequence 611611, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1  
 ; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002 11 20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 611611  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-719-900-611611

Query Match 1.4%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 28;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
US-10-925-448-10
Query Match      1.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1748 GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1773
Db 26 GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 8
US-10-969-164-6/c
; Sequence 6, Application US/10969164
; Publication No. US20050065322A1
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/10/969,164
; CURRENT FILING DATE: 2004-10-20
; PRIOR APPLICATION NUMBER: US/09/527,345
; PRIOR FILING DATE: 1999-03-17
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7231
US-10-969-164-6

Query Match      1.4%; Score 25.2; DB 1; Length 26;
Best Local Similarity 96.2%; Pred. No. 28;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1748 GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1773
Db 26 BAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 9
US-09-859-012-37/c
; Sequence 37, Application US/09859012
; Publication No. US20040253632A1
; GENERAL INFORMATION:
; APPLICANT: RHODE, PETER
; APPLICANT: WEIDMAN, VAUGHAN
; APPLICANT: WEIDANZ, JON A.
; APPLICANT: BURKHARDT, MARTIN
; APPLICANT: CARD, KIMBERLYN F.
; APPLICANT: TAL, RONY
; APPLICANT: ACEVEDO, JORGE
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: MODULATION OF T CELL RECEPTOR INTERACTIONS
; FILE REFERENCE: 49444 (71758)
; CURRENT APPLICATION NUMBER: US/09/859,012
; CURRENT FILING DATE: 2001-05-16
; PRIOR APPLICATION NUMBER: 60/206,920
; PRIOR FILING DATE: 2000-05-25
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; NAME/KEY: modified_base
```

```
; LOCATION: (27)
; OTHER INFORMATION: A, C, G, or T
US-09-859-012-37

Query Match      1.4%; Score 25.2; DB 1; Length 27;
Best Local Similarity 96.2%; Pred. No. 31;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1774
Db 26 HAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 10
US-10-838-122-51/c
; Sequence 51, Application US/10838122
; Publication No. US20050064554A1
; GENERAL INFORMATION:
; APPLICANT: FISHER, LAURENT BERNARD
; APPLICANT: CACHET, NATHALIE MICHELE
; APPLICANT: BARZU-LE-ROUX, SIMONA
; TITLE OF INVENTION: CANINE GHRH GENE, POLYPEPTIDES AND METHODS OF USE
; FILE REFERENCE: MER 03-007
; CURRENT APPLICATION NUMBER: US/10/838,122
; CURRENT FILING DATE: 2004-05-03
; PRIOR APPLICATION NUMBER: 60/467,405
; PRIOR FILING DATE: 2003-05-01
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 51
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (27)
; OTHER INFORMATION: a, t, c or g
US-10-838-122-51

Query Match      1.4%; Score 25.2; DB 1; Length 27;
Best Local Similarity 96.2%; Pred. No. 31;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1748 GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1773
Db 26 BAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 11
US-10-719-900-174229
; Sequence 174229, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 174229
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-174229

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
```







RESULT 6  
US-10-787-442-39/c  
; Sequence 39, Application US/10787442  
; Publication No. US20040260065A1  
; GENERAL INFORMATION:  
; APPLICANT: Novak, Julia E.  
; APPLICANT: Presnell, Scott R.  
; APPLICANT: Sprecher, Cindy A.  
; APPLICANT: Foster, Donald C.  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Gross, Jane A.  
; APPLICANT: Johnston, Janet V.  
; APPLICANT: Nelson, Andrew J.  
; APPLICANT: Dillon, Stacey R.  
; APPLICANT: Hammond, Angela K.  
; TITLE OF INVENTION: NOVEL CYTOKINE ZALPHALL LIGAND  
; FILE REFERENCE: 99-16  
; CURRENT APPLICATION NUMBER: US/10/787,442  
; CURRENT FILING DATE: 2004-02-26  
; PRIOR APPLICATION NUMBER: US/09/522,217  
; PRIOR FILING DATE: 2000-03-09  
; PRIOR APPLICATION NUMBER: US 60/123,547  
; PRIOR FILING DATE: 1999-03-09  
; PRIOR APPLICATION NUMBER: US 60/123,904

STREET: 100 ABBOTT PARK ROAD  
 CITY: ABBOTT PARK  
 STATE: IL  
 COUNTRY: USA  
 ZIP: 60064-3500  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: DOS  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/10/925,448  
 FILING DATE: 25-AUG-2004  
 CLASSIFICATION: <Unknown>  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US/09/092,296  
 FILING DATE: 05-JUNE-1998  
 APPLICATION NUMBER: 60/048,810  
 FILING DATE: 05-JUN-1997  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Becker, Cheryl L.  
 REGISTRATION NUMBER: 35,441  
 REFERENCE/DOCKET NUMBER: 6104.US.01  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 847/935-1729  
 TELEFAX: 847/938-2623  
 TELEX: <Unknown>  
 INFORMATION FOR SEQ ID NO: 10:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 26 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 SEQUENCE DESCRIPTION: SEQ ID NO: 10:

OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: oligonucleotide  
US-10-601-140A-11

Query Match 1.6%; Score 28.6; DB 1; Length 35;  
Best Local Similarity 88.6%; Pred. No. 21;  
Matches 31; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1739 AAAGAAAGTGAAGAAAAA 1773  
Db 35 AAAAAAAAAAAAAAAAAA 1

RESULT 2

US-10-601-140A-12/c  
Sequence 12, Application US/10601140A  
Publication No. US20050053942A1  
GENERAL INFORMATION:  
APPLICANT: KAUPPINEN, SAKARI  
APPLICANT: JACOBSEN, NANA  
TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
TITLE OF INVENTION: NUCLEOTIDE SEQUENCE  
FILE REFERENCE: 57764(71994)  
CURRENT APPLICATION NUMBER: US/10/601,140A  
CURRENT FILING DATE: 2003-06-20  
PRIOR APPLICATION NUMBER: US 60/390,928  
PRIOR FILING DATE: 2002-06-24  
NUMBER OF SEQ ID NOS: 45  
SOFTWARE: PatentIn Ver. 3.2  
SEQ ID NO 12  
LENGTH: 35  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: oligonucleotide

FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (16)  
OTHER INFORMATION: LNA monomer  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (18)  
OTHER INFORMATION: LNA monomer  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (20)  
OTHER INFORMATION: LNA monomer  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (22)  
OTHER INFORMATION: LNA monomer  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (24)  
OTHER INFORMATION: LNA monomer  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (26)  
OTHER INFORMATION: LNA monomer  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (28)  
OTHER INFORMATION: LNA monomer  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (30)  
OTHER INFORMATION: LNA monomer  
FEATURE:  
NAME/KEY: modified\_base  
LOCATION: (32)  
OTHER INFORMATION: LNA monomer  
FEATURE:

NAME/KEY: modified\_base  
LOCATION: (34)  
OTHER INFORMATION: LNA monomer  
US-10-601-140A-12

Query Match 1.6%; Score 28.6; DB 1; Length 35;  
Best Local Similarity 88.6%; Pred. No. 21;  
Matches 31; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1739 AAAGAAAGTGAAGAAAAA 1773  
Db 35 AAAAAAAAAAAAAAAAAA 1

RESULT 3

US-10-764-799-8  
Sequence 8, Application US/10764799  
Publication No. US20040253612A1  
GENERAL INFORMATION:  
APPLICANT: Szostak, Jack W.  
APPLICANT: Roberts, Richard W.  
APPLICANT: Liu, Rihe  
TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN  
TITLE OF INVENTION: FUSIONS  
FILE REFERENCE: 00786/350005  
CURRENT APPLICATION NUMBER: US/10/764,799  
CURRENT FILING DATE: 2004-01-26  
PRIOR APPLICATION NUMBER: US/09/247,190  
PRIOR FILING DATE: 1999-02-09  
PRIOR APPLICATION NUMBER: 60/035,963  
PRIOR FILING DATE: 1997-01-21  
PRIOR APPLICATION NUMBER: 60/064,491  
PRIOR FILING DATE: 1997-11-06  
PRIOR APPLICATION NUMBER: 09/007,005  
PRIOR FILING DATE: 1998-01-14  
NUMBER OF SEQ ID NOS: 38  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 8  
LENGTH: 29  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Translation template  
US-10-764-799-8

Query Match 1.6%; Score 28; DB 1; Length 29;  
Best Local Similarity 100.0%; Pred. No. 16;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1776  
Db 1 AAAAAAAAAAAAAAAAAA 28

RESULT 4

US-10-848-922-98  
Sequence 98, Application US/10848922  
Publication No. US20040235138A1  
GENERAL INFORMATION:  
APPLICANT: Weisburg, William G.  
APPLICANT: Bungo, Jennifer J.  
TITLE OF INVENTION: Compositions, Methods and Kits for Determining the Presence of  
TITLE OF INVENTION: Trichomonas vaginalis in a Test Sample  
FILE REFERENCE: GP142-02.UT  
CURRENT APPLICATION NUMBER: US/10/848,922  
CURRENT FILING DATE: 2004-05-18  
PRIOR APPLICATION NUMBER: 60/472,028  
PRIOR FILING DATE: 2003-05-19  
NUMBER OF SEQ ID NOS: 105  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 98  
LENGTH: 33  
TYPE: DNA

C 253	15	0.8	15	1	US-10-601-140A-5	Sequence 5, Appli	Sequence 5, Appli
C 254	15	0.8	15	1	US-10-601-140A-16	Sequence 16, Appl	Sequence 16, Appl
C 255	15	0.8	15	1	US-10-601-140A-19	Sequence 19, Appl	Sequence 19, Appl
C 256	15	0.8	15	1	US-10-938-661A-22	Sequence 22, Appl	Sequence 22, Appl
C 257	15	0.8	17	1	US-09-780-164-870	Sequence 870, App	Sequence 870, App
C 258	14.8	0.8	18	1	US-10-349-143-5494	Sequence 5494, Ap	Sequence 5494, Ap
C 259	14.4	0.8	16	1	US-10-164-915-3	Sequence 3, Appli	Sequence 3, Appli
C 260	14.4	0.8	16	1	US-10-138-674-6065	Sequence 6065, Ap	Sequence 6065, Ap
C 261	14.4	0.8	16	1	US-10-138-674-6066	Sequence 6066, Ap	Sequence 6066, Ap
C 262	14.4	0.8	16	1	US-10-287-949A-6065	Sequence 6065, Ap	Sequence 6065, Ap
C 263	14.4	0.8	16	1	US-10-287-949A-6066	Sequence 6066, Ap	Sequence 6066, Ap
C 264	14.4	0.8	17	1	US-09-866-108-10431	Sequence 10431, A	Sequence 10431, A
C 265	14.4	0.8	17	1	US-09-866-108-10433	Sequence 10433, A	Sequence 10433, A
C 266	14.4	0.8	17	1	US-09-780-164-447	Sequence 447, App	Sequence 447, App
C 267	14.4	0.8	17	1	US-10-156-306-268	Sequence 268, App	Sequence 268, App
C 268	14.4	0.8	17	1	US-10-156-306-1283	Sequence 1283, Ap	Sequence 1283, Ap
C 269	14.4	0.8	17	1	US-10-156-306-3637	Sequence 3637, Ap	Sequence 3637, Ap
C 270	14.4	0.8	17	1	US-10-238-700-456	Sequence 456, App	Sequence 456, App
C 271	14.4	0.8	17	1	US-10-307-005-1679	Sequence 1679, Ap	Sequence 1679, Ap
C 272	14.4	0.8	17	1	US-10-307-005-1680	Sequence 1680, Ap	Sequence 1680, Ap
C 273	14.4	0.8	17	1	US-10-138-674-2690	Sequence 2690, Ap	Sequence 2690, Ap
C 274	14.4	0.8	17	1	US-10-138-674-5541	Sequence 5541, Ap	Sequence 5541, Ap
C 275	14.4	0.8	17	1	US-10-287-949A-2690	Sequence 2690, Ap	Sequence 2690, Ap
C 276	14.4	0.8	17	1	US-10-287-949A-5541	Sequence 5541, Ap	Sequence 5541, Ap
C 277	14.4	0.8	17	1	US-10-723-361-10431	Sequence 10431, A	Sequence 10431, A
C 278	14.4	0.8	17	1	US-10-723-361-10433	Sequence 10433, A	Sequence 10433, A
C 279	14.4	0.8	17	1	US-10-724-270-456	Sequence 456, App	Sequence 456, App
C 280	14.4	0.8	17	1	US-09-969-373-1693	Sequence 1693, Ap	Sequence 1693, Ap
C 281	14.4	0.8	18	1	US-09-882-945A-108	Sequence 108, App	Sequence 108, App
C 282	14.4	0.8	18	1	US-10-314-657-180	Sequence 180, App	Sequence 180, App
C 283	14.4	0.8	18	1	US-10-333-429-219	Sequence 219, App	Sequence 219, App
C 284	14.4	0.8	18	1	US-10-807-114-108	Sequence 108, App	Sequence 108, App
C 285	14.4	0.8	18	1	US-10-655-362-108	Sequence 108, App	Sequence 108, App
C 286	14.4	0.8	18	1	US-10-473-193-180	Sequence 180, App	Sequence 180, App
C 287	14	0.8	14	1	US-10-830-484-3	Sequence 3, Appli	Sequence 3, Appli
C 288	14	0.8	14	1	US-10-764-393-11	Sequence 11, Appl	Sequence 11, Appl
C 289	14	0.8	14	1	US-10-764-389-11	Sequence 11, Appl	Sequence 11, Appl
C 290	14	0.8	14	1	US-10-855-595-21	Sequence 21, Appl	Sequence 21, Appl
C 291	14	0.8	14	1	US-10-763-076-11	Sequence 11, Appl	Sequence 11, Appl
C 292	14	0.8	14	1	US-10-855-532-21	Sequence 21, Appl	Sequence 21, Appl
C 293	14	0.8	14	1	US-10-764-388-11	Sequence 11, Appl	Sequence 11, Appl
C 294	14	0.8	15	1	US-10-601-140A-21	Sequence 21, Appl	Sequence 21, Appl
C 295	14	0.8	17	1	US-09-866-108-10429	Sequence 10429, A	Sequence 10429, A
C 296	14	0.8	17	1	US-09-866-108-10430	Sequence 10430, A	Sequence 10430, A
C 297	14	0.8	17	1	US-09-827-998-823	Sequence 823, App	Sequence 823, App
C 298	14	0.8	17	1	US-09-827-998-824	Sequence 824, App	Sequence 824, App
C 299	14	0.8	17	1	US-09-827-998-825	Sequence 825, App	Sequence 825, App
C 300	14	0.8	17	1	US-09-827-998-826	Sequence 826, App	Sequence 826, App
C 301	14	0.8	17	1	US-09-818-875-1463	Sequence 1463, Ap	Sequence 1463, Ap
C 302	14	0.8	17	1	US-09-818-875-1464	Sequence 1464, Ap	Sequence 1464, Ap
C 303	14	0.8	17	1	US-09-848-754A-2095	Sequence 2095, Ap	Sequence 2095, Ap
C 304	14	0.8	17	1	US-09-848-754A-2096	Sequence 2096, Ap	Sequence 2096, Ap
C 305	14	0.8	17	1	US-10-060-756A-1353	Sequence 1353, Ap	Sequence 1353, Ap
C 306	14	0.8	17	1	US-10-060-756A-1354	Sequence 1354, Ap	Sequence 1354, Ap
C 307	14	0.8	17	1	US-10-060-756A-1355	Sequence 1355, Ap	Sequence 1355, Ap
C 308	14	0.8	17	1	US-10-060-756A-1356	Sequence 1356, Ap	Sequence 1356, Ap
C 309	14	0.8	17	1	US-10-096-125-8	Sequence 8, Appli	Sequence 8, Appli
C 310	14	0.8	17	1	US-10-238-700-1122	Sequence 1122, Ap	Sequence 1122, Ap
C 311	14	0.8	17	1	US-10-238-700-1123	Sequence 1123, Ap	Sequence 1123, Ap
C 312	14	0.8	17	1	US-10-209-787-1463	Sequence 1463, Ap	Sequence 1463, Ap
C 313	14	0.8	17	1	US-10-209-787-1464	Sequence 1464, Ap	Sequence 1464, Ap
C 314	14	0.8	17	1	US-10-261-185-1463	Sequence 1463, Ap	Sequence 1463, Ap
C 315	14	0.8	17	1	US-10-261-185-1464	Sequence 1464, Ap	Sequence 1464, Ap
C 316	14	0.8	17	1	US-10-675-685-823	Sequence 823, App	Sequence 823, App
C 317	14	0.8	17	1	US-10-675-685-824	Sequence 824, App	Sequence 824, App
C 318	14	0.8	17	1	US-10-675-685-825	Sequence 825, App	Sequence 825, App
C 319	14	0.8	17	1	US-10-675-685-826	Sequence 826, App	Sequence 826, App
C 320	14	0.8	17	1	US-10-676-154-219	Sequence 219, App	Sequence 219, App
C 321	14	0.8	17	1	US-10-723-361-10429	Sequence 10429, A	Sequence 10429, A
C 322	14	0.8	17	1	US-10-723-361-10430	Sequence 10430, A	Sequence 10430, A
C 323	14	0.8	17	1	US-10-681-074-1463	Sequence 1463, Ap	Sequence 1463, Ap
C 324	14	0.8	17	1	US-10-681-074-1464	Sequence 1464, Ap	Sequence 1464, Ap
C 325	14	0.8	17	1	US-10-724-270-1122	Sequence 1122, Ap	Sequence 1122, Ap
C 326	14	0.8	17	1	US-10-724-270-1123	Sequence 1123, Ap	Sequence 1123, Ap
C 327	13.8	0.8	17	1	US-09-866-108-874	Sequence 874, App	Sequence 874, App
C 328	13.8	0.8	17	1	US-09-866-108-10428	Sequence 10428, A	Sequence 10428, A
C 329	13.8	0.8	17	1	US-09-866-108-10434	Sequence 10434, A	Sequence 10434, A
C 330	13.8	0.8	17	1	US-09-827-998-423	Sequence 423, App	Sequence 423, App
C 331	13.8	0.8	17	1	US-09-827-998-821	Sequence 821, App	Sequence 821, App
C 332	13.8	0.8	17	1	US-09-827-998-822	Sequence 822, App	Sequence 822, App
C 333	13.8	0.8	17	1	US-09-927-046-305	Sequence 305, App	Sequence 305, App
C 334	13.8	0.8	17	1	US-09-927-046-661	Sequence 661, App	Sequence 661, App
C 335	13.8	0.8	17	1	US-09-927-046-1253	Sequence 1253, Ap	Sequence 1253, Ap
C 336	13.8	0.8	17	1	US-09-927-046-1678	Sequence 1678, Ap	Sequence 1678, Ap
C 337	13.8	0.8	17	1	US-09-877-478-2466	Sequence 2466, Ap	Sequence 2466, Ap
C 338	13.8	0.8	17	1	US-09-848-754A-1292	Sequence 1292, Ap	Sequence 1292, Ap
C 339	13.8	0.8	17	1	US-09-848-754A-1293	Sequence 1293, Ap	Sequence 1293, Ap
C 340	13.8	0.8	17	1	US-09-848-754A-2380	Sequence 2380, Ap	Sequence 2380, Ap
C 341	13.8	0.8	17	1	US-09-848-754A-2718	Sequence 2718, Ap	Sequence 2718, Ap
C 342	13.8	0.8	17	1	US-09-930-423-952	Sequence 952, App	Sequence 952, App
C 343	13.8	0.8	17	1	US-09-930-423-954	Sequence 954, App	Sequence 954, App
C 344	13.8	0.8	17	1	US-09-930-423-1445	Sequence 1445, Ap	Sequence 1445, Ap
C 345	13.8	0.8	17	1	US-09-827-395A-789	Sequence 789, App	Sequence 789, App
C 346	13.8	0.8	17	1	US-09-745-237A-952	Sequence 952, App	Sequence 952, App
C 347	13.8	0.8	17	1	US-09-745-237A-954	Sequence 954, App	Sequence 954, App
C 348	13.8	0.8	17	1	US-09-745-237A-1445	Sequence 1445, Ap	Sequence 1445, Ap
C 349	13.8	0.8	17	1	US-10-156-306-1493	Sequence 1493, Ap	Sequence 1493, Ap
C 350	13.8	0.8	17	1	US-10-238-700-145	Sequence 145, App	Sequence 145, App
C 351	13.8	0.8	17	1	US-10-331-907-354	Sequence 354, App	Sequence 354, App
C 352	13.8	0.8	17	1	US-10-430-882-789	Sequence 789, App	Sequence 789, App
C 353	13.8	0.8	17	1	US-10-335-977-9894	Sequence 9894, Ap	Sequence 9894, Ap
C 354	13.8	0.8	17	1	US-10-342-902-2466	Sequence 2466, Ap	Sequence 2466, Ap
C 355	13.8	0.8	17	1	US-10-675-685-423	Sequence 423, App	Sequence 423, App
C 356	13.8	0.8	17	1	US-10-675-685-821	Sequence 821, App	Sequence 821, App
C 357	13.8	0.8	17	1	US-10-675-685-822	Sequence 822, App	Sequence 822, App
C 358	13.8	0.8	17	1	US-10-138-674-837	Sequence 837, App	Sequence 837, App
C 359	13.8	0.8	17	1	US-10-138-674-2964	Sequence 2964, Ap	Sequence 2964, Ap
C 360	13.8	0.8	17	1	US-10-138-674-2965	Sequence 2965, Ap	Sequence 2965, Ap
C 361	13.8	0.8	17	1	US-10-138-674-3602	Sequence 3602, Ap	Sequence 3602, Ap
C 362	13.8	0.8	17	1	US-10-138-674-3603	Sequence 3603, Ap	Sequence 3603, Ap
C 363	13.8	0.8	17	1	US-10-287-949A-837	Sequence 837, App	Sequence 837, App
C 364	13.8	0.8	17	1	US-10-287-949A-2964	Sequence 2964, Ap	Sequence 2964, Ap
C 365	13.8	0.8	17	1	US-10-287-949A-2965	Sequence 2965, Ap	Sequence 2965, Ap
C 366	13.8	0.8	17	1	US-10-287-949A-3602	Sequence 3602, Ap	Sequence 3602, Ap
C 367	13.8	0.8	17	1	US-10-287-949A-3603	Sequence 3603, Ap	Sequence 3603, Ap
C 368	13.8	0.8	17	1	US-10-669-841-2269	Sequence 2269, Ap	Sequence 2269, Ap
C 369	13.8	0.8	17	1	US-10-723-361-874	Sequence 874, App	Sequence 874, App
C 370	13.8	0.8	17	1	US-10-723-361-10428	Sequence 10428, A	Sequence 10428, A
C 371	13.8	0.8	17	1	US-10-723-361-10434	Sequence 10434, A	Sequence 10434, A
C 372	13.8	0.8	17	1	US-10-724-270-145	Sequence 145, App	Sequence 145, App

## ALIGNMENTS

## RESULT 1

US-10-601-140A-11/c  
; Sequence 11, Application US/10601140A  
; Publication No. US20050053942A1  
; GENERAL INFORMATION:  
; APPLICANT: KAUPPINEN, SAKARI  
; APPLICANT: JACOBSEN, NANA  
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE  
; FILE REFERENCE: 57764 (71994)  
; CURRENT APPLICATION NUMBER: US/10/601,140A  
; CURRENT FILING DATE: 2003-06-20  
; PRIOR APPLICATION NUMBER: US 60/390,928  
; PRIOR FILING DATE: 2002-06-24  
; NUMBER OF SEQ ID NOS: 45  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 11  
; LENGTH: 35  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:



C 107	19	1.1	19	1	1	US-10-619-906-3	Sequence 3, Appli	180	17	0.9	21	1	US-10-751-736-11059	Sequence 11059, A
C 108	19	1.1	19	1	1	US-10-760-940-1	Sequence 1, Appli	181	17	0.9	21	1	US-10-751-736-11060	Sequence 11060, A
C 109	19	1.1	19	1	1	US-10-913-246-24	Sequence 24, Appl	C 182	16.8	0.9	20	1	US-10-149-352-11	Sequence 11, Appl
C 110	19	1.1	19	1	1	US-10-934-890-24	Sequence 24, Appl	183	16.8	0.9	20	1	US-10-174-559-25	Sequence 25, Appl
C 111	19	1.1	19	1	1	US-10-700-884-23	Sequence 23, Appl	184	16.8	0.9	21	1	US-10-168-989-42	Sequence 42, Appl
C 112	19	1.1	20	1	1	US-10-728-078-14	Sequence 14, Appl	185	16.8	0.9	21	1	US-10-842-142-10	Sequence 10, Appl
C 113	19	1.1	20	1	1	US-10-620-642-34	Sequence 34, Appl	186	16.8	0.9	21	1	US-10-842-142-94	Sequence 94, Appl
C 114	19	1.1	21	1	1	US-10-751-736-10823	Sequence 10823, A	187	16.8	0.9	21	1	US-10-842-142-114	Sequence 114, App
C 115	19	1.1	21	1	1	US-10-751-736-11009	Sequence 11009, A	C 188	16.8	0.9	21	1	US-10-751-736-2282	Sequence 2282, Ap
C 116	19	1.1	21	1	1	US-10-751-736-11015	Sequence 11015, A	189	16.8	0.9	21	1	US-10-751-736-8632	Sequence 8632, Ap
C 117	18.8	1.1	22	1	1	US-10-831-778-61	Sequence 61, Appl	190	16.8	0.9	21	1	US-10-751-736-9055	Sequence 9055, Ap
C 118	18.4	1.0	21	1	1	US-10-751-736-10795	Sequence 10795, A	191	16.8	0.9	21	1	US-10-751-736-9059	Sequence 9059, Ap
C 119	18.4	1.0	21	1	1	US-10-751-736-10861	Sequence 10861, A	192	16.8	0.9	21	1	US-10-751-736-10780	Sequence 10780, A
C 120	18.4	1.0	21	1	1	US-10-751-736-10888	Sequence 10888, A	193	16.8	0.9	21	1	US-10-751-736-10783	Sequence 10783, A
C 121	18.4	1.0	21	1	1	US-10-751-736-11110	Sequence 11110, A	194	16.8	0.9	21	1	US-10-751-736-10787	Sequence 10787, A
C 122	18.4	1.0	21	1	1	US-10-751-736-11126	Sequence 11126, A	195	16.8	0.9	21	1	US-10-751-736-10864	Sequence 10864, A
C 123	18.4	1.0	21	1	1	US-10-751-736-11206	Sequence 11206, A	196	16.8	0.9	21	1	US-10-751-736-10930	Sequence 10930, A
C 124	18.4	1.0	21	1	1	US-10-751-736-11344	Sequence 11344, A	197	16.8	0.9	21	1	US-10-751-736-11041	Sequence 11041, A
C 125	18.4	1.0	21	1	1	US-10-751-736-11383	Sequence 11383, A	198	16.8	0.9	21	1	US-10-751-736-11042	Sequence 11042, A
C 126	18.4	1.0	21	1	1	US-10-751-736-11434	Sequence 11434, A	199	16.8	0.9	21	1	US-10-751-736-11177	Sequence 11177, A
C 127	18	1.0	18	1	1	US-10-849-072-21	Sequence 21, Appl	200	16.8	0.9	21	1	US-10-751-736-11332	Sequence 11332, A
C 128	18	1.0	18	1	1	US-10-849-072-23	Sequence 23, Appl	C 201	16.8	0.9	21	1	US-10-751-736-11381	Sequence 11381, A
C 129	18	1.0	18	1	1	US-10-831-778-913	Sequence 913, App	C 202	16.8	0.9	21	1	US-10-751-736-12929	Sequence 12929, A
C 130	18	1.0	18	1	1	US-10-831-778-939	Sequence 939, App	C 203	16.4	0.9	18	1	US-10-872-984-5	Sequence 5, Appli
C 131	18	1.0	18	1	1	US-10-776-933-150	Sequence 150, App	C 204	16.4	0.9	18	1	US-10-872-984-6	Sequence 6, Appli
C 132	18	1.0	18	1	1	US-10-674-159A-112	Sequence 112, App	C 205	16.4	0.9	19	1	US-10-665-951-388	Sequence 388, App
C 133	18	1.0	18	1	1	US-10-776-917-141	Sequence 141, App	C 206	16.4	0.9	19	1	US-10-665-951-815	Sequence 815, App
C 134	18	1.0	18	1	1	US-10-766-096-9	Sequence 9, Appli	C 207	16.4	0.9	19	1	US-10-758-155-388	Sequence 388, App
C 135	18	1.0	18	1	1	US-10-872-984-7	Sequence 7, Appli	C 208	16.4	0.9	19	1	US-10-758-155-815	Sequence 815, App
C 136	18	1.0	18	1	1	US-10-638-141-10	Sequence 10, Appl	C 209	16.4	0.9	20	1	US-10-238-011-36	Sequence 36, Appl
C 137	18	1.0	18	1	1	US-10-776-934-741	Sequence 741, App	C 210	16.4	0.9	20	1	US-10-274-095-36	Sequence 36, Appl
C 138	18	1.0	18	1	1	US-10-601-140A-24	Sequence 24, Appl	C 211	16	0.9	16	1	US-10-755-118-94	Sequence 94, Appl
C 139	18	1.0	18	1	1	US-10-884-617-2	Sequence 2, Appli	C 212	16	0.9	17	1	US-09-780-164-445	Sequence 445, App
C 140	18	1.0	18	1	1	US-10-669-962-28	Sequence 28, Appl	C 213	16	0.9	17	1	US-10-608-863-3	Sequence 3, Appli
C 141	18	1.0	19	1	1	US-10-913-246-22	Sequence 22, Appl	C 214	16	0.9	17	1	US-10-608-863-4	Sequence 4, Appli
C 142	18	1.0	19	1	1	US-10-934-890-22	Sequence 22, Appl	C 215	16	0.9	17	1	US-10-608-863-5	Sequence 5, Appli
C 143	18	1.0	20	1	1	US-10-620-642-32	Sequence 32, Appl	C 216	16	0.9	20	1	US-09-853-688-39	Sequence 39, Appl
C 144	18	1.0	20	1	1	US-10-620-642-33	Sequence 33, Appl	C 217	16	0.9	20	1	US-10-788-318-39	Sequence 39, Appl
C 145	18	1.0	21	1	1	US-10-751-736-10900	Sequence 10900, A	C 218	16	0.9	20	1	US-10-831-778-431	Sequence 431, App
C 146	18	1.0	21	1	1	US-10-751-736-10901	Sequence 10901, A	C 219	15.8	0.9	19	1	US-10-619-906-11	Sequence 11, Appl
C 147	17.8	1.0	21	1	1	US-10-751-736-8629	Sequence 8629, Ap	C 220	15.8	0.9	19	1	US-10-619-906-13	Sequence 13, Appl
C 148	17.8	1.0	21	1	1	US-10-751-736-9058	Sequence 9058, Ap	C 221	15.4	0.9	17	1	US-09-866-108-10432	Sequence 10432, A
C 149	17.8	1.0	21	1	1	US-10-751-736-10786	Sequence 10786, A	C 222	15.4	0.9	17	1	US-09-780-164-446	Sequence 66, Appl
C 150	17.8	1.0	21	1	1	US-10-751-736-10951	Sequence 10951, A	C 223	15.4	0.9	17	1	US-09-780-164-446	Sequence 446, App
C 151	17.8	1.0	21	1	1	US-10-751-736-11113	Sequence 11113, A	C 224	15.4	0.9	17	1	US-10-106-831-23	Sequence 23, Appl
C 152	17.8	1.0	21	1	1	US-10-751-736-11176	Sequence 11176, A	C 225	15.4	0.9	17	1	US-10-138-674-8254	Sequence 8254, Ap
C 153	17.8	1.0	21	1	1	US-10-751-736-11179	Sequence 11179, A	C 226	15.4	0.9	17	1	US-10-138-674-8255	Sequence 8255, Ap
C 154	17.8	1.0	21	1	1	US-10-751-736-11209	Sequence 11209, A	C 227	15.4	0.9	17	1	US-10-287-949A-8254	Sequence 8254, Ap
C 155	17.8	1.0	21	1	1	US-10-751-736-11269	Sequence 11269, A	C 228	15.4	0.9	17	1	US-10-287-949A-8255	Sequence 8255, Ap
C 156	17.8	1.0	21	1	1	US-10-751-736-11380	Sequence 11380, A	C 229	15.4	0.9	17	1	US-10-723-361-10432	Sequence 10432, A
C 157	17.8	1.0	21	1	1	US-10-751-736-11404	Sequence 11404, A	C 230	15.4	0.9	17	1	US-10-753-962-23	Sequence 23, Appl
C 158	17.8	1.0	21	1	1	US-10-751-736-11437	Sequence 11437, A	C 231	15.4	0.9	17	1	US-10-712-633-1532	Sequence 1532, Ap
C 159	17.8	1.0	21	1	1	US-10-751-736-11464	Sequence 11464, A	C 232	15.4	0.9	17	1	US-10-712-633-1533	Sequence 1533, Ap
C 160	17.4	1.0	20	1	1	US-10-238-011-32	Sequence 32, Appl	C 233	15.4	0.9	33	1	US-10-848-922-98	Sequence 98, Appl
C 161	17.4	1.0	21	1	1	US-10-751-736-8824	Sequence 8824, Ap	C 234	15	0.8	15	1	US-10-830-484-4	Sequence 4, Appli
C 162	17.4	1.0	21	1	1	US-10-751-736-8825	Sequence 8825, Ap	C 235	15	0.8	15	1	US-10-755-118-3	Sequence 3, Appli
C 163	17.4	1.0	21	1	1	US-10-751-736-9031	Sequence 9031, Ap	C 236	15	0.8	15	1	US-10-755-118-4	Sequence 4, Appli
C 164	17.4	1.0	21	1	1	US-10-751-736-10793	Sequence 10793, A	C 237	15	0.8	15	1	US-10-755-118-31	Sequence 31, Appl
C 165	17.4	1.0	21	1	1	US-10-751-736-10855	Sequence 10855, A	C 238	15	0.8	15	1	US-10-755-118-32	Sequence 32, Appl
C 166	17.4	1.0	21	1	1	US-10-751-736-11006	Sequence 11006, A	C 239	15	0.8	15	1	US-10-755-118-36	Sequence 36, Appl
C 167	17.4	1.0	21	1	1	US-10-751-736-11143	Sequence 11143, A	C 240	15	0.8	15	1	US-10-755-118-38	Sequence 38, Appl
C 168	17.4	1.0	21	1	1	US-10-751-736-11207	Sequence 11207, A	C 241	15	0.8	15	1	US-10-755-118-39	Sequence 39, Appl
C 169	17.4	1.0	21	1	1	US-10-751-736-11296	Sequence 11296, A	C 242	15	0.8	15	1	US-10-755-118-40	Sequence 40, Appl
C 170	17.4	1.0	21	1	1	US-10-751-736-11297	Sequence 11297, A	C 243	15	0.8	15	1	US-10-755-118-43	Sequence 43, Appl
C 171	17.4	1.0	21	1	1	US-10-751-736-11345	Sequence 11345, A	C 244	15	0.8	15	1	US-10-755-118-44	Sequence 44, Appl
C 172	17.4	1.0	21	1	1	US-10-751-736-11432	Sequence 11432, A	C 245	15	0.8	15	1	US-10-755-118-45	Sequence 45, Appl
C 173	17.4	1.0	21	1	1	US-10-751-736-11449	Sequence 11449, A	C 246	15	0.8	15	1	US-10-755-118-48	Sequence 48, Appl
C 174	17	0.9	18	1	1	US-10-669-962-27	Sequence 27, Appl	C 247	15	0.8	15	1	US-10-755-118-49	Sequence 49, Appl
C 175	17	0.9	18	1	1	US-10-669-962-29	Sequence 29, Appl	C 248	15	0.8	15	1	US-10-770-989-9	Sequence 9, Appli
C 176	17	0.9	19	1	1	US-10-800-487-162	Sequence 162, App	C 249	15	0.8	15	1	US-10-833-502-9	Sequence 9, Appli
C 177	17	0.9	19	1	1	US-10-800-487-328	Sequence 328, App	C 250	15	0.8	15	1	US-10-939-214-54	Sequence 54, Appl
C 178	17	0.9	20	1	1	US-10-644-052A-376	Sequence 376, App	C 251	15	0.8	15	1	US-10-939-214-55	Sequence 55, Appl
C 179	17	0.9	20	1	1	US-10-644-052A-377	Sequence 377, App	C 252	15	0.8	15	1	US-10-239-919A-4	Sequence 4, Appli



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:24:23 ; Search time 5 Seconds  
(without alignments)  
5.228 Million cell updates/sec

Title: US-10-619-906-2  
Perfect score: 1790  
Sequence: 1 atgaatttcctcatgat.....aaaaacggaattcccgga 1790

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 371 seqs, 7301 residues

Total number of hits satisfying chosen parameters: 742

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 372 summaries

Database : rnpb2.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	28.6	1.6	35	1	US-10-601-140A-11
C 2	28.6	1.6	35	1	US-10-601-140A-12
C 3	28	1.6	29	1	US-10-764-799-8
C 4	27.4	1.5	33	1	US-10-848-922-98
C 5	27	1.5	27	1	US-10-831-778-911
C 6	26	1.5	26	1	US-10-787-442-39
C 7	26	1.5	26	1	US-10-925-448-10
C 8	25.2	1.4	26	1	US-10-969-164-6
C 9	25.2	1.4	27	1	US-09-859-012-37
C 10	25.2	1.4	27	1	US-10-838-122-51
C 11	25	1.4	25	1	US-10-719-900-174229
C 12	25	1.4	25	1	US-10-719-900-309852
C 13	25	1.4	25	1	US-10-719-900-446213
C 14	25	1.4	25	1	US-10-719-900-480521
C 15	25	1.4	25	1	US-10-719-900-512977
C 16	25	1.4	25	1	US-10-719-900-611611
C 17	25	1.4	25	1	US-10-719-900-761329
C 18	25	1.4	25	1	US-10-719-900-860595
C 19	25	1.4	25	1	US-10-719-900-879471
C 20	25	1.4	25	1	US-10-719-900-908157
C 21	25	1.4	25	1	US-10-719-900-962529
C 22	25	1.4	25	1	US-10-809-189-125365
C 23	25	1.4	25	1	US-10-809-189-125366
C 24	25	1.4	25	1	US-10-809-189-125367
C 25	25	1.4	25	1	US-10-809-189-125368
C 26	25	1.4	25	1	US-10-809-189-125369
C 27	25	1.4	25	1	US-10-809-189-125370
C 28	25	1.4	25	1	US-10-809-189-125371
C 29	25	1.4	25	1	US-10-809-189-125372
C 30	25	1.4	25	1	US-10-809-189-125373
C 31	25	1.4	25	1	US-10-809-189-125374
C 32	25	1.4	25	1	US-10-809-189-125375
C 33	25	1.4	25	1	US-10-809-189-125376

34	25	1.4	25	1	US-10-809-189-125377	Sequence 125377,
35	25	1.4	25	1	US-10-809-189-125378	Sequence 125378,
36	25	1.4	25	1	US-10-809-189-125379	Sequence 125379,
37	25	1.4	25	1	US-10-809-189-125380	Sequence 125380,
38	25	1.4	25	1	US-10-809-189-125381	Sequence 125381,
39	25	1.4	25	1	US-10-809-189-125382	Sequence 125382,
40	25	1.4	25	1	US-10-809-189-125383	Sequence 125383,
41	25	1.4	25	1	US-10-809-189-125384	Sequence 125384,
C 42	25	1.4	26	1	US-10-787-442-38	Sequence 38, Appl
C 43	25	1.4	26	1	US-10-969-164-7	Sequence 7, Appli
C 44	25	1.4	28	1	US-10-942-251-8	Sequence 8, Appli
C 45	24.6	1.4	25	1	US-10-942-251-9	Sequence 9, Appli
C 46	24.4	1.4	28	1	US-10-942-251-12	Sequence 12, Appl
C 47	24	1.3	24	1	US-10-831-778-433	Sequence 433, App
C 48	24	1.3	24	1	US-10-831-778-961	Sequence 961, App
C 49	24	1.3	24	1	US-10-831-778-962	Sequence 962, App
C 50	24	1.3	24	1	US-10-357-930-14833	Sequence 14833, A
C 51	24	1.3	24	1	US-10-942-251-3	Sequence 3, Appli
C 52	23.4	1.3	25	1	US-10-719-900-174230	Sequence 174230,
C 53	23.4	1.3	25	1	US-10-719-900-309853	Sequence 309853,
C 54	23.4	1.3	25	1	US-10-719-900-446212	Sequence 446212,
C 55	23.4	1.3	25	1	US-10-719-900-480520	Sequence 480520,
C 56	23.4	1.3	25	1	US-10-719-900-512976	Sequence 512976,
C 57	23.4	1.3	25	1	US-10-719-900-611610	Sequence 611610,
C 58	23.4	1.3	25	1	US-10-719-900-761328	Sequence 761328,
C 59	23.4	1.3	25	1	US-10-719-900-860596	Sequence 860596,
C 60	23.4	1.3	25	1	US-10-719-900-879472	Sequence 879472,
C 61	23.4	1.3	25	1	US-10-719-900-908158	Sequence 908158,
C 62	23.4	1.3	25	1	US-10-719-900-962530	Sequence 962530,
C 63	22	1.2	24	1	US-10-721-793-285	Sequence 285, App
C 64	21	1.2	21	1	US-10-831-778-912	Sequence 912, App
C 65	21	1.2	21	1	US-10-751-736-11011	Sequence 11011, A
C 66	21	1.2	21	1	US-10-751-736-11014	Sequence 11014, A
C 67	21	1.2	21	1	US-10-830-287A-7	Sequence 7, Appli
C 68	21	1.2	21	1	US-10-601-140A-43	Sequence 43, Appl
C 69	20.8	1.2	24	1	US-10-872-063-161	Sequence 161, App
C 70	20.2	1.1	22	1	US-10-664-000-3	Sequence 3, Appli
C 71	20.2	1.1	22	1	US-10-601-140A-32	Sequence 32, Appl
C 72	20.2	1.1	22	1	US-10-601-140A-45	Sequence 45, Appl
C 73	20	1.1	20	1	US-09-976-900A-55	Sequence 55, Appl
C 74	20	1.1	20	1	US-10-661-415-12	Sequence 12, Appl
C 75	20	1.1	20	1	US-10-661-415-15	Sequence 15, Appl
C 76	20	1.1	20	1	US-10-831-778-226	Sequence 226, App
C 77	20	1.1	20	1	US-10-831-778-556	Sequence 556, App
C 78	20	1.1	20	1	US-10-831-778-560	Sequence 560, App
C 79	20	1.1	20	1	US-10-728-078-23	Sequence 23, Appl
C 80	20	1.1	20	1	US-10-601-140A-1	Sequence 1, Appli
C 81	20	1.1	20	1	US-10-601-140A-2	Sequence 2, Appli
C 82	20	1.1	20	1	US-10-601-140A-3	Sequence 3, Appli
C 83	20	1.1	20	1	US-10-601-140A-4	Sequence 4, Appli
C 84	20	1.1	20	1	US-10-601-140A-6	Sequence 6, Appli
C 85	20	1.1	20	1	US-10-601-140A-7	Sequence 7, Appli
C 86	20	1.1	20	1	US-10-601-140A-8	Sequence 8, Appli
C 87	20	1.1	20	1	US-10-601-140A-9	Sequence 9, Appli
C 88	20	1.1	20	1	US-10-601-140A-10	Sequence 10, Appl
C 89	20	1.1	20	1	US-10-601-140A-23	Sequence 23, Appl
C 90	20	1.1	20	1	US-10-601-140A-34	Sequence 34, Appl
C 91	20	1.1	20	1	US-10-601-140A-40	Sequence 40, Appl
C 92	20	1.1	20	1	US-10-601-140A-44	Sequence 44, Appl
C 93	20	1.1	20	1	US-10-876-086-49	Sequence 49, Appl
C 94	20	1.1	21	1	US-10-751-736-11012	Sequence 11012, A
C 95	20	1.1	21	1	US-10-913-246-23	Sequence 23, Appl
C 96	20	1.1	21	1	US-10-934-890-23	Sequence 23, Appl
C 97	19.4	1.1	21	1	US-10-751-736-10792	Sequence 10792, A
C 98	19.4	1.1	21	1	US-10-751-736-10822	Sequence 10822, A
C 99	19.4	1.1	21	1	US-10-751-736-11008	Sequence 11008, A
C 100	19.4	1.1	21	1	US-10-751-736-11125	Sequence 11125, A
C 101	19.2	1.1	24	1	US-09-776-479-60	Sequence 60, Appl
C 102	19.2	1.1	24	1	US-09-776-479-60	Sequence 60, Appl
C 103	19.2	1.1	24	1	US-10-112-653-54	Sequence 54, Appl
C 104	19.2	1.1	24	1	US-10-017-995-60	Sequence 60, Appl
C 105	19.2	1.1	24	1	US-10-314-578-60	Sequence 60, Appl
C 106	19.2	1.1	24	1	US-10-831-778-60	Sequence 60, Appl

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:22:17 ; Search time 2 Seconds  
(without alignments)  
5.665 Million cell updates/sec

Title: US-10-619-906-2  
Perfect score: 1790  
Sequence: 1 atgaatttctcatgatg.....aaaaacggaattccccggga 1790

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 169 seqs, 3165 residues

Total number of hits satisfying chosen parameters: 338

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 172 summaries

Database : rni2.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	#	Description
C 1	25.2	1.4	26	1	US-09-923-236-6	Sequence 6, Appli
2	25	1.4	25	1	US-09-396-196G-125365	Sequence 125365,
3	25	1.4	25	1	US-09-396-196G-125366	Sequence 125366,
4	25	1.4	25	1	US-09-396-196G-125367	Sequence 125367,
5	25	1.4	25	1	US-09-396-196G-125368	Sequence 125368,
6	25	1.4	25	1	US-09-396-196G-125369	Sequence 125369,
7	25	1.4	25	1	US-09-396-196G-125370	Sequence 125370,
8	25	1.4	25	1	US-09-396-196G-125371	Sequence 125371,
9	25	1.4	25	1	US-09-396-196G-125372	Sequence 125372,
10	25	1.4	25	1	US-09-396-196G-125373	Sequence 125373,
11	25	1.4	25	1	US-09-396-196G-125374	Sequence 125374,
12	25	1.4	25	1	US-09-396-196G-125375	Sequence 125375,
13	25	1.4	25	1	US-09-396-196G-125376	Sequence 125376,
14	25	1.4	25	1	US-09-396-196G-125377	Sequence 125377,
15	25	1.4	25	1	US-09-396-196G-125378	Sequence 125378,
16	25	1.4	25	1	US-09-396-196G-125379	Sequence 125379,
17	25	1.4	25	1	US-09-396-196G-125380	Sequence 125380,
18	25	1.4	25	1	US-09-396-196G-125381	Sequence 125381,
19	25	1.4	25	1	US-09-396-196G-125382	Sequence 125382,
20	25	1.4	25	1	US-09-396-196G-125383	Sequence 125383,
21	25	1.4	25	1	US-09-396-196G-125384	Sequence 125384,
C 22	25	1.4	25	1	US-09-859-736-1	Sequence 1, Appli
C 23	25	1.4	25	1	US-09-859-736-2	Sequence 2, Appli
C 24	25	1.4	26	1	US-09-923-236-7	Sequence 7, Appli
C 25	25	1.4	28	1	US-09-213-834B-8	Sequence 8, Appli
C 26	24.6	1.4	25	1	US-09-213-834B-9	Sequence 9, Appli
C 27	24.4	1.4	28	1	US-09-213-834B-12	Sequence 12, Appli
28	24	1.3	24	1	US-09-926-028-28	Sequence 28, Appl
C 29	24	1.3	24	1	US-09-213-834B-3	Sequence 3, Appli
C 30	24	1.3	24	1	US-10-009-962-10	Sequence 10, Appl
C 31	24	1.3	24	1	US-09-859-736-5	Sequence 5, Appli
C 32	21.8	1.2	26	1	US-09-853-646A-3	Sequence 3, Appli
C 33	21	1.2	21	1	US-09-859-736-6	Sequence 6, Appli

34	20.8	1.2	25	1	US-09-853-646A-4	Sequence 4, Appli
35	20	1.1	20	1	US-09-976-618A-55	Sequence 55, Appl
36	20	1.1	20	1	US-09-976-968A-55	Sequence 55, Appl
C 37	20	1.1	20	1	US-10-234-764-10	Sequence 10, Appl
38	20	1.1	20	1	US-09-975-059A-55	Sequence 55, Appl
C 39	20	1.1	20	1	US-09-859-736-3	Sequence 3, Appli
C 40	20	1.1	20	1	US-09-859-736-4	Sequence 4, Appli
41	19	1.1	21	1	US-09-696-791-4459	Sequence 4459, Ap
C 42	18.6	1.0	23	1	US-08-287-959-25	Sequence 25, Appl
C 43	18	1.0	18	1	US-09-809-545A-84	Sequence 84, Appl
C 44	18	1.0	18	1	US-10-352-704-12	Sequence 12, Appl
45	18	1.0	18	1	US-10-352-704-18	Sequence 18, Appl
C 46	17	0.9	17	1	US-09-766-253-132	Sequence 132, App
C 47	17	0.9	17	1	US-09-685-664B-1075	Sequence 1075, Ap
48	17	0.9	18	1	US-08-390-850-1070	Sequence 1070, Ap
49	17	0.9	18	1	US-08-435-634-1070	Sequence 1070, Ap
50	16.8	0.9	21	1	US-08-338-355-3	Sequence 3, Appli
51	16.4	0.9	18	1	US-09-904-744-1	Sequence 1, Appli
52	16	0.9	16	1	US-09-766-253-131	Sequence 131, App
C 53	16	0.9	17	1	US-09-685-664B-1074	Sequence 1074, Ap
C 54	16	0.9	17	1	US-09-685-664B-1076	Sequence 1076, Ap
C 55	16	0.9	17	1	US-09-090-672B-105	Sequence 105, App
C 56	16	0.9	17	1	US-09-090-672B-106	Sequence 106, App
C 57	16	0.9	17	1	US-09-090-672B-107	Sequence 107, App
C 58	16	0.9	18	1	US-09-904-744-2	Sequence 2, Appli
59	16	0.9	20	1	US-09-844-521-80	Sequence 80, Appl
60	15.8	0.9	19	1	US-09-696-791-4044	Sequence 4044, Ap
61	15.4	0.9	17	1	US-08-390-850-495	Sequence 495, App
62	15.4	0.9	17	1	US-08-435-634-495	Sequence 495, App
C 63	15.4	0.9	17	1	US-09-866-108A-10432	Sequence 10432, A
C 64	15.4	0.9	17	1	US-09-685-664B-1077	Sequence 1077, Ap
65	15	0.8	15	1	US-09-081-646-558	Sequence 558, App
C 66	15	0.8	15	1	US-10-352-704-10	Sequence 10, Appl
67	15	0.8	15	1	US-10-352-704-16	Sequence 16, Appl
C 68	15	0.8	17	1	US-09-685-664B-1073	Sequence 1073, Ap
69	14.8	0.8	18	1	US-08-390-850-21	Sequence 21, Appl
70	14.8	0.8	18	1	US-08-390-850-1074	Sequence 1074, Ap
71	14.8	0.8	18	1	US-08-390-850-1117	Sequence 1117, Ap
72	14.8	0.8	18	1	US-08-390-850-1129	Sequence 1129, Ap
73	14.8	0.8	18	1	US-08-435-634-21	Sequence 21, Appl
74	14.8	0.8	18	1	US-08-435-634-1074	Sequence 1074, Ap
75	14.8	0.8	18	1	US-08-435-634-1117	Sequence 1117, Ap
76	14.8	0.8	18	1	US-08-435-634-1129	Sequence 1129, Ap
C 77	14.8	0.8	18	1	US-09-255-893-36	Sequence 36, Appl
C 78	14.8	0.8	18	1	US-09-422-978-5494	Sequence 5494, Ap
C 79	14.4	0.8	16	1	US-09-371-772B-6065	Sequence 6065, Ap
C 80	14.4	0.8	16	1	US-09-371-772B-6066	Sequence 6066, Ap
C 81	14.4	0.8	16	1	US-09-479-005A-177	Sequence 177, App
82	14.4	0.8	17	1	US-08-390-850-446	Sequence 446, App
C 83	14.4	0.8	17	1	US-08-373-124A-1000	Sequence 1000, Ap
C 84	14.4	0.8	17	1	US-08-373-124A-2083	Sequence 2083, Ap
85	14.4	0.8	17	1	US-08-435-634-446	Sequence 446, App
C 86	14.4	0.8	17	1	US-08-435-628-1000	Sequence 1000, Ap
C 87	14.4	0.8	17	1	US-08-435-628-2083	Sequence 2083, Ap
88	14.4	0.8	17	1	US-08-584-040-5830	Sequence 5830, Ap
89	14.4	0.8	17	1	US-09-371-772B-2690	Sequence 2690, Ap
C 90	14.4	0.8	17	1	US-09-371-772B-5541	Sequence 5541, Ap
C 91	14.4	0.8	17	1	US-09-866-108A-10431	Sequence 10431, A
C 92	14.4	0.8	17	1	US-09-866-108A-10433	Sequence 10433, A
C 93	14.4	0.8	17	1	US-09-685-664B-1078	Sequence 1078, Ap
94	14.4	0.8	17	1	US-09-685-664B-2690	Sequence 2690, Ap
C 95	14.4	0.8	18	1	US-09-402-618B-108	Sequence 108, App
C 96	14	0.8	14	1	US-09-859-736-7	Sequence 7, Appli
97	14	0.8	16	1	US-08-527-060-14	Sequence 14, Appl
98	14	0.8	16	1	US-09-479-005A-441	Sequence 441, App
99	14	0.8	16	1	US-09-696-791-4149	Sequence 4149, Ap
100	14	0.8	16	1	US-09-696-791-4370	Sequence 4370, Ap
101	14	0.8	17	1	US-09-827-998-823	Sequence 823, App
102	14	0.8	17	1	US-09-827-998-824	Sequence 824, App
103	14	0.8	17	1	US-09-827-998-825	Sequence 825, App
104	14	0.8	17	1	US-09-827-998-826	Sequence 826, App
C 105	14	0.8	17	1	US-09-866-108A-10429	Sequence 10429, A
C 106	14	0.8	17	1	US-09-866-108A-10430	Sequence 10430, A

107	14	0.8	17	1	US-09-404-912-219	Sequence 219, App
108	14	0.8	17	1	US-09-685-664B-1072	Sequence 1072, Ap
109	13.8	0.8	17	1	US-08-281-940-29	Sequence 29, Appl
110	13.8	0.8	17	1	US-08-390-850-496	Sequence 496, App
111	13.8	0.8	17	1	US-08-390-850-497	Sequence 497, App
112	13.8	0.8	17	1	US-08-390-850-516	Sequence 516, App
113	13.8	0.8	17	1	US-08-390-850-517	Sequence 517, App
114	13.8	0.8	17	1	US-08-390-850-537	Sequence 537, App
115	13.8	0.8	17	1	US-08-390-850-538	Sequence 538, App
116	13.8	0.8	17	1	US-08-390-850-540	Sequence 540, App
117	13.8	0.8	17	1	US-08-390-850-541	Sequence 541, App
118	13.8	0.8	17	1	US-08-390-850-609	Sequence 609, App
119	13.8	0.8	17	1	US-08-390-850-694	Sequence 694, App
120	13.8	0.8	17	1	US-08-435-634-496	Sequence 496, App
121	13.8	0.8	17	1	US-08-435-634-497	Sequence 497, App
122	13.8	0.8	17	1	US-08-435-634-516	Sequence 516, App
123	13.8	0.8	17	1	US-08-435-634-517	Sequence 517, App
124	13.8	0.8	17	1	US-08-435-634-538	Sequence 538, App
125	13.8	0.8	17	1	US-08-435-634-540	Sequence 540, App
126	13.8	0.8	17	1	US-08-435-634-541	Sequence 541, App
127	13.8	0.8	17	1	US-08-435-634-609	Sequence 609, App
128	13.8	0.8	17	1	US-08-435-634-694	Sequence 694, App
129	13.8	0.8	17	1	US-08-710-134-29	Sequence 29, Appl
130	13.8	0.8	17	1	US-08-485-885-29	Sequence 29, Appl
131	13.8	0.8	17	1	US-09-077-205-35	Sequence 35, Appl
132	13.8	0.8	17	1	US-08-584-040-2292	Sequence 2292, Ap
133	13.8	0.8	17	1	US-08-584-040-6127	Sequence 6127, Ap
134	13.8	0.8	17	1	US-08-584-040-6128	Sequence 6128, Ap
135	13.8	0.8	17	1	US-08-584-040-7818	Sequence 7818, Ap
136	13.8	0.8	17	1	US-08-584-040-7819	Sequence 7819, Ap
137	13.8	0.8	17	1	US-09-060-299-354	Sequence 354, App
138	13.8	0.8	17	1	US-09-402-923A-354	Sequence 354, App
139	13.8	0.8	17	1	US-09-371-772B-837	Sequence 837, App
140	13.8	0.8	17	1	US-09-371-772B-2964	Sequence 2964, Ap
141	13.8	0.8	17	1	US-09-371-772B-2965	Sequence 2965, Ap
142	13.8	0.8	17	1	US-09-371-772B-3602	Sequence 3602, Ap
143	13.8	0.8	17	1	US-09-371-772B-3603	Sequence 3603, Ap
144	13.8	0.8	17	1	US-09-827-998-423	Sequence 423, App
145	13.8	0.8	17	1	US-09-827-998-821	Sequence 821, App
146	13.8	0.8	17	1	US-09-827-998-822	Sequence 822, App
147	13.8	0.8	17	1	US-09-866-108A-874	Sequence 874, App
148	13.8	0.8	17	1	US-09-866-108A-10428	Sequence 10428, A
149	13.8	0.8	17	1	US-09-866-108A-10434	Sequence 10434, A
150	13.8	0.8	17	1	US-09-685-664B-837	Sequence 837, App
151	13.8	0.8	17	1	US-09-685-664B-2964	Sequence 2964, Ap
152	13.8	0.8	17	1	US-09-685-664B-2965	Sequence 2965, Ap
153	13.8	0.8	17	1	US-09-685-664B-3602	Sequence 3602, Ap
154	13.8	0.8	17	1	US-09-685-664B-3603	Sequence 3603, Ap
155	13.8	0.8	17	1	US-08-292-620A-41	Sequence 41, Appl
156	13.4	0.7	15	1	US-08-585-684B-1740	Sequence 1740, Ap
157	13.4	0.7	15	1	US-09-071-845-41	Sequence 41, Appl
158	13.4	0.7	15	1	US-09-038-073-1740	Sequence 1740, Ap
159	13.4	0.7	15	1	US-08-753-147-134	Sequence 134, App
160	13.4	0.7	16	1	US-09-371-772B-6067	Sequence 6067, Ap
161	13.4	0.7	16	1	US-08-291-932A-93	Sequence 93, Appl
162	13	0.7	15	1	US-08-864-224-2	Sequence 2, Appli
163	13	0.7	16	1	US-09-122-384-2	Sequence 2, Appli
164	13	0.7	16	1	US-09-396-196G-125371	Sequence 125371,
165	13	0.7	25	1	US-09-396-196G-125372	Sequence 125372,
166	13	0.7	25	1	US-08-753-147-134	Sequence 134, App
167	12.8	0.7	16	1	US-08-667-338B-5	Sequence 5, Appli
168	12.8	0.7	16	1	US-09-179-665-5	Sequence 5, Appli
169	12.8	0.7	16	1	US-09-371-772B-7106	Sequence 7106, Ap
170	12.8	0.7	16	1	US-09-479-005A-185	Sequence 185, App
171	12.8	0.7	16	1	US-09-931-381A-7	Sequence 7, Appli
172	12.8	0.7	16	1		

ALIGNMENTS

```
; Sequence 6, Application US/09923236
; Patent No. 6828419
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/09/923,236
; CURRENT FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7231
US-09-923-236-6

Query Match          1.4%; Score 25.2; DB 1; Length 26;
Best Local Similarity 96.2%; Pred. No. 12;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1748 GAAAAAAAAAAAAAAAAAAAAAAAAA 1773
Db      26 BAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 2
US-09-396-196G-125365
; Sequence 125365, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125365
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125365

Query Match          1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1237 ACACACTTCCAGGAATCAAGCCTA 1261
Db      1 ACACACTTCCAGGAATCAAGCCTA 25

RESULT 3
US-09-396-196G-125366
; Sequence 125366, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
```

;  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125366  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-09-396-196G-125366

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1243 TTCCCAGGAATCAAGCCTAAAAATTG 1267  
|||  
Db 1 TTCCCAGGAATCAAGCCTAAAAATTG 25

RESULT 4  
US-09-396-196G-125367  
; Sequence 125367, Application US/09396196G  
; Patent No. 6821724  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125367  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-09-396-196G-125367

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1441 TATTACATATTCACCTCTATGCTCAG 1465  
|||  
Db 1 TATTACATATTCACCTCTATGCTCAG 25

RESULT 5  
US-09-396-196G-125368  
; Sequence 125368, Application US/09396196G  
; Patent No. 6821724  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125368  
; LENGTH: 25  
; TYPE: DNA

;  
; ORGANISM: mus musculus  
US-09-396-196G-125368

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1444 TACATATTCACCTCTATGCTCAGGGT 1468  
|||  
Db 1 TACATATTCACCTCTATGCTCAGGGT 25

RESULT 6  
US-09-396-196G-125369  
; Sequence 125369, Application US/09396196G  
; Patent No. 6821724  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125369  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-09-396-196G-125369

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 ATATTCACCTCTATGCTCAGGGTGTA 1471  
|||  
Db 1 ATATTCACCTCTATGCTCAGGGTGTA 25

RESULT 7  
US-09-396-196G-125370  
; Sequence 125370, Application US/09396196G  
; Patent No. 6821724  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 125370  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-09-396-196G-125370

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1453 ACTCTATGCTCAGGGTGTAATG 1477  
|||



Db 1 ACTCTATGCTCAGGGTGTAACATG 25

RESULT 8

US-09-396-196G-125371

; Sequence 125371, Application US/09396196G

; Patent No. 6821724

; GENERAL INFORMATION:

; APPLICANT: Michael Mittmann

; APPLICANT: David Lockhart

; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1

; CURRENT APPLICATION NUMBER: US/09/396,196G

; CURRENT FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 125371

; LENGTH: 25

; TYPE: DNA

; ORGANISM: mus musculus

US-09-396-196G-125371

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 11;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1513 CAGGTCACACACACATAGTTACACA 1537

|||||

Db 1 CAGGTCACACACACATAGTTACACA 25

RESULT 9

US-09-396-196G-125372

; Sequence 125372, Application US/09396196G

; Patent No. 6821724

; GENERAL INFORMATION:

; APPLICANT: Michael Mittmann

; APPLICANT: David Mack

; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1

; CURRENT APPLICATION NUMBER: US/09/396,196G

; CURRENT FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 125372

; LENGTH: 25

; TYPE: DNA

; ORGANISM: mus musculus

US-09-396-196G-125372

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 11;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 GTCACACACACATAGTTACACAGAA 1540

|||||

Db 1 GTCACACACACATAGTTACACAGAA 25

RESULT 10

US-09-396-196G-125373

; Sequence 125373, Application US/09396196G

; Patent No. 6821724

; GENERAL INFORMATION:

; APPLICANT: Michael Mittmann

; APPLICANT: David Mack

; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1

; CURRENT APPLICATION NUMBER: US/09/396,196G

; CURRENT FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 125373

; LENGTH: 25

; TYPE: DNA

; ORGANISM: mus musculus

US-09-396-196G-125373

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 11;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1588 TTCTATTCTTAATTTTGAAAGTGCA 1612

|||||

Db 1 TTCTATTCTTAATTTTGAAAGTGCA 25

RESULT 11

US-09-396-196G-125374

; Sequence 125374, Application US/09396196G

; Patent No. 6821724

; GENERAL INFORMATION:

; APPLICANT: Michael Mittmann

; APPLICANT: David Mack

; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1

; CURRENT APPLICATION NUMBER: US/09/396,196G

; CURRENT FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 125374

; LENGTH: 25

; TYPE: DNA

; ORGANISM: mus musculus

US-09-396-196G-125374

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 11;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1612 ATGGTTCAGAGGCCCAACTGGTTTAT 1636

|||||

Db 1 ATGGTTCAGAGGCCCAACTGGTTTAT 25

RESULT 12

US-09-396-196G-125375

; Sequence 125375, Application US/09396196G

; Patent No. 6821724

; GENERAL INFORMATION:

; APPLICANT: Michael Mittmann

; APPLICANT: David Mack

; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1

; CURRENT APPLICATION NUMBER: US/09/396,196G

; CURRENT FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

```

; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125375
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125375

Query Match
1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1681 AGAATTACTCTCTGTCTTTACTGA 1705
Db 1 AGAATTACTCTCTGTCTTTACTGA 25

RESULT 13
US-09-396-196G-125376
; Sequence 125376, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125376
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125376

Query Match
1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1684 ATTACTCTCTCTGTCTTTACTGAAAT 1708
Db 1 ATTACTCTCTCTGTCTTTACTGAAAT 25

RESULT 14
US-09-396-196G-125377
; Sequence 125377, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125377
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125377

Query Match
1.4%; Score 25; DB 1; Length 25;
```

```

Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1273 GTCCTCTATTTCAAAAGACACTACT 1297
Db 1 GTCCTCTATTTCAAAAGACACTACT 25

RESULT 15
US-09-396-196G-125378
; Sequence 125378, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125378
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125378

Query Match
1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1276 CTCTATTTCAAAAGACACTACTACA 1300
Db 1 CTCTATTTCAAAAGACACTACTACA 25

RESULT 16
US-09-396-196G-125379
; Sequence 125379, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125379
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125379

Query Match
1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1279 TATTTCAAAAGACACTACTACTCT 1303
Db 1 TATTTCAAAAGACACTACTACTCT 25

RESULT 17
```

```

US-09-396-196G-125380
; Sequence 125380, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125380
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125380

```

Query Match	1.4%;	Score 25;	DB 1;	Length 25;
Best Local Similarity	100.0%;	Pred. No. 11;		
Matches 25;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1297	TACATCTTCCAGGAGCCTATCAAT	1321	
db	1	TACATCTTCCAGGAGCCTATCAAT	25	

	Query Match	1.4%	Score 25;	DB 1;	Length 25;
	Best Local Similarity	100.0%;	Pred. No. 11;		
	Matches 25;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1303	TTCCAAGGAGCCTATCAATTGGAAT	1327		
db	1	TTCCAAGGAGCCTATCAATTGGAAT	25		

```

; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125382
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125382

```

	Query Match	1.4%	Score 25;	DB 1;	Length 25;
	Best Local Similarity	100.0%;	Pred. No. 11;		
	Matches 25;	Conservative 0;	Mismatches 0;	Indels	
QY	1336	CTGTTCCGTCGTGCACCAAAACAT	1360		
Db	1	CTGTTCCGTCGTGCACCAAAACAT	25		

```

; TITLE OF INVENTION: Methods of Genetic Analysis
; APPLICANT: Affymetrix, Inc.
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125384
; LENGTH: 25

```

```
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125384

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1339 TTCCGTCGTGTACCAAAACATTGA 1363
Db 1 TTCCGTCGTGTACCAAAACATTGA 25

RESULT 22
US-09-859-736-1/c
; Sequence 1, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CATa oligonucleotide
US-09-859-736-1

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 23
US-09-859-736-2/c
; Sequence 2, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CATb oligonucleotide
US-09-859-736-2

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 24
US-09-923-236-7/c
; Sequence 7, Application US/09923236
; Patent No. 6828419
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/09/923,236
; CURRENT FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764a
US-09-923-236-7

Query Match      1.4%; Score 25; DB 1; Length 26;
Best Local Similarity 100.0%; Pred.No. 13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 25
US-09-213-834B-8/c
; Sequence 8, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; TITLE OF INVENTION: NUCLEIC ACIDS INTO CIRCULAR VECTORS
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-8

Query Match      1.4%; Score 25; DB 1; Length 28;
Best Local Similarity 100.0%; Pred.No. 16;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1752 AAAAAAAAAAAAAAAAAAAAAA 1776
Db 28 AAAAAAAAAAAAAAAAAAAAAA 4

RESULT 26
US-09-213-834B-9/c
; Sequence 9, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
```



```

; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; TITLE OF INVENTION: NUCLEIC ACIDS INTO CIRCULAR VECTORS
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-9

```

```

Query Match      1.4%; Score 24.6; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 13;
Matches 24; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1752 AAAAAAAAAAAAAAAAAAAAAAC 1776
Db 25 AAAAAAAAAAAAAAAAAAAAAAY 1

```

```

RESULT 27
US-09-213-834B-12/c
; Sequence 12, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; TITLE OF INVENTION: NUCLEIC ACIDS INTO CIRCULAR VECTORS
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-12

```

```

Query Match      1.4%; Score 24.4; DB 1; Length 28;
Best Local Similarity 96.2%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1752 AAAAAAAAAAAAAAAAAAAAAACG 1777
Db 28 AAAAAAAAAAAAAAAAAAAAAAGG 3

```

```

RESULT 28
US-09-926-028-28
; Sequence 28, Application US/09926028
; Patent No. 6806049
; GENERAL INFORMATION:
; APPLICANT: MAEKAWA, TAKAMI
; APPLICANT: MITSUI, AKIRA
; APPLICANT: DATE, MASAYO
; APPLICANT: FUKUDA, HISAO
; APPLICANT: TAKAHARA, YOSHIYUKI
; TITLE OF INVENTION: METHOD FOR ANALYZING EXPRESSION FREQUENCIES OF GENES
; FILE REFERENCE: 212833USOPCT
; CURRENT APPLICATION NUMBER: US/09/926,028
; CURRENT FILING DATE: 2001-08-16
; PRIOR APPLICATION NUMBER: PCT/JP00/00902
; PRIOR FILING DATE: 2000-02-17
; PRIOR APPLICATION NUMBER: JP 11-038538
; PRIOR FILING DATE: 1999-02-17

```

```

; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA
; FEATURE:
; NAME/KEY: polyA signal
; LOCATION: (1)..(24)
; OTHER INFORMATION:
US-09-926-028-28

```

```

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAA 1772
Db 1 AAAAAAAAAAAAAAAAAAAAA 24

```

```

RESULT 29
US-09-213-834B-3/c
; Sequence 3, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; TITLE OF INVENTION: NUCLEIC ACIDS INTO CIRCULAR VECTORS
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-3

```

```

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAAAAAAAAAAAAAAAA 1

```

```

RESULT 30
US-10-009-962-10/c
; Sequence 10, Application US/10009962
; Patent No. 6825321
; GENERAL INFORMATION:
; APPLICANT: ITO, KIKUKATSU
; TITLE OF INVENTION: Plant Thermogenic Genes and Proteins
; FILE REFERENCE: 2001-1838A/LC/00653
; CURRENT APPLICATION NUMBER: US/10/009,962
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: PCT/JP00/03806
; PRIOR FILING DATE: 2000-06-12
; PRIOR APPLICATION NUMBER: JP11-167439
; PRIOR FILING DATE: 1999-06-14
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: DNA Primer  
US-10-009-962-10

Query Match 1.3%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
|||  
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 31  
US-09-859-736-5/c  
; Sequence 5, Application US/09859736  
; Patent No. 6838244  
; GENERAL INFORMATION:  
; APPLICANT: LI, WAN-LIANG ROBERT  
; APPLICANT: ZHOU, JIAN S.  
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF  
; FILE REFERENCE: 16517.248  
; CURRENT APPLICATION NUMBER: US/09/859,736  
; CURRENT FILING DATE: 2001-05-18  
; PRIOR APPLICATION NUMBER: 60/205,452  
; PRIOR FILING DATE: 2000-05-19  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 24  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: CATAB oligonucleotide  
US-09-859-736-5

Query Match 1.3%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772  
|||  
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 32  
US-09-853-646A-3  
; Sequence 3, Application US/09853646A  
; Patent No. 6825038  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaides, Nicholas  
; APPLICANT: Sass, Philip  
; APPLICANT: Grasso, Luigi  
; APPLICANT: Kinzler, Kenneth  
; APPLICANT: Vogelstein, Bert  
; TITLE OF INVENTION: A METHOD FOR GENERATING HYPERMUTABLE  
; FILE REFERENCE: 01107.00138  
; CURRENT APPLICATION NUMBER: US/09/853,646A  
; CURRENT FILING DATE: 2001-05-14  
; PRIOR APPLICATION NUMBER: 60/204,769  
; PRIOR FILING DATE: 2000-05-17  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 26  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Recombinant DNA  
US-09-853-646A-3

Query Match 1.2%; Score 21.8; DB 1; Length 26;  
Best Local Similarity 92.0%; Pred. No. 33;  
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1747 TGAATAAAAAAAAAAAAAAAAAA 1771  
|||  
Db 2 TGGCAAAAAAAAAAAAAAAAAA 26

RESULT 33  
US-09-859-736-6/c  
; Sequence 6, Application US/09859736  
; Patent No. 6838244  
; GENERAL INFORMATION:  
; APPLICANT: LI, WAN-LIANG ROBERT  
; APPLICANT: ZHOU, JIAN S.  
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF  
; FILE REFERENCE: 16517.248  
; CURRENT APPLICATION NUMBER: US/09/859,736  
; CURRENT FILING DATE: 2001-05-18  
; PRIOR APPLICATION NUMBER: 60/205,452  
; PRIOR FILING DATE: 2000-05-19  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 6  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: dt oligonucleotide  
US-09-859-736-6

Query Match 1.2%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1769  
|||  
Db 21 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 34  
US-09-853-646A-4  
; Sequence 4, Application US/09853646A  
; Patent No. 6825038  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaides, Nicholas  
; APPLICANT: Sass, Philip  
; APPLICANT: Grasso, Luigi  
; APPLICANT: Kinzler, Kenneth  
; APPLICANT: Vogelstein, Bert  
; TITLE OF INVENTION: A METHOD FOR GENERATING HYPERMUTABLE  
; FILE REFERENCE: 01107.00138  
; CURRENT APPLICATION NUMBER: US/09/853,646A  
; CURRENT FILING DATE: 2001-05-14  
; PRIOR APPLICATION NUMBER: 60/204,769  
; PRIOR FILING DATE: 2000-05-17  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Recombinant DNA  
US-09-853-646A-4

Query Match 1.2%; Score 20.8; DB 1; Length 25;  
Best Local Similarity 91.7%; Pred. No. 39;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;



US-09-859-736-4/c  
; APPLICANT: Elghanian, Robert  
; APPLICANT: Taton, Thomas A.  
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO  
; FILE REFERENCE: 00-713-i15  
; CURRENT APPLICATION NUMBER: US/09/975,059A  
; PRIOR FILING DATE: 2001-10-11  
; PRIOR FILING DATE: 2000-06-26  
; PRIOR FILING DATE: 1999-06-25  
; PRIOR FILING DATE: 1999-01-29  
; PRIOR FILING DATE: 1997-07-21  
; PRIOR FILING DATE: 1996-07-29  
; PRIOR FILING DATE: 2000-04-26  
; NUMBER OF SEQ ID NOS: 64  
; SOFTWARE: Microsoft Word 2000  
; SEQ ID NO 55  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: random  
; OTHER INFORMATION: synthetic sequence  
US-09-975-059A-55

Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
| | | | | | | | | | | | | | | | | |  
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 39  
US-09-859-736-3/c  
; Sequence 3, Application US/09859736  
; Patent No. 6838244  
; GENERAL INFORMATION:  
; APPLICANT: LI, WAN-LIANG ROBERT  
; APPLICANT: ZHOU, JIAN S.  
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF  
; FILE REFERENCE: 16517.248  
; CURRENT APPLICATION NUMBER: US/09/859,736  
; CURRENT FILING DATE: 2001-05-18  
; PRIOR APPLICATION NUMBER: 60/205,452  
; PRIOR FILING DATE: 2000-05-19  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 3  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: CAT1 oligonucleotide  
US-09-859-736-3

Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
| | | | | | | | | | | | | | | | | |  
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 40

US-09-859-736-4/c  
; Sequence 4, Application US/09859736  
; Patent No. 6838244  
; GENERAL INFORMATION:  
; APPLICANT: LI, WAN-LIANG ROBERT  
; APPLICANT: ZHOU, JIAN S.  
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF  
; FILE REFERENCE: 16517.248  
; CURRENT APPLICATION NUMBER: US/09/859,736  
; CURRENT FILING DATE: 2001-05-18  
; PRIOR APPLICATION NUMBER: 60/205,452  
; PRIOR FILING DATE: 2000-05-19  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: CAT2 oligonucleotide  
US-09-859-736-4

Query Match 1.1%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768  
| | | | | | | | | | | | | | | | | |  
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 41  
US-09-696-791-4459  
; Sequence 4459, Application US/09696791  
; Patent No. 6770633  
; GENERAL INFORMATION:  
; APPLICANT: Robbins, Joan M.  
; APPLICANT: Tritz, Richard  
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE  
; TITLE OF INVENTION: SKIN AND EYE DISEASES  
; FILE REFERENCE: 480124.407  
; CURRENT APPLICATION NUMBER: US/09/696,791  
; CURRENT FILING DATE: 2000-10-25  
; NUMBER OF SEQ ID NOS: 4523  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 4459  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Homo sapien  
; FEATURE:  
; OTHER INFORMATION: MMP-3 ribozyme recognition site  
US-09-696-791-4459

Query Match 1.1%; Score 19; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTCACTCCCTCTATGGA 768  
| | | | | | | | | | | | | | | | | |  
Db 3 CATTCACTCCCTCTATGGA 21

RESULT 42  
US-08-287-959-25/c  
; Sequence 25, Application US/08287959  
; Patent No. 5639651  
; GENERAL INFORMATION:  
; APPLICANT: Weisbach, Lawrence  
; APPLICANT: Bernards, Andre  
; APPLICANT: Settleman, Jeffrey  
; TITLE OF INVENTION: GAP-RELATED GENE  
; NUMBER OF SEQUENCES: 26



;;  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Fish & Richardson  
;; STREET: 225 Franklin Street  
;; CITY: Boston  
;; STATE: MA  
;; COUNTRY: U.S.A.  
;; ZIP: 02110  
;;  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patent In Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; FILING DATE: August 9, 1994  
;; CLASSIFICATION: 514  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Clark, Paul C.  
;; REGISTRATION NUMBER: 30,162  
;; REFERENCE/DOCKET NUMBER: 00786/181001  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617) 542-5070  
;; TELEFAX: (617) 542-8906  
;; TELEX: 200154  
;; INFORMATION FOR SEQ ID NO: 25:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 23 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: double  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA (genomic)  
;; US-08-287-959-25

Query Match 1.0%; Score 18.6; DB 1; Length 23;  
Best Local Similarity 73.9%; Pred. No. 57;  
Matches 17; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 631 CATGAACCTGGCCATTCCTTGGG 653  
Db 23 CATGAACCTGGCCAYKBYCTGGG 1

RESULT 43  
US-09-809-545A-84/c  
; Sequence 84, Application US/09809545A  
; Patent No. 6800455  
; GENERAL INFORMATION:  
; APPLICANT: Stanton, Lawrence W.  
; APPLICANT: White, R. Tyler  
; TITLE OF INVENTION: SECRETED FACTORS  
; FILE REFERENCE: SCIOS.017A  
; CURRENT APPLICATION NUMBER: US/09/809,545A  
; CURRENT FILING DATE: 2001-03-14  
; NUMBER OF SEQ ID NOS: 84  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 84  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Oligos corresponding to polylinker sequence.  
US-09-809-545A-84

Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 33;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 44

US-10-352-704-12/c  
; Sequence 12, Application US/10352704  
; Patent No. 6825339  
; GENERAL INFORMATION:  
; APPLICANT: Chatelain, Francois  
; Kumarev, Viktor  
; TITLE OF INVENTION: Process for Preparing Polynucleotides on  
; a Solid Support and Apparatus Permitting its  
; Implementation  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Jacobson, Price, Holman & Stern  
; STREET: 400 Seventh St. N.W.  
; CITY: Washington D.C  
; STATE: D.C  
; COUNTRY: U.S.A.  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/352,704  
; FILING DATE: 28-Jan-2003  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/358,556A  
; FILING DATE: 14-DEC-1994  
; APPLICATION NUMBER: FR 9315164  
; FILING DATE: 16-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Player, William E.  
; REGISTRATION NUMBER: 31,409  
; REFERENCE/DOCKET NUMBER: 10577/P58418  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202)638-6666  
; TELEFAX: (202) 393-5350  
; TELEX: RCA 248593 IDEA UR  
; INFORMATION FOR SEQ ID NO: 12:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 1..18  
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:  
US-10-352-704-12

Query Match 1.0%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 33;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766  
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 45  
US-10-352-704-18  
; Sequence 18, Application US/10352704  
; Patent No. 6825339  
; GENERAL INFORMATION:  
; APPLICANT: Chatelain, Francois  
; Kumarev, Viktor  
; TITLE OF INVENTION: Process for Preparing Polynucleotides on  
; a Solid Support and Apparatus Permitting its

```

;
; Implementation
;
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C
; STATE: D.C
; COUNTRY: U.S.A.
; ZIP: 20004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704
; FILING DATE: 28-Jan-2003
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/358,556A
; FILING DATE: 14-DEC-1994
; APPLICATION NUMBER: FR 9315164
; FILING DATE: 16-DEC-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
;
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
;
US-10-352-704-18

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766
Db 1 AAAAAAAAAAAAAAAAAA 18

RESULT 46
US-09-766-253-132/c
; Sequence 132, Application US/09766253
; Patent No. 6808880
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; Lingner, Joachim
; Nakamura, Toru
; Chapman, Karen B.
; Morin, Gregg B.
; Harley, Calvin
; Andrews, William H.
; TITLE OF INVENTION: No. 6808880el Telomerase
; NUMBER OF SEQUENCES: 171
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
;

```

```

;
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/766,253
; FILING DATE: 19-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/846,017
; FILING DATE: 1997-04-25
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002920US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 132:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 132:
;
US-09-766-253-132

Query Match 0.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1765
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 47
US-09-685-664B-1075/c
; Sequence 1075, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1075
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
;
US-09-685-664B-1075

Query Match 0.9%; Score 17; DB 1; Length 17;

```

Best Local Similarity 100.0%; Pred. No. 37;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1748 GAAAAAAAAAAAAAA 1764  
Db 17 GAAAAAAAAAAAAAA 1

RESULT 48  
US-08-390-850-1070  
; Sequence 1070, Application US/08390850  
; Patent No. 5612215  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,850  
FILING DATE: February 17, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5612215ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1070:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-1070

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 64.7%; Pred. No. 44;  
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 750 CATTGAGTCCCTCTATG 766  
Db 2 CAUCAGUCCCUAUG 18

RESULT 49  
US-08-435-634-1070  
; Sequence 1070, Application US/08435634

Patent No. 5731295  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,634  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5731295ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1070:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-634-1070

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 64.7%; Pred. No. 44;  
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 750 CATTGAGTCCCTCTATG 766  
Db 2 CAUCAGUCCCUAUG 18

RESULT 50  
US-08-338-355-3  
; Sequence 3, Application US/08338355  
; Patent No. 5583035  
; GENERAL INFORMATION:  
; APPLICANT: Kretschmer, Axel; Antonicek, Horst-  
; APPLICANT: Peter; Baumgarten, Jorg; Loebberding,  
; APPLICANT: Antonius; Mielke, Burkhard; Springer,  
; APPLICANT: Wolfgang; Stropp, Udo; Struck, Mark-  
; APPLICANT: Michael; Biesent, Lothar; Rubsamen-  
; APPLICANT: Waigmann, Helga; Suhartono, Hary;

APPLICANT: Hausner, Thomas-Peter  
TITLE OF INVENTION: EXPRESSION VECTORS AND THEIR  
USE IN THE PREPARATION OF HIV-  
TITLE OF INVENTION: RESISTANT HUMAN CELLS FOR  
TITLE OF INVENTION: THERAPEUTIC APPLICATIONS  
NUMBER OF SEQUENCES: 8  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: SPRUNG HORN KRAMER & WOODS  
STREET: 660 White Plains Road  
CITY: Tarrytown  
STATE: New York  
COUNTRY: U.S.A.  
ZIP: 10591-5144  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.5 inch, 720 KB storage  
COMPUTER: Sharp PC-4600  
OPERATING SYSTEM: DOS  
SOFTWARE: WordPerfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/338,355  
FILING DATE: 14-NOV-1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/987,506  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Kurt G. Briscoe  
REGISTRATION NUMBER: 33,141  
REFERENCE/DOCKET NUMBER: Bayer 8638-KGB  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (914) 332-1700  
TELEFAX: (914) 332-1844  
TELEX:  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 21 nucleotides  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-338-355-3

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 72;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1575 TTTTTCACCTTCATTCTATT 1594  
|||||  
Db 1 TTTTTCACCTGCATTCTACT 20

RESULT 51  
US-09-904-744-1  
Sequence 1, Application US/09904744  
Patent No. 6828142  
GENERAL INFORMATION:  
APPLICANT: Barbera-Guillem, Emilio  
APPLICANT: Nelson, M. Bud  
APPLICANT: Castro, Stephanie  
TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form  
TITLE OF INVENTION: dendrimers in a signal amplification system  
FILE REFERENCE: B-73  
CURRENT APPLICATION NUMBER: US/09/904,744  
CURRENT FILING DATE: 2001-07-13  
PRIOR APPLICATION NUMBER: 09/437076  
PRIOR FILING DATE: 1999-11-09  
PRIOR APPLICATION NUMBER: 60/107828  
PRIOR FILING DATE: 1998-11-10  
NUMBER OF SEQ ID NOS: 6  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 1  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence

FEATURE:  
OTHER INFORMATION: synthesized  
US-09-904-744-1  
Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 94.4%; Pred. No. 53;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1746 GTGAAAAAAAAAAAAA 1763  
|||||  
Db 1 GGGAAAAAAAAAAAAA 18  
RESULT 52  
US-09-766-253-131  
Sequence 131, Application US/09766253  
Patent No. 6808880  
GENERAL INFORMATION:  
APPLICANT: Cech, Thomas R.  
Lingner, Joachim  
Nakamura, Toru  
Chapman, Karen B.  
Morin, Gregg B.  
Harley, Calvin  
Andrews, William H.  
TITLE OF INVENTION: No. 6808880el Telomerase  
NUMBER OF SEQUENCES: 171  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, 8th Floor  
CITY: San Francisco  
STATE: California  
COUNTRY: United States of America  
ZIP: 94111  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/766,253  
FILING DATE: 19-Jan-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/846,017  
FILING DATE: 1997-04-25  
APPLICATION NUMBER: US 08/724,643  
FILING DATE: 01-OCT-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Apple, Randolph T.  
REGISTRATION NUMBER: 36,429  
REFERENCE/DOCKET NUMBER: 015389-002920US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
INFORMATION FOR SEQ ID NO: 131:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 131:  
US-09-766-253-131

Query Match 0.9%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 42;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1764  
|||||  
Db 1 AAAAAAAAAAAAAA 16



RESULT 53  
US-09-685-664B-1074/c  
; Sequence 1074, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1074  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-1074

Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 50;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAA 1764  
Db 17 AAAAAAAAAAAAAAA 2

RESULT 54  
US-09-685-664B-1076/c  
; Sequence 1076, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1076  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-1076

Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 50;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1748 AAAAAAAAAAAAAAA 1763  
Db 17 AAAAAAAAAAAAAAA 2

Db 16 GAAAAAAAAAAAAAA 1

RESULT 55  
US-09-090-672B-105/c  
; Sequence 105, Application US/09090672B  
; Patent No. 6828428  
; GENERAL INFORMATION:  
; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura, Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada, Shigemasa; Takei, Masami  
; TITLE OF INVENTION: IGA Nephropathy-Related Genes  
; NUMBER OF SEQUENCES: 111  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto  
; STREET: 30 Rockefeller Plaza  
; CITY: New York  
; STATE: New York  
; ZIP: 10112-3801  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
; COMPUTER: Compaq PC  
; OPERATING SYSTEM: Windows 95  
; SOFTWARE: WordPerfect 8.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/090,672B  
; FILING DATE: 04-JUNE-1998  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP97/04468  
; FILING DATE: 05-DEC-1997  
; APPLICATION NUMBER: JP-8-325763  
; FILING DATE: 05-DEC-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Perry, Lawrence S.  
; REGISTRATION NUMBER: 31865  
; REFERENCE/DOCKET NUMBER: 766.21  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 218-2100  
; TELEFAX: (212) 218-2200  
; INFORMATION FOR SEQ ID NO: 105:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: other nucleic acid, synthetic DNA  
US-09-090-672B-105

Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 50;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1761 AAAAAAAAAAAAAAC 1776  
Db 16 AAAAAAAAAAAAAAC 1

RESULT 56  
US-09-090-672B-106/c  
; Sequence 106, Application US/09090672B  
; Patent No. 6828428  
; GENERAL INFORMATION:  
; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura, Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada, Shigemasa; Takei, Masami  
; TITLE OF INVENTION: IGA Nephropathy-Related Genes  
; NUMBER OF SEQUENCES: 111  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto  
; STREET: 30 Rockefeller Plaza  
; CITY: New York  
; STATE: New York

; ZIP: 10112-3801  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
; COMPUTER: Compaq PC  
; OPERATING SYSTEM: Windows 95  
; SOFTWARE: WordPerfect 8.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/090,672B  
; FILING DATE: 04-JUNE-1998  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP97/04468  
; FILING DATE: 05-DEC-1997  
; APPLICATION NUMBER: JP-8-325763  
; FILING DATE: 05-DEC-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Perry, Lawrence S.  
; REGISTRATION NUMBER: 31865  
; REFERENCE/DOCKET NUMBER: 766.21  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 218-2100  
; TELEFAX: (212) 218-2200  
; INFORMATION FOR SEQ ID NO: 106:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: other nucleic acid, synthetic DNA  
; US-09-090-672B-106  
  
Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 50;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1761 AAAAAAAAAAAAAAAC 1776  
Db 16 AAAAAAAAAAAAAAAC 1  
  
RESULT 57  
US-09-090-672B-107/c  
; Sequence 107, Application US/09090672B  
; Patent No. 6828428  
; GENERAL INFORMATION:  
; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,  
; APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,  
; APPLICANT: Shigenasa; Takei, Masami  
; TITLE OF INVENTION: Iga Nephropathy-Related Genes  
; NUMBER OF SEQUENCES: 111  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto  
; STREET: 30 Rockefeller Plaza  
; CITY: New York  
; STATE: New York  
; ZIP: 10112-3801  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
; COMPUTER: Compaq PC  
; OPERATING SYSTEM: Windows 95  
; SOFTWARE: WordPerfect 8.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/090,672B  
; FILING DATE: 04-JUNE-1998  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP97/04468  
; FILING DATE: 05-DEC-1997  
; APPLICATION NUMBER: JP-8-325763  
; FILING DATE: 05-DEC-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Perry, Lawrence S.  
; REGISTRATION NUMBER: 31865

; REFERENCE/DOCKET NUMBER: 766.21  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 218-2100  
; TELEFAX: (212) 218-2200  
; INFORMATION FOR SEQ ID NO: 107:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: other nucleic acid, synthetic DNA  
; US-09-090-672B-107  
  
Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 50;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1748 GAAAAAAAAAAAAA 1763  
Db 17 GAAAAAAAAAAAAA 2  
  
RESULT 58  
US-09-904-744-2/c  
; Sequence 2, Application US/09904744  
; Patent No. 6828142  
; GENERAL INFORMATION:  
; APPLICANT: Barbera-Guillem, Emilio  
; APPLICANT: Nelson, M. Bud  
; APPLICANT: Castro, Stephanie  
; TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form  
; TITLE OF INVENTION: dendrimers in a signal amplification system  
; FILE REFERENCE: B-73  
; CURRENT APPLICATION NUMBER: US/09/904,744  
; PRIOR FILING DATE: 2001-07-13  
; PRIOR APPLICATION NUMBER: 09/437076  
; PRIOR FILING DATE: 1999-11-09  
; PRIOR APPLICATION NUMBER: 60/107828  
; PRIOR FILING DATE: 1998-11-10  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthesized  
; US-09-904-744-2  
  
Query Match 0.9%; Score 16; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 59;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1761 AAAAAAAAAAAAAAC 1776  
Db 18 AAAAAAAAAAAAAAC 3  
  
RESULT 59  
US-09-844-521-80  
; Sequence 80, Application US/09844521  
; Patent No. 6492172  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Harris Busch  
; APPLICANT: Jacqueline Wyatt  
; TITLE OF INVENTION: ANTISENSE MODULATION OF GU PROTEIN EXPRESSION  
; FILE REFERENCE: RTS-0163  
; CURRENT APPLICATION NUMBER: US/09/844,521  
; CURRENT FILING DATE: 2001-04-27  
; NUMBER OF SEQ ID NOS: 87  
; SEQ ID NO 80  
; LENGTH: 20

```
;
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-844-521-80

Query Match          0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1294 TACTACATCTTCCAAG 1309
      |||||
Db 5 TACTACATCTTCCAAG 20

RESULT 60
US-09-696-791-4044
; Sequence 4044, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4044
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: PCNA HH ribozyme binding site
US-09-696-791-4044

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1717 TTTTGTCTTTCTTAAATAA 1735
      | |||||
Db 1 TATTGTTTCTGTAATAA 19

RESULT 61
US-08-390-850-495
; Sequence 495, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5

QY 1717 TTTTGTCTTTCTTAAATAA 1735
      | |||||
Db 1 TATTGTTTCTGTAATAA 19

RESULT 62
US-08-435-634-495
; Sequence 495, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: 08/152,487
```

```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 495:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-495

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 60;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 616 TTCCTTGTGCTTCA 632
      ::|||::|||::|||
Db 1 UUCCUUGUUGCUGCUA 17

RESULT 62
US-08-435-634-495
; Sequence 495, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
```





Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 631 CATGAACCTGGCCAT 645  
Db 1 CATGAACCTGGCCAT 15

RESULT 66

US-10-352-704-10/c  
; Sequence 10, Application US/10352704  
; Patent No. 6825339  
; GENERAL INFORMATION:  
; APPLICANT: Chatelain, Francois  
; Kumarev, Viktor  
; TITLE OF INVENTION: Process for Preparing Polynucleotides on  
; a Solid Support and Apparatus Permitting its  
; Implementation  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Jacobson, Price, Holman & Stern  
; STREET: 400 Seventh St. N.W.  
; CITY: Washington D.C  
; STATE: D.C  
; COUNTRY: U.S.A.  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/352,704  
; FILING DATE: 28-Jan-2003  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/358,556A  
; FILING DATE: 14-DEC-1994  
; APPLICATION NUMBER: FR 9315164  
; FILING DATE: 16-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Player, William E.  
; REGISTRATION NUMBER: 31,409  
; REFERENCE/DOCKET NUMBER: 10577/P58418  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 638-6666  
; TELEFAX: (202) 393-5350  
; TELEX: RCA 248593 IDEA UR  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 1..15  
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:

US-10-352-704-10

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 46;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAA 1763  
Db 15 AAAAAAAAAAAAAA 1  
RESULT 67

US-10-352-704-16  
; Sequence 16, Application US/10352704  
; Patent No. 6825339  
; GENERAL INFORMATION:  
; APPLICANT: Chatelain, Francois  
; Kumarev, Viktor  
; TITLE OF INVENTION: Process for Preparing Polynucleotides on  
; a Solid Support and Apparatus Permitting its  
; Implementation  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Jacobson, Price, Holman & Stern  
; STREET: 400 Seventh St. N.W.  
; CITY: Washington D.C  
; STATE: D.C  
; COUNTRY: U.S.A.  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/352,704  
; FILING DATE: 28-Jan-2003  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/358,556A  
; FILING DATE: 14-DEC-1994  
; APPLICATION NUMBER: FR 9315164  
; FILING DATE: 16-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Player, William E.  
; REGISTRATION NUMBER: 31,409  
; REFERENCE/DOCKET NUMBER: 10577/P58418  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 638-6666  
; TELEFAX: (202) 393-5350  
; TELEX: RCA 248593 IDEA UR  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 1..15  
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:

US-10-352-704-16

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 46;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAA 1763  
Db 1 AAAAAAAAAAAAAA 15  
RESULT 68  
US-09-685-664B-1073/c  
; Sequence 1073, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1073
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1073

Query Match      0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1763
Db 17 AAAAAAAAAAAAAA 3

RESULT 69
US-08-390-850-21
; Sequence 21, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

;
; INFORMATION FOR SEQ ID NO: 1073:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-1074

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 82;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-21

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 82;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 870 AATCCTTTTCTTTAAAGA 887
Db 1 AAUCCUGAUCUUUAAAGA 18

RESULT 70
US-08-390-850-1074
; Sequence 1074, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1074:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-1074

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 82;
```

Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886  
| | | | | : : : : | | | |  
Db 1 AAUCCUGAUCUUAAAG 18

RESULT 71

US-08-390-850-1117

; Sequence 1117, Application US/08390850

; Patent No. 5612215

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwiggen, James

; APPLICANT: Gustofson, John

; APPLICANT: Stinchcomb, Dan T.

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

; NUMBER OF SEQUENCES: 1151

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/390,850

FILING DATE: February 17, 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/354,920

FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5612215ember 12, 1993

APPLICATION NUMBER: 07/989,848

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1117:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-390-850-1117

Query Match 0.8%; Score 14.8; DB 1; Length 18;

Best Local Similarity 50.0%; Pred. No. 82;

Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 621 TGTGCTGTTTCATGAAC 638  
: : : : : : : : : : : : : :  
Db 1 UGUUGCUGCUAUGAGCU 18

RESULT 72

US-08-390-850-1129

; Sequence 1129, Application US/08390850

; Patent No. 5612215

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwiggen, James

; APPLICANT: Gustofson, John

; APPLICANT: Stinchcomb, Dan T.

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

; NUMBER OF SEQUENCES: 1151

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/390,850

FILING DATE: February 17, 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/354,920

FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5612215ember 12, 1993

APPLICATION NUMBER: 07/989,848

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1129:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-390-850-1129

Query Match 0.8%; Score 14.8; DB 1; Length 18;

Best Local Similarity 50.0%; Pred. No. 82;

Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886  
| | | | | : : : : | | | |  
Db 1 AAUCCUGAUCUUAAAG 18

RESULT 73

US-08-435-634-21

; Sequence 21, Application US/08435634

; Patent No. 5731295

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwiggen, James

; APPLICANT: Gustofson, John

; APPLICANT: Stinchcomb, Dan T.

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

; NUMBER OF SEQUENCES: 1151

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon





```
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1117:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-435-634-1117
```

```
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 50.0%; Pred. No. 82;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 621 TGTGCTGTTTCATGAAC 638
Db 1 UGUUGCUGCUCAUGACU 18
```

```
RESULT 76
US-08-435-634-1129
; Sequence 1129, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
```

```
;
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1129:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-435-634-1129

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 50.0%; Pred. No. 82;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 869 AAATCCTTTTCTTTAAAG 886
Db 1 AAUUCUGUUCUUUAAAG 18
```

```
RESULT 77
US-09-255-893-36/c
; Sequence 36, Application US/09255893A
; Patent No. 6008344
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPASE A2 GROUP IV EXPRESSION
; FILE REFERENCE: RTS-0055
; CURRENT APPLICATION NUMBER: US/09/255,893A
; CURRENT FILING DATE: 1999-02-23
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 36
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-09-255-893-36
```

```
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 82;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 577 GCAGAAACGTGGACTAA 594
Db 18 GCAGAAAGTGGGCTAA 1
```

```
RESULT 78
US-09-422-978-5494/c
; Sequence 5494, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
```

```

; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5494
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-4676 for SEQ 1560,
US-09-422-978-5494

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 82;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 691 CCCACCTACAGATACCTT 708
Db 18 CCCACCTGAGATACCTT 1

RESULT 79
US-09-371-772B-6065/c
; Sequence 6065, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6065
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6065

Query Match      0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1521 ACACACATAGTTACAC 1536
Db 16 ACACACACAGTTACAC 1

RESULT 80
US-09-371-772B-6066/c
; Sequence 6066, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26

```

```

; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6066
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6066

Query Match      0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1519 ACACACATAGTTAC 1534
Db 16 ACACACACAGTTAC 1

RESULT 81
US-09-479-005A-177/c
; Sequence 177, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MHB00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 177
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-177

Query Match      0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1576 TTTTTCATTTCATTCT 1591
Db 16 TTTTTCATTTCATTGT 1

RESULT 82
US-08-390-850-446
; Sequence 446, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

```

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,850  
FILING DATE: February 17, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5612215ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 446:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-446

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 79;  
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 317 ACCTCATTACAGGAT 332  
|||:|:|:|:|:|:|:  
Db 1 ACCUAAUUACAGGAU 16

RESULT 83  
US-08-373-124A-1000/c  
Sequence 1000, Application US/08373124A  
Patent No. 5646042  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth  
APPLICANT: McSwiggen, James  
APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
TITLE OF INVENTION: CANCER USING RIBOZYMES  
NUMBER OF SEQUENCES: 2627  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/373,124A  
FILING DATE: January 13, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/245,466

FILING DATE: May 18, 1994  
APPLICATION NUMBER: 08/192,943  
FILING DATE: February 7, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
APPLICATION NUMBER: 07/936,422  
FILING DATE: August 26, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/035  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1000:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-373-124A-1000

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 79;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCATTACAAAATTAA 1560  
|||:|:|:|:|:|:|:  
Db 17 GCATTACAAAATTAA 2

RESULT 84  
US-08-373-124A-2083/c  
Sequence 2083, Application US/08373124A  
Patent No. 5646042  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth  
APPLICANT: McSwiggen, James  
APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
TITLE OF INVENTION: CANCER USING RIBOZYMES  
NUMBER OF SEQUENCES: 2627  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/373,124A  
FILING DATE: January 13, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/245,466  
FILING DATE: May 18, 1994  
APPLICATION NUMBER: 08/192,943  
FILING DATE: February 7, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
APPLICATION NUMBER: 07/936,422  
FILING DATE: August 26, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard

```

; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2083:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-2083

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1545 GCTTTTACAAAATTAA 1560
Db      17 GCATTTACAAAATTAA 2

RESULT 85
US-08-435-634-446
; Sequence 446, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 446:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-1000
```

```

; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-446

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 79;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      317 ACCTCACTTACAGGAT 332
Db      1 ACCUAACTUACAGGAU 16

RESULT 86
US-08-435-628-1000/c
; Sequence 1000, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1000:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-1000
```



```

Query Match      0.8%;   Score 14.4;   DB 1;   Length 17;
Best Local Similarity 93.8%;   Pred. NO. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1545 GCTTTTACAAAATTAA 1560  
||| . ||| ||| ||| ||| |||  
Db 17 GCATTTCAAAATTAA 2

RESULT 87  
US-08-435-628-2083/c  
; Sequence 2083, Application US/08435628  
; Patent No. 5817796  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071

```

Query Match      0.8%;   Score 14.4;   DB 1;   Length 17;
Best Local Similarity 93.8%;   Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1545 GCTTTTACAAAATTAA 1560

```

Db          17 GCATTACAAAAATTAA 2

RESULT 88
US-08-584-040-5830
; Sequence 5830, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5830:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-5830

```

```

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 79;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

```

Qy 297 GTCAAGATGGATGAAG 312  
|:|||||:|:|:|  
Db 1 GUCAAGAUGAUGAAG 16

RESULT 89  
US-09-371-772B-2690  
; Sequence 2690, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: MCSwiggien, Jim  
; APPLICANT: Stinchcomb, Dan

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2690

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 79;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      297  GTCAAGATGGATGAAG 312
Db      1    GUCAAGAUGAUGAAG 16
      |:||||: ||:||||

RESULT 90
US-09-371-772B-5541/c
; Sequence 5541, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5541

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1521 ACACACATAGTTACAC 1536
Db      17  ACACACACAGTTACAC 2
      ||||||| |||||||

RESULT 91
US-09-866-108A-10431/c
; Sequence 10431, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
```

```
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10431

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      838  AGTTTGATGCTGTCA 853
Db      17  ACTTTGATGCTGTCA 2
      ||||||| |||||||

RESULT 92
US-09-866-108A-10433/c
; Sequence 10433, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10433
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10433

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 837 GAGTTTTCATGCTGTC 852
Db 16 GACTTTTCATGCTGTC 1

RESULT 93
US-09-685-664B-1078/c
; Sequence 1078, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1078
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1078

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1747 TGAATAAAAAAAAAAAAA 1762
Db 16 TGAATAAAAAAAAAAAAA 1

RESULT 94
US-09-685-664B-2690
; Sequence 2690, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2690

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 79;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 297 GTCAAGATGGATGAAG 312
Db 1 GUCAAGAUUGAUGAAG 16

RESULT 95
US-09-402-618B-108/c
; Sequence 108, Application US/09402618B
; Patent No. 6709815
; GENERAL INFORMATION:
; APPLICANT: Dong, Fang
; APPLICANT: Lyamichev, Victor
; APPLICANT: Prudent, James
; APPLICANT: Fors, Lance
; APPLICANT: Neri, Bruce
; APPLICANT: Brow, Mary Ann
; APPLICANT: Anderson, Todd
; APPLICANT: Dahlberg, James
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides
; FILE REFERENCE: FORS-04012
; CURRENT APPLICATION NUMBER: US/09/402,618B
; CURRENT FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/US98/03194
; PRIOR FILING DATE: 1998-05-05
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 108
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-402-618B-108

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 813 ATCAACTTTCGTGCAC 828
Db 16 AACAACTTTCGTGCAC 1

RESULT 96
US-09-859-736-7/c
; Sequence 7, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:

APPLICANT: LI, WAN-LIANG ROBERT  
APPLICANT: ZHOU, JIAN S.  
TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF  
FILE REFERENCE: 16517.248  
CURRENT APPLICATION NUMBER: US/09/859,736  
PRIOR FILING DATE: 2001-05-18  
PRIOR APPLICATION NUMBER: 60/205,452  
PRIOR FILING DATE: 2000-05-19  
NUMBER OF SEQ ID NOS: 7  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 7  
LENGTH: 14  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: dt oligonucleotide  
US-09-859-736-7

Query Match 0.8%; Score 14; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 51;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1762  
Db 14 AAAAAAAAAAAAAA 1

RESULT 97  
US-08-527-060-14  
Sequence 14, Application US/08527060  
Patent No. 5834440  
GENERAL INFORMATION:  
APPLICANT: Goldenberg, Tsvi  
APPLICANT: Tritz, Richard  
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT  
TITLE OF INVENTION: AND/OR PREVENTION OF RESTENOSIS  
NUMBER OF SEQUENCES: 35  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: SEED and BERRY  
STREET: 6300 Columbia Center, 701 Fifth Avenue  
CITY: Seattle  
STATE: Washington  
COUNTRY: USA  
ZIP: 98104-7092  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/527,060  
FILING DATE: 12-SEP-1995  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: McMasters, David D.  
REGISTRATION NUMBER: 33,963  
REFERENCE/DOCKET NUMBER: 480124.402C1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206) 622-4900  
TELEFAX: (206) 682-6031  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-527-060-14

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 74;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTCACCAA 832  
Db 1 TTTCTGTCACCAA 14  
RESULT 98  
US-09-479-005A-441  
Sequence 441, Application US/09479005A  
Patent No. 6656731  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity  
FILE REFERENCE: MBH00-884-C  
CURRENT APPLICATION NUMBER: US/09/479,005A  
CURRENT FILING DATE: 2000-01-07  
PRIOR APPLICATION NUMBER: US 09/444,209  
PRIOR FILING DATE: 1999-11-19  
PRIOR APPLICATION NUMBER: US 09/159,274  
PRIOR FILING DATE: 1998-09-22  
PRIOR APPLICATION NUMBER: US 60/059,473  
PRIOR FILING DATE: 1997-09-22  
NUMBER OF SEQ ID NOS: 1208  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 441  
LENGTH: 16  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-479-005A-441

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 57.1%; Pred. No. 74;  
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1706 AATGTAACATGTTT 1719  
Db 1 AAUGUAAACAUUUU 14

RESULT 99  
US-09-696-791-4149  
Sequence 4149, Application US/09696791  
Patent No. 6770633  
GENERAL INFORMATION:  
APPLICANT: Robbins, Joan M.  
APPLICANT: Tritz, Richard  
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE  
TITLE OF INVENTION: SKIN AND EYE DISEASES  
FILE REFERENCE: 480124.407  
CURRENT APPLICATION NUMBER: US/09/696,791  
CURRENT FILING DATE: 2000-10-25  
NUMBER OF SEQ ID NOS: 4523  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 4149  
LENGTH: 16  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
OTHER INFORMATION: Hairpin ribozyme recognition site for PCNA  
US-09-696-791-4149

Query Match 0.8%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 74;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTTCTGTCACCAA 832  
Db 1 TTTCTGTCACCAA 14

RESULT 100  
US-09-696-791-4370  
Sequence 4370, Application US/09696791  
Patent No. 6770633



```
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4370
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Hammerhead ribozyme recognition site for PCNA
US-09-696-791-4370

Query Match          0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      819 TTTCTGTGTCACCAAA 832
Db      1 TTTCTGTGTCACCAAA 14

RESULT 101
US-09-827-998-823
; Sequence 823, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-823

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1181 GGAGGTATGATGTG 1194
Db      4 GGAGGTATGATGTG 17

RESULT 102
US-09-827-998-824
; Sequence 824, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-824

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1181 GGAGGTATGATGTG 1194
Db      3 GGAGGTATGATGTG 16

RESULT 103
US-09-827-998-825
; Sequence 825, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 825
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-825

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1181 GGAGGTATGATGTG 1194
Db      2 GGAGGTATGATGTG 15

RESULT 104
US-09-827-998-826
; Sequence 826, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 826
; LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-826

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1181 GGAGGTATGATGTG 1194
Db      1 GGAGGTATGATGTG 14

RESULT 105
US-09-866-108A-10429/c
; Sequence 10429, Application US/098666108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10429
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10429

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      840 TTTTGATGCTGTCA 853
Db      17 TTTTGATGCTGTCA 4

RESULT 106
US-09-866-108A-10430/c
; Sequence 10430, Application US/098666108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10429
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10429

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      840 TTTTGATGCTGTCA 853
Db      17 TTTTGATGCTGTCA 4

RESULT 107
US-09-404-912-219
; Sequence 219, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 219
; LENGTH: 17
; TYPE: DNA
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10430
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10430

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      840 TTTTGATGCTGTCA 853
Db      16 TTTTGATGCTGTCA 3

RESULT 107
US-09-404-912-219
; Sequence 219, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 219
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo Sapiens
US-09-404-912-219

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1483 ATAATGTAACAGGA 1496
Db 4 ATAATGTAACAGGA 17

RESULT 108
US-09-685-664B-1072/c
; Sequence 1072, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1072
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1072

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1762
Db 17 AAAAAAAAAAAAAA 4

RESULT 109
US-08-281-940-29/c
; Sequence 29, Application US/08281940
; Patent No. 5589330
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.
; TITLE OF INVENTION: METHOD FOR MULTIPLE ALLELE-SPECIFIC
; TITLE OF INVENTION: DISEASE ANALYSIS
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARBY & DARBY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/281,940
```

```
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: LUDWIG, S. PETER
; REGISTRATION NUMBER: 25351
; REFERENCE/DOCKET NUMBER: 0372/09696
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212/527-7700
; TELEFAX: 212/753-6237
; TELEX: 236687
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapien
; IMMEDIATE SOURCE:
; CLONE: Q493XM
US-08-281-940-29

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1584 TTCATTCTATTCTTAAT 1600
Db 17 TTCATTCTGTCTTAGT 1

RESULT 110
US-08-390-850-496
; Sequence 496, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
```

TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 496:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-496

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 93;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 623 TTGCTGTTTCATGAACCTT 639  
Db 1 UUGCUGCUCAUGAGCUU 17

RESULT 111

US-08-390-850-497  
Sequence 497, Application US/08390850  
Patent No. 5612215  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,850  
FILING DATE: February 17, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5612215ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 497:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-497

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 93;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 631 CATGAACCTTGCCCATTC 647  
Db 1 CAUGAGCUUGGCCACUC 17

RESULT 112

US-08-390-850-516  
Sequence 516, Application US/08390850  
Patent No. 5612215  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,850  
FILING DATE: February 17, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5612215ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 516:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-516

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 93;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 750 CATTGAGTCCCTCTATG 766  
Db 1 CAUCCAAUCCCUCAUG 17

RESULT 113



```
US-08-390-850-517
; Sequence 517, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James.
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 517:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-390-850-517
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 93;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 754 CAGTCCCTCTATGGAGC 770
|| :|||:|:|:|
Db 1 CAAUCCUUAUGGACC 17

RESULT 114
US-08-390-850-537
; Sequence 537, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
```

```
US-08-390-850-517
; Sequence 517, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 537:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-390-850-537
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 93;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTTCTTTAAAG 886
|| :|:|:|:|
Db 1 AAUUCUGUUCUUAAAG 17

RESULT 115
US-08-390-850-538
; Sequence 538, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
```



```

; INFORMATION FOR SEQ ID NO: 541:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-541

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 93;  
Matches 9; Conservative 6; Mismatches 2; Indels

Qy 875 TTTTCTTTAAAGACTGG 891  
: : | : : | | | | | |  
Db 1 UGUUCUUUAAAGACAGG 17

RESULT 118  
US-08-390-850-609  
; Sequence 609, Application US/08390850  
; Patent No. 5612215  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 93;  
Matches 11; Conservative 4; Mismatches 2; Indels

QY 1179 CTGGAGGTATGATGTGA 1195  
||:||||:|:|:|  
db 1 CUGGAGGUUUGAUGAGA 17

RESULT 119

US-08-390-850-694/c

; Sequence 694, Application US/08390850

; Patent No. 5612215

; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwiggen, James

; APPLICANT: Gustofson, John

; APPLICANT: Stinchcomb, Dan T.

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

; NUMBER OF SEQUENCES: 1151

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FastSEQ Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/390,850

; FILING DATE: February 17, 1995

; PRIORITY APPLICATION DATA:

; APPLICATION NUMBER: 08/354,920

; FILING DATE: December 13, 1994

; APPLICATION NUMBER: 08/152,487

; FILING DATE: No. 5612215ember 12, 1993

; APPLICATION NUMBER: 07/989,848

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 211/084

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 694:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-390-850-694

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Qy 896 TCTGGTGGAAAGCTTCCT 912  
||| ||| ||| ||| ||| ||| ||| |||  
db 17 TCTCGTGGAAAGCTCCCT 1

RESULT 120  
US-08-435-634-496  
; Sequence 496, Application US/08435634  
; Patent No. 5731295  
; GENERAL INFORMATION:

;; APPLICANT: Draper, Kenneth G.  
;; APPLICANT: Pavco, Pamela  
;; APPLICANT: McSwiggen, James  
;; APPLICANT: Gustofson, John  
;; APPLICANT: Stinchcomb, Dan T.  
;; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
;; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
;; NUMBER OF SEQUENCES: 1151  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Lyon & Lyon  
;; STREET: 633 West Fifth Street  
;; CITY: Los Angeles  
;; STATE: California  
;; COUNTRY: U.S.A.  
;; ZIP: 90071  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
;; MEDIUM TYPE: storage  
;; COMPUTER: IBM Compatible  
;; OPERATING SYSTEM: IBM P.C. DOS 5.0  
;; SOFTWARE: FastSEQ Version 1.5  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/435,634  
;; FILING DATE: 05-MAY-1995  
;; CLASSIFICATION: 514  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/390,850  
;; FILING DATE: February 17, 1995  
;; APPLICATION NUMBER: 08/354,920  
;; FILING DATE: December 13, 1994  
;; APPLICATION NUMBER: 08/152,487  
;; FILING DATE: No. 5731295ember 12, 1993  
;; APPLICATION NUMBER: 07/989,848  
;; FILING DATE: December 7, 1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Warburg, Richard  
;; REGISTRATION NUMBER: 32,327  
;; REFERENCE/DOCKET NUMBER: 211/084  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (213) 489-1600  
;; TELEFAX: (213) 955-0440  
;; TELEX: 67-3510  
;; INFORMATION FOR SEQ ID NO: 496:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
US-08-435-634-496  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 93;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
QY 623 TTGCTGTTTCATGAACTT 639  
Db 1 UUGCUGCUCAUGAGCUU 17  
RESULT 121  
US-08-435-634-497  
; Sequence 497, Application US/08435634  
; Patent No. 5731295  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151

;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Lyon & Lyon  
;; STREET: 633 West Fifth Street  
;; CITY: Los Angeles  
;; STATE: California  
;; COUNTRY: U.S.A.  
;; ZIP: 90071  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
;; MEDIUM TYPE: storage  
;; COMPUTER: IBM Compatible  
;; OPERATING SYSTEM: IBM P.C. DOS 5.0  
;; SOFTWARE: FastSEQ Version 1.5  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/435,634  
;; FILING DATE: 05-MAY-1995  
;; CLASSIFICATION: 514  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/390,850  
;; FILING DATE: February 17, 1995  
;; APPLICATION NUMBER: 08/354,920  
;; FILING DATE: December 13, 1994  
;; APPLICATION NUMBER: 08/152,487  
;; FILING DATE: No. 5731295ember 12, 1993  
;; APPLICATION NUMBER: 07/989,848  
;; FILING DATE: December 7, 1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Warburg, Richard  
;; REGISTRATION NUMBER: 32,327  
;; REFERENCE/DOCKET NUMBER: 211/084  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (213) 489-1600  
;; TELEFAX: (213) 955-0440  
;; TELEX: 67-3510  
;; INFORMATION FOR SEQ ID NO: 497:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
US-08-435-634-497  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 93;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
QY 631 CATGAACCTTGCCATTC 647  
Db 1 CAUGAGCUUGGCCACUC 17  
RESULT 122  
US-08-435-634-516  
; Sequence 516, Application US/08435634  
; Patent No. 5731295  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071





```
; FILING DATE: NO. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 537:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-537

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 93;
Matches      8; Conservative      2; Mismatches      0; Gaps      0;

QY      870 AATCCTTTTCTTTAAAG 886
Db      1 AAUCUGUUCUUUAAAG 17

RESULT 125
US-08-435-634-538
; Sequence 538, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 540:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TELECOMMUNICATION INFORMATION:
```

```
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 538:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-538

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 93;
Matches      8; Conservative      7; Mismatches      2; Indels      0; Gaps      0;

QY      871 ATCCTTTTCTTTAAAGA 887
Db      1 AUUCUGUUCUUUAAAGA 17

RESULT 126
US-08-435-634-540
; Sequence 540, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 540:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TELECOMMUNICATION INFORMATION:
```

```
; TOPOLOGY: linear
US-08-435-634-540

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 874 CTTTCTTTAAAGACTG 890
Db 1 CUGUUCUUUAAAGACAG 17

RESULT 127
US-08-435-634-541
; Sequence 541, Application US/084355634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 541:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-541

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 875 TTTTCTTTAAAGACTGG 891
```

```
Db 1 UGUUCUUUAAAGACAG 17

RESULT 128
US-08-435-634-609
; Sequence 609, Application US/084355634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 609:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-609

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 93;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1179 CTGGAGGTATGATGTA 1195
Db 1 CUGGAGGUUGAUGAGA 17

RESULT 129
US-08-435-634-694/c
; Sequence 694, Application US/084355634
; Patent No. 5731295
```

```

;
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 694:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-435-634-694
;
; Query Match 0.8%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 88.2%; Pred. No. 93;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; Qy 896 TCTGTGGAAGCTTCCT 912
; Db 17 TCTGTGGAAGCTCCCT 1
;
; RESULT 130
; US-08-710-134-29/c
; Sequence 29, Application US/08710134
; Patent No. 5834181
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.
; TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
; SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genzyme Corporation
; STREET: One Mountain Road

```

```

;
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 01701
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/710,134
; FILING DATE: 13-SEP-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: IG5-8.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 508-872-8400
; TELEFAX: 508-872-5415
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Oligonucleotides"
;
; US-08-710-134-29
;
; Query Match 0.8%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 88.2%; Pred. No. 93;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; Qy 1584 TTCATTCTATTCTTAAT 1600
; Db 17 TTCATTCTGTTCTTAGT 1
;
; RESULT 131
; US-08-485-885-29/c
; Sequence 29, Application US/08485885
; Patent No. 5849483
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.
; TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
; SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genzyme Corporation
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 01701
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,885
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; REFERENCE/DOCKET NUMBER: GEN4-12.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 508-872-8400
; TELEFAX: 508-872-5415
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:

```





```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 6127:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-6127

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 29 TACAGGTATCTGCCTGT 45
Db 1 UACUGGUUUCUGCCUGU 17

RESULT 135
US-08-584-040-6128
; Sequence 6128, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; INFORMATION FOR SEQ ID NO: 6128:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 6128:

```

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-6128

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 30 ACAGGTATCTGCCTGTG 46
Db 1 ACUGGUUUCUGCCUGUG 17

RESULT 136
US-08-584-040-7818/c
; Sequence 7818, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7818:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7818

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAA 1765

```

Db 17 AAACAAAAAACAAAAA 1

RESULT 137  
US-08-584-040-7819/c  
; Sequence 7819, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 7819:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

US-08-584-040-7819

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1765  
Db 17 AAACAAAAAACAAAAA 1

RESULT 138  
US-09-060-299-354/c  
; Sequence 354, Application US/09060299  
; Patent No. 6545137  
; GENERAL INFORMATION:  
; APPLICANT: Todd, John A  
; APPLICANT: Hess, John W  
; APPLICANT: Caskey, Charles T

; APPLICANT: Cox, Roger D  
; APPLICANT: Gerhold, David  
; APPLICANT: Hammond, Holly  
; APPLICANT: Hey, Patricia  
; APPLICANT: Kawaguchi, Yoshihiko  
; APPLICANT: Merriman, Tony R  
; APPLICANT: Metzker, Michael L  
; TITLE OF INVENTION: No. 6545137el Receptor  
; NUMBER OF SEQUENCES: 455  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Nixon and Vanderhye  
; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: US  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/060,299  
; FILING DATE: 15-APR-1998  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/043,553  
; FILING DATE: 15-APR-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/048,740  
; FILING DATE: 05-JUN-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: B J Sadoff  
; REGISTRATION NUMBER: 36,663  
; REFERENCE/DOCKET NUMBER: 620-35  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (703)816-4091  
; TELEFAX: (703)816-4100  
; INFORMATION FOR SEQ ID NO: 354:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-09-060-299-354

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 762 CTATGGAGCCCCAGTGA 778  
Db 17 CCATGGAGCCCCGAGTGA 1

RESULT 139  
US-09-402-923A-354/c  
; Sequence 354, Application US/09402923A  
; Patent No. 6555654  
; GENERAL INFORMATION:  
; APPLICANT: Todd, John A  
; APPLICANT: Hess, John W  
; APPLICANT: Caskey, Charles T  
; APPLICANT: Cox, Roger D  
; APPLICANT: Gerhold, David  
; APPLICANT: Hammond, Holly  
; APPLICANT: Hey, Patricia  
; APPLICANT: Kawaguchi, Yoshihiko  
; APPLICANT: Merriman, Tony R  
; APPLICANT: Metzker, Michael L  
; TITLE OF INVENTION: No. 6555654el LDL-Receptor  
; NUMBER OF SEQUENCES: 455  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Nixon and Vanderhye

STREET: 1100 No. 6555654th Glebe Road, Eighth Floor  
CITY: Arlington  
STATE: Virginia  
COUNTRY: US  
ZIP: VA 22201-4714  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/402,923A  
FILING DATE: 14-Feb-2001  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/GB98/01102  
FILING DATE: 15-APR-1998  
APPLICATION NUMBER: US 60/043,553  
FILING DATE: 15-APR-1997  
APPLICATION NUMBER: US 60/048,740  
FILING DATE: 05-JUN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: B.J.Sadoff  
REGISTRATION NUMBER: 36,663  
REFERENCE/DOCKET NUMBER: 620-81  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703)816-4091  
TELEFAX: (703)816-4100  
INFORMATION FOR SEQ ID NO: 354:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 354:  
US-09-402-923A-354

```

Query Match      0.8%;   Score 13.8;   DB 1;   Length 17;
Best Local Similarity 88.2%;   Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Qy 762 CTATGGAGCCCCAGTGA 778  
Db 17 CCATGGAGCCCCAGTGA 1

RESULT 140  
 US-09-371-772B-837/c  
 ; Sequence 837, Application US/09371772B  
 ; Patent No. 6566127  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
 ; APPLICANT: Pavco, Pam  
 ; APPLICANT: McSwiggen, Jim  
 ; APPLICANT: Stinchcomb, Dan  
 ; APPLICANT: Escobedo, Jaime  
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
 ; FILE REFERENCE: MBHB00,876-J (237/198)  
 ; CURRENT APPLICATION NUMBER: US/09/371,772B  
 ; CURRENT FILING DATE: 1999-08-10  
 ; PRIOR APPLICATION NUMBER: US 60/005,974  
 ; PRIOR FILING DATE: 1995-10-26  
 ; PRIOR APPLICATION NUMBER: US 08/584,040  
 ; PRIOR FILING DATE: 1996-01-08  
 ; NUMBER OF SEQ ID NOS: 14225  
 ; SOFTWARE: PatentIn version 3.0  
 ; SEQ ID NO 837  
 ; LENGTH: 17  
 ; TYPE: RNA  
 ; ORGANISM: Homo sapiens  
 US-09-371-772B-837

Query Match 0.8%; Score 13.8; DB 1; Length 17;

```

Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      217 GACAACTCAACTCTGGC 233
      ||||| |||||
Db      17 GACAACTCAACTCTGGC 1

RESULT 141
US-09-371-772B-2964
; Sequence 2964, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Cond
; FILE REFERENCE: MBHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2964
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2964

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 93;  
Matches 9; Conservative 6; Mismatches 2; Indels

Qy 29 TACAGGTATCTGCCTGT 45  
:|:|:|:|:|:|:|:  
pb 1 UACUGGUUUCUGCCUGU 17

RESULT 142  
 US-09-371-772B-2965  
 ; Sequence 2965, Application US/09371772B  
 ; Patent No. 6566127  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
 ; APPLICANT: Pavco, Pam  
 ; APPLICANT: McSwiggen, Jim  
 ; APPLICANT: Stinchcomb, Dan  
 ; APPLICANT: Escobedo, Jaime  
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
 ; FILE REFERENCE: MHB00,876-J (237/198)  
 ; CURRENT APPLICATION NUMBER: US/09/371,772B  
 ; CURRENT FILING DATE: 1999-08-10  
 ; PRIOR APPLICATION NUMBER: US 60/005,974  
 ; PRIOR FILING DATE: 1995-10-26  
 ; PRIOR APPLICATION NUMBER: US 08/584,040  
 ; PRIOR FILING DATE: 1996-01-08  
 ; NUMBER OF SEQ ID NOS: 14225  
 ; SOFTWARE: PatentIn version 3.0  
 ; SEQ ID NO 2965  
 ; LENGTH: 17  
 ; TYPE: RNA  
 ; ORGANISM: Mus sp.  
 US-09-371-772B-2965

Query Match	0.8%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	58.8%	Pred. No. 93;		



Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 30 ACAGGTATCTGCTGTG 46  
|||:::|:|:|:  
Db 1 ACUGGUUCUGCCUG 17

RESULT 143  
US-09-371-772B-3602/c  
; Sequence 3602, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3602  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-3602

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1749 AAAAAAAAAAAAAA 1765  
|||:::|:|:|:  
Db 17 AAACAAAAAACAAAAA 1

RESULT 144  
US-09-371-772B-3603/c  
; Sequence 3603, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3603  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-3603

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765  
|||:::|:|:|:  
Db 17 AAACAAAAAACAAAAA 1

RESULT 145  
US-09-827-998-423  
; Sequence 423, Application US/09827998  
; Patent No. 6656700  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; APPLICANT: Shannon, Mark  
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
; FILE REFERENCE: MDhMORF-8  
; CURRENT APPLICATION NUMBER: US/09/827,998  
; CURRENT FILING DATE: 2001-04-06  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; NUMBER OF SEQ ID NOS: 1881  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6656700  
; SEQ ID NO 423  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-827-998-423

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 39 TGCCTGTGGGCTGCTC 55  
|||:::|:|:|:  
Db 1 TGCCTGTGGGCTTCTC 17

RESULT 146  
US-09-827-998-821  
; Sequence 821, Application US/09827998  
; Patent No. 6656700  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; APPLICANT: Shannon, Mark  
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
; FILE REFERENCE: MDhMORF-8  
; CURRENT APPLICATION NUMBER: US/09/827,998  
; CURRENT FILING DATE: 2001-04-06  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; NUMBER OF SEQ ID NOS: 1881  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6656700  
; SEQ ID NO 821  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-827-998-821

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1176 CTACTGGAGGTATGATG 1192  
|||:::|:|:|:  
Db 1 CTAGGGGAGGTATGATG 17

RESULT 147

```
US-09-827-998-822
; Sequence 822, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-822
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1177 TACTGGAGGTATGATGT 1193
      || |||||
Db      1 TAGGGGAGGTATGATGT 17
```

```
RESULT 148
US-09-866-108A-874/c
; Sequence 874, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 874
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-874
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1131 CTTTGACCCCACTTCGCC 1147
      |||||
Db      17 CTTTGACCCCTCCTCGCC 1
```

```
RESULT 149
US-09-866-108A-10428/c
; Sequence 10428, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10428
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10428
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      841 TTTGATGCTGTCAAC 857
      |||||
Db      17 TTTGATGCTGTCAAC 1
```

```
RESULT 150
US-09-866-108A-10434/c
; Sequence 10434, Application US/09866108A
; Patent No. 6686188
```

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10434
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10434

Query Match ( 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 835 TTGACTTTTGATGCTGT 851
Db 17 TCGACTTTTGATGCTGT 1

RESULT 151
US-09-685-664B-837/c
; Sequence 837, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-837

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 217 GACAACTCAACTCTGGC 233
Db 17 GACAACTCAACTCTGGC 1

RESULT 152
US-09-685-664B-2964
; Sequence 2964, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2964
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2964

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 29 TACAGGTATCTGCCTGT 45
Db 1 UACUGGUUUCUGCCUGU 17

RESULT 153
US-09-685-664B-2965
; Sequence 2965, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 8231
```

; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2965  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-09-685-664B-2965

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 93;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 30 ACAGGTATCTGCCTGTG 46  
Db 1 ACUGGUUCUGCCUG 17

RESULT 154  
US-09-685-664B-3602/c  
; Sequence 3602, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3602  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-09-685-664B-3602

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765  
Db 17 AAACAAAAAACAAAAA 1

RESULT 155  
US-09-685-664B-3603/c  
; Sequence 3603, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3603  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-09-685-664B-3603

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 93;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765  
Db 17 AAACAAAAAACAAAAA 1

RESULT 156  
US-08-292-620A-41  
; Sequence 41, Application US/08292620A  
; Patent No. 5837542  
; GENERAL INFORMATION:  
; APPLICANT: Susan Grimm  
; APPLICANT: Dan T. Stinchcomb  
; APPLICANT: James McSwiggen  
; APPLICANT: Sean Sullivan  
; APPLICANT: Kenneth G. Draper  
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF INTRACELLULAR ADHESION MOLECULE-1 (I-CAM-1)  
; NUMBER OF SEQUENCES: 2390  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/292,620A  
; FILING DATE: August 17, 1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; PRIOR APPLICATION DATA: including application described below:  
; PRIOR APPLICATION NUMBER: 08/008,895  
; FILING DATE: January 19, 1993  
; APPLICATION NUMBER: 07/989,849  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 208/149  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 41:  
; SEQUENCE CHARACTERISTICS:



```

; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-41
Query Match          0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 73;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 969 TGCTATTCAAGCTGC 983
   :||:|:|:|:|:|
Db 1 UGCUAUUCAACUGC 15

RESULT 157
US-08-585-684B-1740
; Sequence 1740, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1740:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-1740
Query Match          0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 73;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1483 ATAATGTAACAGGAA 1497
   |||:|:|:|:|:|
Db 1 AGAAUGUAACAGGAA 15

RESULT 158
```

```

US-09-071-845-41
; Sequence 41, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 41:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-41
Query Match          0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 73;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 969 TGCTATTCAAGCTGC 983
   :||:|:|:|:|:|
Db 1 UGCUAUUCAACUGC 15

RESULT 159
US-09-038-073-1740
; Sequence 1740, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
```



; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-291-932A-93
;
; Query Match 0.7%; Score 13; DB 1; Length 15;
; Best Local Similarity 69.2%; Pred. No. 82;
; Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 809 CACCATCAACTTT 821
; Db 2 CACCAUCAACUUU 14
;
; RESULT 163
; US-08-664-224-2/c
; Sequence 2, Application US/08864224
; Patent No. 5851808
; GENERAL INFORMATION:
; APPLICANT: Elledge, Stephen J.
; APPLICANT: Liu, Qinghua
; TITLE OF INVENTION: Rapid Subcloning Using Site-Specific
; TITLE OF INVENTION: Recombination
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94104
; COMPUTER READABLE FORM:

Two

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/864,224
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: BCM-02681
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
;
; US-08-864-224-2
;
; Query Match 0.7%; Score 13; DB 1; Length 16;
; Best Local Similarity 100.0%; Pred. No. 98;
; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 1778 GAATTCCTCCGGGA 1790
; Db 16 GAATTCCTCCGGGA 4
;
; RESULT 164
; US-09-122-384-2/c
; Sequence 2, Application US/09122384A
; Patent No. 6828093
; GENERAL INFORMATION:
; APPLICANT: Elledge, Stephen J.
; APPLICANT: Liu, Qinghua
; TITLE OF INVENTION: Improved Rapid Subcloning Using Site-Specific
; TITLE OF INVENTION: Recombination
; FILE REFERENCE: 120541-1005
; CURRENT APPLICATION NUMBER: US/09/122,384A
; CURRENT FILING DATE: 1998-07-24
; EARLIER APPLICATION NUMBER: 08/864,224
; EARLIER FILING DATE: 1997-02-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;
; US-09-122-384-2
;
; Query Match 0.7%; Score 13; DB 1; Length 16;
; Best Local Similarity 100.0%; Pred. No. 98;
; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 1778 GAATTCCTCCGGGA 1790
; Db 16 GAATTCCTCCGGGA 4
;
; RESULT 165
; US-09-396-196G-125371/c
; Sequence 125371, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann

APPLICANT: David Mack  
APPLICANT: David Lockhart  
APPLICANT: Affymetrix, Inc.  
TITLE OF INVENTION: Methods of Genetic Analysis  
FILE REFERENCE: 3101.1  
CURRENT APPLICATION NUMBER: US/09/396,196G  
PRIOR FILING DATE: 1999-09-15  
PRIOR FILING DATE: 1998-09-17  
NUMBER OF SEQ ID NOS: 127806  
SOFTWARE: FastSEQ for Windows Version 4.0  
SEQ ID NO 125371  
LENGTH: 25  
TYPE: DNA  
ORGANISM: mus musculus  
US-09-396-196G-125371

Query Match 0.7%; Score 13; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 2.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1467 GTGTAACATATGTG 1479  
|||||  
Db 24 GTGTAACATATGTG 12

RESULT 166  
US-09-396-196G-125372/c  
Sequence 125372, Application US/09396196G  
Patent No. 6821724  
GENERAL INFORMATION:  
APPLICANT: Michael Mittmann  
APPLICANT: David Mack  
APPLICANT: David Lockhart  
APPLICANT: Affymetrix, Inc.  
TITLE OF INVENTION: Methods of Genetic Analysis  
FILE REFERENCE: 3101.1  
CURRENT APPLICATION NUMBER: US/09/396,196G  
PRIOR FILING DATE: 1999-09-15  
PRIOR FILING DATE: 1998-09-17  
NUMBER OF SEQ ID NOS: 127806  
SOFTWARE: FastSEQ for Windows Version 4.0  
SEQ ID NO 125372  
LENGTH: 25  
TYPE: DNA  
ORGANISM: mus musculus  
US-09-396-196G-125372

Query Match 0.7%; Score 13; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 2.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1467 GTGTAACATATGTG 1479  
|||||  
Db 21 GTGTAACATATGTG 9

RESULT 167  
US-08-753-147-134/c  
Sequence 134, Application US/08753147  
Patent No. 5770372  
GENERAL INFORMATION:  
APPLICANT: Concannon, Patrick  
TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene  
NUMBER OF SEQUENCES: 196  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Christensen O'Connor Johnson and Kindness  
STREET: 1420 5th Avenue  
CITY: Seattle  
STATE: Washington  
COUNTRY: USA  
ZIP: 98101-2347

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/753,147  
FILING DATE:  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Sheiness, Diana K.  
REGISTRATION NUMBER: 35,356  
REFERENCE/DOCKET NUMBER: VMRC-1-9714  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206) 743-4387  
TELEFAX: (206) 224 0779  
INFORMATION FOR SEQ ID NO: 134:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
US-08-753-147-134

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 151 AACTTCCTAAAGAAA 166  
|||||  
Db 16 AATTTCCTAAAGAGA 1

RESULT 168  
US-08-667-338B-5/c  
Sequence 5, Application US/08667338B  
Patent No. 5871918  
GENERAL INFORMATION:  
APPLICANT: Thorpe, H. H.  
APPLICANT: Johnston, Dean H.  
APPLICANT: Napier, Mary E.  
APPLICANT: Loomis, Carson R.  
APPLICANT: Sistare, Mark F.  
APPLICANT: Kim, Jinheung  
TITLE OF INVENTION: Electrochemical Detection of Nucleic  
TITLE OF INVENTION: Acid Hybridization  
NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Kenneth D. Sibley  
STREET: PO Box 37428  
CITY: Raleigh  
STATE: NC  
COUNTRY: US  
ZIP: 27627

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/667,338B  
FILING DATE: 20-JUN-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/016,625  
FILING DATE: 19-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/060,949



```
; FILING DATE: 27-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5470-107B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-854-1400
; TELEFAX: 919-854-1401
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; ANTI-SENSE: NO
US-08-667-338B-5

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1426 TTTTATAAGTATATTT 1441
Db      16 TTTTATACCTATATTT 1

RESULT 169
US-09-179-665-5/c
; Sequence 5, Application US/09179665
; Patent No. 6132971
; GENERAL INFORMATION:
; APPLICANT: Thorpe, H. H.
; APPLICANT: Johnston, Dean H.
; APPLICANT: Napier, Mary E.
; APPLICANT: Loomis, Carson R.
; APPLICANT: Sistare, Mark F.
; APPLICANT: Kim, Jinheung
; TITLE OF INVENTION: Electrochemical Detection of Nucleic
; TITLE OF INVENTION: Acid Hybridization
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: PO Box 37428
; CITY: Raleigh
; STATE: NC
; COUNTRY: US
; ZIP: 27627
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/179,665
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/667,338
; FILING DATE: 20-JUN-1996
; APPLICATION NUMBER: US 60/016,625
; FILING DATE: 19-APR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/060,949
; FILING DATE: 27-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5470-107B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-854-1400
; TELEFAX: 919-854-1401
```

```
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; ANTI-SENSE: NO
US-09-179-665-5

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1426 TTTTATAAGTATATTT 1441
Db      16 TTTTATACCTATATTT 1

RESULT 170
US-09-371-772B-7106
; Sequence 7106, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7106
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-7106

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      296 GGTC AAGATGGATGAA 311
Db      1 GGUA AAGAUUGAUGAA 16

RESULT 171
US-09-479-005A-185
; Sequence 185, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBHB00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
```

```

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 185
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-185

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1761 AAAAAAAAAAAAAAC 1776
Db 1 AAUAAAAAAAAAAC 16

RESULT 172
US-09-931-381A-7
; Sequence 7, Application US/09931381A
; Patent No. 6692922
; GENERAL INFORMATION:
; APPLICANT: Butcher, Eugene C.
; APPLICANT: Kunkel, Eric J.
; APPLICANT: Pan, Junliang
; APPLICANT: Soler-Ferran, Dulce
; TITLE OF INVENTION: Method for Identifying Agents Which
; TITLE OF INVENTION: Modulate Chemokine "Mec"-Induced Functions of CCR3 and/or
; TITLE OF INVENTION: CCR10
; FILE REFERENCE: 1855.2010-003
; CURRENT APPLICATION NUMBER: US/09/931,381A
; CURRENT FILING DATE: 2001-08-15
; PRIOR APPLICATION NUMBER: U.S. 09/638,914
; PRIOR FILING DATE: 2000-08-15
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: intron
; LOCATION: (1)...(8)
; NAME/KEY: exon
; LOCATION: (9)...(16)
; OTHER INFORMATION: 16
US-09-931-381A-7

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1650 TCTAACACCTTCAAG 1665
Db 1 TCTAACACGCTTCATG 16

Search completed: May 13, 2005, 12:22:21
Job time : 3 secs
```

**THIS PAGE BLANK (USPTO)**